[
  {
    "id": "b45c68bb-b308-4d66-8d30-dcc813b9272c",
    "question_number": 1,
    "question": "A 32-year-old woman undergoes a dental procedure and receives a large volume of lidocaine with adrenaline for local anaesthesia. Minutes later, she develops sudden confusion, perioral tingling, followed by seizures and then collapses with bradycardia and hypotension. What is the recommended first-line intravenous therapy to reverse her cardiovascular toxicity?",
    "options": [
      "IV 20% lipid emulsion",
      "IV calcium gluconate",
      "IV sodium bicarbonate",
      "IM glucagon",
      "IV atropine"
    ],
    "correct_answer": "IV 20% lipid emulsion",
    "explanation": "**Explanation**\nThe patient is exhibiting signs of **systemic local anaesthetic toxicity** following lidocaine administration, progressing from neurological symptoms (confusion, tingling, seizures) to life-threatening cardiovascular compromise (bradycardia, hypotension, collapse). **Intravenous 20% lipid emulsion** is the evidence-based antidote for severe local anaesthetic toxicity. This treatment acts as a 'lipid sink,' rapidly binding lipid-soluble anaesthetic molecules in the plasma, reducing their effect on cardiac and neural tissues, and facilitating their clearance. This therapy is supported by national guidelines and should be initiated alongside standard resuscitation measures. Other options listed do not address the underlying toxicity mechanism and would not reverse the cardiovascular effects of local anaesthetic overdose.\n\n**Key Points**\n- Local anaesthetic toxicity can cause CNS and CVS collapse.\n- IV 20% lipid emulsion is the recommended reversal agent for severe toxicity.\n- Initial bolus: 1.5 mL/kg over 1 minute, followed by infusion (15 mL/kg/h).\n- Continue infusion and repeat bolus if instability persists (max 12 mL/kg).\n- Management should always include standard resuscitation (CPR) if needed.\n- Propofol is NOT a suitable substitute for lipid emulsion.\n- Consult Toxbase or national guidelines for detailed protocols.\n\n**Clinical Relevance**\nRecognising and treating local anaesthetic toxicity promptly is vital to prevent cardiac arrest and death, particularly in emergency, dental, and minor surgical settings. National and BNF guidance supports early lipid emulsion therapy, and all clinicians administering local anaesthetics should be familiar with this protocol.\n\n**Memory Anchor**\nThink 'lipid sink' for local anaesthetic toxicity—emulsify and neutralise the anaesthetic.",
    "bullet_explanations": {
      "IV 20% lipid emulsion": "Correct – this is the first-line antidote for systemic local anaesthetic toxicity.",
      "IV calcium gluconate": "Incorrect – used for hyperkalaemia or calcium channel blocker toxicity, not local anaesthetic toxicity.",
      "IV sodium bicarbonate": "Incorrect – used in tricyclic antidepressant overdose or severe metabolic acidosis, not for local anaesthetic toxicity.",
      "IM glucagon": "Incorrect – glucagon is indicated in beta-blocker overdose and should be given IV, not IM, if used.",
      "IV atropine": "Incorrect – atropine treats bradycardia due to vagal causes but does not reverse local anaesthetic toxicity."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Prescribing Safety",
    "topic": "High-risk drugs (warfarin, insulin, opioids)",
    "keywords": [
      "local anaesthetic toxicity",
      "lipid emulsion",
      "lidocaine overdose",
      "toxicity reversal",
      "emergency antidote"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Severe local anaesthetic-induced cardiovascular toxicity",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/severe-local-anaesthetic-induced-cardiovascular-toxicity/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0178cf56-783e-4e0e-82b6-a07137de2b34",
    "question_number": 2,
    "question": "A 45-year-old woman with a history of HIV presents with several weeks of mildly itchy, red, scaly patches affecting her eyebrows, sides of her nose, and behind her ears. She notes that the rash tends to worsen in the winter months. What is the most likely diagnosis?",
    "options": [
      "Seborrhoeic dermatitis",
      "Psoriasis vulgaris",
      "Allergic contact dermatitis",
      "Lichen planus",
      "Acne rosacea"
    ],
    "correct_answer": "Seborrhoeic dermatitis",
    "explanation": "**Explanation**\n**Seborrhoeic dermatitis** is a chronic, relapsing inflammatory skin disorder that mainly affects areas rich in sebaceous glands, such as the scalp, nasolabial folds, eyebrows, and behind the ears. It presents as erythematous patches with greasy, yellowish scales and often causes mild itching. The condition commonly flares in colder months. Key risk factors include immunosuppression (e.g. HIV) and certain neurological conditions. In contrast, psoriasis vulgaris typically affects the extensor surfaces and scalp with thicker, silvery scales. Allergic contact dermatitis is usually sharply demarcated and linked to a specific allergen exposure. Lichen planus presents with violaceous, flat-topped papules, and rosacea causes facial flushing and papulopustular lesions, not scales or itch in sebaceous areas.\n\n**Key Points**\n- Seborrhoeic dermatitis commonly affects sebaceous-rich areas (scalp, nasolabial folds, eyebrows, retroauricular regions).\n- Often associated with chronic relapsing course and increased prevalence in HIV and neurological disease.\n- Symptoms may worsen in the winter or periods of stress.\n- Typical features: erythematous, mildly itchy patches with greasy or yellowish scaling.\n- Differentiated from psoriasis by thinner, less well-defined scales and location.\n- Rosacea lacks scaling and is not typically pruritic.\n- Allergic contact dermatitis is usually confined to areas of direct allergen exposure.\n\n**Clinical Relevance**\nRecognising seborrhoeic dermatitis is crucial as it is common, especially in immunosuppressed individuals, and responds well to antifungal and mild anti-inflammatory treatments. Early identification ensures appropriate management and avoids unnecessary investigations or misdiagnosis.\n\n**Memory Anchor**\nRemember 'S for Sebaceous, S for Seborrhoeic'—both involve oily skin regions.",
    "bullet_explanations": {
      "Seborrhoeic dermatitis": "Correct – Presents with red, scaly patches in sebum-rich areas, especially in immunosuppressed patients.",
      "Psoriasis vulgaris": "Incorrect – Typically affects extensor surfaces and scalp, with thick silvery scales rather than greasy, mild scales.",
      "Allergic contact dermatitis": "Incorrect – Usually well-demarcated, linked to allergen exposure, and not limited to sebaceous areas.",
      "Lichen planus": "Incorrect – Characterised by violaceous, flat-topped papules, often on wrists and ankles, not face or scalp.",
      "Acne rosacea": "Incorrect – Causes facial erythema and papules but lacks scaling and does not affect ears/scalp."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Seborrhoeic dermatitis",
    "keywords": [
      "seborrhoeic dermatitis",
      "scaly rash",
      "sebaceous areas",
      "HIV",
      "chronic eczema"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Seborrhoeic dermatitis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/seborrhoeic-dermatitis/"
      },
      {
        "source": "BNF",
        "topic_title": "Eczema",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/eczema/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "92723586-0016-4664-8087-f871d91e83f0",
    "question_number": 3,
    "question": "A 30-year-old woman is planning to delay pregnancy for approximately one year and seeks advice about contraceptive options that allow for rapid return to fertility after discontinuation. Which contraceptive method is most likely to be associated with a significant delay in return to fertility after stopping?",
    "options": [
      "Progestogen-only injectable (e.g. depot medroxyprogesterone acetate)",
      "Levonorgestrel-releasing intrauterine system (IUS)",
      "Etonogestrel subdermal implant",
      "Combined oral contraceptive pill",
      "Progestogen-only pill"
    ],
    "correct_answer": "Progestogen-only injectable (e.g. depot medroxyprogesterone acetate)",
    "explanation": "**Explanation**\n**Depot medroxyprogesterone acetate (DMPA)**, a progestogen-only injectable, is well known for causing a **prolonged delay in the return to fertility** after discontinuation, with the median time to conception being around 10 months and up to 1 year or longer in some women. This effect is due to the persistence of the hormone's suppressive effect on the hypothalamic-pituitary-ovarian axis, even after the scheduled dosing interval has elapsed. In contrast, other methods such as the IUS, implant, and oral contraceptives are associated with a rapid return to normal fertility soon after cessation or removal.<br><br>**Key facts:**<ul><li><b>Depot medroxyprogesterone acetate</b>: Median delay to conception ~10 months; up to 12 months or more possible.</li><li><b>Implant, IUS, POP, COCP</b>: Return to fertility is typically rapid following discontinuation/removal.</li><li>The delay is unique to progestogen-only injections and not a general feature of hormonal contraception.</li></ul><br><br><table><thead><tr><th>Method</th><th>Return to Fertility</th></tr></thead><tbody><tr><td>Depot medroxyprogesterone acetate</td><td>Delayed (median 10 months)</td></tr><tr><td>IUS (Mirena)</td><td>Rapid</td></tr><tr><td>Implant</td><td>Rapid</td></tr><tr><td>COCP</td><td>Rapid</td></tr><tr><td>POP</td><td>Rapid</td></tr></tbody></table>\n\n**Key Points**\n- Depot medroxyprogesterone acetate (DMPA) can delay fertility return for up to 12 months or more\n- Implants, IUS, and oral contraceptives typically allow quick return to fertility after cessation\n- The delay is due to prolonged suppression of the reproductive axis by injectable progestogens\n- This distinction is clinically important for women planning future pregnancies\n\n**Clinical Relevance**\nUnderstanding the impact of different contraceptive methods on fertility return is crucial for patient counselling, especially for women wishing to conceive soon after stopping contraception. National guidelines stress the importance of informing patients about the possibility of a prolonged delay with DMPA, whereas most other methods do not have this effect.\n\n**Memory Anchor**\nRemember the 'depot delay': depot injections can delay the day!",
    "bullet_explanations": {
      "Progestogen-only injectable (e.g. depot medroxyprogesterone acetate)": "Correct – this method is associated with a significant and sometimes unpredictable delay in return to fertility after stopping.",
      "Levonorgestrel-releasing intrauterine system (IUS)": "Incorrect – fertility returns rapidly following removal, with no evidence of prolonged delay.",
      "Etonogestrel subdermal implant": "Incorrect – fertility generally returns within days to weeks after removal.",
      "Combined oral contraceptive pill": "Incorrect – while a brief delay is possible, pregnancy rates normalise quickly and are comparable to non-users within 12 months.",
      "Progestogen-only pill": "Incorrect – this has a short half-life and fertility typically returns within days of discontinuation."
    },
    "category": "Reproductive Health",
    "subsection": "Contraception",
    "subsubsection": "Progesterone-only methods",
    "topic": "Progesterone-only methods",
    "keywords": [
      "contraception",
      "fertility return",
      "depot medroxyprogesterone",
      "progestogen-only injectable"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Contraceptives, hormonal",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/contraceptives-hormonal/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Contraception - progestogen-only methods",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/contraception-progestogen-only-methods/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4b2b14e0-0e1e-4530-bcfd-b74f9b7bbb11",
    "question_number": 4,
    "question": "A 7-year-old boy is brought to the GP by his father due to his teacher noticing he is frequently asking for instructions to be repeated and sits closer to the front of the classroom. He has no history of pain or fever. Otoscopy reveals a dull, retracted tympanic membrane on the right, with no signs of infection or discharge. What is the most appropriate initial management?",
    "options": [
      "Refer for formal hearing assessment",
      "Start a course of oral antibiotics",
      "Prescribe nasal corticosteroid spray",
      "Advise watchful waiting for several weeks",
      "Prescribe topical antibiotic ear drops"
    ],
    "correct_answer": "Advise watchful waiting for several weeks",
    "explanation": "**Explanation**\n**Otitis media with effusion (OME)**, also known as glue ear, is a common cause of temporary hearing impairment in children. It presents with a non-painful, non-febrile middle ear effusion and a retracted or dull tympanic membrane, without signs of acute infection. Most cases resolve spontaneously within 6–12 weeks. **Immediate intervention is not indicated unless symptoms significantly impact hearing, development, or education**, or if there are risk factors (e.g. Down syndrome, cleft palate). Antibiotics, topical or oral, as well as nasal steroids, are not recommended due to lack of evidence. Initial management in otherwise well children is to observe and review after a period of watchful waiting.\n\n**Key Points**\n- OME is characterised by middle ear fluid without acute signs of infection.\n- Self-resolves in most children within 6–12 weeks.\n- No role for antibiotics, decongestants, or topical treatments in uncomplicated OME.\n- Formal hearing assessment or ENT referral is only needed if symptoms persist beyond 3 months or there is a risk to speech, language, or learning.\n- Children with Down syndrome or cleft palate require earlier specialist input.\n\n**Clinical Relevance**\nRecognising glue ear and avoiding unnecessary antibiotics or steroids is important for antimicrobial stewardship and patient safety. Early referral is reserved for children with persistent symptoms or those at risk of developmental delay. These recommendations are supported by NICE and BNF guidelines.",
    "bullet_explanations": {
      "Refer for formal hearing assessment": "Not required at initial presentation unless symptoms persist for >3 months or there is significant developmental impact.",
      "Start a course of oral antibiotics": "Ineffective in OME; antibiotics are not recommended for non-infective middle ear effusions.",
      "Prescribe nasal corticosteroid spray": "Lacks supporting evidence for OME management; not recommended.",
      "Advise watchful waiting for several weeks": "Correct—most cases resolve without intervention; observation is first-line.",
      "Prescribe topical antibiotic ear drops": "Indicated for otorrhoea post-grommet, not for uncomplicated OME without infection."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Otitis media with effusion in children",
    "keywords": [
      "glue ear",
      "otitis media with effusion",
      "child hearing loss",
      "ENT",
      "watchful waiting"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Otitis media with effusion",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/otitis-media-with-effusion/"
      },
      {
        "source": "BNF",
        "topic_title": "Ear",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/ear/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "14e86220-1ba1-46bd-b13b-a262367ce5ef",
    "question_number": 5,
    "question": "A 42-year-old man presents with new onset itchy, well-demarcated, scaly plaques on his scalp and behind the ears. He has no significant past medical history and is otherwise well. Which is the most appropriate first-line treatment for his scalp lesions?",
    "options": [
      "Topical potent corticosteroid",
      "Oral methotrexate",
      "Phototherapy (narrowband UVB)",
      "Topical vitamin D analogue",
      "Coal tar shampoo"
    ],
    "correct_answer": "Topical potent corticosteroid",
    "explanation": "**Explanation**\n**Potent topical corticosteroids** are recommended as the initial treatment for scalp psoriasis. These medications reduce inflammation and scaling, and are effective for localised lesions. They can be prescribed in formulations such as solutions, gels, foams, or shampoos to aid application to the scalp. This approach is supported by both the BNF and NICE CKS, which state that potent topical corticosteroids should be used once daily for up to four weeks before considering alternative regimens. Other options, such as vitamin D analogues or coal tar, are usually reserved for patients who cannot tolerate corticosteroids or have not achieved adequate control after first-line therapy. Systemic agents and phototherapy are only indicated for extensive or refractory disease.\n\n**Key Points**\n- Potent topical corticosteroids are first-line for scalp psoriasis.\n- Alternative topical agents (e.g. vitamin D analogues) are considered if corticosteroids fail or are contraindicated.\n- Systemic therapies and phototherapy are reserved for severe, extensive, or treatment-resistant cases.\n- Coal tar shampoos are less effective as monotherapy for severe scalp psoriasis.\n- <table><thead><tr><th>Scalp Psoriasis Therapy</th><th>Indication</th></tr></thead><tbody><tr><td>Potent topical corticosteroid</td><td>First-line, localised disease</td></tr><tr><td>Topical vitamin D analogue</td><td>Second-line or steroid intolerance</td></tr><tr><td>Phototherapy</td><td>Extensive/refractory cases</td></tr><tr><td>Oral methotrexate</td><td>Severe, generalised/inadequate topical response</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising that potent topical corticosteroids are the mainstay for initial management of scalp psoriasis ensures rapid and effective symptom control, reduces morbidity, and aligns with national guidelines. Inappropriate escalation to systemic therapy or phototherapy can lead to unnecessary side effects and resource use.\n\n**Memory Anchor**\nScalp = Steroid Start: Always initiate with a potent topical corticosteroid for scalp psoriasis.",
    "bullet_explanations": {
      "Topical potent corticosteroid": "Correct – First-line treatment for mild to moderate scalp psoriasis, as per guidelines.",
      "Oral methotrexate": "Incorrect – Reserved for severe, widespread, or refractory psoriasis when topical therapy fails.",
      "Phototherapy (narrowband UVB)": "Incorrect – Indicated only if topical treatments are unsuccessful or disease is extensive.",
      "Topical vitamin D analogue": "Incorrect – Considered second-line for scalp psoriasis if potent corticosteroids are inadequate or not tolerated.",
      "Coal tar shampoo": "Incorrect – Not recommended as monotherapy for severe scalp psoriasis; may be adjunctive."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Psoriasis types",
    "keywords": [
      "scalp psoriasis",
      "topical corticosteroid",
      "first-line",
      "dermatology"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Psoriasis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/psoriasis/"
      },
      {
        "source": "BNF",
        "topic_title": "Psoriasis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/psoriasis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5da32ffb-f1f3-4c14-a82b-c85a7b94333b",
    "question_number": 6,
    "question": "A 41-year-old woman is attending for a routine health check and asks how often she should have cervical screening, given her last test (HPV primary screening) was negative and she has no symptoms. According to current UK guidelines, what is the standard recall interval for cervical screening for women aged 25–64 with a negative HPV result?",
    "options": [
      "Five years",
      "Annually",
      "Every two years",
      "Every four years",
      "Every ten years"
    ],
    "correct_answer": "Five years",
    "explanation": "**Explanation**\n**NHS cervical screening guidance in England and the UK now recommends a five-year interval for women aged 25–64 who have a negative high-risk HPV result.** This change is based on evidence that primary HPV testing is highly sensitive for detecting women at risk of developing cervical cancer, and a negative result indicates a very low risk of significant pathology in the next five years. Previously, women aged 25–49 were recalled every three years, but the increased reassurance from a negative HPV test has allowed the extension of the interval to five years for all women aged 25–64. More frequent screening is reserved for specific high-risk groups or those with abnormal previous results.\n\n**Key Points**\n- Primary HPV testing is the current standard for cervical screening in the UK.\n- A negative HPV result confers a low risk of developing cervical cancer in the next five years.\n- Routine recall interval is now every five years for women aged 25–64 with a negative result.\n- Annual or more frequent screening is only for high-risk populations (e.g., immunocompromised).\n- Women aged 65+ are only recalled if they have not been screened since 50 or have recent abnormalities.\n\n**Clinical Relevance**\nBeing aware of the updated cervical screening intervals is crucial for advising patients and ensuring adherence to best practice. The move to a five-year recall for women aged 25–64 is based on strong evidence favouring the safety and effectiveness of primary HPV screening, per national recommendations.\n\n**Memory Anchor**\nRemember: ‘Five for HPV’—a negative HPV screen means five years until the next test.",
    "bullet_explanations": {
      "Five years": "Correct—this is the routine recall interval for women aged 25–64 with a negative HPV screen.",
      "Annually": "Incorrect—annual screening is reserved for certain high-risk patients (e.g., HIV positive or previous severe CIN).",
      "Every two years": "Incorrect—two-year intervals are not standard for routine cervical screening in the UK.",
      "Every four years": "Incorrect—four-year intervals are not part of the UK cervical screening programme.",
      "Every ten years": "Incorrect—this interval is too long; it does not reflect national screening recommendations."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Menstrual Disorders",
    "topic": "Amenorrhoea",
    "keywords": [
      "cervical screening",
      "HPV",
      "screening interval",
      "women's health"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cervical screening",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cervical-screening/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "774f7ddc-b17d-4f4f-aa1a-20d355022caa",
    "question_number": 7,
    "question": "Which of the following medications is well recognised for its potential to cause ototoxicity leading to sensorineural hearing loss?",
    "options": [
      "Quinine",
      "Ramipril",
      "Atorvastatin",
      "Doxycycline",
      "Metformin"
    ],
    "correct_answer": "Quinine",
    "explanation": "**Explanation**\n**Quinine** is well established as an ototoxic medication, capable of causing sensorineural hearing loss and tinnitus. Ototoxicity refers to drug-induced damage to the inner ear or vestibulocochlear nerve, resulting in symptoms such as hearing loss, tinnitus, and sometimes vertigo. Quinine, used for malaria and occasionally for leg cramps, can cause both reversible and irreversible auditory damage. Other commonly ototoxic medications include aminoglycoside antibiotics (e.g., gentamicin), loop diuretics (e.g., furosemide), high-dose aspirin, and certain chemotherapy agents. The other drugs listed do not have a significant association with ototoxicity.\n\n**Key Points**\n- Ototoxicity primarily affects the inner ear/cochlea and vestibulocochlear nerve.\n- Quinine is a well-known cause of drug-induced hearing loss.\n- Other ototoxic drugs: aminoglycosides, loop diuretics, some chemotherapies, high-dose salicylates.\n- Symptoms may include hearing loss, tinnitus, and balance disturbance.\n- Routine medications for hypertension, cholesterol, or diabetes (e.g., ramipril, atorvastatin, metformin) are not linked to ototoxicity.\n\n**Clinical Relevance**\nIt is important to take a thorough drug history in patients presenting with hearing loss, as certain medications—including quinine—can cause or exacerbate sensorineural hearing impairment. Early recognition and discontinuation of the offending agent can prevent permanent damage. This approach aligns with NICE CKS guidance on assessing adults with new or progressive hearing loss.\n\n**Memory Anchor**\nRemember: **'Quinine causes cochlear quakes'**—both begin with 'Q'.",
    "bullet_explanations": {
      "Quinine": "Correct – Quinine is a recognised cause of ototoxicity and can lead to hearing loss.",
      "Ramipril": "Incorrect – Ramipril is an ACE inhibitor not associated with ototoxic effects.",
      "Atorvastatin": "Incorrect – Statins are not linked to hearing loss or ototoxicity.",
      "Doxycycline": "Incorrect – This antibiotic does not have ototoxic properties.",
      "Metformin": "Incorrect – An oral hypoglycaemic agent without known ototoxic potential."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Hearing loss causes",
    "topic": "Hearing loss causes",
    "keywords": [
      "ototoxicity",
      "quinine",
      "hearing loss",
      "sensorineural",
      "medication adverse effect"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hearing loss in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hearing-loss-in-adults/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7c15164f-695d-4274-8b90-5a062c85142f",
    "question_number": 8,
    "question": "A 4-year-old boy with a known history of atopic dermatitis presents to the emergency department with a sudden outbreak of painful, grouped vesicles on his forehead and periorbital region. His skin appears inflamed, and he has a low-grade fever. What is the most appropriate next step in his management?",
    "options": [
      "Arrange same-day hospital admission for systemic antiviral therapy",
      "Start topical hydrocortisone cream",
      "Prescribe an oral antibiotic",
      "Advise increased emollient use and monitor at home",
      "Apply topical fusidic acid"
    ],
    "correct_answer": "Arrange same-day hospital admission for systemic antiviral therapy",
    "explanation": "**Explanation**\n**Eczema herpeticum** is a severe viral infection caused by herpes simplex virus superimposed on atopic eczema. It presents with rapidly worsening, painful eczema and clusters of vesicles, often accompanied by fever. This is a dermatological emergency due to the risk of systemic dissemination and severe complications, including ocular involvement or secondary bacterial infection. The correct approach is immediate hospital admission for systemic antiviral treatment, typically intravenous aciclovir, under specialist supervision. **Topical steroids or antibiotics will not address the underlying viral infection and could worsen the condition.**\n\n**Key Points**\n- Eczema herpeticum = herpes simplex infection complicating atopic eczema\n- Key features: sudden worsening, painful grouped blisters/erosions, fever\n- Urgent systemic antiviral therapy (e.g., IV aciclovir) is required\n- Delay can result in severe or life-threatening complications\n- Topical or oral antibiotics are ineffective against herpes simplex\n- Topical steroids risk worsening viral infections\n\n**Clinical Relevance**\nEczema herpeticum is a paediatric dermatological emergency. Early recognition and prompt referral for antiviral therapy are critical to prevent serious morbidity. NICE and BNF guidelines stress the need for same-day specialist management when this diagnosis is suspected.\n\n**Memory Anchor**\nHerpeticum = Hospital (HH): Herpeticum needs Hospital care.",
    "bullet_explanations": {
      "Arrange same-day hospital admission for systemic antiviral therapy": "Correct. Eczema herpeticum requires urgent hospital admission and IV antivirals.",
      "Start topical hydrocortisone cream": "Incorrect. Topical steroids may worsen viral skin infections and are contraindicated here.",
      "Prescribe an oral antibiotic": "Incorrect. Antibiotics treat secondary bacterial infection, not the primary viral cause.",
      "Advise increased emollient use and monitor at home": "Incorrect. This delays essential antiviral therapy and puts the child at risk.",
      "Apply topical fusidic acid": "Incorrect. Fusidic acid is for bacterial skin infection, not herpes simplex virus."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Common Infections",
    "topic": "Eczema herpeticum",
    "keywords": [
      "eczema herpeticum",
      "herpes simplex",
      "paediatric dermatology",
      "antiviral admission"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Eczema",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/eczema/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Eczema - atopic",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/eczema-atopic/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2a4a63a0-59ec-43bf-ab59-c66600f0f5f7",
    "question_number": 9,
    "question": "A 39-year-old man presents with anxiety, unexplained weight loss, and tremor. On examination, he has bilateral lid retraction and a smooth, symmetrically enlarged thyroid. What is the expected pattern on a radioactive iodine uptake scan in the most likely diagnosis?",
    "options": [
      "Diffuse, increased uptake throughout the thyroid gland",
      "Single 'hot' nodule with background suppression",
      "Multiple patchy areas of increased and decreased uptake",
      "Minimal uptake across the gland",
      "No detectable uptake"
    ],
    "correct_answer": "Diffuse, increased uptake throughout the thyroid gland",
    "explanation": "**Explanation**\n**Graves' disease** is the most common cause of hyperthyroidism with eye involvement (orbitopathy) and a symmetrically enlarged, non-nodular goitre. On a radioactive iodine uptake scan, the hallmark finding is a **homogenous, diffusely increased uptake** across the entire thyroid gland. This reflects the global stimulation of the gland by TSH receptor antibodies. In contrast, other causes of hyperthyroidism—such as toxic multinodular goitre or solitary toxic adenoma—display focal or patchy uptake patterns. Thyroiditis or exogenous hormone use are associated with low or absent uptake.\n\n**Key Points**\n- Graves' disease: diffuse, homogenous increased uptake\n- Toxic nodular goitre: patchy or multiple focal uptake\n- Toxic adenoma: single hot nodule with suppressed background\n- Thyroiditis: low or absent uptake\n- Ophthalmopathy is strongly suggestive of Graves' disease\n\n**Clinical Relevance**\nRecognising the typical uptake pattern in Graves' disease is essential for differentiating it from other causes of thyrotoxicosis. This guides management and ensures appropriate identification of associated complications such as Graves' orbitopathy. Refer to NICE and BNF guidance for investigation and management of hyperthyroidism.",
    "bullet_explanations": {
      "Diffuse, increased uptake throughout the thyroid gland": "Correct – this is typical of Graves' disease due to global stimulation by autoantibodies.",
      "Single 'hot' nodule with background suppression": "Incorrect – seen in toxic adenoma, not associated with diffuse goitre or orbitopathy.",
      "Multiple patchy areas of increased and decreased uptake": "Incorrect – seen in toxic multinodular goitre, usually with nodular thyroid on exam.",
      "Minimal uptake across the gland": "Incorrect – would be expected in subacute thyroiditis or following recent iodine exposure.",
      "No detectable uptake": "Incorrect – characteristic of thyroiditis or exogenous thyroid hormone use, not Graves' disease."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Thyroid",
    "subsubsection": "Hyperthyroidism",
    "topic": "Graves vs toxic nodular goitre",
    "keywords": [
      "Graves' disease",
      "radioactive iodine uptake",
      "hyperthyroidism",
      "thyroid scan",
      "orbitopathy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hyperthyroidism",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hyperthyroidism/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Hyperthyroidism",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hyperthyroidism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d2c3d042-f41f-46af-b2fb-a919724af3dd",
    "question_number": 10,
    "question": "A 3-month-old girl presents to the health visitor with persistent diarrhoea, frequent regurgitation, and an itchy, erythematous rash. Her symptoms began a few days after she transitioned from exclusive breastfeeding to standard cow’s milk-based formula. She is otherwise well, with normal weight gain and no respiratory distress. What is the most appropriate formula to recommend next for this infant?",
    "options": [
      "Extensively hydrolysed formula",
      "Amino acid-based formula",
      "Lactose-free formula",
      "Soy-based formula",
      "High-calorie formula"
    ],
    "correct_answer": "Extensively hydrolysed formula",
    "explanation": "**Explanation**\n**Extensively hydrolysed formula** is the recommended initial alternative for infants with suspected mild-to-moderate cow’s milk protein allergy. In these formulas, cow’s milk proteins are broken down into small peptides, significantly reducing their allergenicity while still providing adequate nutrition. This approach is effective in the majority of affected infants. Amino acid-based formulas are reserved for severe or refractory cases, as they are less palatable and more expensive. Lactose-free and soy-based formulas are not first-line for cow’s milk protein allergy: the former addresses lactose intolerance, not protein allergy, and the latter is not recommended in infants under 6 months due to potential allergenicity and phytoestrogen content. High-calorie formulas are typically used for infants with increased nutritional needs, not for allergy management.\n\n**Key Points**\n- Cow’s milk protein allergy is common in infancy, presenting with gastrointestinal and dermatological symptoms.\n- Extensively hydrolysed formula is suitable for most cases of mild-to-moderate cow’s milk allergy.\n- Amino acid-based formula is reserved for severe or treatment-resistant cases.\n- Soy-based formulas are generally avoided in infants under 6 months.\n- Lactose-free formulas treat lactose intolerance, not protein allergy.\n- <table><thead><tr><th>Formula Type</th><th>Indication</th></tr></thead><tbody><tr><td>Extensively hydrolysed</td><td>Mild-moderate cow's milk allergy</td></tr><tr><td>Amino acid-based</td><td>Severe/refractory allergy</td></tr><tr><td>Lactose-free</td><td>Lactose intolerance</td></tr><tr><td>Soy-based</td><td>Alternative >6 months if needed</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising and appropriately managing cow’s milk protein allergy is essential to prevent ongoing symptoms, nutritional compromise, and carer distress. NICE guidelines recommend extensively hydrolysed formulas for most infants with mild-to-moderate allergy, reserving escalation to amino acid-based formulas for severe or non-responding cases.",
    "bullet_explanations": {
      "Extensively hydrolysed formula": "Correct – first-line for most infants with suspected cow’s milk protein allergy.",
      "Amino acid-based formula": "Incorrect – indicated only in severe or refractory allergy cases.",
      "Lactose-free formula": "Incorrect – used for lactose intolerance, not protein allergy.",
      "Soy-based formula": "Incorrect – not recommended under 6 months due to risk of allergy and phytoestrogen exposure.",
      "High-calorie formula": "Incorrect – used for infants with increased energy needs, not for allergy management."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Nutrition & Development",
    "topic": "Iron deficiency anaemia",
    "keywords": [
      "cow's milk protein allergy",
      "hydrolysed formula",
      "infant feeding",
      "paediatrics"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cow's milk allergy in children",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cows-milk-allergy-in-children/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "01ef5cc3-a030-4971-97d8-59425c8c6fb4",
    "question_number": 11,
    "question": "A 7-year-old girl is brought to the emergency department with a 3-day history of fever, right-sided ear pain, and new onset swelling behind the right ear. Her temperature is 38.7°C. Examination reveals a tender, erythematous swelling over the mastoid process with the pinna pushed forwards. What is the most appropriate immediate management step?",
    "options": [
      "Urgent ENT referral for hospital admission",
      "Start oral amoxicillin and review in 48 hours",
      "Prescribe topical antibiotic and steroid ear drops",
      "Advise regular analgesia and safety-netting only",
      "Arrange outpatient audiology assessment"
    ],
    "correct_answer": "Urgent ENT referral for hospital admission",
    "explanation": "**Explanation**\n**Mastoiditis is a serious complication of acute otitis media** characterised by swelling, erythema, and tenderness over the mastoid bone, often with displacement of the pinna. This presentation indicates a likely extension of infection beyond the middle ear, which can quickly progress to life-threatening intracranial complications. **Immediate ENT referral for hospital admission** is essential for prompt specialist assessment, intravenous antibiotics, and possible surgical intervention. Oral antibiotics or conservative measures are inappropriate in the presence of suspected mastoiditis or other severe complications.\n\n**Key Points**\n- Mastoiditis should be suspected with post-auricular swelling, erythema, and protruding pinna.\n- Hospital admission is required for suspected acute otitis media complications (mastoiditis, meningitis, facial nerve palsy).\n- Delays in specialist management risk serious morbidity, including intracranial spread.\n- Oral antibiotics alone are insufficient for complicated cases.\n- Outpatient management is unsuitable when red flag features are present.\n\n**Clinical Relevance**\nRecognising and urgently referring children with complications of acute otitis media aligns with NICE and BNF guidance to improve outcomes and prevent severe sequelae. Early specialist input is vital in suspected mastoiditis.\n\n**Memory Anchor**\nThink 'Mastoiditis = Mastoid swelling = Must admit'.",
    "bullet_explanations": {
      "Urgent ENT referral for hospital admission": "Correct—mastoiditis is a medical emergency requiring immediate specialist input.",
      "Start oral amoxicillin and review in 48 hours": "Incorrect—oral antibiotics are inadequate for suspected mastoiditis or severe complications.",
      "Prescribe topical antibiotic and steroid ear drops": "Incorrect—topical therapy is not effective for middle ear or mastoid infections and inappropriate here.",
      "Advise regular analgesia and safety-netting only": "Incorrect—conservative measures are unsafe in the presence of a suspected complication.",
      "Arrange outpatient audiology assessment": "Incorrect—hearing assessment does not address the acute and potentially life-threatening infection."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Otitis media (acute/effusion)",
    "keywords": [
      "mastoiditis",
      "acute otitis media complications",
      "ENT emergency",
      "paediatric ENT",
      "mastoid swelling"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Otitis media - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/otitis-media-acute/"
      },
      {
        "source": "BNF",
        "topic_title": "Ear",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/ear/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c31cd237-6afb-4a01-8597-eeac612b645d",
    "question_number": 12,
    "question": "A 25-year-old woman at 18 weeks' gestation attends her GP with dysuria and urinary urgency. Urinalysis is positive for nitrites and leucocytes. What is the most appropriate initial management?",
    "options": [
      "Start nitrofurantoin and send a midstream urine sample for culture",
      "Advise increased fluid intake and cranberry products",
      "Prescribe ciprofloxacin empirically",
      "Start doxycycline after obtaining a urine sample",
      "Monitor symptoms only and defer antibiotics"
    ],
    "correct_answer": "Start nitrofurantoin and send a midstream urine sample for culture",
    "explanation": "**Explanation**\nPregnant women presenting with symptomatic urinary tract infection require **immediate antibacterial therapy** due to increased risks of maternal and fetal complications. **Nitrofurantoin is the recommended first-line agent** for uncomplicated lower UTI in pregnancy, provided it is not used in the last trimester (due to risk of neonatal haemolysis). Prior to starting treatment, a **midstream urine sample should be sent for culture and sensitivity** to guide therapy. Options such as ciprofloxacin and doxycycline are contraindicated in pregnancy due to potential adverse fetal effects. Non-antibiotic approaches, such as cranberry products or watchful waiting, are inappropriate as they do not address the infection and do not prevent complications.\n\n**Key Points**\n- Symptomatic UTI in pregnancy requires urgent empirical antibiotic treatment\n- Nitrofurantoin is first-line unless near term\n- Obtain MSU for culture before starting antibiotics\n- Ciprofloxacin and doxycycline are contraindicated in pregnancy\n- Delaying treatment or using non-antibiotic measures risks maternal and fetal harm\n\n**Clinical Relevance**\nPrompt recognition and treatment of UTI in pregnancy is essential to reduce risk of pyelonephritis, preterm labour, and fetal morbidity. UK guidelines recommend immediate empiric therapy and confirmatory culture in all pregnant women presenting with UTI symptoms.",
    "bullet_explanations": {
      "Start nitrofurantoin and send a midstream urine sample for culture": "Correct – This follows guideline-recommended management for symptomatic UTI in pregnancy.",
      "Advise increased fluid intake and cranberry products": "Incorrect – Fluids and cranberry products may help prevent recurrent UTI, but do not treat active infection.",
      "Prescribe ciprofloxacin empirically": "Incorrect – Ciprofloxacin is contraindicated in pregnancy due to risk of fetal musculoskeletal toxicity.",
      "Start doxycycline after obtaining a urine sample": "Incorrect – Doxycycline is contraindicated in pregnancy due to teratogenic risks.",
      "Monitor symptoms only and defer antibiotics": "Incorrect – Delaying antibiotics in symptomatic pregnant women risks serious maternal and fetal complications."
    },
    "category": "Renal & Urology",
    "subsection": "Urology",
    "subsubsection": "Infections",
    "topic": "UTIs in pregnancy",
    "keywords": [
      "UTI",
      "pregnancy",
      "nitrofurantoin",
      "urine culture",
      "antibiotics"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Urinary-tract infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/urinary-tract-infections/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4accc5e6-7b9d-4ab1-ae20-0e59bb0878c4",
    "question_number": 13,
    "question": "Which long-term complication is most strongly associated with recurrent untreated Neisseria gonorrhoeae infections in women?",
    "options": [
      "Infertility due to pelvic inflammatory disease",
      "Development of cervical cancer",
      "Ovarian abscess formation",
      "Reactive arthritis",
      "Lymphogranuloma venereum"
    ],
    "correct_answer": "Infertility due to pelvic inflammatory disease",
    "explanation": "**Explanation**\n**Infertility due to pelvic inflammatory disease (PID)** is the most common and significant long-term complication of repeated gonorrhoea infections in women. Gonorrhoea, caused by Neisseria gonorrhoeae, can ascend from the lower genital tract to infect the upper reproductive organs, leading to PID. Chronic or recurrent PID results in scarring and adhesions within the fallopian tubes, which increases the risk of tubal factor infertility. While other complications such as disseminated infection and arthritis can occur, infertility secondary to PID is the primary concern after repeated or untreated infections. Notably, lymphogranuloma venereum is caused by specific serovars of Chlamydia trachomatis, not gonorrhoea, and cervical cancer is primarily associated with persistent HPV infection rather than Neisseria gonorrhoeae.\n\n**Key Points**\n- Gonorrhoea is a common cause of pelvic inflammatory disease (PID) in women.\n- Repeated or untreated infections significantly raise the risk of tubal scarring and infertility.\n- PID can present with pelvic pain, abnormal bleeding, and may be asymptomatic in some cases.\n- Cervical cancer is associated with human papillomavirus (HPV) infection, not gonorrhoea.\n- Lymphogranuloma venereum is a complication of Chlamydia trachomatis, not Neisseria gonorrhoeae.\n- Arthropathy (reactive arthritis) can occur but is much less frequent than infertility.\n- <table><thead><tr><th>Complication</th><th>Most Common Causative STI</th></tr></thead><tbody><tr><td>PID/Infertility</td><td>Chlamydia, Gonorrhoea</td></tr><tr><td>Cervical cancer</td><td>HPV</td></tr><tr><td>LGV</td><td>Chlamydia (L1-L3)</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising and promptly treating gonorrhoea is essential to prevent PID and its sequelae, including infertility. This underlines the importance of sexual health screening, partner notification, and adherence to national guidelines for STI management.",
    "bullet_explanations": {
      "Infertility due to pelvic inflammatory disease": "Correct: Chronic or recurrent gonorrhoea can lead to PID, which is a leading cause of tubal infertility in women.",
      "Development of cervical cancer": "Incorrect: Cervical cancer is primarily linked to persistent HPV infection, not Neisseria gonorrhoeae.",
      "Ovarian abscess formation": "Incorrect: Though tubo-ovarian abscess can result from PID, it is a less common complication than infertility.",
      "Reactive arthritis": "Incorrect: Gonococcal infection can rarely cause reactive arthritis, but this is far less common than infertility due to PID.",
      "Lymphogranuloma venereum": "Incorrect: LGV is caused by certain Chlamydia trachomatis serovars, not gonorrhoea."
    },
    "category": "STIs & Sexual Health",
    "subsection": "STIs",
    "subsubsection": "Gonorrhoea",
    "topic": "Gonorrhoea",
    "keywords": [
      "gonorrhoea",
      "pelvic inflammatory disease",
      "infertility",
      "complications",
      "STI"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Gonorrhoea",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/gonorrhoea/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7e63c3a8-f550-4f36-926d-c92a7aa1c70e",
    "question_number": 14,
    "question": "A 45-year-old man with a history of moderate depression is commenced on sertraline after limited response to psychological therapy. He presents to clinic asking about starting a new medication for his recently diagnosed Parkinson’s disease. Which of the following medications should not be prescribed concurrently with sertraline due to the risk of a serious drug interaction?",
    "options": [
      "Rasagiline",
      "Levodopa",
      "Amoxicillin",
      "Paracetamol",
      "Entacapone"
    ],
    "correct_answer": "Rasagiline",
    "explanation": "**Explanation**\n**Rasagiline is a monoamine oxidase inhibitor (MAOI)**, and combining an MAOI with a selective serotonin reuptake inhibitor (SSRI) such as sertraline is contraindicated due to the risk of developing serotonin syndrome. Serotonin syndrome is a potentially life-threatening condition, presenting with symptoms such as neuromuscular hyperactivity, altered mental status, and autonomic instability. To avoid this, a washout period (typically 14 days) should be observed when switching between these classes. Other antiparkinsonian drugs listed do not share this risk. **MAOIs and SSRIs must never be co-prescribed.**\n\n**Key Points**\n- SSRIs (e.g., sertraline) and MAOIs (e.g., rasagiline) should not be combined.\n- Serotonin syndrome can result from this combination: features include agitation, hyperreflexia, fever, and confusion.\n- A 14-day washout period is recommended when switching between SSRIs and MAOIs.\n- Other Parkinson’s drugs such as levodopa and entacapone do not cause this interaction.\n- MAOIs interact with many drugs and certain foods—specialist oversight is required.\n\n**Clinical Relevance**\nAwareness of antidepressant–MAOI interactions is essential in both primary and specialist care, particularly as patients with depression may develop comorbidities requiring polypharmacy. Prescribing these together risks serotonin syndrome, which is a medical emergency. This contraindication is emphasised in national guidelines and drug formularies, such as the BNF.\n\n**Memory Anchor**\nRemember: **'S' for Serotonin, 'S' for Syndrome, 'S' for SSRI + MAOI = Stop!**",
    "bullet_explanations": {
      "Rasagiline": "Correct – It is an MAOI that can cause serotonin syndrome if taken with an SSRI.",
      "Levodopa": "Incorrect – Levodopa does not interact dangerously with SSRIs.",
      "Amoxicillin": "Incorrect – There is no significant interaction between amoxicillin and SSRIs.",
      "Paracetamol": "Incorrect – Paracetamol is safe to use with sertraline.",
      "Entacapone": "Incorrect – Entacapone does not interact with SSRIs in a clinically significant way."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Depression",
    "topic": "SSRIs vs alternatives",
    "keywords": [
      "SSRIs",
      "MAOIs",
      "serotonin syndrome",
      "drug interactions",
      "depression"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Depression",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/depression/"
      },
      {
        "source": "BNF",
        "topic_title": "Antidepressant drugs",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antidepressant-drugs/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5f08b431-73d5-4eed-bb36-a358dd50af3e",
    "question_number": 15,
    "question": "Which ECG leads typically demonstrate ST-segment elevation in an acute inferior myocardial infarction associated with bradycardia and first-degree heart block?",
    "options": [
      "II, III and aVF",
      "V1 to V4",
      "I, aVL, V5 and V6",
      "Global ST elevation in all leads",
      "aVR and V1"
    ],
    "correct_answer": "II, III and aVF",
    "explanation": "**Explanation**\n**Inferior myocardial infarctions** involve the inferior wall of the left ventricle, which is usually supplied by the right coronary artery (RCA). The RCA also often supplies the atrioventricular (AV) node, so infarction in this territory can disrupt conduction and result in bradycardia or varying degrees of heart block (e.g., first-degree AV block). **ST-segment elevation in leads II, III, and aVF** on the ECG is the hallmark of inferior MI. This pattern contrasts with anterior MI (seen in V1-V4), lateral MI (I, aVL, V5, V6), or pericarditis (which causes widespread/global ST elevation). Recognition of this pattern is crucial for prompt diagnosis and management.\n\n**Key Points**\n- Inferior MI most often results from occlusion of the right coronary artery.\n- ECG leads II, III, and aVF correspond to the inferior wall of the left ventricle.\n- Inferior MI can cause AV nodal block and bradycardia due to RCA involvement.\n- Anterior MI is reflected in V1–V4; lateral MI in I, aVL, V5, V6.\n- Global ST elevation suggests pericarditis, not isolated MI.\n\n**Clinical Relevance**\nRecognising the classic ECG territories for myocardial infarction is essential for rapid diagnosis and initiation of reperfusion therapy. Inferior STEMI, especially when accompanied by bradycardia or heart block, points to RCA involvement and may require specific consideration for pacing or avoiding certain drugs. Mastery of ECG localisation underpins acute cardiac care in line with current guidelines.\n\n**Memory Anchor**\nInferior = 'I, II, III' (but really II, III, aVF); RCA supplies both inferior wall and AV node—think 'Right supplies Rhythm'.",
    "bullet_explanations": {
      "II, III and aVF": "Correct: These leads reflect the inferior wall and show ST elevation in inferior MI due to RCA occlusion.",
      "V1 to V4": "Incorrect: ST elevation here indicates anteroseptal MI (LAD territory), not inferior MI.",
      "I, aVL, V5 and V6": "Incorrect: These leads demonstrate changes in lateral MI, not inferior wall infarction.",
      "Global ST elevation in all leads": "Incorrect: This is seen in pericarditis, not in isolated myocardial infarction.",
      "aVR and V1": "Incorrect: ST elevation in aVR may indicate left main or proximal LAD occlusion and not inferior MI."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Acute Coronary Syndromes",
    "topic": "STEMI recognition (ECG criteria, posterior/Right-sided MI)",
    "keywords": [
      "inferior MI",
      "ECG",
      "ST elevation",
      "right coronary artery",
      "first-degree heart block"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "MI - secondary prevention",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/mi-secondary-prevention/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ec5e8092-7dd5-4344-86fc-ca6a022f3ed1",
    "question_number": 16,
    "question": "Which major arterial system is most commonly implicated in posterior circulation ischaemic strokes presenting with isolated visual field deficits?",
    "options": [
      "Vertebrobasilar arteries",
      "Anterior cerebral artery",
      "Middle cerebral artery",
      "Perforating arteries of the basal ganglia",
      "Posterior inferior cerebellar artery"
    ],
    "correct_answer": "Vertebrobasilar arteries",
    "explanation": "**Explanation**\nPosterior circulation strokes typically result from occlusion within the **vertebrobasilar arterial system**, which supplies the brainstem, cerebellum, occipital lobes, and parts of the thalamus. Clinical features such as homonymous hemianopia or cortical blindness often point to infarction in areas supplied by the posterior cerebral arteries, which are branches of the vertebrobasilar system. This contrasts with anterior circulation strokes, which commonly involve the middle and anterior cerebral arteries and present with motor, sensory, or higher cortical deficits. **Key fact:** Visual field loss (e.g., hemianopia) is a classic sign of posterior circulation involvement.\n\n**Key Points**\n- Posterior circulation infarcts (POCI) involve the vertebrobasilar arterial system.\n- The vertebrobasilar system supplies the brainstem, cerebellum, and occipital lobes.\n- Visual symptoms (e.g., hemianopia, cortical blindness) often suggest posterior circulation involvement.\n- Anterior circulation strokes affect motor/sensory cortex and higher cognitive functions.\n- Lacunar strokes involve deep perforating arteries and present differently.\n\n**Clinical Relevance**\nCorrectly identifying the vascular territory in stroke is critical for acute management and prognosis. NICE and BNF guidelines emphasise prompt recognition and multidisciplinary care for all stroke types, with tailored secondary prevention strategies depending on the affected vascular territory.\n\n**Memory Anchor**\nPOCI = Posterior (vertebrobasilar) = Problems with vision and balance",
    "bullet_explanations": {
      "Vertebrobasilar arteries": "Correct – These vessels supply the posterior brain regions most often affected in POCI-type strokes.",
      "Anterior cerebral artery": "Incorrect – This artery is part of the anterior circulation, typically causing contralateral leg weakness.",
      "Middle cerebral artery": "Incorrect – Involved in anterior circulation strokes, leading to face/arm weakness and aphasia.",
      "Perforating arteries of the basal ganglia": "Incorrect – Occlusion produces lacunar (LACI) strokes, not predominantly visual symptoms.",
      "Posterior inferior cerebellar artery": "Incorrect – Linked to lateral medullary (Wallenberg’s) syndrome, not isolated visual field defects."
    },
    "category": "Neurology",
    "subsection": "Stroke & TIA",
    "subsubsection": "FAST/TIA recognition",
    "topic": "Stroke: types",
    "keywords": [
      "posterior circulation infarct",
      "vertebrobasilar",
      "stroke types",
      "visual field loss"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Stroke and TIA",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/stroke-tia/"
      },
      {
        "source": "BNF",
        "topic_title": "Stroke",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/stroke/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2bbd439f-261d-4517-b080-64c97d928e1e",
    "question_number": 17,
    "question": "A 55-year-old man presents with newly developed, rapidly progressing hyperpigmented, velvety plaques in his neck and axillae, accompanied by significant, unexplained weight loss over the past three months. Which type of malignancy is most frequently associated with the sudden onset of acanthosis nigricans in adults?",
    "options": [
      "Gastric adenocarcinoma",
      "Renal cell carcinoma",
      "Ductal carcinoma of the breast",
      "Pancreatic adenocarcinoma",
      "Multiple myeloma"
    ],
    "correct_answer": "Gastric adenocarcinoma",
    "explanation": "**Explanation**\n**Acanthosis nigricans** is characterised by hyperpigmented, velvety skin thickening—most commonly affecting flexural areas such as the neck, axillae, and groin. While this dermatological sign is often linked to benign causes (obesity, insulin resistance), its **abrupt onset and rapid progression in adults, especially with systemic symptoms like weight loss**, strongly suggest a paraneoplastic process. The malignancy most closely associated with malignant acanthosis nigricans is **gastric adenocarcinoma**. Over 90% of cases of malignancy-associated acanthosis nigricans are due to adenocarcinomas of the gastrointestinal tract, with the stomach being the predominant site. Other cancers may rarely be linked, but gastric adenocarcinoma remains the classic and most frequent association. \n\nThis contrasts with breast ductal carcinoma (classically associated with extramammary Paget's disease), pancreatic cancer (linked with migratory thrombophlebitis), and multiple myeloma (which may cause other skin signs such as pityriasis rotunda, but not acanthosis nigricans).\n\n**Key Points**\n<ul><li>Malignant acanthosis nigricans typically presents suddenly in adults with systemic symptoms.</li><li>Gastric adenocarcinoma is the most common underlying cancer.</li><li>Other GI adenocarcinomas can occasionally be implicated.</li><li>Benign causes are more likely in children or gradual onset cases.</li><li>Other malignancies have distinct paraneoplastic skin syndromes.</li></ul><table><thead><tr><th>Skin Sign</th><th>Associated Malignancy</th></tr></thead><tbody><tr><td>Acanthosis nigricans</td><td>Gastric adenocarcinoma</td></tr><tr><td>Extramammary Paget's</td><td>Breast carcinoma</td></tr><tr><td>Migratory thrombophlebitis</td><td>Pancreatic adenocarcinoma</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising acanthosis nigricans as a potential paraneoplastic marker is essential for early cancer detection. In adults with sudden onset and systemic features, prompt investigation for underlying malignancy—particularly gastric adenocarcinoma—is warranted.\n\n**Memory Anchor**\nThink **'A'**canthosis nigricans for **'A'denocarcinoma** (especially of the stomach).",
    "bullet_explanations": {
      "Gastric adenocarcinoma": "Correct – most commonly linked to malignant acanthosis nigricans.",
      "Renal cell carcinoma": "Incorrect – not classically associated with acanthosis nigricans.",
      "Ductal carcinoma of the breast": "Incorrect – more often associated with extramammary Paget’s disease.",
      "Pancreatic adenocarcinoma": "Incorrect – linked with Trousseau's syndrome, not acanthosis nigricans.",
      "Multiple myeloma": "Incorrect – may cause other cutaneous findings, not acanthosis nigricans."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Upper GI",
    "subsubsection": "Dyspepsia & H. pylori",
    "topic": "Alarm features and 2WW criteria",
    "keywords": [
      "acanthosis nigricans",
      "paraneoplastic",
      "gastric adenocarcinoma",
      "skin signs",
      "weight loss"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Melanoma",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/melanoma/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f7e66a08-b045-4859-9519-9f1cf0d523db",
    "question_number": 18,
    "question": "A 68-year-old man with a history of progressive central vision loss is diagnosed with dry (atrophic) age-related macular degeneration (AMD). He is already using low vision aids and taking recommended supplements. Which of the following best describes the current role of medical or surgical treatment for dry AMD in the UK?",
    "options": [
      "There are no proven medical or surgical treatments to reverse or halt dry AMD progression",
      "Photodynamic therapy is recommended to slow disease progression",
      "Intravitreal anti-VEGF injections are first line for all AMD types",
      "Laser photocoagulation is indicated in dry AMD to preserve vision",
      "Retinal transplantation is an emerging standard of care for dry AMD"
    ],
    "correct_answer": "There are no proven medical or surgical treatments to reverse or halt dry AMD progression",
    "explanation": "**Explanation**\n**Dry age-related macular degeneration (AMD) currently has no effective pharmacological or surgical treatment to reverse or halt its progression.** Management focuses on supportive measures, such as visual aids and lifestyle advice, including smoking cessation and nutritional support. While anti-VEGF injections and certain laser therapies show benefit in wet (neovascular) AMD, they are not indicated for dry AMD, which lacks abnormal vessel growth. No retinal transplantation or restorative procedure is available in standard UK practice. Ongoing research continues, but at present, only monitoring and supportive care are recommended.\n\n**Key Points**\n- Dry AMD is managed supportively; no disease-modifying therapies are approved.\n- Anti-VEGF and laser treatments are used only for wet (neovascular) AMD.\n- Visual aids and lifestyle interventions (e.g., smoking cessation) may help maintain function.\n- Retinal transplantation is not available in routine clinical care.\n- Photodynamic therapy is not recommended for dry AMD.\n\n**Clinical Relevance**\nRecognising the distinction between dry and wet AMD is crucial for directing appropriate management and avoiding unnecessary or potentially harmful interventions. UK guidelines (NICE, BNF) stress that only patients with wet-active AMD should be considered for intravitreal anti-VEGF therapy, while dry AMD management remains supportive.",
    "bullet_explanations": {
      "There are no proven medical or surgical treatments to reverse or halt dry AMD progression": "Correct – Only supportive care and risk factor modification are recommended for dry AMD.",
      "Photodynamic therapy is recommended to slow disease progression": "Incorrect – Photodynamic therapy is not indicated for dry AMD; it may be used as adjunct in wet AMD in specific circumstances.",
      "Intravitreal anti-VEGF injections are first line for all AMD types": "Incorrect – Anti-VEGF injections are effective only for wet AMD, not dry AMD.",
      "Laser photocoagulation is indicated in dry AMD to preserve vision": "Incorrect – Laser photocoagulation is not used for dry AMD and is now largely obsolete for most AMD treatment.",
      "Retinal transplantation is an emerging standard of care for dry AMD": "Incorrect – Retinal transplantation is not a clinical option for AMD at present."
    },
    "category": "Ophthalmology",
    "subsection": "Retinal Disorders",
    "subsubsection": "Age-related macular degeneration",
    "topic": "Age-related macular degeneration",
    "keywords": [
      "dry AMD",
      "macular degeneration",
      "supportive management",
      "anti-VEGF",
      "photodynamic therapy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Age-related macular degeneration",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/age-related-macular-degeneration/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Macular degeneration - age-related",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/macular-degeneration-age-related/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "437c26c1-7723-4140-934a-a7418bb580bb",
    "question_number": 19,
    "question": "A 38-year-old woman with a history of severe asthma is prescribed a prolonged course of oral corticosteroids to manage recurrent exacerbations. Which adverse effect is most commonly associated with long-term systemic corticosteroid therapy?",
    "options": [
      "Insomnia",
      "Hyponatraemia",
      "Neutropenia",
      "Bronchospasm",
      "Hyperkalaemia"
    ],
    "correct_answer": "Insomnia",
    "explanation": "**Explanation**\n**Insomnia is a frequent and well-recognised complication of extended systemic corticosteroid use.** Glucocorticoids such as prednisolone disrupt normal circadian rhythms and affect the hypothalamic-pituitary-adrenal (HPA) axis, leading to difficulty initiating or maintaining sleep. The risk is heightened when steroids are taken later in the day, as this further interferes with natural sleep-wake cycles. Recognising and managing this side effect is an important part of patient counselling when prescribing long-term corticosteroids.\n\n**Key Points**\n- Long-term corticosteroid use often causes **sleep disturbances, especially insomnia**.\n- Corticosteroids influence both slow-wave and REM sleep architecture.\n- Adverse effects are more pronounced with evening dosing.\n- Other common side effects include hyperglycaemia, hypertension, and mood changes.\n- Corticosteroids generally **increase sodium retention and potassium loss**, not hyperkalaemia.\n- They can cause **neutrophilia** (not neutropenia) and are not associated with bronchospasm.\n- Hyponatraemia is not characteristic; sodium retention is more common.\n\n**Clinical Relevance**\nInsomnia can significantly affect a patient's quality of life and adherence to therapy. Recognising this risk allows clinicians to advise on morning dosing and implement strategies to minimise sleep disruption. Monitoring for other adverse effects is also essential in long-term corticosteroid therapy, as highlighted in national guidelines.\n\n**Memory Anchor**\nSteroids keep you 'wired'—think of **'steroid sleeplessness'** as a hallmark adverse effect.",
    "bullet_explanations": {
      "Insomnia": "Correct—long-term corticosteroid use frequently causes insomnia due to circadian disruption.",
      "Hyponatraemia": "Incorrect—corticosteroids more often cause sodium retention and fluid overload, not hyponatraemia.",
      "Neutropenia": "Incorrect—corticosteroids tend to cause a rise in neutrophils (neutrophilia), not a reduction.",
      "Bronchospasm": "Incorrect—systemic corticosteroids are used to treat, not cause, bronchospasm.",
      "Hyperkalaemia": "Incorrect—these drugs promote potassium loss, potentially causing hypokalaemia, not hyperkalaemia."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBD",
    "topic": "Steroid-sparing and biologics overview",
    "keywords": [
      "corticosteroid adverse effects",
      "insomnia",
      "prednisolone",
      "long-term steroid therapy",
      "IBD management"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Ulcerative colitis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/ulcerative-colitis/"
      },
      {
        "source": "BNF",
        "topic_title": "Corticosteroids, general use",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/corticosteroids-general-use/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f230501b-087c-457b-a703-eb6ce223ff82",
    "question_number": 20,
    "question": "An elderly woman presents with a persistent, exquisitely painful nodule on the rim of her right ear, present for several months and interfering with sleep. The lesion is firm, well-circumscribed, and has a slight scale but no ulceration or rapid growth. What is the most likely diagnosis?",
    "options": [
      "Chondrodermatitis nodularis helicis",
      "Basal cell carcinoma",
      "Actinic keratosis",
      "Squamous cell carcinoma",
      "Keratoacanthoma"
    ],
    "correct_answer": "Chondrodermatitis nodularis helicis",
    "explanation": "**Explanation**\nChondrodermatitis nodularis helicis presents as a **painful, well-demarcated nodule on the helix or antihelix of the ear**, predominantly affecting older adults. The pain is often severe, especially when pressure is applied (e.g., lying on the ear), and the lesion remains stable over many months. **Rapid growth and ulceration are not typical features.** In contrast, basal cell and squamous cell carcinomas tend to evolve more slowly or may ulcerate, but are rarely as painful. Actinic keratosis may cause scaling but is generally not tender, and keratoacanthomas grow rapidly then regress, unlike the chronicity seen here.\n\n**Key Points**\n- Chondrodermatitis nodularis helicis: benign, chronic, painful nodule of the ear rim\n- Pain and tenderness out of proportion to other differentials\n- Lesion is firm, well-circumscribed, often with a slight scale\n- Most common in older males but can affect women\n- Basal cell carcinoma: rarely painful, slow-growing, sometimes ulcerated\n- Squamous cell carcinoma: faster-growing, may ulcerate, less likely to be so painful\n- Actinic keratosis: scaly, sun-exposed sites, not usually tender\n- Keratoacanthoma: rapid growth, then spontaneous resolution\n\n**Clinical Relevance**\nRecognising chondrodermatitis nodularis helicis is important to avoid unnecessary concern over malignancy and to provide reassurance and conservative management. Its distinct pain and chronicity help differentiate it from skin cancers and pre-malignant lesions.\n\n**Memory Anchor**\nThink 'CHONdrodermatitis' for 'CHrONic', 'painful', cartilage (ear rim) nodules.",
    "bullet_explanations": {
      "Chondrodermatitis nodularis helicis": "Correct; classic presentation: chronic, painful, tender nodule on the ear rim.",
      "Basal cell carcinoma": "Incorrect; typically painless, evolves slowly, and may ulcerate but is not usually tender.",
      "Actinic keratosis": "Incorrect; appears as a rough, scaly patch but is usually not painful or nodular.",
      "Squamous cell carcinoma": "Incorrect; more likely to be ulcerated or rapidly growing, less commonly painful.",
      "Keratoacanthoma": "Incorrect; rapidly enlarges then regresses, unlike the chronic, stable lesion seen here."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Skin Malignancy",
    "topic": "Pre-malignant lesions (actinic keratosis)",
    "keywords": [
      "chondrodermatitis nodularis helicis",
      "painful ear nodule",
      "differential diagnosis",
      "skin lesion",
      "MSRA dermatology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cholesteatoma",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cholesteatoma/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a92c3ed3-4a5f-4509-b016-9ac4434ea258",
    "question_number": 21,
    "question": "A 32-year-old man who wears soft contact lenses presents to his GP with sudden onset severe left eye pain, marked redness, photophobia, and excessive tearing. He reports no trauma. On examination, his visual acuity is slightly reduced, the pupil is round and reactive, and fluorescein staining reveals a well-defined area of green uptake on the cornea. What is the most likely diagnosis?",
    "options": [
      "Corneal ulcer",
      "Acute anterior uveitis",
      "Acute angle-closure glaucoma",
      "Allergic conjunctivitis",
      "Blepharitis"
    ],
    "correct_answer": "Corneal ulcer",
    "explanation": "**Explanation**\n**Corneal ulcer** is most likely in this scenario, given the combination of severe ocular pain, redness, photophobia, and a discrete area of fluorescein uptake in a contact lens wearer. Corneal ulcers are typically infectious and are more common in contact lens users due to increased risk of microbial contamination. The classic sign is a visible epithelial defect on the cornea, which stains green with fluorescein. This presentation contrasts with conditions such as uveitis (which often shows perilimbal injection and constricted pupil) and conjunctivitis (where pain is usually mild and visual acuity preserved). Glaucoma would present with a mid-dilated, poorly reactive pupil and systemic symptoms like headache and nausea.\n\n**Key Points**\n- Corneal ulcers present with severe pain, photophobia, redness, and tearing.\n- Discrete corneal epithelial defects stain green with fluorescein dye.\n- Contact lens wear is a significant risk factor for infectious corneal ulcers.\n- Urgent ophthalmology referral is required due to sight-threatening potential.\n- Other serious red eye causes (e.g. uveitis, acute glaucoma) have distinguishing clinical features.\n\n**Clinical Relevance**\nPrompt recognition of a corneal ulcer is crucial, especially in contact lens users, as delayed treatment risks permanent vision loss. NICE and BNF guidelines emphasise the need for urgent specialist assessment when there is corneal staining, significant pain, or vision changes.\n\n**Memory Anchor**\nContact lens wearer + severe pain + green corneal stain = think corneal ulcer.",
    "bullet_explanations": {
      "Corneal ulcer": "Correct – Severe pain, photophobia, and fluorescein-positive corneal defect are classic for corneal ulcer, especially in contact lens users.",
      "Acute anterior uveitis": "Incorrect – Typically presents with perilimbal redness, photophobia, and often a constricted pupil, but not focal corneal staining.",
      "Acute angle-closure glaucoma": "Incorrect – Usually features a mid-dilated unreactive pupil, marked visual loss, and systemic symptoms (e.g. nausea).",
      "Allergic conjunctivitis": "Incorrect – Rarely causes severe pain or photophobia and does not produce focal corneal staining.",
      "Blepharitis": "Incorrect – Involves eyelid margin inflammation, with irritation or crusting, but not corneal defects or severe pain."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Keratitis",
    "topic": "Keratitis",
    "keywords": [
      "corneal ulcer",
      "contact lens",
      "fluorescein staining",
      "red eye",
      "keratitis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Red eye",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/red-eye/"
      },
      {
        "source": "BNF",
        "topic_title": "Eye, infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/eye-infections/"
      },
      {
        "source": "BNF",
        "topic_title": "Eye",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/eye/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "6e5c30fb-86d1-45da-8c43-2ad6a3a0a519",
    "question_number": 22,
    "question": "A 28-year-old man presents to his GP with a 5-day history of urethral discharge and dysuria. Microscopy confirms the presence of motile flagellated protozoa. What is the most appropriate first-line treatment?",
    "options": [
      "Oral metronidazole",
      "Oral fluconazole",
      "Topical clotrimazole cream",
      "Oral doxycycline",
      "Advice about hygiene and wearing loose underwear"
    ],
    "correct_answer": "Oral metronidazole",
    "explanation": "**Explanation**\n**Oral metronidazole is the recommended first-line therapy for trichomoniasis, a sexually transmitted infection caused by the protozoan Trichomonas vaginalis.** Metronidazole is effective because it disrupts the DNA synthesis of protozoa, leading to their eradication. Current UK guidelines (e.g., NICE CKS) specify oral metronidazole 400–500 mg twice daily for 7 days as the initial choice for both men and women, unless contraindicated. Antifungals and tetracyclines are ineffective against protozoal infections, and lifestyle advice alone does not address the underlying infection.\n\n**Key Points**\n- Trichomoniasis is caused by Trichomonas vaginalis, a flagellated protozoan.\n- First-line treatment is oral metronidazole: 400–500 mg twice daily for 7 days.\n- Alternative antifungals (e.g., fluconazole, clotrimazole) are not effective against protozoa.\n- Doxycycline targets bacterial pathogens, not protozoa.\n- Non-pharmacological advice does not cure trichomoniasis.\n- Sexual partners should also be tested and treated to prevent reinfection.\n- Diagnosis should be confirmed with laboratory testing (e.g., microscopy, PCR).\n\n**Clinical Relevance**\nPrompt recognition and treatment of trichomoniasis is crucial to reduce transmission, prevent complications, and limit co-infection with other STIs. Adhering to evidence-based guidelines, such as those from NICE CKS, ensures optimal outcomes and prevents inappropriate prescribing.\n\n**Memory Anchor**\nRemember: **Metronidazole for Motile (protozoan) Microbes** like Trichomonas.",
    "bullet_explanations": {
      "Oral metronidazole": "Correct – This is the guideline-recommended first-line treatment for trichomoniasis.",
      "Oral fluconazole": "Incorrect – This antifungal targets yeast infections (e.g., candidiasis), not protozoal organisms.",
      "Topical clotrimazole cream": "Incorrect – Topical antifungals treat local fungal infections and are ineffective against systemic protozoa.",
      "Oral doxycycline": "Incorrect – Doxycycline is an antibiotic used for bacterial STIs but not for protozoal infections like trichomoniasis.",
      "Advice about hygiene and wearing loose underwear": "Incorrect – While general advice for genital health, it does not treat the underlying protozoal infection."
    },
    "category": "STIs & Sexual Health",
    "subsection": "STIs",
    "subsubsection": "Trichomoniasis",
    "topic": "Trichomoniasis",
    "keywords": [
      "trichomoniasis",
      "metronidazole",
      "STI treatment",
      "protozoa",
      "sexual health"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Trichomoniasis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/trichomoniasis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e11f1b50-faf7-4365-8a7e-b332158b4116",
    "question_number": 23,
    "question": "During the active management of the third stage of labour in a 28-year-old woman with a history of mild gestational hypertension, which uterotonic agent is preferred to minimise the risk of postpartum haemorrhage?",
    "options": [
      "Oxytocin intramuscular injection",
      "Syntometrine (oxytocin with ergometrine)",
      "Ergometrine maleate alone",
      "Misoprostol tablets",
      "No uterotonic drug required"
    ],
    "correct_answer": "Oxytocin intramuscular injection",
    "explanation": "**Explanation**\n**Oxytocin administered intramuscularly** is the first-line uterotonic for active management of the third stage of labour, particularly in women with hypertension. Oxytocin is effective at reducing the risk of postpartum haemorrhage (PPH) and is associated with fewer side effects—most notably, it does not elevate blood pressure or significantly increase the risk of nausea and vomiting compared to ergometrine or oxytocin-ergometrine combinations. Ergometrine-containing preparations are contraindicated or used with caution in women with hypertensive disorders due to the risk of severe hypertension and related complications. Misoprostol, while an alternative where oxytocin is unavailable, is not the preferred agent in routine UK practice.\n\n**Key Points**\n- Active management of the third stage reduces PPH risk.\n- Oxytocin 10 IU IM is recommended for most women.\n- Ergometrine and Syntometrine can significantly raise blood pressure—avoid in hypertension.\n- Misoprostol is reserved for settings where oxytocin is not available.\n- Uterotonics are given immediately after the birth of the baby and before cord clamping.\n\n**Clinical Relevance**\nCorrect choice of uterotonic in the third stage of labour is essential to prevent PPH and avoid complications, especially in women with hypertensive disorders. National guidelines emphasise oxytocin as the safest and most effective option for most women, including those with raised blood pressure.",
    "bullet_explanations": {
      "Oxytocin intramuscular injection": "Correct – first-line uterotonic for active management, especially in hypertensive patients.",
      "Syntometrine (oxytocin with ergometrine)": "Incorrect – increases risk of hypertensive crisis and should be avoided in women with high blood pressure.",
      "Ergometrine maleate alone": "Incorrect – contraindicated in hypertension due to risk of severe elevation of blood pressure.",
      "Misoprostol tablets": "Incorrect – not first-line in the UK; used only where oxytocin is unavailable.",
      "No uterotonic drug required": "Incorrect – active management always involves a uterotonic to reduce PPH risk."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Late",
    "subsubsection": "Labour & Delivery",
    "topic": "Stages of labour",
    "keywords": [
      "third stage labour",
      "oxytocin",
      "postpartum haemorrhage",
      "hypertension",
      "active management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Obstetrics",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/obstetrics/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5407a763-80c1-40d6-8088-db844cf7e5df",
    "question_number": 24,
    "question": "A 68-year-old woman attends for a routine skin check. On examination, you observe several well-circumscribed, waxy, slightly raised plaques with a 'stuck-on' appearance on her trunk. She is otherwise well and reports no itching or pain. Which skin condition best fits this description?",
    "options": [
      "Seborrhoeic keratoses",
      "Lentigo maligna",
      "Basal cell carcinoma",
      "Actinic keratosis",
      "Dysplastic naevus"
    ],
    "correct_answer": "Seborrhoeic keratoses",
    "explanation": "**Explanation**\n**Seborrhoeic keratoses** are common, benign epidermal tumours seen most frequently in older adults. They typically present as multiple, sharply demarcated, 'stuck-on' papules or plaques that may vary in colour from light tan to black. Their waxy or verrucous surface and lack of symptoms (such as pain or bleeding) help distinguish them from malignant lesions. Unlike melanomas, seborrhoeic keratoses do not change rapidly in size or colour and rarely cause concern unless inflamed or irritated. In contrast, malignant lesions such as lentigo maligna or basal cell carcinoma often present as solitary, irregular lesions and may show signs of ulceration or rapid change.\n\n**Key Points**\n- Seborrhoeic keratoses are benign and very common in the elderly.\n- Appear as well-defined, waxy, 'stuck-on' plaques; colour ranges from tan to dark brown.\n- Usually asymptomatic and found on the trunk, face, and limbs (never on palms/soles).\n- No malignant potential, but can be confused with melanocytic lesions.\n- Malignant lesions often show asymmetry, border irregularity, colour variation, or rapid change.\n- <table><thead><tr><th>Feature</th><th>Seborrhoeic Keratosis</th><th>Melanoma</th></tr></thead><tbody><tr><td>Surface</td><td>Waxy/verrucous</td><td>Variable, often smooth</td></tr><tr><td>Number</td><td>Multiple</td><td>Usually single</td></tr><tr><td>Symptom</td><td>Asymptomatic</td><td>May bleed/itch/change</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising seborrhoeic keratoses is vital to avoid unnecessary referrals or biopsies. Differentiating benign lesions from melanoma and other skin cancers follows guidelines such as the weighted 7-point checklist for suspicious pigmented lesions. Familiarity with classic benign presentations improves patient safety and resource use.\n\n**Memory Anchor**\n'Stuck-on' = Seborrhoeic keratosis",
    "bullet_explanations": {
      "Seborrhoeic keratoses": "Correct – classic appearance with 'stuck-on', waxy plaques in older adults.",
      "Lentigo maligna": "Incorrect – presents as a slowly expanding, irregularly pigmented patch, often on sun-exposed skin.",
      "Basal cell carcinoma": "Incorrect – typically a pearly nodule, may ulcerate, usually solitary and not waxy or 'stuck-on'.",
      "Actinic keratosis": "Incorrect – rough, scaly, flat lesions on sun-exposed sites, often precancerous.",
      "Dysplastic naevus": "Incorrect – atypical mole with irregular border and colour, not waxy or 'stuck-on', and usually fewer in number."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Skin Malignancy",
    "topic": "Pre-malignant lesions (actinic keratosis)",
    "keywords": [
      "seborrhoeic keratosis",
      "benign skin lesion",
      "stuck-on appearance"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Melanoma",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/melanoma/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Skin cancers - recognition and referral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/skin-cancers-recognition-referral/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1242aa7d-0a70-4434-b0c0-fc35aef2869f",
    "question_number": 25,
    "question": "A 61-year-old man with a history of benign prostatic hyperplasia presents to his GP with gradual onset of right-sided scrotal pain and swelling over 4 days. He is in a long-term monogamous relationship and reports no urinary symptoms or urethral discharge. Examination reveals tenderness and swelling localised to the epididymis. He is afebrile and the cremasteric reflex is present. What is the most appropriate initial antibiotic therapy?",
    "options": [
      "Ofloxacin orally for 14 days",
      "Ceftriaxone intramuscularly plus doxycycline orally",
      "Doxycycline orally for 7 days",
      "Trimethoprim orally for 3 days",
      "Nitrofurantoin orally for 5 days"
    ],
    "correct_answer": "Ofloxacin orally for 14 days",
    "explanation": "**Explanation**\n**Older men with epididymo-orchitis and a low risk of sexually transmitted infections (STIs) are most commonly infected by enteric Gram-negative bacteria, particularly Escherichia coli.** In this demographic, empirical treatment should target urinary pathogens rather than chlamydia or gonorrhoea. Oral quinolones—such as ofloxacin—are preferred due to their excellent penetration into the epididymis and reliable coverage of likely causative organisms. A 14-day course is recommended to ensure eradication. **Sexually transmitted pathogens are less likely in older, monogamous men, so regimens directed at STIs (e.g., ceftriaxone and doxycycline) are unnecessary unless the history suggests otherwise.**\n\n**Key Points**\n- Most older men with epididymo-orchitis have infections from urinary tract bacteria (e.g., E. coli), not STIs.\n- Oral quinolones, such as ofloxacin, offer effective coverage and tissue penetration.\n- Recommended duration is 14 days to prevent relapse.\n- STI-focused therapy (ceftriaxone/doxycycline) is for younger or high-risk patients.\n- Always send urine for culture before starting antibiotics, but do not delay treatment.\n- <table><thead><tr><th>Patient group</th><th>Likely pathogens</th><th>First-line treatment</th></tr></thead><tbody><tr><td>Young adults, high STI risk</td><td>Chlamydia, gonorrhoea</td><td>Ceftriaxone IM + doxycycline</td></tr><tr><td>Older adults, low STI risk</td><td>Enteric Gram-negative rods</td><td>Oral quinolone (e.g., ofloxacin)</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the patient's age, sexual history, and risk factors is crucial to select appropriate empirical antibiotics for epididymo-orchitis. Inappropriate therapy can lead to treatment failure and complications. UK guidance supports quinolone use in older men with urinary tract–origin infections. Timely management prevents progression to abscess or sepsis.\n\n**Memory Anchor**\nOlder men = Ofloxacin for Orchi-Epididymitis",
    "bullet_explanations": {
      "Ofloxacin orally for 14 days": "Correct—empirical first-line for older, low STI risk men with likely enteric organism infection.",
      "Ceftriaxone intramuscularly plus doxycycline orally": "Incorrect—used for suspected STI-related epididymo-orchitis in younger or high-risk patients.",
      "Doxycycline orally for 7 days": "Incorrect—covers chlamydia but not enteric Gram-negatives, and is inadequate both in spectrum and duration.",
      "Trimethoprim orally for 3 days": "Incorrect—typically used for simple lower UTI; insufficient coverage and duration for epididymo-orchitis.",
      "Nitrofurantoin orally for 5 days": "Incorrect—effective for lower UTI but does not achieve therapeutic levels in the epididymis."
    },
    "category": "Renal & Urology",
    "subsection": "Urology",
    "subsubsection": "Infections",
    "topic": "Epididymo-orchitis",
    "keywords": [
      "epididymo-orchitis",
      "empirical antibiotics",
      "older men",
      "quinolones",
      "urology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Scrotal pain and swelling",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/scrotal-pain-swelling/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9f38933b-7380-4a03-b5ae-ed2e12d4e4b4",
    "question_number": 26,
    "question": "A 65-year-old man presents with brief episodes of spinning sensation triggered by turning his head to the right, particularly when getting into bed. He denies hearing loss, tinnitus, or ear pain. Which bedside manoeuvre is most appropriate to confirm the suspected diagnosis?",
    "options": [
      "Dix-Hallpike manoeuvre",
      "Pure tone audiometry",
      "Weber and Rinne tests",
      "Otoscopy",
      "Epley manoeuvre"
    ],
    "correct_answer": "Dix-Hallpike manoeuvre",
    "explanation": "**Explanation**\nThe **Dix-Hallpike manoeuvre** is the gold standard bedside test used to diagnose benign paroxysmal positional vertigo (BPPV). It works by provoking vertigo and characteristic nystagmus through rapid positional change, specifically when the affected ear is positioned downward. BPPV typically presents with transient vertigo triggered by specific head movements, without associated auditory symptoms such as hearing loss or tinnitus. The Epley manoeuvre, in contrast, is a therapeutic intervention rather than a diagnostic one. Audiometry, Weber and Rinne tests, and otoscopy are more useful for detecting hearing impairment or middle/outer ear pathology, not for confirming BPPV.\n\n**Key Points**\n- BPPV presents with short-lived, positional vertigo and lacks hearing loss or tinnitus.\n- The Dix-Hallpike manoeuvre reproduces symptoms and nystagmus typical of BPPV.\n- The Epley manoeuvre is used for treatment, not diagnosis.\n- Audiometric tests and otoscopy are indicated for suspected auditory or infective causes.\n- Differentiating BPPV from other causes (Meniere's, vestibular neuronitis, labyrinthitis) is essential.\n\n**Clinical Relevance**\nTimely and accurate diagnosis of BPPV using the Dix-Hallpike manoeuvre ensures appropriate management, avoids unnecessary investigations, and distinguishes BPPV from other causes of vertigo. National guidelines recommend this manoeuvre as the primary diagnostic tool for BPPV in primary care.\n\n**Memory Anchor**\nDix-Hallpike 'Diagnoses'—Epley 'Eases' (treats) BPPV.",
    "bullet_explanations": {
      "Dix-Hallpike manoeuvre": "Correct – confirms BPPV by provoking positional vertigo and nystagmus.",
      "Pure tone audiometry": "Incorrect – assesses hearing loss, useful for Meniere’s disease but not for diagnosing BPPV.",
      "Weber and Rinne tests": "Incorrect – identify conductive vs sensorineural hearing loss, not specific for BPPV.",
      "Otoscopy": "Incorrect – detects middle/outer ear pathology, not diagnostic for BPPV.",
      "Epley manoeuvre": "Incorrect – therapeutic particle repositioning manoeuvre, not a diagnostic test."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Vertigo (BPPV, vestibular neuritis, Meniere’s)",
    "keywords": [
      "BPPV",
      "Dix-Hallpike",
      "vertigo",
      "diagnosis",
      "ENT"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Benign paroxysmal positional vertigo",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/benign-paroxysmal-positional-vertigo/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Vertigo",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/vertigo/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2db7b4a1-0bb9-406f-af3a-e97913343f27",
    "question_number": 27,
    "question": "A 68-year-old woman presents with progressive painless jaundice, unintentional weight loss, and upper abdominal discomfort. Blood tests reveal elevated bilirubin and alkaline phosphatase, with a mildly raised amylase. MRCP shows simultaneous dilatation of the common bile duct and pancreatic duct ('double duct sign'). Which is the most likely underlying diagnosis?",
    "options": [
      "Pancreatic head carcinoma",
      "Acute cholangitis",
      "Chronic pancreatitis",
      "Hepatocellular carcinoma",
      "Gallstone pancreatitis"
    ],
    "correct_answer": "Pancreatic head carcinoma",
    "explanation": "**Explanation**\n**The 'double duct sign'—concurrent dilatation of the common bile duct and pancreatic duct on imaging—is most commonly associated with a tumour at the head of the pancreas, typically pancreatic adenocarcinoma.** This occurs because a mass at the pancreatic head or ampullary region can obstruct both ducts simultaneously. Painless jaundice, weight loss, and mild abdominal pain are classic features. This imaging finding is highly suggestive of a malignant process and is rarely seen in benign conditions. Acute cholangitis and gallstone pancreatitis usually present with acute symptoms and do not characteristically cause the double duct sign. Chronic pancreatitis may cause ductal changes, but the typical presentation differs and the double duct sign is much rarer. Hepatocellular carcinoma affects the liver parenchyma and does not typically cause ductal obstruction in this pattern.<br><br>\n\n**Key Points**\n<ul><li><b>'Double duct sign' on imaging is strongly linked to pancreatic head cancer.</b></li><li>Painless jaundice and weight loss are classic symptoms.</li><li>Benign causes (e.g., chronic pancreatitis) are much less likely.</li><li>Gallstone disease typically causes isolated biliary obstruction.</li><li>Acute cholangitis usually presents with fever and sepsis.</li></ul><br><table><thead><tr><th>Condition</th><th>Ductal involvement</th></tr></thead><tbody><tr><td>Pancreatic head carcinoma</td><td>Both bile and pancreatic ducts</td></tr><tr><td>Chronic pancreatitis</td><td>Possible, but uncommon</td></tr><tr><td>Gallstones</td><td>Bile duct only</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the double duct sign is crucial for early detection of pancreatic malignancy, prompting urgent referral for specialist assessment and improving patient outcomes. NICE recommends further investigation for patients with unexplained obstructive jaundice or suggestive imaging findings.\n\n**Memory Anchor**\nDouble duct = Double danger: suspect tumour at the pancreatic 'head'.",
    "bullet_explanations": {
      "Pancreatic head carcinoma": "Correct—most common cause of the double duct sign, presenting with painless jaundice.",
      "Acute cholangitis": "Incorrect—typically presents with fever, right upper quadrant pain, and jaundice; does not usually cause pancreatic duct dilation.",
      "Chronic pancreatitis": "Incorrect—can very rarely cause double duct sign, but usually presents with recurrent pain and exocrine insufficiency.",
      "Hepatocellular carcinoma": "Incorrect—typically causes parenchymal liver disease and not simultaneous bile and pancreatic duct obstruction.",
      "Gallstone pancreatitis": "Incorrect—may cause biliary and pancreatic inflammation, but simultaneous duct dilatation is not the typical radiological finding."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Biliary & Pancreas",
    "subsubsection": "Gallstone Disease",
    "topic": "ERCP/MRCP roles",
    "keywords": [
      "double duct sign",
      "pancreatic cancer",
      "MRCP",
      "biliary obstruction",
      "jaundice"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Pancreatitis - chronic",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/pancreatitis-chronic/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Pancreatitis - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/pancreatitis-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f4b69354-5f55-49de-adf7-668248b3114e",
    "question_number": 28,
    "question": "A 5-year-old girl develops a high fever and sore throat. On examination, she is noted to have a red, sandpaper-like rash that blanches on pressure, with a prominent 'strawberry tongue'. What is the most likely diagnosis?",
    "options": [
      "Scarlet fever",
      "Rubella",
      "Chickenpox",
      "Coxsackie A16 infection",
      "Measles"
    ],
    "correct_answer": "Scarlet fever",
    "explanation": "**Explanation**\n**Scarlet fever** is caused by group A streptococcus and commonly affects children. It classically presents with a **fine, punctate, erythematous rash with a sandpaper texture**, which blanches on pressure, and often spares the face. Associated features include **fever, pharyngitis or tonsillitis, and a 'strawberry tongue' (enlarged papillae on a red background)**. The rash usually appears 12–48 hours after fever onset, and a furred or coated tongue may be seen early. This constellation of findings distinguishes scarlet fever from other viral exanthems and childhood infections.\n\n**Key Points**\n- Scarlet fever is due to group A streptococcus (Streptococcus pyogenes).\n- Key features: fever, sore throat, sandpaper rash, and strawberry tongue.\n- Rash typically blanches and may spare the face.\n- Other childhood exanthems (e.g., rubella, measles) lack the sandpaper texture and strawberry tongue.\n- Prompt recognition is essential for antibiotic treatment to reduce complications.\n\n**Clinical Relevance**\nEarly diagnosis of scarlet fever is clinically important, as prompt antibiotic therapy reduces the risk of complications such as rheumatic fever and glomerulonephritis. The characteristic sandpaper rash and strawberry tongue are classic clues for this condition.\n\n**Memory Anchor**\nStrawberry tongue and sandpaper rash = Scarlet fever.",
    "bullet_explanations": {
      "Scarlet fever": "Correct; classic presentation with sandpaper rash and strawberry tongue.",
      "Rubella": "Incorrect; typically presents with a mild maculopapular rash and suboccipital lymphadenopathy.",
      "Chickenpox": "Incorrect; presents with a vesicular rash at different stages, not a sandpaper texture.",
      "Coxsackie A16 infection": "Incorrect; causes hand, foot, and mouth disease with oral ulcers and vesicles.",
      "Measles": "Incorrect; associated with Koplik spots, cough, coryza, conjunctivitis, and a morbilliform rash."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Common Infections",
    "topic": "Scarlet fever",
    "keywords": [
      "scarlet fever",
      "strawberry tongue",
      "sandpaper rash",
      "paediatric infection",
      "group A streptococcus"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "30ad3e0e-462f-47d9-a93a-cfd99d2bd80b",
    "question_number": 29,
    "question": "A term male neonate is brought to the neonatal unit at 30 hours old with abdominal distension, persistent bilious vomiting, and failure to pass meconium since birth. Antenatal scans were unremarkable. What is the most likely underlying diagnosis?",
    "options": [
      "Meconium ileus",
      "Duodenal atresia",
      "Necrotising enterocolitis",
      "Gastro-oesophageal reflux (posseting)",
      "Infantile pyloric stenosis"
    ],
    "correct_answer": "Meconium ileus",
    "explanation": "**Explanation**\n**Meconium ileus** is most often seen in the first 48 hours of life, especially in neonates presenting with abdominal distension, failure to pass meconium, and bilious vomiting. This condition results from obstruction of the distal ileum by inspissated meconium, commonly associated with cystic fibrosis. Unlike duodenal atresia, which typically presents in the immediate neonatal period and is often detected antenatally, meconium ileus may become apparent only after feeding begins. Necrotising enterocolitis usually affects preterm infants at a later age, and pyloric stenosis presents weeks later with non-bilious projectile vomiting. Posseting is benign and not associated with abdominal distension or bilious vomiting.\n\n**Key Points**\n- Meconium ileus presents with failure to pass meconium within 24–48 hours, abdominal distension, and bilious vomiting.\n- Strongly linked to cystic fibrosis; may be the first manifestation before diagnosis is confirmed.\n- Duodenal atresia often has a 'double bubble' sign on antenatal ultrasound and presents rapidly after birth.\n- Necrotising enterocolitis typically affects preterm infants and presents after feeds have been established.\n- Pyloric stenosis presents at 2–8 weeks with non-bilious, projectile vomiting, not in the immediate neonatal period.\n- <table><thead><tr><th>Diagnosis</th><th>Timing</th><th>Key Features</th></tr></thead><tbody><tr><td>Meconium ileus</td><td>First 48h</td><td>Abdominal distension, bilious vomit, delayed meconium</td></tr><tr><td>Duodenal atresia</td><td>First hours</td><td>Polyhydramnios, double bubble, early bilious vomit</td></tr><tr><td>NEC</td><td>Days-weeks</td><td>Preterm, feeding intolerance, bloody stools</td></tr><tr><td>Pyloric stenosis</td><td>2–8 weeks</td><td>Projectile non-bilious vomiting, palpable mass</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition of meconium ileus is essential as it may be the first sign of cystic fibrosis, requiring early multidisciplinary management and genetic counselling. Early surgical or medical intervention reduces morbidity associated with bowel obstruction.\n\n**Memory Anchor**\nThink of 'meconium' as the clue: if it won't pass, suspect meconium ileus in a neonate, especially with CF risk.",
    "bullet_explanations": {
      "Meconium ileus": "Correct – classic early neonatal presentation with bowel obstruction and failure to pass meconium, often linked to cystic fibrosis.",
      "Duodenal atresia": "Incorrect – typically presents in the first few hours of life, often with polyhydramnios and a 'double bubble' sign on prenatal scan.",
      "Necrotising enterocolitis": "Incorrect – usually affects preterm infants after the initiation of feeds; not common in term neonates this early.",
      "Gastro-oesophageal reflux (posseting)": "Incorrect – benign, non-bilious, small-volume regurgitation; not associated with abdominal distension or delayed meconium.",
      "Infantile pyloric stenosis": "Incorrect – presents later (2–8 weeks) with non-bilious projectile vomiting, not in the immediate neonatal period."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBD",
    "topic": "UC vs Crohn’s key differences",
    "keywords": [
      "meconium ileus",
      "neonate bowel obstruction",
      "cystic fibrosis",
      "bilious vomiting",
      "newborn GI"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Cystic fibrosis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/cystic-fibrosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ecbcaf82-88fc-4434-9096-70b8e4a95829",
    "question_number": 30,
    "question": "A 70-year-old woman is brought to the emergency department after being found unresponsive at home. On assessment, she opens her eyes only when spoken to, makes incomprehensible noises, and shows abnormal flexion in her right arm but no motor response in her left arm to pain. What is her Glasgow Coma Scale (GCS) score?",
    "options": [
      "8",
      "7",
      "9",
      "10",
      "6"
    ],
    "correct_answer": "8",
    "explanation": "**Explanation**\n**The Glasgow Coma Scale (GCS) is calculated by summing the best responses in three domains: eye opening, verbal response, and motor response.** In this scenario: eye opening to speech scores 3, incomprehensible sounds scores 2 for verbal, and the best motor response (abnormal flexion, i.e. decorticate posturing) scores 3 (since we use the best limb response, not the worst). Thus, her total GCS is 3 (eyes) + 2 (verbal) + 3 (motor) = 8. **A GCS of 8 or below indicates severe impairment of consciousness and is a threshold for considering airway protection.** This calculation is crucial in acute head injury management.\n\n**Key Points**\n- GCS is the sum of eye (max 4), verbal (max 5), and motor (max 6) responses.\n- Always record the best response from either side of the body in each category.\n- Eye opening to voice = 3 points.\n- Incomprehensible verbal sounds = 2 points.\n- Abnormal flexion (decorticate) = 3 points (use best motor response).\n- GCS ≤8 indicates severe impairment and need for airway consideration.\n- A GCS of 15 is normal; 3 is the lowest possible score.\n\n**Clinical Relevance**\nAccurate and prompt assessment of GCS is essential in acute brain injury for triage, prognosis, and airway management decisions. National guidelines advise urgent referral for all patients with a GCS less than 15, and those with GCS of 8 or below may need airway protection due to risk of loss of airway reflexes. This scoring guides both initial management and ongoing monitoring in head injuries.\n\n**Memory Anchor**\nRemember: 'E4 V5 M6'—the GCS domains sum to a maximum of 15. Use the **best** limb response for motor.",
    "bullet_explanations": {
      "6": "Incorrect—This would require multiple responses at the lowest levels, which is not the case here.",
      "7": "Incorrect—This would result from lower scores, but here the best responses total 8.",
      "8": "Correct—This is the sum of eye (3), verbal (2), and motor (3) scores.",
      "9": "Incorrect—An overestimate; would require a higher score in one of the domains.",
      "10": "Incorrect—Too high; the verbal and motor responses are too impaired for this score."
    },
    "category": "Neurology",
    "subsection": "Stroke & TIA",
    "subsubsection": "FAST/TIA recognition",
    "topic": "Glasgow Coma Scale",
    "keywords": [
      "GCS",
      "head injury",
      "coma score",
      "trauma assessment"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Head injury",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/head-injury/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0f618d9a-02e5-4b61-83d2-cf3e920f0915",
    "question_number": 31,
    "question": "A 3-week-old girl is brought to the emergency department after her parents notice a reducible mass in her left groin that becomes more prominent when she cries. She is otherwise well, feeding and stooling normally, and has a normal scrotal exam. What is the most appropriate next step in management?",
    "options": [
      "Urgent referral to paediatric surgery for assessment and repair",
      "Advise watchful waiting and review at 6 months if persist",
      "Arrange orthopaedic review for possible developmental dysplasia",
      "Recommend outpatient ultrasound before further action",
      "Reassure and review only if symptoms of bowel obstruction occur"
    ],
    "correct_answer": "Urgent referral to paediatric surgery for assessment and repair",
    "explanation": "**Explanation**\n**Congenital inguinal hernias in infants carry a significant risk of complications, such as incarceration or strangulation, especially in the first few months of life.** Prompt surgical referral is recommended once the diagnosis is made. Unlike some other lumps in children, such as hydroceles, inguinal hernias are not expected to resolve spontaneously and should not be managed with expectant observation. Delaying referral increases the risk of emergency complications that may threaten bowel viability or cause testicular damage.\n\n**Key Points**\n- Inguinal hernias in infants present as reducible groin swellings.\n- Risk of incarceration is highest in the first year of life.\n- Prompt surgical referral is necessary for all confirmed cases.\n- Hydroceles may be observed, but hernias require intervention.\n- Orthopaedic or ultrasound investigation is not indicated for classic reducible hernias.\n\n**Clinical Relevance**\nEarly identification and referral for congenital inguinal hernias are essential to prevent life-threatening complications. Current guidelines recommend prompt surgical assessment rather than watchful waiting, even in asymptomatic infants.",
    "bullet_explanations": {
      "Urgent referral to paediatric surgery for assessment and repair": "Correct; paediatric inguinal hernias have a high complication risk and require prompt surgical management.",
      "Advise watchful waiting and review at 6 months if persist": "Incorrect; unlike hydroceles, hernias should not be observed, as complications may occur early.",
      "Arrange orthopaedic review for possible developmental dysplasia": "Incorrect; there are no signs of hip dysplasia and the mass is in the groin, not the hip.",
      "Recommend outpatient ultrasound before further action": "Incorrect; diagnosis is clinical and management is surgical, not dependent on imaging.",
      "Reassure and review only if symptoms of bowel obstruction occur": "Incorrect; waiting for complications is unsafe in infants with hernias."
    },
    "category": "Paediatrics",
    "subsection": "Neonatology",
    "subsubsection": "Congenital Conditions",
    "topic": "CHD basics",
    "keywords": [
      "inguinal hernia",
      "paediatric surgery",
      "groin lump",
      "complications",
      "infant"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Abdominal wall hernias",
        "citation": "© NICE, 2025",
        "url": ""
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2ca748bc-f24e-4608-9a05-19bd0e328fab",
    "question_number": 32,
    "question": "A 19-year-old man is assessed for new-onset difficulties at university, including irritability, poor academic performance, and slurred speech. His mother reports a recent tremor in his left hand and slow movements. On examination, he has mild hepatomegaly and golden-brown rings visible at the corneal margin. Which diagnosis best explains this combination of findings?",
    "options": [
      "Wilson's disease",
      "Multiple sclerosis",
      "Parkinson's disease",
      "Alpha-1-antitrypsin deficiency",
      "Huntington's disease"
    ],
    "correct_answer": "Wilson's disease",
    "explanation": "**Explanation**\n**Wilson's disease** is a rare autosomal recessive disorder resulting in impaired copper metabolism, which leads to copper accumulation in the liver, brain (particularly basal ganglia), and eyes. Key features include **neuropsychiatric symptoms** (such as tremor, bradykinesia, dysarthria, and behavioural changes), **hepatic involvement** (from mild hepatomegaly to fulminant liver failure), and the presence of **Kayser-Fleischer rings** (golden-brown deposits at the corneal margin). The combination of **young age**, progressive neurological and psychiatric features, hepatic signs, and characteristic ocular findings is highly suggestive of Wilson's disease. In contrast, other listed conditions either do not present with this multisystem pattern or typically present in a different age group.\n\n**Key Points**\n- Wilson's disease = copper accumulation due to defective ATP7B gene\n- Neurological: tremor, dysarthria, bradykinesia, psychiatric symptoms\n- Hepatic: hepatomegaly, abnormal LFTs, cirrhosis\n- Eye: Kayser-Fleischer rings (brown/green corneal deposits)\n- Onset usually in adolescence or early adulthood\n- Family history may reveal early liver disease/death\n- Diagnosis: low serum ceruloplasmin, increased urinary copper\n\n**Clinical Relevance**\nRecognising Wilson's disease is vital, as early diagnosis and chelation therapy prevent irreversible hepatic and neurological damage. The multisystem involvement distinguishes it from other causes of movement disorders in young adults.\n\n**Memory Anchor**\nKayser-Fleischer rings = copper 'rings' in Wilson's (think 'Wilson's and rings both contain 'W-I-N').",
    "bullet_explanations": {
      "Wilson's disease": "Correct – Features across neurological, hepatic, and ocular systems in a young adult are classic.",
      "Multiple sclerosis": "Incorrect – MS may cause neurological deficits, but does not cause liver disease or Kayser-Fleischer rings.",
      "Parkinson's disease": "Incorrect – Parkinsonism is rare in young adults and lacks hepatic or ocular involvement.",
      "Alpha-1-antitrypsin deficiency": "Incorrect – May cause liver disease, but not neurological symptoms or Kayser-Fleischer rings.",
      "Huntington's disease": "Incorrect – Presents later (typically age 30+), with chorea and psychiatric features, not liver disease or corneal rings."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Movement Disorders",
    "topic": "Management strategies",
    "keywords": [
      "Wilson's disease",
      "Kayser-Fleischer rings",
      "movement disorder",
      "copper metabolism",
      "hepatic neurology"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "5efb9f2f-9350-4b6c-bc88-b4cacb687dfa",
    "question_number": 33,
    "question": "Which antibiotic is considered first-line for treating an uncomplicated lower urinary tract infection in a woman at 16 weeks' gestation?",
    "options": [
      "Nitrofurantoin",
      "Trimethoprim",
      "Ciprofloxacin",
      "Sulfasalazine",
      "No antibiotic treatment is required"
    ],
    "correct_answer": "Nitrofurantoin",
    "explanation": "**Explanation**\n**Nitrofurantoin is the preferred first-line antibiotic for uncomplicated lower urinary tract infections (UTIs) in pregnancy**, especially in the second trimester. This agent is effective and generally safe during pregnancy, with the exception of use near term (from 36 weeks onward) due to the risk of neonatal haemolysis. **Trimethoprim is avoided during the first trimester** because it is a folate antagonist and may increase the risk of neural tube defects. **Ciprofloxacin**, a quinolone, is contraindicated throughout pregnancy due to potential adverse effects on fetal cartilage development. **Sulfasalazine** is not used for UTIs and is contraindicated in pregnancy for this indication. It is important to treat even asymptomatic bacteriuria in pregnant women to prevent complications such as pyelonephritis.\n\n**Key Points**\n- Treating UTIs in pregnancy reduces the risk of pyelonephritis and obstetric complications.\n- Nitrofurantoin is safe in pregnancy except at term (risk of neonatal haemolysis).\n- Trimethoprim is avoided in the first trimester due to teratogenicity.\n- Quinolones (e.g., ciprofloxacin) are contraindicated in pregnancy.\n- Sulfasalazine is not indicated for UTIs.\n- All symptomatic and asymptomatic UTIs in pregnancy require prompt antibiotic treatment.\n\n**Clinical Relevance**\nManaging urinary tract infections appropriately in pregnancy is crucial for maternal and fetal health. National guidelines recommend nitrofurantoin as a safe and effective choice before 36 weeks, while alternative agents should be considered if there are contraindications. This ensures optimal outcomes and minimises avoidable complications.\n\n**Memory Anchor**\nRemember: Nitrofurantoin is 'nice to use' in pregnancy—except Near Term (NT = Nitrofurantoin, No Term).",
    "bullet_explanations": {
      "Nitrofurantoin": "Correct – it is the recommended first-line treatment for UTIs in pregnancy, except at term.",
      "Trimethoprim": "Incorrect – avoided in the first trimester due to risk of neural tube defects; not first-line later in pregnancy.",
      "Ciprofloxacin": "Incorrect – contraindicated throughout pregnancy because of risk to fetal cartilage.",
      "Sulfasalazine": "Incorrect – not an antibiotic used for UTIs and not indicated in pregnancy for this purpose.",
      "No antibiotic treatment is required": "Incorrect – all UTIs in pregnancy should be treated, even if asymptomatic, to prevent complications."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Booking visit tests",
    "keywords": [
      "UTI",
      "pregnancy",
      "antibiotic choice",
      "nitrofurantoin",
      "antenatal care"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "6f403d62-ecf2-4125-8ec0-9a3dd274fae1",
    "question_number": 34,
    "question": "In the NHS Cervical Screening Programme, what is the initial laboratory test performed on cervical samples collected from eligible women during routine screening?",
    "options": [
      "The sample is first tested for high-risk HPV infection",
      "The sample is examined microscopically for abnormal cells (cytology) first",
      "Both high-risk HPV testing and cytology are performed routinely on all samples",
      "The sample is screened for all HPV types, including those causing genital warts",
      "The sample is checked directly for cervical cancer cells"
    ],
    "correct_answer": "The sample is first tested for high-risk HPV infection",
    "explanation": "**Explanation**\n**Current NHS cervical screening uses primary high-risk HPV (hrHPV) testing as the initial step.** This approach identifies women at risk of developing cervical cancer by detecting the presence of hrHPV, the main causative agent in cervical carcinogenesis. If hrHPV is found, only then is liquid-based cytology performed to look for cellular abnormalities. Samples negative for hrHPV require no further testing and women return to routine recall. Screening for all HPV types, including low-risk strains (such as 6 and 11, which cause genital warts), is not carried out. Cytology as the first-line test was the previous protocol but has been replaced due to the higher sensitivity of hrHPV testing.\n\n**Key Points**\n- NHS cervical screening initially tests for high-risk HPV (hrHPV) types only.\n- Cytology is performed only if hrHPV is detected.\n- Low-risk HPV types (e.g., 6 and 11) are not screened for in cervical smear testing.\n- Primary hrHPV testing is more sensitive than cytology for detecting women at risk.\n- Routine recall interval after a negative hrHPV test is 3 years (age 25–49) or 5 years (age 50–64).\n- <table><thead><tr><th>Step</th><th>Test Performed</th></tr></thead><tbody><tr><td>1</td><td>hrHPV testing</td></tr><tr><td>2 (if hrHPV+)</td><td>Cytology</td></tr></tbody></table>\n\n**Clinical Relevance**\nUnderstanding the order and rationale for cervical screening tests is essential for patient counselling and for safe interpretation of screening results. This aligns with national guidelines and is pivotal for cancer prevention.\n\n**Memory Anchor**\nThink: 'HPV first, cells if flagged'—screening follows the virus, not the microscope.",
    "bullet_explanations": {
      "The sample is first tested for high-risk HPV infection": "Correct — this is the current primary approach in the NHS Cervical Screening Programme.",
      "The sample is examined microscopically for abnormal cells (cytology) first": "Incorrect — cytology is reserved for samples positive for hrHPV, not as the first step.",
      "Both high-risk HPV testing and cytology are performed routinely on all samples": "Incorrect — cytology is not performed unless hrHPV is detected.",
      "The sample is screened for all HPV types, including those causing genital warts": "Incorrect — only high-risk HPV types are targeted, not those associated with benign warts.",
      "The sample is checked directly for cervical cancer cells": "Incorrect — the aim is to detect precancerous changes, not direct cancer cells; the process starts with hrHPV detection."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Booking visit tests",
    "keywords": [
      "cervical screening",
      "HPV",
      "cytology",
      "NHS",
      "smear test"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cervical screening",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cervical-screening/"
      },
      {
        "source": "BNF",
        "topic_title": "Human papillomavirus vaccine",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/human-papillomavirus-vaccine/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c0b3c283-6836-46ff-91a4-367e9fda47ce",
    "question_number": 35,
    "question": "A term female infant is brought for newborn screening. She was delivered by elective caesarean section at 39 weeks due to persistent breech position. There is no family history of musculoskeletal disorders. Which musculoskeletal condition is she specifically at increased risk of developing?",
    "options": [
      "Developmental dysplasia of the hip",
      "Osteogenesis imperfecta",
      "Perthes disease",
      "Slipped upper femoral epiphysis",
      "Juvenile idiopathic arthritis"
    ],
    "correct_answer": "Developmental dysplasia of the hip",
    "explanation": "**Explanation**\n**Developmental dysplasia of the hip (DDH) is significantly associated with breech presentation**, especially when this occurs after 36 weeks’ gestation. DDH encompasses a spectrum from mild acetabular dysplasia to frank hip dislocation. Breech position alters mechanical forces on the hip joint during late gestation, increasing the likelihood of abnormal hip development. Other risk factors include female sex, family history, and firstborn status, but breech remains a major independent risk. In contrast, the other listed conditions do not have an established association with breech delivery.\n\n**Key Points**\n<ul><li>Breech presentation after 36 weeks is a well-recognised risk factor for DDH.</li><li>DDH screening includes clinical examination and hip ultrasound in at-risk infants.</li><li>DDH may be asymptomatic at birth but can lead to long-term disability if undetected.</li><li>Other conditions—osteogenesis imperfecta, Perthes disease, SUFE, JIA—are not linked to breech delivery.</li><li>Early diagnosis enables non-surgical management (e.g. Pavlik harness) and improved outcomes.</li></ul>\n\n**Clinical Relevance**\nRecognising risk factors for DDH is crucial for appropriate screening and timely referral, as per national recommendations. Missing DDH may result in preventable disability. Familiarity with the association between breech presentation and DDH enables prompt action in primary care and postnatal settings.\n\n**Memory Anchor**\nRemember: **Breech = Hip** (breech babies need hips checked).",
    "bullet_explanations": {
      "Developmental dysplasia of the hip": "Correct – Breech presentation is a key risk factor for DDH, warranting targeted screening.",
      "Osteogenesis imperfecta": "Incorrect – This is a genetic disorder of collagen and is not related to breech delivery.",
      "Perthes disease": "Incorrect – Typically affects older children, with no link to birth presentation.",
      "Slipped upper femoral epiphysis": "Incorrect – Seen in adolescents and not associated with mode or position of delivery.",
      "Juvenile idiopathic arthritis": "Incorrect – An autoimmune condition of childhood, unrelated to breech birth."
    },
    "category": "Musculoskeletal",
    "subsection": "Arthritis",
    "subsubsection": "Osteoarthritis",
    "topic": "Typical presentation and joints affected",
    "keywords": [
      "developmental dysplasia",
      "breech presentation",
      "DDH screening"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Acute childhood limp",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/acute-childhood-limp/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "6cd958c1-6f49-4126-a574-9dd2b557920a",
    "question_number": 36,
    "question": "Which psychiatric symptom is most commonly associated with Parkinson's disease in older adults?",
    "options": [
      "Depression",
      "Obsessive-compulsive behaviour",
      "Generalised anxiety disorder",
      "Psychosis",
      "Bipolar disorder"
    ],
    "correct_answer": "Depression",
    "explanation": "**Explanation**\n**Depression is the most frequent psychiatric complication in Parkinson's disease (PD)**, affecting up to 50% of patients. The underlying causes are multifactorial, involving both the psychological burden of coping with a progressive, chronic condition and neurobiological changes affecting neurotransmitter systems (dopamine, serotonin, noradrenaline). Depression can precede motor symptoms and significantly impairs quality of life, making its recognition and management crucial in PD. Although other psychiatric and cognitive complications arise as the disease advances, depression remains the earliest and most prevalent psychiatric manifestation.\n\n**Key Points**\n- Depression commonly affects up to half of all patients with Parkinson's disease.\n- It may appear before or alongside motor symptoms.\n- Neurochemical disruptions (dopaminergic, serotonergic, noradrenergic) contribute to mood changes.\n- Depression impacts daily functioning and overall prognosis in PD.\n- Other non-motor psychiatric complications in PD include psychosis, anxiety, and dementia, but these are less common or occur later.\n\n**Clinical Relevance**\nIdentifying and managing depression in Parkinson's disease is vital for improving patient wellbeing and outcomes. NICE and BNF guidelines emphasise the importance of assessing both motor and non-motor symptoms in PD, with depression being a key consideration throughout the disease course.",
    "bullet_explanations": {
      "Depression": "Correct. Depression is the most common psychiatric disorder seen in Parkinson's disease, often preceding or accompanying motor symptoms.",
      "Obsessive-compulsive behaviour": "Incorrect. While impulse control disorders can occur as side effects of dopaminergic therapy, OCD is not the most common psychiatric issue in PD.",
      "Generalised anxiety disorder": "Incorrect. Anxiety is a recognised non-motor symptom, but it is less prevalent than depression in Parkinson's disease.",
      "Psychosis": "Incorrect. Psychosis may develop, especially in advanced PD or due to medication, but it is less common than depression.",
      "Bipolar disorder": "Incorrect. Mania or bipolar disorder is rare in PD and usually linked to medication side effects rather than the disease itself."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Depression",
    "topic": "Diagnostic criteria",
    "keywords": [
      "Parkinson's disease",
      "depression",
      "psychiatric symptoms",
      "non-motor features",
      "diagnosis"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Parkinson's disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/parkinsons-disease/"
      },
      {
        "source": "BNF",
        "topic_title": "Parkinson's disease",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/parkinsons-disease/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "99dff694-317c-4a7d-9757-19d8664ecf83",
    "question_number": 37,
    "question": "Which bacterial pathogen is most closely linked to triggering Guillain-Barré syndrome following a gastrointestinal infection?",
    "options": [
      "Campylobacter jejuni",
      "Salmonella enterica",
      "Listeria monocytogenes",
      "Streptococcus pyogenes",
      "Escherichia coli O157:H7"
    ],
    "correct_answer": "Campylobacter jejuni",
    "explanation": "**Explanation**\n**Campylobacter jejuni** is the most common infectious trigger for Guillain-Barré syndrome (GBS). This acute, immune-mediated polyneuropathy often follows a gastrointestinal or respiratory infection. The pathogenesis involves molecular mimicry: antibodies produced against Campylobacter antigens cross-react with gangliosides on peripheral nerves, leading to demyelination. Approximately 25% of GBS cases are preceded by Campylobacter infection. Distinguishing GBS from other causes of acute flaccid paralysis is essential, as early recognition and supportive management can reduce morbidity.\n\n**Key Points**\n<ul><li>Campylobacter jejuni infection is the leading antecedent in GBS.</li><li>GBS features progressive, symmetrical muscle weakness and areflexia.</li><li>Molecular mimicry causes immune attack on peripheral nerve myelin.</li><li>Other infections (e.g. CMV, EBV) are less commonly associated.</li><li>Prompt recognition is crucial for appropriate intervention.</li></ul>\n\n**Clinical Relevance**\nUnderstanding the link between Campylobacter jejuni and GBS is vital, especially in patients presenting with progressive weakness following recent diarrhoeal illness. Early diagnosis enables timely referral for immunotherapy and monitoring for respiratory compromise.\n\n**Memory Anchor**\nRemember: **\"C for Campylobacter, C for Causes GBS\"**—Campylobacter jejuni is Classic for Guillain-Barré.",
    "bullet_explanations": {
      "Campylobacter jejuni": "Correct – it is the pathogen most strongly associated with GBS.",
      "Salmonella enterica": "Incorrect – can cause gastroenteritis but rarely triggers GBS.",
      "Listeria monocytogenes": "Incorrect – typically causes meningitis in neonates and immunocompromised adults, not GBS.",
      "Streptococcus pyogenes": "Incorrect – associated with pharyngitis and rheumatic fever, not GBS.",
      "Escherichia coli O157:H7": "Incorrect – known for haemolytic uraemic syndrome, not commonly linked with GBS."
    },
    "category": "Neurology",
    "subsection": "Epilepsy",
    "subsubsection": "Focal vs generalised",
    "topic": "Guillain-Barré syndrome aetiology",
    "keywords": [
      "Guillain-Barré",
      "Campylobacter jejuni",
      "immune-mediated neuropathy"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "a92b8214-61e8-4465-95b5-7f59e55f94cc",
    "question_number": 38,
    "question": "A 55-year-old man with polymyalgia rheumatica is being monitored with routine blood tests. His full blood count reveals a neutrophil count of 8.2 x 10⁹/L (reference range 2.0–7.0). He is currently taking prednisolone. What is the most likely cause of his neutrophilia?",
    "options": [
      "Corticosteroid therapy",
      "Ramipril use",
      "Dapagliflozin therapy",
      "Exenatide injection",
      "Amlodipine prescription"
    ],
    "correct_answer": "Corticosteroid therapy",
    "explanation": "**Explanation**\n**Corticosteroid therapy is known to cause a rise in neutrophil count (neutrophilia)** due to several mechanisms, including demargination of neutrophils from the vascular endothelium and delayed neutrophil apoptosis. This effect is a recognised pharmacological response to systemic glucocorticoids such as prednisolone. Other medications listed do not typically result in neutrophilia; some may even cause reductions in white cell count. Neutrophilia in this clinical scenario is therefore most consistent with the effects of ongoing corticosteroid treatment, rather than an adverse drug reaction or underlying infection.\n\n**Key Points**\n- Corticosteroids increase circulating neutrophil count through demargination.\n- Neutrophilia is a common finding in patients on glucocorticoid therapy.\n- Other listed drugs (ramipril, dapagliflozin, exenatide, amlodipine) do not cause neutrophilia.\n- Prednisolone is frequently prescribed for inflammatory conditions such as polymyalgia rheumatica.\n- Routine blood monitoring is important to detect and interpret medication-induced changes.\n\n**Clinical Relevance**\nRecognising corticosteroid-induced neutrophilia prevents unnecessary investigations for infection or haematological disease and aids in the safe monitoring of patients on long-term glucocorticoid therapy, as emphasised in prescribing guidelines.",
    "bullet_explanations": {
      "Corticosteroid therapy": "Correct – Glucocorticoids like prednisolone commonly cause neutrophilia via demargination.",
      "Ramipril use": "Incorrect – ACE inhibitors like ramipril are not associated with neutrophilia; leucopenia is a rare adverse effect.",
      "Dapagliflozin therapy": "Incorrect – SGLT2 inhibitors do not typically affect white cell counts.",
      "Exenatide injection": "Incorrect – GLP-1 agonists do not alter white blood cell parameters.",
      "Amlodipine prescription": "Incorrect – Calcium channel blockers are not linked to neutrophilia; leucopenia is rare."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Anaemias",
    "topic": "Haemolytic anaemia features",
    "keywords": [
      "neutrophilia",
      "corticosteroids",
      "prednisolone",
      "blood count",
      "drug side effects"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Corticosteroids, general use",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/corticosteroids-general-use/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8decf95b-a40f-475a-b118-62620f822db0",
    "question_number": 39,
    "question": "Which Mental Health Act section permits police, with a magistrate's warrant, to enter a private residence and remove an individual suspected of having a mental disorder to a place of safety for assessment?",
    "options": [
      "Section 136",
      "Section 2",
      "Section 135",
      "Section 3",
      "Section 117"
    ],
    "correct_answer": "Section 135",
    "explanation": "**Explanation**\n**Section 135 of the Mental Health Act** authorises the police, with a warrant issued by a magistrate, to enter private premises and remove an individual suspected of having a mental disorder to a place of safety for assessment. This section is specifically designed for situations where entry to a person's home is required, but cannot be gained without legal authority. The warrant is typically granted following an application by an Approved Mental Health Professional (AMHP), who provides evidence of the need for assessment. This section contrasts with Section 136, which applies to individuals found in a public place, not private residences.\n\n**Key Points**\n- Section 135 allows police entry to private property with a magistrate's warrant.\n- It is used when a person suspected of mental disorder needs assessment and cannot be assessed voluntarily.\n- A place of safety can be a hospital, police station, or other approved location.\n- Section 136 is for public places only.\n- AMHP and a registered medical practitioner are generally involved in the process.\n- Section 2 and 3 are for hospital detention, not removal from the community.\n- <table><thead><tr><th>Section</th><th>Purpose</th></tr></thead><tbody><tr><td>135</td><td>Entry to private property; removal for assessment</td></tr><tr><td>136</td><td>Removal from public place to safety</td></tr></tbody></table>\n\n**Clinical Relevance**\nUnderstanding the specific powers provided by different sections of the Mental Health Act is crucial for safe, lawful management of acutely unwell psychiatric patients, especially when they cannot be assessed voluntarily. Section 135 is vital in safeguarding both patient rights and public safety.\n\n**Memory Anchor**\nSection 135 = '1 warrant for 3 (police, AMHP, doctor) to enter 5ome (home)'",
    "bullet_explanations": {
      "Section 136": "Incorrect: Section 136 applies only to individuals found in public places, not private residences.",
      "Section 2": "Incorrect: Section 2 enables hospital detention for assessment but does not grant powers of entry to private property.",
      "Section 135": "Correct: Section 135 authorises police entry to private premises with a warrant for mental health assessment.",
      "Section 3": "Incorrect: Section 3 allows for treatment in hospital but does not cover removal from a home.",
      "Section 117": "Incorrect: Section 117 addresses aftercare following certain sections, not removal or assessment."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Psychosis & Anxiety",
    "subsubsection": "Schizophrenia",
    "topic": "Relapse prevention",
    "keywords": [
      "Mental Health Act",
      "section 135",
      "police powers",
      "warrant",
      "place of safety"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "42ebf37c-5b47-4425-8bd9-792f5cc77a5b",
    "question_number": 40,
    "question": "A 62-year-old woman who underwent a heart transplant 8 years ago presents to her GP with a persistent, scaly nodule on her scalp that has gradually enlarged over 4 months and bled after minor trauma. She takes tacrolimus and mycophenolate mofetil. Which skin malignancy is she at particularly increased risk of due to her immunosuppression?",
    "options": [
      "Squamous cell carcinoma",
      "Basal cell carcinoma",
      "Malignant melanoma",
      "Seborrhoeic keratosis",
      "Pyogenic granuloma"
    ],
    "correct_answer": "Squamous cell carcinoma",
    "explanation": "**Explanation**\nIndividuals who have undergone solid organ transplantation and are maintained on long-term immunosuppressive drugs such as tacrolimus or mycophenolate have a dramatically increased risk of developing **squamous cell carcinoma (SCC) of the skin**. SCC in immunosuppressed patients is more common, often more aggressive, and more likely to recur or metastasise compared to the general population. The classic presentation is a slowly enlarging, firm, hyperkeratotic or ulcerated nodule—commonly on sun-exposed areas—that may bleed with minimal trauma. **Key distinguishing features** versus basal cell carcinoma (BCC) include the more rapid growth and potential for bleeding or ulceration. While BCC is also more frequent in this population, the increase in SCC risk is more pronounced and clinically concerning due to its aggressive behaviour in immunosuppressed patients.\n\n**Key Points**\n- Solid organ transplant recipients are at markedly increased risk for SCC of the skin.\n- SCC often presents as a persistent, scaly, or ulcerated nodule on sun-exposed skin.\n- Immunosuppression (e.g., tacrolimus, ciclosporin, mycophenolate) increases both incidence and aggressiveness of SCC.\n- SCC in these patients is more likely to recur or metastasise compared to non-immunosuppressed individuals.\n- BCC is also more common in this group, but SCC risk is relatively higher and more clinically significant.\n- <table><thead><tr><th>Feature</th><th>SCC</th><th>BCC</th></tr></thead><tbody><tr><td>Common Site</td><td>Sun-exposed</td><td>Sun-exposed</td></tr><tr><td>Appearance</td><td>Scaly, ulcerated, may bleed</td><td>Pearly, rolled edge</td></tr><tr><td>Risk with Immunosuppression</td><td>Very high</td><td>Increased</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising SCC in immunosuppressed patients is vital, as early diagnosis and urgent referral can reduce morbidity from aggressive or metastatic disease. UK guidance recommends a low threshold for urgent referral of suspicious skin lesions in transplant recipients.\n\n**Memory Anchor**\nRemember: 'SCC = Solid organ transplant risk Cancer'",
    "bullet_explanations": {
      "Squamous cell carcinoma": "Correct. Strongly associated with immunosuppression and presents as a persistent, scaly or ulcerated nodule.",
      "Basal cell carcinoma": "Common but less dramatically increased by immunosuppression; rarely bleeds or metastasises.",
      "Malignant melanoma": "Immunosuppression slightly increases risk, but melanoma is less strongly linked and typically presents as a pigmented lesion.",
      "Seborrhoeic keratosis": "Benign, waxy lesions not linked to immunosuppression or bleeding on trauma.",
      "Pyogenic granuloma": "Rapidly growing vascular lesion that bleeds easily, but not associated with immunosuppression or long-term risk."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Skin Malignancy",
    "topic": "Squamous cell carcinoma",
    "keywords": [
      "squamous cell carcinoma",
      "immunosuppression",
      "skin cancer",
      "transplant",
      "risk factors"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Immune response",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/immune-response/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Skin cancers - recognition and referral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/skin-cancers-recognition-referral/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "430a3d60-a895-496d-bab2-64525a8e2d64",
    "question_number": 41,
    "question": "A 65-year-old woman presents with a history of gradual central visual blurring over several months, now reporting a sudden marked decline in her ability to read and recognise faces. She denies pain or photophobia. On examination, a central scotoma is noted, and fundoscopy reveals well-demarcated haemorrhagic lesions at the macula. What is the most likely diagnosis?",
    "options": [
      "Wet (neovascular) age-related macular degeneration",
      "Retinal vein occlusion",
      "Dry age-related macular degeneration",
      "Diabetic macular oedema",
      "Acute angle-closure glaucoma"
    ],
    "correct_answer": "Wet (neovascular) age-related macular degeneration",
    "explanation": "**Explanation**\n**Wet (neovascular) age-related macular degeneration (AMD)** is characterised by sudden or rapid central vision loss, often superimposed on a history of gradual decline. The hallmark is the presence of choroidal neovascularisation, leading to leakage or bleeding beneath the retina, resulting in well-defined macular haemorrhages and a central scotoma. This contrasts with the dry form of AMD, which progresses slowly and rarely presents with acute deterioration or retinal haemorrhage. Other causes of sudden vision loss (e.g., retinal vein occlusion) may show widespread haemorrhages and are not typically limited to the macula nor preceded by gradual central visual decline. Acute angle-closure glaucoma presents with a painful red eye and systemic symptoms, not isolated central loss.\n\n**Key Points**\n- Wet AMD features sudden worsening of central vision after a period of gradual decline.\n- Fundoscopy in wet AMD shows macular haemorrhages due to neovascular leakage.\n- Dry AMD progresses slowly and lacks acute visual deterioration or haemorrhage.\n- Acute angle-closure glaucoma presents with pain, headache, and red eye—absent here.\n- Retinal vein occlusion causes widespread, not macula-restricted, retinal haemorrhage.\n- Diabetic macular oedema typically occurs in known diabetics with different retinal findings.\n\n**Clinical Relevance**\nEarly recognition of wet AMD is crucial, as prompt referral and intravitreal anti-VEGF therapy can preserve vision. NICE guidance recommends urgent ophthalmology referral when wet AMD is suspected due to the risk of rapid vision loss.\n\n**Memory Anchor**\nWet AMD = 'Wet and sudden'—think acute bleeding or leakage at the macula.",
    "bullet_explanations": {
      "Wet (neovascular) age-related macular degeneration": "Correct: Presents with sudden worsening of central vision, central scotoma, and macular haemorrhages.",
      "Retinal vein occlusion": "Usually presents with widespread retinal haemorrhages and sudden vision loss, but not preceded by gradual central decline.",
      "Dry age-related macular degeneration": "Progresses slowly without sudden acute deterioration or macular haemorrhages.",
      "Diabetic macular oedema": "Typically occurs in those with diabetes and displays different fundoscopic findings (hard exudates, retinal thickening).",
      "Acute angle-closure glaucoma": "Presents with a painful red eye, mid-dilated pupil, and systemic symptoms—absent in this scenario."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Acute angle-closure glaucoma",
    "topic": "Age-related macular degeneration",
    "keywords": [
      "wet AMD",
      "central vision loss",
      "macular haemorrhage",
      "ophthalmology",
      "fundoscopy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Age-related macular degeneration",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/age-related-macular-degeneration/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Macular degeneration - age-related",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/macular-degeneration-age-related/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d3be26d5-8f93-490e-8c7f-f3c334a4259b",
    "question_number": 42,
    "question": "At a routine 8-week check, a healthy infant girl is found to have a small, reducible umbilical hernia. She is feeding well and has no symptoms. What is the most appropriate next step in management?",
    "options": [
      "Reassure the parents and monitor for spontaneous resolution",
      "Arrange an urgent surgical referral",
      "Apply an adhesive dressing to support the hernia",
      "Request an abdominal ultrasound scan",
      "Admit for emergency surgical assessment"
    ],
    "correct_answer": "Reassure the parents and monitor for spontaneous resolution",
    "explanation": "**Explanation**\n**Umbilical hernias are common in infants and are usually harmless.** Most close spontaneously by the age of 2–3 years, especially if small and asymptomatic. **No immediate intervention is needed in well infants without complications.** Parents should be advised to observe for rare symptoms of incarceration or strangulation, such as vomiting, pain, or inability to reduce the hernia. **Taping or strapping is discouraged due to lack of benefit and potential skin irritation.** Referral to surgery is only necessary if the hernia persists beyond 2 years of age or becomes complicated.\n\n**Key Points**\n- Most infant umbilical hernias resolve without intervention by age 2–3 years.\n- Urgent referral is only required if there are signs of obstruction or strangulation.\n- Taping or adhesive dressings do not promote closure and may cause harm.\n- Ultrasound is not routinely indicated for uncomplicated, reducible hernias.\n- Monitor and provide safety-netting advice to parents.\n\n**Clinical Relevance**\nRecognising that most paediatric umbilical hernias are benign prevents unnecessary interventions and parental anxiety. Early surgical referral or imaging is reserved for complicated cases or hernias that persist after early childhood.",
    "bullet_explanations": {
      "Reassure the parents and monitor for spontaneous resolution": "Correct: Most infant umbilical hernias close spontaneously; reassurance and observation are appropriate.",
      "Arrange an urgent surgical referral": "Incorrect: Only indicated if the hernia is incarcerated, strangulated, or persists beyond 2 years.",
      "Apply an adhesive dressing to support the hernia": "Incorrect: Not recommended; evidence shows no benefit and possible skin irritation.",
      "Request an abdominal ultrasound scan": "Incorrect: Imaging is unnecessary in typical, reducible, asymptomatic hernias.",
      "Admit for emergency surgical assessment": "Incorrect: Only needed if there are signs of obstruction, strangulation, or acute distress."
    },
    "category": "Paediatrics",
    "subsection": "Neonatology",
    "subsubsection": "Congenital Conditions",
    "topic": "CHD basics",
    "keywords": [
      "umbilical hernia",
      "infant",
      "management",
      "reassurance",
      "paediatrics"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NHS Choices",
        "topic_title": "Umbilical hernia in children",
        "citation": "© Crown copyright",
        "url": "http://www.nhs.uk/conditions/Umbilicalhernia/Pages/Whatisitpage.aspx"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c72ce2fe-019a-4bc1-93a1-d6ab148e2982",
    "question_number": 43,
    "question": "A 71-year-old man presents to his GP with a persistent ulcer over the lateral aspect of his right lower leg, present for 2 months. The wound has not responded to topical dressings or oral antibiotics. On examination, the ulcer is shallow with irregular edges, mild surrounding oedema, and no signs of acute infection. Which initial investigation is most important to guide further management?",
    "options": [
      "Measure the ankle-brachial pressure index (ABPI)",
      "Request a lower limb venous duplex ultrasound",
      "Send a wound swab for bacterial culture",
      "Order rheumatoid factor serology",
      "Arrange an urgent skin biopsy"
    ],
    "correct_answer": "Measure the ankle-brachial pressure index (ABPI)",
    "explanation": "**Explanation**\n**Measuring the ankle-brachial pressure index (ABPI) is essential in the assessment of any chronic leg ulcer before initiating compression therapy.** This test helps to exclude significant arterial insufficiency, which would contraindicate compression and impair ulcer healing. Venous ulcers are most common in the gaiter area and may persist despite antibiotics if the underlying issue is vascular, not infective. Other investigations, such as wound swabs or autoimmune markers, are reserved for cases with clinical suspicion of infection or alternative pathology. ABPI values below 0.9 indicate arterial disease, and values above 1.3 may suggest vessel calcification, both requiring specialist review. <br><br>**In summary:** ABPI is a non-invasive, first-line test that guides safe and effective management of leg ulcers and helps differentiate between venous and arterial aetiologies.\n\n**Key Points**\n- Chronic leg ulcers require vascular assessment before compression therapy.\n- ABPI < 0.9 suggests arterial disease; compression is contraindicated.\n- Venous ulcers are typically located in the gaiter region (ankle to mid-calf).\n- Wound swabs are not routinely indicated unless infection is suspected.\n- Other causes of non-healing ulcers include arterial disease, diabetes, vasculitis, malignancy.\n- <table><thead><tr><th>ABPI Value</th><th>Interpretation</th></tr></thead><tbody><tr><td>0.9 - 1.2</td><td>Normal</td></tr><tr><td>&lt; 0.9</td><td>Arterial disease</td></tr><tr><td>&gt; 1.3</td><td>Calcified vessels (e.g. diabetes)</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurate diagnosis and appropriate initial investigation of chronic leg ulcers are crucial for safe management and to avoid complications. National guidelines recommend ABPI measurement as the primary assessment to differentiate between venous and arterial ulcers and to guide compression therapy, which is the cornerstone of venous ulcer management.\n\n**Memory Anchor**\nABPI = 'A Before P' (Arteries Before Pressure) — always check arteries before applying compression.",
    "bullet_explanations": {
      "Measure the ankle-brachial pressure index (ABPI)": "Correct – Determines arterial supply and safety of compression therapy; first-line in chronic leg ulcers.",
      "Request a lower limb venous duplex ultrasound": "Useful for surgical planning or unclear cases, but not the initial step in primary care evaluation.",
      "Send a wound swab for bacterial culture": "Only indicated if there are clinical signs of infection; not routinely required for non-healing ulcers.",
      "Order rheumatoid factor serology": "Occasionally helpful if vasculitis or autoimmune disease is suspected, but not first-line in typical chronic ulcers.",
      "Arrange an urgent skin biopsy": "Considered if malignancy or atypical ulcer is suspected after initial assessment or if the ulcer fails to heal despite treatment."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Infections",
    "topic": "Cellulitis/erysipelas",
    "keywords": [
      "venous ulcer",
      "chronic leg ulcer",
      "ABPI",
      "vascular assessment",
      "compression therapy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Leg ulcer - venous",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/leg-ulcer-venous/"
      },
      {
        "source": "BNF",
        "topic_title": "Skin infections, antibacterial therapy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/skin-infections-antibacterial-therapy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "106949ab-d220-40d2-acd1-d6239b32b1ef",
    "question_number": 44,
    "question": "A 46-year-old man with a history of granulomatosis with polyangiitis presents with severe, deep, aching pain in his right eye that has persisted for two days. The pain is intense enough to disturb his sleep. He also reports photophobia and a noticeable reduction in vision. On examination, the eye is diffusely red without discharge. Which is the most likely diagnosis?",
    "options": [
      "Scleritis",
      "Acute angle-closure glaucoma",
      "Keratitis",
      "Anterior uveitis",
      "Episcleritis"
    ],
    "correct_answer": "Scleritis",
    "explanation": "**Explanation**\n**Scleritis** is characterised by severe, deep, boring eye pain that often radiates and can be severe enough to wake patients from sleep. It is frequently associated with underlying systemic autoimmune conditions such as granulomatosis with polyangiitis or rheumatoid arthritis. Key distinguishing features include the intensity and nature of the pain, photophobia, and visual impairment. Scleritis involves inflammation of the full thickness of the sclera, making it a sight-threatening condition requiring urgent ophthalmological assessment and systemic therapy. In contrast, **episcleritis** causes mild discomfort or grittiness but rarely severe pain or vision loss. **Anterior uveitis** can present with pain and photophobia but typically involves a dull ache rather than a boring pain, and association with certain systemic diseases differs. **Keratitis** usually presents with foreign body sensation and photophobia, and **acute angle-closure glaucoma** is marked by headache, nausea, and halos around lights, alongside a semi-dilated pupil and a hard, tender globe.\n\n**Key Points**\n- Scleritis presents with severe, boring pain often disturbing sleep.\n- Commonly linked with systemic autoimmune diseases.\n- Sight-threatening—requires urgent specialist referral.\n- Photophobia and reduced vision are frequent.\n- Distinguished from episcleritis by pain severity and risk of visual loss.\n- Episcleritis: mild discomfort, normal vision.\n- Anterior uveitis: dull ache, photophobia, less often linked to granulomatosis with polyangiitis.\n- Acute angle-closure glaucoma: headache, nausea, halos, elevated intraocular pressure.\n- <table><thead><tr><th>Condition</th><th>Pain</th><th>Vision</th><th>Systemic Link</th></tr></thead><tbody><tr><td>Scleritis</td><td>Severe, deep</td><td>Reduced</td><td>Strong</td></tr><tr><td>Episcleritis</td><td>Mild, gritty</td><td>Normal</td><td>Some</td></tr><tr><td>Uveitis</td><td>Dull ache</td><td>Reduced</td><td>Variable</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising scleritis is crucial in general practice and emergency settings, especially in patients with autoimmune disease, as delayed intervention can result in permanent vision loss. NICE guidance emphasises urgent referral for any patient with a red eye and moderate to severe pain or visual changes.\n\n**Memory Anchor**\nScleritis = 'S' for Severe, Sight-threatening, Systemic disease associated.",
    "bullet_explanations": {
      "Scleritis": "Correct—severe, boring pain with photophobia and visual loss, often linked to systemic autoimmune disease.",
      "Acute angle-closure glaucoma": "Incorrect—typically presents with headache, nausea, halos around lights, and a hard, tender eye.",
      "Keratitis": "Incorrect—usually causes foreign body sensation and photophobia; pain is less severe and not typically described as boring.",
      "Anterior uveitis": "Incorrect—can cause photophobia and mild pain, but pain is usually a dull ache, not severe or sleep-disturbing.",
      "Episcleritis": "Incorrect—causes mild discomfort, not severe pain, and does not affect vision."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Episcleritis vs scleritis",
    "topic": "Episcleritis vs scleritis",
    "keywords": [
      "scleritis",
      "red eye",
      "autoimmune",
      "episcleritis",
      "ophthalmology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Red eye",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/red-eye/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "282e783b-b047-4da4-8ca7-79e424876d6b",
    "question_number": 45,
    "question": "In a 54-year-old woman diagnosed with hereditary haemochromatosis and undergoing regular venesection, which pair of laboratory investigations is most appropriate for monitoring her response to treatment?",
    "options": [
      "Serum ferritin and transferrin saturation",
      "Serum iron and ferritin",
      "Serum iron and total iron-binding capacity (TIBC)",
      "Serum ferritin and TIBC",
      "Serum iron and transferrin saturation"
    ],
    "correct_answer": "Serum ferritin and transferrin saturation",
    "explanation": "**Explanation**\n**Serum ferritin** reflects total body iron stores and is the primary marker used to assess iron overload and monitor depletion during venesection in haemochromatosis. **Transferrin saturation** indicates the percentage of transferrin molecules bound with iron, thus reflecting the degree of iron availability in the blood. Monitoring both parameters enables clinicians to assess both iron storage and circulating iron, allowing for safe titration of phlebotomy frequency and early detection of under- or over-treatment. In contrast, serum iron levels can fluctuate considerably with diet and daily variation, while total iron-binding capacity (TIBC) is less sensitive for monitoring disease progress or response to treatment in this context.\n\n**Key Points**\n- Serum ferritin is the main marker for assessing iron overload and response to venesection.\n- Transferrin saturation provides a measure of circulating iron and is elevated in untreated haemochromatosis.\n- Serum iron alone is unreliable due to diurnal and dietary variation.\n- TIBC (total iron-binding capacity) is not a primary monitoring tool in haemochromatosis.\n- Both ferritin and transferrin saturation should decrease toward normal with successful treatment.\n- <table><thead><tr><th>Test</th><th>Use in Monitoring</th></tr></thead><tbody><tr><td>Ferritin</td><td>Yes (iron stores)</td></tr><tr><td>Transferrin saturation</td><td>Yes (iron availability)</td></tr><tr><td>Serum iron</td><td>No (variable)</td></tr><tr><td>TIBC</td><td>No (not sensitive for response)</td></tr></tbody></table>\n\n**Clinical Relevance**\nAppropriate monitoring of iron parameters is essential in hereditary haemochromatosis to prevent complications from both iron overload and excessive iron depletion. National guidelines recommend using ferritin and transferrin saturation to guide and adjust the frequency of venesection, supporting patient safety and treatment effectiveness.\n\n**Memory Anchor**\nThink 'Ferri-Tin & Transferrin Saturation': 'Tin' for storage, 'Transferrin' for transport.",
    "bullet_explanations": {
      "Serum ferritin and transferrin saturation": "Correct – these two markers are the gold standard for monitoring iron overload and response to venesection in haemochromatosis.",
      "Serum iron and ferritin": "Incorrect – serum iron is highly variable and not reliable for monitoring response.",
      "Serum iron and total iron-binding capacity (TIBC)": "Incorrect – both serum iron and TIBC fluctuate and are not recommended for regular monitoring.",
      "Serum ferritin and TIBC": "Incorrect – TIBC is not sensitive enough for monitoring treatment efficacy in haemochromatosis.",
      "Serum iron and transferrin saturation": "Incorrect – transferrin saturation is useful, but serum iron alone is too variable to be used reliably."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Anaemias",
    "topic": "Haemolytic anaemia features",
    "keywords": [
      "haemochromatosis",
      "iron overload",
      "ferritin",
      "transferrin saturation",
      "venesection monitoring"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Iron overload",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/iron-overload/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "843a158e-d9eb-4958-b8f0-250fd389392c",
    "question_number": 46,
    "question": "What is the most frequent endogenous cause of Cushing's syndrome in adults presenting with features such as central obesity, facial rounding, and purple abdominal striae?",
    "options": [
      "ACTH-secreting pituitary adenoma",
      "Adrenal adenoma",
      "Ectopic ACTH-producing tumour",
      "Adrenal carcinoma",
      "Micronodular adrenal hyperplasia"
    ],
    "correct_answer": "ACTH-secreting pituitary adenoma",
    "explanation": "**Explanation**\n**ACTH-secreting pituitary adenoma**, also known as Cushing's disease, is the leading endogenous cause of Cushing's syndrome. This pituitary tumour causes excess adrenocorticotropic hormone (ACTH) release, which in turn stimulates the adrenal glands to produce excessive cortisol. While exogenous glucocorticoid use is overall the most common cause of Cushing's syndrome, among endogenous (internal) causes, pituitary adenomas surpass adrenal or ectopic sources. Classic clinical findings—such as truncal obesity, moon facies, dorsocervical fat pad ('buffalo hump'), and violaceous striae—are hallmarks of cortisol excess but are not specific to the underlying aetiology. Distinguishing Cushing's disease from adrenal or ectopic ACTH sources requires biochemical testing and imaging.\n\n**Key Points**\n- Cushing's syndrome is due to prolonged exposure to elevated cortisol.\n- Most cases overall are caused by **exogenous (iatrogenic) steroid therapy**.\n- Among endogenous causes, pituitary ACTH-secreting tumours (Cushing's disease) are most common.\n- Other endogenous causes include adrenal adenoma/carcinoma and ectopic ACTH secretion, but these are less frequent.\n- Initial screening for hypercortisolism includes dexamethasone suppression test, 24-hour urinary free cortisol, and late-night salivary cortisol.\n- <table><thead><tr><th>Endogenous Cause</th><th>Frequency</th></tr></thead><tbody><tr><td>Pituitary adenoma (Cushing's disease)</td><td>Most common</td></tr><tr><td>Adrenal adenoma/carcinoma</td><td>Less common</td></tr><tr><td>Ectopic ACTH</td><td>Rare</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the most common endogenous cause of Cushing's syndrome is crucial for targeting initial workup and referral. Guidelines recommend specialist endocrinology assessment and appropriate biochemical screening in suspected cases to differentiate between pituitary, adrenal, and ectopic sources, as management strategies differ substantially.",
    "bullet_explanations": {
      "ACTH-secreting pituitary adenoma": "This is the most common endogenous cause of Cushing's syndrome (Cushing's disease).",
      "Adrenal adenoma": "Adrenal adenomas can produce cortisol but are a less frequent endogenous cause than pituitary tumours.",
      "Ectopic ACTH-producing tumour": "Rare, typically associated with small cell lung cancer or other malignancies; not the most common endogenous cause.",
      "Adrenal carcinoma": "Malignant adrenal tumours are a rare source of endogenous Cushing's syndrome.",
      "Micronodular adrenal hyperplasia": "An uncommon cause, usually seen in younger patients or familial syndromes."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Cushing’s Syndrome",
    "topic": "ACTH-dependent vs independent",
    "keywords": [
      "Cushing's syndrome",
      "pituitary adenoma",
      "endogenous",
      "ACTH",
      "differential diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cushing's syndrome",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cushings-syndrome/"
      },
      {
        "source": "BNF",
        "topic_title": "Cushing's syndrome",
        "citation": "© NICE BNFC, 2025",
        "url": "https://bnfc.nice.org.uk/treatment-summaries/cushings-syndrome/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "06754bc7-e4e1-4ac5-9f19-80f2ac6efa85",
    "question_number": 47,
    "question": "A 54-year-old man presents with persistent pruritic lesions on his wrists and ankles. On examination, you observe multiple violaceous, flat-topped, polygonal papules on the flexor surfaces of both wrists. There is no sign of scale, and the rest of his skin and nails are unremarkable. What is the most likely diagnosis?",
    "options": [
      "Lichen planus",
      "Chronic plaque psoriasis",
      "Atopic eczema",
      "Pityriasis alba",
      "Scabies infestation"
    ],
    "correct_answer": "Lichen planus",
    "explanation": "**Explanation**\n**Lichen planus** typically presents as intensely itchy, violaceous (purple), flat-topped, polygonal papules, commonly located on the flexor surfaces of the wrists, ankles, and sometimes the genitalia or oral mucosa. The absence of scale and the distinctive colour and shape help distinguish it from other pruritic dermatoses. **Psoriasis commonly affects extensor surfaces and is often scaly; eczema is characterised by erythema, lichenification, and dryness; pityriasis alba produces pale patches, usually on the face in children; scabies presents with burrows and affects interdigital spaces and the trunk.** Lichen planus remains a clinical diagnosis and is considered immune-mediated, with a chronic relapsing course.\n\n**Key Points**\n- Lichen planus presents with flat-topped, violaceous, polygonal papules.\n- Commonly affects flexor surfaces, wrists, ankles, genitalia, and oral mucosa.\n- Intense pruritus is characteristic.\n- Psoriasis typically affects extensor surfaces and is scaly.\n- Eczema shows erythema, dryness, and lichenification, often in flexures in children.\n- Pityriasis alba causes hypopigmented, fine-scaled patches, mainly on the face of children.\n- Scabies presents with burrows, papules, and intense nocturnal itch, often in web spaces.\n- <table><thead><tr><th>Condition</th><th>Key Features</th></tr></thead><tbody><tr><td>Lichen planus</td><td>Violaceous, flat-topped papules, wrists/ankles, pruritic</td></tr><tr><td>Psoriasis</td><td>Scaly plaques, extensor surfaces, silvery scale</td></tr><tr><td>Eczema</td><td>Itchy, dry, erythematous, flexural in children</td></tr><tr><td>Pityriasis alba</td><td>Pale, fine-scaled patches, typically facial</td></tr><tr><td>Scabies</td><td>Burrows, papules, web spaces, trunk</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising lichen planus is important in primary care to distinguish it from other common pruritic skin conditions. Early identification ensures appropriate management and referral, especially if there is oral or widespread involvement. Understanding the typical morphology and distribution can prevent misdiagnosis and unnecessary treatments.\n\n**Memory Anchor**\nRemember the '6 Ps' of lichen planus: Pruritic, Purple, Polygonal, Planar, Papules, and Plaques.",
    "bullet_explanations": {
      "Lichen planus": "Correct – Classic presentation with violaceous, polygonal papules on flexor surfaces.",
      "Chronic plaque psoriasis": "Incorrect – Psoriasis usually presents on extensor surfaces and is scaly, not violaceous or flat-topped.",
      "Atopic eczema": "Incorrect – Eczema is typically erythematous, lichenified, and affects flexures, especially in children.",
      "Pityriasis alba": "Incorrect – Characterised by pale, fine-scaled patches on the face, mainly in children.",
      "Scabies infestation": "Incorrect – Scabies presents with burrows, papules, and intense itching, often affecting web spaces and trunk."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Lichen planus",
    "keywords": [
      "lichen planus",
      "pruritic papules",
      "flexor surfaces",
      "dermatology diagnosis",
      "MSRA skin"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Psoriasis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/psoriasis/"
      },
      {
        "source": "BNF",
        "topic_title": "Eczema",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/eczema/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "073572e1-78e4-4d7f-a932-27eb2ffb4116",
    "question_number": 48,
    "question": "A 24-year-old man is brought to A&E with acute onset fever, severe headache, photophobia, vomiting, and a rapidly spreading non-blanching purpuric rash on his legs. His temperature is 39°C, pulse 110 bpm, and blood pressure 104/63 mmHg. He is alert but appears distressed and has marked neck stiffness. Blood cultures have been drawn and intravenous access is established. What is the most urgent next step in his management?",
    "options": [
      "Immediate intravenous ceftriaxone administration",
      "Arrange urgent CT head before further treatment",
      "Perform lumbar puncture to confirm diagnosis",
      "Monitor observations and await blood culture results",
      "Start high-dose intravenous dexamethasone"
    ],
    "correct_answer": "Immediate intravenous ceftriaxone administration",
    "explanation": "**Explanation**\n**Acute bacterial meningitis with a purpuric rash suggests meningococcal disease, a medical emergency requiring immediate empirical antibiotic therapy.** Ceftriaxone is the recommended first-line intravenous antibiotic in the UK for suspected meningococcal meningitis. Delaying treatment for imaging or lumbar puncture can be fatal, as early antibiotics significantly reduce mortality. Dexamethasone is sometimes given with or just before antibiotics in certain types of bacterial meningitis, but it must not delay the initiation of antibiotics. Imaging is only indicated prior to lumbar puncture if there are focal neurological signs, papilloedema, or seizures.\n\n**Key Points**\n- Suspect meningococcal disease in bacterial meningitis with non-blanching petechial/purpuric rash.\n- Immediate IV antibiotics (ceftriaxone or cefotaxime) are lifesaving and must not be delayed.\n- Lumbar puncture is contraindicated in unstable patients or those with signs of raised intracranial pressure.\n- Dexamethasone can be considered but should never delay antibiotics.\n- Imaging (CT head) is only required before LP in specific cases (focal neurology, reduced GCS, papilloedema, or seizures).\n- <table><thead><tr><th>Step</th><th>Indication</th></tr></thead><tbody><tr><td>IV Antibiotics</td><td>All suspected cases immediately</td></tr><tr><td>CT Head</td><td>Only if focal signs or reduced consciousness</td></tr><tr><td>Lumbar Puncture</td><td>After stabilisation, if safe</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition and treatment of suspected meningococcal meningitis is vital. UK guidelines (NICE, BNF) emphasise urgent empirical antibiotic therapy to reduce morbidity and mortality. Early intervention is a key patient safety principle in acute care.\n\n**Memory Anchor**\nThink: 'Rash + Rigidity = Rapid Rx (ceftriaxone)'",
    "bullet_explanations": {
      "Immediate intravenous ceftriaxone administration": "Correct – Urgent IV antibiotics save lives and should never be delayed in suspected meningococcal disease.",
      "Arrange urgent CT head before further treatment": "Incorrect – CT is only required if there are focal neurological deficits, papilloedema, new seizures, or reduced consciousness.",
      "Perform lumbar puncture to confirm diagnosis": "Incorrect – LP should be deferred until the patient is stable and after antibiotics have been started; delay risks death.",
      "Monitor observations and await blood culture results": "Incorrect – Passive monitoring delays essential treatment and increases mortality risk.",
      "Start high-dose intravenous dexamethasone": "Incorrect – Dexamethasone may be given with/just before antibiotics, but antibiotics must never be delayed for steroids."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "CNS Infections",
    "topic": "Meningitis empiric therapy by age",
    "keywords": [
      "meningitis",
      "ceftriaxone",
      "meningococcal",
      "empiric antibiotics"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Meningitis - bacterial meningitis and meningococcal disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/meningitis-bacterial-meningitis-meningococcal-disease/"
      },
      {
        "source": "BNF",
        "topic_title": "Central nervous system infections, antibacterial therapy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/central-nervous-system-infections-antibacterial-therapy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "3ef8aa3f-a35b-4d4e-81b5-01beb218806a",
    "question_number": 49,
    "question": "A 39-year-old woman, who smokes 18 cigarettes daily, attends to discuss starting the combined oral contraceptive pill. Which of the following factors constitutes an absolute (UKMEC 4) contraindication to prescribing the COCP?",
    "options": [
      "Age over 35 years and smoking more than 15 cigarettes daily",
      "Breastfeeding at 10 weeks postpartum",
      "BMI of 28 kg/m²",
      "Migraine without aura",
      "Family history of venous thromboembolism at age 58"
    ],
    "correct_answer": "Age over 35 years and smoking more than 15 cigarettes daily",
    "explanation": "**Explanation**\n**Women aged over 35 who smoke more than 15 cigarettes per day should not be prescribed the combined oral contraceptive pill (COCP), as this is classified as a UKMEC 4 (absolute) contraindication.** This combination significantly increases the risk of cardiovascular events such as myocardial infarction and stroke due to synergistic effects of oestrogen and tobacco on vascular pathology. Other options listed, while potentially requiring caution or further assessment, do not meet the threshold for a UKMEC 4 contraindication in this scenario.\n\n**Key Points**\n- UKMEC 4 = absolute contraindication: risks outweigh benefits, COCP not to be prescribed.\n- Age >35 and smoking >15 cigarettes/day is UKMEC 4 for COCP.\n- Breastfeeding <6 weeks postpartum is UKMEC 4; after 6 weeks, risk lowers to UKMEC 2-3 depending on other factors.\n- Migraine with aura is UKMEC 3 or 4; migraine without aura is usually UKMEC 1 or 2.\n- BMI >35 kg/m² is UKMEC 3; BMI 25–29 is not a contraindication.\n- Family history of VTE <45 years is UKMEC 3; at older ages, not a direct contraindication.\n\n**Clinical Relevance**\nAssessing UKMEC criteria is crucial for safe contraceptive prescribing, as certain combinations—like age and heavy smoking—substantially increase the risk of serious adverse events. This ensures patient safety and adherence to national guidelines.\n\n**Memory Anchor**\nRemember: '35 and 15'—Age over 35 plus 15+ cigarettes daily is a red line for COCP.",
    "bullet_explanations": {
      "Age over 35 years and smoking more than 15 cigarettes daily": "This combination is a UKMEC 4 (absolute) contraindication to COCP due to high cardiovascular risk.",
      "Breastfeeding at 10 weeks postpartum": "Breastfeeding between 6 weeks and 6 months postpartum is UKMEC 2 (advantages generally outweigh risks) for COCP.",
      "BMI of 28 kg/m²": "This BMI does not contraindicate COCP; UKMEC 3 applies only at BMI >35 kg/m².",
      "Migraine without aura": "Migraine without aura is not an absolute contraindication; only migraine with aura is UKMEC 3 or 4.",
      "Family history of venous thromboembolism at age 58": "Family history of VTE is only a UKMEC 3 contraindication if the event occurred before age 45."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Combined pill",
    "keywords": [
      "COCP",
      "UKMEC contraindications",
      "smoking",
      "age over 35",
      "contraceptive safety"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "b41d121e-59bd-4189-bd5d-d5cfeadb7667",
    "question_number": 50,
    "question": "A 54-year-old woman, whose last menstrual period was 9 months ago, asks whether she still needs to use contraception. She reports classic menopausal symptoms, including night sweats and mood changes. According to UK recommendations, how long should she continue contraception after her final period at her age?",
    "options": [
      "Contraception is required until 12 months after her last period",
      "Contraception is no longer necessary",
      "Contraception is required until 24 months after her last period",
      "Contraception should be continued for 18 months after her last period",
      "Contraception must be used until 36 months after the last period"
    ],
    "correct_answer": "Contraception is required until 12 months after her last period",
    "explanation": "**Explanation**\nWomen over 50 years of age are advised to continue contraception until they have had 12 consecutive months of amenorrhoea, as this is the clinical threshold for diagnosing menopause. **Menopause is confirmed after 12 months without periods**. Stopping contraception before this interval risks unintended pregnancy, as spontaneous ovulation may still occur until menopause is certain. By contrast, women under 50 are advised to wait 24 months. This approach ensures safe transition through the perimenopausal period, when ovulatory cycles can be unpredictable.\n\n**Key Points**\n- Menopause is diagnosed clinically after 12 months of amenorrhoea.\n- Women >50 years should use contraception until 12 months after the last period.\n- Women <50 years require contraception for 24 months after the last period.\n- Perimenopause is characterised by irregular cycles and symptoms, but ovulation may still occur.\n- Stopping contraception prematurely can result in unintended pregnancy.\n\n**Clinical Relevance**\nProviding clear advice on contraception duration during the menopausal transition is essential to prevent unplanned pregnancies, as per NICE guidance. Many women remain at risk of conception until menopause is confirmed, making tailored advice a key aspect of perimenopausal care.\n\n**Memory Anchor**\nRemember: **'12 after 50, 24 before 50'** for contraception after last period.",
    "bullet_explanations": {
      "Contraception is required until 12 months after her last period": "Correct; this aligns with UK guidance for women over 50 years.",
      "Contraception is no longer necessary": "Incorrect; menopause is not confirmed until 12 months of amenorrhoea.",
      "Contraception is required until 24 months after her last period": "Incorrect; this interval is recommended for women under 50 years.",
      "Contraception should be continued for 18 months after her last period": "Incorrect; there is no guideline recommending 18 months as a threshold.",
      "Contraception must be used until 36 months after the last period": "Incorrect; this duration greatly exceeds guideline recommendations and is unnecessary."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Contraindications",
    "keywords": [
      "contraception",
      "menopause",
      "amenorrhoea",
      "perimenopause",
      "guidelines"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Menopause",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/menopause/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b0ed5536-3591-46a8-8d89-efb24e0d452a",
    "question_number": 51,
    "question": "A 58-year-old man with longstanding type 2 diabetes attends his annual review. He is taking metformin and gliclazide, and his most recent HbA1c is 64 mmol/mol. He has a history of hypertension (on amlodipine) and recurrent episodes of balanitis. He is anxious about starting injectable treatments. What is the most appropriate next step to optimise his glycaemic control?",
    "options": [
      "Add sitagliptin to his current regimen",
      "Discontinue all oral medications and start once-daily insulin",
      "Switch gliclazide to pioglitazone",
      "Add dapagliflozin to metformin and gliclazide",
      "Start exenatide in addition to current therapy"
    ],
    "correct_answer": "Add sitagliptin to his current regimen",
    "explanation": "**Explanation**\n**NICE guidelines recommend adding a third oral agent for patients with type 2 diabetes inadequately controlled on dual therapy (metformin plus sulfonylurea) if their HbA1c remains above target (generally >58 mmol/mol).** Sitagliptin (a DPP-4 inhibitor) is a suitable choice as it does not cause weight gain or hypoglycaemia and is taken orally. SGLT2 inhibitors—such as dapagliflozin—should be used cautiously or avoided in people with recurrent genitourinary infections because they increase the risk of mycotic genital and urinary tract infections. GLP-1 agonists (like exenatide) are typically reserved for those with BMI ≥35 or when triple oral therapy is not tolerated or contraindicated. Insulin may be considered if oral options are unsuitable, but this patient is needle-averse. Switching to pioglitazone is not indicated without a trial of triple therapy.\n\n**Key Points**\n- Triple oral therapy is recommended when dual therapy fails to control HbA1c in type 2 diabetes.\n- DPP-4 inhibitors (e.g., sitagliptin) are safe oral add-ons with minimal side effects.\n- SGLT2 inhibitors should be avoided in patients with recurrent genital or urinary tract infections.\n- GLP-1 agonists require specific criteria for initiation (e.g., high BMI, triple oral therapy failure).\n- Insulin is usually reserved for patients who cannot tolerate or do not achieve control with oral agents.\n\n**Clinical Relevance**\nSelecting the correct add-on therapy for type 2 diabetes requires consideration of comorbidities, side effect profiles, and patient preferences. NICE guidance supports the addition of a DPP-4 inhibitor in this scenario, avoiding agents that may worsen pre-existing conditions.\n\n**Memory Anchor**\nDPP-4 inhibitors are 'Diabetes Pill Partners'—easy oral add-ons when SGLT2 inhibitors are contraindicated.",
    "bullet_explanations": {
      "Add sitagliptin to his current regimen": "Correct – DPP-4 inhibitors are appropriate oral third-line agents when SGLT2 inhibitors are contraindicated.",
      "Discontinue all oral medications and start once-daily insulin": "Incorrect – Insulin may be considered if oral therapy fails, but patient preference and needle aversion make it less suitable here.",
      "Switch gliclazide to pioglitazone": "Incorrect – Switching is not recommended unless intolerant to sulfonylureas; triple oral therapy should be tried first.",
      "Add dapagliflozin to metformin and gliclazide": "Incorrect – SGLT2 inhibitors increase risk of genital/urinary infections, which this patient already experiences.",
      "Start exenatide in addition to current therapy": "Incorrect – GLP-1 agonists are reserved for those with high BMI (≥35) or failure/intolerance of triple oral therapy."
    },
    "category": "Diabetes – Chronic",
    "subsection": "Type 2 Diabetes",
    "subsubsection": "Metformin first-line and intolerance",
    "topic": "Metformin first-line and intolerance",
    "keywords": [
      "type 2 diabetes",
      "triple therapy",
      "DPP-4 inhibitor",
      "SGLT2 inhibitor contraindication",
      "HbA1c management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Type 2 diabetes mellitus",
        "citation": "© NICE, 2022",
        "url": "https://cks.nice.org.uk/topics/diabetes-type-2/management/management-adults/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "392d793c-629d-4760-b542-c8ed89505773",
    "question_number": 52,
    "question": "Which disease-modifying antirheumatic drug (DMARD) is most commonly associated with the development of proteinuria as a notable adverse effect?",
    "options": [
      "Sulfasalazine",
      "Azathioprine",
      "Gold (sodium aurothiomalate)",
      "Methotrexate",
      "Hydroxychloroquine"
    ],
    "correct_answer": "Gold (sodium aurothiomalate)",
    "explanation": "**Explanation**\n**Gold (sodium aurothiomalate)** is a classic DMARD that is now rarely used but is notable for its potential to cause proteinuria due to nephrotoxicity. Gold can induce membranous nephropathy, leading to protein loss in the urine, and regular monitoring of urinary protein is mandated during therapy. This side effect is much more characteristic and clinically significant with gold than with most other DMARDs. In contrast, while other DMARDs can have renal effects, proteinuria is a hallmark adverse effect strongly associated with gold therapy, necessitating prompt drug cessation if it develops.<br><br>Other DMARDs (such as methotrexate, sulfasalazine, and hydroxychloroquine) have different toxicity profiles, with gold being uniquely linked to renal protein loss.\n\n**Key Points**\n- Gold (sodium aurothiomalate) is linked to proteinuria due to its nephrotoxic potential.\n- Proteinuria can signal the onset of gold-induced nephropathy.\n- Routine urinalysis is required for patients on gold therapy.\n- Immediate discontinuation is recommended if significant proteinuria develops.\n- Other DMARDs rarely cause proteinuria as a primary adverse effect.\n\n**Clinical Relevance**\nRecognising drug-specific adverse effects is essential for monitoring and patient safety in rheumatology. Proteinuria in a patient on gold therapy is a clinical red flag and requires urgent review and typically cessation of therapy. This underlines the importance of regular monitoring protocols for DMARDs, as recommended by national guidelines.\n\n**Memory Anchor**\nThink 'golden urine'—gold therapy can make urine abnormal due to protein loss.",
    "bullet_explanations": {
      "Sulfasalazine": "More commonly causes reversible oligospermia and GI upset, not proteinuria.",
      "Azathioprine": "Can cause bone marrow suppression and hepatotoxicity but is not classically linked to proteinuria.",
      "Gold (sodium aurothiomalate)": "Correct – most frequently associated with proteinuria among DMARDs due to nephrotoxicity.",
      "Methotrexate": "Mainly causes hepatotoxicity and myelosuppression; renal protein loss is not typical.",
      "Hydroxychloroquine": "Noted for risk of retinopathy; renal adverse effects are rare."
    },
    "category": "Musculoskeletal",
    "subsection": "Arthritis",
    "subsubsection": "Rheumatoid Arthritis",
    "topic": "DMARD initiation and monitoring",
    "keywords": [
      "DMARD",
      "gold",
      "proteinuria",
      "rheumatoid arthritis",
      "adverse effect"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Rheumatic disease, suppressing drugs",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/rheumatic-disease-suppressing-drugs/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "DMARDs",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/dmards/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a79d5d26-3458-455e-8846-d2ba69239bc2",
    "question_number": 53,
    "question": "A 29-year-old woman at 36 weeks’ gestation is brought to maternity triage with sudden onset of severe, constant lower abdominal pain and a brief episode of vaginal bleeding that has now mostly stopped. She appears pale, is sweating profusely, and is hypotensive. On abdominal examination, her uterus is rigid and extremely tender. What is the most likely diagnosis?",
    "options": [
      "Placental abruption",
      "Placenta praevia",
      "Preterm labour",
      "Uterine rupture",
      "Placental insufficiency"
    ],
    "correct_answer": "Placental abruption",
    "explanation": "**Explanation**\n**Placental abruption** is characterised by the premature separation of the placenta from the uterine wall, often presenting with sudden, severe, continuous abdominal pain, a firm ('woody') and tender uterus, and signs of maternal shock. Vaginal bleeding may be absent or minimal, as blood can be concealed behind the placenta. This clinical picture contrasts with placenta praevia, which typically causes painless vaginal bleeding, and labour, where pain is intermittent and uterine tone remains soft between contractions. Uterine rupture is rare and usually associated with a history of uterine surgery, presenting with acute pain and loss of fetal station. Placental insufficiency is a chronic condition, not associated with acute pain or haemodynamic instability.\n\n**Key Points**\n- Placental abruption presents with **continuous abdominal pain**, often severe.\n- The uterus feels **firm, woody, and tender** on palpation.\n- Maternal shock may be **disproportionate to visible blood loss**; bleeding can be concealed.\n- Placenta praevia is generally painless, with bright red vaginal bleeding.\n- Labour pain is intermittent and associated with contractions.\n- Uterine rupture is rare, often linked to previous uterine surgery, and presents catastrophically.\n- Placental insufficiency leads to fetal growth issues, not acute maternal symptoms.\n\n**Clinical Relevance**\nRecognising placental abruption is essential for urgent maternal and fetal management, as it can rapidly lead to haemorrhagic shock and fetal compromise. Prompt diagnosis and multidisciplinary response are vital to optimise outcomes.\n\n**Memory Anchor**\nAbruption: **A**cute pain, **A**brupt onset, and **A**naemia/shock out of proportion to visible bleeding.",
    "bullet_explanations": {
      "Placental abruption": "Correct – Sudden, severe abdominal pain, firm uterus, and shock are classic findings.",
      "Placenta praevia": "Incorrect – Usually causes painless bleeding without uterine tenderness or rigidity.",
      "Preterm labour": "Incorrect – Labour pain is intermittent, with a relaxed uterus between contractions.",
      "Uterine rupture": "Incorrect – Rare without prior uterine surgery; presents with sudden pain and fetal parts palpable in the abdomen.",
      "Placental insufficiency": "Incorrect – Causes chronic fetal growth restriction, not acute pain or haemodynamic compromise."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Late",
    "subsubsection": "Labour & Delivery",
    "topic": "Shoulder dystocia",
    "keywords": [
      "placental abruption",
      "antepartum haemorrhage",
      "woody uterus",
      "pregnancy emergencies"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "dbe6f6af-fdca-4299-bcf0-2243b4eece24",
    "question_number": 54,
    "question": "Which medication is recommended to reduce the frequency of vertigo episodes in patients with Ménière's disease?",
    "options": [
      "Betahistine",
      "Cinnarizine",
      "Prochlorperazine",
      "Chlorphenamine",
      "Promethazine"
    ],
    "correct_answer": "Betahistine",
    "explanation": "**Explanation**\n**Betahistine** is a histamine analogue used prophylactically in Ménière's disease to decrease the number and severity of vertigo attacks. It is believed to improve microcirculation in the inner ear, thereby reducing endolymphatic pressure—the underlying issue in Ménière's disease. While other agents such as prochlorperazine, promethazine, and cinnarizine can relieve acute vertiginous symptoms, only betahistine is consistently recommended for long-term prevention of recurrent attacks. This distinction is important because acute symptom relief does not alter disease progression or attack frequency.\n\n**Key Points**\n<ul><li><b>Betahistine</b> is first-line for prevention of Ménière's disease attacks.</li><li>It acts by enhancing inner ear blood flow and reducing endolymphatic pressure.</li><li>Other agents (e.g. prochlorperazine, cinnarizine) are used for acute symptom control, not prevention.</li><li>Diagnosis of Ménière's disease requires episodes of vertigo, hearing loss, and other aural symptoms.</li><li>Acute attack management and prophylaxis are distinct in therapy.</li></ul><table><thead><tr><th>Drug</th><th>Main Role in Ménière's</th></tr></thead><tbody><tr><td>Betahistine</td><td>Prevention</td></tr><tr><td>Prochlorperazine</td><td>Acute symptom relief</td></tr><tr><td>Cinnarizine</td><td>Acute symptom relief</td></tr></tbody></table>\n\n**Clinical Relevance**\nBetahistine is widely prescribed in primary care and ENT for patients with recurrent Ménière's disease. Distinguishing between agents used for prevention and those for acute episodes is essential for optimal patient management in accordance with NICE and BNF recommendations.\n\n**Memory Anchor**\nRemember: 'Beta' for 'Better prevention' of Ménière's attacks.",
    "bullet_explanations": {
      "Betahistine": "Correct – Only betahistine is recommended for long-term prevention of Ménière's attacks.",
      "Cinnarizine": "Incorrect – Used to reduce acute vertigo symptoms, not for prevention of attacks.",
      "Prochlorperazine": "Incorrect – Useful for acute relief of nausea/vertigo, not for prophylaxis.",
      "Chlorphenamine": "Incorrect – An antihistamine for allergies, not indicated for Ménière's disease.",
      "Promethazine": "Incorrect – Antiemetic effective during acute attacks, no role in attack prevention."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Vertigo (BPPV, vestibular neuritis, Meniere’s)",
    "keywords": [
      "Meniere's disease",
      "betahistine",
      "vertigo prevention"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "MÃ©niÃ¨re's disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/menieres-disease/"
      },
      {
        "source": "BNF",
        "topic_title": "Nausea and labyrinth disorders",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/nausea-and-labyrinth-disorders/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a6c630b8-d658-46fd-b8cd-aa1a7d3a3ee2",
    "question_number": 55,
    "question": "During emergency surgery for perforated diverticulitis with generalised peritonitis, which statement best reflects standard practice regarding stoma formation in a Hartmann's procedure?",
    "options": [
      "An end colostomy is typically brought out on the left side of the abdomen",
      "A primary anastomosis is performed in most emergency cases",
      "A loop ileostomy is the stoma of choice",
      "The stoma should be spouted for faecal diversion",
      "A colostomy is usually sited on the right side of the abdomen"
    ],
    "correct_answer": "An end colostomy is typically brought out on the left side of the abdomen",
    "explanation": "**Explanation**\n**Hartmann's procedure** involves resection of the diseased rectosigmoid colon (commonly for perforation or malignancy), closure of the rectal stump, and formation of an end colostomy. In this operation, the colostomy is almost always brought out through the left iliac fossa, corresponding to the anatomical location of the sigmoid colon. This is in contrast to an ileostomy, which would be sited on the right. Primary anastomosis is usually avoided in the emergency setting due to high risk of leak in the presence of peritonitis. Colostomies are not spouted, as the bowel content is less irritant and the stoma is typically flush with the skin.\n\n**Key Points**\n- Hartmann's procedure is common in complicated diverticulitis or obstructing/perforated colorectal cancer\n- End colostomy is fashioned in the left iliac fossa (left side of abdomen)\n- Primary anastomosis is generally avoided in peritonitis\n- Colostomies are flush, while ileostomies may be spouted\n- Right-sided stomas are typically ileostomies, not colostomies\n\n**Clinical Relevance**\nUnderstanding the anatomical principles of stoma formation is crucial for safe emergency colorectal surgery. Left-sided end colostomies are standard after Hartmann's procedure, reducing complications and aligning with surgical anatomy. This knowledge aids in patient counselling and post-operative care.\n\n**Memory Anchor**\nColostomy = left, Ileostomy = right (think: L for Left/Colostomy, I for Ileostomy/Right)",
    "bullet_explanations": {
      "An end colostomy is typically brought out on the left side of the abdomen": "Correct. The sigmoid colon exits to the left lower abdomen, making this the standard site for colostomy following Hartmann's procedure.",
      "A primary anastomosis is performed in most emergency cases": "Incorrect. In the presence of peritonitis, primary anastomosis is avoided due to high risk of anastomotic leak.",
      "A loop ileostomy is the stoma of choice": "Incorrect. Hartmann's procedure involves end colostomy, not ileostomy.",
      "The stoma should be spouted for faecal diversion": "Incorrect. Colostomies are usually flush with skin, not spouted; spouted stomas are characteristic of ileostomies.",
      "A colostomy is usually sited on the right side of the abdomen": "Incorrect. Right-sided stomas are generally ileostomies, not colostomies."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "Diverticular Disease",
    "topic": "Uncomplicated vs complicated presentations",
    "keywords": [
      "Hartmann's procedure",
      "colostomy",
      "stoma position",
      "diverticulitis",
      "emergency surgery"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diverticular disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/diverticular-disease/"
      },
      {
        "source": "BNF",
        "topic_title": "Gastro-intestinal system infections, antibacterial therapy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/gastro-intestinal-system-infections-antibacterial-therapy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1d4b60c0-35e8-4fad-91e2-2e77fb35792d",
    "question_number": 56,
    "question": "Which medication class is considered first-line pharmacological therapy for a 35-year-old man diagnosed with panic disorder, who has not responded to psychological interventions alone?",
    "options": [
      "Selective serotonin reuptake inhibitor (SSRI)",
      "Tricyclic antidepressant (TCA)",
      "Serotonin-noradrenaline reuptake inhibitor (SNRI)",
      "Mirtazapine",
      "Benzodiazepine"
    ],
    "correct_answer": "Selective serotonin reuptake inhibitor (SSRI)",
    "explanation": "**Explanation**\n**SSRIs are the recommended first-line pharmacological treatment for panic disorder** due to their favourable safety profile and tolerability compared to other antidepressant classes. SSRIs, such as sertraline, escitalopram, and paroxetine, have robust evidence for efficacy in panic disorder and are less toxic in overdose than tricyclic antidepressants. While SNRIs like venlafaxine are licensed for panic disorder, they are not first-line. TCAs (e.g., clomipramine, imipramine) may be used second-line if SSRIs are ineffective or not tolerated, but carry a higher risk of side effects. Benzodiazepines are generally reserved for short-term use due to dependency concerns. Mirtazapine is not routinely used for panic disorder.\n\n**Key Points**\n<ul><li><b>SSRIs are the drug class of choice for panic disorder after psychological therapy.</b></li><li>SSRIs are generally better tolerated and safer in overdose than TCAs or SNRIs.</li><li>Common SSRIs used: sertraline, paroxetine, escitalopram.</li><li>TCAs (e.g., clomipramine) are considered second-line due to adverse effects.</li><li>SNRIs (e.g., venlafaxine) can be considered but are not first-line.</li><li>Benzodiazepines are reserved for short-term or acute use due to dependence risk.</li></ul><table><thead><tr><th>Treatment</th><th>Panic Disorder Role</th></tr></thead><tbody><tr><td>SSRI</td><td>First-line</td></tr><tr><td>TCA</td><td>Second-line</td></tr><tr><td>SNRI</td><td>Alternative</td></tr><tr><td>Benzodiazepine</td><td>Short-term/adjunct</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising that SSRIs are preferred for panic disorder helps clinicians initiate safe and effective therapy, aligning with BNF and NICE recommendations. Knowing when to escalate to second-line or adjunct medications is crucial for patient safety and optimal outcomes.\n\n**Memory Anchor**\nThink 'S' for SSRIs and 'Start'—SSRIs are the starting medication for panic disorder.",
    "bullet_explanations": {
      "Selective serotonin reuptake inhibitor (SSRI)": "Correct – SSRIs are first-line for panic disorder according to guidelines.",
      "Tricyclic antidepressant (TCA)": "Incorrect – TCAs like clomipramine are used second-line due to side effects.",
      "Serotonin-noradrenaline reuptake inhibitor (SNRI)": "Incorrect – SNRIs may be licensed but are not first-line for panic disorder.",
      "Mirtazapine": "Incorrect – Mirtazapine is not routinely used for panic disorder.",
      "Benzodiazepine": "Incorrect – Benzodiazepines are reserved for short-term relief and not first-line."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Psychosis & Anxiety",
    "subsubsection": "Anxiety Disorders",
    "topic": "Panic disorder",
    "keywords": [
      "panic disorder",
      "SSRI",
      "first-line",
      "pharmacological treatment",
      "anxiety"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Antidepressant drugs",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antidepressant-drugs/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "563d4532-0c2b-4a9a-a7eb-0aa202f75cd9",
    "question_number": 57,
    "question": "A 37-year-old man presents to neurology clinic after experiencing a witnessed seizure. He describes an episode in which rhythmic, jerking movements began in his right foot and then progressed upwards to involve the entire leg. What is the most likely anatomical origin of his seizure?",
    "options": [
      "Frontal lobe",
      "Temporal lobe",
      "Occipital lobe",
      "Parietal lobe",
      "Generalised onset"
    ],
    "correct_answer": "Frontal lobe",
    "explanation": "**Explanation**\n**Jacksonian march** refers to the spread of clonic motor activity in a sequential, contiguous fashion (often starting distally and progressing proximally, such as from the foot to the leg or hand to arm). This classic pattern is characteristic of motor seizures arising from the **primary motor cortex**, which is located in the precentral gyrus of the frontal lobe. By contrast, seizures originating in the temporal lobe more commonly cause automatisms or aura phenomena, while occipital lobe seizures often present with visual disturbances. Parietal lobe involvement typically causes sensory, not motor, symptoms. Generalised onset seizures lack a focal onset or sequential progression.\n\n**Key Points**\n- **Jacksonian march** = sequential, spreading clonic movements (often distal to proximal).\n- Originates from the **primary motor cortex** in the frontal lobe.\n- Temporal lobe seizures: automatisms, psychic or sensory auras.\n- Occipital lobe seizures: visual symptoms.\n- Parietal lobe seizures: sensory disturbances.\n- Generalised seizures: no focal onset or progression.\n\n**Clinical Relevance**\nRecognising the anatomical localisation of focal seizures is essential for diagnosis and management. The presence of Jacksonian march strongly suggests a frontal lobe origin, guiding both further investigation and potential surgical consideration.\n\n**Memory Anchor**\nThink 'Frontal for Foot-to-Face'—the Jacksonian march classically begins in the distal limb and 'marches' up the motor cortex strip in the frontal lobe.",
    "bullet_explanations": {
      "Frontal lobe": "Correct – Jacksonian march motor seizures originate in the primary motor cortex of the frontal lobe.",
      "Temporal lobe": "Incorrect – Temporal lobe seizures typically cause automatisms or sensory/psychic auras, not progressive motor symptoms.",
      "Occipital lobe": "Incorrect – Occipital lobe seizures usually present with visual symptoms, such as hallucinations or loss of vision.",
      "Parietal lobe": "Incorrect – Parietal lobe seizures are usually sensory, not motor, in nature.",
      "Generalised onset": "Incorrect – Generalised seizures involve both hemispheres simultaneously and lack the focal, sequential progression seen in Jacksonian march."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Epilepsy",
    "topic": "Focal vs generalised",
    "keywords": [
      "Jacksonian march",
      "focal epilepsy",
      "frontal lobe",
      "motor seizure",
      "epilepsy localisation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Epilepsy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/epilepsy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c06c8ba0-5508-48d8-92a1-42034cd35dec",
    "question_number": 58,
    "question": "A father brings his 7-month-old son to your surgery after hearing about an outbreak of rotavirus at a local playgroup. The child has not received any doses of the oral rotavirus vaccine so far. The father asks if his son can now begin the rotavirus vaccination course. What is the most appropriate advice to give?",
    "options": [
      "Explain that the rotavirus vaccine cannot be started at this age due to safety concerns",
      "Arrange for a single dose of the oral rotavirus vaccine to be given immediately",
      "Offer the first dose now and schedule the second dose in 4 weeks’ time",
      "Advise that the vaccine is unavailable on the NHS but can be obtained privately",
      "Recommend giving the two-dose course 3 months apart"
    ],
    "correct_answer": "Explain that the rotavirus vaccine cannot be started at this age due to safety concerns",
    "explanation": "**Explanation**\n**The oral rotavirus vaccine must be started before 15 weeks of age** due to the increased risk of intussusception if initiated later. The second dose must be completed by 24 weeks. Since this child is already 7 months (over 28 weeks), it is not safe or appropriate to start the vaccination course now. This restriction is in place to minimise potential adverse effects and because the period of highest risk for severe rotavirus infection has generally passed by this age. Vaccination schedules are strictly regulated for safety and efficacy, and exceptions are not made for late starters.\n\n**Key Points**\n- Rotavirus vaccine is given orally and is live attenuated.\n- First dose: must be administered before 15 weeks of age.\n- Second dose: must be completed before 24 weeks of age.\n- Starting the course after 15 weeks increases the risk of intussusception.\n- Vaccination cannot be initiated after the age cut-off, even if the child is unvaccinated.\n- The vaccine is provided on the NHS for eligible age groups only.\n\n**Clinical Relevance**\nStrict adherence to the rotavirus vaccination schedule is essential for both patient safety and public health. Delayed vaccination is not permitted due to the risk of adverse events and reduced efficacy. Clinicians should provide clear guidance to parents and document discussions about vaccine eligibility and timing.",
    "bullet_explanations": {
      "Explain that the rotavirus vaccine cannot be started at this age due to safety concerns": "Correct – initiation after 15 weeks is not permitted due to increased risk of adverse effects.",
      "Arrange for a single dose of the oral rotavirus vaccine to be given immediately": "Incorrect – a single dose is insufficient, and the vaccine course cannot be started at this age.",
      "Offer the first dose now and schedule the second dose in 4 weeks’ time": "Incorrect – both the first and second dose are outside the recommended age window.",
      "Advise that the vaccine is unavailable on the NHS but can be obtained privately": "Incorrect – the issue is age eligibility, not NHS availability; private providers should also adhere to safety guidelines.",
      "Recommend giving the two-dose course 3 months apart": "Incorrect – the dosing interval is too long and age restrictions still apply."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "GI Infections",
    "topic": "C. difficile testing and treatment",
    "keywords": [
      "rotavirus",
      "vaccination schedule",
      "paediatrics",
      "oral vaccine",
      "immunisation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Rotavirus vaccine",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/rotavirus-vaccine/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2c54261a-f8cf-4ccd-9b87-6beb7c925f83",
    "question_number": 59,
    "question": "What is the most characteristic ECG finding in a patient with acute pericarditis?",
    "options": [
      "Saddle-shaped ST segment elevation",
      "Broad QRS complexes with left bundle branch block pattern",
      "Peaked T waves",
      "Biphasic T waves in anterior leads",
      "Pathological Q waves"
    ],
    "correct_answer": "Saddle-shaped ST segment elevation",
    "explanation": "**Explanation**\n**Acute pericarditis** often presents with a sharp, pleuritic chest pain that is relieved by sitting forward and worsened when lying flat. The most characteristic ECG feature is a **diffuse, saddle-shaped (concave upwards) ST segment elevation** across multiple leads, often accompanied by PR segment depression. This pattern helps differentiate pericarditis from myocardial infarction, where ST elevation is usually localised to leads reflecting the affected coronary artery. Other ECG changes such as T wave inversion can occur later, but the early and classic hallmark is the widespread concave ST elevation.\n\n**Key Points**\n- Acute pericarditis typically causes widespread, concave ST elevation on ECG.\n- PR segment depression is another supportive ECG finding.\n- Chest pain in pericarditis is sharp, pleuritic, and improves on sitting forward.\n- Pericarditis is associated with conditions like connective tissue diseases (e.g., SLE).\n- In contrast, ST elevation in MI is usually localised and often has reciprocal changes.\n\n**Clinical Relevance**\nRecognising the typical ECG pattern of pericarditis is crucial to distinguish it from acute coronary syndromes and avoid unnecessary invasive management. NICE CKS emphasises the importance of integrating clinical history, examination, and ECG findings to guide diagnosis and referral in patients with chest pain.\n\n**Memory Anchor**\nThink 'PERIcarditis' = 'PERImeter' = widespread, not localised, ST elevation.",
    "bullet_explanations": {
      "Saddle-shaped ST segment elevation": "Correct – this is the hallmark ECG finding in acute pericarditis.",
      "Broad QRS complexes with left bundle branch block pattern": "Incorrect – this pattern suggests a conduction abnormality, not pericarditis.",
      "Peaked T waves": "Incorrect – these are most commonly seen in hyperkalaemia.",
      "Biphasic T waves in anterior leads": "Incorrect – often seen in Wellens' syndrome or ischaemia.",
      "Pathological Q waves": "Incorrect – these indicate previous myocardial infarction, not pericarditis."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Stable Coronary Disease",
    "topic": "Typical vs atypical angina (risk stratification)",
    "keywords": [
      "pericarditis",
      "ECG",
      "ST elevation",
      "chest pain"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Chest pain",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/chest-pain/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4ed4578e-8ed4-4635-975b-765386ef15db",
    "question_number": 60,
    "question": "A 55-year-old woman is reviewed in clinic for persistent hypertension despite adherence to ramipril, chlorthalidone, and amlodipine. She mentions occasional episodes of muscle cramps. Laboratory tests reveal a potassium of 3.1 mmol/L (3.5–5.0). What is the most appropriate initial test to confirm the suspected diagnosis?",
    "options": [
      "Plasma aldosterone/renin ratio",
      "24-hour urine catecholamines",
      "Abdominal CT scan",
      "Renal artery duplex ultrasound",
      "Adrenal vein sampling"
    ],
    "correct_answer": "Plasma aldosterone/renin ratio",
    "explanation": "**Explanation**\n**Resistant hypertension in conjunction with hypokalaemia** strongly suggests primary hyperaldosteronism (Conn’s syndrome). **Aldosterone excess leads to sodium retention (hypertension) and potassium loss (hypokalaemia)**. The recommended first-line investigation is measuring the plasma aldosterone/renin ratio, as primary hyperaldosteronism is characterised by a **high aldosterone with suppressed renin**. Only after biochemical confirmation should imaging (to localise the source) or adrenal vein sampling (to distinguish unilateral from bilateral disease) be considered. Other secondary causes of hypertension may present similarly, but hypokalaemia is a hallmark of mineralocorticoid excess.\n\n**Key Points**\n- Primary hyperaldosteronism = hypertension + hypokalaemia\n- Aldosterone/renin ratio is the recommended initial screening test\n- High ratio = inappropriate aldosterone secretion with renin suppression\n- Imaging is only indicated after biochemical confirmation\n- Other causes (e.g. phaeochromocytoma, renovascular disease) have different initial screens\n\n**Clinical Relevance**\nResistant hypertension requires prompt identification of secondary causes, as targeted treatment can significantly improve blood pressure control and reduce long-term cardiovascular risk. UK guidelines recommend checking the aldosterone/renin ratio for cases of suspected primary hyperaldosteronism before considering further imaging or referral.\n\n**Memory Anchor**\n\"Aldo then Image\": Always do aldosterone/renin ratio before imaging in suspected Conn's syndrome.",
    "bullet_explanations": {
      "Plasma aldosterone/renin ratio": "Correct – This is the recommended initial screening test for primary hyperaldosteronism.",
      "24-hour urine catecholamines": "Incorrect – Used to screen for phaeochromocytoma, not mineralocorticoid excess.",
      "Abdominal CT scan": "Incorrect – Performed after biochemical confirmation to localise the lesion.",
      "Renal artery duplex ultrasound": "Incorrect – Used to investigate renovascular hypertension, which does not typically cause hypokalaemia.",
      "Adrenal vein sampling": "Incorrect – Reserved for distinguishing unilateral from bilateral disease after diagnosis is made."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Adrenal",
    "subsubsection": "Primary Aldosteronism",
    "topic": "When to screen (resistant HTN, hypoK)",
    "keywords": [
      "primary hyperaldosteronism",
      "aldosterone/renin ratio",
      "resistant hypertension",
      "hypokalaemia",
      "Conn's syndrome"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "81df9523-ba8f-42a9-88c5-6f66f4e095af",
    "question_number": 61,
    "question": "Which is the most appropriate initial therapy for a middle-aged man presenting with violaceous, flat-topped papules on the anterior wrists and oral mucosa, accompanied by prominent Wickham’s striae and mild nail changes?",
    "options": [
      "Potent topical corticosteroids",
      "Topical antifungal cream",
      "Oral prednisolone",
      "Topical vitamin D analogue",
      "Simple emollient therapy"
    ],
    "correct_answer": "Potent topical corticosteroids",
    "explanation": "**Explanation**\n**Potent topical corticosteroids are the first-line treatment for cutaneous lichen planus.** This condition presents with characteristic flat-topped, violaceous papules, often with Wickham’s striae (fine white lines). Potent topical corticosteroids reduce inflammation and pruritus, leading to improvement of skin lesions and prevention of further progression. Other treatments, including oral steroids, are reserved for severe, widespread, or refractory cases. Topical antifungals and vitamin D analogues are not effective for lichen planus, and emollients alone are insufficient for disease control.\n\n**Key Points**\n- Lichen planus typically affects middle-aged adults, often involving wrists, legs, and the oral cavity.\n- Wickham’s striae (fine white lines) are a classic sign.\n- Potent topical corticosteroids reduce inflammation and are standard initial therapy.\n- Oral steroids are reserved for severe or generalised disease.\n- Topical vitamin D analogues are used for psoriasis, not lichen planus.\n- Topical antifungals target fungal infections, not autoimmune dermatoses.\n- Emollients may soothe skin but do not address the underlying pathology.\n\n**Clinical Relevance**\nPrompt recognition and management of lichen planus, especially with potent topical corticosteroids, leads to symptom relief and minimises complications, such as scarring or nail loss. This reflects BNF and dermatology guideline recommendations for first-line therapy.\n\n**Memory Anchor**\n‘Lichen planus likes potent steroids’—potent topical corticosteroids are the mainstay.",
    "bullet_explanations": {
      "Potent topical corticosteroids": "Correct—these are first-line for cutaneous lichen planus as they effectively suppress inflammation.",
      "Topical antifungal cream": "Incorrect—antifungals are used for fungal infections, not for autoimmune or inflammatory rashes like lichen planus.",
      "Oral prednisolone": "Incorrect—oral steroids are reserved for severe, widespread, or refractory cases, not as initial therapy.",
      "Topical vitamin D analogue": "Incorrect—these are effective in psoriasis, not in lichen planus.",
      "Simple emollient therapy": "Incorrect—emollients may offer comfort but do not treat the underlying inflammatory process."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Lichen planus",
    "keywords": [
      "lichen planus",
      "topical corticosteroid",
      "Wickham’s striae"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Topical corticosteroids",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/topical-corticosteroids/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "dfe49856-23c3-42e9-a8f3-26b02a99e1a9",
    "question_number": 62,
    "question": "A 34-year-old woman attends her booking appointment at 9 weeks' gestation. She had gestational diabetes in her previous pregnancy but her glucose levels normalised after delivery. What is the most appropriate step to screen for gestational diabetes in this pregnancy?",
    "options": [
      "Arrange an oral glucose tolerance test as soon as possible after booking",
      "Check a random blood glucose at booking and repeat at 28 weeks",
      "Wait until 24–28 weeks to arrange an oral glucose tolerance test",
      "Start metformin and advise self-monitoring of blood glucose now",
      "Request an HbA1c at booking to screen for gestational diabetes"
    ],
    "correct_answer": "Arrange an oral glucose tolerance test as soon as possible after booking",
    "explanation": "**Explanation**\nWomen with a history of gestational diabetes are at **significantly increased risk of recurrence** in subsequent pregnancies. Current guidelines recommend that these women should be offered an **oral glucose tolerance test (OGTT) as soon as possible after booking** to detect undiagnosed diabetes or early hyperglycaemia. Delaying testing until 24–28 weeks risks missing early cases, and HbA1c is not sufficiently sensitive for diagnosing gestational diabetes. Plasma glucose-based OGTT remains the gold standard for diagnosis in pregnancy.\n\n**Key Points**\n- History of gestational diabetes is a strong risk factor for recurrence.\n- An OGTT should be performed as early as possible in the current pregnancy.\n- Early detection enables timely intervention to reduce maternal and fetal complications.\n- HbA1c and random glucose are not reliable for screening gestational diabetes in pregnancy.\n- Repeat OGTT at 24–28 weeks may be considered if the initial test is normal.\n\n**Clinical Relevance**\nPrompt identification and management of gestational diabetes reduces the risk of adverse outcomes such as macrosomia, pre-eclampsia, and neonatal hypoglycaemia. Following national guidance ensures consistent, evidence-based care for at-risk women.\n\n**Memory Anchor**\nOGTT = 'Go To Test' as soon as booking for those with past GDM.",
    "bullet_explanations": {
      "Arrange an oral glucose tolerance test as soon as possible after booking": "Correct – Early OGTT is recommended for women with previous gestational diabetes.",
      "Check a random blood glucose at booking and repeat at 28 weeks": "Incorrect – Random glucose is not sensitive enough to detect gestational diabetes.",
      "Wait until 24–28 weeks to arrange an oral glucose tolerance test": "Incorrect – High-risk women should be tested earlier, not just at 24–28 weeks.",
      "Start metformin and advise self-monitoring of blood glucose now": "Incorrect – Metformin is not started for screening; diagnosis must be confirmed first.",
      "Request an HbA1c at booking to screen for gestational diabetes": "Incorrect – HbA1c is not validated for diagnosing gestational diabetes in pregnancy."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Acute",
    "subsubsection": "DKA",
    "topic": "Diagnostic criteria and triggers",
    "keywords": [
      "gestational diabetes",
      "pregnancy",
      "oral glucose tolerance test",
      "screening",
      "recurrence risk"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetes, pregnancy and breast-feeding",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetes-pregnancy-and-breast-feeding/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9d0ee103-1b0d-4241-95fa-18642989593c",
    "question_number": 63,
    "question": "A 58-year-old man with poorly controlled hypertension attends a routine retinal screening. On fundoscopy, you observe generalised arteriolar narrowing and increased vessel tortuosity, but there are no haemorrhages, exudates, or papilloedema. According to the Keith-Wagener classification, what is the most appropriate grade of hypertensive retinopathy for these findings?",
    "options": [
      "Grade 1 hypertensive retinopathy",
      "Grade 3 hypertensive retinopathy",
      "Grade 0 hypertensive retinopathy",
      "Grade 2 hypertensive retinopathy",
      "Grade 4 hypertensive retinopathy"
    ],
    "correct_answer": "Grade 1 hypertensive retinopathy",
    "explanation": "**Explanation**\n**Grade 1 hypertensive retinopathy** is characterised by generalised arteriolar narrowing and increased tortuosity, sometimes accompanied by an enhanced light reflex (often termed 'silver wiring'). No haemorrhages, exudates, or papilloedema are seen at this stage. Grades progress in severity, with higher grades involving additional features such as arteriovenous nipping (Grade 2), retinal haemorrhages and exudates (Grade 3), and papilloedema (Grade 4). Recognising these early changes is essential as they indicate chronic vascular damage due to hypertension but without acute or severe manifestations.\n\n**Key Points**\n- Grade 1: Generalised arteriolar narrowing and tortuosity only.\n- Grade 2: Grade 1 features plus arteriovenous nipping.\n- Grade 3: Grade 2 features plus retinal haemorrhages, cotton-wool spots, and hard exudates.\n- Grade 4: All previous features with papilloedema.\n- Fundoscopic findings help stratify the severity of hypertension-related end-organ damage.\n\n**Clinical Relevance**\nEarly recognition of hypertensive retinopathy grades enables clinicians to assess the chronicity and severity of hypertension, guiding risk assessment and management. Detecting even mild changes (Grade 1) highlights the need for tighter blood pressure control to prevent progression to vision-threatening complications.\n\n**Memory Anchor**\nThink '1 = 1 change': only narrowed/tortuous arterioles in Grade 1.",
    "bullet_explanations": {
      "Grade 1 hypertensive retinopathy": "Correct; this grade includes only arteriolar narrowing and tortuosity without haemorrhages or exudates.",
      "Grade 3 hypertensive retinopathy": "Incorrect; Grade 3 includes haemorrhages and exudates, which are not present in this case.",
      "Grade 0 hypertensive retinopathy": "Incorrect; Grade 0 is assigned when there are no detectable retinal changes.",
      "Grade 2 hypertensive retinopathy": "Incorrect; this requires additional features such as arteriovenous nipping.",
      "Grade 4 hypertensive retinopathy": "Incorrect; this represents the most severe form, with papilloedema in addition to other changes."
    },
    "category": "Ophthalmology",
    "subsection": "Neuro-ophthalmology",
    "subsubsection": "Papilloedema",
    "topic": "Hypertensive retinopathy",
    "keywords": [
      "hypertensive retinopathy",
      "Keith-Wagener classification",
      "fundoscopy",
      "arteriolar narrowing",
      "retinal changes"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hypertension",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8d0c8df7-97a1-4cd3-a295-05d035dec417",
    "question_number": 64,
    "question": "A 29-year-old woman with a history of left-sided ulcerative colitis presents to clinic with mild rectal bleeding and increased stool frequency (3 times daily). She has been in remission for several years and is not on maintenance treatment. Her vital signs are stable and she is systemically well. What is the most appropriate first-line therapy for her current flare?",
    "options": [
      "Rectal mesalazine",
      "Oral corticosteroids",
      "Intravenous corticosteroids",
      "Oral mesalazine",
      "Rectal corticosteroids"
    ],
    "correct_answer": "Rectal mesalazine",
    "explanation": "**Explanation**\n**Rectal (topical) mesalazine** is recommended as first-line therapy for a mild-to-moderate flare of distal (left-sided or proctosigmoid) ulcerative colitis. This approach targets local inflammation effectively with fewer systemic side effects than oral or intravenous treatments. Oral mesalazine is considered if rectal therapy is insufficient or if the disease extends beyond the distal colon. Systemic corticosteroids are reserved for moderate-to-severe flares or failure of aminosalicylates. Rectal corticosteroids may be considered adjunctively but are not first-line. Intravenous steroids are only indicated for severe, systemically unwell cases.\n\n**Key Points**\n- Mild-to-moderate distal UC flares: treat first with rectal aminosalicylates (mesalazine).\n- Oral mesalazine is added if rectal therapy is inadequate or for more extensive disease.\n- Systemic corticosteroids (oral/IV) are reserved for moderate/severe cases or if aminosalicylates fail.\n- Intravenous steroids: only for severe, systemically unwell patients.\n- Rectal corticosteroids: alternative or adjunct, not first-line.\n- <table><thead><tr><th>Treatment</th><th>Indication</th></tr></thead><tbody><tr><td>Rectal mesalazine</td><td>First-line for mild distal UC</td></tr><tr><td>Oral mesalazine</td><td>Extensive disease or add-on</td></tr><tr><td>Oral/IV steroids</td><td>Moderate/severe flares</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurate identification of flare severity and use of rectal aminosalicylates can control symptoms promptly and reduce unnecessary systemic steroid exposure, aligning with national guidelines for ulcerative colitis management.",
    "bullet_explanations": {
      "Rectal mesalazine": "Correct—first-line treatment for mild-to-moderate distal UC flares.",
      "Oral corticosteroids": "Incorrect—reserved for moderate-to-severe or unresponsive cases.",
      "Intravenous corticosteroids": "Incorrect—only for severe, systemically unwell presentations.",
      "Oral mesalazine": "Incorrect—can be used if rectal therapy fails or for more extensive disease, not first-line for distal flares.",
      "Rectal corticosteroids": "Incorrect—may be used if mesalazine not tolerated, but not preferred first-line."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBD",
    "topic": "UC vs Crohn’s key differences",
    "keywords": [
      "ulcerative colitis",
      "rectal mesalazine",
      "mild flare",
      "aminosalicylate",
      "topical therapy"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "7a37569c-5d93-40e0-b60d-9f0bc7b1259b",
    "question_number": 65,
    "question": "What is the recommended first-line antibiotic regimen for an otherwise healthy 25-year-old pregnant woman diagnosed with an uncomplicated lower urinary tract infection at 16 weeks' gestation?",
    "options": [
      "7-day course of nitrofurantoin",
      "3-day course of cefalexin",
      "7-day course of trimethoprim",
      "3-day course of amoxicillin",
      "5-day course of fosfomycin"
    ],
    "correct_answer": "7-day course of nitrofurantoin",
    "explanation": "**Explanation**\n**Nitrofurantoin is the first-line antibiotic for lower urinary tract infection in pregnancy**, unless the woman is near term (at which point it should be avoided due to the risk of neonatal haemolysis). **Pregnant women require a 7-day course of antibiotics** for UTI, rather than the shorter courses often used in non-pregnant adults. Prompt and appropriate antibiotic treatment is crucial as untreated UTI in pregnancy increases the risk of complications such as preterm labour and low birth weight. Other options (e.g., trimethoprim, fosfomycin, and amoxicillin) are not considered first-line in the UK for pregnant women, and some may be contraindicated depending on gestational age.\n\n**Key Points**\n- Nitrofurantoin is first-line for lower UTI in most stages of pregnancy except at term.\n- Course duration for pregnant women: 7 days (not 3 days as in non-pregnant adults).\n- Trimethoprim is avoided in the first trimester due to risk of neural tube defects.\n- Amoxicillin and cefalexin are alternatives but not first-line; local resistance patterns may apply.\n- Prompt treatment of UTI in pregnancy reduces risk of preterm birth and fetal complications.\n- Fosfomycin is not routinely recommended for pregnant women in the UK.\n\n**Clinical Relevance**\nAppropriate antibiotic selection and duration for UTIs in pregnancy are essential to avoid serious maternal and fetal complications. Following national guidelines ensures patient safety and minimises antimicrobial resistance.\n\n**Memory Anchor**\nPregnant = Prolonged (7-day) Nitrofurantoin (unless at term)",
    "bullet_explanations": {
      "7-day course of nitrofurantoin": "Correct – first-line for lower UTI in pregnancy unless near term.",
      "3-day course of cefalexin": "Incorrect – course too short; cefalexin is only an alternative if nitrofurantoin unsuitable.",
      "7-day course of trimethoprim": "Incorrect – trimethoprim is contraindicated in the first trimester and not first-line.",
      "3-day course of amoxicillin": "Incorrect – not first-line and 3-day course is inadequate for pregnancy.",
      "5-day course of fosfomycin": "Incorrect – not standard UK guidance for pregnant women with UTI."
    },
    "category": "Renal & Urology",
    "subsection": "Urology",
    "subsubsection": "Infections",
    "topic": "UTIs in pregnancy",
    "keywords": [
      "UTI",
      "pregnancy",
      "antibiotic",
      "nitrofurantoin",
      "treatment"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "0b206b50-623a-49ba-99d2-3d2d08b201dc",
    "question_number": 66,
    "question": "A 35-year-old man presents with progressive loss of peripheral vision, recent onset of erectile dysfunction, and intermittent headaches. Visual field testing confirms bitemporal hemianopia. MRI shows a 2.8 cm pituitary lesion compressing the optic chiasm. His serum prolactin is markedly elevated at 7,200 mU/L (normal range 102–496). What is the most appropriate initial management for this patient?",
    "options": [
      "Start dopamine agonist therapy (e.g. cabergoline or bromocriptine)",
      "Arrange urgent trans-sphenoidal surgical resection",
      "Begin external beam radiotherapy",
      "Prescribe high-dose corticosteroids",
      "Observe and repeat MRI scan in 3 months"
    ],
    "correct_answer": "Start dopamine agonist therapy (e.g. cabergoline or bromocriptine)",
    "explanation": "**Explanation**\n**Dopamine agonists such as cabergoline and bromocriptine are the first-line treatment for prolactin-secreting pituitary macroadenomas, even when the tumour is compressing the optic chiasm and causing visual field defects.** These agents act by suppressing prolactin secretion and often lead to rapid tumour shrinkage, which can reverse visual symptoms within days to weeks. Surgery is reserved for cases where medical therapy fails or is not tolerated, and radiotherapy is rarely first-line due to its delayed effect and potential adverse outcomes. Immediate surgical intervention is only considered if there is acute and severe visual deterioration unresponsive to medical therapy. High-dose corticosteroids have no proven benefit in prolactinoma management unless there is apoplexy, and observation alone risks further visual compromise.\n\n**Key Points**\n- Dopamine agonists are first-line for prolactinomas, regardless of tumour size or neurological symptoms.\n- Cabergoline and bromocriptine both lower prolactin and shrink tumours.\n- Visual field defects from chiasmal compression can often reverse with medical therapy.\n- Surgical resection is reserved for dopamine agonist resistance, intolerance, or rapidly worsening vision not improving with medication.\n- Radiotherapy is a third-line option due to delayed efficacy and side effect profile.\n- Timely medical therapy can avoid unnecessary surgery and preserve vision.\n\n**Clinical Relevance**\nPrompt recognition and initiation of dopamine agonist therapy in patients with macroprolactinomas and visual compromise is critical, as medical management is highly effective and avoids the morbidity of surgery. This aligns with UK guidance and evidence-based best practice.\n\n**Memory Anchor**\nThink 'D for Dopamine, D for Debulking'—dopamine agonists shrink prolactinomas rapidly.",
    "bullet_explanations": {
      "Start dopamine agonist therapy (e.g. cabergoline or bromocriptine)": "Correct – This is the recommended first-line treatment for prolactinomas, even with mass effect.",
      "Arrange urgent trans-sphenoidal surgical resection": "Incorrect – Surgery is not first-line unless there is acute visual deterioration unresponsive to medication or intolerance/resistance to dopamine agonists.",
      "Begin external beam radiotherapy": "Incorrect – Radiotherapy is reserved for rare refractory cases and has delayed effects.",
      "Prescribe high-dose corticosteroids": "Incorrect – Steroids are not indicated in prolactinoma management unless there is pituitary apoplexy.",
      "Observe and repeat MRI scan in 3 months": "Incorrect – Observation would risk further vision loss as prompt treatment is needed."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Calcium, Pituitary & Metabolic",
    "subsubsection": "Pituitary",
    "topic": "Prolactinoma diagnosis and dopamine agonists",
    "keywords": [
      "prolactinoma",
      "dopamine agonist",
      "pituitary macroadenoma",
      "visual field defect"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Dopamine-receptor agonists",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/dopamine-receptor-agonists/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e12cb7be-79ab-4dd9-bc02-abdc491d4b92",
    "question_number": 67,
    "question": "A 32-year-old father presents after developing paroxysms of severe coughing for the past 8 days, sometimes leading to vomiting. His 2-month-old son, who recently started to cough, was born before his partner received the recommended pertussis booster in pregnancy. Which antibiotic is most appropriate to prescribe to the father to limit disease transmission, assuming he is within the window for effective therapy?",
    "options": [
      "Azithromycin",
      "Phenoxymethylpenicillin",
      "Doxycycline",
      "Supportive care only",
      "Flucloxacillin"
    ],
    "correct_answer": "Azithromycin",
    "explanation": "**Explanation**\n**Azithromycin** is the antibiotic of choice for suspected pertussis (whooping cough) when the onset of cough is within the past 21 days. Although antibiotics do not significantly alter the clinical course for the affected adult, they are essential for eradicating Bordetella pertussis from the nasopharynx and curtailing onward transmission, especially to vulnerable contacts, such as young infants. Macrolides (azithromycin, clarithromycin, or erythromycin) are recommended; amoxicillin, penicillins, and tetracyclines are not first-line in UK guidance. Early antibiotic treatment reduces the period of infectiousness, which is particularly important when household contacts include unvaccinated or partially immunised infants who are at high risk of severe complications. Supportive care alone would not prevent further spread, and other antibiotics listed lack adequate efficacy against pertussis.\n\n**Key Points**\n- Pertussis is highly contagious, especially dangerous for infants.\n- Macrolide antibiotics (azithromycin, clarithromycin, erythromycin) are recommended within 21 days of symptom onset.\n- Antibiotic therapy does not alter course for the index patient, but reduces transmission.\n- Penicillins and tetracyclines are not recommended for pertussis eradication.\n- Infants <6 months with suspected pertussis require hospital assessment.\n\n**Clinical Relevance**\nPrompt recognition and correct antibiotic prescribing for pertussis are essential in primary care, not only for patient management but also for safeguarding vulnerable infants in the household. Following UK guidelines ensures appropriate public health measures are taken, including school exclusion and contact prophylaxis.",
    "bullet_explanations": {
      "Azithromycin": "Correct – Macrolides are recommended for pertussis within 21 days of cough onset to reduce infectivity.",
      "Phenoxymethylpenicillin": "Incorrect – Penicillins are ineffective against Bordetella pertussis and not recommended for eradication.",
      "Doxycycline": "Incorrect – Doxycycline is not first-line for pertussis and is not recommended in UK guidelines.",
      "Supportive care only": "Incorrect – While supportive care is necessary, antibiotic therapy is required to reduce transmission within 21 days.",
      "Flucloxacillin": "Incorrect – Flucloxacillin is used for staphylococcal infections, not pertussis."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Whooping cough - azithromycin or clarithromycin if the onset of cough is within the previous 21 days",
    "keywords": [
      "pertussis",
      "whooping cough",
      "macrolide",
      "azithromycin",
      "transmission"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "82c145b7-9d6c-4b86-9e66-cff008553c2c",
    "question_number": 68,
    "question": "Which chronic liver disease is currently the leading cause of hepatocellular carcinoma in the UK?",
    "options": [
      "Alpha-1 antitrypsin deficiency",
      "Hepatitis C infection",
      "Hepatitis B infection",
      "Hereditary haemochromatosis",
      "Long-term anabolic steroid use"
    ],
    "correct_answer": "Hepatitis C infection",
    "explanation": "**Explanation**\n**Hepatitis C infection is the predominant cause of hepatocellular carcinoma (HCC) in the United Kingdom.** Chronic infection with hepatitis C virus (HCV) leads to ongoing hepatic inflammation and progressive fibrosis, ultimately resulting in cirrhosis in a significant proportion of patients. Cirrhosis is the primary risk factor for HCC development in these individuals. While hepatitis B is the most frequent global cause of HCC, its prevalence is much lower in the UK, largely due to effective vaccination and public health measures. Other causes, such as hereditary haemochromatosis and alpha-1 antitrypsin deficiency, are important but account for fewer cases. Anabolic steroid use may occasionally result in hepatic tumours, but this remains rare compared to the burden from viral hepatitis.\n\n**Key Points**\n- Hepatitis C is the most common cause of HCC in the UK.\n- Chronic HCV infection increases the risk of cirrhosis, which in turn drives HCC formation.\n- Hepatitis B is the most common cause of HCC worldwide, particularly in endemic regions.\n- Hereditary haemochromatosis and alpha-1 antitrypsin deficiency are rare but recognised contributors to HCC.\n- Anabolic steroid-induced HCC is very uncommon.\n\n**Clinical Relevance**\nUnderstanding the aetiology of hepatocellular carcinoma is vital for targeted screening and public health interventions. In the UK, patients with chronic hepatitis C require regular surveillance for HCC due to their increased risk, as outlined in national guidelines.",
    "bullet_explanations": {
      "Alpha-1 antitrypsin deficiency": "A rare genetic condition that can cause liver disease and occasionally HCC, but contributes to a small minority of cases in the UK.",
      "Hepatitis C infection": "Correct. The main cause of HCC in the UK due to chronic liver inflammation and cirrhosis from HCV infection.",
      "Hepatitis B infection": "Major global cause of HCC, especially in Asia and Africa, but less common in the UK due to low prevalence.",
      "Hereditary haemochromatosis": "Can lead to HCC via iron overload and cirrhosis, but is much less common than HCV in the UK population.",
      "Long-term anabolic steroid use": "Rarely associated with hepatic tumours, including HCC, but accounts for a very small proportion of cases."
    },
    "category": "Hepatology",
    "subsection": "Chronic Liver Disease & Cirrhosis",
    "subsubsection": "Aetiologies (alcohol, NAFLD, viral, autoimmune)",
    "topic": "Aetiologies (alcohol, NAFLD, viral, autoimmune)",
    "keywords": [
      "hepatocellular carcinoma",
      "hepatitis C",
      "liver cancer",
      "UK epidemiology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hepatitis C",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hepatitis-c/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5f7248dd-9b35-47c1-8d7f-c3a9aed69171",
    "question_number": 69,
    "question": "A 68-year-old woman presents to the emergency department with sudden onset of upper abdominal pain, fever, and new-onset jaundice. She has a history of gallstones. On examination, her temperature is 38.3°C, blood pressure is 94/58 mmHg, and she appears mildly confused. What is the most likely diagnosis?",
    "options": [
      "Ascending cholangitis",
      "Acute cholecystitis",
      "Gallstone pancreatitis",
      "Acute viral hepatitis",
      "Biliary colic"
    ],
    "correct_answer": "Ascending cholangitis",
    "explanation": "**Explanation**\n**Ascending cholangitis** is a severe infection of the biliary tree, typically caused by bacterial invasion secondary to biliary obstruction (most often gallstones). The classic presentation is Charcot's triad: right upper quadrant pain, fever, and jaundice. In severe cases, hypotension and confusion may develop (Reynolds' pentad), indicating systemic involvement and possible sepsis. Systemic upset and jaundice are not usually seen in acute cholecystitis, which more commonly presents with localised pain and fever but without marked jaundice. Viral hepatitis typically causes jaundice and malaise but lacks the acute abdominal pain and sepsis features. Biliary colic is episodic and lacks systemic features, while gallstone pancreatitis presents with epigastric pain and may have jaundice, but fever and confusion are not classic findings.\n\n**Key Points**\n- **Charcot's triad:** RUQ pain, fever, and jaundice suggest ascending cholangitis.\n- Hypotension and confusion (Reynolds' pentad) indicate severe disease.\n- Most common cause: bacterial infection due to gallstone obstruction.\n- Acute cholecystitis usually does not present with jaundice or confusion.\n- <table><thead><tr><th>Feature</th><th>Ascending Cholangitis</th><th>Acute Cholecystitis</th></tr></thead><tbody><tr><td>RUQ pain</td><td>Yes</td><td>Yes</td></tr><tr><td>Fever</td><td>Yes</td><td>Yes</td></tr><tr><td>Jaundice</td><td>Yes</td><td>Rare</td></tr><tr><td>Hypotension/confusion</td><td>Possible (severe)</td><td>Rare</td></tr></tbody></table>\n- Prompt recognition is essential due to risk of sepsis and organ failure.\n\n**Clinical Relevance**\nAscending cholangitis is a medical emergency requiring rapid identification and management with antibiotics, supportive care, and biliary decompression. Failure to recognise this syndrome can lead to sepsis and multi-organ failure. NICE guidelines recommend urgent admission and intervention for any patient with suspected cholangitis.\n\n**Memory Anchor**\nCharcot's triad: 'RUQ pain, fever, jaundice' for cholangitis; add hypotension and confusion for Reynolds' pentad (severe cases).",
    "bullet_explanations": {
      "Ascending cholangitis": "Correct – Classic triad of RUQ pain, fever, and jaundice, often progressing to hypotension and confusion in severe cases.",
      "Acute cholecystitis": "Incorrect – Presents with RUQ pain and fever but typically without jaundice or confusion.",
      "Gallstone pancreatitis": "Incorrect – Causes epigastric pain and possibly jaundice but fever and confusion are uncommon.",
      "Acute viral hepatitis": "Incorrect – Causes jaundice and malaise but not usually fever with acute abdominal pain and hypotension.",
      "Biliary colic": "Incorrect – Characterised by episodic pain without systemic features like fever or jaundice."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Biliary & Pancreas",
    "subsubsection": "Gallstone Disease",
    "topic": "Biliary colic vs cholecystitis vs choledocholithiasis",
    "keywords": [
      "ascending cholangitis",
      "Charcot's triad",
      "gallstones",
      "biliary sepsis",
      "RUQ pain"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cholecystitis - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cholecystitis-acute/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Gallstones",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/gallstones/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "293a6e4f-38aa-46c7-a950-29ab1e2bd06f",
    "question_number": 70,
    "question": "A 34-year-old man presents with a 3-day history of left eye discomfort, increased tearing, and marked sensitivity to light. He is otherwise healthy but recalls having cold sores in the past. Examination reveals a red, watery left eye with mild lid swelling. Fluorescein staining demonstrates a branching (dendritic) corneal lesion. What is the first-line pharmacological treatment for this condition?",
    "options": [
      "Topical aciclovir",
      "Topical fusidic acid",
      "Oral prednisolone",
      "Lubricating eye drops",
      "Oral amoxicillin"
    ],
    "correct_answer": "Topical aciclovir",
    "explanation": "**Explanation**\n**Topical aciclovir** is the recommended first-line therapy for herpes simplex epithelial keratitis. The diagnosis is based on the presence of a characteristic dendritic corneal ulcer, often accompanied by pain, photophobia, watering, and a red eye. Herpes simplex virus (HSV) is the most common cause of this presentation, particularly in individuals with a history of oral herpes. Topical antiviral agents such as aciclovir inhibit viral replication at the corneal surface, facilitating resolution of the infection and reducing the risk of complications such as corneal scarring or vision loss. Bacterial antibiotics, corticosteroids, and lubricants do not address the underlying viral cause and may be harmful or ineffective in this setting. Initiation of topical antivirals should be accompanied by urgent ophthalmology referral, as per current guidelines.\n\n**Key Points**\n- Herpes simplex keratitis typically presents with unilateral red eye, pain, watering, and photophobia.\n- Dendritic ulcers on fluorescein staining are diagnostic for HSV epithelial keratitis.\n- First-line treatment is topical antiviral therapy (e.g., aciclovir).\n- Topical corticosteroids are contraindicated in untreated HSV keratitis due to risk of worsening infection.\n- Lubricants may provide symptom relief but do not treat the infection.\n- Ophthalmology referral is required for all cases of suspected HSV keratitis.\n\n**Clinical Relevance**\nPrompt recognition and treatment of herpes simplex keratitis are essential to prevent long-term visual impairment. National guidelines emphasise topical antivirals and same-day specialist assessment to minimise the risk of corneal complications.",
    "bullet_explanations": {
      "Topical aciclovir": "Correct – This is the first-line treatment for herpes simplex keratitis presenting with a dendritic corneal ulcer.",
      "Topical fusidic acid": "Incorrect – This is used for superficial bacterial eye infections, not for viral keratitis.",
      "Oral prednisolone": "Incorrect – Systemic corticosteroids are not indicated and can worsen active herpes simplex eye disease.",
      "Lubricating eye drops": "Incorrect – They relieve discomfort but do not treat the viral infection or prevent complications.",
      "Oral amoxicillin": "Incorrect – This is an antibacterial agent with no efficacy against herpes simplex virus."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Keratitis",
    "topic": "Keratitis",
    "keywords": [
      "herpes simplex keratitis",
      "dendritic ulcer",
      "topical aciclovir"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Herpes simplex - ocular",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/herpes-simplex-ocular/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "275dda00-5673-4a7e-9b03-f44eed07e84f",
    "question_number": 71,
    "question": "A 54-year-old woman is referred to endocrinology after reporting persistent headaches, coarsening of facial features, increased spacing between her teeth, and new onset of carpal tunnel symptoms. She mentions her gloves and shoes no longer fit. On examination, her blood pressure is 162/100 mmHg. What is the most likely underlying diagnosis?",
    "options": [
      "Acromegaly",
      "Cushing's syndrome",
      "Phaeochromocytoma",
      "Prolactinoma",
      "Diabetes insipidus"
    ],
    "correct_answer": "Acromegaly",
    "explanation": "**Explanation**\n**Acromegaly** results from excessive growth hormone (GH) secretion, almost always due to a pituitary adenoma. Overproduction of GH leads to increased insulin-like growth factor-1 (IGF-1), causing characteristic soft tissue and bony overgrowth. Patients often present with enlarged hands and feet (evidenced by rings, gloves, or shoes no longer fitting), coarsened facial features, jaw prognathism, and increased interdental spacing. Headaches are common due to the mass effect of the pituitary tumour. Hypertension and symptoms such as carpal tunnel syndrome are also frequently seen. Galactorrhoea may occur if the adenoma co-secretes prolactin. This constellation of features is specific for acromegaly and not seen in other endocrine disorders listed here.\n\n**Key Points**\n- Acromegaly is due to excess GH, usually from a pituitary adenoma.\n- Classic signs: enlarged hands/feet, coarsened facial features, jaw changes, increased shoe/glove size.\n- Associated symptoms: headaches (pituitary mass), hypertension, carpal tunnel syndrome.\n- Galactorrhoea may be present if prolactin is co-secreted.\n- Other pituitary or adrenal disorders do not cause bony or soft tissue overgrowth.\n- Diagnosis is confirmed with elevated IGF-1 and failure to suppress GH on glucose tolerance testing.\n\n**Clinical Relevance**\nRecognising the classic phenotype of acromegaly is vital, as early diagnosis and treatment reduce the risk of cardiovascular and metabolic complications. The condition is rare, and its insidious onset means symptoms are often overlooked. UK best practice is to confirm biochemical diagnosis before imaging the pituitary. Reference: BNF – Hypothalamic and anterior pituitary hormones.\n\n**Memory Anchor**\nAcromegaly = **A**ccessories (rings, gloves, shoes) no longer fit due to **A**dult bone and soft tissue overgrowth.",
    "bullet_explanations": {
      "Acromegaly": "Correct: Progressive enlargement of extremities, facial changes, and hypertension point to excess GH.",
      "Cushing's syndrome": "Incorrect: Presents with central obesity, facial rounding, striae, and muscle weakness, not bony overgrowth.",
      "Phaeochromocytoma": "Incorrect: Typically causes episodic headaches, palpitations, and sweating due to catecholamine excess; no extremity or facial changes.",
      "Prolactinoma": "Incorrect: Causes galactorrhoea and menstrual disturbance but not soft tissue or bone growth.",
      "Diabetes insipidus": "Incorrect: Manifests as polyuria and polydipsia, not physical changes or hypertension."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Calcium, Pituitary & Metabolic",
    "subsubsection": "Pituitary",
    "topic": "Acromegaly screening (IGF-1) and Rx",
    "keywords": [
      "acromegaly",
      "growth hormone",
      "pituitary adenoma",
      "enlarged extremities",
      "MSRA endocrinology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypothalamic and anterior pituitary hormones",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypothalamic-and-anterior-pituitary-hormones/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e36f26b9-02f2-410a-b49c-47e8a5067ec1",
    "question_number": 72,
    "question": "A 71-year-old woman presents to her GP after noticing two separate episodes of painless visible haematuria over the past month. She has no fever, dysuria, or other urinary symptoms. Urinalysis confirms +++ blood, but is negative for leukocytes and nitrites. What is the most appropriate next step in her investigation?",
    "options": [
      "Urgent suspected cancer referral for cystoscopy",
      "Non-urgent renal ultrasound",
      "Urine cytology",
      "Repeat urinalysis in one week",
      "Empirical antibiotics for presumed UTI"
    ],
    "correct_answer": "Urgent suspected cancer referral for cystoscopy",
    "explanation": "**Explanation**\nTwo episodes of painless visible haematuria in a patient over 45 years old, without evidence of infection, should prompt an **urgent referral for cystoscopy via the suspected cancer pathway**. This is because painless macroscopic haematuria is a red flag for underlying urological malignancy, particularly bladder or renal cancer. **Cystoscopy is the gold standard for visualising the bladder mucosa and detecting tumours**. Imaging (such as ultrasound or CT) and other non-invasive tests (e.g., cytology, urine biomarkers) may assist with staging or monitoring but do not replace initial cystoscopic assessment. Importantly, empirical antibiotics or delayed testing are inappropriate when infection is not indicated on urinalysis. Early diagnosis is crucial to improve outcomes in urological cancers.<br><br><b>Key Points:</b><ul><li>Painless visible haematuria in older adults warrants urgent cancer referral.</li><li>Cystoscopy is essential for evaluating possible bladder cancer.</li><li>Absence of infection markers on urinalysis excludes UTI as the cause.</li><li>Imaging and urine cytology are not first-line for initial assessment.</li><li>Prompt action reduces diagnostic delay and improves prognosis.</li></ul><br><br><b>Clinical Relevance:</b> Visible haematuria is a recognised 'red flag' for urological malignancy. NICE guidance supports urgent referral for visible haematuria in adults over 45 without infection, enabling earlier detection and treatment of bladder or renal cancers (<a href=\"https://cks.nice.org.uk/topics/urological-cancers-recognition-referral/\">NICE CKS</a>).<br><br><b>Memory Anchor:</b> \"Cystoscopy for Cancer Concern in Cases of Clear (visible) Blood.\"\n\n**Key Points**\n<ul><li>Painless visible haematuria in older adults warrants urgent cancer referral.</li><li>Cystoscopy is essential for evaluating possible bladder cancer.</li><li>Absence of infection markers on urinalysis excludes UTI as the cause.</li><li>Imaging and urine cytology are not first-line for initial assessment.</li><li>Prompt action reduces diagnostic delay and improves prognosis.</li></ul>\n\n**Clinical Relevance**\nVisible haematuria is a recognised 'red flag' for urological malignancy. NICE guidance supports urgent referral for visible haematuria in adults over 45 without infection, enabling earlier detection and treatment of bladder or renal cancers.\n\n**Memory Anchor**\n\"Cystoscopy for Cancer Concern in Cases of Clear (visible) Blood.\"",
    "bullet_explanations": {
      "Urgent suspected cancer referral for cystoscopy": "Correct – NICE recommends urgent cystoscopic assessment for visible haematuria in patients over 45 without infection.",
      "Non-urgent renal ultrasound": "Incorrect – Ultrasound may help with staging but does not replace prompt cystoscopy for initial diagnosis.",
      "Urine cytology": "Incorrect – Cytology may be used adjunctively, especially for upper tract tumours, but is not first-line for visible haematuria.",
      "Repeat urinalysis in one week": "Incorrect – Delaying referral risks missed or delayed cancer diagnosis.",
      "Empirical antibiotics for presumed UTI": "Incorrect – No evidence of infection on urinalysis; antibiotics are not indicated."
    },
    "category": "Renal & Urology",
    "subsection": "Urology",
    "subsubsection": "Malignancy",
    "topic": "Red flag haematuria",
    "keywords": [
      "visible haematuria",
      "bladder cancer",
      "cystoscopy",
      "urgent referral",
      "red flag"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Urological cancers - recognition and referral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/urological-cancers-recognition-referral/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "dc758e56-5e50-4c11-adf2-ae87d2234283",
    "question_number": 73,
    "question": "A 37-year-old man presents to the GP with a sudden onset of pain, redness, and excessive tearing in his right eye. He reports mild photophobia but no visual loss. On examination, there is a unilateral red eye and fluorescein staining reveals a branching, dendritic pattern on the cornea. What is the most appropriate immediate management in primary care?",
    "options": [
      "Urgent ophthalmology referral and consider starting topical aciclovir",
      "Prescribe topical corticosteroids and arrange routine review",
      "Initiate oral antibiotics and safety net for worsening",
      "Administer oral aciclovir and discharge with advice",
      "Reassure and arrange follow-up in one week"
    ],
    "correct_answer": "Urgent ophthalmology referral and consider starting topical aciclovir",
    "explanation": "**Explanation**\nThe patient's presentation—**unilateral red eye, photophobia, and dendritic corneal ulcer on fluorescein staining**—is characteristic of **herpes simplex keratitis**. This is an ophthalmic emergency due to the risk of corneal scarring and vision loss. **Immediate referral to specialist eye services (eye casualty or emergency eye clinic) is required** for diagnosis confirmation and prompt antiviral therapy. In some settings, GPs may be advised to start topical aciclovir if specialist review is delayed, but corticosteroids are contraindicated as they can exacerbate herpes simplex infection.\n\n**Key Points**\n- Herpes simplex keratitis presents with eye pain, redness, photophobia, and watery discharge.\n- Dendritic (branching) corneal ulcers are pathognomonic and visualised with fluorescein.\n- Urgent specialist referral is essential to prevent sight-threatening complications.\n- Topical aciclovir is the mainstay of treatment; corticosteroids are avoided in primary care.\n- Delayed or inappropriate treatment can lead to corneal scarring or perforation.\n\n**Clinical Relevance**\nEarly recognition of herpes simplex keratitis in primary care is vital for sight preservation. GPs must be aware that topical steroids are contraindicated and urgent ophthalmology input is needed, in line with NICE CKS recommendations.\n\n**Memory Anchor**\nDendritic = HSV keratitis = antiviral + urgent eye review",
    "bullet_explanations": {
      "Urgent ophthalmology referral and consider starting topical aciclovir": "Correct—herpes simplex keratitis requires immediate specialist assessment and topical antivirals.",
      "Prescribe topical corticosteroids and arrange routine review": "Incorrect—steroids worsen herpes simplex keratitis and risk severe complications.",
      "Initiate oral antibiotics and safety net for worsening": "Incorrect—bacterial infection is not suggested by a dendritic ulcer; antibiotics are ineffective for HSV.",
      "Administer oral aciclovir and discharge with advice": "Incorrect—oral antivirals are not first-line for epithelial keratitis; specialist assessment is needed.",
      "Reassure and arrange follow-up in one week": "Incorrect—delayed management risks corneal damage and visual loss."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Keratitis",
    "topic": "Herpes simplex keratitis",
    "keywords": [
      "herpes simplex keratitis",
      "dendritic ulcer",
      "red eye",
      "topical aciclovir",
      "urgent referral"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Herpes simplex - ocular",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/herpes-simplex-ocular/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b3808cf8-7cdc-42fb-93d9-4a26850b8163",
    "question_number": 74,
    "question": "A 45-year-old man presents to the acute medical unit with sudden onset pleuritic chest pain and mild breathlessness. He experienced a similar episode last year and was diagnosed with a deep vein thrombosis at that time. He has no current haemodynamic instability, and his oxygen saturations are normal. His 2-level Wells score is 1.5 (for previous DVT), and blood tests, including D-dimer, are sent. Interim anticoagulation is started as the D-dimer result will take several hours. The D-dimer returns as negative. What is the most appropriate next step in managing this patient?",
    "options": [
      "Discontinue anticoagulation and investigate for other causes",
      "Refer for urgent CT pulmonary angiogram",
      "Repeat the D-dimer in 24 hours",
      "Continue anticoagulation while monitoring for clinical deterioration",
      "Switch to low molecular weight heparin"
    ],
    "correct_answer": "Discontinue anticoagulation and investigate for other causes",
    "explanation": "**Explanation**\n**A Wells score of 4 or less indicates a low clinical probability for pulmonary embolism (PE). If the D-dimer is negative, PE is effectively excluded and anticoagulation should be stopped to avoid unnecessary bleeding risk.** Current guidelines recommend discontinuation of anticoagulation in this scenario and prompt consideration of alternative diagnoses for the patient’s symptoms. Continuing anticoagulation or pursuing further imaging is unnecessary unless new features develop. This approach minimises harm and ensures resources are used appropriately.\n\n**Key Points**\n- Wells score ≤4 = 'PE unlikely'; proceed to D-dimer testing.\n- Negative D-dimer with low Wells score effectively rules out PE.\n- Anticoagulation should be discontinued if PE is excluded.\n- Alternative diagnoses (e.g., musculoskeletal pain, pneumonia, ACS) should be considered.\n- Further PE-specific imaging is not needed with negative D-dimer and low pre-test probability.\n- Continuing anticoagulation without indication increases bleeding risk.\n\n**Clinical Relevance**\nAdhering to evidence-based algorithms for suspected PE reduces unnecessary anticoagulation and imaging, improving patient safety and optimising care. NICE guidance is clear that a negative D-dimer with low Wells score allows safe exclusion of PE, supporting prompt focus on alternative diagnoses.\n\n**Memory Anchor**\nWells ≤4 + negative D-dimer = 'Stop anticoagulation, seek another cause.'",
    "bullet_explanations": {
      "Discontinue anticoagulation and investigate for other causes": "Correct—PE is ruled out with low Wells score and negative D-dimer; stop anticoagulation and seek alternative diagnosis.",
      "Refer for urgent CT pulmonary angiogram": "Incorrect—CTPA is only indicated if Wells >4 or D-dimer is positive.",
      "Repeat the D-dimer in 24 hours": "Incorrect—Repeat testing is unnecessary with a valid negative result and no new symptoms.",
      "Continue anticoagulation while monitoring for clinical deterioration": "Incorrect—Unnecessary anticoagulation poses avoidable bleeding risk if PE is excluded.",
      "Switch to low molecular weight heparin": "Incorrect—Changing anticoagulant is not indicated as anticoagulation is not needed if PE is ruled out."
    },
    "category": "Respiratory",
    "subsection": "Infective",
    "subsubsection": "Pulmonary Embolism",
    "topic": "Wells score, PERC, YEARS algorithms",
    "keywords": [
      "pulmonary embolism",
      "Wells score",
      "D-dimer",
      "anticoagulation",
      "diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Pulmonary embolism",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/pulmonary-embolism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "892c7b7f-188d-41bb-990a-e9a736b28f1d",
    "question_number": 75,
    "question": "A 38-year-old woman with type 2 diabetes, hypertension, and hyperlipidaemia attends her first antenatal appointment after a positive pregnancy test. Which of the following medications should be discontinued immediately upon confirmation of pregnancy due to teratogenic risk?",
    "options": [
      "Atorvastatin",
      "Amitriptyline",
      "Lercanidipine",
      "Metformin",
      "Sertraline"
    ],
    "correct_answer": "Atorvastatin",
    "explanation": "**Explanation**\n**Statins, such as atorvastatin, are contraindicated in pregnancy due to their teratogenic potential and risk of congenital abnormalities.** These drugs interfere with cholesterol synthesis, a process essential for fetal development. Current guidelines recommend discontinuing statin therapy before conception or as soon as pregnancy is confirmed. Other commonly used medications, such as metformin, certain antihypertensives, and antidepressants, may be continued with appropriate clinical judgement and discussion of risks and benefits, but statins should always be stopped immediately.\n\n**Key Points**\n- Statins carry a significant teratogenic risk and must be stopped if pregnancy is confirmed.\n- Cholesterol is vital for fetal organogenesis; inhibiting its synthesis can lead to malformations.\n- Metformin is generally safe in pregnancy and often continued for diabetes management.\n- Lercanidipine (a calcium channel blocker) has no strong evidence of harm in pregnancy.\n- Antidepressants require risk-benefit analysis; abrupt cessation is rarely indicated.\n- BNF and NICE guidelines explicitly advise against statin use during pregnancy.\n\n**Clinical Relevance**\nRecognising medications contraindicated in pregnancy is essential for safe antenatal care. Statins must be promptly discontinued to avoid preventable fetal harm, as advised by national guidelines. This knowledge is crucial for clinicians managing women with chronic diseases who become pregnant.\n\n**Memory Anchor**\nStatins = STOP in pregnancy",
    "bullet_explanations": {
      "Atorvastatin": "Correct – Statins are contraindicated in pregnancy and should be discontinued immediately due to teratogenic risk.",
      "Amitriptyline": "Incorrect – This antidepressant is considered safe in pregnancy; abrupt cessation is not required.",
      "Lercanidipine": "Incorrect – While not first-line, it is not known to cause fetal harm and does not require immediate cessation.",
      "Metformin": "Incorrect – This drug is often continued during pregnancy for glycaemic control if benefits outweigh risks.",
      "Sertraline": "Incorrect – Selective serotonin reuptake inhibitors can be used in pregnancy if benefits outweigh risks; sudden cessation is not recommended."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "High-risk pregnancy identification",
    "keywords": [
      "statins",
      "pregnancy contraindications",
      "antenatal medications",
      "atorvastatin",
      "teratogenic drugs"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetes, pregnancy and breast-feeding",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetes-pregnancy-and-breast-feeding/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1cf513a7-092b-4717-8efb-58d9f7c0e6d3",
    "question_number": 76,
    "question": "A 33-year-old woman presents with chronic pelvic pain that worsens during her periods and reports pain during intercourse. She also notes that she and her partner have struggled to conceive for over a year. Which condition most likely explains her symptoms?",
    "options": [
      "Endometriosis",
      "Pelvic inflammatory disease",
      "Adenomyosis",
      "Cervical ectropion",
      "Polycystic ovary syndrome (PCOS)"
    ],
    "correct_answer": "Endometriosis",
    "explanation": "**Explanation**\n**Endometriosis** is characterised by the presence of endometrial-like tissue outside the uterus, leading to symptoms such as chronic pelvic pain, dysmenorrhoea (painful menstruation), and deep dyspareunia (painful intercourse). It is a common cause of subfertility in women of reproductive age. The pain often worsens during menstruation due to cyclical bleeding and inflammation within ectopic endometrial tissue. Unlike other causes, the combination of period-related pain, sexual pain, and reduced fertility is highly suggestive of endometriosis, especially with a chronic pattern and impact on quality of life. Differential diagnoses such as PID, adenomyosis, or PCOS can cause pelvic pain or subfertility but typically lack this specific triad or have distinguishing features (e.g., PCOS more often presents with oligo/amenorrhoea and signs of androgen excess).\n\n**Key Points**\n- Endometriosis presents with cyclical pelvic pain, dysmenorrhoea, and deep dyspareunia.\n- Subfertility is a key associated complication.\n- Symptoms are often chronic and can significantly impact daily life.\n- Physical examination and imaging may be normal; laparoscopy is required for definitive diagnosis.\n- First-line management includes analgesia and hormonal therapy; fertility concerns require specialist input.\n- <table><thead><tr><th>Feature</th><th>Endometriosis</th><th>PID</th><th>PCOS</th></tr></thead><tbody><tr><td>Dysmenorrhoea</td><td>Yes (cyclical)</td><td>Possible</td><td>No/rare</td></tr><tr><td>Dyspareunia</td><td>Yes (deep)</td><td>May be present</td><td>No</td></tr><tr><td>Subfertility</td><td>Common</td><td>Possible</td><td>Common</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising endometriosis is vital in women with cyclical pelvic pain and fertility difficulties. Early diagnosis and multidisciplinary management improve quality of life and reproductive outcomes. UK guidelines emphasise considering endometriosis in women with this symptom profile and involving specialist care when fertility is affected.\n\n**Memory Anchor**\nThink '3 Ds': Dysmenorrhoea, Dyspareunia, and Difficulty conceiving = Endometriosis.",
    "bullet_explanations": {
      "Endometriosis": "Correct – Classic triad of cyclical pelvic pain, dyspareunia, and subfertility.",
      "Pelvic inflammatory disease": "Usually presents with acute pelvic pain, abnormal discharge, fever, and often has a more acute onset.",
      "Adenomyosis": "Leads to heavy, painful periods but rarely causes deep dyspareunia or subfertility.",
      "Cervical ectropion": "May cause post-coital bleeding but does not present with chronic pelvic pain or subfertility.",
      "Polycystic ovary syndrome (PCOS)": "Typically presents with oligo/amenorrhoea, hirsutism, and subfertility, not cyclical pain or dyspareunia."
    },
    "category": "Gynaecology",
    "subsection": "Menstrual Disorders",
    "subsubsection": "Dysmenorrhoea",
    "topic": "Endometriosis",
    "keywords": [
      "endometriosis",
      "dysmenorrhoea",
      "subfertility",
      "chronic pelvic pain"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Endometriosis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/endometriosis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Endometriosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/endometriosis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Dysmenorrhoea",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/dysmenorrhoea/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0e697e77-7d50-4522-863a-1a3b7c6e9f4b",
    "question_number": 77,
    "question": "A 62-year-old man with a history of stable angina is currently prescribed bisoprolol 5 mg once daily, aspirin 75 mg daily, and atorvastatin 20 mg nightly. Despite good adherence, he continues to experience exertional chest pain that limits his daily activities. What is the most appropriate adjustment to his antianginal regimen to improve symptom control?",
    "options": [
      "Switch bisoprolol to ivabradine",
      "Increase atorvastatin dose",
      "Add a long-acting dihydropyridine calcium-channel blocker",
      "Add isosorbide mononitrate MR",
      "Refer immediately for coronary angiography"
    ],
    "correct_answer": "Add a long-acting dihydropyridine calcium-channel blocker",
    "explanation": "**Explanation**\n**When angina symptoms persist on a beta-blocker, the recommended next step is to add a long-acting dihydropyridine calcium-channel blocker (such as amlodipine).** This combination is supported by both BNF and NICE guidelines, as it targets myocardial oxygen demand and vasodilation through complementary mechanisms. Dihydropyridines like amlodipine do not cause bradycardia and can be safely combined with beta-blockers, improving angina control without significant risk of heart block. Alternative agents (such as nitrates, nicorandil, or ivabradine) are reserved for cases where beta-blockers and calcium-channel blockers are contraindicated or not tolerated, or as third-line options if dual therapy is insufficient.\n\n**Key Points**\n- First-line: Beta-blocker or calcium-channel blocker for stable angina symptom control.\n- If symptoms persist on a beta-blocker, add a long-acting dihydropyridine calcium-channel blocker (e.g., amlodipine).\n- Nitrates (e.g., isosorbide mononitrate) and other agents (e.g., nicorandil, ivabradine) are considered second- or third-line.\n- Ivabradine is not first-choice unless beta-blockers and calcium-channel blockers are contraindicated or not tolerated.\n- Referral for revascularisation is considered after failure of maximal tolerated dual therapy.\n- <table><thead><tr><th>Step</th><th>Antianginal Management</th></tr></thead><tbody><tr><td>1</td><td>Beta-blocker or CCB</td></tr><tr><td>2</td><td>Add CCB (if on BB) or vice versa</td></tr><tr><td>3</td><td>Add nitrate/nicorandil/other (if dual fails)</td></tr><tr><td>4</td><td>Specialist referral</td></tr></tbody></table>\n\n**Clinical Relevance**\nFollowing a structured, evidence-based approach to antianginal therapy ensures optimal symptom control and minimises unnecessary escalation to more invasive treatments. This is directly aligned with NICE and BNF recommendations for stable angina management.\n\n**Memory Anchor**\nThink 'B + CCB before N': Beta-blocker plus Calcium Channel Blocker before Nitrates.",
    "bullet_explanations": {
      "Switch bisoprolol to ivabradine": "Ivabradine is not first-line unless beta-blockers or calcium-channel blockers are contraindicated or not tolerated.",
      "Increase atorvastatin dose": "Upping statin dose addresses lipid control, not immediate angina symptoms.",
      "Add a long-acting dihydropyridine calcium-channel blocker": "Correct—recommended next step for persistent angina on beta-blocker monotherapy.",
      "Add isosorbide mononitrate MR": "A long-acting nitrate is reserved for third-line or if beta-blockers and CCBs are not tolerated.",
      "Refer immediately for coronary angiography": "Referral is considered only after failure of dual antianginal therapy at maximal tolerated doses."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Stable Coronary Disease",
    "topic": "Antianginal therapy ladder (beta-blocker, CCB, nitrates, nicorandil)",
    "keywords": [
      "stable angina",
      "antianginal therapy",
      "calcium channel blocker",
      "beta-blocker",
      "NICE guidelines"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Stable angina",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/stable-angina/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Angina",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/angina/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "65556901-e1c4-49c6-861e-0de5d5e8ffd8",
    "question_number": 78,
    "question": "A 35-year-old woman is found unconscious after a fall at work. On examination: she opens her eyes only to speech, makes incomprehensible noises, and shows abnormal flexion in response to pain. What is her Glasgow Coma Scale (GCS) score?",
    "options": [
      "6",
      "8",
      "9",
      "7",
      "11"
    ],
    "correct_answer": "8",
    "explanation": "**Explanation**\n**The Glasgow Coma Scale (GCS)** is a widely used tool for assessing the level of consciousness in patients with acute brain injury. It measures three domains: eye opening, verbal response, and motor response. In this scenario: eye opening to speech scores 3, incomprehensible sounds score 2 on verbal response, and abnormal flexion to pain is a motor score of 3. Adding these together (3 + 2 + 3) gives a total GCS of 8. This score indicates a severe reduction in consciousness and warrants urgent referral to hospital for further assessment and management. The scores should always be interpreted in the clinical context and repeated as necessary.<br><br><b>Key GCS components:</b><br>• Eye opening (E): to speech = 3<br>• Verbal response (V): incomprehensible sounds = 2<br>• Motor response (M): abnormal flexion = 3<br>Total: 3 + 2 + 3 = 8.\n\n**Key Points**\n- GCS assesses eye, verbal, and motor responses separately.\n- A GCS of 8 or below is considered a marker of severe brain injury.\n- GCS should be monitored over time to detect changes.\n- Immediate transfer to hospital is required if GCS <15 after head injury.\n- Clinical context and repeated assessments are essential.\n- <table><thead><tr><th>Domain</th><th>Score</th><th>Description</th></tr></thead><tbody><tr><td>Eye</td><td>3</td><td>Opens to speech</td></tr><tr><td>Verbal</td><td>2</td><td>Incomprehensible sounds</td></tr><tr><td>Motor</td><td>3</td><td>Abnormal flexion</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurate scoring of the GCS is essential in the initial assessment of head injury, guiding urgent referral and management. UK guidelines highlight the importance of immediate specialist assessment for any GCS below 15, as this can indicate significant brain injury and risk of deterioration.\n\n**Memory Anchor**\nRemember 'EVM' (Eyes, Voice, Movement); 3-2-3 pattern in severe injuries.",
    "bullet_explanations": {
      "6": "Incorrect – This would require lower scores in at least one domain; the described findings total 8.",
      "7": "Incorrect – Would be the total if either eye or motor response scored one less.",
      "8": "Correct – Eye opening to speech (3) + incomprehensible sounds (2) + abnormal flexion (3) = 8.",
      "9": "Incorrect – Would require at least one higher score, e.g., a better verbal or motor response.",
      "11": "Incorrect – Only possible with much higher responses in multiple domains."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Stroke & TIA",
    "topic": "FAST/TIA recognition",
    "keywords": [
      "Glasgow Coma Scale",
      "head injury",
      "GCS assessment",
      "neurological status"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Head injury",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/head-injury/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fc51b039-947e-4c38-bd0d-a56cdd7f3382",
    "question_number": 79,
    "question": "A 57-year-old Black British man with a history of well-controlled gout attends for hypertension review. He is currently taking amlodipine 10 mg once daily but his recent clinic blood pressures have averaged 152/86 mmHg. Which additional antihypertensive agent is most appropriate to initiate according to UK guidelines?",
    "options": [
      "Lisinopril",
      "Atenolol",
      "Verapamil",
      "Spironolactone",
      "Doxazosin"
    ],
    "correct_answer": "Lisinopril",
    "explanation": "**Explanation**\n**UK hypertension guidelines recommend a stepwise approach to blood pressure control.** For adults aged over 55 or of Black African or African-Caribbean origin without diabetes, a calcium channel blocker is first-line. If blood pressure remains uncontrolled, an ACE inhibitor (like lisinopril), an angiotensin receptor blocker (ARB), or a thiazide-like diuretic should be added. The patient is already on the maximum recommended dose of a calcium channel blocker, so the next step is to introduce an ACE inhibitor, unless contraindicated. Other options are reserved for later stages or specific indications.\n\n**Key Points**\n- Step 1: Start with a calcium channel blocker in adults >55 or Black ethnicity (no diabetes).\n- Step 2: If BP remains above target, add an ACE inhibitor, ARB, or thiazide-like diuretic.\n- Amlodipine (a CCB) alone is insufficient here; lisinopril (an ACE inhibitor) is the correct next agent.\n- Beta-blockers, alpha-blockers, and spironolactone are not recommended at this stage unless there is resistant hypertension.\n- <table><thead><tr><th>Step</th><th>Medication</th></tr></thead><tbody><tr><td>1</td><td>CCB</td></tr><tr><td>2</td><td>+ ACEi/ARB or thiazide-like diuretic</td></tr><tr><td>3</td><td>CCB + ACEi/ARB + thiazide-like diuretic</td></tr><tr><td>4</td><td>Consider specialist options (spironolactone, alpha/beta-blocker)</td></tr></tbody></table>\n\n**Clinical Relevance**\nFollowing the recommended antihypertensive ladder improves blood pressure control and reduces cardiovascular risk, and ensures safe, evidence-based escalation of therapy in primary care.\n\n**Memory Anchor**\nRemember: 'A for ACE inhibitor comes After Amlodipine.'",
    "bullet_explanations": {
      "Lisinopril": "Correct: ACE inhibitor is the recommended next step after a calcium channel blocker if BP is uncontrolled.",
      "Atenolol": "Incorrect: Beta-blockers are not recommended as second-line unless other options are unsuitable or in specific comorbidities.",
      "Verapamil": "Incorrect: Adding another calcium channel blocker is not advised; amlodipine is already at maximal dose.",
      "Spironolactone": "Incorrect: Reserved for resistant hypertension (step 4), not for second-line addition.",
      "Doxazosin": "Incorrect: Alpha-blockers are only considered at step 4 if other agents are ineffective or not tolerated."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "NICE A/C/D ladder and special cases",
    "keywords": [
      "hypertension",
      "ACE inhibitor",
      "stepwise therapy",
      "amlodipine",
      "lisinopril"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "aea6cf34-1804-46b7-af10-14750dd1a969",
    "question_number": 80,
    "question": "A 72-year-old woman with a history of previous myocardial infarction presents to the acute medical unit with a sudden onset of rapid, regular palpitations. Her vital signs are stable: heart rate 138 bpm, blood pressure 132/78 mmHg, and oxygen saturation 96% on room air. She is alert and denies chest pain or breathlessness. ECG reveals a regular broad complex tachycardia with a QRS duration of 145 ms. What is the most appropriate initial management?",
    "options": [
      "IV amiodarone",
      "Synchronous DC cardioversion",
      "IV magnesium sulphate",
      "Carotid sinus massage",
      "IV adenosine"
    ],
    "correct_answer": "IV amiodarone",
    "explanation": "**Explanation**\n**IV amiodarone is the first-line pharmacological therapy for a stable, regular broad complex tachycardia, most commonly ventricular tachycardia (VT)**. The patient's history of ischaemic heart disease and the ECG findings (regular, broad QRS) support a diagnosis of monomorphic VT. In the absence of adverse features such as hypotension, shock, ongoing chest pain, or heart failure, immediate synchronised DC cardioversion is not indicated. Instead, controlled pharmacological cardioversion with amiodarone is recommended. This approach is supported by national guidelines and helps avoid unnecessary procedural risks. **Adenosine and carotid sinus massage are reserved for narrow complex tachycardias or when SVT with aberrancy is suspected**, not for clear VT. Magnesium is used for specific scenarios such as torsades de pointes (polymorphic VT), not monomorphic VT.\n\n**Key Points**\n- Broad complex tachycardia with regular rhythm and ischaemic heart disease is likely ventricular tachycardia.\n- Assess for adverse features: hypotension, ischaemia, shock, or acute heart failure.\n- Stable patients are managed first with IV anti-arrhythmic drugs—amiodarone is preferred.\n- Unstable patients require immediate DC cardioversion.\n- Adenosine and vagal manoeuvres are not suitable for monomorphic VT.\n- Magnesium sulphate is mainly for polymorphic VT (e.g., torsades de pointes).\n\n**Clinical Relevance**\nTimely recognition and correct management of broad complex tachycardia in stable patients is essential to prevent progression to instability or cardiac arrest. Amiodarone is the preferred anti-arrhythmic agent in these cases, aligning with BNF and Resuscitation Council (UK) recommendations.",
    "bullet_explanations": {
      "IV amiodarone": "Correct—first-line for stable, regular broad complex tachycardia (likely VT) in a patient without adverse features.",
      "Synchronous DC cardioversion": "Incorrect—reserved for patients who are unstable or have adverse features.",
      "IV magnesium sulphate": "Incorrect—primarily indicated for polymorphic VT (torsades de pointes), not for regular monomorphic VT.",
      "Carotid sinus massage": "Incorrect—used for some SVTs, but not for ventricular tachycardia.",
      "IV adenosine": "Incorrect—appropriate for SVT or uncertain diagnosis, not for confirmed monomorphic VT."
    },
    "category": "Cardiovascular",
    "subsection": "Arrhythmias & Conduction",
    "subsubsection": "Ventricular Arrhythmias",
    "topic": "VT vs SVT with aberrancy differentiation",
    "keywords": [
      "ventricular tachycardia",
      "broad complex tachycardia",
      "amiodarone",
      "arrhythmia management",
      "ECG"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Arrhythmias",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/arrhythmias/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e12769a8-046a-4890-9140-f782c779ff5e",
    "question_number": 81,
    "question": "Which of the following factors are used in the GRACE score to estimate 6-month mortality risk in patients presenting with non-ST elevation acute coronary syndromes?",
    "options": [
      "Age, ECG changes, troponin, renal function",
      "Heart rate, lactate, troponin, liver function tests",
      "Blood pressure, ECG changes, liver function tests, lactate",
      "Age, blood glucose, CRP, renal function",
      "Blood pressure, liver function tests, CRP, ECG changes"
    ],
    "correct_answer": "Age, ECG changes, troponin, renal function",
    "explanation": "**Explanation**\n**The GRACE (Global Registry of Acute Coronary Events) score** is an established risk stratification tool used in patients with non-ST elevation acute coronary syndromes (NSTEMI and unstable angina) to estimate their in-hospital and 6-month mortality. The key variables included in the GRACE score are: age, heart rate, systolic blood pressure, serum creatinine (as a marker of renal function), ECG changes (such as ST-segment deviation), cardiac arrest at admission, elevated cardiac biomarkers (such as troponin), and Killip class (signs of heart failure). **Liver function tests and lactate are not part of the GRACE calculation**, as hepatic dysfunction and lactate levels are not specific predictors of mortality in this context. The focus is on factors most closely associated with adverse outcomes in acute coronary syndromes.\n\n**Key Points**\n- The GRACE score estimates risk of death following non-ST elevation ACS.\n- Included variables: age, heart rate, systolic blood pressure, serum creatinine (renal function), ECG changes, cardiac arrest at admission, troponin, and Killip class.\n- Liver function tests and lactate are not included in the GRACE score.\n- ECG changes for the score focus on ST-segment deviation.\n- Renal function is a critical predictor due to risk of acute kidney injury in MI.\n\n**Clinical Relevance**\nAccurate risk stratification in NSTEMI/UA guides management such as early invasive strategies and intensity of secondary prevention. Knowing the GRACE score criteria is essential for safe, evidence-based care and aligns with NICE guidelines for acute coronary syndromes.\n\n**Memory Anchor**\nGRACE: **G**eriatric age, **R**enal function, **A**rrhythmia/cardiac arrest, **C**ardiac enzymes (troponin), **E**CG changes.",
    "bullet_explanations": {
      "Age, ECG changes, troponin, renal function": "Correct – these are all core components of the GRACE score for ACS risk stratification.",
      "Heart rate, lactate, troponin, liver function tests": "Incorrect – lactate and liver function are not included in the GRACE score; only heart rate and troponin are relevant.",
      "Blood pressure, ECG changes, liver function tests, lactate": "Incorrect – while blood pressure and ECG changes are included, liver function tests and lactate are not.",
      "Age, blood glucose, CRP, renal function": "Incorrect – blood glucose and CRP are not part of the GRACE score, though age and renal function are.",
      "Blood pressure, liver function tests, CRP, ECG changes": "Incorrect – only blood pressure and ECG changes are relevant; liver function tests and CRP are not included."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Acute Coronary Syndromes",
    "topic": "NSTEMI/UA risk scores (GRACE/TIMI) and management",
    "keywords": [
      "GRACE score",
      "NSTEMI",
      "risk stratification",
      "acute coronary syndrome"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Acute coronary syndromes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/acute-coronary-syndromes/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e5281d35-9c9c-49d2-a2ce-0e85d164a8d9",
    "question_number": 82,
    "question": "A 67-year-old man presents to his GP with a sudden onset of right upper abdominal pain, fever, and jaundice. He describes the pain as severe and colicky, and he has a history of previous episodes of milder right upper quadrant discomfort that resolved spontaneously. On examination, he is febrile and appears unwell with scleral icterus. What is the most likely diagnosis?",
    "options": [
      "Acute cholangitis",
      "Acute cholecystitis",
      "Gallstone pancreatitis",
      "Biliary colic",
      "Acute hepatitis"
    ],
    "correct_answer": "Acute cholangitis",
    "explanation": "**Explanation**\n**Acute cholangitis** is characterised by infection and obstruction of the biliary tree, typically presenting with Charcot’s triad: fever, right upper quadrant pain, and jaundice. This classic symptom constellation is a distinguishing feature not usually seen together in other biliary or hepatic conditions. The underlying cause is often a gallstone impacted in the common bile duct, leading to bacterial infection. In contrast, acute cholecystitis usually features constant pain, fever, and tenderness but without jaundice. Biliary colic does not cause fever or jaundice, and gallstone pancreatitis typically presents with epigastric pain radiating to the back and may not include jaundice unless there is biliary obstruction.\n\n**Key Points**\n- Charcot’s triad: fever, jaundice, right upper quadrant pain is highly suggestive of acute cholangitis.\n- Acute cholangitis is a medical emergency due to risk of sepsis and multi-organ failure.\n- History of intermittent biliary pain supports underlying gallstone disease.\n- Acute cholecystitis: constant pain, fever, Murphy’s sign, but usually no jaundice.\n- Gallstone pancreatitis: epigastric pain, elevated amylase/lipase, may have jaundice if obstruction.\n- Biliary colic: episodic pain, no fever, no jaundice.\n- <table><thead><tr><th>Diagnosis</th><th>Key Features</th></tr></thead><tbody><tr><td>Acute cholangitis</td><td>Fever, RUQ pain, jaundice</td></tr><tr><td>Cholecystitis</td><td>RUQ pain, fever, Murphy’s sign</td></tr><tr><td>Biliary colic</td><td>Colicky RUQ pain only</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising acute cholangitis promptly is vital, as it can rapidly progress to sepsis and organ failure. Early diagnosis enables urgent antibiotic therapy and biliary drainage, in line with national guidelines.\n\n**Memory Anchor**\nCharcot’s triad = Cholangitis (three C’s: Charcot, Cholangitis, Common bile duct).",
    "bullet_explanations": {
      "Acute cholangitis": "Correct. Presents with fever, jaundice, and right upper quadrant pain (Charcot’s triad).",
      "Acute cholecystitis": "Incorrect. Typically causes RUQ pain and fever, but jaundice is uncommon unless complicated.",
      "Gallstone pancreatitis": "Incorrect. Usually presents with epigastric pain radiating to the back and raised amylase/lipase; jaundice may occur with obstruction but fever less typical.",
      "Biliary colic": "Incorrect. Causes episodic RUQ pain without fever or jaundice.",
      "Acute hepatitis": "Incorrect. Can cause jaundice and systemic symptoms, but not typically severe RUQ pain and fever together."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Biliary & Pancreas",
    "subsubsection": "Gallstone Disease",
    "topic": "Biliary colic vs cholecystitis vs choledocholithiasis",
    "keywords": [
      "acute cholangitis",
      "Charcot's triad",
      "biliary obstruction",
      "gallstones"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cholecystitis - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cholecystitis-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1f5f7b05-1884-449b-8d58-9bb79a44e1eb",
    "question_number": 83,
    "question": "A 27-year-old woman attends the walk-in centre with a painful, swollen lesion on her right upper eyelid margin, present for 4 days. She reports mild conjunctival redness but no visual changes or systemic symptoms. On examination, there is a tender, erythematous papule at the lid margin with associated mild conjunctivitis. What is the best initial management approach?",
    "options": [
      "Warm compresses with analgesia and topical antibiotic",
      "Cool compresses and oral antibiotics",
      "Warm compresses and oral antibiotics",
      "Topical antibiotic alone",
      "Incision and drainage"
    ],
    "correct_answer": "Warm compresses with analgesia and topical antibiotic",
    "explanation": "**Explanation**\n**Styes (hordeola) are acute, localised infections of the eyelid margin, typically presenting as a painful, erythematous papule.** First-line management is usually conservative, with warm compresses and analgesia. However, if there is concomitant mild conjunctivitis, adding a topical antibiotic is recommended to address potential secondary infection. **Oral antibiotics are not first-line and are generally reserved for more severe or unresponsive cases.** Incision and drainage are rarely needed and only considered if a persistent abscess develops.\n\n**Key Points**\n- Styes are self-limiting and often resolve with conservative treatment.\n- Warm compresses promote drainage and symptom relief.\n- Topical antibiotics are considered if there is associated conjunctivitis.\n- Oral antibiotics are reserved for severe or refractory cases.\n- Incision and drainage are not routine and are only for persistent abscesses.\n- <table><thead><tr><th>Treatment</th><th>Indication</th></tr></thead><tbody><tr><td>Warm compress + analgesia</td><td>Simple stye</td></tr><tr><td>+ Topical antibiotic</td><td>With conjunctivitis</td></tr><tr><td>Oral antibiotic</td><td>Severe/complicated infection</td></tr><tr><td>Incision & drainage</td><td>Persistent abscess</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising when to add topical antibiotics in stye management is essential to prevent complications such as spreading infection. Following NICE guidance ensures safe, effective treatment and avoids unnecessary use of oral antibiotics.\n\n**Memory Anchor**\nWarm compress for stye; add topical antibiotic if conjunctivitis is present.",
    "bullet_explanations": {
      "Warm compresses with analgesia and topical antibiotic": "Correct – This is the recommended approach for a stye with associated conjunctivitis.",
      "Cool compresses and oral antibiotics": "Incorrect – Cool compresses are not recommended for styes, and oral antibiotics are not first-line.",
      "Warm compresses and oral antibiotics": "Incorrect – Oral antibiotics are reserved for more severe or unresponsive cases.",
      "Topical antibiotic alone": "Incorrect – Conservative measures (warm compress) are always advised initially, even with antibiotics.",
      "Incision and drainage": "Incorrect – This is not first-line; reserved for persistent or complicated lesions."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Conjunctivitis (viral/bacterial/allergic)",
    "topic": "Conjunctivitis (viral/bacterial/allergic)",
    "keywords": [
      "stye",
      "hordeolum",
      "conjunctivitis",
      "eyelid infection",
      "topical antibiotic"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Styes (hordeola)",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/styes-hordeola/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "311ad93a-e7e9-4706-959b-db6d587d8375",
    "question_number": 84,
    "question": "Which of the following would most clearly indicate that an adult patient lacks mental capacity to make a decision about medical treatment under UK law?",
    "options": [
      "The patient is unable to retain relevant information long enough to make a decision",
      "The patient refuses treatment recommended by the clinical team",
      "The patient has a diagnosis of severe brain injury",
      "The patient communicates decisions using a communication aid",
      "The patient expresses a wish for discharge that may be influenced by addiction"
    ],
    "correct_answer": "The patient is unable to retain relevant information long enough to make a decision",
    "explanation": "**Explanation**\nAssessing capacity requires that the patient is able to **understand, retain, weigh up, and communicate** information relevant to the decision. If a patient cannot retain information long enough to make an informed choice, this demonstrates a failure of one of the legal standards of capacity. Memory impairment, as seen in some neurological conditions, may specifically prevent information retention even if other thought processes remain intact. This inability to hold information, rather than simply disagreeing with medical advice or having a particular diagnosis, is a fundamental reason to conclude that capacity is lacking. The law is clear that the *process* of decision-making—not the outcome or diagnosis—determines capacity.\n\n**Key Points**\n- Capacity assessment involves four criteria: understand, retain, use/weigh, and communicate\n- A patient must be able to retain information long enough to make the decision\n- A diagnosis alone (e.g. brain injury or Korsakoff syndrome) does not determine capacity\n- Unwise decisions or disagreement with clinicians does not mean lack of capacity\n- Use of communication aids does not affect assessment if the decision is communicated\n- <table><thead><tr><th>Capacity Criteria</th><th>Description</th></tr></thead><tbody><tr><td>Understand</td><td>Grasp relevant information</td></tr><tr><td>Retain</td><td>Remember it long enough to decide</td></tr><tr><td>Use/Weigh</td><td>Balance the pros and cons</td></tr><tr><td>Communicate</td><td>Express the choice by any means</td></tr></tbody></table>\n\n**Clinical Relevance**\nDetermining mental capacity is a core clinical and legal responsibility, especially for consent and refusal of treatment. The Mental Capacity Act and GMC guidance specify that inability to retain information is a key reason for lacking capacity. Awareness of this helps safeguard patient autonomy and ensures decisions are made lawfully.",
    "bullet_explanations": {
      "The patient is unable to retain relevant information long enough to make a decision": "Correct – inability to retain information is a primary legal reason for lacking capacity.",
      "The patient refuses treatment recommended by the clinical team": "Incorrect – patients can refuse treatment, even unwisely, if they have capacity.",
      "The patient has a diagnosis of severe brain injury": "Incorrect – diagnosis alone does not determine capacity; assessment of decision-making ability is required.",
      "The patient communicates decisions using a communication aid": "Incorrect – capacity can be present if the decision is communicated in any way.",
      "The patient expresses a wish for discharge that may be influenced by addiction": "Incorrect – motive does not determine capacity; must assess ability to understand and retain information."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Substance Misuse",
    "subsubsection": "Alcohol",
    "topic": "Thiamine and Wernicke’s",
    "keywords": [
      "capacity assessment",
      "retaining information",
      "mental capacity",
      "consent",
      "Korsakoff"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "GMC",
        "topic_title": "Circumstances that affect the decision-making process (part 3 of 4)\n76-86",
        "citation": "© GMC 2025",
        "url": "https://www.gmc-uk.org/professional-standards/the-professional-standards/decision-making-and-consent/circumstances-that-affect-the-decision-making-process-continued-2"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a1bf5221-b3e9-4c11-9a4a-c9b463d38bcd",
    "question_number": 85,
    "question": "A 5-year-old girl is found unresponsive and not breathing in a school playground. After confirming she is not breathing and her airway is clear, what is the first step in basic life support according to current paediatric guidelines?",
    "options": [
      "Deliver 5 initial rescue breaths",
      "Begin chest compressions at a 30:2 ratio",
      "Start chest compressions at a 15:2 ratio",
      "Administer a precordial thump",
      "Give 2 rescue breaths"
    ],
    "correct_answer": "Deliver 5 initial rescue breaths",
    "explanation": "**Explanation**\n**The initial step in paediatric basic life support (BLS) is to provide 5 rescue breaths** once unresponsiveness and lack of normal breathing are confirmed. This differs from adult BLS, where chest compressions are started immediately. Children most commonly experience cardiac arrest secondary to hypoxia, often due to respiratory causes. Therefore, establishing effective ventilation with 5 initial rescue breaths is crucial to improve the chance of successful resuscitation. Only after these breaths should chest compressions be commenced, using the appropriate compression-to-ventilation ratio depending on the number of rescuers.\n\n**Key Points**\n- Paediatric cardiac arrests are often due to respiratory failure, not primary cardiac causes.\n- 5 rescue breaths are given first in paediatric BLS before chest compressions.\n- Adult BLS starts with chest compressions; paediatric BLS starts with rescue breaths.\n- Chest compressions follow at either 15:2 (two rescuers) or 30:2 (single rescuer).\n- Precordial thump is not recommended in paediatric basic life support.\n- <table><thead><tr><th>Step</th><th>Paediatric BLS</th><th>Adult BLS</th></tr></thead><tbody><tr><td>Initial breaths</td><td>5 rescue breaths</td><td>Not given</td></tr><tr><td>Chest compressions</td><td>After breaths</td><td>Immediately</td></tr></tbody></table>\n\n**Clinical Relevance**\nKnowing the correct paediatric resuscitation sequence is essential for all clinicians, as prompt ventilation improves survival in children with respiratory-driven arrests. This follows Resuscitation Council (UK) and BNF recommendations.\n\n**Memory Anchor**\nChildren need 'Five First' rescue breaths—think of the 'Five for Life' rule in paediatric BLS.",
    "bullet_explanations": {
      "Deliver 5 initial rescue breaths": "Correct – these are given first in paediatric BLS to address likely respiratory causes.",
      "Begin chest compressions at a 30:2 ratio": "Incorrect – this is started after initial rescue breaths, and only if a single rescuer is present.",
      "Start chest compressions at a 15:2 ratio": "Incorrect – this ratio is used with two rescuers, but only after the 5 initial rescue breaths.",
      "Administer a precordial thump": "Incorrect – this is not recommended in children and is not part of basic life support protocols.",
      "Give 2 rescue breaths": "Incorrect – 5, not 2, rescue breaths are required initially in paediatric BLS."
    },
    "category": "Paediatric Emergencies",
    "subsection": "Resuscitation",
    "subsubsection": "Paediatric BLS/ALS differences",
    "topic": "Paediatric BLS/ALS differences",
    "keywords": [
      "paediatric resuscitation",
      "basic life support",
      "rescue breaths",
      "BLS sequence",
      "child CPR"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Cardiopulmonary resuscitation",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/cardiopulmonary-resuscitation/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e873bde8-0854-4593-b217-1258113b550a",
    "question_number": 86,
    "question": "A 67-year-old man reports a sudden, painless loss of vision in his left eye upon waking this morning. Fundoscopic examination reveals widespread flame-shaped and dot-blot retinal haemorrhages. What is the most likely diagnosis?",
    "options": [
      "Central retinal vein occlusion",
      "Retinal detachment",
      "Optic neuritis",
      "Acute angle-closure glaucoma",
      "Central retinal artery occlusion"
    ],
    "correct_answer": "Central retinal vein occlusion",
    "explanation": "**Explanation**\n**Central retinal vein occlusion (CRVO)** is characterised by sudden, painless monocular visual loss, typically with extensive retinal haemorrhages visible on fundoscopy. The haemorrhages occur due to obstruction of the central retinal vein, leading to increased venous pressure, capillary leakage, and blood extravasation into the retina. Unlike arterial occlusion, which shows a pale retina with a cherry-red spot, CRVO presents with a 'blood and thunder' appearance due to numerous retinal haemorrhages. There is usually no pain, which helps distinguish it from other acute causes of visual loss such as acute angle-closure glaucoma (which is painful and associated with a red, hard eye and mid-dilated pupil) or optic neuritis (which often involves painful eye movements). Retinal detachment is more often preceded by flashes and floaters and shows a detached, billowing retina on examination, not extensive haemorrhages.\n\n**Key Points**\n<ul><li>Sudden, painless, unilateral visual loss suggests a vascular event in the retina or optic nerve.</li><li>CRVO presents with widespread retinal haemorrhages ('blood and thunder' appearance) on fundoscopy.</li><li>Arterial occlusion shows a pale retina and cherry-red spot; pain is absent but so are haemorrhages.</li><li>Acute glaucoma features pain, red eye, fixed mid-dilated pupil, and visual loss.</li><li>Optic neuritis has pain (especially on eye movement) and often affects young adults.</li><li>Retinal detachment typically presents with visual field defects, flashes, floaters, and visible detachment.</li></ul><table><thead><tr><th>Diagnosis</th><th>Key Fundoscopy Finding</th></tr></thead><tbody><tr><td>CRVO</td><td>Widespread retinal haemorrhages</td></tr><tr><td>CRAO</td><td>Pale retina, cherry-red spot</td></tr><tr><td>Retinal detachment</td><td>Detached, folded retina</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising CRVO is critical, as prompt referral to ophthalmology is needed to assess for potential complications and underlying risk factors such as hypertension and diabetes. Differentiating causes of acute visual loss ensures appropriate and timely management, reducing the risk of permanent vision impairment.",
    "bullet_explanations": {
      "Central retinal vein occlusion": "Correct – Sudden painless visual loss with widespread retinal haemorrhages is classic for CRVO.",
      "Retinal detachment": "Incorrect – Usually preceded by flashes/floaters and shows a detached retina, not widespread haemorrhages.",
      "Optic neuritis": "Incorrect – Typically associated with pain, especially on eye movement, and less likely in this age group.",
      "Acute angle-closure glaucoma": "Incorrect – Presents with severe ocular pain, red eye, mid-dilated fixed pupil, and hazy cornea.",
      "Central retinal artery occlusion": "Incorrect – Causes sudden painless vision loss but shows a pale retina and cherry-red spot, not extensive haemorrhages."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Retinal Disorders",
    "topic": "Retinal vein occlusion",
    "keywords": [
      "central retinal vein occlusion",
      "sudden vision loss",
      "fundoscopy",
      "retinal haemorrhages"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Retinal detachment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/retinal-detachment/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Glaucoma",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/glaucoma/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "db9584ce-1620-4dc1-9db6-d01bcf12fe86",
    "question_number": 87,
    "question": "A 56-year-old woman, recently menopausal, reports bothersome hot flushes and night sweats. She is unable to use hormone replacement therapy due to a personal history of breast cancer. Which of the following is the most appropriate non-hormonal pharmacological option to help manage her vasomotor symptoms?",
    "options": [
      "Citalopram",
      "Tibolone",
      "Clonidine",
      "Gabapentin",
      "Evening primrose oil"
    ],
    "correct_answer": "Citalopram",
    "explanation": "**Explanation**\n**Selective serotonin reuptake inhibitors (SSRIs) such as citalopram are recommended as first-line non-hormonal therapy for vasomotor menopausal symptoms in women for whom hormone replacement therapy (HRT) is contraindicated, such as those with a history of breast cancer.** SSRIs can reduce both the frequency and severity of hot flushes and night sweats. Other options like evening primrose oil lack robust evidence for efficacy, while tibolone is a synthetic steroid with estrogenic effects, making it unsuitable for women with a history of, or high risk for, breast cancer. Clonidine may be considered, but it often causes unacceptable side effects and is less effective than SSRIs. Gabapentin can also help with vasomotor symptoms but is generally used if SSRIs are not tolerated or contraindicated.\n\n**Key Points**\n- SSRIs (e.g. citalopram) are effective for vasomotor symptoms when HRT is inappropriate.\n- Tibolone has oestrogenic activity and is not suitable for women at risk of breast cancer.\n- Clonidine may be used but commonly causes troublesome side effects.\n- Evening primrose oil has insufficient evidence for treating menopausal symptoms.\n- Gabapentin can be considered as a second-line non-hormonal option.\n\n**Clinical Relevance**\nMenopausal symptoms are common and can significantly impact quality of life. HRT is the gold standard but is contraindicated in women with or at high risk of breast cancer. SSRIs, recommended by NICE, offer an evidence-based alternative. Awareness of safe and effective non-hormonal options is essential for patient-centred care.\n\n**Memory Anchor**\nRemember 'SSRIs Soothe Sweats' when HRT is not an option.",
    "bullet_explanations": {
      "Citalopram": "Correct – SSRIs like citalopram are effective and recommended for vasomotor symptoms when HRT is contraindicated.",
      "Tibolone": "Incorrect – Tibolone has oestrogenic effects and increases breast cancer risk, so is unsuitable for this patient.",
      "Clonidine": "Incorrect – Although it may help, clonidine is less effective and has more side effects than SSRIs.",
      "Gabapentin": "Incorrect – Gabapentin can be used if SSRIs are not suitable, but SSRIs are first-line non-hormonal therapy.",
      "Evening primrose oil": "Incorrect – There is little evidence to support its use for menopausal vasomotor symptoms."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Menstrual Disorders",
    "topic": "Amenorrhoea",
    "keywords": [
      "menopause",
      "vasomotor symptoms",
      "HRT contraindication",
      "SSRIs",
      "citalopram"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Menopause",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/menopause/"
      },
      {
        "source": "BNF",
        "topic_title": "Sex hormones",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/sex-hormones/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b0d78d90-ce09-4d01-89ca-d94ed770be33",
    "question_number": 88,
    "question": "A 32-year-old woman attends her midwife for a routine antenatal assessment at 14 weeks’ gestation. She feels well and has no urinary or systemic symptoms. A midstream urine sample, sent as part of her booking investigations, reveals significant bacteriuria with Escherichia coli. What is the most appropriate next step in her management?",
    "options": [
      "Start a 7-day course of nitrofurantoin",
      "Reassure and offer no treatment unless she becomes symptomatic",
      "Start a 7-day course of trimethoprim",
      "Begin labetalol and aspirin in addition to antibiotics",
      "Delay antibiotics and repeat the urine culture in one week"
    ],
    "correct_answer": "Start a 7-day course of nitrofurantoin",
    "explanation": "**Explanation**\n**Asymptomatic bacteriuria in pregnancy should always be treated**, regardless of symptoms, due to the increased risk of progression to symptomatic urinary tract infection and pyelonephritis, which can lead to adverse maternal and fetal outcomes. **Nitrofurantoin is the first-line oral antibiotic in the first and second trimesters**, provided there is no contraindication such as G6PD deficiency or advanced gestation (near term). Trimethoprim is avoided in the first trimester due to risk of neural tube defects. Observation alone is not appropriate in pregnancy, and initiation of antihypertensives or aspirin is not indicated unless there are additional risk factors or signs of pre-eclampsia.\n\n**Key Points**\n- Asymptomatic bacteriuria is defined as >100,000 colony-forming units/mL of a single organism on urine culture in a patient without urinary symptoms.\n- Pregnant women with asymptomatic bacteriuria must be treated to reduce the risk of pyelonephritis and associated obstetric complications.\n- First-line treatment in the first and second trimester is a 7-day course of nitrofurantoin.\n- Trimethoprim is contraindicated in the first trimester due to teratogenicity.\n- Observation without treatment is not recommended in pregnancy.\n- Routine antihypertensives and aspirin are not indicated unless hypertension or pre-eclampsia is diagnosed.\n\n**Clinical Relevance**\nPrompt antibiotic treatment of asymptomatic bacteriuria in pregnancy is essential to prevent serious complications such as acute pyelonephritis, preterm labour, and low birth weight. This is reflected in national guidance including the BNF and NICE recommendations.\n\n**Memory Anchor**\nRemember: **Pregnancy + bacteriuria = treat, even if asymptomatic**.",
    "bullet_explanations": {
      "Start a 7-day course of nitrofurantoin": "Correct – Nitrofurantoin is first-line for asymptomatic bacteriuria in pregnancy (except near term).",
      "Reassure and offer no treatment unless she becomes symptomatic": "Incorrect – Asymptomatic bacteriuria in pregnancy always requires treatment to prevent complications.",
      "Start a 7-day course of trimethoprim": "Incorrect – Trimethoprim is avoided in the first trimester due to risk of neural tube defects.",
      "Begin labetalol and aspirin in addition to antibiotics": "Incorrect – There is no indication for antihypertensives or aspirin without hypertension or pre-eclampsia risk.",
      "Delay antibiotics and repeat the urine culture in one week": "Incorrect – Immediate antibiotic therapy is recommended; delaying increases the risk of pyelonephritis."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Booking visit tests",
    "keywords": [
      "asymptomatic bacteriuria",
      "pregnancy",
      "nitrofurantoin",
      "antenatal",
      "urinary tract infection"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Urinary-tract infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/urinary-tract-infections/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2370342e-2bc8-4230-b818-5e016cf56e50",
    "question_number": 89,
    "question": "A 35-year-old man presents for a routine health check. On examination, you notice several small, central red papules with radiating thin vessels on his upper chest that blanch with pressure. He mentions starting a new medication for hypertension several months ago. Which type of medication is most likely associated with the development of these skin findings?",
    "options": [
      "Oestrogen-containing therapy",
      "Beta-blockers",
      "Metformin",
      "Loop diuretics",
      "ACE inhibitors"
    ],
    "correct_answer": "Oestrogen-containing therapy",
    "explanation": "**Explanation**\n**Spider naevi** are vascular lesions characterised by a central red papule with surrounding fine vessels (telangiectasia), most often observed on the face, neck, or upper chest. They blanch on pressure and refill from the centre when released. While a single lesion can be normal, the presence of multiple spider naevi is abnormal and is frequently linked to elevated oestrogen levels. **Excess oestrogen**—either endogenous (as in liver disease or pregnancy) or exogenous (from medications such as the combined oral contraceptive pill or hormone replacement therapy)—can induce these lesions. The association is due to oestrogen’s effects on superficial blood vessels. Other options listed are not recognised causes of spider naevi.\n\n**Key Points**\n- Spider naevi = central red papule with radiating vessels, blanching with pressure.\n- Multiple lesions suggest underlying pathology—often excess oestrogen.\n- Common associations: liver cirrhosis, pregnancy, oestrogen-containing medications.\n- Lesions refill from the centre after pressure (contrast: telangiectasia, refill from edge).\n- Other options (beta-blockers, metformin, loop diuretics, ACE inhibitors) are not causative.\n\n**Clinical Relevance**\nRecognising spider naevi and their clinical associations, especially with oestrogen exposure and liver dysfunction, is crucial for early identification of underlying systemic disease or iatrogenic causes.\n\n**Memory Anchor**\nSpider naevi are linked to 'OEstrogen' (think 'OEstrogen = OEyes on the chest').",
    "bullet_explanations": {
      "Oestrogen-containing therapy": "Correct – Oestrogen excess (from medications or endogenous sources) can cause spider naevi.",
      "Beta-blockers": "Incorrect – These are not associated with spider naevi formation.",
      "Metformin": "Incorrect – Used in diabetes, not linked with spider angiomas.",
      "Loop diuretics": "Incorrect – No association with these vascular lesions.",
      "ACE inhibitors": "Incorrect – Not recognised as a cause of spider naevi."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Common Presentations",
    "topic": "Benign naevi",
    "keywords": [
      "spider naevi",
      "oestrogen",
      "skin lesions",
      "angioma",
      "dermatology"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "ad2fd5a0-0f2b-4aa2-8154-24634ec9efda",
    "question_number": 90,
    "question": "A 56-year-old man with a history of poorly controlled coeliac disease presents with two months of progressive fatigue, unintentional weight loss, intermittent fevers, and drenching night sweats. He also reports new-onset lower abdominal discomfort and has noticed enlarged lymph nodes in his groin. Blood tests show a persistently raised tissue transglutaminase (tTG) antibody despite adherence to a gluten-free diet. Which of the following best explains his current presentation?",
    "options": [
      "Enteropathy-associated T cell lymphoma",
      "Refractory coeliac disease (type 1)",
      "Reactive lymphadenopathy secondary to infection",
      "Sarcoidosis",
      "Tuberculous lymphadenitis"
    ],
    "correct_answer": "Enteropathy-associated T cell lymphoma",
    "explanation": "**Explanation**\n**Enteropathy-associated T cell lymphoma (EATL)** is a rare but serious complication of coeliac disease, particularly in patients with longstanding or poorly controlled disease. EATL typically presents with systemic symptoms such as unexplained weight loss, persistent fever, night sweats, and lymphadenopathy, features that distinguish it from typical or even refractory coeliac disease. While classic symptoms of coeliac disease include diarrhoea, fatigue, and nutritional deficiencies, the emergence of constitutional 'B symptoms' (fever, night sweats, weight loss) and lymph node enlargement is highly suggestive of lymphoma rather than simple autoimmune or infectious processes. In this scenario, the ongoing elevation of tTG antibodies and the presence of inguinal lymphadenopathy further support the diagnosis of lymphoma associated with coeliac disease rather than other causes such as infection or sarcoidosis.\n\n**Key Points**\n- EATL is a rare T-cell lymphoma linked to chronic or untreated coeliac disease.\n- Systemic 'B symptoms' (fever, night sweats, weight loss) and lymphadenopathy are key warning signs.\n- Refractory coeliac disease can be a pre-malignant state, especially type 2.\n- Malignancy risk increases in coeliac disease with poor dietary adherence or late diagnosis.\n- Differentiating EATL from infection or autoimmune causes relies on clinical context and persistent symptoms.\n\n**Clinical Relevance**\nRecognising EATL is crucial, as it requires urgent specialist referral and management. Early identification of alarm symptoms in patients with coeliac disease can improve outcomes and aligns with national guidelines on coeliac disease complications.",
    "bullet_explanations": {
      "Enteropathy-associated T cell lymphoma": "Correct – Presents with constitutional symptoms and lymphadenopathy in coeliac disease.",
      "Refractory coeliac disease (type 1)": "Incorrect – Lacks 'B symptoms' or lymphadenopathy; type 1 is not malignant.",
      "Reactive lymphadenopathy secondary to infection": "Incorrect – Infective nodes are usually acute and resolve; two-month history and systemic symptoms are less typical.",
      "Sarcoidosis": "Incorrect – Sarcoidosis usually presents with pulmonary involvement, erythema nodosum, or hypercalcaemia; not typically associated with coeliac disease.",
      "Tuberculous lymphadenitis": "Incorrect – Could cause systemic symptoms and lymphadenopathy, but lacks supporting risk factors or exposure history in this case."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Upper GI",
    "subsubsection": "Dyspepsia & H. pylori",
    "topic": "Alarm features and 2WW criteria",
    "keywords": [
      "coeliac disease",
      "lymphoma",
      "enteropathy-associated T cell lymphoma",
      "alarm features",
      "weight loss"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Coeliac disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/coeliac-disease/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ee28d192-7e28-4e72-ac2a-8b0c047c239b",
    "question_number": 91,
    "question": "A 34-year-old woman at 28 weeks gestation is found to have a fasting plasma glucose of 6.2 mmol/L following a routine antenatal screen. There is no evidence of fetal macrosomia or polyhydramnios. What is the most appropriate next step in her management?",
    "options": [
      "Initiate dietary and lifestyle advice with self-monitoring of blood glucose",
      "Start insulin therapy immediately",
      "Begin metformin alongside dietary advice",
      "Repeat the oral glucose tolerance test in 4 weeks",
      "Reassure her that no intervention is required"
    ],
    "correct_answer": "Initiate dietary and lifestyle advice with self-monitoring of blood glucose",
    "explanation": "**Explanation**\n**Diet and exercise advice is the recommended initial intervention** for gestational diabetes when the fasting plasma glucose is below 7 mmol/L, unless there are complicating features like macrosomia or hydramnios. Self-monitoring of blood glucose should be commenced to assess glycaemic control. If targets are not achieved within 1–2 weeks, metformin may be considered. **Insulin is reserved for higher fasting glucose (>7 mmol/L) or if there are complications.** This approach minimises unnecessary pharmacological intervention during pregnancy and aligns with current guidelines.\n\n**Key Points**\n- Fasting plasma glucose <7 mmol/L in gestational diabetes: start with lifestyle modification.\n- Monitor blood glucose levels to assess response.\n- Introduce metformin if glucose targets are not met after 1–2 weeks of non-pharmacological measures.\n- Immediate insulin is indicated if fasting glucose ≥7 mmol/L or if complications are present.\n- Overtreatment should be avoided to reduce maternal and fetal risks.\n\n**Clinical Relevance**\nFollowing evidence-based stepwise management for gestational diabetes ensures optimal maternal and fetal outcomes and minimises unnecessary drug exposure. This question reflects the NICE-aligned approach as summarised by the BNF.",
    "bullet_explanations": {
      "Initiate dietary and lifestyle advice with self-monitoring of blood glucose": "Correct – first-line for gestational diabetes with fasting glucose <7 mmol/L and no complications.",
      "Start insulin therapy immediately": "Incorrect – insulin is reserved for fasting glucose ≥7 mmol/L or if there are specific complications.",
      "Begin metformin alongside dietary advice": "Incorrect – metformin should be considered only if lifestyle changes do not achieve glucose targets within 1–2 weeks.",
      "Repeat the oral glucose tolerance test in 4 weeks": "Incorrect – diagnosis is already established; prompt intervention is required.",
      "Reassure her that no intervention is required": "Incorrect – gestational diabetes requires active management to reduce maternal and fetal risks."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Acute",
    "subsubsection": "Perioperative Glycaemia",
    "topic": "Sick-day rules",
    "keywords": [
      "gestational diabetes",
      "dietary advice",
      "pregnancy hyperglycaemia",
      "BNF guidelines"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetes, pregnancy and breast-feeding",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetes-pregnancy-and-breast-feeding/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "84672251-3aff-4748-b48a-8469967b04d8",
    "question_number": 92,
    "question": "A 65-year-old woman with recently diagnosed type 2 diabetes is reviewed in clinic. She discontinued modified-release metformin due to persistent gastrointestinal upset, despite dose adjustments. Her recent HbA1c is 60 mmol/mol, and her calculated 10-year QRISK3 cardiovascular risk is 18%. She has no existing cardiovascular disease, does not smoke, and reports good adherence to diet and exercise advice. Which is the most appropriate pharmacological treatment to initiate next?",
    "options": [
      "Start empagliflozin",
      "Reintroduce standard-release metformin at a lower dose",
      "Start gliclazide",
      "Offer further lifestyle advice only",
      "Start pioglitazone"
    ],
    "correct_answer": "Start empagliflozin",
    "explanation": "**Explanation**\n**Empagliflozin, an SGLT2 inhibitor, is recommended as first-line monotherapy for type 2 diabetes when metformin is not tolerated or contraindicated, particularly in patients with a high risk of cardiovascular disease (QRISK >10%).** This patient has already attempted modified-release metformin without success, indicating genuine intolerance. Her elevated HbA1c and increased cardiovascular risk make SGLT2 inhibitor monotherapy appropriate, as it offers both glycaemic control and cardiovascular protection. Other agents, such as sulfonylureas or pioglitazone, do not carry the same cardiovascular benefit profile in this context. Lifestyle advice alone is insufficient given her significantly raised HbA1c.\n\n**Key Points**\n- SGLT2 inhibitors are preferred if metformin is not tolerated **and** cardiovascular risk is high (QRISK >10% or established CVD).\n- Modified-release metformin is often tried for GI side effects; failure indicates true intolerance.\n- SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin) have proven benefits for both glycaemic and cardiovascular outcomes.\n- Sulfonylureas and pioglitazone are alternatives, but do not offer the same CV risk reduction.\n- High HbA1c (>53 mmol/mol) warrants prompt escalation to pharmacological therapy.\n\n**Clinical Relevance**\nCurrent NICE guidelines prioritise SGLT2 inhibitor monotherapy for patients with type 2 diabetes who cannot tolerate metformin and have increased cardiovascular risk. This approach optimises both metabolic and cardiovascular outcomes, reflecting a shift towards risk-stratified diabetes care.\n\n**Memory Anchor**\nThink \"SGLT2 for CVD risk\" when metformin fails.",
    "bullet_explanations": {
      "Start empagliflozin": "Correct—SGLT2 inhibitor monotherapy is recommended for metformin-intolerant patients at high cardiovascular risk.",
      "Reintroduce standard-release metformin at a lower dose": "Incorrect—The patient could not tolerate even modified-release metformin, so re-challenging is not appropriate.",
      "Start gliclazide": "Incorrect—Sulfonylureas are an option but do not offer the same cardiovascular benefits as SGLT2 inhibitors in this context.",
      "Offer further lifestyle advice only": "Incorrect—Her HbA1c is significantly above target, so pharmacological therapy is needed.",
      "Start pioglitazone": "Incorrect—While pioglitazone is an alternative, SGLT2 inhibitors are preferred due to added cardiovascular benefit."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "SGLT2 inhibitors (CV/renal benefits)",
    "keywords": [
      "SGLT2 inhibitor",
      "metformin intolerance",
      "type 2 diabetes",
      "cardiovascular risk",
      "empagliflozin"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Type 2 diabetes in adults: Management",
        "citation": "© NICE, 2023",
        "url": "https://cks.nice.org.uk/topics/diabetes-type-2/management/management/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8b7ea942-1cb4-4fa3-9063-8edaa2b96dd9",
    "question_number": 93,
    "question": "A 45-year-old man is admitted with a confirmed proximal deep vein thrombosis (DVT) two weeks after undergoing elective knee arthroscopy. He has no history of cancer or chronic illness, and his kidney and liver function are normal. What is the recommended minimum duration of anticoagulation therapy for this provoked DVT?",
    "options": [
      "Six weeks of anticoagulation",
      "Three months of anticoagulation",
      "Six months of anticoagulation",
      "Continue anticoagulation indefinitely",
      "Anticoagulation not required if provoked"
    ],
    "correct_answer": "Three months of anticoagulation",
    "explanation": "**Explanation**\n**A provoked DVT—such as one occurring after recent surgery—should be treated with anticoagulation for at least three months.** Evidence and guideline consensus indicate that a three-month course is sufficient for most patients with a clear provoking factor (e.g., surgery, trauma, immobility) and no ongoing risk. Longer durations (such as six months or indefinite) are reserved for unprovoked events or if there are persistent risk factors. Shorter courses (such as six weeks) are inadequate for preventing recurrence, and lifelong anticoagulation is not indicated unless there are ongoing risks or recurrent events. Not treating a proven DVT is unsafe, regardless of provoking factors.\n\n**Key Points**\n- Recent surgery is a classic provoking factor for DVT.\n- Three months is the standard recommended treatment duration for provoked DVT.\n- Longer anticoagulation (≥6 months) is reserved for unprovoked DVT or ongoing risk factors.\n- Anticoagulation is always required for confirmed DVT, regardless of cause.\n- Choice of agent (DOAC, LMWH, VKA) depends on comorbidities and patient preference.\n\n**Clinical Relevance**\nCorrectly identifying the minimum anticoagulation duration for provoked DVT is crucial to prevent recurrence without exposing patients to unnecessary bleeding risk. National guidelines (NICE, BNF) standardise a three-month course for most provoked cases, supporting safe and effective practice.\n\n**Memory Anchor**\nProvoked = '3 months' (think '3' for 'triggered')",
    "bullet_explanations": {
      "Six weeks of anticoagulation": "Too short; evidence shows increased recurrence risk with less than three months' therapy.",
      "Three months of anticoagulation": "Correct; standard guideline-based duration for provoked DVT.",
      "Six months of anticoagulation": "Exceeds the recommended duration for a provoked DVT unless additional risk factors exist.",
      "Continue anticoagulation indefinitely": "Reserved for recurrent or unprovoked VTE, not a single provoked event.",
      "Anticoagulation not required if provoked": "Incorrect; all confirmed DVTs require anticoagulation, regardless of cause."
    },
    "category": "Cardiovascular",
    "subsection": "Hypertension & Vascular",
    "subsubsection": "Venous thromboembolism",
    "topic": "Venous thromboembolism - length of anticoagulation",
    "keywords": [
      "DVT",
      "provoked",
      "anticoagulation duration",
      "VTE",
      "three months"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Deep vein thrombosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/deep-vein-thrombosis/"
      },
      {
        "source": "BNF",
        "topic_title": "Venous thromboembolism",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/venous-thromboembolism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1823e746-b491-4673-87a4-6b724a10a9b2",
    "question_number": 94,
    "question": "A 62-year-old man with metastatic prostate cancer is undergoing treatment with a gonadorelin analogue. He now presents with bilateral breast enlargement. Which medication is most likely responsible for this adverse effect?",
    "options": [
      "Goserelin",
      "Tamoxifen",
      "Amiodarone",
      "Cyproterone acetate",
      "Finasteride"
    ],
    "correct_answer": "Goserelin",
    "explanation": "**Explanation**\n**Goserelin** is a gonadorelin (GnRH) analogue commonly used in the management of advanced prostate cancer. This class of medication suppresses the hypothalamic-pituitary-gonadal axis, resulting in reduced androgen (testosterone) production. The subsequent fall in androgen relative to oestrogen increases the oestrogen:androgen ratio, leading to the development of gynaecomastia. This is a well-recognised adverse effect of GnRH analogues. In contrast, tamoxifen is an anti-oestrogen agent and is sometimes used to treat or prevent gynaecomastia, not cause it. Other options listed are not typical causes of this side effect.\n\n**Key Points**\n<ul><li><b>Goserelin</b> is a GnRH agonist used for prostate cancer therapy.</li><li>Suppresses testosterone, increasing the oestrogen:androgen ratio.</li><li>This hormonal imbalance can cause gynaecomastia in men.</li><li>Tamoxifen is used to manage gynaecomastia, rather than induce it.</li><li>Other listed drugs do not commonly cause gynaecomastia.</li></ul>\n\n**Clinical Relevance**\nRecognising drug-induced gynaecomastia is important in oncology and endocrinology. Identifying the culprit medication allows for appropriate counselling and, if necessary, management or preventative strategies (such as prophylactic tamoxifen) to be considered.\n\n**Memory Anchor**\nGnRH analogues 'Grow' breast tissue in men—'G' for Goserelin and Gynaecomastia.",
    "bullet_explanations": {
      "Goserelin": "Correct – GnRH analogues like goserelin can cause gynaecomastia by reducing androgen levels.",
      "Tamoxifen": "Incorrect – Tamoxifen is actually used to treat or prevent gynaecomastia, not cause it.",
      "Amiodarone": "Incorrect – Amiodarone can cause thyroid dysfunction but is not associated with gynaecomastia.",
      "Cyproterone acetate": "Incorrect – While it is an anti-androgen, it is more likely to cause sexual dysfunction or liver effects, not primary gynaecomastia.",
      "Finasteride": "Incorrect – Finasteride may rarely cause gynaecomastia, but it is far less likely than GnRH analogues in this context."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Microvascular Complications",
    "topic": "Erectile dysfunction management",
    "keywords": [
      "gynaecomastia",
      "prostate cancer",
      "goserelin",
      "GnRH analogue",
      "drug side effects"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Tamoxifen - managing adverse effects",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/tamoxifen-managing-adverse-effects/"
      },
      {
        "source": "BNF",
        "topic_title": "Androgens, anti-androgens and anabolic steroids",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/androgens-anti-androgens-and-anabolic-steroids/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "099d6f4d-650f-4380-a171-3640e8b0b1c2",
    "question_number": 95,
    "question": "A 44-year-old woman presents with sudden-onset left-sided facial weakness, severe ear pain, and a cluster of fluid-filled blisters on her pinna. She also reports spinning vertigo and mild hearing loss. On examination, she is unable to close her left eye or raise her left eyebrow. What is the most appropriate initial management?",
    "options": [
      "Initiate combined oral aciclovir and prednisolone",
      "Prescribe oral flucloxacillin",
      "Start oral prednisolone monotherapy",
      "Treat with oral prochlorperazine",
      "Arrange urgent MRI to exclude tumour"
    ],
    "correct_answer": "Initiate combined oral aciclovir and prednisolone",
    "explanation": "**Explanation**\n**Ramsay Hunt syndrome** (herpes zoster oticus) is characterised by the triad of facial nerve palsy, ear pain, and a vesicular rash on the external ear. The causative agent is varicella-zoster virus reactivation within the geniculate ganglion. Management should include both an antiviral (typically aciclovir) and a corticosteroid (such as prednisolone), as this combination has been shown to improve facial nerve recovery rates compared to either agent alone. **Prompt initiation** of therapy is critical, ideally within 72 hours of symptom onset, to maximise the chance of full neurological recovery and minimise complications like permanent facial weakness or postherpetic neuralgia. Antivirals alone or steroids alone are suboptimal, and antibiotics such as flucloxacillin are not indicated unless secondary bacterial infection is suspected.\n\n**Key Points**\n- Ramsay Hunt syndrome presents with facial palsy, otalgia, and vesicular rash around the ear.\n- Caused by varicella-zoster virus reactivation affecting the facial nerve.\n- Best managed with **both oral aciclovir and prednisolone**.\n- Starting treatment within 72 hours gives the best outcomes.\n- Antibiotics are not indicated unless there is evidence of secondary infection.\n- Symptomatic treatments (e.g., prochlorperazine) may help vertigo but do not address the underlying cause.\n\n**Clinical Relevance**\nRecognising Ramsay Hunt syndrome promptly and initiating combined antiviral and steroid therapy is essential for optimising facial nerve recovery and preventing long-term sequelae. This is a key guideline-supported management point and a common clinical scenario in both primary and urgent care.\n\n**Memory Anchor**\nRemember: **'Vesicles on the ear with facial palsy = Virus + steroid (A + P)'**.",
    "bullet_explanations": {
      "Initiate combined oral aciclovir and prednisolone": "Correct – this is the evidence-based first-line treatment for Ramsay Hunt syndrome.",
      "Prescribe oral flucloxacillin": "Incorrect – flucloxacillin is for bacterial skin infections, not viral reactivation.",
      "Start oral prednisolone monotherapy": "Incorrect – prednisolone alone is less effective than combination therapy for this condition.",
      "Treat with oral prochlorperazine": "Incorrect – prochlorperazine may relieve vertigo but does not treat the underlying viral cause or inflammation.",
      "Arrange urgent MRI to exclude tumour": "Incorrect – imaging is not first-line in classic presentations with vesicular rash and acute facial palsy."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Vertigo (BPPV, vestibular neuritis, Meniere’s)",
    "keywords": [
      "Ramsay Hunt syndrome",
      "facial nerve palsy",
      "herpes zoster oticus",
      "aciclovir",
      "prednisolone"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "48f836cc-f6de-43ed-b3ca-a9f4dccca73c",
    "question_number": 96,
    "question": "A 29-year-old woman reports a thin, malodorous vaginal discharge without associated itching or soreness. Microscopy of a high vaginal swab reveals clue cells. She has a known allergy to metronidazole. Which is the most appropriate first-line treatment for her condition?",
    "options": [
      "Oral doxycycline",
      "Topical clindamycin cream",
      "Oral azithromycin",
      "Topical clotrimazole",
      "Oral metronidazole"
    ],
    "correct_answer": "Topical clindamycin cream",
    "explanation": "**Explanation**\nThe presence of clue cells on microscopy is highly suggestive of **bacterial vaginosis (BV)**, a condition marked by an overgrowth of anaerobic bacteria and reduced lactobacilli in the vaginal flora. For symptomatic women, **oral metronidazole** is generally the preferred treatment. However, this patient has a documented metronidazole allergy, making it unsuitable. In such cases, **topical clindamycin cream** is an effective and guideline-approved alternative for non-pregnant women. Other systemic antibiotics listed are not effective against BV, and topical antifungals do not target the responsible bacteria.\n\n**Key Points**\n<ul><li><b>Clue cells</b> are pathognomonic for bacterial vaginosis.</li><li>BV is associated with a thin, homogenous, malodorous discharge but minimal inflammation.</li><li>First-line therapy is usually oral metronidazole.</li><li>For those intolerant/allergic to metronidazole, <b>topical clindamycin cream</b> is recommended.</li><li>BV is not typically associated with itching or soreness (distinguishes from candidiasis).</li><li>Empirical treatment is appropriate if symptoms and risk factors align.</li></ul><br><table><thead><tr><th>Treatment</th><th>Indication in BV</th></tr></thead><tbody><tr><td>Oral metronidazole</td><td>First-line (if no allergy)</td></tr><tr><td>Topical clindamycin</td><td>Alternative (if metronidazole unsuitable)</td></tr></tbody></table>\n\n**Clinical Relevance**\nCorrectly identifying and treating BV is important due to its association with adverse reproductive outcomes, including increased risk of STIs and obstetric complications. NICE CKS recommends topical clindamycin as a safe and effective alternative in cases of metronidazole allergy.\n\n**Memory Anchor**\nClue cells = Clindamycin if metronidazole can't be used.",
    "bullet_explanations": {
      "Oral doxycycline": "Incorrect—doxycycline is not effective for BV and is not recommended in guidelines.",
      "Topical clindamycin cream": "Correct—recommended alternative to metronidazole in non-pregnant women with BV and metronidazole allergy.",
      "Oral azithromycin": "Incorrect—azithromycin is used for certain STIs, not for the management of BV.",
      "Topical clotrimazole": "Incorrect—clotrimazole treats fungal infections, not bacterial vaginosis.",
      "Oral metronidazole": "Incorrect—first-line for BV, but contraindicated in patients with a metronidazole allergy."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Menstrual Disorders",
    "topic": "Heavy menstrual bleeding",
    "keywords": [
      "bacterial vaginosis",
      "clue cells",
      "clindamycin",
      "vaginal discharge",
      "metronidazole allergy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Bacterial vaginosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/bacterial-vaginosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "76ed4bd9-9968-4d5e-a253-c03c5221c72d",
    "question_number": 97,
    "question": "A 3-year-old boy presents with sudden-onset, severe, intermittent abdominal pain and repeated episodes of vomiting. His mother reports that he becomes pale and curls up during the painful episodes, but between attacks he appears exhausted. On examination, you palpate a tender mass in the right lower abdomen. He is currently haemodynamically stable. Which is the most appropriate initial investigation to confirm the diagnosis?",
    "options": [
      "Abdominal ultrasound scan",
      "Contrast-enhanced CT scan",
      "Abdominal X-ray",
      "Air-contrast enema",
      "MRI abdomen"
    ],
    "correct_answer": "Abdominal ultrasound scan",
    "explanation": "**Explanation**\n**Abdominal ultrasound** is the first-line investigation in a child with suspected intussusception. This condition typically presents in young children with intermittent, severe abdominal pain, vomiting, and sometimes a palpable abdominal mass. Ultrasound offers high sensitivity and specificity for detecting intussusception and is non-invasive, making it ideal for initial assessment in stable patients. It can directly visualise the characteristic 'target' or 'donut' sign. Other imaging modalities, such as CT or contrast enema, are not first-line due to higher radiation exposure or risk, and are reserved for specific scenarios or if ultrasound is inconclusive. Abdominal X-ray may help exclude perforation but is not diagnostic for intussusception in most cases.\n\n**Key Points**\n- Intussusception commonly affects children aged 6 months to 3 years.\n- Classic symptoms: intermittent severe pain, vomiting, pallor, and a palpable abdominal mass.\n- Abdominal ultrasound is highly sensitive and specific for diagnosis.\n- CT and MRI are rarely needed in initial paediatric assessment.\n- Contrast enema is therapeutic as well as diagnostic but not first-line if the child is stable and diagnosis is uncertain.\n- Abdominal X-ray is mainly used to exclude perforation or obstruction.\n\n**Clinical Relevance**\nRapid and accurate diagnosis of intussusception is critical to prevent complications such as bowel necrosis or perforation. National guidelines recommend abdominal ultrasound as the preferred initial investigation in stable children with suggestive features, supporting safe and timely management.\n\n**Memory Anchor**\nRemember the 'target sign' on ultrasound for intussusception in young children.",
    "bullet_explanations": {
      "Abdominal ultrasound scan": "Correct – first-line, non-invasive, and highly sensitive for intussusception.",
      "Contrast-enhanced CT scan": "Incorrect – rarely indicated initially in children due to radiation and sufficient ultrasound accuracy.",
      "Abdominal X-ray": "Incorrect – may detect obstruction or perforation but not sensitive or specific for intussusception.",
      "Air-contrast enema": "Incorrect – may be used for diagnosis and treatment, but ultrasound is preferred for initial assessment.",
      "MRI abdomen": "Incorrect – not practical or necessary in the acute setting for children with suspected intussusception."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "Diverticular Disease",
    "topic": "CT diagnosis and severity",
    "keywords": [
      "intussusception",
      "paediatric abdominal pain",
      "ultrasound",
      "acute abdomen",
      "diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Abdominal pain - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/abdominal-pain-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "52ec7bf7-8310-4e29-8b15-e0bc111c8c39",
    "question_number": 98,
    "question": "A 58-year-old woman presents with a persistent dry cough and exertional dyspnoea. On examination, fine inspiratory crackles are noted at the lung bases. You suspect a diagnosis of idiopathic pulmonary fibrosis. Which investigation is most appropriate to confirm this diagnosis?",
    "options": [
      "High-resolution computed tomography (HRCT) of the chest",
      "Serum angiotensin-converting enzyme (ACE) measurement",
      "Magnetic resonance imaging (MRI) of the thorax",
      "Bronchoalveolar lavage via bronchoscopy",
      "Pleural biopsy"
    ],
    "correct_answer": "High-resolution computed tomography (HRCT) of the chest",
    "explanation": "**Explanation**\n**High-resolution CT (HRCT) scanning is the gold standard for confirming idiopathic pulmonary fibrosis (IPF).** HRCT provides detailed images that reveal hallmark features of IPF, such as subpleural basal-predominant reticular changes, honeycombing, and traction bronchiectasis. These findings are essential for diagnosis and often negate the need for lung biopsy. Other modalities either lack sensitivity/specificity for interstitial lung disease (ILD) or are primarily used for alternative diagnoses. For example, serum ACE is more associated with sarcoidosis, not IPF, and pleural biopsy is not indicated as IPF involves the lung parenchyma, not the pleura. Bronchoscopy may be used to exclude infection or alternative diagnoses but is not first-line for IPF. MRI, while useful for soft tissue imaging, does not provide adequate parenchymal detail for IPF diagnosis.\n\n**Key Points**\n<ul><li>HRCT is the investigation of choice for suspected IPF.</li><li>Characteristic HRCT findings: peripheral, basal reticular opacities, honeycombing, traction bronchiectasis.</li><li>Serum ACE aids diagnosis of sarcoidosis, not IPF.</li><li>Pleural biopsy is not relevant as IPF affects lung interstitium, not pleura.</li><li>Bronchoscopy is reserved for atypical presentations or to rule out alternative causes.</li></ul><table><thead><tr><th>Test</th><th>Main Use</th></tr></thead><tbody><tr><td>HRCT</td><td>Diagnosis of ILD/IPF</td></tr><tr><td>Serum ACE</td><td>Sarcoidosis (not IPF)</td></tr><tr><td>Pleural biopsy</td><td>Pleural disease (not IPF)</td></tr></tbody></table>\n\n**Clinical Relevance**\nTimely and accurate diagnosis of IPF is crucial, as management and prognosis differ significantly from other interstitial lung diseases. UK and international guidelines emphasise HRCT for diagnosis, avoiding unnecessary invasive procedures and ensuring appropriate referral to specialist ILD services.\n\n**Memory Anchor**\nRemember: **'H' in HRCT for 'Honeycombing' in IPF**.",
    "bullet_explanations": {
      "High-resolution computed tomography (HRCT) of the chest": "Correct—HRCT best visualises interstitial changes characteristic of IPF.",
      "Serum angiotensin-converting enzyme (ACE) measurement": "Incorrect—mainly used in sarcoidosis, not specific or sensitive for IPF.",
      "Magnetic resonance imaging (MRI) of the thorax": "Incorrect—MRI lacks sufficient parenchymal detail for interstitial lung disease.",
      "Bronchoalveolar lavage via bronchoscopy": "Incorrect—not first-line; helps exclude other diagnoses but not confirm IPF.",
      "Pleural biopsy": "Incorrect—IPF affects the lung interstitium, not the pleura."
    },
    "category": "Respiratory",
    "subsection": "Interstitial & Vascular",
    "subsubsection": "ILD",
    "topic": "IPF vs non-IPF patterns",
    "keywords": [
      "idiopathic pulmonary fibrosis",
      "HRCT",
      "interstitial lung disease",
      "diagnosis",
      "investigation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Sarcoidosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/sarcoidosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "23f0c466-9346-466e-b92e-6ca37f99e243",
    "question_number": 99,
    "question": "A 67-year-old man with a diagnosis of heart failure with reduced ejection fraction (LVEF 38%) attends follow-up. He is taking ramipril, bisoprolol and furosemide, but continues to experience significant breathlessness on exertion. His renal function and serum potassium are within normal limits. According to current guidelines, which additional long-term therapy should be considered next to improve his prognosis?",
    "options": [
      "Add a mineralocorticoid receptor antagonist such as spironolactone",
      "Introduce diltiazem for symptomatic relief",
      "Switch furosemide to bendroflumethiazide",
      "Start dobutamine infusion as an outpatient",
      "Increase the dose of ramipril beyond the recommended maximum"
    ],
    "correct_answer": "Add a mineralocorticoid receptor antagonist such as spironolactone",
    "explanation": "**Explanation**\n**Mineralocorticoid receptor antagonists (MRAs), such as spironolactone or eplerenone, are recommended as add-on therapy for patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite optimised treatment with an ACE inhibitor (or ARB) and a beta-blocker.** MRAs have been shown to reduce both morbidity and mortality in these patients. Before initiation, it is important to confirm that renal function and serum potassium are within safe limits to minimise the risk of hyperkalaemia. Other options either lack evidence for long-term prognosis improvement in HFrEF or are contraindicated.\n\n**Key Points**\n- First-line therapy for HFrEF includes an ACE inhibitor (or ARB) and a beta-blocker.\n- If symptoms persist, a mineralocorticoid receptor antagonist should be added unless contraindicated.\n- Spironolactone and eplerenone have a proven mortality benefit in HFrEF.\n- Renal function and potassium should be monitored before and during MRA therapy.\n- Other agents (thiazides, diltiazem, inotropes) do not improve long-term prognosis in chronic stable HFrEF.\n\n**Clinical Relevance**\nAdding an MRA is a guideline-driven step in managing persistent symptoms in HFrEF, improving survival and reducing hospitalisations. This reflects NICE and BNF guidance and is a key aspect of evidence-based heart failure care.",
    "bullet_explanations": {
      "Add a mineralocorticoid receptor antagonist such as spironolactone": "Correct; recommended next step when symptoms persist despite ACE inhibitor (or ARB) and beta-blocker.",
      "Introduce diltiazem for symptomatic relief": "Incorrect; non-dihydropyridine calcium channel blockers like diltiazem are contraindicated in HFrEF due to negative inotropic effects.",
      "Switch furosemide to bendroflumethiazide": "Incorrect; thiazide diuretics are not suitable for chronic heart failure, especially if fluid overload is moderate to severe.",
      "Start dobutamine infusion as an outpatient": "Incorrect; dobutamine is an intravenous inotrope used for acute decompensated heart failure, not for stable chronic management.",
      "Increase the dose of ramipril beyond the recommended maximum": "Incorrect; exceeding recommended doses does not enhance benefit and increases risk of adverse effects."
    },
    "category": "Heart Failure",
    "subsection": "Chronic HFrEF",
    "subsubsection": "GDMT sequencing (ACEi/ARB/ARNI, BB, MRA, SGLT2i)",
    "topic": "GDMT sequencing (ACEi/ARB/ARNI, BB, MRA, SGLT2i)",
    "keywords": [
      "heart failure",
      "mineralocorticoid receptor antagonist",
      "spironolactone",
      "HFrEF",
      "chronic management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Chronic heart failure",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/chronic-heart-failure/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Heart failure - chronic",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/heart-failure-chronic/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1676c2fc-7488-4ed1-aa00-d83310e9dc75",
    "question_number": 100,
    "question": "Which statement accurately reflects current UK recommendations regarding pertussis vaccination in pregnancy?",
    "options": [
      "Pregnant women should receive the pertussis vaccine after 20 weeks gestation if not already vaccinated.",
      "The pertussis vaccine is only indicated for infants and not for adults.",
      "Pregnant women should wait until after 36 weeks gestation for pertussis vaccination.",
      "Pertussis vaccination should be avoided in all women during pregnancy.",
      "Pertussis vaccination is recommended only for children under 10 years old."
    ],
    "correct_answer": "Pregnant women should receive the pertussis vaccine after 20 weeks gestation if not already vaccinated.",
    "explanation": "**Explanation**\nThe UK immunisation schedule recommends **pertussis vaccination for all pregnant women**, ideally after 20 weeks of gestation if not previously vaccinated. This strategy provides **passive immunity to newborns**, who are particularly vulnerable to severe pertussis before their own immunisations. The vaccine is not routinely given to non-pregnant adults, but healthcare workers and pregnant women are exceptions. It is not necessary to wait until late in pregnancy, as **vaccination between 20 and 32 weeks is optimal** to maximise antibody transfer across the placenta. Delaying beyond this window, or avoiding vaccination altogether, increases risk to the newborn. There is no evidence that the vaccine is unsafe during pregnancy, and it is a crucial public health intervention to prevent neonatal pertussis.\n\n**Key Points**\n- Pertussis vaccination is recommended in every pregnancy, ideally after 20 weeks gestation.\n- Provides passive immunity to infants too young to be vaccinated.\n- Not routinely offered to non-pregnant adults except certain healthcare workers.\n- Vaccine is safe and effective during pregnancy.\n- Vaccination after 20 weeks ensures optimal antibody transfer.\n\n**Clinical Relevance**\nUnderstanding the timing and rationale for pertussis vaccination in pregnancy is crucial to prevent severe pertussis in infants, aligning with UK public health policy and reducing neonatal morbidity and mortality.\n\n**Memory Anchor**\nThink 'protect the newborn': pertussis vaccine after 20 weeks for every pregnancy.",
    "bullet_explanations": {
      "Pregnant women should receive the pertussis vaccine after 20 weeks gestation if not already vaccinated.": "Correct – this follows UK recommendations to protect infants by vaccinating mothers after 20 weeks gestation.",
      "The pertussis vaccine is only indicated for infants and not for adults.": "Incorrect – while routine immunisation is for infants, it is also recommended for pregnant women and some healthcare workers.",
      "Pregnant women should wait until after 36 weeks gestation for pertussis vaccination.": "Incorrect – earlier vaccination (after 20 weeks) is advised to allow sufficient antibody transfer to the foetus.",
      "Pertussis vaccination should be avoided in all women during pregnancy.": "Incorrect – the vaccine is specifically recommended in pregnancy to protect the newborn.",
      "Pertussis vaccination is recommended only for children under 10 years old.": "Incorrect – while primary and booster immunisations target children, pregnant women are a key exception."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Influenza red flags and antivirals",
    "keywords": [
      "pertussis",
      "pregnancy",
      "vaccination",
      "whooping cough",
      "maternal immunisation"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Pertussis vaccine",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/pertussis-vaccine/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "35f53591-3b73-4b3a-89bd-2e0c7db9dccf",
    "question_number": 101,
    "question": "A 3-week-old female infant, born by elective caesarean section in breech position at 39 weeks’ gestation, is brought to the community clinic for a routine postnatal check. She is feeding well and meeting developmental milestones. No abnormal findings were noted on her newborn physical examination. Which screening investigation should be arranged specifically due to her birth history?",
    "options": [
      "Hip ultrasound scan at 6 weeks",
      "Serum ferritin measurement",
      "Echocardiogram",
      "Anti-endomysial antibody test",
      "Abdominal ultrasound scan"
    ],
    "correct_answer": "Hip ultrasound scan at 6 weeks",
    "explanation": "**Explanation**\n**All infants born in breech position at or after 36 weeks’ gestation require a hip ultrasound scan at 6 weeks to screen for developmental dysplasia of the hip (DDH)**, regardless of delivery method or absence of symptoms. Breech positioning increases the risk of abnormal hip development due to mechanical factors in utero. Early detection via ultrasound is critical, as DDH may not be evident on physical examination and prompt intervention can prevent long-term mobility issues. Other investigations listed are not warranted by breech birth alone and are not part of routine screening in this scenario.\n\n**Key Points**\n- Breech presentation at or after 36 weeks is a key risk factor for DDH.\n- Hip ultrasound at 6 weeks is recommended, even if the newborn exam is normal.\n- DDH may be missed clinically; imaging improves detection.\n- Early treatment of DDH (e.g. with a Pavlik harness) improves outcomes.\n- No indication for coeliac or iron studies in well infants at this age.\n- Routine cardiac or abdominal imaging is not indicated in isolated breech presentation.\n\n**Clinical Relevance**\nTimely DDH screening in high-risk infants such as those with breech presentation aligns with UK and international guidelines, preventing late diagnosis and reducing future disability. Clinicians must be vigilant in arranging appropriate imaging even when the newborn examination is unremarkable.\n\n**Memory Anchor**\nBreech = Both hips need a scan at 6 weeks.",
    "bullet_explanations": {
      "Hip ultrasound scan at 6 weeks": "Correct – required for DDH screening in breech-presenting infants at or after 36 weeks.",
      "Serum ferritin measurement": "Incorrect – not indicated unless there are concerns about anaemia or feeding difficulties.",
      "Echocardiogram": "Incorrect – not routinely required in the absence of cardiac signs or symptoms.",
      "Anti-endomysial antibody test": "Incorrect – coeliac screening is inappropriate in asymptomatic, milk-fed infants.",
      "Abdominal ultrasound scan": "Incorrect – not standard for breech birth without specific abdominal findings."
    },
    "category": "Paediatrics",
    "subsection": "Neonatology",
    "subsubsection": "Congenital Conditions",
    "topic": "CHD basics",
    "keywords": [
      "breech",
      "developmental dysplasia of the hip",
      "DDH screening",
      "neonatal hip ultrasound"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Acute childhood limp",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/acute-childhood-limp/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d662b213-217d-4d5c-92ce-41897c47c093",
    "question_number": 102,
    "question": "A 31-year-old woman, currently 36 weeks pregnant, previously had a newborn who developed early-onset Group B Streptococcus (GBS) sepsis. What is the recommended intrapartum management in her current pregnancy to reduce the risk of GBS infection in the neonate?",
    "options": [
      "Offer maternal intravenous antibiotics during labour",
      "Administer prophylactic intravenous antibiotics to the newborn at birth",
      "Monitor the newborn for signs of sepsis for 48 hours after delivery",
      "Administer oral antibiotics to the mother during pregnancy",
      "Only treat if the mother becomes febrile during labour"
    ],
    "correct_answer": "Offer maternal intravenous antibiotics during labour",
    "explanation": "**Explanation**\n**Women with a previous infant affected by early- or late-onset GBS disease should receive intravenous antibiotics during labour as prophylaxis.** This intervention substantially reduces the risk of vertical transmission of GBS during delivery, thereby decreasing the likelihood of early-onset GBS sepsis in the newborn. Routine prophylactic antibiotics for the newborn are not indicated unless there are clinical signs of sepsis. Maternal antibiotics are not administered in the antenatal period unless there is evidence of GBS infection during pregnancy. Monitoring the newborn alone does not prevent infection but is important if risk factors persist or if the baby becomes symptomatic.\n\n**Key Points**\n<ul><li>Previous baby with GBS disease is a clear indication for intrapartum antibiotic prophylaxis.</li><li>IV benzylpenicillin is the typical first-line agent used during labour.</li><li>Prophylactic antibiotics are not routinely given to the neonate unless unwell.</li><li>No evidence supports antenatal oral antibiotics for GBS prevention.</li><li>Maternal fever in labour is a separate indication, but prior GBS disease in a sibling requires planned prophylaxis regardless of pyrexia.</li></ul>\n\n**Clinical Relevance**\nProphylactic antibiotics in labour significantly reduce neonatal morbidity and mortality from GBS sepsis. Following national guidelines ensures best outcomes and aligns with patient safety priorities, especially for women with clear risk factors.\n\n**Memory Anchor**\nGBS = Give (antibiotics) Before (labour ends) to Stop (sepsis)",
    "bullet_explanations": {
      "Offer maternal intravenous antibiotics during labour": "Correct: Standard prophylaxis for women with a previous GBS-affected baby.",
      "Administer prophylactic intravenous antibiotics to the newborn at birth": "Incorrect: The neonate only requires antibiotics if unwell or symptomatic, not routinely.",
      "Monitor the newborn for signs of sepsis for 48 hours after delivery": "Incorrect: Monitoring is important but does not prevent infection. Prophylaxis is indicated.",
      "Administer oral antibiotics to the mother during pregnancy": "Incorrect: Oral antibiotics in pregnancy are not recommended for GBS prevention.",
      "Only treat if the mother becomes febrile during labour": "Incorrect: Prior affected baby is an absolute indication for prophylaxis, regardless of maternal temperature."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Sepsis & Bacteraemia",
    "topic": "Blood cultures and empiric antibiotics",
    "keywords": [
      "group B streptococcus",
      "intrapartum prophylaxis",
      "neonatal sepsis",
      "maternal antibiotics",
      "GBS management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Neonatal infection, antibacterial therapy",
        "citation": "© NICE BNFC, 2025",
        "url": "https://bnfc.nice.org.uk/treatment-summaries/neonatal-infection-antibacterial-therapy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ade53724-0711-4300-80df-1ee85043e3d2",
    "question_number": 103,
    "question": "A 28-year-old man reports intense, sharp anal pain that begins during bowel movements and lingers for some time afterwards. He also notices small streaks of bright red blood on the toilet paper. On examination, there is marked tenderness at the posterior anal margin, though no palpable lumps or external swelling are present. What is the most likely diagnosis?",
    "options": [
      "Anal fissure",
      "Perianal abscess",
      "Thrombosed external haemorrhoid",
      "Solitary rectal ulcer",
      "Proctitis"
    ],
    "correct_answer": "Anal fissure",
    "explanation": "**Explanation**\n**Anal fissure is characterised by severe, sharp pain during and after defecation, often accompanied by bright red rectal bleeding.** The pain is typically described as 'tearing' and is out of proportion to the size of the lesion. Most fissures are located in the posterior midline, as in this case. Unlike haemorrhoids, which cause swelling or lumps, fissures present with a linear split and marked tenderness. Perianal abscesses cause constant, throbbing pain and swelling, while proctitis involves more diffuse rectal discomfort and tenesmus. Solitary rectal ulcer is rare and usually not associated with acute, sharp pain during defecation.\n\n**Key Points**\n- Anal fissures typically cause sharp, severe pain during defecation.\n- Bright red blood is often seen on wiping, not mixed with stool.\n- Posterior midline location is most common.\n- Pain may persist after passing stool due to sphincter spasm.\n- No palpable mass or swelling is present, differentiating from haemorrhoids or abscess.\n- Chronic fissures may have a skin tag or indurated edges.\n- <table><thead><tr><th>Condition</th><th>Key Symptoms</th><th>Exam Findings</th></tr></thead><tbody><tr><td>Anal fissure</td><td>Sharp pain, bleeding on wiping</td><td>Linear split, posterior midline</td></tr><tr><td>Thrombosed haemorrhoid</td><td>Constant, severe pain; swelling</td><td>Firm, purple lump at anal verge</td></tr><tr><td>Proctitis</td><td>Tenesmus, discharge, dull pain</td><td>Diffuse rectal tenderness</td></tr></tbody></table>\n\n**Clinical Relevance**\nAnal fissures are a common cause of painful rectal bleeding in young adults. Early recognition and conservative management—such as stool softeners and topical analgesia—can prevent chronicity and reduce morbidity. Recognising the classic features prevents misdiagnosis and unnecessary interventions. Refer to NICE CKS and BNF for management details.\n\n**Memory Anchor**\nFissure = Fissure (tear) = F for 'Frightening pain on defecation'",
    "bullet_explanations": {
      "Anal fissure": "Correct – Classic presentation of sharp, severe pain on defecation with bright red bleeding and posterior tenderness.",
      "Perianal abscess": "Incorrect – Would present with constant, throbbing pain and a fluctuant, tender swelling near the anus.",
      "Thrombosed external haemorrhoid": "Incorrect – Causes constant pain and a palpable, purplish lump at the anal verge.",
      "Solitary rectal ulcer": "Incorrect – Presents with rectal bleeding and discomfort, but not with acute, sharp pain triggered by defecation.",
      "Proctitis": "Incorrect – Involves rectal discomfort, tenesmus, and possible discharge, but not sharp pain on defecation."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBD",
    "topic": "UC vs Crohn’s key differences",
    "keywords": [
      "anal fissure",
      "painful defecation",
      "rectal bleeding"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Anal fissure",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/anal-fissure/"
      },
      {
        "source": "BNF",
        "topic_title": "Anal fissure",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/anal-fissure/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "49a10a9b-06a4-43b5-90ad-71c6b340a8e8",
    "question_number": 104,
    "question": "A 70-year-old woman presents with several months of epigastric discomfort, early satiety, persistent nausea, and unintentional weight loss. She has a longstanding history of autoimmune gastritis. What is the most probable diagnosis underlying her symptoms?",
    "options": [
      "Gastric cancer",
      "Chronic pancreatitis",
      "Multiple myeloma",
      "Acute lymphoblastic leukaemia",
      "Gastro-oesophageal reflux disease (GORD)"
    ],
    "correct_answer": "Gastric cancer",
    "explanation": "**Explanation**\n**Gastric cancer is the most likely diagnosis in this scenario, given the combination of upper gastrointestinal symptoms (dyspepsia, abdominal pain, early satiety, nausea) and unintended weight loss in an older patient, particularly with a history of autoimmune gastritis (closely related to pernicious anaemia).** Pernicious anaemia and chronic atrophic gastritis are well-established risk factors for gastric carcinoma due to long-standing mucosal inflammation and intestinal metaplasia. The insidious onset and non-specific symptoms often delay diagnosis. Other options are less likely based on the presenting features and risk factors.\n\n**Key Points**\n- Gastric cancer risk increases with age and chronic atrophic gastritis/pernicious anaemia.\n- Early symptoms are non-specific: dyspepsia, nausea, anorexia, and weight loss.\n- Red flag symptoms (weight loss, persistent dyspepsia, anaemia) in the elderly warrant urgent investigation.\n- Chronic pancreatitis typically presents with chronic pain and steatorrhoea, not early satiety.\n- Multiple myeloma usually manifests with bone pain, anaemia, and hypercalcaemia.\n- Acute leukaemia presents with constitutional symptoms, bruising, and frequent infections.\n- GORD rarely causes significant weight loss or persistent nausea.\n- <table><thead><tr><th>Condition</th><th>Key Features</th></tr></thead><tbody><tr><td>Gastric cancer</td><td>Weight loss, dyspepsia, nausea, risk factors (e.g. pernicious anaemia)</td></tr><tr><td>Chronic pancreatitis</td><td>Epigastric pain, malabsorption, diabetes</td></tr><tr><td>Myeloma</td><td>Bone pain, anaemia</td></tr><tr><td>Leukaemia</td><td>Bruising, infections</td></tr><tr><td>GORD</td><td>Heartburn, regurgitation</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising alarm features such as weight loss, persistent nausea, and risk factors like pernicious anaemia is crucial for early identification and referral of upper GI malignancy. NICE guidelines highlight the importance of urgent endoscopic investigation in older adults with new-onset dyspepsia and red flag symptoms.\n\n**Memory Anchor**\nRemember: **Pernicious anaemia predisposes to gastric cancer**—think 'Pernicious = Pre-cancerous stomach'.",
    "bullet_explanations": {
      "Gastric cancer": "Correct – fits the clinical picture and risk factors; classic early features are subtle and include dyspepsia, early satiety, and weight loss.",
      "Chronic pancreatitis": "Incorrect – usually causes chronic abdominal pain and steatorrhoea, not early satiety or significant weight loss as a primary feature.",
      "Multiple myeloma": "Incorrect – presents with bone pain, fatigue, hypercalcaemia, and renal impairment, not dyspepsia or nausea.",
      "Acute lymphoblastic leukaemia": "Incorrect – typically presents with fatigue, frequent infections, bruising, and cytopenias.",
      "Gastro-oesophageal reflux disease (GORD)": "Incorrect – common but rarely causes significant weight loss or persistent nausea, especially in the absence of reflux symptoms."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Upper GI",
    "subsubsection": "Dyspepsia & H. pylori",
    "topic": "Alarm features and 2WW criteria",
    "keywords": [
      "gastric cancer",
      "pernicious anaemia",
      "alarm features",
      "dyspepsia",
      "weight loss"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Dyspepsia - unidentified cause",
        "citation": "© NICE, 2025",
        "url": "https://cks.nice.org.uk/topics/dyspepsia-unidentified-cause/"
      },
      {
        "source": "NICE",
        "topic_title": "Suspected cancer: recognition and referral",
        "citation": "© NICE, 2024",
        "url": "https://www.nice.org.uk/guidance/ng12"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "720431b2-84df-46a4-93ff-5ab42f99fed3",
    "question_number": 105,
    "question": "A 60-year-old man develops a pulmonary embolism following hospitalisation for elective hip replacement surgery. He has no history of malignancy or previous thromboembolic events. After initial stabilisation on low molecular weight heparin (LMWH), what is the recommended total duration of anticoagulation therapy for this provoked pulmonary embolism?",
    "options": [
      "Six weeks of anticoagulation",
      "Three months of anticoagulation",
      "Six months of anticoagulation",
      "Indefinite anticoagulation",
      "Stop anticoagulation after hospital discharge"
    ],
    "correct_answer": "Three months of anticoagulation",
    "explanation": "**Explanation**\n**Three months of anticoagulation** is the standard recommended duration for a pulmonary embolism (PE) that is 'provoked' by a transient major risk factor such as recent surgery or immobilisation. Current UK guidelines advise a minimum of three months' anticoagulation for most patients with a first episode of provoked PE. This strikes a balance between reducing the risk of recurrence and minimising bleeding risk. Longer courses are generally reserved for unprovoked events or ongoing risk factors. **Shorter durations (e.g. 6 weeks) are insufficient, and indefinite anticoagulation is not routinely recommended in provoked cases without ongoing risk.**\n\n**Key Points**\n- Provoked PE = clear transient risk factor (e.g. surgery, immobility)\n- Standard therapy duration: 3 months\n- DOACs (e.g. apixaban, rivaroxaban) are first-line unless contraindicated\n- Longer anticoagulation considered for unprovoked PE, recurrent events, or active cancer\n- Stopping anticoagulation immediately or after a short period increases recurrence risk\n\n**Clinical Relevance**\nDetermining the correct duration of anticoagulation in PE is crucial for patient safety and aligns with NICE and BNF recommendations. Over- or under-treatment can respectively increase bleeding or recurrence risk. Recognising the distinction between provoked and unprovoked events is central to tailoring therapy.\n\n**Memory Anchor**\nProvoked PE: **'3 for surgery'** – three months for surgery/immobility-related PE.",
    "bullet_explanations": {
      "Six weeks of anticoagulation": "Six weeks is too short for a PE; guidelines recommend at least three months.",
      "Three months of anticoagulation": "Correct – standard recommendation for a provoked event with a transient major risk factor.",
      "Six months of anticoagulation": "Six months may be considered for unprovoked or recurrent PE, but not usually for a first provoked event.",
      "Indefinite anticoagulation": "Reserved for recurrent unprovoked PE, persistent risk factors, or some cancer cases.",
      "Stop anticoagulation after hospital discharge": "Stopping anticoagulation early is unsafe and increases recurrence risk."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Primary prevention: QRISK, statin thresholds, lifestyle",
    "topic": "Anticoagulation duration in provoked PE",
    "keywords": [
      "pulmonary embolism",
      "anticoagulation duration",
      "provoked PE",
      "VTE management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Pulmonary embolism",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/pulmonary-embolism/"
      },
      {
        "source": "BNF",
        "topic_title": "Venous thromboembolism",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/venous-thromboembolism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4d25189f-566d-4276-86d0-dc9990dfea32",
    "question_number": 106,
    "question": "What is the recommended first-line antibiotic therapy for an adult presenting with confirmed uncomplicated urogenital Neisseria gonorrhoeae infection, before sensitivities are available?",
    "options": [
      "Intramuscular ceftriaxone",
      "Oral doxycycline",
      "Topical miconazole",
      "Oral aciclovir",
      "Intramuscular benzylpenicillin"
    ],
    "correct_answer": "Intramuscular ceftriaxone",
    "explanation": "**Explanation**\n**Intramuscular ceftriaxone** is the first-line treatment for uncomplicated gonorrhoea according to national guidelines, due to its excellent efficacy and low resistance rates. Alternative regimens are not recommended without susceptibility data, as Neisseria gonorrhoeae has developed widespread resistance to many oral antibiotics, including penicillins and azithromycin. Treatment should be administered as a single intramuscular injection. Partner notification and test of cure are also essential aspects of management to prevent ongoing transmission and monitor for treatment failure. Other agents listed are ineffective or inappropriate for gonorrhoea.\n\n**Key Points**\n- Neisseria gonorrhoeae is increasingly resistant to oral antibiotics.\n- Ceftriaxone intramuscular injection (single dose) is recommended first-line.\n- Penicillin and oral cephalosporins are no longer reliable due to resistance.\n- Alternative regimens require specialist input and susceptibility results.\n- Contact tracing and follow-up for test of cure are key management steps.\n\n**Clinical Relevance**\nCorrect antibiotic selection for gonorrhoea reduces complications and curbs the development of antimicrobial resistance. Following guideline-recommended therapy protects both individual patients and public health. Delay or incorrect therapy can lead to persistent infection, complications, and further transmission.\n\n**Memory Anchor**\nRemember: Gonorrhoea = 'G' for 'Give' IM Ceftriaxone.",
    "bullet_explanations": {
      "Intramuscular ceftriaxone": "Correct—first-line recommended treatment for uncomplicated gonorrhoea.",
      "Oral doxycycline": "Incorrect—may be used for chlamydia, not for primary gonorrhoea treatment.",
      "Topical miconazole": "Incorrect—antifungal, not active against Neisseria gonorrhoeae.",
      "Oral aciclovir": "Incorrect—antiviral, used for HSV, not bacterial STIs.",
      "Intramuscular benzylpenicillin": "Incorrect—no longer effective due to resistance, not recommended for gonorrhoea."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Genitourinary Infections",
    "topic": "Gonorrhoea: diagnosis and first-line therapy",
    "keywords": [
      "gonorrhoea",
      "ceftriaxone",
      "STI treatment",
      "Neisseria gonorrhoeae",
      "sexual health"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Gonorrhoea",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/gonorrhoea/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Urethritis - male",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/urethritis-male/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d4c9c2f9-6751-4f65-93d7-7e6afef92fc0",
    "question_number": 107,
    "question": "Which of the following is a recognised risk factor warranting routine hip ultrasound screening for developmental dysplasia of the hip in a newborn?",
    "options": [
      "Breech presentation at or after 36 weeks’ gestation",
      "Instrumental (forceps) delivery",
      "Maternal age over 40 years",
      "Low birth weight",
      "Maternal body mass index above 30"
    ],
    "correct_answer": "Breech presentation at or after 36 weeks’ gestation",
    "explanation": "**Explanation**\n**Breech presentation at or after 36 weeks’ gestation** is a well-established risk factor for developmental dysplasia of the hip (DDH), and infants with this history are offered a hip ultrasound screening at 6 weeks, irrespective of their presentation at delivery. Other major risk factors include a first-degree family history of early hip problems and clinical findings suggestive of hip instability. Instrumental delivery, maternal age, low birth weight, and maternal BMI are not considered independent risk factors for DDH. Early identification is vital to initiate timely interventions and reduce long-term complications.\n\n**Key Points**\n- Breech presentation at or after 36 weeks is a key risk factor for DDH.\n- Other risk factors include positive neonatal hip examination and family history.\n- Instrumental delivery and maternal demographics (age, BMI) are not independent risk factors.\n- Routine clinical hip examination is performed for all newborns.\n- Ultrasound screening is reserved for those with specific risk factors.\n\n**Clinical Relevance**\nIdentifying infants at risk for DDH is crucial in general practice and paediatrics to prevent permanent disability. National guidelines recommend targeted ultrasound screening only for those with specific risk factors, optimising resource use and improving outcomes.\n\n**Memory Anchor**\nRemember: 'Breech or Bloodline' = Breech presentation or family history prompt hip ultrasound.",
    "bullet_explanations": {
      "Breech presentation at or after 36 weeks’ gestation": "Correct – This is a recognised risk factor prompting hip ultrasound screening.",
      "Instrumental (forceps) delivery": "Incorrect – Instrumental delivery alone is not an independent risk factor for DDH.",
      "Maternal age over 40 years": "Incorrect – Maternal age does not directly increase the risk of DDH.",
      "Low birth weight": "Incorrect – Low birth weight is not a routine indication for hip ultrasound.",
      "Maternal body mass index above 30": "Incorrect – Maternal obesity is not considered a risk factor for DDH screening."
    },
    "category": "Paediatrics",
    "subsection": "Neonatology",
    "subsubsection": "Congenital Conditions",
    "topic": "CHD basics",
    "keywords": [
      "developmental dysplasia of the hip",
      "DDH",
      "breech presentation",
      "hip ultrasound",
      "paediatric screening"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Acute childhood limp",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/acute-childhood-limp/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0170b513-3f95-4e34-8022-582aa0f1a92c",
    "question_number": 108,
    "question": "A 13-year-old overweight male presents with a three-week history of dull, intermittent pain in his left groin, which worsens with physical activity. Examination reveals discomfort on internal rotation of the hip, but knee and lumbar examination are unremarkable. What is the most likely diagnosis?",
    "options": [
      "Slipped upper femoral epiphysis",
      "Osgood-Schlatter disease",
      "Juvenile idiopathic arthritis",
      "Patellofemoral pain syndrome",
      "Transient synovitis"
    ],
    "correct_answer": "Slipped upper femoral epiphysis",
    "explanation": "**Explanation**\n**Slipped upper femoral epiphysis (SUFE)** most often affects overweight adolescent boys during periods of rapid growth. The condition occurs when the femoral head slips posteriorly and inferiorly at the growth plate, resulting in hip or referred knee or thigh pain. A hallmark is pain on internal rotation of the hip, sometimes with an antalgic gait, but often with preserved flexion. This presentation contrasts with other common paediatric hip and knee disorders by age, risk factors, and examination findings.\n\n**Key Points**\n- SUFE typically presents in **adolescents (10–16 years)**, especially those who are overweight.\n- Pain may be felt in the **hip, groin, thigh, or even the knee** due to referred pain.\n- Physical examination usually shows **painful and limited internal rotation of the hip**.\n- Risk factors include **obesity** and rapid growth spurts.\n- X-rays (AP and frog-leg lateral) confirm the diagnosis.\n- Early identification is crucial to prevent complications such as avascular necrosis.\n\n**Clinical Relevance**\nRecognising SUFE promptly is vital, as delayed diagnosis can lead to serious complications including joint deformity and avascular necrosis. Adolescents presenting with unexplained hip, groin, or knee pain—especially if overweight—should be assessed carefully for SUFE and referred urgently for imaging.\n\n**Memory Anchor**\n**SUFE**: 'Some Unstable Femur Epiphysis'—think overweight teens with hip pain worsened by movement.",
    "bullet_explanations": {
      "Slipped upper femoral epiphysis": "Correct – classic in obese adolescents with hip/groin pain and restricted internal rotation.",
      "Osgood-Schlatter disease": "Incorrect – causes anterior knee pain at the tibial tuberosity, not hip or groin pain.",
      "Juvenile idiopathic arthritis": "Incorrect – more likely to cause joint swelling, morning stiffness, and can affect multiple joints.",
      "Patellofemoral pain syndrome": "Incorrect – presents as diffuse anterior knee pain, exacerbated by stairs or sitting, not hip pain.",
      "Transient synovitis": "Incorrect – common in younger children, often post-viral, and patients typically refuse to bear weight, with more global hip movement restriction."
    },
    "category": "Musculoskeletal",
    "subsection": "Trauma & Orthopaedics",
    "subsubsection": "Fractures",
    "topic": "Paediatric fractures",
    "keywords": [
      "SUFE",
      "adolescent hip pain",
      "paediatric orthopaedics"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "7c678e0a-cd07-467b-9f64-e17626d64791",
    "question_number": 109,
    "question": "A 47-year-old man is brought in by his partner after she observed several episodes where he appears dazed and unresponsive for about a minute. During these episodes, he exhibits repetitive hand rubbing and does not answer when spoken to. Afterwards, he is confused and cannot recall what happened. What type of seizure is most likely responsible for these events?",
    "options": [
      "Focal impaired awareness seizure",
      "Focal aware seizure",
      "Generalised tonic–clonic seizure",
      "Absence seizure",
      "Myoclonic seizure"
    ],
    "correct_answer": "Focal impaired awareness seizure",
    "explanation": "**Explanation**\n**Focal impaired awareness seizures** (previously called complex partial seizures) are characterised by impaired consciousness and automatisms such as lip smacking or hand rubbing. These seizures may begin with an aura (e.g., a sensation of unreality or déjà vu), followed by altered responsiveness and involuntary, repetitive movements. Postictal confusion and amnesia for the event are typical, distinguishing them from focal aware seizures (where awareness is retained) and absence seizures (which are shorter and lack automatisms in adults).\n\n**Key Points**\n- Focal impaired awareness seizures involve **loss of awareness** during the event.\n- Automatisms (e.g., lip smacking, hand rubbing) are common.\n- Patients usually have **no memory** of the seizure itself.\n- An aura may precede the seizure, indicating focal onset.\n- Distinguished from absence seizures, which are brief, lack postictal confusion, and rarely feature automatisms in adults.\n- <table><thead><tr><th>Seizure Type</th><th>Awareness</th><th>Automatisms</th><th>Postictal State</th></tr></thead><tbody><tr><td>Focal aware</td><td>Preserved</td><td>Rare</td><td>No</td></tr><tr><td>Focal impaired</td><td>Impaired</td><td>Common</td><td>Yes</td></tr><tr><td>Absence</td><td>Impaired (brief)</td><td>No (in adults)</td><td>Minimal</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurately classifying seizure types is crucial for appropriate management and prognosis. Focal impaired awareness seizures may be mistaken for psychiatric or behavioural issues. Early recognition and referral, as recommended by NICE, ensure prompt specialist assessment and reduce risk of injury or complications.\n\n**Memory Anchor**\nThink 'focal' for localised onset and 'impaired awareness' for the unresponsive, confused period with automatisms.",
    "bullet_explanations": {
      "Focal impaired awareness seizure": "Correct – This seizure type matches the description of automatisms and impaired awareness with postictal confusion.",
      "Focal aware seizure": "Incorrect – Awareness remains intact in focal aware seizures; the patient would recall the episode.",
      "Generalised tonic–clonic seizure": "Incorrect – These involve convulsive movements and loss of consciousness, not automatisms with preserved posture.",
      "Absence seizure": "Incorrect – Absence seizures are brief, usually occur in children, and rarely include automatisms or postictal confusion in adults.",
      "Myoclonic seizure": "Incorrect – Myoclonic seizures cause sudden jerks without impaired awareness or automatisms."
    },
    "category": "Neurology",
    "subsection": "Epilepsy",
    "subsubsection": "Focal vs generalised",
    "topic": "Focal vs generalised",
    "keywords": [
      "focal impaired awareness",
      "seizure classification",
      "automatisms",
      "epilepsy diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Epilepsy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/epilepsy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "34e72c71-04d7-4623-b8dc-4d99b06719c5",
    "question_number": 110,
    "question": "Which medication is most commonly associated with ototoxicity leading to tinnitus and hearing impairment, particularly in older adults receiving treatment for heart failure or oedema?",
    "options": [
      "Furosemide",
      "Tramadol",
      "Ezetimibe",
      "Lofepramine",
      "Digoxin"
    ],
    "correct_answer": "Furosemide",
    "explanation": "**Explanation**\n**Furosemide**, a loop diuretic, is well-known to cause ototoxicity, especially when administered at high doses or rapidly intravenously. This adverse effect can present as bilateral tinnitus and hearing loss, which are sometimes reversible upon discontinuation but may become permanent with continued exposure or high serum levels. The mechanism involves disruption of electrolyte homeostasis in the inner ear, particularly affecting the cochlear hair cells. This risk is heightened in elderly patients, those with renal impairment, or concurrent use of other ototoxic drugs. In contrast, tramadol, ezetimibe, lofepramine, and digoxin are not typically associated with ototoxic side effects.\n\n**Key Points**\n- Furosemide is a loop diuretic frequently implicated in drug-induced ototoxicity.\n- Ototoxicity may manifest as tinnitus and sensorineural hearing loss.\n- Risk is increased with high doses, rapid IV administration, or renal impairment.\n- Symptoms may be reversible if detected early and the drug is stopped.\n- Other listed drugs do not commonly affect hearing.\n- <table><thead><tr><th>Drug</th><th>Ototoxic Risk</th></tr></thead><tbody><tr><td>Furosemide</td><td>High</td></tr><tr><td>Tramadol</td><td>None</td></tr><tr><td>Ezetimibe</td><td>None</td></tr><tr><td>Lofepramine</td><td>None</td></tr><tr><td>Digoxin</td><td>None</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising medications that can cause ototoxicity is crucial for early intervention and prevention of permanent hearing loss, especially in older adults or those with multiple comorbidities. National guidelines advise careful monitoring and prompt cessation of ototoxic drugs if hearing symptoms develop.",
    "bullet_explanations": {
      "Furosemide": "Correct – Loop diuretics like furosemide are a recognised cause of ototoxicity, especially at high doses or in susceptible patients.",
      "Tramadol": "Incorrect – Although tramadol has CNS side effects, it does not typically cause hearing loss or tinnitus.",
      "Ezetimibe": "Incorrect – Ezetimibe primarily causes gastrointestinal side effects and does not affect hearing.",
      "Lofepramine": "Incorrect – This TCA may cause anticholinergic effects but is not linked to ototoxicity.",
      "Digoxin": "Incorrect – Digoxin toxicity can cause visual disturbances but is not associated with tinnitus or hearing impairment."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Prescribing Safety",
    "topic": "High-risk drugs (warfarin, insulin, opioids)",
    "keywords": [
      "ototoxicity",
      "furosemide",
      "loop diuretics",
      "hearing loss"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Ear",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/ear/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Hearing loss in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hearing-loss-in-adults/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "850dfab2-ec64-49d4-9870-50e5f927b9b2",
    "question_number": 111,
    "question": "A 37-year-old woman frequently attends her GP with a wide range of physical complaints, including headaches, abdominal pain, and joint discomfort. Despite extensive investigations over the past three years, no underlying organic cause has been identified. She continues to seek reassurance but remains dissatisfied when tests are normal. What is the most likely diagnosis?",
    "options": [
      "Somatisation disorder",
      "Conversion disorder",
      "Factitious disorder",
      "Illness anxiety disorder",
      "Malingering"
    ],
    "correct_answer": "Somatisation disorder",
    "explanation": "**Explanation**\n**Somatisation disorder** is characterised by multiple, recurring physical symptoms affecting various organ systems, persisting over several years, with no identifiable organic cause despite thorough assessment. Patients often remain unconvinced by negative test results and persistently seek medical attention. This differs from conversion disorder, where neurological symptoms predominate, and from illness anxiety disorder (hypochondriasis), where the primary concern is fear of a specific illness rather than multiple physical symptoms. Factitious disorder involves intentional symptom fabrication for the psychological role of being a patient, whereas malingering is associated with clear external incentives.\n\n**Key Points**\n- Somatisation disorder involves multiple unexplained physical symptoms for at least 2 years.\n- Patients do not accept reassurance from negative investigations.\n- Distinct from illness anxiety disorder, which focuses on fear of specific illnesses rather than multiple symptoms.\n- Factitious disorder and malingering involve conscious symptom fabrication, with malingering motivated by external gain.\n- Conversion disorder presents with neurological symptoms (e.g., paralysis, seizures) not explained by medical conditions.\n\n**Clinical Relevance**\nRecognising somatisation disorder is crucial to prevent unnecessary investigations and interventions. It allows for more appropriate management, including psychological support and regular, structured follow-up.\n\n**Memory Anchor**\nSomatisation = 'So many symptoms', over a long duration, with no organic explanation.",
    "bullet_explanations": {
      "Somatisation disorder": "Correct: Involves multiple unexplained physical symptoms over years, unresponsive to reassurance.",
      "Conversion disorder": "Incorrect: Presents with neurological symptoms (e.g., paralysis, seizures) rather than varied physical complaints.",
      "Factitious disorder": "Incorrect: Involves intentional production of symptoms for psychological reasons, not for external gain.",
      "Illness anxiety disorder": "Incorrect: Focuses on preoccupation with a specific illness rather than multiple symptoms.",
      "Malingering": "Incorrect: Symptoms are feigned for obvious external rewards (e.g., drugs, financial gain)."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Depression",
    "topic": "Diagnostic criteria",
    "keywords": [
      "somatisation",
      "unexplained symptoms",
      "diagnosis",
      "medically unexplained",
      "psychiatry"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "30e0d66a-c3e5-4377-a0e4-0692fe4cfa67",
    "question_number": 112,
    "question": "A 27-year-old woman is prescribed clarithromycin for a respiratory tract infection. She uses a progestogen-only pill for contraception and is concerned the antibiotic may reduce its effectiveness. What is the correct advice regarding her contraception while taking clarithromycin?",
    "options": [
      "No additional contraceptive precautions are necessary with this antibiotic.",
      "Stop the progestogen-only pill and use alternative contraception during the antibiotic course.",
      "Use additional barrier contraception throughout the antibiotic course and for 7 days afterwards.",
      "Double the dose of the progestogen-only pill while taking the antibiotic.",
      "Delay starting the antibiotic until the next pill-free interval."
    ],
    "correct_answer": "No additional contraceptive precautions are necessary with this antibiotic.",
    "explanation": "**Explanation**\nClarithromycin, like most broad-spectrum antibiotics, does not interact with the progestogen-only pill (POP) and does **not reduce its contraceptive efficacy**. The **only antibiotics known to affect hormonal contraception are the enzyme-inducing types**, such as rifampicin and rifabutin, which increase hepatic metabolism of contraceptive hormones and can compromise efficacy. Other antibiotics, including macrolides, do not have this effect. However, if the antibiotic causes significant vomiting or diarrhoea, absorption of the contraceptive pill can be impaired—this is not a drug interaction but a pharmacokinetic effect related to gastrointestinal upset. **Routine advice is to continue the POP as normal unless using enzyme-inducing antibiotics or persistent vomiting/diarrhoea occurs.**\n\n**Key Points**\n- Enzyme-inducing antibiotics (e.g. rifampicin) can reduce hormonal contraceptive efficacy.\n- Macrolides (e.g. clarithromycin, erythromycin) do not induce liver enzymes.\n- No extra contraceptive precautions are needed with broad-spectrum antibiotics and the POP.\n- Vomiting or diarrhoea may affect pill absorption but is not a drug interaction.\n- Unnecessary changes to contraception can reduce adherence and increase risk of unintended pregnancy.\n\n**Clinical Relevance**\nUnderstanding which medications interact with hormonal contraception is vital for patient counselling and avoiding unnecessary anxiety or changes in contraceptive practice. This guidance aligns with national standards to promote safe and effective contraception advice.\n\n**Memory Anchor**\nRemember: 'Rifampicin Rifampinces'—only rifampicin/rifabutin are enzyme inducers affecting contraceptive pills.",
    "bullet_explanations": {
      "No additional contraceptive precautions are necessary with this antibiotic.": "Correct: Clarithromycin does not affect the efficacy of the progestogen-only pill.",
      "Stop the progestogen-only pill and use alternative contraception during the antibiotic course.": "Incorrect: There is no need to stop the POP when taking clarithromycin.",
      "Use additional barrier contraception throughout the antibiotic course and for 7 days afterwards.": "Incorrect: Only required for enzyme-inducing antibiotics, not for clarithromycin.",
      "Double the dose of the progestogen-only pill while taking the antibiotic.": "Incorrect: This is not recommended or necessary; it does not improve efficacy.",
      "Delay starting the antibiotic until the next pill-free interval.": "Incorrect: This is unnecessary and could delay appropriate treatment."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Drug interactions",
    "topic": "Common drug interactions",
    "keywords": [
      "progestogen-only pill",
      "antibiotics",
      "contraception",
      "drug interaction"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "0cc2541c-32a6-4f08-9581-955c879cfbc8",
    "question_number": 113,
    "question": "A 54-year-old woman with a long history of heavy alcohol intake attends the clinic complaining of persistent tingling and numbness in both feet. Examination reveals reduced sensation in a stocking distribution, with no muscle weakness or cranial nerve involvement. Which of the following is the most likely diagnosis?",
    "options": [
      "Alcohol-related peripheral neuropathy",
      "Guillain-Barré syndrome",
      "Chronic inflammatory demyelinating polyneuropathy (CIDP)",
      "Charcot-Marie-Tooth disease",
      "Cerebellar ataxia"
    ],
    "correct_answer": "Alcohol-related peripheral neuropathy",
    "explanation": "**Explanation**\n**Alcohol-related peripheral neuropathy** commonly presents as a chronic, symmetrical, distal sensory neuropathy, especially in individuals with prolonged alcohol misuse. Symptoms include numbness, tingling, and burning sensations, most often affecting the feet in a stocking distribution. Motor involvement is usually mild or absent early on. Laboratory findings may reveal raised liver enzymes, such as gamma-glutamyl transpeptidase (GGT), supporting ongoing alcohol misuse. This contrasts with conditions like Guillain-Barré syndrome (which is typically acute, rapidly progressive, and motor-dominant) and inherited neuropathies such as Charcot-Marie-Tooth disease (which often present earlier in life and have characteristic motor features). CIDP often manifests with progressive motor weakness and sensory symptoms, but usually includes proximal involvement and areflexia. Cerebellar ataxia is characterised primarily by coordination deficits, not distal sensory loss.\n\n**Key Points**\n- Alcohol misuse is a well-recognised cause of distal, symmetrical peripheral neuropathy.\n- Symptoms are predominantly sensory (numbness, tingling), with a 'stocking' distribution.\n- Motor involvement and cranial nerve signs are usually absent or mild.\n- Other common causes of sensory neuropathy include diabetes and vitamin B12 deficiency.\n- Investigations should include blood glucose, vitamin B12, and liver function tests.\n- <table><thead><tr><th>Feature</th><th>Alcoholic Neuropathy</th><th>Guillain-Barré</th></tr></thead><tbody><tr><td>Onset</td><td>Gradual, chronic</td><td>Acute, rapid</td></tr><tr><td>Symptoms</td><td>Sensory > motor</td><td>Motor > sensory</td></tr></tbody></table>\n\n**Clinical Relevance**\nAlcohol-related neuropathy is a frequent complication in individuals with chronic alcohol misuse and should be considered in patients presenting with distal sensory symptoms, especially when liver enzyme abnormalities are present. Early recognition aids in risk factor modification and symptom management. NICE CKS highlights the importance of evaluating for common reversible causes of sensory neuropathy, including alcohol misuse, diabetes, and vitamin deficiencies.\n\n**Memory Anchor**\nThink 'alcohol = stocking numbness' for distal, symmetrical neuropathy in drinkers.",
    "bullet_explanations": {
      "Alcohol-related peripheral neuropathy": "Correct – Presents as distal, symmetrical sensory loss in heavy drinkers.",
      "Guillain-Barré syndrome": "Incorrect – Typically has acute onset and motor-predominant weakness.",
      "Chronic inflammatory demyelinating polyneuropathy (CIDP)": "Incorrect – More often features progressive motor weakness and proximal involvement.",
      "Charcot-Marie-Tooth disease": "Incorrect – Inherited, usually presents earlier with motor and sensory deficits.",
      "Cerebellar ataxia": "Incorrect – Primarily causes coordination problems, not stocking sensory loss."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Substance Misuse",
    "subsubsection": "Alcohol",
    "topic": "Liver complications",
    "keywords": [
      "alcoholic neuropathy",
      "sensory neuropathy",
      "stocking distribution",
      "liver enzymes",
      "chronic alcohol use"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Sensory neuropathy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/sensory-neuropathy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fc83242e-a681-406d-ae17-b2d331f60b60",
    "question_number": 114,
    "question": "Which cervical nerve root is primarily assessed when eliciting the triceps tendon reflex during a neurological examination?",
    "options": [
      "C7–C8",
      "C5–C6",
      "C6–C7",
      "C3–C4",
      "C5–C7"
    ],
    "correct_answer": "C7–C8",
    "explanation": "**Explanation**\n**The triceps tendon reflex primarily tests the integrity of the C7 nerve root, with some contribution from C8.** When the triceps tendon is tapped, an intact C7 (and to a lesser extent C8) nerve root will cause contraction of the triceps muscle and extension at the elbow. Abnormalities in this reflex can indicate a lesion or compression at the C7 or C8 level, which may be due to cervical radiculopathy. This is a key part of the neurological assessment for upper limb weakness, pain, or sensory changes. In contrast, other upper limb reflexes (such as the biceps and brachioradialis) test different nerve roots: biceps reflex assesses C5/C6 and brachioradialis reflex primarily tests C6.\n\n**Key Points**\n- Triceps reflex = C7 (mainly), C8 (to a lesser degree)\n- Biceps reflex = C5–C6\n- Brachioradialis (supinator) reflex = C6\n- Absent triceps reflex may indicate C7/C8 radiculopathy or nerve injury\n- Upper limb tendon reflexes are key for localising neurological lesions\n\n**Clinical Relevance**\nAccurate localisation of neurological signs to specific nerve roots is essential in diagnosing cervical radiculopathy and other neuropathies, guiding both further investigation and management (see NICE CKS). Reflex testing remains a cornerstone of the neurological examination.\n\n**Memory Anchor**\nThink 'Triceps = 7 letters = C7' for the main nerve root.",
    "bullet_explanations": {
      "C7–C8": "Correct – the triceps reflex predominantly assesses C7, with some C8 involvement.",
      "C5–C6": "Incorrect – these roots are tested by the biceps reflex, not triceps.",
      "C6–C7": "Incorrect – C6 is mainly involved in the brachioradialis reflex; C7 is correct but C6 is not for triceps.",
      "C3–C4": "Incorrect – these roots supply neck muscles, not upper limb reflexes.",
      "C5–C7": "Incorrect – while C5 and C6 are involved in biceps and supinator reflexes, only C7 is relevant for triceps."
    },
    "category": "Neurology",
    "subsection": "Stroke & TIA",
    "subsubsection": "FAST/TIA recognition",
    "topic": "Upper limb reflexes and nerve root localisation",
    "keywords": [
      "triceps reflex",
      "C7 nerve root",
      "cervical radiculopathy",
      "neurological examination"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Neck pain - cervical radiculopathy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/neck-pain-cervical-radiculopathy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "29c6af14-3c3e-4d93-bf6c-f0db654ad481",
    "question_number": 115,
    "question": "Which of the following statements about St John’s Wort as a treatment for depression is INCORRECT?",
    "options": [
      "Its adverse effect profile is comparable to placebo in clinical studies.",
      "It has demonstrated efficacy in mild to moderate depression.",
      "St John’s Wort is a potent inducer of cytochrome P450 enzymes.",
      "It acts primarily as a monoamine oxidase inhibitor.",
      "Concomitant use may lead to serotonin syndrome when combined with other serotonergic drugs."
    ],
    "correct_answer": "It acts primarily as a monoamine oxidase inhibitor.",
    "explanation": "**Explanation**\nSt John’s Wort does NOT primarily act as a monoamine oxidase inhibitor (MAOI); instead, its main mechanism is thought to involve inhibition of the reuptake of serotonin, noradrenaline, and dopamine—similar to selective serotonin reuptake inhibitors (SSRIs). **This distinction is clinically important, as its interaction profile and risk of serotonin syndrome stem from its SSRI-like activity, not MAOI effects.** Trials show it can be effective for mild to moderate depression, and its adverse effects are usually mild and comparable to placebo. However, St John’s Wort is a known inducer of cytochrome P450 enzymes, which can reduce the effectiveness of many drugs, including hormonal contraceptives. It can also cause serotonin syndrome if taken with other serotonergic medications.\n\n**Key Points**\n<ul><li>St John’s Wort mainly inhibits serotonin, noradrenaline, and dopamine reuptake—not MAO.</li><li>It is effective for mild-moderate depression in some studies.</li><li>Adverse effect rates similar to placebo in trials.</li><li>Induces CYP450 enzymes, reducing efficacy of many medicines.</li><li>Can precipitate serotonin syndrome if combined with other serotonergic agents.</li></ul><table><thead><tr><th>Property</th><th>St John’s Wort</th></tr></thead><tbody><tr><td>Main Mechanism</td><td>Serotonin reuptake inhibition</td></tr><tr><td>MAOI activity</td><td>No</td></tr><tr><td>P450 induction</td><td>Yes</td></tr><tr><td>Effectiveness</td><td>Mild-moderate depression</td></tr></tbody></table>\n\n**Clinical Relevance**\nHerbal products like St John’s Wort are widely used and can interact with commonly prescribed drugs, especially via CYP450 induction. Recognising its true mechanism is essential when assessing risk for drug interactions or serotonin syndrome. NICE and BNF caution against its use due to variable preparation and potential for significant interactions.\n\n**Memory Anchor**\nRemember: St John’s Wort 'Worts' like an SSRI, not as an MAOI.",
    "bullet_explanations": {
      "Its adverse effect profile is comparable to placebo in clinical studies.": "Correct—studies show adverse effects with St John’s Wort are generally similar to placebo.",
      "It has demonstrated efficacy in mild to moderate depression.": "Correct—clinical trials support its benefit for mild to moderate depression.",
      "St John’s Wort is a potent inducer of cytochrome P450 enzymes.": "Correct—it strongly induces CYP450, leading to numerous drug interactions.",
      "It acts primarily as a monoamine oxidase inhibitor.": "Incorrect—its main action is SSRI-like, not as an MAOI.",
      "Concomitant use may lead to serotonin syndrome when combined with other serotonergic drugs.": "Correct—there is a risk of serotonin syndrome when combined with SSRIs or other serotonergic agents."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Depression",
    "topic": "First-line therapy",
    "keywords": [
      "St John's Wort",
      "depression",
      "mechanism",
      "drug interactions",
      "serotonin syndrome"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Contraceptives, interactions",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/contraceptives-interactions/"
      },
      {
        "source": "BNF",
        "topic_title": "Depression",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/depression/"
      },
      {
        "source": "BNF",
        "topic_title": "Antidepressant drugs",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antidepressant-drugs/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "812df84a-8773-4b9a-a2ab-56efe001c4f7",
    "question_number": 116,
    "question": "Which of the following adverse effects is most commonly associated with the use of tamsulosin in the management of lower urinary tract symptoms due to benign prostatic enlargement in an elderly male patient?",
    "options": [
      "Dizziness and postural hypotension",
      "Nocturia and sleep disturbance",
      "Urinary retention and dry mouth",
      "Erectile dysfunction and loss of libido",
      "Urgency and haematuria"
    ],
    "correct_answer": "Dizziness and postural hypotension",
    "explanation": "**Explanation**\n**Tamsulosin is an alpha-1 adrenergic receptor blocker** used for relieving lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Its main mechanism is to relax smooth muscle in the bladder neck and prostate, thereby improving urine flow. However, the alpha-blocking action can also cause **systemic vasodilation**, leading to side-effects such as dizziness and postural (orthostatic) hypotension, particularly in older adults. These vasodilatory effects are well recognised and patients should be counselled about the risk of feeling light-headed, especially when standing up quickly. Other potential side effects (such as abnormal ejaculation) are less common, and tamsulosin does not significantly impact libido or erectile function.**\n\n\n\n**Key Points**\n<ul><li>Alpha-1 blockers like tamsulosin are first-line for moderate-to-severe LUTS in BPH.</li><li>Common adverse effects: dizziness and postural hypotension due to vasodilation.</li><li>Tamsulosin is less likely to cause erectile dysfunction compared to 5-alpha-reductase inhibitors.</li><li>Warn patients about the risk of falls, especially elderly individuals.</li><li>Abnormal ejaculation is possible, but not the most common side-effect.</li></ul>\n\n**Clinical Relevance**\nRecognising the side effect profile of tamsulosin is important for safe prescribing in men with BPH, especially to prevent falls in elderly patients. National guidelines and the BNF highlight postural hypotension as a key adverse effect. Counselling patients can reduce morbidity and improve adherence.",
    "bullet_explanations": {
      "Dizziness and postural hypotension": "Correct – these are the most frequent side-effects due to the drug’s vasodilatory properties.",
      "Nocturia and sleep disturbance": "Incorrect – nocturia is a symptom of BPH, not a typical side-effect of tamsulosin.",
      "Urinary retention and dry mouth": "Incorrect – tamsulosin improves urinary flow and does not cause retention; dry mouth is more typical of antimuscarinics.",
      "Erectile dysfunction and loss of libido": "Incorrect – tamsulosin does not usually affect erectile function or libido; these are more associated with other BPH medicines.",
      "Urgency and haematuria": "Incorrect – urgency is a BPH symptom, not a drug side-effect, and tamsulosin does not cause haematuria."
    },
    "category": "Renal & Urology",
    "subsection": "Urology",
    "subsubsection": "Obstruction",
    "topic": "BPH",
    "keywords": [
      "tamsulosin",
      "side effects",
      "BPH",
      "postural hypotension",
      "alpha blocker"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Lower urinary tract symptoms in males",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/lower-urinary-tract-symptoms-in-males/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "3886502e-3906-46a0-90c4-fb4c42cba9ae",
    "question_number": 117,
    "question": "After a 45-year-old woman undergoes resection and primary anastomosis for a sigmoid colon cancer, the surgical team decides to divert the faecal stream to protect the new join. Which type of stoma is typically preferred in this setting for both effective diversion and ease of later reversal?",
    "options": [
      "Loop ileostomy",
      "End colostomy",
      "Loop colostomy",
      "End ileostomy",
      "Colonic mucous fistula"
    ],
    "correct_answer": "Loop ileostomy",
    "explanation": "**Explanation**\nA <b>loop ileostomy</b> is commonly used to divert the faecal stream away from a distal colonic or rectal anastomosis. This reduces the risk of anastomotic leakage by minimising passage of stool through the new join, allowing it to heal. <b>Loop ileostomies are generally straightforward to reverse</b> because both the proximal and distal bowel ends are preserved and readily accessible. In contrast, end stomas often entail loss or inaccessibility of the distal bowel, making reversal more complex or even impossible. Loop colostomies are an alternative but are less commonly used due to higher reversal risks and poorer healing of colonic tissue compared to small bowel. Mucous fistulas serve to decompress the distal bowel but do not defunction the proximal anastomosis.\n\n**Key Points**\n- Loop ileostomies effectively divert the faecal stream from the colon/rectum.\n- Reversal of a loop ileostomy is generally simpler and safer than end stomas.\n- End stomas (colostomy or ileostomy) are usually permanent and not ideal for temporary diversion.\n- Loop colostomy is less preferred due to higher risk of complications on reversal.\n- Colonic mucous fistula provides decompression, not diversion.\n- <table><thead><tr><th>Stoma Type</th><th>Defunctioning</th><th>Ease of Reversal</th></tr></thead><tbody><tr><td>Loop ileostomy</td><td>Yes</td><td>Easy</td></tr><tr><td>Loop colostomy</td><td>Yes</td><td>More complex</td></tr><tr><td>End stoma</td><td>No</td><td>Difficult/rare</td></tr><tr><td>Mucous fistula</td><td>No</td><td>N/A</td></tr></tbody></table>\n\n**Clinical Relevance**\nAppropriate stoma selection after colorectal surgery is crucial for minimising anastomotic complications and facilitating future restoration of bowel continuity. Loop ileostomies are preferred for temporary diversion, as recommended in surgical guidelines, and are associated with lower morbidity upon reversal.\n\n**Memory Anchor**\nRemember: 'Loop for the group'—loop ileostomy is the team player for temporary protection.",
    "bullet_explanations": {
      "Loop ileostomy": "Correct – best for temporary diversion with straightforward future reversal.",
      "End colostomy": "Incorrect – typically permanent; reversal is difficult and often not feasible.",
      "Loop colostomy": "Incorrect – can divert the colon, but reversal is higher risk and less commonly chosen.",
      "End ileostomy": "Incorrect – usually permanent and not intended for short-term protection.",
      "Colonic mucous fistula": "Incorrect – decompresses the bowel but does not divert faecal flow from the anastomosis."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "Diverticular Disease",
    "topic": "Uncomplicated vs complicated presentations",
    "keywords": [
      "loop ileostomy",
      "stoma reversal",
      "colonic anastomosis",
      "defunctioning",
      "bowel diversion"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Stoma care",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/stoma-care/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "27b6d27a-7e9e-4aa2-93ba-cac32dded1a4",
    "question_number": 118,
    "question": "A 28-year-old primigravida at 13 weeks' gestation attends her routine antenatal appointment. A vaginal swab, performed due to increased discharge, returns positive for group B Streptococcus (GBS). She is otherwise well and her pregnancy is progressing normally. What is the most appropriate management regarding the GBS finding?",
    "options": [
      "Reassure now; plan intrapartum intravenous antibiotics",
      "Start immediate oral penicillin",
      "Prescribe oral erythromycin until delivery",
      "Arrange weekly vaginal swabs for GBS monitoring",
      "Advise elective caesarean section at term"
    ],
    "correct_answer": "Reassure now; plan intrapartum intravenous antibiotics",
    "explanation": "**Explanation**\n**Group B Streptococcus (GBS) is a common vaginal commensal and its isolation in an asymptomatic pregnant woman does not require treatment during the antenatal period.** Immediate antimicrobial therapy does not eradicate colonisation at the time of delivery, so it does not prevent neonatal infection. The evidence and guidelines recommend offering intrapartum intravenous benzylpenicillin for women with GBS detected in the current pregnancy, as this is proven to reduce the risk of early-onset neonatal GBS disease. Oral antibiotics antenatally, repeated swabs, or planned caesarean section are not indicated solely due to GBS colonisation. <br><br>**Key facts:** Intrapartum antibiotic prophylaxis is the intervention that reduces vertical transmission and newborn morbidity/mortality.\n\n**Key Points**\n- GBS colonisation in pregnancy is common and often asymptomatic.\n- Routine antenatal treatment is not recommended if asymptomatic.\n- Intrapartum intravenous benzylpenicillin is indicated during labour.\n- Oral antibiotics before labour do not prevent neonatal GBS disease.\n- There is no UK screening programme for GBS—testing is based on clinical indication.\n- GBS UTI in pregnancy is treated at time of diagnosis and also requires intrapartum prophylaxis.\n\n**Clinical Relevance**\nThis approach is based on national guidelines and aims to reduce the risk of serious neonatal GBS infection, a leading cause of early-onset sepsis. Understanding this management pathway is essential for safe and evidence-based antenatal care.\n\n**Memory Anchor**\nGBS: Give Benzylpenicillin at Birth (not Before!)",
    "bullet_explanations": {
      "Reassure now; plan intrapartum intravenous antibiotics": "Correct—this reduces neonatal GBS risk without unnecessary antenatal antibiotic exposure.",
      "Start immediate oral penicillin": "Incorrect—antenatal oral antibiotics do not reduce neonatal GBS transmission risk.",
      "Prescribe oral erythromycin until delivery": "Incorrect—no evidence supports prolonged oral antibiotics for antenatal GBS colonisation.",
      "Arrange weekly vaginal swabs for GBS monitoring": "Incorrect—repeat swabbing is not recommended; results do not alter management.",
      "Advise elective caesarean section at term": "Incorrect—caesarean is not indicated for GBS colonisation alone."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "High-risk pregnancy identification",
    "keywords": [
      "group B Streptococcus",
      "antenatal care",
      "intrapartum antibiotics",
      "GBS",
      "pregnancy infection"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "RCOG",
        "topic_title": "GBS in pregnancy",
        "citation": "© Royal College of Obstetricians and Gynaecologists",
        "url": ""
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a630dcd0-f6ab-45ba-94e2-b23674f96f20",
    "question_number": 119,
    "question": "Which of the following infectious agents associated with acute diarrhoea typically has the longest incubation period before symptom onset?",
    "options": [
      "Giardia lamblia",
      "Campylobacter jejuni",
      "Bacillus cereus",
      "Salmonella enterica",
      "Shigella sonnei"
    ],
    "correct_answer": "Giardia lamblia",
    "explanation": "**Explanation**\n**Giardia lamblia** is a protozoan parasite that causes giardiasis, a form of gastroenteritis recognised for its relatively long incubation period—usually 1 to 2 weeks, but occasionally up to 6 weeks. This is significantly longer than the incubation periods of common bacterial causes of gastroenteritis, which typically present within hours to a few days following ingestion of the pathogen. Recognising this difference is crucial when investigating cases of persistent or delayed-onset diarrhoea, especially following travel or exposure to contaminated water. In contrast, bacterial pathogens such as *Campylobacter jejuni*, *Bacillus cereus*, *Salmonella enterica*, and *Shigella sonnei* generally present within a much shorter timeframe after exposure due to their differing pathogenic mechanisms and host responses.\n\n**Key Points**\n<ul><li><b>Giardia lamblia</b>: Incubation period 7–14 days (can be longer).</li><li>Bacterial gastroenteritis (Campylobacter, Salmonella, Shigella, Bacillus cereus): Incubation usually <6 days.</li><li>Giardiasis often linked to contaminated water or recent travel.</li><li>Acute diarrhoea lasting &gt;14 days should prompt consideration of parasitic causes.</li><li>Incubation period can guide diagnostic and public health decisions.</li></ul><table><thead><tr><th>Pathogen</th><th>Typical Incubation</th></tr></thead><tbody><tr><td>Giardia lamblia</td><td>1–2 weeks (up to 6 weeks)</td></tr><tr><td>Campylobacter</td><td>2–5 days</td></tr><tr><td>Salmonella</td><td>6–72 hours</td></tr><tr><td>Bacillus cereus</td><td>1–16 hours</td></tr><tr><td>Shigella</td><td>1–3 days</td></tr></tbody></table>\n\n**Clinical Relevance**\nUnderstanding incubation periods is essential for distinguishing between different causes of gastroenteritis, particularly in cases of prolonged diarrhoea or outbreaks. Correctly identifying longer incubation periods can prompt appropriate investigations and public health interventions, as recommended in NICE guidance.\n\n**Memory Anchor**\nRemember: 'Giardia Goes the Distance'—longest incubation.",
    "bullet_explanations": {
      "Giardia lamblia": "Correct – incubation period is typically 1–2 weeks, sometimes much longer.",
      "Campylobacter jejuni": "Incorrect – usually presents within 2–5 days of exposure.",
      "Bacillus cereus": "Incorrect – symptoms develop rapidly, within hours (1–16 hours) after ingestion.",
      "Salmonella enterica": "Incorrect – incubation period is generally 6–72 hours.",
      "Shigella sonnei": "Incorrect – typically presents within 1–3 days."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Upper GI",
    "subsubsection": "Dyspepsia & H. pylori",
    "topic": "Alarm features and 2WW criteria",
    "keywords": [
      "gastroenteritis",
      "incubation period",
      "giardiasis",
      "acute diarrhoea",
      "infectious causes"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Gastroenteritis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/gastroenteritis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1e39bf3f-064c-4821-9c16-0e4eaec39b9a",
    "question_number": 120,
    "question": "Which of the following adverse effects should a patient be specifically warned about when starting amiodarone therapy for arrhythmia management?",
    "options": [
      "Pulmonary fibrosis",
      "Nephrotoxicity",
      "Oligomenorrhoea",
      "Medication-induced phaeochromocytoma",
      "Chronic diarrhoea"
    ],
    "correct_answer": "Pulmonary fibrosis",
    "explanation": "**Explanation**\n**Amiodarone** is a potent class III antiarrhythmic agent frequently used for rhythm control in various arrhythmias, especially atrial fibrillation. One of its most serious and well-recognised adverse effects is **pulmonary fibrosis**, a potentially life-threatening interstitial lung disease. Patients on amiodarone require close monitoring for respiratory symptoms and routine chest imaging may be indicated in some cases. Other notable side effects include thyroid dysfunction (either hypo- or hyperthyroidism), corneal deposits, skin discolouration (slate-grey), and hepatic toxicity. **Pulmonary toxicity is unique among commonly prescribed antiarrhythmics and must be discussed at initiation.**\n\n**Key Points**\n- Amiodarone is associated with pulmonary fibrosis, which can be severe and irreversible.\n- Other side effects: thyroid dysfunction, corneal deposits, slate-grey skin pigmentation, and hepatic toxicity.\n- It is not nephrotoxic, does not cause oligomenorrhoea, phaeochromocytoma, or chronic diarrhoea.\n- Patients should be educated about early symptoms of lung disease (e.g., dyspnoea, cough).\n- <table><thead><tr><th>Side Effect</th><th>Features</th></tr></thead><tbody><tr><td>Pulmonary fibrosis</td><td>Progressive dyspnoea, dry cough, crackles on examination</td></tr><tr><td>Thyroid dysfunction</td><td>Hypo- or hyperthyroidism</td></tr><tr><td>Corneal deposits</td><td>Visual halos, usually benign</td></tr></tbody></table>\n\n**Clinical Relevance**\nAmiodarone is widely prescribed in cardiology. Awareness of its pulmonary toxicity is crucial because early detection can prevent progression to irreversible lung disease. National guidelines recommend regular review and patient counselling at the start of therapy.\n\n**Memory Anchor**\n\"Ami-Odorone\" – Ami (lungs, as in 'air'), Odor (odd, as in 'odd' for rare but serious lung toxicity).",
    "bullet_explanations": {
      "Pulmonary fibrosis": "Correct – a well-known and serious complication of amiodarone therapy.",
      "Nephrotoxicity": "Incorrect – amiodarone is not associated with kidney toxicity.",
      "Oligomenorrhoea": "Incorrect – this is not a recognised side effect of amiodarone.",
      "Medication-induced phaeochromocytoma": "Incorrect – amiodarone does not induce phaeochromocytoma.",
      "Chronic diarrhoea": "Incorrect – diarrhoea is not a typical side effect of amiodarone."
    },
    "category": "Cardiovascular",
    "subsection": "Arrhythmias & Conduction",
    "subsubsection": "Atrial Fibrillation/Flutter",
    "topic": "Rate vs rhythm control initial choices",
    "keywords": [
      "amiodarone",
      "pulmonary fibrosis",
      "side effects",
      "arrhythmia",
      "patient counselling"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Amiodarone: Adverse Effects",
        "citation": "© NICE, 2025",
        "url": ""
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1fc7b538-2386-486e-b740-099dea3d6046",
    "question_number": 121,
    "question": "Which of the following is a known complication that should be monitored for in children diagnosed with cystic fibrosis?",
    "options": [
      "Cystic fibrosis-related diabetes",
      "Congenital hypothyroidism",
      "Bicuspid aortic valve",
      "Cystic hygroma",
      "Meckel's diverticulum"
    ],
    "correct_answer": "Cystic fibrosis-related diabetes",
    "explanation": "**Explanation**\n**Cystic fibrosis-related diabetes (CFRD)** is a recognised and important complication of cystic fibrosis. The thick secretions characteristic of cystic fibrosis progressively damage the pancreas, impairing both exocrine and endocrine function. Over time, this can result in insulin deficiency due to destruction of the pancreatic islets, leading to a unique form of diabetes seen in this patient group. Regular screening for CFRD is recommended, as it can impact nutritional status, pulmonary function, and overall prognosis. This contrasts with conditions like congenital hypothyroidism or cardiac malformations, which are not directly linked to cystic fibrosis.\n\n**Key Points**\n- Cystic fibrosis can lead to pancreatic insufficiency, affecting both digestion and glucose regulation.\n- Cystic fibrosis-related diabetes is distinct from type 1 and type 2 diabetes.\n- Annual screening for diabetes is advised in children with cystic fibrosis, especially after age 10.\n- Other complications include recurrent pulmonary infections, liver disease, and reduced bone mineral density.\n- Early detection of CFRD allows for better nutritional management and improved outcomes.\n\n**Clinical Relevance**\nOngoing monitoring for CFRD is an established part of cystic fibrosis care as per UK guidelines. Early recognition and management can reduce morbidity and improve quality of life. Familiarity with the multisystem impact of cystic fibrosis is essential for all clinicians involved in paediatric or general medical care.\n\n**Memory Anchor**\nCF = 'Cystic Fibrosis' and 'Cystic Fibrosis-related Diabetes'—both share the initials.",
    "bullet_explanations": {
      "Cystic fibrosis-related diabetes": "Correct. Pancreatic damage from cystic fibrosis can cause insulin deficiency and diabetes.",
      "Congenital hypothyroidism": "Incorrect. Hypothyroidism is not associated with cystic fibrosis.",
      "Bicuspid aortic valve": "Incorrect. This cardiac defect is not linked to cystic fibrosis; more commonly seen in Turner syndrome.",
      "Cystic hygroma": "Incorrect. This lymphatic malformation is not a complication of cystic fibrosis.",
      "Meckel's diverticulum": "Incorrect. Meckel's diverticulum is unrelated to cystic fibrosis, though meconium ileus is a recognised GI complication."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Genetics",
    "subsubsection": "Common Syndromes",
    "topic": "Cystic fibrosis features and complications",
    "keywords": [
      "cystic fibrosis",
      "diabetes",
      "paediatrics",
      "complications",
      "pancreatic insufficiency"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Cystic fibrosis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/cystic-fibrosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "bdfafb1f-54ba-4e6c-aba6-852401beec90",
    "question_number": 122,
    "question": "A 5-year-old boy, recently started at school, presents with a two-week history of worsening, paroxysmal cough episodes, some ending with vomiting. He has not received any childhood immunisations. Examination is unremarkable and he is otherwise well. What is the most appropriate initial treatment?",
    "options": [
      "Oral azithromycin",
      "Oral amoxicillin",
      "Supportive care only",
      "Single dose of oral prednisolone",
      "Intravenous ceftriaxone"
    ],
    "correct_answer": "Oral azithromycin",
    "explanation": "**Explanation**\n**Whooping cough (pertussis) should be suspected in children with a prolonged, paroxysmal cough, especially if unvaccinated and post-tussive vomiting is present.** Early antibiotic treatment within three weeks of symptom onset can reduce transmission and may ameliorate symptoms. **Azithromycin, a macrolide antibiotic, is recommended as first-line therapy**, particularly in children who cannot tolerate erythromycin or where compliance might be improved with shorter dosing. Supportive care alone is insufficient within this time window, and other antibiotic options or corticosteroids are not indicated for pertussis. Early recognition and prompt macrolide initiation are essential, especially in unvaccinated individuals.\n\n**Key Points**\n- Pertussis typically presents with paroxysmal cough, post-tussive vomiting, and absence of immunisation.\n- Macrolides (azithromycin, clarithromycin, or erythromycin) are first-line within 21 days of cough onset.\n- Supportive care alone is reserved for those presenting later (>3 weeks after onset).\n- Penicillins and corticosteroids are not effective for pertussis.\n- Hospital admission is considered for infants <6 months or those with severe symptoms.\n- <table><thead><tr><th>Condition</th><th>First-Line Therapy</th></tr></thead><tbody><tr><td>Pertussis</td><td>Azithromycin (macrolide)</td></tr><tr><td>Croup</td><td>Dexamethasone</td></tr><tr><td>Tonsillitis</td><td>Phenoxymethylpenicillin</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising and managing pertussis early is crucial to prevent complications and reduce community transmission, especially in unvaccinated children. NICE and BNF guidelines prioritise macrolide antibiotics in this context.",
    "bullet_explanations": {
      "Oral azithromycin": "Correct—macrolide antibiotics are first-line for pertussis within three weeks of symptoms.",
      "Oral amoxicillin": "Incorrect—amoxicillin is not effective against Bordetella pertussis.",
      "Supportive care only": "Incorrect—supportive care alone is insufficient in early pertussis; antibiotics are indicated.",
      "Single dose of oral prednisolone": "Incorrect—steroids are used for croup, not for pertussis.",
      "Intravenous ceftriaxone": "Incorrect—ceftriaxone is used for meningitis or severe sepsis, not for uncomplicated pertussis."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Common Infections",
    "topic": "Bronchiolitis",
    "keywords": [
      "pertussis",
      "whooping cough",
      "macrolide",
      "childhood infections",
      "azithromycin"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Whooping cough",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/whooping-cough/"
      },
      {
        "source": "BNF",
        "topic_title": "Respiratory system infections, antibacterial therapy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/respiratory-system-infections-antibacterial-therapy/"
      },
      {
        "source": "BNF",
        "topic_title": "Antibacterials, use for prophylaxis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antibacterials-use-for-prophylaxis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a360d733-a067-4ca4-b467-ee1c13e5155a",
    "question_number": 123,
    "question": "According to NICE guidelines, which of the following intrapartum findings requires immediate commencement of continuous electronic fetal monitoring (CTG) during labour?",
    "options": [
      "Fresh vaginal bleeding develops during labour",
      "Maternal temperature of 37.5°C",
      "History of previous caesarean section",
      "Maternal anxiety regarding delivery",
      "Blood pressure of 140/90 mmHg"
    ],
    "correct_answer": "Fresh vaginal bleeding develops during labour",
    "explanation": "**Explanation**\n**Fresh vaginal bleeding that arises during labour is a recognised indicator for immediate continuous CTG monitoring**, as it may signal serious complications such as placental abruption or placenta praevia, both of which can compromise fetal wellbeing. NICE intrapartum care guidelines specify that new-onset vaginal bleeding in labour is a significant risk factor for fetal hypoxia and requires close observation of the fetal heart rate. In contrast, a maternal temperature below 38°C, a previous caesarean, mild hypertension (140/90 mmHg), or maternal anxiety are not, by themselves, absolute indications for continuous CTG monitoring.\n\n**Key Points**\n- Continuous CTG is indicated for *new fresh vaginal bleeding* during labour.\n- Other triggers include: suspected chorioamnionitis/sepsis (temp ≥38°C), severe hypertension (≥160/110 mmHg), oxytocin use, and significant meconium.\n- Fresh bleeding may reflect placental abruption or praevia, both obstetric emergencies.\n- Mild hypertension (140/90 mmHg) or low-grade fever do not independently warrant continuous CTG.\n- <table><thead><tr><th>Intrapartum Factor</th><th>CTG Indicated?</th></tr></thead><tbody><tr><td>Fresh vaginal bleeding</td><td>Yes</td></tr><tr><td>Maternal temp 37.5°C</td><td>No</td></tr><tr><td>BP 140/90 mmHg</td><td>No</td></tr><tr><td>Oxytocin use</td><td>Yes</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition of indications for continuous CTG monitoring is essential to detect and manage fetal compromise early, reducing the risk of perinatal morbidity and mortality. This follows NICE guidance for safe intrapartum care.\n\n**Memory Anchor**\nRemember: **'Bleeding, Bugs, Blood Pressure, and Drugs'** (Fresh bleeding, infection ≥38°C, severe hypertension, oxytocin) = continuous CTG.",
    "bullet_explanations": {
      "Fresh vaginal bleeding develops during labour": "Correct—new fresh bleeding during labour is a clear trigger for continuous CTG due to risk of acute fetal compromise.",
      "Maternal temperature of 37.5°C": "Incorrect—a temperature must reach 38°C or above to indicate CTG for infection.",
      "History of previous caesarean section": "Incorrect—previous caesarean alone is not an absolute indication for continuous CTG monitoring.",
      "Maternal anxiety regarding delivery": "Incorrect—anxiety is not a clinical indication for continuous CTG.",
      "Blood pressure of 140/90 mmHg": "Incorrect—severe hypertension (≥160/110 mmHg), not mild elevation, warrants CTG."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Late",
    "subsubsection": "Labour & Delivery",
    "topic": "Stages of labour",
    "keywords": [
      "CTG",
      "intrapartum monitoring",
      "fresh vaginal bleeding",
      "labour",
      "obstetrics"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Obstetrics",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/obstetrics/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d317140a-57d2-479b-9fa4-13ed8dea0a7a",
    "question_number": 124,
    "question": "A 62-year-old man of African-Caribbean origin attends a nurse-led hypertension review. He has been taking amlodipine 10 mg daily, but his blood pressure remains persistently elevated at 158/96 mmHg on repeated readings. He has no history of diabetes or chronic kidney disease. According to current guidelines, what is the next best step in managing his hypertension?",
    "options": [
      "Add an angiotensin receptor blocker or a thiazide-like diuretic",
      "Increase amlodipine to 20 mg daily",
      "Switch amlodipine to ramipril",
      "Add spironolactone",
      "Start metoprolol"
    ],
    "correct_answer": "Add an angiotensin receptor blocker or a thiazide-like diuretic",
    "explanation": "**Explanation**\n**For patients of African or African-Caribbean descent without diabetes, initial hypertension therapy is typically a calcium channel blocker (CCB). If blood pressure remains uncontrolled on optimal CCB dosage (such as amlodipine 10 mg), guidelines recommend adding either an angiotensin receptor blocker (ARB) or a thiazide-like diuretic as the next step.** ACE inhibitors can also be considered, but ARBs are often preferred in this group due to a higher risk of ACE inhibitor–induced angioedema. Increasing amlodipine above 10 mg is not standard practice due to increased side effects, and switching to another class alone would not achieve optimal blood pressure control. Spironolactone is reserved for resistant hypertension at later stages, and beta-blockers like metoprolol are not first-line in uncomplicated hypertension without specific indications.\n\n**Key Points**\n- Stepwise hypertension management is based on patient age, ethnicity, and comorbidities.\n- For black patients without diabetes, start with a CCB; if uncontrolled, add ARB or thiazide-like diuretic.\n- Maximal recommended dose of amlodipine is 10 mg daily.\n- Spironolactone is reserved for resistant hypertension (step 4) after three agents.\n- Beta-blockers are not routinely used for primary hypertension unless other indications exist.\n\n**Clinical Relevance**\nAdhering to guideline-based stepwise escalation is essential for safe and effective hypertension management, especially in populations with increased cardiovascular risk, such as those of African or Caribbean origin. This approach minimises adverse effects while maximising blood pressure control and reducing long-term complications. Refer to the BNF and NICE guidance for up-to-date recommendations.",
    "bullet_explanations": {
      "Add an angiotensin receptor blocker or a thiazide-like diuretic": "Correct; this is the recommended next step for black patients after monotherapy with a calcium channel blocker fails to achieve control.",
      "Increase amlodipine to 20 mg daily": "Incorrect; doses above 10 mg daily are not recommended due to increased risk of side effects.",
      "Switch amlodipine to ramipril": "Incorrect; swapping to an ACE inhibitor alone does not follow the guideline-recommended combination approach.",
      "Add spironolactone": "Incorrect; spironolactone is used in resistant hypertension after three antihypertensives are maximised.",
      "Start metoprolol": "Incorrect; beta-blockers are not first-line for hypertension unless there are specific indications such as angina or heart failure."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "NICE A/C/D ladder and special cases",
    "keywords": [
      "hypertension",
      "stepwise management",
      "calcium channel blocker",
      "black ethnicity",
      "BNF guidelines"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "6559e2e1-ea82-48bb-a934-87f80e6aa28e",
    "question_number": 125,
    "question": "Which adverse effect is most commonly associated with aminoglycoside antibiotics such as gentamicin when used to treat severe urinary tract infections?",
    "options": [
      "Nephrotoxicity",
      "Peripheral neuropathy",
      "Hepatitis",
      "Visual disturbances",
      "Ankle oedema"
    ],
    "correct_answer": "Nephrotoxicity",
    "explanation": "**Explanation**\n**Aminoglycosides, such as gentamicin, are well known for their risk of nephrotoxicity.** This adverse effect occurs due to the accumulation of the drug in renal tubular cells, leading to tubular damage and a reduction in kidney function. The risk increases with higher doses and prolonged therapy, making careful monitoring of renal function and serum gentamicin levels essential. In contrast, gentamicin is not classically associated with hepatitis, visual problems, peripheral neuropathy, or peripheral oedema as primary complications. **Ototoxicity** is another important but less common side effect. Regular monitoring and dose adjustments according to renal function help mitigate nephrotoxicity risk.\n\n**Key Points**\n- Gentamicin is an aminoglycoside antibiotic used for severe Gram-negative infections.\n- Nephrotoxicity is the most frequent serious complication, especially with prolonged use.\n- Renal impairment may manifest as rising serum creatinine and reduced urine output.\n- Ototoxicity (hearing or vestibular toxicity) is another recognised risk.\n- Other listed adverse effects (hepatitis, visual changes, oedema, neuropathy) are not typical for aminoglycosides.\n\n**Clinical Relevance**\nGentamicin and related aminoglycosides are frequently used for severe urinary and systemic infections. Monitoring renal function during therapy is vital, as nephrotoxicity can be reversible if detected early but may become irreversible with continued exposure. Awareness of this risk informs safer prescribing and patient monitoring.",
    "bullet_explanations": {
      "Nephrotoxicity": "Correct – Gentamicin is most commonly associated with kidney toxicity.",
      "Peripheral neuropathy": "Incorrect – This is not a common adverse effect of gentamicin.",
      "Hepatitis": "Incorrect – Gentamicin is not known to cause liver inflammation.",
      "Visual disturbances": "Incorrect – Gentamicin does not cause optic or visual side effects.",
      "Ankle oedema": "Incorrect – Oedema is not a typical complication of aminoglycoside therapy."
    },
    "category": "Renal & Urology",
    "subsection": "Acute Kidney Injury",
    "subsubsection": "Causes",
    "topic": "Drugs",
    "keywords": [
      "gentamicin",
      "aminoglycoside",
      "nephrotoxicity",
      "renal injury",
      "adverse effects"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Pyelonephritis - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/pyelonephritis-acute/"
      },
      {
        "source": "BNF",
        "topic_title": "Urinary-tract infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/urinary-tract-infections/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4d4e8716-5ebd-40e2-b7e1-ae3f1ac63f15",
    "question_number": 126,
    "question": "A 45-year-old woman with persistent symptoms of acromegaly following trans-sphenoidal resection of a pituitary adenoma is being reviewed in the endocrinology clinic. Despite surgery, her growth hormone levels remain elevated. What is the most appropriate first-line medication to manage her ongoing condition?",
    "options": [
      "Octreotide",
      "Bromocriptine",
      "Levothyroxine",
      "Hydrocortisone",
      "Empagliflozin"
    ],
    "correct_answer": "Octreotide",
    "explanation": "**Explanation**\nOctreotide, a somatostatin analogue, is considered the first-line medical therapy for persistent or residual acromegaly after surgery. **Octreotide directly inhibits the secretion of growth hormone (GH) from the pituitary gland**, addressing the underlying hormonal excess. In contrast, dopamine agonists such as bromocriptine are generally less effective than somatostatin analogues for this purpose. Other options listed do not target GH excess and are not indicated in acromegaly management.\n\n**Key Points**\n- Acromegaly most commonly results from a GH-secreting pituitary adenoma.\n- Trans-sphenoidal surgery is the initial treatment of choice.\n- Medical therapy is indicated if surgery is incomplete or not possible.\n- Somatostatin analogues (e.g., octreotide) are first-line medical agents.\n- Dopamine agonists (e.g., bromocriptine) are less effective but may be considered if somatostatin analogues are not tolerated.\n- Growth hormone antagonists (e.g., pegvisomant) are used in resistant cases.\n\n**Clinical Relevance**\nTimely recognition and treatment of persistent acromegaly are crucial to reduce morbidity from complications such as cardiovascular disease and diabetes. **NICE and BNF guidelines recommend somatostatin analogues as first-line medical therapy when surgery is inadequate.**\n\n**Memory Anchor**\nOctreotide = 'O' for 'Ongoing GH overproduction' in acromegaly.",
    "bullet_explanations": {
      "Octreotide": "Correct – first-line somatostatin analogue for persistent acromegaly after surgery.",
      "Bromocriptine": "Incorrect – less effective than somatostatin analogues, reserved for select or intolerant cases.",
      "Levothyroxine": "Incorrect – used for hypothyroidism, not indicated for acromegaly.",
      "Hydrocortisone": "Incorrect – prescribed for adrenal insufficiency, not for GH excess.",
      "Empagliflozin": "Incorrect – SGLT2 inhibitor for diabetes management, not relevant to acromegaly."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Calcium, Pituitary & Metabolic",
    "subsubsection": "Pituitary",
    "topic": "Acromegaly screening (IGF-1) and Rx",
    "keywords": [
      "acromegaly",
      "octreotide",
      "somatostatin analogue",
      "pituitary adenoma",
      "growth hormone"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Dopamine-receptor agonists",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/dopamine-receptor-agonists/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d1ff3d66-a078-4f39-8ac1-3fc11001beef",
    "question_number": 127,
    "question": "According to UK maternal mortality reporting, which time frame is used to define a maternal death for audit and surveillance purposes?",
    "options": [
      "From conception until six weeks post-delivery",
      "From 20 weeks' gestation until the end of pregnancy",
      "From onset of labour until 48 hours postpartum",
      "From conception until 48 hours postpartum",
      "From 20 weeks' gestation until six months postpartum"
    ],
    "correct_answer": "From conception until six weeks post-delivery",
    "explanation": "**Explanation**\n**Maternal death** is defined in the UK as the death of a woman while pregnant or within 42 days (six weeks) of the end of pregnancy, irrespective of the pregnancy's outcome, duration, or site. This definition is crucial for national surveillance and audit of maternal mortality, ensuring that all deaths potentially related to pregnancy, childbirth, and the immediate postpartum period are captured. Deaths occurring after this six-week window are classified separately (e.g., late maternal deaths). Other options suggest shorter or longer periods, but the standard and internationally recognised time frame is up to six weeks postpartum.\n\n**Key Points**\n- Maternal death includes deaths during pregnancy and up to 42 days after pregnancy ends.\n- This definition is used for national statistics and audits (e.g., MBRRACE-UK).\n- The six-week window ensures comprehensive inclusion of deaths related to pregnancy and birth.\n- Deaths beyond 42 days are recorded as 'late maternal deaths' and analysed separately.\n- The definition is based on WHO and UK guidelines.\n\n**Clinical Relevance**\nAccurately identifying maternal deaths is vital for improving obstetric care and informing public health strategies. Understanding the time frame ensures correct reporting and helps target interventions to reduce pregnancy-related morbidity and mortality.\n\n**Memory Anchor**\nRemember: 'Six weeks' is the key period for maternal death reporting—pregnancy plus 42 days.",
    "bullet_explanations": {
      "From conception until six weeks post-delivery": "Correct—this matches the definition used in UK maternal mortality audits.",
      "From 20 weeks' gestation until the end of pregnancy": "Incorrect—this omits early pregnancy and the postpartum period.",
      "From onset of labour until 48 hours postpartum": "Incorrect—this is too narrow and excludes many relevant deaths.",
      "From conception until 48 hours postpartum": "Incorrect—the postpartum period for maternal death extends to six weeks, not just 48 hours.",
      "From 20 weeks' gestation until six months postpartum": "Incorrect—the recognised postpartum period for maternal death is six weeks (42 days), not six months."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "High-risk pregnancy identification",
    "keywords": [
      "maternal death",
      "definition",
      "postpartum period",
      "maternal mortality",
      "obstetric surveillance"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Obstetrics",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/obstetrics/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a3e60b56-120d-4505-bc3a-fd9b57f3ff64",
    "question_number": 128,
    "question": "A 48-year-old male lorry driver is diagnosed with stage 2 hypertension following ambulatory blood pressure monitoring. His average daytime blood pressure is 158/98 mmHg, and he has no symptoms or evidence of target organ damage. What is the appropriate advice regarding his fitness to continue driving professionally?",
    "options": [
      "He can continue driving and does not need to notify the DVLA unless his blood pressure exceeds 180/100 mmHg.",
      "He should immediately stop driving and inform the DVLA regardless of blood pressure readings.",
      "He must self-certify as unfit for 5 days, then return to work if asymptomatic.",
      "He may continue driving but must check his blood pressure every 12 hours.",
      "He can only work a maximum of 40 hours per week due to his hypertension diagnosis."
    ],
    "correct_answer": "He can continue driving and does not need to notify the DVLA unless his blood pressure exceeds 180/100 mmHg.",
    "explanation": "**Explanation**\n**For group 2 licence holders (bus and lorry drivers), the DVLA mandates notification ONLY if blood pressure is consistently above 180 mmHg systolic or 100 mmHg diastolic.** Since this patient has stage 2 hypertension but does not meet the threshold for mandatory reporting and has no symptoms or target organ damage, he is not required to stop driving or inform the DVLA at this stage. He should, however, receive standard antihypertensive treatment and regular follow-up to ensure control below DVLA limits. **There are no restrictions on working hours or mandatory frequent BP checks unless clinical circumstances change.**\n\n**Key Points**\n- DVLA notification is required for group 2 drivers if BP >180 systolic or >100 diastolic mmHg.\n- Stage 2 hypertension: clinic BP ≥160/100 but <180/120 mmHg, ambulatory/home BP ≥150/95 mmHg.\n- No need to stop driving or notify DVLA if BP is below notification threshold and asymptomatic.\n- Symptomatic drivers or those with target organ damage may require further assessment.\n- Antihypertensive therapy should be initiated as per NICE/BNF guidelines.\n\n**Clinical Relevance**\nCorrect advice about driving and hypertension is crucial for patient safety and legal compliance, especially for group 2 (bus/lorry) drivers. Inappropriate restriction can impact livelihoods, while failure to act when indicated risks public safety.\n\n**Memory Anchor**\nDVLA threshold: Group 2 drivers must stop and notify if BP >180/100 mmHg.",
    "bullet_explanations": {
      "He can continue driving and does not need to notify the DVLA unless his blood pressure exceeds 180/100 mmHg.": "Correct – notification and driving restrictions apply only if BP exceeds these limits for group 2 drivers.",
      "He should immediately stop driving and inform the DVLA regardless of blood pressure readings.": "Incorrect – only required if BP >180/100 mmHg or if symptomatic or with target organ damage.",
      "He must self-certify as unfit for 5 days, then return to work if asymptomatic.": "Incorrect – self-certification is not necessary unless symptoms develop or BP exceeds DVLA thresholds.",
      "He may continue driving but must check his blood pressure every 12 hours.": "Incorrect – there is no requirement for such frequent self-monitoring for fitness to drive.",
      "He can only work a maximum of 40 hours per week due to his hypertension diagnosis.": "Incorrect – there are no work hour restrictions based solely on hypertension diagnosis."
    },
    "category": "Cardiovascular",
    "subsection": "Hypertension & Vascular",
    "subsubsection": "Hypertension",
    "topic": "Diagnosis (ambulatory/home thresholds)",
    "keywords": [
      "hypertension",
      "DVLA",
      "fitness to drive",
      "stage 2 hypertension",
      "blood pressure thresholds"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "baf1ab06-d5a0-4719-a169-13f3091121c6",
    "question_number": 129,
    "question": "A 29-year-old man attends an endocrine clinic reporting increased irritability, unexplained weight loss, and sweating over recent months. Examination reveals a regular pulse of 88 bpm and a non-tender, diffusely enlarged thyroid gland. Blood tests show: TSH <0.05 mU/L (low), free T4 27 pmol/L (raised), and positive anti-thyroid peroxidase antibodies. What is the most likely underlying diagnosis?",
    "options": [
      "Graves' disease",
      "Toxic multinodular goitre",
      "Hashimoto's thyroiditis",
      "De Quervain's (subacute) thyroiditis",
      "Thyroid carcinoma"
    ],
    "correct_answer": "Graves' disease",
    "explanation": "**Explanation**\n**Graves' disease is the most likely diagnosis** in this scenario. The key findings supporting this are: persistent thyrotoxic symptoms (e.g. irritability, weight loss, sweating), a suppressed TSH with elevated free T4 (overt hyperthyroidism), and the presence of anti-thyroid peroxidase antibodies. Graves' disease is an autoimmune disorder in which antibodies stimulate the TSH receptor, causing increased thyroid hormone production and diffuse goitre. While anti-thyroid peroxidase antibodies are more commonly associated with Hashimoto's thyroiditis, they are also present in a significant proportion of Graves' disease cases. Other causes such as toxic multinodular goitre typically present in older individuals and often show nodularity on examination. Thyroiditis (e.g. De Quervain's) may cause transient hyperthyroidism but is usually associated with tenderness, elevated inflammatory markers, and recent viral illness. Thyroid cancer rarely presents with overt hyperthyroidism and usually manifests as a solitary nodule.\n\n**Key Points**\n- Overt hyperthyroidism: suppressed TSH, elevated free T4\n- Graves' disease: most common cause of primary hyperthyroidism in young adults\n- Anti-thyroid peroxidase antibodies are found in both Graves' and Hashimoto's, but clinical context differs\n- Diffuse, non-tender goitre is typical of Graves' disease\n- Other causes (e.g. multinodular goitre, thyroiditis, malignancy) have distinct clinical features\n\n**Clinical Relevance**\nAccurate diagnosis of the underlying cause of hyperthyroidism is crucial for guiding management, including the choice of antithyroid drugs, radioiodine, or surgery. Recognising Graves' disease on the basis of clinical and biochemical features is essential, as it is the leading cause of hyperthyroidism in young adults. National guidelines recommend referral to endocrinology for all new cases of hyperthyroidism. (References: NICE CKS, BNF)",
    "bullet_explanations": {
      "Graves' disease": "Correct – autoimmune TSH receptor stimulation is the most likely cause given the age, clinical features, and biochemistry.",
      "Toxic multinodular goitre": "Incorrect – more common in older adults, usually presents with nodular rather than diffuse goitre.",
      "Hashimoto's thyroiditis": "Incorrect – typically causes hypothyroidism; hyperthyroid phase is rare and transient.",
      "De Quervain's (subacute) thyroiditis": "Incorrect – usually painful with raised ESR and recent viral infection; hyperthyroidism is transient.",
      "Thyroid carcinoma": "Incorrect – rarely causes hyperthyroidism, typically presents as a solitary, firm, or irregular nodule."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Thyroid",
    "subsubsection": "Hyperthyroidism",
    "topic": "Graves vs toxic nodular goitre",
    "keywords": [
      "Graves' disease",
      "hyperthyroidism",
      "goitre",
      "thyroid antibodies"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hyperthyroidism",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hyperthyroidism/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Hyperthyroidism",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hyperthyroidism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "19f73837-1411-4bcb-a051-1017be8c3e75",
    "question_number": 130,
    "question": "Which retinal condition is most frequently responsible for visual impairment in middle-aged adults, and is commonly associated with findings such as neovascularisation, retinal haemorrhages, and evidence of previous panretinal photocoagulation on fundoscopy?",
    "options": [
      "Diabetic retinopathy",
      "Central retinal vein occlusion",
      "Retinitis pigmentosa",
      "Optic neuritis with optic atrophy",
      "Branch retinal vein occlusion"
    ],
    "correct_answer": "Diabetic retinopathy",
    "explanation": "**Explanation**\n**Diabetic retinopathy** is the leading cause of blindness among adults in the middle-aged population (typically 35–65 years). It develops as a microvascular complication of diabetes mellitus, resulting in progressive retinal damage. Key fundoscopy findings include microaneurysms, dot/blot haemorrhages, hard exudates, neovascularisation, and sometimes signs of previous laser therapy (panretinal photocoagulation). This condition is distinguished from vascular occlusions by its bilateral nature and its strong association with longstanding diabetes. Retinitis pigmentosa, in contrast, presents with bone spicule pigmentation and night blindness, while vein occlusion characteristically presents unilaterally with sudden vision loss and extensive haemorrhages. Optic neuritis typically results in disc pallor but lacks the neovascular or haemorrhagic changes seen in diabetic retinopathy.\n\n**Key Points**\n- Diabetic retinopathy is the most common cause of blindness in adults aged 35–65.\n- Characteristic findings: microaneurysms, haemorrhages, exudates, neovascularisation, and previous laser scars.\n- Risk increases with duration and poor control of diabetes.\n- Fundoscopy may reveal evidence of panretinal photocoagulation (laser scars).\n- Other causes (e.g. central retinal vein occlusion) are less common and usually unilateral.\n\n**Clinical Relevance**\nRecognition of diabetic retinopathy and its complications is essential for timely referral and vision preservation. Annual retinal screening is recommended for all diabetic patients, and prompt identification of sight-threatening changes can prevent irreversible vision loss.",
    "bullet_explanations": {
      "Diabetic retinopathy": "Correct – the most frequent cause of blindness in middle-aged adults, with characteristic retinal changes and history of laser treatment.",
      "Central retinal vein occlusion": "Incorrect – typically causes sudden, unilateral vision loss with widespread haemorrhages, but does not commonly have laser scars or bilateral involvement.",
      "Retinitis pigmentosa": "Incorrect – presents with night blindness and bone spicule pigmentation, not with vascular or laser-related changes.",
      "Optic neuritis with optic atrophy": "Incorrect – leads to disc pallor and visual loss, but lacks the exudative or neovascular features of diabetic retinopathy.",
      "Branch retinal vein occlusion": "Incorrect – presents with sectoral retinal changes and is less common as a cause of bilateral blindness; laser marks may be present but not as in proliferative diabetic retinopathy."
    },
    "category": "Ophthalmology",
    "subsection": "Retinal Disorders",
    "subsubsection": "Diabetic retinopathy",
    "topic": "Diabetic retinopathy",
    "keywords": [
      "diabetic retinopathy",
      "retinal disease",
      "adult blindness",
      "fundoscopy"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "6a4ab3eb-0cee-4a04-b289-1f6f89c3a747",
    "question_number": 131,
    "question": "A 32-year-old woman falls while ice skating and lands on her left hand. She complains of wrist pain and tenderness at the anatomical snuffbox. X-ray reveals a non-displaced fracture of the proximal pole of the scaphoid. Which is the most appropriate initial management?",
    "options": [
      "Surgical fixation of the fracture",
      "Below-elbow cast for 6 weeks",
      "Futuro splint with review in 2 weeks",
      "Immediate analgesia and early mobilisation",
      "Below-elbow cast for 12 weeks"
    ],
    "correct_answer": "Surgical fixation of the fracture",
    "explanation": "**Explanation**\n**Proximal pole scaphoid fractures** present a significant risk of avascular necrosis due to their precarious blood supply, which is largely retrograde and dependent on the dorsal carpal branch of the radial artery. Even if non-displaced, these fractures frequently fail to heal with conservative management and are prone to non-union. **Surgical fixation** is therefore recommended to ensure stability and promote union by providing direct fixation, usually with a headless compression screw. This approach reduces the risk of complications such as non-union and avascular necrosis, which are common if only casting is used for this location of scaphoid injury.<br><br>Conservative treatments (casting or splinting) are reserved for distal or waist fractures of the scaphoid, where the blood supply is more robust and the risk of non-union is much lower. Prolonged immobilisation does not resolve the underlying issue of poor proximal pole vascularity.\n\n**Key Points**\n- Proximal pole scaphoid fractures have limited blood supply and high risk of avascular necrosis.\n- Non-displaced fractures at the proximal pole still require surgical fixation.\n- Casting is suitable for scaphoid waist or distal pole fractures with reliable blood supply.\n- Surgical fixation reduces risk of non-union in proximal pole injuries.\n- Extended casting increases the risk of joint stiffness and muscle wasting without improving union rates for proximal pole fractures.\n\n**Clinical Relevance**\nScaphoid fractures are common in young adults following falls on an outstretched hand. Recognising when surgical intervention is necessary—especially for proximal pole fractures—is crucial for preventing long-term morbidity. Current best practice guidelines recommend prompt surgical fixation for these injuries to optimise outcomes.\n\n**Memory Anchor**\nRemember: 'Proximal pole? Proceed to pin!'—proximal scaphoid fractures require operative fixation.",
    "bullet_explanations": {
      "Surgical fixation of the fracture": "Correct—proximal pole fractures need surgical intervention due to high risk of avascular necrosis.",
      "Below-elbow cast for 6 weeks": "Suitable for non-displaced waist or distal scaphoid fractures, not proximal pole injuries.",
      "Futuro splint with review in 2 weeks": "Insufficient for any scaphoid fracture; used for minor soft tissue injuries, not fractures.",
      "Immediate analgesia and early mobilisation": "Early mobilisation is inappropriate for scaphoid fractures due to risk of non-union.",
      "Below-elbow cast for 12 weeks": "Prolonged casting is ineffective for proximal pole fractures and increases risk of complications."
    },
    "category": "Trauma & Orthopaedics",
    "subsection": "Fractures",
    "subsubsection": "Scaphoid fracture imaging",
    "topic": "Scaphoid fracture imaging",
    "keywords": [
      "scaphoid fracture",
      "proximal pole",
      "surgical fixation",
      "avascular necrosis",
      "wrist injury"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "cfeb9500-9b2e-48f0-afff-c2ab0262793b",
    "question_number": 132,
    "question": "A 45-year-old woman with newly diagnosed pulmonary tuberculosis is started on a standard treatment regimen, including isoniazid, rifampicin, pyrazinamide, and ethambutol. The medical team also prescribes pyridoxine alongside her therapy. What adverse effect of isoniazid is pyridoxine specifically used to prevent?",
    "options": [
      "Peripheral neuropathy",
      "Optic neuritis",
      "Neutropenia",
      "Renal impairment",
      "Hepatotoxicity"
    ],
    "correct_answer": "Peripheral neuropathy",
    "explanation": "**Explanation**\n**Isoniazid**, a key anti-tubercular medication, can cause a dose-dependent peripheral neuropathy due to its interference with pyridoxine (vitamin B6) metabolism. The risk is increased in patients with factors such as diabetes, malnutrition, HIV, or alcoholism. **Co-prescribing pyridoxine prevents deficiency** and reduces the incidence of this sensory neuropathy, which typically presents as numbness, tingling, or burning in the extremities. This adverse effect is distinct from other complications of anti-TB drugs, such as hepatotoxicity or optic neuritis, and is not mitigated by pyridoxine supplementation.\n\n**Key Points**\n- Isoniazid can cause pyridoxine deficiency leading to peripheral neuropathy.\n- Pyridoxine (vitamin B6) is routinely prescribed with isoniazid to reduce this risk.\n- Peripheral neuropathy presents as numbness or paraesthesia in a glove-and-stocking distribution.\n- Other first-line TB drugs have different major toxicities (e.g., ethambutol—optic neuritis, rifampicin—hepatotoxicity).\n- Patients at higher risk: diabetes, malnutrition, HIV, alcoholism.\n\n**Clinical Relevance**\nIn clinical practice, pyridoxine co-prescription is standard in tuberculosis therapy protocols involving isoniazid to ensure patient safety and minimise neurological complications, especially in vulnerable populations.\n\n**Memory Anchor**\nThink: 'INH = Isoniazid Nerve Harm'—prevented by B6 (pyridoxine).",
    "bullet_explanations": {
      "Peripheral neuropathy": "Correct—pyridoxine prevents isoniazid-induced peripheral neuropathy.",
      "Optic neuritis": "Incorrect—this is primarily a complication of ethambutol, not prevented by pyridoxine.",
      "Neutropenia": "Incorrect—neutropenia is not a typical side effect of isoniazid nor prevented by pyridoxine.",
      "Renal impairment": "Incorrect—renal impairment is not a recognised complication of isoniazid or prevented by pyridoxine.",
      "Hepatotoxicity": "Incorrect—while isoniazid may cause hepatotoxicity, pyridoxine does not prevent this."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Community vs hospital-acquired pneumonia",
    "keywords": [
      "isoniazid",
      "pyridoxine",
      "peripheral neuropathy",
      "tuberculosis",
      "adverse effects"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "3f525e98-72f5-4ff0-b5e3-5e7d694bf3cf",
    "question_number": 133,
    "question": "Which contraceptive method is most likely to result in a delayed return to fertility after discontinuation?",
    "options": [
      "Progestogen-only injectable",
      "Levonorgestrel intrauterine system",
      "Combined oral contraceptive pill",
      "Male condoms",
      "Progestogen-only implant"
    ],
    "correct_answer": "Progestogen-only injectable",
    "explanation": "**Explanation**\n**Progestogen-only injectable contraception, such as depot medroxyprogesterone acetate (Depo-Provera), is uniquely associated with a potentially prolonged delay in the return to fertility after stopping use.** While other methods—such as intrauterine systems, oral contraceptives, and implants—allow fertility to return rapidly (typically within a month), the injectable can delay ovulation for up to a year after the last injection in some women. This prolonged effect is due to the depot formulation and the time required for hormone levels to fall sufficiently to resume normal ovarian activity. This makes progestogen-only injectables less suitable for women planning pregnancy soon after cessation.\n\n**Key Points**\n- Progestogen-only injectables may delay return to fertility by up to 12 months.\n- Other methods (IUS, oral contraceptives, implant) typically allow rapid return to fertility.\n- Barrier methods (e.g., condoms) have no effect on fertility return.\n- Depot medroxyprogesterone acetate is the main injectable used in the UK.\n- Important to discuss future fertility plans when choosing contraception.\n\n**Clinical Relevance**\nWhen counselling women about contraception, especially those planning pregnancy in the near future, it is essential to discuss the potential for delayed fertility with progestogen-only injectables. This ensures informed decision-making and aligns with national guidance on patient-centred contraceptive care.\n\n**Memory Anchor**\nRemember: 'Depot delays'—depot injections can delay fertility.",
    "bullet_explanations": {
      "Progestogen-only injectable": "Correct—this method is known for a potential delay in the return to fertility post-discontinuation.",
      "Levonorgestrel intrauterine system": "Incorrect—fertility typically returns quickly after removal.",
      "Combined oral contraceptive pill": "Incorrect—most women regain fertility within a month of stopping.",
      "Male condoms": "Incorrect—no impact on fertility after discontinuation.",
      "Progestogen-only implant": "Incorrect—fertility returns rapidly after removal."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Progesterone-only methods",
    "keywords": [
      "contraception",
      "fertility return",
      "progestogen injectable",
      "depot medroxyprogesterone",
      "Depo-Provera"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Contraception - assessment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/contraception-assessment/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Contraception - progestogen-only methods",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/contraception-progestogen-only-methods/"
      },
      {
        "source": "BNF",
        "topic_title": "Contraceptives, hormonal",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/contraceptives-hormonal/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d89b4e9e-0596-4332-bdbf-37dc534475fe",
    "question_number": 134,
    "question": "A 32-year-old woman with a history of psoriatic arthritis experiences sudden onset of left eye discomfort, redness, photophobia, and blurred vision. Examination reveals a constricted, irregular pupil and visible layering of white cells in the anterior chamber. What is the most likely diagnosis?",
    "options": [
      "Anterior uveitis",
      "Corneal abrasion",
      "Scleritis",
      "Viral conjunctivitis",
      "Posterior uveitis"
    ],
    "correct_answer": "Anterior uveitis",
    "explanation": "**Explanation**\n**Anterior uveitis** is characterised by inflammation of the iris and anterior ciliary body, presenting with acute eye pain, redness, photophobia, blurred vision, and sometimes hypopyon (layering of white cells in the anterior chamber). The pupil may appear constricted and irregular due to adhesions (posterior synechiae). These features, combined with the patient's underlying autoimmune condition (psoriatic arthritis), make anterior uveitis the most probable diagnosis. Scleritis may cause severe eye pain and redness, but does not typically present with hypopyon or an irregular pupil. Posterior uveitis affects the back of the eye and usually presents with floaters and painless visual loss. Corneal abrasion is associated with pain and photophobia, but not with hypopyon or abnormal pupils. Viral conjunctivitis presents with diffuse redness and watery discharge but lacks photophobia, hypopyon, and pupil changes.\n\n**Key Points**\n- Anterior uveitis commonly presents with eye pain, redness, photophobia, and decreased vision.\n- Irregular, constricted pupil is a classic finding due to posterior synechiae.\n- Hypopyon indicates significant anterior chamber inflammation.\n- Autoimmune diseases (e.g., HLA-B27 spondyloarthropathies) are strong risk factors.\n- Posterior uveitis causes floaters and painless vision changes, not acute redness or photophobia.\n- Scleritis and viral conjunctivitis lack hypopyon and pupil irregularity.\n\n**Clinical Relevance**\nRecognising the classic signs of anterior uveitis—especially in patients with autoimmune backgrounds—is critical, as prompt ophthalmology referral and treatment can prevent permanent vision loss. Early intervention with topical steroids and cycloplegics is often required. National guidelines recommend urgent assessment for any suspected uveitis.\n\n**Memory Anchor**\nThink 'anterior' for acute painful red eye with pupil changes and photophobia—especially in HLA-B27 conditions.",
    "bullet_explanations": {
      "Anterior uveitis": "Correct—classic features are acute pain, redness, photophobia, irregular pupil and hypopyon, often linked to autoimmune disease.",
      "Corneal abrasion": "Incorrect—causes pain and photophobia but does not cause hypopyon or pupil irregularity.",
      "Scleritis": "Incorrect—causes deep eye pain and redness, but not hypopyon or irregular pupil; more often associated with rheumatoid arthritis.",
      "Viral conjunctivitis": "Incorrect—causes red, watery eye without hypopyon, photophobia, or pupil changes.",
      "Posterior uveitis": "Incorrect—presents with floaters and blurred vision but not acute pain, redness, or photophobia."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Anterior uveitis",
    "topic": "Anterior uveitis",
    "keywords": [
      "anterior uveitis",
      "red eye",
      "autoimmune",
      "hypopyon",
      "irregular pupil"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Uveitis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/uveitis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "58c010ba-4c1d-4c4e-b476-7f9f5a45c76c",
    "question_number": 135,
    "question": "A 27-year-old woman presents with a tender, red lump at the margin of her left lower eyelid that has developed over 48 hours. She reports mild discomfort but no visual changes or systemic symptoms. On examination, a small, yellowish point is visible at the lid margin. What is the most appropriate first-line management?",
    "options": [
      "Advise regular warm compresses and provide simple analgesia",
      "Refer urgently to ophthalmology",
      "Prescribe oral co-amoxiclav",
      "Apply topical aciclovir cream",
      "Arrange incision and drainage in primary care"
    ],
    "correct_answer": "Advise regular warm compresses and provide simple analgesia",
    "explanation": "**Explanation**\n**Warm compresses and simple analgesia are the cornerstone of initial management for a stye (hordeolum).** This common eyelid infection, often caused by Staphylococcus aureus, is generally self-limiting and rarely requires antibiotics or specialist intervention. Warm compresses help to soften the lesion and promote spontaneous drainage of pus, while analgesia relieves discomfort. Most cases resolve within a week. Referral or invasive procedures are only necessary if there are complications or lack of improvement after conservative treatment. Antibiotics are not routinely indicated unless there is evidence of spreading infection.\n\n**Key Points**\n- Styes (hordeola) are acute infections of eyelid glands, typically staphylococcal.\n- Self-care with warm compresses (10–15 min, 3–4 times/day) promotes drainage.\n- Simple analgesia addresses mild pain or discomfort.\n- Antibiotics and incision are reserved for complications (e.g. cellulitis, abscess).\n- Urgent ophthalmology referral is only required for severe infection or orbital spread.\n\n**Clinical Relevance**\nRecognising and managing styes in primary care prevents unnecessary antibiotic use and referrals. NICE CKS guidelines recommend conservative measures as first-line treatment, emphasising patient reassurance and safety-netting in case of worsening symptoms.",
    "bullet_explanations": {
      "Advise regular warm compresses and provide simple analgesia": "Correct—this is the recommended initial management for an uncomplicated stye.",
      "Refer urgently to ophthalmology": "Incorrect—referral is only indicated if there are complications, such as orbital cellulitis, or lack of response to conservative measures.",
      "Prescribe oral co-amoxiclav": "Incorrect—oral antibiotics are not needed unless there is clear evidence of spreading infection beyond the eyelid.",
      "Apply topical aciclovir cream": "Incorrect—aciclovir is used for herpetic infections, not bacterial styes.",
      "Arrange incision and drainage in primary care": "Incorrect—incision is reserved for persistent lesions or abscesses and should generally be performed by specialists."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Blepharitis",
    "topic": "Blepharitis",
    "keywords": [
      "stye",
      "hordeolum",
      "eyelid infection",
      "warm compress",
      "primary care"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Styes (hordeola)",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/styes-hordeola/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c5c76780-0cd4-41fb-9068-e940a17f8506",
    "question_number": 136,
    "question": "Which class of antibiotics is specifically associated with an increased risk of Achilles tendon rupture, particularly in physically active adults?",
    "options": [
      "Macrolides (e.g. clarithromycin)",
      "Penicillins (e.g. benzylpenicillin)",
      "Fluoroquinolones (e.g. ciprofloxacin)",
      "Tetracyclines (e.g. doxycycline)",
      "Nitrofurantoin"
    ],
    "correct_answer": "Fluoroquinolones (e.g. ciprofloxacin)",
    "explanation": "**Explanation**\n**Fluoroquinolones, such as ciprofloxacin, are well recognised for their potential to cause Achilles tendon disorders, including tendinitis and tendon rupture.** This risk can occur within days of starting the antibiotic and is increased in athletes, older adults, and those taking corticosteroids. The underlying mechanism involves disruption of collagen synthesis and increased matrix metalloproteinases, leading to tendon weakening. Prompt cessation of the fluoroquinolone and appropriate referral are necessary if tendon symptoms develop. Other antibiotic classes do not share this adverse effect profile.\n\n**Key Points**\n- Fluoroquinolones are uniquely associated with tendon pathology.\n- Risk of tendon rupture is higher in older adults, those on corticosteroids, and athletes.\n- Symptoms can present rapidly after starting treatment.\n- Immediate discontinuation is advised if tendinopathy develops.\n- Other antibiotic classes (macrolides, penicillins, tetracyclines, nitrofurantoin) do not cause tendon rupture.\n\n**Clinical Relevance**\nBeing aware of fluoroquinolone-related tendon injury is crucial for safe prescribing, particularly in patients at increased risk or those presenting with new-onset tendon pain. Early recognition and cessation of the offending agent prevents long-term morbidity. National guidelines, such as NICE CKS, highlight the importance of identifying and managing this adverse drug reaction.\n\n**Memory Anchor**\nThink 'F for Fluoroquinolone, F for Fibre (tendon fibre) Failure'.",
    "bullet_explanations": {
      "Macrolides (e.g. clarithromycin)": "Incorrect—macrolides are not associated with tendon rupture; main risks include GI upset and QT prolongation.",
      "Penicillins (e.g. benzylpenicillin)": "Incorrect—penicillins have no recognised link to tendon disorders.",
      "Fluoroquinolones (e.g. ciprofloxacin)": "Correct—this antibiotic class is strongly linked to Achilles tendon rupture.",
      "Tetracyclines (e.g. doxycycline)": "Incorrect—tetracyclines may cause photosensitivity but not tendonopathy.",
      "Nitrofurantoin": "Incorrect—used for UTIs, nitrofurantoin can cause pulmonary and neurological side effects but not tendon rupture."
    },
    "category": "Musculoskeletal",
    "subsection": "Soft Tissue Injuries",
    "subsubsection": "Tendon rupture management",
    "topic": "Tendon rupture management",
    "keywords": [
      "fluoroquinolone",
      "Achilles tendon rupture",
      "antibiotic adverse effects"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Achilles tendinopathy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/achilles-tendinopathy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fe49dee0-1dac-455e-99c1-9ea29c3ba030",
    "question_number": 137,
    "question": "A 26-year-old man presents to his GP with three days of mild throat discomfort and a dry cough. He feels generally well, has no fever, and is eating and drinking normally. Examination reveals a mildly erythematous pharynx without exudate, and non-tender cervical lymphadenopathy. What is the most appropriate next step in his management?",
    "options": [
      "Advise rest, fluids, and simple analgesia",
      "Prescribe a 5-day course of phenoxymethylpenicillin",
      "Arrange a throat swab for microbiological analysis",
      "Initiate a short course of oral corticosteroids",
      "Prescribe a salbutamol inhaler for symptomatic relief"
    ],
    "correct_answer": "Advise rest, fluids, and simple analgesia",
    "explanation": "**Explanation**\nThe most appropriate management is to provide supportive advice—**rest, maintain hydration, and use simple analgesia such as paracetamol or ibuprofen**. This presentation is typical of a mild, likely viral, sore throat without features suggesting a severe bacterial infection. Guidelines recommend using clinical prediction scores (such as Centor or FeverPAIN) to assess the need for antibiotics. This patient has no fever, no tonsillar exudate, non-tender lymph nodes, and a cough, all of which point away from streptococcal infection. **Antibiotics are not indicated** in such low-risk cases, and most sore throats resolve spontaneously within a week. There is no role for routine throat swabs or inhalers in this context, and corticosteroids are not recommended for uncomplicated sore throat.\n\n**Key Points**\n- Most sore throats are viral and self-limiting.\n- Antibiotics should be reserved for those with higher clinical scores or severe/systemic illness.\n- Simple analgesia and maintaining hydration are first-line.\n- Centor or FeverPAIN criteria help guide management.\n- Routine throat swabs are not advised for uncomplicated sore throat.\n- Oral corticosteroids and inhalers are not indicated in mild, uncomplicated cases.\n\n**Clinical Relevance**\nFollowing NICE and BNF guidance reduces unnecessary antibiotic use and supports antimicrobial stewardship. Recognising uncomplicated viral sore throat prevents over-treatment and helps set appropriate patient expectations.",
    "bullet_explanations": {
      "Advise rest, fluids, and simple analgesia": "Correct—supportive management is sufficient for mild, likely viral sore throat.",
      "Prescribe a 5-day course of phenoxymethylpenicillin": "Incorrect—antibiotics are not indicated without features suggesting streptococcal infection or high clinical score.",
      "Arrange a throat swab for microbiological analysis": "Incorrect—routine throat swabs are not recommended for typical acute sore throat.",
      "Initiate a short course of oral corticosteroids": "Incorrect—corticosteroids are not appropriate for uncomplicated sore throat.",
      "Prescribe a salbutamol inhaler for symptomatic relief": "Incorrect—there is no evidence for inhalers in managing a simple sore throat."
    },
    "category": "Respiratory",
    "subsection": "Infective",
    "subsubsection": "Community-Acquired Pneumonia",
    "topic": "Typical vs atypical pathogens",
    "keywords": [
      "sore throat",
      "antibiotics",
      "Centor",
      "self-limiting",
      "supportive care"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Oropharyngeal infections, antibacterial therapy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/oropharyngeal-infections-antibacterial-therapy/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Sore throat - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/sore-throat-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c6feb30e-2ebe-4ede-abac-176a3b30c223",
    "question_number": 138,
    "question": "Which medication should be co-prescribed to prevent peripheral neuropathy in patients receiving isoniazid for active tuberculosis?",
    "options": [
      "Pyridoxine",
      "Metoclopramide",
      "Azithromycin",
      "Hydrocortisone",
      "Clarithromycin"
    ],
    "correct_answer": "Pyridoxine",
    "explanation": "**Explanation**\n**Pyridoxine (vitamin B6) is routinely given with isoniazid to prevent peripheral neuropathy.** Isoniazid increases the excretion of vitamin B6, leading to a deficiency that can manifest as numbness, tingling, and other neuropathic symptoms. Prophylactic pyridoxine supplementation significantly reduces this risk, particularly in individuals with additional risk factors such as diabetes, malnutrition, alcoholism, or pregnancy. The other listed drugs do not prevent this side effect and are not indicated for this purpose.\n\n**Key Points**\n- Isoniazid can cause vitamin B6 deficiency, leading to peripheral neuropathy.\n- Pyridoxine supplementation prevents this complication.\n- Peripheral neuropathy risk is higher in certain populations (e.g. malnutrition, pregnancy).\n- Other anti-tuberculous agents (e.g. rifampicin, ethambutol, pyrazinamide) do not prevent neuropathy.\n- Routine co-prescription of pyridoxine with isoniazid is standard in TB therapy.\n\n**Clinical Relevance**\nPeripheral neuropathy is a well-recognised and preventable complication of isoniazid therapy in tuberculosis. National and international guidelines recommend pyridoxine supplementation to minimise this risk, improving treatment tolerability and adherence.\n\n**Memory Anchor**\nThink 'Isoniazid = Isoni-a-zid(e) B6', as B6 (pyridoxine) must always ride alongside.",
    "bullet_explanations": {
      "Pyridoxine": "Correct – Prevents isoniazid-induced peripheral neuropathy by replenishing vitamin B6.",
      "Metoclopramide": "Incorrect – Used for nausea; does not prevent neuropathy.",
      "Azithromycin": "Incorrect – An antibiotic for respiratory infections; not indicated for TB neuropathy prevention.",
      "Hydrocortisone": "Incorrect – Steroid used in certain TB complications (e.g. meningeal TB), not for neuropathy.",
      "Clarithromycin": "Incorrect – An antibiotic sometimes used in atypical mycobacterial infections, not for neuropathy prevention."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Community vs hospital-acquired pneumonia",
    "keywords": [
      "isoniazid",
      "peripheral neuropathy",
      "pyridoxine",
      "tuberculosis",
      "vitamin B6"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "15977898-ae3f-4bb1-ac5c-ba68c0d89369",
    "question_number": 139,
    "question": "A 28-year-old semi-professional cyclist collapses during a race. He recovers consciousness within a minute and reports no prior warning symptoms. On examination, his cardiovascular findings are normal. His resting ECG reveals sinus rhythm with T wave inversion in leads V1 to V3. Which diagnosis best explains his presentation and ECG findings?",
    "options": [
      "Arrhythmogenic right ventricular cardiomyopathy",
      "Hypertrophic cardiomyopathy",
      "Brugada syndrome",
      "Pulmonary embolism",
      "Physiological athletic heart changes"
    ],
    "correct_answer": "Arrhythmogenic right ventricular cardiomyopathy",
    "explanation": "**Explanation**\n**Arrhythmogenic right ventricular cardiomyopathy (ARVC)** is an inherited disorder marked by progressive fibrofatty replacement of the right ventricular myocardium, which predisposes to ventricular arrhythmias and sudden cardiac events, especially during exertion. **T wave inversion in V1–V3 in patients older than 14 years without right bundle branch block is a major diagnostic criterion** for ARVC. The typical scenario is a young athlete experiencing syncope or collapse during exercise. Although ECG findings such as epsilon waves are more specific, T wave inversion in these leads is often the earliest clue. This presentation should prompt urgent cardiac imaging and consideration of genetic testing. ARVC is distinct from other causes of exertional syncope by its characteristic ECG pattern and association with arrhythmic risk.\n\n**Key Points**\n- ARVC is a key cause of sudden cardiac death in young athletes.\n- ECG: T wave inversion in V1–V3 (without RBBB) is a major diagnostic feature.\n- Syncope during exertion is a classic presentation.\n- Fibrofatty infiltration of the right ventricle predisposes to arrhythmias.\n- Diagnosis often requires cardiac MRI and genetic testing.\n\n**Clinical Relevance**\nRecognising ARVC in young patients with exertional syncope and specific ECG changes is crucial for preventing sudden cardiac death. Early identification enables appropriate restriction from competitive sports and implementation of preventive strategies, as per current cardiology guidelines.\n\n**Memory Anchor**\nARVC = Arrhythmia Risk in the Right Ventricle with Characteristic T wave Changes",
    "bullet_explanations": {
      "Arrhythmogenic right ventricular cardiomyopathy": "Correct – Classic scenario: young athlete, exertional syncope, T wave inversion V1–V3.",
      "Hypertrophic cardiomyopathy": "Incorrect – HCM often causes sudden death in athletes but usually shows deep, widespread T wave inversion and signs of LVH; right precordial T inversion is less typical.",
      "Brugada syndrome": "Incorrect – Brugada presents with coved ST elevation in V1–V3, not isolated T wave inversion.",
      "Pulmonary embolism": "Incorrect – PE may cause syncope and ECG changes (e.g., S1Q3T3, tachycardia), but isolated T inversion in V1–V3 is not typical.",
      "Physiological athletic heart changes": "Incorrect – Athletic heart may show sinus bradycardia or mild voltage criteria for LVH, but not isolated pathological T wave inversion in V1–V3."
    },
    "category": "Cardiovascular",
    "subsection": "Heart Failure",
    "subsubsection": "Cardiomyopathies",
    "topic": "Arrhythmogenic right ventricular cardiomyopathy recognition",
    "keywords": [
      "ARVC",
      "syncope",
      "athlete",
      "ECG",
      "T wave inversion"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "5f5f4db7-0137-4359-8f27-4d76461d27b6",
    "question_number": 140,
    "question": "A 14-year-old girl who recently arrived from Nigeria presents to a GP clinic for a routine health check. She has not previously received the BCG vaccine. What is the most appropriate action before considering BCG vaccination in this patient?",
    "options": [
      "Arrange a tuberculin (Mantoux) skin test",
      "Offer immediate BCG vaccination without further tests",
      "Order a chest X-ray to screen for active tuberculosis",
      "Prescribe prophylactic isoniazid for six months",
      "Reassure that no intervention is necessary"
    ],
    "correct_answer": "Arrange a tuberculin (Mantoux) skin test",
    "explanation": "**Explanation**\n**Children aged 6 years or older who are new entrants from countries with high tuberculosis (TB) incidence (≥40 cases per 100,000 per year) must have a tuberculin (Mantoux) skin test prior to BCG vaccination.** This is to exclude previous TB exposure or latent infection. Vaccinating individuals with a positive tuberculin test offers no benefit and increases the risk of local adverse reactions. Only those who are tuberculin-negative should proceed to vaccination. If the Mantoux test is positive (≥5 mm induration), the child should be referred to a TB clinic for further assessment rather than receiving BCG.\n\n**Key Points**\n- BCG is indicated for unvaccinated, tuberculin-negative children under 16 from high TB prevalence regions.\n- A tuberculin skin test is **mandatory in children 6 years and older** before BCG administration.\n- BCG should not be given to anyone with a positive Mantoux test due to risk of severe reaction.\n- A positive tuberculin result warrants referral for possible latent or active TB investigation.\n- BCG vaccination is not a substitute for TB treatment or prophylaxis.\n\n**Clinical Relevance**\nAccurately determining tuberculin status in children from high-incidence regions before BCG vaccination is a cornerstone of UK TB prevention policy. This approach prevents inappropriate vaccination and ensures timely identification of latent or active TB, as per national and BNF guidance.\n\n**Memory Anchor**\nRemember: 'Test before you protect' — Mantoux first if over 6 years from high-risk country.",
    "bullet_explanations": {
      "Arrange a tuberculin (Mantoux) skin test": "Correct—this is required in children aged 6 or older before BCG vaccination.",
      "Offer immediate BCG vaccination without further tests": "Incorrect—risk of vaccinating someone with latent TB; Mantoux test is essential first.",
      "Order a chest X-ray to screen for active tuberculosis": "Incorrect—not indicated as the first step in an asymptomatic patient for BCG eligibility.",
      "Prescribe prophylactic isoniazid for six months": "Incorrect—chemoprophylaxis is not indicated without evidence of latent or active TB.",
      "Reassure that no intervention is necessary": "Incorrect—BCG is recommended for this group, but only after negative Mantoux testing."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Community vs hospital-acquired pneumonia",
    "keywords": [
      "BCG vaccine",
      "Mantoux test",
      "tuberculosis screening",
      "child immigrant",
      "vaccination protocol"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Bacillus Calmette-GuÃ©rin vaccine",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/bacillus-calmette-guerin-vaccine/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0dea3898-c863-4177-9e33-670c37ee8cdd",
    "question_number": 141,
    "question": "A 54-year-old woman is investigated for increasing fatigue, generalised itching, and progressive jaundice. Liver function tests reveal a raised alkaline phosphatase and ALT. Serology is positive for anti-mitochondrial antibodies. What is the most likely diagnosis?",
    "options": [
      "Primary biliary cholangitis",
      "Autoimmune hepatitis",
      "Acute hepatitis B infection",
      "Drug-induced cholestasis",
      "Gallstone obstruction"
    ],
    "correct_answer": "Primary biliary cholangitis",
    "explanation": "**Explanation**\n**Primary biliary cholangitis (PBC) is characterised by cholestatic liver enzyme derangement (notably raised ALP), progressive pruritus, and the presence of anti-mitochondrial antibodies (AMAs) in the majority of cases.** PBC primarily affects middle-aged women and presents insidiously with fatigue and itching, often followed by jaundice. The presence of AMAs is highly specific for PBC and distinguishes it from other causes of cholestatic and hepatitic liver injury. Other diagnoses such as gallstone disease or drug-induced cholestasis may present with similar biochemistry but lack the serological hallmark of AMAs.\n\n**Key Points**\n- PBC typically affects women aged 40–60.\n- Pruritus is a classic early symptom, often preceding jaundice.\n- Liver biochemistry shows raised ALP and variable transaminase elevation.\n- Anti-mitochondrial antibodies (AMAs) are present in >90% of PBC cases.\n- Autoimmune hepatitis is associated with ANA and SMA, not AMAs.\n- Gallstone obstruction rarely causes positive AMA.\n- Treatment with ursodeoxycholic acid is first line.\n- <table><thead><tr><th>Feature</th><th>PBC</th><th>Autoimmune Hepatitis</th><th>Gallstones</th></tr></thead><tbody><tr><td>Gender</td><td>Female</td><td>Female</td><td>Any</td></tr><tr><td>Key Antibody</td><td>AMA</td><td>ANA/SMA</td><td>None</td></tr><tr><td>ALP</td><td>High</td><td>Normal or mild ↑</td><td>High</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising primary biliary cholangitis is crucial for early intervention and management, reducing the risk of progression to cirrhosis. The presence of anti-mitochondrial antibodies is a diagnostic hallmark, guiding appropriate therapy such as ursodeoxycholic acid. (See BNF guidance).\n\n**Memory Anchor**\n\"M for M\": Middle-aged women, anti-Mitochondrial antibodies, and chronic itch (pruritus).",
    "bullet_explanations": {
      "Primary biliary cholangitis": "Correct – Strongly associated with AMAs and cholestatic enzyme elevation.",
      "Autoimmune hepatitis": "Incorrect – Typically presents with ANA/SMA positivity, not AMAs, and more pronounced ALT elevation.",
      "Acute hepatitis B infection": "Incorrect – Presents with marked transaminase rise and positive hepatitis B serology, not AMAs.",
      "Drug-induced cholestasis": "Incorrect – Can cause cholestatic LFTs but is not associated with AMA positivity.",
      "Gallstone obstruction": "Incorrect – Causes cholestasis and jaundice but does not lead to positive anti-mitochondrial antibodies."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Hepatology",
    "subsubsection": "Cholestatic Disease",
    "topic": "PSC/PBC recognition",
    "keywords": [
      "primary biliary cholangitis",
      "anti-mitochondrial antibody",
      "cholestatic liver disease"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Primary biliary cholangitis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/primary-biliary-cholangitis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2768a404-e22d-4b54-96f5-ed8af7478d66",
    "question_number": 142,
    "question": "A 61-year-old woman attends her GP because of a persistent, non-healing ulcer on the lateral border of her tongue. She first noticed the lesion about a month ago, and it has not resolved despite avoiding potential irritants and using topical analgesics. She has no significant medical history, does not smoke, and drinks alcohol occasionally. What is the most appropriate next step in her management?",
    "options": [
      "Urgent referral to oral and maxillofacial surgery for specialist assessment",
      "Prescribe topical corticosteroid and review in 2 weeks",
      "Advise use of chlorhexidine mouthwash and monitor for improvement",
      "Refer routinely to a dentist for further evaluation",
      "Arrange blood tests to check for vitamin deficiencies before referral"
    ],
    "correct_answer": "Urgent referral to oral and maxillofacial surgery for specialist assessment",
    "explanation": "**Explanation**\nAn **oral ulcer persisting for more than 3 weeks** with no obvious benign cause should prompt an **urgent referral** to an oral and maxillofacial specialist for assessment and possible biopsy. This is crucial to exclude **oral malignancy**, particularly squamous cell carcinoma, which can present insidiously as a chronic, painless or intermittently painful ulcer. While minor aphthous ulcers are common and often self-limiting, any unexplained persistent ulcer—especially in older adults—warrants prompt investigation. **Early identification of oral cancer significantly improves prognosis.** Topical treatments and blood tests can be considered for benign, short-duration ulcers but are not appropriate for lesions of this duration.\n\n**Key Points**\n<ul><li>Any unexplained oral ulceration lasting more than 3 weeks requires urgent specialist referral.</li><li>Oral cancer may present as a painless, non-healing ulcer, especially in older adults.</li><li>Delaying referral to trial topical or symptomatic therapy is not recommended in persistent cases.</li><li>First-line management for short-duration, recurrent aphthous ulcers is topical corticosteroids.</li><li>Routine dental or blood investigations should not delay referral in suspicious cases.</li></ul><table><thead><tr><th>Ulcer duration</th><th>Management</th></tr></thead><tbody><tr><td>&lt;3 weeks, typical history</td><td>Symptomatic treatment</td></tr><tr><td>&gt;3 weeks, unexplained</td><td>Urgent specialist referral</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition and referral of persistent oral ulcers aligns with national guidance to ensure early detection of oral cancers. Generalists play a key role in identifying red flags and facilitating timely specialist input, reducing diagnostic delays and improving outcomes.\n\n**Memory Anchor**\nRemember: '3 weeks = refer' for unexplained oral ulcers.",
    "bullet_explanations": {
      "Urgent referral to oral and maxillofacial surgery for specialist assessment": "Correct – any unexplained oral ulcer persisting beyond 3 weeks must be referred urgently to rule out malignancy.",
      "Prescribe topical corticosteroid and review in 2 weeks": "Incorrect – topical steroids are for typical, short-lived aphthous ulcers; this approach risks delaying cancer diagnosis.",
      "Advise use of chlorhexidine mouthwash and monitor for improvement": "Incorrect – suitable for mild, self-limiting ulcers, not persistent unexplained lesions.",
      "Refer routinely to a dentist for further evaluation": "Incorrect – routine dental referral is inappropriate for possible malignancy; urgent specialist input is needed.",
      "Arrange blood tests to check for vitamin deficiencies before referral": "Incorrect – bloods can be useful for systemic causes, but should not delay urgent referral for a potential cancer."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Throat",
    "topic": "ENT red flags",
    "keywords": [
      "oral ulcer",
      "urgent referral",
      "oral cancer",
      "persistent mouth ulcer",
      "ENT red flag"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Aphthous ulcer",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/aphthous-ulcer/"
      },
      {
        "source": "BNF",
        "topic_title": "Oral ulceration and inflammation",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/oral-ulceration-and-inflammation/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f03f9a6d-2097-4b0c-b627-a19fc37901ab",
    "question_number": 143,
    "question": "A 62-year-old man develops persistent watery diarrhoea with pale, floating stools three months after ileal resection for Crohn’s disease. Which therapy is most appropriate for managing his ongoing symptoms?",
    "options": [
      "Cholestyramine",
      "Loperamide",
      "Creon (pancreatic enzyme replacement)",
      "Bismuth subsalicylate",
      "Oral rehydration solution"
    ],
    "correct_answer": "Cholestyramine",
    "explanation": "**Explanation**\n**Cholestyramine** is a bile acid sequestrant that binds bile acids in the intestinal lumen, thereby preventing their cathartic effect in the colon. After ileal resection or cholecystectomy, excess bile acids can escape reabsorption and reach the colon, where they cause secretory diarrhoea and steatorrhoea. By trapping these bile acids, cholestyramine addresses the underlying pathophysiology, not just symptom relief. This distinguishes it from agents that only slow transit or replace unrelated enzymes.\n\n**Key Points**\n- Bile acid malabsorption is common after cholecystectomy or ileal resection.\n- Excess bile acids in the colon increase water and electrolyte secretion, causing diarrhoea.\n- Cholestyramine binds bile acids, reducing their irritant effect.\n- Symptomatic improvement often occurs within days of starting treatment.\n- Other antidiarrhoeal agents do not address the underlying bile acid-driven mechanism.\n\n**Clinical Relevance**\nRecognising bile acid diarrhoea is essential in patients with chronic diarrhoea post-cholecystectomy or ileal resection. Treating the underlying mechanism with a bile acid sequestrant is recommended in current UK guidance for persistent symptoms.\n\n**Memory Anchor**\nRemember: 'Chole' for cholestyramine and cholecystectomy—both relate to bile.",
    "bullet_explanations": {
      "Cholestyramine": "Correct – directly targets bile acid-induced diarrhoea by binding bile acids in the gut.",
      "Loperamide": "Incorrect – reduces stool frequency by slowing transit but does not address bile acid excess.",
      "Creon (pancreatic enzyme replacement)": "Incorrect – indicated for pancreatic insufficiency, not bile acid diarrhoea.",
      "Bismuth subsalicylate": "Incorrect – used for acute infectious diarrhoea, not chronic bile acid malabsorption.",
      "Oral rehydration solution": "Incorrect – replaces lost fluids, suitable for acute diarrhoea, not long-term management."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Biliary & Pancreas",
    "subsubsection": "Gallstone Disease",
    "topic": "Gallstone pancreatitis basics",
    "keywords": [
      "bile acid diarrhoea",
      "cholestyramine",
      "cholecystectomy",
      "chronic diarrhoea",
      "malabsorption"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "be6e6aa0-80b0-46e8-9db4-c0c04e6d4762",
    "question_number": 144,
    "question": "A 6-month-old boy is found to have a rapidly enlarging, bright red, raised lesion on his upper eyelid, partially covering his right pupil. The lesion was not present at birth but has grown significantly over the past 2 months. Which medication is currently considered first-line for treating this lesion when intervention is indicated?",
    "options": [
      "Oral propranolol",
      "Pulsed dye laser therapy",
      "Surgical removal",
      "Topical timolol",
      "Intralesional corticosteroid injection"
    ],
    "correct_answer": "Oral propranolol",
    "explanation": "**Explanation**\n**Oral propranolol is now the first-line treatment for problematic infantile haemangiomas**, particularly when the lesion threatens vision, airway, or causes significant cosmetic or functional impairment. Its use has largely replaced corticosteroids due to higher efficacy and a more favourable side effect profile. Propranolol acts by inducing vasoconstriction, inhibiting angiogenic growth factors, and promoting apoptosis in endothelial cells. Rapid improvement is often observed within days to weeks. In contrast, other modalities like corticosteroids and laser are reserved for select cases or used adjunctively.\n\n**Key Points**\n- Infantile haemangiomas often appear after birth and grow rapidly in the first months.\n- Indications for treatment include risk to vision, airway, or important function.\n- Propranolol is effective, with a rapid onset of action and generally good safety in infants.\n- Steroids, previously first-line, are now secondary due to inferior outcomes.\n- Laser and surgery are not first-line for large, deep, or periocular haemangiomas.\n\n**Clinical Relevance**\nRecognising when and how to intervene in infantile haemangiomas is crucial, especially for lesions threatening visual development. Current guidelines and paediatric practice endorse oral propranolol as the standard of care for significant lesions, reflecting its superior efficacy and safety. Early referral and treatment can prevent long-term morbidity.\n\n**Memory Anchor**\nRemember: **'P' for Propranolol, 'P' for Problematic haemangiomas**—the modern first-line therapy.",
    "bullet_explanations": {
      "Oral propranolol": "Correct: First-line for problematic infantile haemangiomas due to efficacy and safety.",
      "Pulsed dye laser therapy": "Incorrect: Used for superficial or residual lesions, not first-line for deep or obstructive haemangiomas.",
      "Surgical removal": "Incorrect: Reserved for refractory cases or complications; not initial therapy.",
      "Topical timolol": "Incorrect: Sometimes used for small, superficial haemangiomas, but not appropriate for large or vision-threatening lesions.",
      "Intralesional corticosteroid injection": "Incorrect: Previously used but now largely superseded by propranolol due to less effectiveness and more risks."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Common Infections",
    "topic": "Other vascular anomalies",
    "keywords": [
      "infantile haemangioma",
      "propranolol",
      "paediatric dermatology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Beta-adrenoceptor blocking drugs",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/beta-adrenoceptor-blocking-drugs/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f8d55c09-dbe2-47c7-8a49-e1daf64e2e27",
    "question_number": 145,
    "question": "In relation to trinucleotide repeat disorders such as myotonic dystrophy, what best describes the genetic phenomenon known as 'anticipation'?",
    "options": [
      "Symptoms begin at a younger age in each successive generation",
      "The condition becomes milder with each generation",
      "Family members frequently misattribute unrelated symptoms to the disorder",
      "Psychological distress in carriers due to knowledge of genetic risk",
      "Routine screening of relatives to optimise early intervention"
    ],
    "correct_answer": "Symptoms begin at a younger age in each successive generation",
    "explanation": "**Explanation**\n**Anticipation** refers to the pattern seen in certain genetic disorders, particularly those caused by trinucleotide repeat expansions (such as myotonic dystrophy and Huntington’s disease), where **the disorder manifests at an earlier age and/or with increased severity in each successive generation**. This typically results from further expansion of the unstable repeat sequence when passed from parent to child. In Huntington’s disease, for example, expansion of CAG repeats in the HTT gene increases the risk of earlier onset of symptoms in affected offspring. Anticipation is not about psychological effects or screening, nor does it mean the disease becomes less severe.\n\n**Key Points**\n- Anticipation = earlier onset and/or increased severity in following generations\n- Most commonly seen in trinucleotide repeat disorders (e.g., Huntington’s, myotonic dystrophy)\n- Caused by further expansion of DNA repeat sequences during transmission\n- Distinct from psychological impact or routine screening protocols\n- Does not mean the disease becomes milder in families\n\n**Clinical Relevance**\nRecognising anticipation is crucial during genetic counselling for families affected by disorders such as Huntington’s disease or myotonic dystrophy, as it affects prognosis, family planning, and psychological support needs.\n\n**Memory Anchor**\nRemember: 'Anticipation' = 'Accelerated Age of Appearance' in affected families.",
    "bullet_explanations": {
      "Symptoms begin at a younger age in each successive generation": "Correct—this is the definition of anticipation in genetic conditions with repeat expansions.",
      "The condition becomes milder with each generation": "Incorrect—anticipation refers to earlier or more severe disease, not milder.",
      "Family members frequently misattribute unrelated symptoms to the disorder": "Incorrect—this describes illness attribution, not anticipation.",
      "Psychological distress in carriers due to knowledge of genetic risk": "Incorrect—this refers to the emotional impact, not genetic anticipation.",
      "Routine screening of relatives to optimise early intervention": "Incorrect—screening is good practice but not the definition of anticipation."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Genetics",
    "subsubsection": "Basic Principles",
    "topic": "Penetrance and expressivity",
    "keywords": [
      "anticipation",
      "trinucleotide repeat",
      "genetic counselling",
      "Huntington",
      "myotonic dystrophy"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "5da68f23-c3bd-4cce-8933-d8ad98d68869",
    "question_number": 146,
    "question": "A 4-year-old boy is brought to a community pharmacy by his father, who reports that the child has been complaining of intense itching around his anus at night. The father has also noticed small, white, thread-like worms in his son's stool. What is the most appropriate management for this child and his household?",
    "options": [
      "Advise hygiene measures only for the child and household",
      "Prescribe a single dose of mebendazole for the child and all household members, with hygiene advice",
      "Prescribe topical clotrimazole and recommend good hand hygiene",
      "Prescribe oral miconazole for two weeks for the whole family",
      "Treat only symptomatic individuals with mebendazole, no further action"
    ],
    "correct_answer": "Prescribe a single dose of mebendazole for the child and all household members, with hygiene advice",
    "explanation": "**Explanation**\n**Threadworm (Enterobius vermicularis) is a common parasitic infection in children, classically causing nocturnal perianal pruritus and visible white worms in the stool.** Transmission occurs easily through the faecal-oral route, making household spread highly likely. **Mebendazole is the first-line treatment for threadworm infection in children over 6 months and adults.** Due to the high rate of asymptomatic carriage and reinfection among close contacts, all household members should be treated simultaneously, regardless of symptoms. **Equally important is strict hygiene advice** (frequent handwashing, short nails, daily morning baths, and washing bedding/clothes) to break the transmission cycle and prevent recurrence.\n\n**Key Points**\n- Threadworm is the most common helminthic infection in UK children.\n- Typical presentation includes night-time perianal itching and visible worms.\n- Mebendazole (single dose) is recommended for all household contacts >6 months old.\n- Effective management requires both pharmacological and hygiene interventions.\n- Reinfection is common without comprehensive household treatment.\n- <table><thead><tr><th>Measure</th><th>Recommended?</th></tr></thead><tbody><tr><td>Mebendazole (all household)</td><td>Yes</td></tr><tr><td>Topical antifungals</td><td>No</td></tr><tr><td>Hygiene advice</td><td>Essential</td></tr></tbody></table>\n\n**Clinical Relevance**\nThreadworm infestations are frequently encountered in UK paediatric practice. NICE CKS and the BNF both emphasise the need to treat all household contacts and reinforce hygiene to prevent re-infection. Missing household treatment leads to persistent cycles of infection, affecting child wellbeing and family dynamics.\n\n**Memory Anchor**\nThreadworm: Treat the Team (all household) with mebendazole & hygiene.",
    "bullet_explanations": {
      "Advise hygiene measures only for the child and household": "Incorrect: Hygiene advice alone is insufficient for children over 6 months; pharmacological treatment is necessary.",
      "Prescribe a single dose of mebendazole for the child and all household members, with hygiene advice": "Correct: This is the recommended approach per NICE and BNF.",
      "Prescribe topical clotrimazole and recommend good hand hygiene": "Incorrect: Clotrimazole is an antifungal and not effective against threadworm.",
      "Prescribe oral miconazole for two weeks for the whole family": "Incorrect: Miconazole is an antifungal, not an anti-helminthic agent.",
      "Treat only symptomatic individuals with mebendazole, no further action": "Incorrect: Asymptomatic household members commonly harbour infection; all should be treated."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Common Infections",
    "topic": "UTI in infants",
    "keywords": [
      "threadworm",
      "mebendazole",
      "household treatment",
      "paediatric parasites",
      "hygiene advice"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Threadworm",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/threadworm/"
      },
      {
        "source": "BNF",
        "topic_title": "Helminth infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/helminth-infections/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "37eec16d-d837-4c20-b26e-a5e48b611dde",
    "question_number": 147,
    "question": "A 35-year-old woman has experienced recurrent episodes of abdominal pain with frequent, loose stools for over a month. She also reports unintended weight loss and intermittent rectal bleeding. Which condition is the most likely cause of her chronic diarrhoea?",
    "options": [
      "Irritable bowel syndrome",
      "Coeliac disease",
      "Ulcerative colitis",
      "Gastroenteritis",
      "Laxative misuse"
    ],
    "correct_answer": "Ulcerative colitis",
    "explanation": "**Explanation**\n**Ulcerative colitis**, a form of inflammatory bowel disease, is characterised by chronic relapsing inflammation of the colon and rectum. Key features include prolonged diarrhoea, often with blood and mucus, abdominal discomfort, and systemic symptoms like weight loss. The presence of rectal bleeding and weight loss distinguishes it from functional disorders such as irritable bowel syndrome. Unlike acute gastroenteritis, symptoms persist beyond two weeks. Coeliac disease may cause chronic diarrhoea and weight loss, but rectal bleeding is not typical. Laxative misuse usually lacks associated systemic features. IBS rarely causes nocturnal symptoms, weight loss, or bleeding.\n\n**Key Points**\n- Ulcerative colitis presents with persistent diarrhoea, rectal bleeding, and weight loss.\n- Distinguish from IBS by presence of 'red flag' symptoms (blood, weight loss).\n- Chronic diarrhoea (lasting >4 weeks) warrants investigation for IBD and malignancy.\n- Coeliac disease causes malabsorption but not rectal bleeding.\n- Acute diarrhoea (<14 days) is more likely infectious.\n\n**Clinical Relevance**\nRecognising the hallmark signs of ulcerative colitis is crucial for early referral and investigation, as per NICE guidance. Persistent diarrhoea with systemic features should prompt consideration of inflammatory or malignant pathology, ensuring timely diagnosis and management.",
    "bullet_explanations": {
      "Irritable bowel syndrome": "Incorrect – IBS causes chronic diarrhoea but not rectal bleeding or weight loss.",
      "Coeliac disease": "Incorrect – Coeliac disease may cause chronic diarrhoea and weight loss, but rectal bleeding is not a typical feature.",
      "Ulcerative colitis": "Correct – Ulcerative colitis matches the combination of chronic diarrhoea, bleeding, and weight loss.",
      "Gastroenteritis": "Incorrect – Gastroenteritis is acutely self-limiting and usually lasts less than two weeks.",
      "Laxative misuse": "Incorrect – Laxative misuse can cause diarrhoea, but usually lacks systemic symptoms and rectal bleeding."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBD",
    "topic": "UC vs Crohn’s key differences",
    "keywords": [
      "ulcerative colitis",
      "chronic diarrhoea",
      "rectal bleeding",
      "IBD",
      "red flags"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diarrhoea - adult's assessment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/diarrhoea-adults-assessment/"
      },
      {
        "source": "BNF",
        "topic_title": "Diarrhoea (acute)",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diarrhoea-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1eda8afc-c318-476b-9b2e-6c19fe12d1fb",
    "question_number": 148,
    "question": "A 66-year-old woman in a care home develops fever and suprapubic discomfort. She has an indwelling urinary catheter, changed every four weeks, and it was last changed nine days ago. Her urine is noted to be cloudy and malodorous. You prescribe a 7-day course of trimethoprim and provide safety netting advice. What is the most important next step in her management?",
    "options": [
      "Remove or replace the urinary catheter promptly",
      "Advise the patient to increase daily fluid intake to 2.5 litres",
      "Arrange a routine urology referral for cystoscopy",
      "Prescribe a prophylactic course of cranberry extract",
      "Request a bladder irrigation by nursing staff"
    ],
    "correct_answer": "Remove or replace the urinary catheter promptly",
    "explanation": "**Explanation**\nFor catheter-associated urinary tract infections (CAUTIs), **removal or replacement of the catheter is crucial** if it has been in place for more than 7 days and infection develops. Long-term catheters quickly become colonised with bacteria and biofilm, which can perpetuate infection even after antibiotics are started. Prompt catheter change helps eliminate the nidus of infection, reduces risk of recurrence, and is recommended alongside immediate antibiotic treatment. **Fluid advice, cranberry products, and bladder washouts are not evidence-based acute interventions**, and cystoscopy is not indicated for straightforward CAUTI without concerning features.\n\n**Key Points**\n- Remove or change catheters older than 7 days in suspected CAUTI.\n- Start antibiotics without delay; send urine for culture before starting.\n- Catheter change reduces bacterial load and biofilm formation.\n- Routine cystoscopy is not required for simple, first-episode CAUTI.\n- Cranberry products and bladder irrigation lack evidence for acute CAUTI management.\n- Advise on fluids for general hydration, but it is not the primary management step.\n\n**Clinical Relevance**\nCAUTIs are common in patients with long-term catheters. National guidelines (BNF, NICE CKS) emphasise catheter removal or change to optimise treatment and prevent recurrent infections. This is a high-value clinical intervention, reducing complications and antimicrobial resistance.\n\n**Memory Anchor**\nRemember: 'Catheter out, infection out'—removal or replacement is key in CAUTI.",
    "bullet_explanations": {
      "Remove or replace the urinary catheter promptly": "Correct—removing or changing the catheter disrupts biofilm and helps resolve infection per guidelines.",
      "Advise the patient to increase daily fluid intake to 2.5 litres": "Increased fluids may aid general wellbeing but are not a key intervention for CAUTI resolution.",
      "Arrange a routine urology referral for cystoscopy": "Not indicated unless there are recurrent, persistent, or complicated infections or red flag symptoms.",
      "Prescribe a prophylactic course of cranberry extract": "Cranberry may help prevent recurrent UTI in some, but is not appropriate for acute management, especially in CAUTI.",
      "Request a bladder irrigation by nursing staff": "Bladder washouts are not routinely recommended and do not address the underlying colonisation source."
    },
    "category": "Renal & Urology",
    "subsection": "Urology",
    "subsubsection": "Infections",
    "topic": "Cystitis",
    "keywords": [
      "catheter-associated UTI",
      "CAUTI",
      "catheter change",
      "urinary infection",
      "primary care"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Urinary-tract infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/urinary-tract-infections/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Urinary tract infection (lower) - men",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/urinary-tract-infection-lower-men/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ffa0e790-45ed-4efe-80d3-b820fcd5895b",
    "question_number": 149,
    "question": "A 57-year-old woman with no significant past medical history attends a routine GP appointment. She is concerned about her cardiovascular health, as her sister was recently diagnosed with angina. She currently smokes 15 cigarettes per day, has a BMI of 28 kg/m², and her blood pressure is 130/84 mmHg. She is asymptomatic and reports no chest pain or dyspnoea. After advising her to stop smoking, what is the most appropriate next step to assess her cardiovascular risk?",
    "options": [
      "Arrange a fasting lipid profile and calculate her QRISK score",
      "Refer urgently for a cardiac stress test",
      "Start atorvastatin 20 mg without further assessment",
      "Reassure her that her age alone means she is at low risk",
      "Initiate orlistat to reduce her BMI"
    ],
    "correct_answer": "Arrange a fasting lipid profile and calculate her QRISK score",
    "explanation": "**Explanation**\nThe recommended approach for assessing cardiovascular disease (CVD) risk in adults over 40 is to use a validated risk calculator such as QRISK, which incorporates factors including age, blood pressure, smoking status, BMI, and lipid profile. **A fasting lipid profile is needed to obtain total cholesterol and HDL values, which are essential for accurate QRISK calculation.** This allows for objective risk stratification and informs decisions about primary prevention, including statin therapy if the 10-year risk is ≥10%. Merely starting medication or providing reassurance without formal risk assessment is not evidence-based practice.\n\n**Key Points**\n- QRISK is the recommended tool for CVD risk assessment in UK adults aged 40–84.\n- A lipid profile is required to calculate QRISK, as it incorporates cholesterol/HDL ratio.\n- Statin therapy is considered if the calculated 10-year CVD risk is ≥10%.\n- Formal risk assessment is necessary even in asymptomatic individuals with risk factors.\n- Lifestyle advice (e.g., smoking cessation) should always be offered, but medication decisions require risk quantification.\n- <table><thead><tr><th>Risk Factor</th><th>Included in QRISK?</th></tr></thead><tbody><tr><td>Age</td><td>Yes</td></tr><tr><td>Blood Pressure</td><td>Yes</td></tr><tr><td>Smoking</td><td>Yes</td></tr><tr><td>BMI</td><td>Yes</td></tr><tr><td>Lipid Profile</td><td>Yes</td></tr></tbody></table>\n\n**Clinical Relevance**\nUsing validated tools like QRISK ensures that patients receive appropriate, evidence-based interventions for primary prevention of cardiovascular events. It supports shared decision-making and reduces both under- and over-treatment in primary care.\n\n**Memory Anchor**\nRemember: QRISK = Quantification Required for Initial Statin Knowledge.",
    "bullet_explanations": {
      "Arrange a fasting lipid profile and calculate her QRISK score": "Correct – This is the evidence-based approach for primary CVD risk assessment in asymptomatic adults with risk factors.",
      "Refer urgently for a cardiac stress test": "Incorrect – Functional testing is reserved for those with symptoms suggestive of ischaemia, not for asymptomatic risk assessment.",
      "Start atorvastatin 20 mg without further assessment": "Incorrect – Statin therapy should only be initiated after formal risk calculation unless there is very high risk (e.g., familial hypercholesterolaemia).",
      "Reassure her that her age alone means she is at low risk": "Incorrect – Risk must be formally assessed; age alone does not rule out significant risk, especially with other risk factors.",
      "Initiate orlistat to reduce her BMI": "Incorrect – Orlistat is not first-line for primary CVD prevention and should not be used solely for risk modification in this context."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Primary prevention: QRISK, statin thresholds, lifestyle",
    "topic": "Primary prevention: QRISK, statin thresholds, lifestyle",
    "keywords": [
      "QRISK",
      "lipid profile",
      "cardiovascular risk",
      "primary prevention",
      "statin"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cardiovascular risk assessment and lipid modification",
        "citation": "© NICE, 2025",
        "url": "https://cks.nice.org.uk/topics/cvd-risk-assessment/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a535cf0e-0a1a-4850-a67e-07f27ff8676d",
    "question_number": 150,
    "question": "Which oral anticoagulant is the only licensed option for lifelong thromboprophylaxis in a patient with a newly implanted mechanical mitral valve?",
    "options": [
      "Edoxaban",
      "Rivaroxaban",
      "Warfarin",
      "Dabigatran",
      "Aspirin"
    ],
    "correct_answer": "Warfarin",
    "explanation": "**Explanation**\n**Warfarin is the sole oral anticoagulant licensed in the UK for long-term prevention of thromboembolism in patients with mechanical heart valves.** Direct oral anticoagulants (DOACs)—including edoxaban, rivaroxaban, and dabigatran—are not approved for this indication, as clinical trials have shown increased risk of valve thrombosis and bleeding compared to warfarin. Aspirin alone does not provide adequate antithrombotic protection for mechanical valves. Warfarin’s efficacy and safety stem from its dose titration via INR monitoring, allowing for personalised anticoagulation intensity.\n\n**Key Points**\n- Mechanical heart valves require lifelong oral anticoagulation to prevent thrombosis.\n- Warfarin (a vitamin K antagonist) is the only licensed agent for this purpose in the UK.\n- DOACs (edoxaban, dabigatran, rivaroxaban) are not licensed for mechanical valves due to safety concerns.\n- Aspirin may be used as adjunctive therapy in some cases, but never as sole agent for mechanical valves.\n- INR monitoring is mandatory with warfarin to ensure therapeutic anticoagulation.\n\n**Clinical Relevance**\nCorrect selection of anticoagulation post-mechanical valve replacement is critical to prevent catastrophic valve thrombosis or embolic stroke. NICE and international guidelines continue to recommend warfarin as standard of care for patients with mechanical heart valves.\n\n**Memory Anchor**\nWarfarin for valves: 'W' for Warfarin, 'W' for mechanical Works",
    "bullet_explanations": {
      "Edoxaban": "Not licensed for use in mechanical heart valves; associated with higher risk of valve thrombosis.",
      "Rivaroxaban": "A direct factor Xa inhibitor; not approved for mechanical valve anticoagulation.",
      "Warfarin": "Correct—only oral agent licensed and proven safe for this indication.",
      "Dabigatran": "A direct thrombin inhibitor; trials have shown harm in mechanical valve patients.",
      "Aspirin": "Insufficient as monotherapy in mechanical valve prostheses; only considered adjunctively."
    },
    "category": "Cardiovascular",
    "subsection": "Valvular & Structural",
    "subsubsection": "Aortic Stenosis",
    "topic": "Endocarditis prophylaxis basics",
    "keywords": [
      "mechanical valve",
      "warfarin",
      "anticoagulation",
      "prosthetic valve",
      "DOAC"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Anticoagulation - oral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/anticoagulation-oral/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "57459c37-7ca0-4f9e-abf2-a6352eafca59",
    "question_number": 151,
    "question": "A 70-year-old man presents with a rapidly enlarging, dome-shaped nodule on the dorsal surface of his hand. The lesion has developed a central keratin-filled crater over the past two months. What is the most appropriate next step in management?",
    "options": [
      "Urgent two-week wait referral to dermatology",
      "Routine dermatology referral",
      "Start topical 5-fluorouracil",
      "Reassurance and observation for spontaneous resolution",
      "Apply topical hydrocortisone"
    ],
    "correct_answer": "Urgent two-week wait referral to dermatology",
    "explanation": "**Explanation**\n**Keratoacanthoma is a rapidly growing skin tumour that can closely resemble squamous cell carcinoma (SCC) both clinically and histologically.** Because it is impossible to reliably distinguish keratoacanthoma from SCC without histological examination, the recommended approach is to treat any suspicious lesion—particularly those with recent rapid growth, a raised edge, and a central keratinous core—as a potential skin cancer. **UK guidelines advise prompt assessment via a two-week wait pathway for suspected SCC or other rapidly developing suspicious skin lesions**. Observation or delay risks missing a malignant diagnosis and could result in worse outcomes for the patient.\n\n**Key Points**\n<ul><li>Keratoacanthoma presents as a rapidly growing, crateriform nodule, often with a keratin plug.</li><li>Distinguishing keratoacanthoma from SCC without biopsy is not possible.</li><li>Urgent specialist referral (two-week wait) is recommended for suspicious skin cancers.</li><li>Topical therapies such as 5-FU are not appropriate for potentially malignant or indeterminate lesions.</li><li>Routine referral or reassurance may delay necessary diagnosis and management.</li></ul><table><thead><tr><th>Lesion</th><th>Referral type</th></tr></thead><tbody><tr><td>Suspected SCC/keratoacanthoma</td><td>Urgent (2-week wait)</td></tr><tr><td>Suspected BCC</td><td>Routine (unless rapid growth/size/site)</td></tr><tr><td>Actinic keratosis</td><td>Topical therapy/routine</td></tr></tbody></table>\n\n**Clinical Relevance**\nEarly identification and urgent referral of possible skin cancers is critical for optimal outcomes and minimising morbidity. NICE guidelines emphasise a high index of suspicion for rapidly evolving lesions, particularly in older adults. Prompt action prevents delays in cancer diagnosis and treatment.\n\n**Memory Anchor**\nKeratoacanthoma = 'Can't tell from SCC' → 'Can't wait' (Urgent referral needed)",
    "bullet_explanations": {
      "Urgent two-week wait referral to dermatology": "Correct. Rapidly growing, crateriform lesions suspicious for keratoacanthoma or SCC require urgent specialist assessment for diagnosis and management.",
      "Routine dermatology referral": "Incorrect. Routine referral is not appropriate for rapidly evolving lesions with malignant potential; urgent assessment is required.",
      "Start topical 5-fluorouracil": "Incorrect. 5-FU is used for actinic keratosis or superficial BCC, not for indeterminate or potentially malignant nodules.",
      "Reassurance and observation for spontaneous resolution": "Incorrect. Although keratoacanthoma may regress, observation risks missing SCC, which requires prompt treatment.",
      "Apply topical hydrocortisone": "Incorrect. Topical steroids are not indicated for suspicious skin tumours and may mask important clinical features."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Skin Malignancy",
    "topic": "Skin cancer referral criteria",
    "keywords": [
      "keratoacanthoma",
      "skin cancer referral",
      "squamous cell carcinoma",
      "urgent dermatology",
      "skin malignancy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Skin cancers - recognition and referral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/skin-cancers-recognition-referral/"
      },
      {
        "source": "BNF",
        "topic_title": "Photodamage",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/photodamage/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b4e91f51-c173-49e6-be02-d42ea3ea3221",
    "question_number": 152,
    "question": "A 10-day-old male infant is brought to an urgent care clinic for spontaneous bruising noted on his arms and legs. He was born in Poland via uncomplicated caesarean section, is exclusively breastfed, and has not received any vitamin K supplementation. His INR is 4. Which of the following factors most increases his risk of developing vitamin K deficiency bleeding?",
    "options": [
      "Exclusive breastfeeding",
      "Male sex",
      "Caesarean section birth",
      "Being 10 days old",
      "Primigravida mother"
    ],
    "correct_answer": "Exclusive breastfeeding",
    "explanation": "**Explanation**\n**Exclusive breastfeeding** is the key risk factor for vitamin K deficiency bleeding (VKDB) in neonates who have not received prophylactic vitamin K. Human breast milk contains insufficient vitamin K to meet the newborn's needs, unlike formula milk, which is supplemented. Neonates naturally have low vitamin K stores due to poor placental transfer, and without supplementation, exclusively breastfed infants are at higher risk of serious bleeding complications, including raised INR and spontaneous bruising. Neither the method of delivery, gender, nor birth order significantly increases the risk. Neonatal guidelines therefore recommend universal vitamin K prophylaxis at birth to prevent VKDB.\n\n**Key Points**\n- Neonates are born with low vitamin K stores due to limited placental transfer.\n- Vitamin K is essential for synthesis of clotting factors II, VII, IX, and X.\n- Breast milk contains low levels of vitamin K, while formula is supplemented.\n- Without vitamin K prophylaxis, exclusively breastfed infants are at increased risk of VKDB.\n- Routine vitamin K administration at birth is recommended to prevent serious bleeding.\n- Other factors (method of delivery, sex, being the first child) do not independently increase VKDB risk.\n\n**Clinical Relevance**\nRecognising exclusive breastfeeding as a major risk factor for vitamin K deficiency bleeding is crucial, especially in infants born outside the UK or where vitamin K prophylaxis was omitted. Prompt identification and supplementation prevent potentially life-threatening haemorrhage.\n\n**Memory Anchor**\nThink 'K for Clotting'—breast milk is low in vitamin K, so exclusively breastfed babies without prophylaxis are vulnerable.",
    "bullet_explanations": {
      "Exclusive breastfeeding": "Correct. Breast milk is naturally low in vitamin K, so exclusively breastfed infants not given prophylaxis are at greatest risk.",
      "Male sex": "Incorrect. Sex does not affect the risk of vitamin K deficiency bleeding.",
      "Caesarean section birth": "Incorrect. The mode of delivery does not significantly influence the risk of VKDB.",
      "Being 10 days old": "Incorrect. The age itself is not a risk factor; VKDB can occur within the first weeks if vitamin K is not supplemented.",
      "Primigravida mother": "Incorrect. Being a first-time mother does not increase the infant’s risk of VKDB."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Nutrition",
    "subsubsection": "Micronutrients",
    "topic": "Vitamin K deficiency",
    "keywords": [
      "vitamin K deficiency",
      "VKDB",
      "breastfeeding",
      "newborn bleeding",
      "micronutrients"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Vitamins",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/vitamins/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9e84d8c6-c165-4d4a-9af0-3bc2c86ded10",
    "question_number": 153,
    "question": "Which investigation is considered the gold standard for diagnosing degenerative cervical myelopathy, and why are plain cervical spine X-rays not sufficient for this purpose?",
    "options": [
      "MRI scan, because it can visualise spinal cord compression and soft tissue changes",
      "Cervical spine X-ray, because it reliably demonstrates neural impingement",
      "CT myelography, as it is preferred over MRI for initial assessment",
      "Electromyography (EMG), due to its ability to localise cord compression",
      "Bone scintigraphy, since it detects early degenerative changes"
    ],
    "correct_answer": "MRI scan, because it can visualise spinal cord compression and soft tissue changes",
    "explanation": "**Explanation**\n**MRI is the investigation of choice for suspected degenerative cervical myelopathy (DCM), as it directly visualises the spinal cord, neural elements, and surrounding soft tissues.** Plain cervical spine radiographs cannot adequately assess the spinal cord or the degree of compression, because they are limited to showing bone structure and gross alignment. While X-rays may reveal degenerative bony changes, these are common and not specific for DCM, and their absence does not rule out cord compression. MRI provides crucial information about disc herniation, ligament hypertrophy, and the presence or absence of cord compression, which are essential for diagnosis and management planning. In contrast, X-rays lack sensitivity and specificity for DCM and are mainly useful for excluding trauma or gross instability, not for assessing neural compromise.\n\n**Key Points**\n- MRI is the definitive imaging study for suspected degenerative cervical myelopathy.\n- Plain cervical spine X-rays have limited diagnostic value in DCM—cannot visualise soft tissues or spinal cord.\n- Radiographs may show spondylotic changes, but these are common and not diagnostic.\n- Absence of radiological changes on X-ray does not exclude cord compression.\n- MRI findings must be interpreted alongside clinical features for a diagnosis.\n\n**Clinical Relevance**\nAccurate and timely diagnosis of DCM is vital to prevent irreversible neurological deficits. NICE CKS and other guidelines recommend MRI as first-line imaging when myelopathy is suspected, reserving plain radiographs for trauma or instability. Understanding the limitations of X-rays avoids misdiagnosis and ensures appropriate specialist referral.",
    "bullet_explanations": {
      "MRI scan, because it can visualise spinal cord compression and soft tissue changes": "Correct – MRI provides detailed images of the spinal cord and soft tissue structures, essential for diagnosing DCM.",
      "Cervical spine X-ray, because it reliably demonstrates neural impingement": "Incorrect – X-rays do not show soft tissue or cord compression, and degenerative changes are often non-specific.",
      "CT myelography, as it is preferred over MRI for initial assessment": "Incorrect – CT myelography is reserved for cases where MRI is contraindicated; MRI is preferred for initial assessment.",
      "Electromyography (EMG), due to its ability to localise cord compression": "Incorrect – EMG may help assess nerve function but cannot identify structural cord compression.",
      "Bone scintigraphy, since it detects early degenerative changes": "Incorrect – Bone scans are not used for diagnosing DCM and cannot assess neural structures."
    },
    "category": "Musculoskeletal",
    "subsection": "Spinal",
    "subsubsection": "Spinal cord compression",
    "topic": "Spinal cord compression",
    "keywords": [
      "degenerative cervical myelopathy",
      "MRI",
      "cervical spine",
      "diagnosis",
      "radiology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Neck pain - cervical radiculopathy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/neck-pain-cervical-radiculopathy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9d20e464-7a72-4a59-a0fe-9639ad307e50",
    "question_number": 154,
    "question": "A 52-year-old woman with a long history of excessive alcohol consumption presents with progressive fatigue, jaundice, and abdominal discomfort over several weeks. Her blood tests reveal AST 210 IU/L, ALT 90 IU/L, and a mildly raised bilirubin. Which diagnosis is most strongly supported by these findings?",
    "options": [
      "Alcoholic hepatitis",
      "Acute cholecystitis",
      "Non-alcoholic steatohepatitis (NASH)",
      "Acute pancreatitis",
      "Hepatitis A"
    ],
    "correct_answer": "Alcoholic hepatitis",
    "explanation": "**Explanation**\n**Alcoholic hepatitis** typically occurs in individuals with prolonged, heavy alcohol intake. It presents with symptoms such as jaundice, right upper quadrant pain, fatigue, and anorexia. A key laboratory clue is a disproportionate elevation of AST compared to ALT (often with an AST:ALT ratio >2:1), reflecting alcohol-induced mitochondrial injury and impaired ALT synthesis. In contrast, acute viral hepatitides or NASH usually show ALT greater than or similar to AST. The clinical context and biochemistry here are classic for alcoholic hepatitis, rather than acute cholecystitis, viral hepatitis, or metabolic liver disease.\n\n**Key Points**\n- **AST:ALT ratio >2:1 is characteristic of alcoholic hepatitis**\n- Symptoms include jaundice, fatigue, anorexia, and right upper quadrant discomfort\n- History of significant alcohol use is essential for diagnosis\n- Other causes of hepatitis (viral, NASH) typically do not show this enzyme pattern\n- Diagnosis is clinical but may be supported by imaging and exclusion of other causes\n\n**Clinical Relevance**\nRecognising the pattern of liver enzyme elevation in alcoholic hepatitis is critical for early diagnosis and management. National guidance highlights the importance of identifying alcohol-related liver disease and differentiating it from other hepatitides, as management and complications differ significantly. Prompt recognition allows for interventions, including alcohol cessation support and specialist referral, which can improve prognosis.\n\n**Memory Anchor**\nThink 'AST for Alcohol': **AST Always Surpasses ALT** in Alcoholic hepatitis.",
    "bullet_explanations": {
      "Alcoholic hepatitis": "Correct – Classic biochemistry and clinical history point to alcohol-induced liver injury.",
      "Acute cholecystitis": "Incorrect – Would typically present with acute pain, fever, and markedly raised inflammatory markers, not this enzyme pattern.",
      "Non-alcoholic steatohepatitis (NASH)": "Incorrect – More common in metabolic syndrome; usually shows ALT equal to or greater than AST.",
      "Acute pancreatitis": "Incorrect – Would show raised amylase/lipase and marked abdominal pain, not this liver enzyme pattern.",
      "Hepatitis A": "Incorrect – Presents with acute hepatitis, but ALT is typically higher than AST and there is usually an epidemiological link or recent travel."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Hepatology",
    "subsubsection": "Alcohol-Related Liver Disease",
    "topic": "Alcoholic hepatitis severity (Maddrey)",
    "keywords": [
      "alcoholic hepatitis",
      "AST ALT ratio",
      "jaundice",
      "liver enzymes",
      "alcohol-related liver disease"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Alcohol dependence",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/alcohol-dependence/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Jaundice in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/jaundice-in-adults/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Cirrhosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cirrhosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "086e202c-d33f-46d4-b63a-181eb7db2b57",
    "question_number": 155,
    "question": "Which of the following statements about sodium valproate is INCORRECT?",
    "options": [
      "It can cause hair loss in some patients.",
      "It commonly leads to increased appetite and weight gain.",
      "Its use during pregnancy is associated with a significant risk of teratogenicity.",
      "It is an inducer of cytochrome P450 enzymes.",
      "It may cause gastrointestinal side effects such as nausea."
    ],
    "correct_answer": "It is an inducer of cytochrome P450 enzymes.",
    "explanation": "**Explanation**\nSodium valproate is actually a **cytochrome P450 inhibitor**, not an inducer. This distinction is important as it can affect the metabolism of other drugs, potentially increasing their plasma concentrations and risk of toxicity. By contrast, drugs such as carbamazepine and phenytoin are classic P450 inducers, which can decrease the levels of co-administered medications. Sodium valproate is commonly associated with side effects such as **alopecia (hair loss), weight gain, and gastrointestinal upset**. Its use in pregnancy is strongly cautioned against due to a **high risk of congenital malformations and neurodevelopmental disorders** in the fetus.\n\n**Key Points**\n<ul><li><b>Sodium valproate inhibits cytochrome P450 enzymes</b>, not induces them.</li><li>Common adverse effects: weight gain, alopecia, nausea, and ataxia.</li><li>Highly teratogenic – associated with neural tube defects and neurodevelopmental delay if used in pregnancy.</li><li>Current UK guidelines restrict valproate use in women and men under 55 years, unless no alternatives exist.</li><li>Important to consider drug interactions due to P450 inhibition.</li></ul><table><thead><tr><th>Effect</th><th>P450 Inducer</th><th>P450 Inhibitor</th></tr></thead><tbody><tr><td>Carbamazepine</td><td>Yes</td><td>No</td></tr><tr><td>Sodium valproate</td><td>No</td><td>Yes</td></tr></tbody></table>\n\n**Clinical Relevance**\nUnderstanding the pharmacokinetic properties of sodium valproate is vital to safe prescribing, particularly regarding drug interactions and its teratogenic potential. Current MHRA and NICE guidance place strict limitations on its use, especially in women of childbearing potential, to reduce the risk of fetal harm.\n\n**Memory Anchor**\nValproate = 'Very Potent Inhibitor' (VPI): think 'Valproate P450 Inhibitor'",
    "bullet_explanations": {
      "It can cause hair loss in some patients.": "Alopecia is a recognised adverse effect of sodium valproate.",
      "It commonly leads to increased appetite and weight gain.": "Weight gain is a well-documented side effect of sodium valproate.",
      "Its use during pregnancy is associated with a significant risk of teratogenicity.": "Valproate is highly teratogenic and should be avoided in pregnancy unless no alternatives exist.",
      "It is an inducer of cytochrome P450 enzymes.": "Incorrect—valproate is a P450 inhibitor, not an inducer.",
      "It may cause gastrointestinal side effects such as nausea.": "Nausea and other GI symptoms are common with sodium valproate."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Pharmacokinetics",
    "topic": "Drug interactions",
    "keywords": [
      "sodium valproate",
      "P450 inhibitor",
      "adverse effects",
      "teratogenicity",
      "pharmacokinetics"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Epilepsy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/epilepsy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8007b55a-4dcf-44f0-a25f-5f1985d17a52",
    "question_number": 156,
    "question": "A 35-year-old man presents with a two-week history of anterior neck pain, low-grade fever, and malaise following an upper respiratory tract infection. Examination reveals a tender, diffusely enlarged thyroid gland. His blood tests show suppressed TSH, markedly raised free T4, and an ESR of 70 mm/hr. A radionuclide thyroid scan demonstrates globally reduced uptake. What is the most likely diagnosis?",
    "options": [
      "Subacute (De Quervain's) thyroiditis",
      "Acute suppurative thyroiditis",
      "Toxic multinodular goitre",
      "Sick euthyroid syndrome",
      "Hashimoto's thyroiditis"
    ],
    "correct_answer": "Subacute (De Quervain's) thyroiditis",
    "explanation": "**Explanation**\nSubacute (De Quervain's) thyroiditis typically presents with a **tender, painful thyroid gland**, often following a recent viral infection. **Key features include transient thyrotoxicosis** (suppressed TSH, high T4), **elevated inflammatory markers** (e.g., ESR), and **globally reduced uptake on radionuclide thyroid scanning**. The thyroid hormone excess is due to release of preformed hormone from inflamed follicles, not increased synthesis, explaining the reduced uptake. The condition is usually self-limiting and may progress to transient hypothyroidism before recovery. It is distinct from other thyroid disorders by the combination of pain, systemic symptoms, and inflammatory markers.<br><br><b>Contrast:</b> Graves' disease and toxic multinodular goitre show increased or patchy uptake, and are not typically painful. Acute suppurative thyroiditis presents with severe pain and systemic sepsis and is rare. Hashimoto's is usually painless and chronic.\n\n**Key Points**\n<ul><li><b>Tender, painful thyroid gland</b> following viral illness is characteristic.</li><li>Thyroid function: <b>suppressed TSH, elevated T4/T3</b> (transient thyrotoxicosis).</li><li><b>ESR/CRP are raised</b> (inflammatory process).</li><li><b>Radionuclide scan: globally reduced uptake</b> (distinguishes from Graves'/TMG).</li><li>Usually self-limiting; may lead to transient hypothyroid phase.</li></ul><table><thead><tr><th>Feature</th><th>Subacute Thyroiditis</th><th>Graves/TMG</th></tr></thead><tbody><tr><td>Thyroid pain</td><td>Yes</td><td>No</td></tr><tr><td>Inflammatory markers</td><td>Raised</td><td>Normal</td></tr><tr><td>Scan uptake</td><td>Reduced</td><td>Normal/increased</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising subacute thyroiditis is crucial as management is supportive—antithyroid drugs are not indicated, and inappropriate use can be avoided. The diagnosis is based on clinical features, biochemistry, and thyroid imaging, as outlined in UK guidelines.\n\n**Memory Anchor**\nDe Quervain's = 'De Quivering' (painful, inflamed, post-viral, low uptake)",
    "bullet_explanations": {
      "Subacute (De Quervain's) thyroiditis": "Correct – classic presentation with pain, post-viral onset, raised ESR, and low uptake on scan.",
      "Acute suppurative thyroiditis": "Incorrect – typically presents with marked systemic illness and often in immunocompromised or children; rare and usually associated with abscess.",
      "Toxic multinodular goitre": "Incorrect – causes hyperthyroidism but is usually painless and shows patchy increased uptake on scan.",
      "Sick euthyroid syndrome": "Incorrect – occurs in severe illness, with abnormal TFTs but no thyroid pain or swelling.",
      "Hashimoto's thyroiditis": "Incorrect – usually presents as a painless, chronic goitre and may cause hypothyroidism; scan may show reduced uptake but not acutely painful."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Thyroid",
    "subsubsection": "Hyperthyroidism",
    "topic": "Graves vs toxic nodular goitre",
    "keywords": [
      "subacute thyroiditis",
      "De Quervain's",
      "thyrotoxicosis",
      "thyroid pain",
      "radionuclide scan"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hyperthyroidism",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hyperthyroidism/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Hyperthyroidism",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hyperthyroidism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2d02c108-f7f1-40c2-bff2-f110cf5a0f67",
    "question_number": 157,
    "question": "A 22-year-old woman with newly diagnosed moderate depressive disorder starts fluoxetine after declining psychological therapy. She has no recent suicidal plans but has previously expressed suicidal ideation. What is the most appropriate interval for her initial follow-up review after commencing the SSRI?",
    "options": [
      "Review after 1 week",
      "Review after 2 weeks",
      "Review after 4 weeks",
      "Review after 3 months",
      "Review after 6 weeks"
    ],
    "correct_answer": "Review after 1 week",
    "explanation": "**Explanation**\nYoung adults (aged 18 to 25) who begin SSRI treatment for depression are at a higher risk of developing or experiencing a worsening of suicidal thoughts, especially in the initial stages of therapy. **National guidelines recommend an early review—specifically after one week—for these patients, regardless of the SSRI used.** This early review is crucial for monitoring emerging suicidal ideation, side effects, and treatment adherence, rather than for assessing efficacy, which typically takes several weeks to become evident. In contrast, adults over 25 years of age without increased suicide risk are generally reviewed after two weeks, but a one-week review is mandatory for younger patients or anyone with elevated suicide risk factors.\n\n**Key Points**\n- SSRIs can increase suicidal thoughts in patients under 25, especially early in treatment.\n- First review should be scheduled after 1 week for those aged 18–25 or with suicide risk.\n- Purpose: assess for suicidal ideation, adverse effects, and support adherence.\n- Therapeutic effects usually take 2–4 weeks to emerge; initial review is about safety.\n- Longer intervals (2–4 weeks) are appropriate only in lower-risk, older adults.\n- <table><thead><tr><th>Patient Group</th><th>First Review</th></tr></thead><tbody><tr><td>Aged 18–25 or suicide risk</td><td>1 week</td></tr><tr><td>Other adults</td><td>2 weeks</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt early follow-up for young adults starting SSRIs is a key safety measure to identify emergent suicidal ideation and ensure appropriate ongoing support, as highlighted in national prescribing guidance. Delayed review risks missing early adverse effects or changes in risk profile.\n\n**Memory Anchor**\nThink: '1 week for under 25s or suicide risk'—1 week, 1 warning.",
    "bullet_explanations": {
      "Review after 1 week": "Correct—early review is essential for patients under 25 or with suicide risk.",
      "Review after 2 weeks": "Incorrect—this is the standard interval for adults over 25 without increased risk.",
      "Review after 4 weeks": "Incorrect—too long to wait for initial safety monitoring in this age group.",
      "Review after 3 months": "Incorrect—far too delayed for initial follow-up, risks missing adverse effects.",
      "Review after 6 weeks": "Incorrect—does not align with safety recommendations for early monitoring."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Depression",
    "topic": "First-line therapy",
    "keywords": [
      "depression",
      "SSRI",
      "suicide risk",
      "follow-up",
      "young adults"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Depression",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/depression/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "522c0abd-b0aa-44d4-a325-5fbe5218f493",
    "question_number": 158,
    "question": "Which of the following best describes the primary contraceptive mechanism of the copper intrauterine device (IUD) when used for emergency contraception?",
    "options": [
      "It is cytotoxic to sperm and ova",
      "It suppresses ovulation",
      "It thickens cervical mucus",
      "It induces DNA mutation in sperm",
      "It prevents endometrial proliferation"
    ],
    "correct_answer": "It is cytotoxic to sperm and ova",
    "explanation": "**Explanation**\n**Copper IUDs used for emergency contraception primarily work by releasing copper ions, which are toxic to sperm and ova.** This cytotoxic effect impairs sperm motility and viability, and disrupts the functioning of the ovum, thereby preventing fertilisation. Unlike hormonal methods, the copper IUD does not suppress ovulation or primarily alter cervical mucus. Its main action is to create a hostile uterine environment that is not conducive to gamete survival or fertilisation. The device may also inhibit implantation, but this is a secondary mechanism.\n\n**Key Points**\n- Copper IUDs act by releasing copper ions, which are directly toxic to sperm and ova.\n- This prevents fertilisation by impairing sperm motility and viability.\n- Suppression of ovulation is not a mechanism of copper IUDs.\n- Hormonal emergency contraception (e.g. levonorgestrel) works mainly by inhibiting ovulation.\n- The thickening of cervical mucus is a feature of progestogen-only contraceptive pills, not copper IUDs.\n\n**Clinical Relevance**\nUnderstanding the distinct mechanisms of emergency contraception is essential for appropriate counselling and selection of methods. The copper IUD provides the most effective emergency contraception and can be used up to five days after unprotected intercourse.\n\n**Memory Anchor**\nThink 'Copper = Cytotoxic' for IUDs.",
    "bullet_explanations": {
      "It is cytotoxic to sperm and ova": "Correct—copper ions from the IUD are toxic to sperm and ova, preventing fertilisation.",
      "It suppresses ovulation": "Incorrect—copper IUDs do not inhibit ovulation; hormonal contraceptives like levonorgestrel do.",
      "It thickens cervical mucus": "Incorrect—this is a mechanism of progestogen-only contraceptives, not copper IUDs.",
      "It induces DNA mutation in sperm": "Incorrect—copper is toxic but does not cause DNA mutations in sperm.",
      "It prevents endometrial proliferation": "Incorrect—some hormonal contraceptives reduce endometrial growth, but this is not the primary action of copper IUDs."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Emergency contraception",
    "keywords": [
      "copper IUD",
      "emergency contraception",
      "mechanism of action",
      "cytotoxicity"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "0aa85b1d-5444-43e2-b1c5-9fe9f36f11fb",
    "question_number": 159,
    "question": "A 36-year-old woman presents to A&E with a severe exacerbation of asthma. She has received high-flow oxygen, repeated nebulised salbutamol and ipratropium, and intravenous hydrocortisone with little improvement. Her peak expiratory flow remains at 40% of predicted. Which is the most appropriate next step in her acute management?",
    "options": [
      "Administer intravenous magnesium sulphate",
      "Start non-invasive ventilation",
      "Give intravenous salbutamol infusion",
      "Administer intravenous aminophylline",
      "Give intramuscular adrenaline"
    ],
    "correct_answer": "Administer intravenous magnesium sulphate",
    "explanation": "**Explanation**\n**Intravenous magnesium sulphate** is recommended as the next step for adults with severe asthma who fail to respond to first-line therapy (oxygen, inhaled/nebulised beta-agonists, ipratropium, and corticosteroids). Magnesium sulphate acts as a bronchodilator by inhibiting smooth muscle contraction and reducing inflammation. UK guidelines advise its use before aminophylline or intravenous beta-agonists due to its favourable safety profile and efficacy in this context. It is not routinely used in mild or moderate attacks but is specifically indicated when there is inadequate response to initial acute management. Options such as aminophylline and intravenous salbutamol are reserved for more refractory or life-threatening cases, often under specialist supervision.\n\n**Key Points**\n- IV magnesium sulphate is indicated for acute severe asthma unresponsive to initial therapy.\n- It is administered as a single intravenous dose (usually 1.2–2 g over 20 minutes).\n- Magnesium sulphate is preferred before aminophylline or IV beta-agonists due to safety and efficacy.\n- Aminophylline and IV salbutamol are reserved for refractory or life-threatening cases.\n- Non-invasive ventilation and IM adrenaline are not recommended in standard severe asthma management.\n\n**Clinical Relevance**\nRecognising when to escalate to intravenous magnesium sulphate is crucial in acute asthma care. This aligns with national guidance and can reduce morbidity by improving bronchodilation when first-line treatments do not suffice. Timely intervention can avert respiratory failure and the need for invasive support.\n\n**Memory Anchor**\nMagnesium makes muscles 'mellow'—think magnesium for unresponsive muscles in acute asthma.",
    "bullet_explanations": {
      "Administer intravenous magnesium sulphate": "Correct—magnesium sulphate is the recommended next step for severe asthma unresponsive to initial therapy.",
      "Start non-invasive ventilation": "Incorrect—NIV is not routinely indicated in acute severe asthma and may delay necessary escalation/intubation.",
      "Give intravenous salbutamol infusion": "Incorrect—IV salbutamol is reserved for life-threatening or refractory cases, usually after magnesium has been tried.",
      "Administer intravenous aminophylline": "Incorrect—Aminophylline is not first-line; it is considered only after magnesium sulphate and under senior supervision.",
      "Give intramuscular adrenaline": "Incorrect—IM adrenaline is used for anaphylaxis, not standard asthma exacerbations, and carries significant risks."
    },
    "category": "Respiratory",
    "subsection": "Obstructive Airway",
    "subsubsection": "Asthma",
    "topic": "Acute severe/life-threatening criteria",
    "keywords": [
      "acute asthma",
      "magnesium sulphate",
      "bronchodilator",
      "severe asthma management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Asthma, acute",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/asthma-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fdac6043-1ed7-443d-b0bf-f00d86cf85b5",
    "question_number": 160,
    "question": "A 28-year-old woman presents with secondary amenorrhoea. Hormonal testing reveals low FSH and LH levels. Which of the following underlying conditions is a recognised cause of hypogonadotrophic hypogonadism?",
    "options": [
      "Polycystic ovary syndrome",
      "Premature ovarian insufficiency",
      "Haemochromatosis",
      "Mumps oophoritis",
      "Turner syndrome"
    ],
    "correct_answer": "Haemochromatosis",
    "explanation": "**Explanation**\n**Haemochromatosis** leads to pathological iron accumulation, which can deposit in the pituitary gland and disrupt gonadotropin secretion. This results in **hypogonadotrophic hypogonadism**—characterised by low levels of both FSH and LH—due to impaired hypothalamic or pituitary function. Unlike primary gonadal failure (which raises FSH/LH), this is a secondary cause. Other listed conditions either cause hypergonadotrophic hypogonadism (e.g. Turner syndrome, premature ovarian insufficiency, mumps oophoritis) or do not typically suppress gonadotropins (e.g. PCOS).\n\n**Key Points**\n- Hypogonadotrophic hypogonadism = low FSH/LH due to hypothalamic or pituitary dysfunction\n- Haemochromatosis can cause pituitary iron overload, impairing gonadotropin release\n- Primary gonadal failure (e.g. Turner syndrome, POI) = elevated FSH/LH (hypergonadotrophic)\n- PCOS is usually associated with normal or mildly raised gonadotropins, not suppression\n- <table><thead><tr><th>Condition</th><th>FSH/LH Pattern</th><th>Typical Cause</th></tr></thead><tbody><tr><td>Haemochromatosis</td><td>Low</td><td>Pituitary dysfunction</td></tr><tr><td>Turner syndrome</td><td>High</td><td>Primary ovarian failure</td></tr><tr><td>PCOS</td><td>Normal/slightly high</td><td>Ovarian dysfunction</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising causes of secondary hypogonadism is crucial for appropriate referral and management. Haemochromatosis, though often overlooked, should be considered in patients with unexplained hypogonadotrophic hypogonadism, as early identification allows for intervention to prevent further systemic complications.\n\n**Memory Anchor**\nThink 'Haemo' for 'Hormone pit' (haemochromatosis affects the pituitary).",
    "bullet_explanations": {
      "Polycystic ovary syndrome": "PCOS typically causes normal or mildly increased gonadotropins, not hypogonadotrophic hypogonadism.",
      "Premature ovarian insufficiency": "This results in hypergonadotrophic hypogonadism (high FSH/LH) due to primary ovarian failure.",
      "Haemochromatosis": "Correct. It can damage the pituitary and lead to hypogonadotrophic hypogonadism.",
      "Mumps oophoritis": "Mumps infection damages the ovaries, causing primary failure and raised FSH/LH.",
      "Turner syndrome": "A chromosomal disorder causing primary ovarian failure and elevated gonadotropins."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Infertility",
    "topic": "Causes",
    "keywords": [
      "hypogonadotrophic hypogonadism",
      "haemochromatosis",
      "infertility",
      "secondary amenorrhoea"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Amenorrhoea",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/amenorrhoea/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f7e0b905-92fb-4008-b133-a08ba7520340",
    "question_number": 161,
    "question": "A 32-year-old woman with no significant medical history presents to her GP with sharp right iliac fossa pain and light vaginal spotting. She is 7 weeks pregnant by dates. Clinical examination is unremarkable and she is haemodynamically stable. Which diagnostic test is most sensitive for identifying an ectopic pregnancy in this scenario?",
    "options": [
      "Transvaginal pelvic ultrasound scan",
      "Serum progesterone measurement",
      "Pelvic MRI scan",
      "Serial urinary pregnancy tests",
      "Abdominal X-ray"
    ],
    "correct_answer": "Transvaginal pelvic ultrasound scan",
    "explanation": "**Explanation**\n**Transvaginal ultrasound is the gold standard for diagnosing ectopic pregnancy in women with early pregnancy symptoms.** This imaging modality provides high-resolution views of the uterus, adnexa, and surrounding pelvic structures, allowing direct visualisation of an intrauterine or extrauterine gestational sac. It is more sensitive than transabdominal ultrasound, especially in early gestation, and is recommended as the first-line diagnostic tool when ectopic pregnancy is suspected. Other tests, such as serum progesterone or serial urinary pregnancy tests, do not reliably confirm the location of a pregnancy. MRI and X-ray are not appropriate first-line investigations in this context.\n\n**Key Points**\n- Transvaginal ultrasound provides superior pelvic detail compared to transabdominal approaches.\n- Accurate localisation of pregnancy is crucial for appropriate management of ectopic pregnancy.\n- Serum markers alone cannot reliably distinguish between intrauterine and ectopic pregnancies.\n- X-rays and MRI are not indicated for early pregnancy complications due to low yield and, for X-ray, radiation risk.\n- <table><thead><tr><th>Test</th><th>Role in Suspected Ectopic</th></tr></thead><tbody><tr><td>Transvaginal US</td><td>First-line, highest sensitivity</td></tr><tr><td>Serum β-hCG</td><td>Adjunct, not diagnostic alone</td></tr><tr><td>MRI</td><td>Rarely used, not routine</td></tr></tbody></table>\n\n**Clinical Relevance**\nEctopic pregnancy is a potentially life-threatening diagnosis that must be excluded in any woman of reproductive age with early pregnancy and abdominal pain or bleeding. National guidelines, including NICE, consistently recommend transvaginal ultrasound as the investigation of choice. Timely and accurate diagnosis can prevent serious complications such as tubal rupture and maternal morbidity.\n\n**Memory Anchor**\nRemember: **'Transvaginal for Tubal'**—the best way to visualise a suspected ectopic pregnancy.",
    "bullet_explanations": {
      "Transvaginal pelvic ultrasound scan": "Correct – This is the most sensitive and specific initial investigation for ectopic pregnancy.",
      "Serum progesterone measurement": "Incorrect – Progesterone levels may support but cannot confirm or exclude ectopic pregnancy.",
      "Pelvic MRI scan": "Incorrect – Not routinely used for early pregnancy assessment; reserved for complex cases.",
      "Serial urinary pregnancy tests": "Incorrect – May confirm ongoing pregnancy but not the location; not diagnostic for ectopic pregnancy.",
      "Abdominal X-ray": "Incorrect – Not indicated in pregnancy; provides no information about pregnancy location and involves unnecessary radiation."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Ectopic pregnancy",
    "keywords": [
      "ectopic pregnancy",
      "transvaginal ultrasound",
      "early pregnancy bleeding"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Ectopic pregnancy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/ectopic-pregnancy/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Miscarriage",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/miscarriage/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "76b49e83-f32b-4135-b29b-f1561b479b2b",
    "question_number": 162,
    "question": "A 64-year-old woman presents with ongoing irritation, crusting, and redness at the margins of both eyelids, particularly in the mornings. She reports intermittent itching and a gritty sensation in her eyes. What is the most likely diagnosis?",
    "options": [
      "Blepharitis",
      "Chalazion",
      "Ectropion",
      "Stye (hordeolum)",
      "Dacryocystitis"
    ],
    "correct_answer": "Blepharitis",
    "explanation": "**Explanation**\n**Blepharitis** is a chronic inflammatory condition affecting the eyelid margins, commonly presenting with bilateral symptoms such as irritation, redness, crusting, and a gritty sensation. Symptoms are often worse in the morning due to overnight accumulation of debris. In contrast, a chalazion is a painless, slow-growing lump away from the lid margin, while a stye is a painful, acute swelling. Ectropion causes outward turning of the eyelid, leading to watering rather than irritation at the lid margin. Dacryocystitis typically involves pain and swelling at the medial canthus, not the lid margin. Blepharitis may be associated with seborrhoeic dermatitis or rosacea and can lead to complications like stye or chalazion formation, chronic conjunctivitis, and, rarely, keratopathy and corneal ulceration if untreated.\n\n**Key Points**\n- Blepharitis presents as bilateral eyelid margin irritation with crusting and redness.\n- Symptoms are typically worse in the morning.\n- Associated with seborrhoeic dermatitis, rosacea, and dry eye disease.\n- Complications: stye, chalazion, chronic conjunctivitis, rarely corneal ulcer.\n- Diagnosis is clinical; management focuses on eyelid hygiene and warm compresses.\n- <table><thead><tr><th>Feature</th><th>Blepharitis</th><th>Chalazion</th><th>Stye</th></tr></thead><tbody><tr><td>Pain</td><td>No/Minimal</td><td>No</td><td>Yes</td></tr><tr><td>Location</td><td>Lid margin</td><td>Away from margin</td><td>Lid margin</td></tr><tr><td>Onset</td><td>Chronic</td><td>Chronic</td><td>Acute</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising blepharitis is vital in primary care, as it is a leading cause of chronic red eye symptoms and eyelid discomfort. Early diagnosis and patient education on eyelid hygiene can prevent complications and reduce recurrence. Persistent or atypical presentations may require specialist referral.\n\n**Memory Anchor**\nBlepharitis = 'Bleph' for 'both lids' and 'flakes' (crusts at the margin).",
    "bullet_explanations": {
      "Blepharitis": "Correct: Characterised by bilateral chronic irritation, crusting, and redness at the eyelid margins.",
      "Chalazion": "Incorrect: Typically a painless, slow-growing lump away from the lid margin, not associated with crusting.",
      "Ectropion": "Incorrect: Outward turning of the eyelid; presents with watering and exposure symptoms rather than margin crusting.",
      "Stye (hordeolum)": "Incorrect: Painful, acute, localised swelling at the lid margin, usually unilateral and tender.",
      "Dacryocystitis": "Incorrect: Infection of the lacrimal sac, presenting with pain and swelling at the inner canthus, not the lid margin."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Conjunctivitis (viral/bacterial/allergic)",
    "topic": "Blepharitis",
    "keywords": [
      "blepharitis",
      "eyelid margin",
      "chronic red eye",
      "crusting",
      "ophthalmology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Blepharitis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/blepharitis/"
      },
      {
        "source": "BNF",
        "topic_title": "Eye, infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/eye-infections/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9c8e7ea0-53ff-41fe-9a64-5bcccd1fe974",
    "question_number": 163,
    "question": "A 4-year-old boy is brought to the GP after a witnessed episode where he turned pale, collapsed suddenly after a minor bump, had some brief limb jerking, and appeared blue around the lips. He recovered fully within a minute, with no prolonged confusion. What feature most reliably helps distinguish a reflex anoxic seizure from an epileptic seizure in this scenario?",
    "options": [
      "Rapid and complete recovery after the event",
      "Presence of limb jerking during the episode",
      "Perioral cyanosis observed during collapse",
      "Initial loss of consciousness with fall to floor",
      "Brief pallor preceding the episode"
    ],
    "correct_answer": "Rapid and complete recovery after the event",
    "explanation": "**Explanation**\n**Reflex anoxic seizures** are characterised by a sudden loss of consciousness in response to a brief trigger, such as pain or fright, often with transient limb jerking and pallor. Unlike epileptic seizures, they are followed by **rapid and full recovery, typically within seconds to a minute**, and there is minimal or no post-ictal confusion. In contrast, **epileptic seizures** often result in a longer period of confusion or drowsiness after the event (the post-ictal phase). Other features like jerking, cyanosis, and collapse can occur in both conditions, making the **duration and nature of recovery the key discriminating factor**.\n\n**Key Points**\n- Reflex anoxic seizures are typically triggered by pain or emotional stimuli.\n- Both seizure types may present with collapse, limb movements, and cyanosis.\n- Rapid, spontaneous, and full recovery is typical of reflex anoxic seizures.\n- Epileptic seizures often have a prolonged post-ictal phase with confusion.\n- Clinical context and history are crucial in differentiating between the two.\n\n**Clinical Relevance**\nDifferentiating reflex anoxic seizures from epilepsy is essential for avoiding unnecessary investigations and treatment. Recognising the rapid recovery pattern in reflex anoxic seizures helps guide appropriate reassurance and management, while prolonged confusion suggests epilepsy and the need for further neurological assessment, as highlighted in NICE CKS guidelines.\n\n**Memory Anchor**\nRemember: 'A for Anoxic, A for Abrupt recovery'.",
    "bullet_explanations": {
      "Rapid and complete recovery after the event": "This is characteristic of reflex anoxic seizures and distinguishes them from epileptic seizures, which usually have a longer post-ictal period.",
      "Presence of limb jerking during the episode": "Both reflex anoxic and epileptic seizures can have limb jerking, so this does not distinguish between them.",
      "Perioral cyanosis observed during collapse": "Cyanosis can occur in both seizure types due to transient hypoxia.",
      "Initial loss of consciousness with fall to floor": "Sudden collapse is common to both reflex anoxic and epileptic seizures.",
      "Brief pallor preceding the episode": "Pallor is typical in reflex anoxic seizures but can occasionally occur in epilepsy, so it is not reliably distinguishing."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Neurology",
    "topic": "Epilepsy syndromes",
    "keywords": [
      "reflex anoxic seizure",
      "epilepsy",
      "paediatric syncope",
      "post-ictal",
      "differentiation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Epilepsy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/epilepsy/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Blackouts and syncope",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/blackouts-syncope/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7eb3b216-4816-4d6f-8312-135248d2db87",
    "question_number": 164,
    "question": "What is the recommended first-line acute treatment for a 10-year-old presenting with episodic migraine characterised by unilateral headaches, photophobia, and occasional vomiting, who has not responded adequately to paracetamol?",
    "options": [
      "Nasal sumatriptan spray",
      "Amitriptyline prophylaxis",
      "Oral morphine",
      "Regular topiramate",
      "Botulinum toxin injections"
    ],
    "correct_answer": "Nasal sumatriptan spray",
    "explanation": "**Explanation**\n**Nasal sumatriptan spray** is the preferred first-line acute therapy for paediatric migraine when simple analgesics such as paracetamol or ibuprofen are insufficient. Triptans, specifically intranasal formulations like sumatriptan, have demonstrated efficacy and a favourable safety profile in children and adolescents. **Oral triptans are less commonly used in this age group due to slower onset and less evidence.** Prophylactic agents and other interventions are reserved for frequent or disabling attacks and require specialist input. Opioids are strongly discouraged due to risk of medication overuse headache and adverse effects. Botulinum toxin is not indicated for paediatric migraine.\n\n**Key Points**\n- Migraine in children often presents with unilateral, throbbing headaches and associated symptoms (photophobia, nausea, vomiting).\n- First-line acute treatment: simple analgesia (paracetamol or ibuprofen).\n- If inadequate, use **nasal sumatriptan** (a 5HT1-receptor agonist, unlicensed but recommended by BNF and NICE).\n- Antiemetics (e.g., prochlorperazine) may be added if significant nausea or vomiting.\n- Prophylactic medications are considered only for frequent, severe attacks — and usually under specialist care.\n- Opioids and botulinum toxin are not recommended in paediatric migraine management.\n\n**Clinical Relevance**\nRecognising and managing migraine in children is essential in primary care. Guidelines recommend a stepwise approach, starting with simple analgesics and escalating to triptans when needed. Early and appropriate intervention improves quality of life and prevents unnecessary school absence. Always assess for red flag symptoms that might suggest a secondary headache disorder.",
    "bullet_explanations": {
      "Nasal sumatriptan spray": "Correct – recommended first-line acute treatment if simple analgesics fail in children with migraine.",
      "Amitriptyline prophylaxis": "Incorrect – used as a prophylactic agent, not for acute attacks and not first-line in children.",
      "Oral morphine": "Incorrect – opioids are discouraged due to risk of medication overuse headache and other adverse effects.",
      "Regular topiramate": "Incorrect – considered for prophylaxis in severe, frequent migraine, and requires specialist advice; not for acute relief.",
      "Botulinum toxin injections": "Incorrect – not indicated for paediatric migraine, reserved for specific adult cases with chronic migraine."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Headache",
    "topic": "Migraine features",
    "keywords": [
      "paediatric migraine",
      "first-line treatment",
      "sumatriptan nasal spray",
      "acute management",
      "child headache"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Migraine",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/migraine/"
      },
      {
        "source": "BNF",
        "topic_title": "Migraine",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/migraine/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "bef7a728-67d5-4486-a1b5-5c0684aea2b0",
    "question_number": 165,
    "question": "A 61-year-old man with hypertension and a history of chronic kidney disease presents to clinic complaining of an irritating, non-productive cough that started several weeks after beginning ramipril. His blood pressure is well controlled, and he is otherwise asymptomatic. What is the most appropriate adjustment to his antihypertensive regimen?",
    "options": [
      "Switch ramipril to candesartan",
      "Reassure that the cough should resolve spontaneously in a few months",
      "Add a thiazide diuretic to ramipril",
      "Replace ramipril with amlodipine",
      "Advise that the cough is unlikely to be medication-related"
    ],
    "correct_answer": "Switch ramipril to candesartan",
    "explanation": "**Explanation**\n**ACE inhibitors are well known to cause a persistent dry cough in up to 15% of patients**, due to accumulation of bradykinin. This adverse effect can occur any time after initiation, often within weeks. If the cough is troublesome and persistent, the first-line strategy is to discontinue the ACE inhibitor and **switch to an angiotensin II receptor blocker (ARB)** such as candesartan, which offers similar cardiovascular and renal benefits but rarely causes cough, because ARBs do not affect bradykinin metabolism. Continuing the ACE inhibitor in the hope the cough will settle is inappropriate when symptoms interfere with quality of life. Swapping to a calcium channel blocker or adding a thiazide is not guideline-recommended as a direct replacement for ACE inhibitor intolerance, and dismissing the symptom as unrelated risks patient harm.<br><br>**Key Points:**<br><ul><li>ACE inhibitor–induced cough is common and can be persistent</li><li>ARBs are the recommended alternative if cough develops</li><li>ARBs do not increase bradykinin and are unlikely to cause cough</li><li>Continue monitoring BP and renal function after switching</li><li>Do not continue ACE inhibitors if cough is troublesome</li></ul><br><br>**Clinical Relevance:**<br>Recognising and managing ACE inhibitor–induced cough is important to maintain patient adherence and optimise cardiovascular risk reduction. National guidelines (including NICE and BNF) recommend an ARB as the preferred substitute, maximising benefit while minimising adverse effects.<br><br>**Memory Anchor:**<br>ACE = \"A Cough Expected\"; ARB = \"A Rare (Bradykinin) cough\"",
    "bullet_explanations": {
      "Switch ramipril to candesartan": "Correct – ARBs are recommended for patients who develop ACE inhibitor–induced cough.",
      "Reassure that the cough should resolve spontaneously in a few months": "Incorrect – The cough usually persists while on ACE inhibitors and affects quality of life.",
      "Add a thiazide diuretic to ramipril": "Incorrect – Adding a diuretic does not address the cause of cough and is not indicated here.",
      "Replace ramipril with amlodipine": "Incorrect – CCBs are not the first-line substitute for ACE inhibitor intolerance per guidelines.",
      "Advise that the cough is unlikely to be medication-related": "Incorrect – The timing and nature of the cough are highly suggestive of an ACE inhibitor side effect."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "ACE inhibitor intolerance: ARB substitution",
    "keywords": [
      "ACE inhibitor",
      "cough",
      "ARB",
      "hypertension",
      "antihypertensive guidelines"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Drugs affecting the renin-angiotensin system",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/drugs-affecting-the-renin-angiotensin-system/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9f29381a-6c0a-42d1-bc7a-ddc5012e9baf",
    "question_number": 166,
    "question": "A 30-year-old woman, five days after an uncomplicated vaginal delivery, reports feeling overwhelmed, tearful, and irritable. She is struggling with sleep but denies thoughts of self-harm or suicidal ideation. There is no prior psychiatric history. What is the most appropriate next step in her management?",
    "options": [
      "Provide reassurance and normalise her experience",
      "Refer for urgent psychiatric assessment",
      "Initiate selective serotonin reuptake inhibitor therapy",
      "Arrange for cognitive behavioural therapy",
      "Admit to a mother and baby psychiatric unit"
    ],
    "correct_answer": "Provide reassurance and normalise her experience",
    "explanation": "**Explanation**\n**The woman is experiencing the 'baby blues', a common and self-limiting phenomenon affecting up to 70% of new mothers within the first week postpartum.** Symptoms such as mood lability, tearfulness, irritability, and mild anxiety are typical. These symptoms usually resolve spontaneously within two weeks and do not indicate postnatal depression or psychosis. **No active psychological or pharmacological intervention is needed.** Instead, support, empathy, and reassurance are the mainstay. In contrast, postnatal depression typically presents later (after two weeks) and is more severe and persistent, often requiring formal assessment and treatment.\n\n**Key Points**\n- Baby blues typically arise within 3–7 days postpartum and resolve within two weeks.\n- Symptoms include mood swings, tearfulness, anxiety, and irritability.\n- No specific treatment is required; symptoms are self-limiting.\n- Postnatal depression persists beyond two weeks and impacts daily functioning.\n- Risk factors for more serious conditions include personal/family psychiatric history.\n- Active interventions (antidepressants, urgent psychiatric input, or psychotherapy) are not indicated for baby blues.\n\n**Clinical Relevance**\nRecognising the baby blues prevents unnecessary medicalisation and anxiety for new mothers. It is crucial to differentiate between this normal adjustment and pathological postnatal depression, as per NICE guidance, to ensure timely intervention when appropriate.",
    "bullet_explanations": {
      "Provide reassurance and normalise her experience": "Correct. Baby blues require only support, reassurance, and monitoring.",
      "Refer for urgent psychiatric assessment": "Incorrect. There is no indication of psychosis, suicidal ideation, or severe mood disorder.",
      "Initiate selective serotonin reuptake inhibitor therapy": "Incorrect. Antidepressants are not indicated for baby blues, only for confirmed depression.",
      "Arrange for cognitive behavioural therapy": "Incorrect. Psychological therapies are reserved for persistent or severe symptoms.",
      "Admit to a mother and baby psychiatric unit": "Incorrect. Reserved for severe psychiatric illness with risk to mother or infant."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Bleeding in pregnancy",
    "keywords": [
      "baby blues",
      "postnatal mood",
      "early postpartum",
      "normal emotional response"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Depression - antenatal and postnatal",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/depression-antenatal-postnatal/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9c0d7239-a33a-4382-940f-89d619248bd8",
    "question_number": 167,
    "question": "A 67-year-old man residing in a care home is brought to the Emergency Department with a 3-day history of lethargy, productive cough, and confusion. On arrival, he is hypotensive (BP 88/56 mmHg), tachycardic (HR 128 bpm), tachypnoeic (RR 28/min), febrile (38.9°C), and his oxygen saturations are 89% on room air. Auscultation reveals decreased air entry and crackles over the left lung base. After initiating high-flow oxygen, obtaining blood cultures, and establishing intravenous access, what is the most urgent next step in his management?",
    "options": [
      "Start intravenous broad-spectrum antibiotics immediately",
      "Arrange urgent chest CT scan",
      "Request a critical care review before further interventions",
      "Administer intravenous corticosteroids",
      "Prescribe antiviral therapy (e.g., oseltamivir)"
    ],
    "correct_answer": "Start intravenous broad-spectrum antibiotics immediately",
    "explanation": "**Explanation**\nThis patient exhibits signs of severe community-acquired pneumonia with sepsis, as evidenced by confusion, hypotension, hypoxaemia, tachycardia, and raised respiratory rate. **Immediate administration of intravenous broad-spectrum antibiotics is vital and should not be delayed, even while further investigations are ongoing.** Early antimicrobial therapy is the single most effective intervention in reducing sepsis-related mortality; each hour of delay increases the risk of death. Supportive care (oxygen, fluids) is also critical but must be accompanied by timely antibiotics. **Steroids are not routinely indicated for sepsis in the absence of specific indications (e.g., adrenal insufficiency).** Critical care referral is appropriate if the patient deteriorates, but only after completing initial sepsis management steps.\n\n**Key Points**\n<ul><li>Sepsis requires immediate recognition and intervention.</li><li>Give intravenous antibiotics as soon as possible, ideally within an hour.</li><li>High-flow oxygen and intravenous fluids are also part of the initial management ('sepsis six').</li><li>Delaying antibiotics increases mortality risk (8% per hour of delay).</li><li>Steroids are not routinely used unless there is refractory shock or other indications.</li></ul>\n\n**Clinical Relevance**\nEarly antibiotic administration is strongly recommended in national sepsis guidelines and is a key quality indicator in acute care. Delays are associated with avoidable deaths, making this a high-yield area for both exams and clinical practice.\n\n**Memory Anchor**\nRemember: 'Sepsis Six' — O2, IV fluids, IV antibiotics, blood cultures, lactate, urine output.",
    "bullet_explanations": {
      "Start intravenous broad-spectrum antibiotics immediately": "Correct – Timely antibiotics are the most crucial intervention and should follow oxygen and IV access in sepsis.",
      "Arrange urgent chest CT scan": "Incorrect – Imaging may be helpful but must not delay life-saving antibiotics.",
      "Request a critical care review before further interventions": "Incorrect – Initial sepsis management should not be postponed for specialist input.",
      "Administer intravenous corticosteroids": "Incorrect – Steroids are not first-line in sepsis unless there is refractory shock or a specific indication.",
      "Prescribe antiviral therapy (e.g., oseltamivir)": "Incorrect – There is no evidence of viral illness; antibiotics are needed for likely bacterial pneumonia."
    },
    "category": "Respiratory",
    "subsection": "Infective",
    "subsubsection": "Community-Acquired Pneumonia",
    "topic": "Severity scoring (CURB-65) and disposition",
    "keywords": [
      "sepsis",
      "pneumonia",
      "antibiotics",
      "community-acquired",
      "acute management"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "eb779f11-76ec-4cbe-a7fb-510e65ffb711",
    "question_number": 168,
    "question": "What is the most common causative organism of acute epiglottitis in unimmunised young children?",
    "options": [
      "Haemophilus influenzae type b",
      "Neisseria meningitidis group B",
      "Staphylococcus aureus",
      "Streptococcus pneumoniae",
      "Haemophilus influenzae type a"
    ],
    "correct_answer": "Haemophilus influenzae type b",
    "explanation": "**Explanation**\n**Haemophilus influenzae type b (Hib)** is the primary pathogen historically responsible for acute epiglottitis in children, especially those who have not received full immunisation. Hib infection can cause rapid airway obstruction, making this condition a medical emergency. Since the introduction of the Hib vaccine into the UK childhood immunisation schedule, the incidence of epiglottitis due to Hib has dramatically decreased, but it remains a key organism to recognise in at-risk (especially unimmunised) populations. Other bacteria may cause epiglottitis, but Hib remains the classic and most important cause in paediatrics.\n\n**Key Points**\n- Haemophilus influenzae type b is the classical cause of acute epiglottitis in children.\n- Epiglottitis presents with stridor, drooling, and risk of airway compromise.\n- The introduction of the Hib vaccine has made the condition rare in countries with high vaccine coverage.\n- Other organisms (e.g. S. aureus, S. pneumoniae) can cause epiglottitis, but are less common.\n- Hib can also cause severe infections such as meningitis and septicaemia.\n- <table><thead><tr><th>Organism</th><th>Associated Illness</th></tr></thead><tbody><tr><td>H. influenzae type b</td><td>Epiglottitis, meningitis, sepsis</td></tr><tr><td>N. meningitidis B</td><td>Meningococcal meningitis/sepsis</td></tr><tr><td>S. aureus</td><td>Skin/soft tissue infections</td></tr><tr><td>S. pneumoniae</td><td>Pneumonia, otitis media</td></tr></tbody></table>\n\n**Clinical Relevance**\nTimely recognition of Hib as the main cause of paediatric epiglottitis is essential for effective management and public health response, including notification and prophylaxis for contacts. Awareness of the impact of immunisation on disease incidence underpins both acute care and preventive strategies.\n\n**Memory Anchor**\nHib = 'H' for Haemophilus, 'ib' for 'Influenzae b' = 'Hot Infected Breathing' (stridor/drooling)",
    "bullet_explanations": {
      "Haemophilus influenzae type b": "Correct – this is the classic and most important cause of acute epiglottitis in children.",
      "Neisseria meningitidis group B": "Incorrect – usually causes meningitis or septicaemia, not epiglottitis.",
      "Staphylococcus aureus": "Incorrect – can cause respiratory and soft tissue infections but rarely causes epiglottitis.",
      "Streptococcus pneumoniae": "Incorrect – mainly associated with pneumonia and otitis media.",
      "Haemophilus influenzae type a": "Incorrect – a rare cause of invasive disease and not typically associated with epiglottitis."
    },
    "category": "Paediatrics",
    "subsection": "Neonatology",
    "subsubsection": "Sepsis in neonates",
    "topic": "Sepsis in neonates",
    "keywords": [
      "epiglottitis",
      "Haemophilus influenzae type b",
      "paediatric emergency",
      "Hib vaccine",
      "upper airway obstruction"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Haemophilus influenzae type b conjugate vaccine",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/haemophilus-influenzae-type-b-conjugate-vaccine/"
      },
      {
        "source": "BNF",
        "topic_title": "Antibacterials, use for prophylaxis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antibacterials-use-for-prophylaxis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "38494fb3-7bc2-480b-bce8-aee9ac1e179d",
    "question_number": 169,
    "question": "A 17-year-old woman with established type 1 diabetes is admitted with vomiting, abdominal discomfort, and drowsiness after missing several insulin doses due to illness. Her capillary blood glucose is 20 mmol/L, blood ketones are 4.5 mmol/L, and venous blood gas reveals pH 7.18 and bicarbonate 11 mmol/L. After initial intravenous fluid resuscitation, what is the next best step in her acute management?",
    "options": [
      "Commence fixed-rate intravenous insulin infusion (0.1 units/kg/hour) and continue her usual long-acting insulin",
      "Start variable-rate intravenous insulin infusion and stop all subcutaneous insulin",
      "Continue both her short-acting and long-acting subcutaneous insulin while starting fixed-rate IV insulin",
      "Initiate fixed-rate intravenous insulin infusion and discontinue all injectable insulins",
      "Begin variable-rate intravenous insulin infusion and continue only her short-acting insulin"
    ],
    "correct_answer": "Commence fixed-rate intravenous insulin infusion (0.1 units/kg/hour) and continue her usual long-acting insulin",
    "explanation": "**Explanation**\nIn diabetic ketoacidosis (DKA), after initial fluid resuscitation, **fixed-rate intravenous insulin infusion (usually 0.1 units/kg/hour)** is commenced to suppress ketogenesis and reduce blood glucose. **Long-acting (basal) insulin should be continued** to prevent rebound hyperglycaemia or ketosis once the IV insulin is stopped, as its effects persist and overlap. Short-acting (bolus) insulin is withheld to avoid insulin stacking and hypoglycaemia. This protocol is distinct from the management of hyperosmolar hyperglycaemic state (HHS), where insulin may be delayed until after adequate fluid replacement. Variable-rate insulin infusions are not appropriate for DKA, as a fixed rate is needed to address acidosis and ketonaemia effectively.\n\n**Key Points**\n- DKA is diagnosed by hyperglycaemia, ketonaemia (>3 mmol/L), and metabolic acidosis (pH <7.3, bicarbonate <15 mmol/L).\n- Initial management is rapid IV fluid replacement.\n- Fixed-rate IV insulin (0.1 units/kg/hour) is used after fluids to suppress ketone production.\n- Continue long-acting (basal) insulin to ensure basal coverage.\n- Withhold short-acting insulin during IV insulin therapy.\n- Incorrect insulin protocols can lead to rebound ketosis or hypoglycaemia.\n\n**Clinical Relevance**\nCorrect DKA management protocols are essential to reduce the risk of cerebral oedema, hypoglycaemia, and prevent recurrence of ketosis. National guidelines emphasise continuing basal insulin during IV insulin infusions to ensure a smooth transition and safe recovery.",
    "bullet_explanations": {
      "Commence fixed-rate intravenous insulin infusion (0.1 units/kg/hour) and continue her usual long-acting insulin": "This is the recommended protocol for DKA management to ensure ongoing basal insulin coverage and safe resolution of ketosis.",
      "Start variable-rate intravenous insulin infusion and stop all subcutaneous insulin": "Variable-rate insulin is not appropriate for DKA, and omitting basal insulin risks rebound hyperglycaemia.",
      "Continue both her short-acting and long-acting subcutaneous insulin while starting fixed-rate IV insulin": "Short-acting insulin should be withheld to avoid hypoglycaemia and insulin stacking during IV infusion.",
      "Initiate fixed-rate intravenous insulin infusion and discontinue all injectable insulins": "Discontinuing basal insulin can lead to recurrence of ketosis once the IV insulin is stopped.",
      "Begin variable-rate intravenous insulin infusion and continue only her short-acting insulin": "Variable-rate insulin and continuation of only short-acting insulin is incorrect and unsafe in DKA."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Acute",
    "subsubsection": "DKA",
    "topic": "Fluid and insulin protocol",
    "keywords": [
      "DKA",
      "fixed-rate insulin",
      "basal insulin",
      "acute diabetes management",
      "IV fluids"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetic hyperglycaemic emergencies",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetic-hyperglycaemic-emergencies/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7d53365a-ce1d-4732-ba1a-9f694a3bd434",
    "question_number": 170,
    "question": "A 24-year-old woman attends your clinic with a 10-day history of a pink, slightly scaly oval patch on her upper arm, followed by the recent appearance of several smaller, similar lesions distributed symmetrically across her trunk and proximal limbs. She denies any systemic symptoms and is otherwise well. What is the most likely diagnosis?",
    "options": [
      "Pityriasis rosea",
      "Guttate psoriasis",
      "Nummular eczema",
      "Tinea corporis",
      "Lichen planus"
    ],
    "correct_answer": "Pityriasis rosea",
    "explanation": "**Explanation**\n**Pityriasis rosea** is an acute, self-limiting rash that typically begins with a single, larger 'herald patch'—a pink, round or oval, slightly scaly lesion. Within days to weeks, multiple smaller, salmon-coloured patches appear, often distributed along the lines of skin tension on the trunk and proximal limbs, creating a 'Christmas tree' pattern. The herald patch and the secondary eruption, combined with an absence of systemic symptoms, are highly characteristic and distinguish pityriasis rosea from conditions like guttate psoriasis (which lacks a herald patch and is more scaly), tinea corporis (which often has central clearing and is more annular), and lichen planus (which features violaceous, flat-topped papules).\n\n\n\n**Key Points**\n<ul><li>Herald patch often precedes secondary rash by several days to weeks.</li><li>Common in young adults (10–35 years).</li><li>Lesions are oval, pink/red, slightly raised and scaly, mainly on trunk and proximal limbs.</li><li>Distribution is typically symmetrical and may follow skin cleavage lines.</li><li>Condition is self-limiting, usually resolving within 2–3 months.</li></ul>\n<table><thead><tr><th>Feature</th><th>Pityriasis rosea</th><th>Guttate psoriasis</th></tr></thead><tbody><tr><td>Initial lesion</td><td>Herald patch</td><td>No herald patch</td></tr><tr><td>Secondary rash</td><td>Oval, scaly, 'Christmas tree'</td><td>Small 'tear drop' papules</td></tr><tr><td>Systemic symptoms</td><td>Absent</td><td>Sometimes (sore throat)</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising pityriasis rosea is important to avoid unnecessary investigations and reassure patients, as it is benign and self-limiting. Most cases require no treatment beyond symptomatic relief for itch. Awareness of characteristic features helps differentiate it from other rashes with similar presentations.\n\n**Memory Anchor**\nThe 'herald patch' is the classic clue—think of it as a 'herald' announcing the arrival of the generalised rash.",
    "bullet_explanations": {
      "Pityriasis rosea": "Correct – classic history of herald patch followed by multiple smaller lesions in a symmetrical pattern.",
      "Guttate psoriasis": "Incorrect – usually presents as numerous small, tear-drop, scaly papules, often after streptococcal infection, without a herald patch.",
      "Nummular eczema": "Incorrect – typically features coin-shaped plaques but lacks a herald patch and characteristic distribution.",
      "Tinea corporis": "Incorrect – annular lesions with central clearing and active edge, and usually not preceded by a single larger lesion.",
      "Lichen planus": "Incorrect – presents as violaceous, flat-topped papules, often with Wickham's striae, not a herald patch."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Eczema/atopic dermatitis",
    "keywords": [
      "pityriasis rosea",
      "herald patch",
      "rash diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Pityriasis rosea",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/pityriasis-rosea/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a24f02ba-c62b-42d5-ac53-fa134c92c3c3",
    "question_number": 171,
    "question": "Which primary headache disorder is characteristically treated with high-flow 100% oxygen during acute attacks?",
    "options": [
      "Cluster headache",
      "Migraine",
      "Tension-type headache",
      "Giant cell arteritis",
      "Medication overuse headache"
    ],
    "correct_answer": "Cluster headache",
    "explanation": "**Explanation**\n**Cluster headache** is a severe, unilateral headache often centred around the eye, accompanied by autonomic symptoms such as lacrimation, nasal congestion, and restlessness. Acute attacks are typically aborted using either **subcutaneous or intranasal triptans** or high-flow 100% oxygen therapy, which is unique among primary headaches. Neither migraines nor tension-type headaches respond to oxygen therapy. Cluster headaches are characterised by frequent, short-lasting (15 minutes to 3 hours) attacks, often occurring in bouts (clusters) over several weeks. Giant cell arteritis and medication overuse headache are not managed with oxygen.\n\n**Key Points**\n- Cluster headache: excruciating, unilateral, orbital/supraorbital pain\n- Associated with ipsilateral autonomic features (tearing, redness, nasal symptoms)\n- Short attacks (15 mins – 3 hours), often in 'clusters' over weeks\n- Acute treatment: high-flow 100% oxygen or subcutaneous/intranasal triptans\n- Other headache types (migraine, tension-type, GCA, MOH) are not managed with oxygen\n\n**Clinical Relevance**\nRecognising cluster headache is crucial, as its management differs markedly from other headache types; oxygen therapy provides rapid relief and should be considered in all confirmed cases, as recommended by NICE and the BNF.\n\n**Memory Anchor**\nCluster = 'clouds' of attacks = Oxygen for relief",
    "bullet_explanations": {
      "Cluster headache": "Correct – Oxygen therapy is an established first-line treatment for acute cluster headache attacks.",
      "Migraine": "Incorrect – Oxygen is not routinely effective for migraine; first-line treatments include NSAIDs and triptans.",
      "Tension-type headache": "Incorrect – Managed with simple analgesia and lifestyle measures, not oxygen.",
      "Giant cell arteritis": "Incorrect – Requires urgent corticosteroids; oxygen has no role.",
      "Medication overuse headache": "Incorrect – Managed by withdrawal of overused medication, not oxygen."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Headache",
    "topic": "Cluster headache",
    "keywords": [
      "cluster headache",
      "oxygen therapy",
      "primary headache",
      "acute treatment",
      "trigeminal autonomic cephalalgia"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Headache - cluster",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/headache-cluster/"
      },
      {
        "source": "BNF",
        "topic_title": "Cluster headache and other trigeminal autonomic cephalalgias",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/cluster-headache-and-other-trigeminal-autonomic-cephalalgias/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "328911a0-e085-4e7d-bde6-534835c17796",
    "question_number": 172,
    "question": "A 7-year-old girl develops a sudden onset of fever and sore throat. Two days later, she presents with a fine, rough, erythematous rash over her trunk and flexures, sparing her palms and soles. Examination reveals circumoral pallor and a 'strawberry' tongue. What is the recommended first-line treatment for this condition?",
    "options": [
      "Oral phenoxymethylpenicillin (penicillin V) for 10 days and exclusion from school for 24 hours after starting antibiotics",
      "Symptomatic care only with calamine lotion and exclusion until all lesions have crusted",
      "Initiate oral aciclovir for 10 days",
      "High-dose aspirin therapy",
      "No medication required; return to school when afebrile"
    ],
    "correct_answer": "Oral phenoxymethylpenicillin (penicillin V) for 10 days and exclusion from school for 24 hours after starting antibiotics",
    "explanation": "**Explanation**\nThe child is displaying classic features of **scarlet fever**, a toxin-mediated illness caused by Group A Streptococcus. Key clinical features include a sore throat, fever, and a characteristic sandpaper-like rash, often accompanied by circumoral pallor and a 'strawberry' tongue. Management involves a **10-day course of oral phenoxymethylpenicillin (penicillin V)** to reduce symptom duration, prevent complications, and decrease transmission. School exclusion is advised until at least **24 hours after starting antibiotics**, as infectivity drops significantly after this period. Delaying or omitting antibiotics increases risk of suppurative (e.g. otitis media) and non-suppurative complications (e.g. rheumatic fever, post-streptococcal glomerulonephritis).<br><br>Alternative antibiotics are reserved for those with penicillin allergy.\n\n**Key Points**\n<ul><li>Scarlet fever presents with fever, sore throat, and a sandpaper-like rash sparing palms/soles.</li><li>First-line treatment: oral phenoxymethylpenicillin (penicillin V) for 10 days.</li><li>Exclude from school for at least 24 hours after starting antibiotics.</li><li>Complications include otitis media, peritonsillar abscess, rheumatic fever, and glomerulonephritis.</li><li>Antibiotic treatment reduces symptom severity, transmission, and risk of complications.</li></ul><table><thead><tr><th>Feature</th><th>Scarlet Fever</th></tr></thead><tbody><tr><td>Rash texture</td><td>Sandpaper, punctate</td></tr><tr><td>Tongue</td><td>'Strawberry'</td></tr><tr><td>School exclusion</td><td>24h after antibiotics</td></tr></tbody></table>\n\n**Clinical Relevance**\nScarlet fever is a notifiable, highly contagious illness in children. Prompt antibiotic therapy is recommended to prevent complications and limit outbreaks, as per national guidance. Recognising the classic presentation and instituting correct management is crucial for patient safety and public health.\n\n**Memory Anchor**\nScarlet fever: 'Strawberry tongue' and 'Sandpaper rash'—treat with Penicillin V for 10 days.",
    "bullet_explanations": {
      "Oral phenoxymethylpenicillin (penicillin V) for 10 days and exclusion from school for 24 hours after starting antibiotics": "Correct—this is the recommended first-line management for scarlet fever.",
      "Symptomatic care only with calamine lotion and exclusion until all lesions have crusted": "Incorrect—this is appropriate for chickenpox, not scarlet fever.",
      "Initiate oral aciclovir for 10 days": "Incorrect—aciclovir is used for varicella-zoster infections (e.g. chickenpox), not for scarlet fever.",
      "High-dose aspirin therapy": "Incorrect—this is indicated for Kawasaki disease, not for scarlet fever.",
      "No medication required; return to school when afebrile": "Incorrect—scarlet fever requires antibiotic treatment to prevent complications and transmission."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Community vs hospital-acquired pneumonia",
    "keywords": [
      "scarlet fever",
      "penicillin V",
      "childhood rash",
      "sandpaper rash",
      "school exclusion"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Scarlet fever",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/scarlet-fever/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8790d035-3748-4af1-92ed-1cb9d7ff74cc",
    "question_number": 173,
    "question": "A 34-year-old woman reports sudden onset weakness affecting the entire right side of her face. She is unable to close her right eye fully or raise her right eyebrow. No limb weakness, dysphasia, or sensory deficits are present. Which type of facial nerve lesion best explains her symptoms?",
    "options": [
      "Right facial nerve lower motor neuron lesion",
      "Right facial nerve upper motor neuron lesion",
      "Left facial nerve upper motor neuron lesion",
      "Lateral medullary syndrome",
      "Left facial nerve lower motor neuron lesion"
    ],
    "correct_answer": "Right facial nerve lower motor neuron lesion",
    "explanation": "**Explanation**\n**Lower motor neuron (LMN) lesions of the facial nerve cause weakness of all muscles of facial expression on the affected side, including both the forehead and lower face.** This is because the LMN supplies the entire ipsilateral side of the face. In contrast, upper motor neuron (UMN) lesions typically spare the forehead due to bilateral cortical innervation. In this case, inability to close the eye and raise the eyebrow, along with mouth droop, indicate that both upper and lower facial muscles are involved, supporting a LMN lesion. There are no other neurological deficits, making other causes like stroke or brainstem syndromes less likely.\n\n**Key Points**\n<ul><li>LMN facial nerve lesions involve both upper and lower facial muscles on one side, including the forehead.</li><li>UMN facial nerve lesions typically spare forehead movement due to dual innervation.</li><li>Bell's palsy is the most common cause of acute, unilateral LMN facial weakness in the absence of other neurological symptoms.</li><li>Associated symptoms can include inability to close the eye, loss of nasolabial fold, and drooping of the mouth.</li><li>Presence of additional neurological deficits suggests alternative diagnoses, such as brainstem stroke.</li></ul>\n\n**Clinical Relevance**\nDistinguishing between upper and lower motor neuron facial nerve lesions is essential in the acute setting to guide management, referral, and investigation. Bell's palsy presents as a lower motor neuron lesion and is a clinical diagnosis made when other causes of facial weakness are excluded. Prompt recognition ensures appropriate eye care and consideration of corticosteroid therapy, as outlined in national guidelines.\n\n**Memory Anchor**\nLMN = 'Lose the entire side' (forehead + mouth); UMN = 'Upper face is Upheld'",
    "bullet_explanations": {
      "Right facial nerve lower motor neuron lesion": "Correct – causes complete unilateral facial weakness, including forehead and eye closure.",
      "Right facial nerve upper motor neuron lesion": "Incorrect – would spare the forehead due to bilateral upper facial innervation.",
      "Left facial nerve upper motor neuron lesion": "Incorrect – would cause right lower facial weakness only, with forehead sparing.",
      "Lateral medullary syndrome": "Incorrect – presents with vertigo, ataxia, and multiple cranial nerve deficits, not isolated facial weakness.",
      "Left facial nerve lower motor neuron lesion": "Incorrect – would cause left-sided total facial weakness, not right."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Stroke & TIA",
    "topic": "FAST/TIA recognition",
    "keywords": [
      "facial nerve",
      "lower motor neuron",
      "Bell's palsy",
      "neurology",
      "facial weakness"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Bell's palsy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/bells-palsy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0d002022-d563-4214-9d47-721f85db1bbf",
    "question_number": 174,
    "question": "A 54-year-old man is referred to endocrinology after routine blood tests reveal elevated calcium at 2.85 mmol/L (reference 2.1–2.6) and low phosphate at 0.68 mmol/L (reference 0.8–1.4). He reports mild fatigue and recent episodes of constipation but feels otherwise well. His parathyroid hormone (PTH) is 49 pg/mL (reference 10–55), and his vitamin D is within the normal range. What is the most likely underlying diagnosis?",
    "options": [
      "Primary hyperparathyroidism",
      "Secondary hyperparathyroidism",
      "Tertiary hyperparathyroidism",
      "Milk-alkali syndrome",
      "Hypervitaminosis D"
    ],
    "correct_answer": "Primary hyperparathyroidism",
    "explanation": "**Explanation**\n**Primary hyperparathyroidism** is characterised by excessive secretion of parathyroid hormone (PTH), most often due to a benign adenoma. This leads to persistent hypercalcaemia and hypophosphataemia, as seen in this patient. PTH may fall anywhere within or just above the reference range, but is 'inappropriately normal' in the context of high calcium, as a healthy response would be PTH suppression. Key symptoms such as fatigue and constipation are typical of hypercalcaemia. Secondary and tertiary hyperparathyroidism are associated with chronic renal disease and do not present with isolated hypercalcaemia. Milk-alkali syndrome and hypervitaminosis D may cause hypercalcaemia, but would not feature a raised or inappropriately unsuppressed PTH.\n\n**Key Points**\n<ul><li>Primary hyperparathyroidism most often presents with hypercalcaemia and hypophosphataemia.</li><li>PTH is elevated or 'inappropriately normal' relative to calcium level.</li><li>Common symptoms: fatigue, constipation, thirst, polyuria.</li><li>Distinguish from secondary/tertiary hyperparathyroidism, which are typically associated with renal pathology.</li><li>Other causes of hypercalcaemia (e.g., vitamin D toxicity, milk-alkali syndrome) suppress PTH.</li><li>See table below for key differences:</li></ul><table><thead><tr><th>Condition</th><th>Calcium</th><th>PTH</th><th>Phosphate</th></tr></thead><tbody><tr><td>Primary HPT</td><td>High</td><td>Normal/high</td><td>Low</td></tr><tr><td>Secondary HPT</td><td>Low/normal</td><td>High</td><td>Low/high</td></tr><tr><td>Tertiary HPT</td><td>High</td><td>High</td><td>Low/high</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising primary hyperparathyroidism is crucial as it is a frequent cause of hypercalcaemia, particularly in older adults. Early diagnosis allows appropriate management, including assessment for parathyroidectomy, osteoporosis risk, and monitoring for complications such as nephrolithiasis and cardiovascular disease. NICE and BNF guidance recommend thorough evaluation and consider surgery as first-line treatment where appropriate.\n\n**Memory Anchor**\nThink 'bones, stones, abdominal groans, and psychic moans' for hypercalcaemia in primary hyperparathyroidism.",
    "bullet_explanations": {
      "Primary hyperparathyroidism": "Correct—fits the biochemical profile (high calcium, low phosphate, non-suppressed PTH) and typical symptoms.",
      "Secondary hyperparathyroidism": "Incorrect—usually occurs in chronic renal disease with low/normal calcium and raised PTH.",
      "Tertiary hyperparathyroidism": "Incorrect—seen in chronic renal failure, with very high PTH and usually longstanding history.",
      "Milk-alkali syndrome": "Incorrect—hypercalcaemia with suppressed PTH, typically due to excessive calcium/alkali intake.",
      "Hypervitaminosis D": "Incorrect—causes hypercalcaemia and suppressed PTH; vitamin D level is not elevated here."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Calcium, Pituitary & Metabolic",
    "subsubsection": "Calcium Disorders",
    "topic": "Hypercalcaemia (PTH-mediated vs non-PTH)",
    "keywords": [
      "primary hyperparathyroidism",
      "hypercalcaemia",
      "PTH",
      "diagnosis",
      "endocrinology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hyperparathyroidism",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hyperparathyroidism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d0a347b5-9eeb-4f13-8d3d-cfde07363da9",
    "question_number": 175,
    "question": "A 58-year-old woman with a history of hypertension and mild COPD attends for review of her exertional chest discomfort, occurring reliably when she walks uphill. She is currently taking diltiazem and uses glyceryl trinitrate spray as needed. Despite this, her symptoms persist. Which additional medication is most appropriate to add for further symptom control?",
    "options": [
      "Isosorbide mononitrate",
      "Atenolol",
      "Bisoprolol",
      "Ivabradine",
      "Paracetamol"
    ],
    "correct_answer": "Isosorbide mononitrate",
    "explanation": "**Explanation**\n**Isosorbide mononitrate** is a long-acting nitrate, recommended as a next-line antianginal therapy when symptoms persist despite optimal use of a rate-limiting calcium channel blocker and when beta-blockers are contraindicated (e.g., due to COPD, asthma, or intolerance). Beta-blockers and non-dihydropyridine calcium channel blockers (like diltiazem or verapamil) should not be combined because of the risk of severe bradycardia or heart block. NICE and BNF guidelines recommend considering a long-acting nitrate, ivabradine, nicorandil, or ranolazine in this scenario. Isosorbide mononitrate is well established for reducing angina frequency and improving exercise tolerance, making it the preferred option here. \n\n**Key facts:** Beta-blockers are first-line, but contraindicated in significant airflow limitation; when monotherapy fails, add a drug from another class unless contraindicated; and do not combine rate-limiting CCBs with beta-blockers.\n\n**Key Points**\n<ul><li>Long-acting nitrates are second-line for stable angina if beta-blockers are contraindicated or not tolerated.</li><li>Beta-blockers should be avoided in patients with significant obstructive lung disease and when using rate-limiting CCBs.</li><li>Diltiazem and verapamil must not be combined with beta-blockers due to risk of bradyarrhythmia.</li><li>Alternative add-on therapies include ivabradine, nicorandil, or ranolazine.</li><li>Paracetamol has no role in angina management.</li></ul>\n\n**Clinical Relevance**\nIn clinical practice, selecting antianginal therapy requires careful consideration of comorbidities. For patients with respiratory disease or those on rate-limiting calcium channel blockers, beta-blockers are inappropriate. Guidance from NICE and BNF supports the use of long-acting nitrates or other non-beta-blocker options to optimise angina control and reduce cardiovascular risk.\n\n**Memory Anchor**\nThink 'N' for 'Nitrate' when 'N'ot suitable for beta-blocker or 'N'on-dihydropyridine CCB combination.",
    "bullet_explanations": {
      "Isosorbide mononitrate": "Correct. A long-acting nitrate is recommended next-line when beta-blockers are contraindicated and symptoms persist despite a rate-limiting CCB.",
      "Atenolol": "Incorrect. Beta-blockers are contraindicated with COPD and should not be used with diltiazem due to bradycardia risk.",
      "Bisoprolol": "Incorrect. Similar to atenolol, bisoprolol is a beta-blocker and is unsuitable in this context.",
      "Ivabradine": "Incorrect. While a possible alternative, isosorbide mononitrate is more established; ivabradine is generally reserved if nitrates are not tolerated or effective.",
      "Paracetamol": "Incorrect. Paracetamol does not treat angina and has no role in antianginal therapy."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Stable Coronary Disease",
    "topic": "Antianginal therapy ladder (beta-blocker, CCB, nitrates, nicorandil)",
    "keywords": [
      "stable angina",
      "antianginal therapy",
      "nitrates",
      "beta-blocker contraindication",
      "calcium channel blocker"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Stable angina",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/stable-angina/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Angina",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/angina/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5cfeaa33-db55-4ea7-95d8-198f75e12baa",
    "question_number": 176,
    "question": "Which antipsychotic is least likely to cause hyperprolactinaemia in a patient who develops galactorrhoea and breast discomfort while being treated for schizophrenia?",
    "options": [
      "Aripiprazole",
      "Chlorpromazine",
      "Olanzapine",
      "Risperidone",
      "Amisulpride"
    ],
    "correct_answer": "Aripiprazole",
    "explanation": "**Explanation**\n**Aripiprazole** is distinguished among antipsychotics by its low propensity to elevate prolactin levels, making it the preferred option in patients who experience symptoms of hyperprolactinaemia, such as breast tenderness, enlargement, or galactorrhoea, during antipsychotic therapy. This is due to its unique partial agonist activity at dopamine D2 receptors, which contrasts with the antagonistic action of most other antipsychotics that commonly increase prolactin. In contrast, risperidone and amisulpride are well known for causing significant prolactin elevation, and typical antipsychotics like chlorpromazine can also raise prolactin. Olanzapine can cause mild increases but is less likely than risperidone or amisulpride.\n\n**Key Points**\n- Antipsychotics that are dopamine antagonists (especially D2 antagonists) commonly cause hyperprolactinaemia.\n- Symptoms of hyperprolactinaemia include galactorrhoea, breast tenderness, menstrual irregularities, and sexual dysfunction.\n- Aripiprazole is a partial D2 agonist and is least likely to elevate prolactin.\n- Risperidone and amisulpride are associated with high rates of prolactin-related side effects.\n- Chlorpromazine, a typical antipsychotic, also commonly increases prolactin.\n- Olanzapine has a lower risk but is not completely free from this side effect.\n\n**Clinical Relevance**\nUnderstanding the side effect profiles of antipsychotic medications allows clinicians to tailor therapy to individual needs, reducing the burden of adverse effects and improving adherence. Minimising prolactin-related side effects is especially important in young adults and women, where symptoms may cause distress or impact long-term health.\n\n**Memory Anchor**\n‘A’ for Aripiprazole and ‘A’ for Absent (prolactin rise).",
    "bullet_explanations": {
      "Aripiprazole": "Correct – minimal risk of increasing prolactin; ideal for patients with hyperprolactinaemia.",
      "Chlorpromazine": "Incorrect – typical antipsychotic with a high likelihood of prolactin elevation.",
      "Olanzapine": "Incorrect – may cause mild prolactin elevation, but risk is lower than risperidone or amisulpride.",
      "Risperidone": "Incorrect – among the highest risk for increasing prolactin.",
      "Amisulpride": "Incorrect – also strongly associated with hyperprolactinaemia."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Psychosis & Anxiety",
    "subsubsection": "Schizophrenia",
    "topic": "Antipsychotic choice",
    "keywords": [
      "antipsychotic",
      "hyperprolactinaemia",
      "aripiprazole",
      "side effects",
      "schizophrenia"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "7d683a15-68d8-4f87-b58c-2f732267af91",
    "question_number": 177,
    "question": "A 65-year-old man with long-standing hypothyroidism is found to have a suppressed TSH and elevated free T4 on his latest blood tests after an increase in his levothyroxine dose. What long-term complication is he at particular risk of if his thyroid hormone levels remain excessive?",
    "options": [
      "Osteoporosis",
      "Hyperparathyroidism",
      "Type 2 diabetes mellitus",
      "Conn's syndrome",
      "Graves’ ophthalmopathy"
    ],
    "correct_answer": "Osteoporosis",
    "explanation": "**Explanation**\n**Excess thyroid hormone from over-replacement with levothyroxine accelerates bone turnover, increasing osteoclast-mediated bone resorption and reducing bone mineral density.** Chronic suppression of TSH and persistently high free T4, as seen in this patient, is a recognised risk factor for osteoporosis, especially in the elderly. This outcome is unrelated to the underlying cause of hypothyroidism; it results from iatrogenic thyrotoxicosis. Monitoring thyroid function and adjusting levothyroxine dosing is essential to mitigate this risk. Other endocrine complications (e.g., Conn’s syndrome or Graves’ ophthalmopathy) are not directly linked to excess levothyroxine.\n\n**Key Points**\n- Levothyroxine over-replacement can cause subclinical or overt thyrotoxicosis.\n- Iatrogenic thyrotoxicosis is associated with increased risk of osteoporosis.\n- Excess thyroid hormone increases bone resorption via osteoclast activation.\n- Elderly patients are particularly vulnerable to bone loss and fractures.\n- Routine monitoring of TSH and free T4 helps prevent overtreatment.\n- <table><thead><tr><th>Effect</th><th>Levothyroxine Over-replacement</th></tr></thead><tbody><tr><td>TSH</td><td>Suppressed</td></tr><tr><td>Free T4</td><td>Elevated</td></tr><tr><td>Risk</td><td>Osteoporosis, atrial fibrillation</td></tr></tbody></table>\n\n**Clinical Relevance**\nEnsuring appropriate levothyroxine dosing in hypothyroid patients minimises the risk of osteoporosis, especially in older adults. Regular thyroid function monitoring and dose adjustment in line with guidelines are crucial to safe long-term management.\n\n**Memory Anchor**\nThink 'Thyroxine Thins the Bones' as a reminder of over-replacement and osteoporosis risk.",
    "bullet_explanations": {
      "Osteoporosis": "Correct – Excess thyroid hormone increases bone resorption, raising osteoporosis risk with prolonged over-replacement.",
      "Hyperparathyroidism": "Incorrect – Not caused by excess thyroid hormone; unrelated to levothyroxine dosing.",
      "Type 2 diabetes mellitus": "Incorrect – No direct link to thyroxine over-replacement.",
      "Conn's syndrome": "Incorrect – Primary hyperaldosteronism, not associated with thyroid hormone levels.",
      "Graves’ ophthalmopathy": "Incorrect – Specific to Graves’ disease, not iatrogenic thyrotoxicosis from levothyroxine."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Thyroid",
    "subsubsection": "Hypothyroidism",
    "topic": "Levothyroxine dosing/monitoring",
    "keywords": [
      "levothyroxine",
      "osteoporosis",
      "thyroxine over-replacement",
      "TSH suppression"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hypothyroidism",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hypothyroidism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2b71c1f6-0ce7-4657-8dfd-42308bd4f0af",
    "question_number": 178,
    "question": "A 59-year-old man with type 2 diabetes has persistent hyperglycaemia (HbA1c 66 mmol/mol) despite being on the maximum tolerated dose of metformin. He previously discontinued a sulfonylurea due to repeated hypoglycaemic episodes. His BMI is 25 kg/m², and he has no evidence of cardiovascular or renal disease. What is the most appropriate next pharmacological step to improve his glycaemic control?",
    "options": [
      "Add either a DPP-4 inhibitor, pioglitazone, or an SGLT2 inhibitor",
      "Initiate basal insulin therapy",
      "Refer for bariatric surgery",
      "Start GLP-1 receptor agonist (e.g., exenatide)",
      "Switch to repaglinide monotherapy"
    ],
    "correct_answer": "Add either a DPP-4 inhibitor, pioglitazone, or an SGLT2 inhibitor",
    "explanation": "**Explanation**\n**For patients with type 2 diabetes who remain inadequately controlled on metformin and cannot tolerate sulfonylureas (due to hypoglycaemia or other adverse effects), UK guidelines recommend adding a DPP-4 inhibitor, pioglitazone (a thiazolidinedione), or an SGLT2 inhibitor as the next step.** Each of these agents offers distinct benefits: DPP-4 inhibitors have a low risk of hypoglycaemia; pioglitazone improves insulin sensitivity (but may cause weight gain); SGLT2 inhibitors can promote mild weight loss and may benefit cardiovascular outcomes, though these advantages are most relevant in those with established CV disease or high risk. GLP-1 receptor agonists (e.g., exenatide) are reserved for specific indications, typically after failure of triple oral therapy or in patients with higher BMI. Insulin is considered when oral therapies fail. Bariatric surgery is not indicated unless BMI is ≥35 kg/m² (or sometimes ≥30 with comorbidities). Repaglinide is rarely used and unsuitable for combination therapy beyond metformin.\n\n**Key Points**\n- If metformin alone is inadequate and sulfonylureas are not tolerated, add a DPP-4 inhibitor, pioglitazone, or SGLT2 inhibitor.\n- DPP-4 inhibitors: weight neutral, low hypoglycaemia risk.\n- SGLT2 inhibitors: promote weight loss, potential CV/renal benefits.\n- Pioglitazone: improves insulin sensitivity but may cause weight gain and fluid retention.\n- GLP-1 RAs are injectable and reserved for patients with high BMI or after failure of triple oral therapy.\n- Insulin is reserved for those not controlled on triple therapy.\n- Bariatric surgery is only considered for BMI ≥35 kg/m² (or ≥30 with complications).\n\n**Clinical Relevance**\nSelecting the appropriate oral therapy escalation in type 2 diabetes is crucial for optimising glycaemic control while minimising adverse effects, especially hypoglycaemia. UK and international guidelines support a tailored approach based on comorbidities, previous drug tolerance, and patient preference. This knowledge is essential for safe and effective diabetes management in primary care and specialist settings.",
    "bullet_explanations": {
      "Add either a DPP-4 inhibitor, pioglitazone, or an SGLT2 inhibitor": "Correct—recommended next oral agents if metformin alone is insufficient and sulfonylureas are not tolerated.",
      "Initiate basal insulin therapy": "Insulin is reserved for inadequate glycaemic control despite triple oral therapy, not as the immediate next step.",
      "Refer for bariatric surgery": "Not indicated at BMI 25 kg/m²; surgery is reserved for BMI ≥35 kg/m² (or ≥30 with comorbidities).",
      "Start GLP-1 receptor agonist (e.g., exenatide)": "GLP-1 RAs are injectable and generally reserved for those with higher BMI or after failure of triple therapy.",
      "Switch to repaglinide monotherapy": "Repaglinide is rarely used and not suitable for escalation beyond metformin if combination therapy is needed."
    },
    "category": "Diabetes – Chronic",
    "subsection": "Type 2 Diabetes",
    "subsubsection": "Metformin first-line and intolerance",
    "topic": "Metformin first-line and intolerance",
    "keywords": [
      "type 2 diabetes",
      "oral hypoglycaemic agents",
      "triple therapy",
      "DPP-4 inhibitor",
      "SGLT2 inhibitor"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Type 2 diabetes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/type-2-diabetes/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e9d02cf6-8243-4af7-bc16-8213a033b161",
    "question_number": 179,
    "question": "A 42-year-old man presents with gradual hearing loss in his left ear. On examination, Rinne's test is positive bilaterally (air conduction lasts longer than bone conduction), but Weber's test lateralises to the right ear. What is the most likely explanation for these findings?",
    "options": [
      "Left sensorineural hearing loss",
      "Normal bilateral hearing",
      "Right conductive hearing loss",
      "Bilateral conductive hearing loss",
      "Right sensorineural hearing loss"
    ],
    "correct_answer": "Left sensorineural hearing loss",
    "explanation": "**Explanation**\n**Rinne's test** is considered 'positive' when air conduction (AC) is greater than bone conduction (BC), which is normal or seen in sensorineural hearing loss. **Weber's test** lateralises to the unaffected (right) side in the presence of a sensorineural deficit on the opposite (left) side. This occurs because the affected ear is less able to perceive the sound transmitted via bone conduction. If there were a conductive loss, Weber's would lateralise to the affected side and Rinne's would be negative (BC > AC) on that side. Therefore, the findings indicate a sensorineural deficit in the left ear.\n\n**Key Points**\n- Rinne's: AC > BC = normal or sensorineural loss\n- Weber's: Lateralises to unaffected ear in sensorineural loss\n- Weber's: Lateralises to affected ear in conductive loss\n- Conductive loss: Rinne's negative (BC > AC)\n- Sensorineural loss: Rinne's positive (AC > BC), Weber's lateralises to opposite side\n- <table><thead><tr><th>Type</th><th>Rinne's</th><th>Weber's</th></tr></thead><tbody><tr><td>Normal</td><td>AC > BC</td><td>Midline</td></tr><tr><td>Conductive</td><td>BC > AC (affected)</td><td>Lateralises to affected</td></tr><tr><td>Sensorineural</td><td>AC > BC</td><td>Lateralises to unaffected</td></tr></tbody></table>\n\n**Clinical Relevance**\nDistinguishing between conductive and sensorineural hearing loss is critical for diagnosis and appropriate referral. Tuning fork tests provide a rapid bedside assessment, enabling targeted further investigation and management, as highlighted in NICE guidelines.\n\n**Memory Anchor**\nWeber goes to the 'Wrong' side in sensorineural loss (i.e., the unaffected ear).",
    "bullet_explanations": {
      "Left sensorineural hearing loss": "Correct – sensorineural loss on the left causes Weber to lateralise to the right, with Rinne's positive bilaterally.",
      "Normal bilateral hearing": "Incorrect – normal hearing would show Rinne's positive and Weber's central (no lateralisation).",
      "Right conductive hearing loss": "Incorrect – would present with Weber's lateralising to the right and Rinne's negative on the right.",
      "Bilateral conductive hearing loss": "Incorrect – both Rinne's would be negative (BC > AC), and Weber's would not lateralise.",
      "Right sensorineural hearing loss": "Incorrect – would cause Weber's to lateralise to the left (unaffected side), not the right."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Hearing loss causes",
    "keywords": [
      "Rinne test",
      "Weber test",
      "sensorineural hearing loss",
      "tuning fork",
      "ENT"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hearing loss in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hearing-loss-in-adults/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7904e7d1-5109-4948-85d1-d0137327ff20",
    "question_number": 180,
    "question": "A 28-year-old woman presents to the urgent care centre with a swollen left ankle and pain on movement. She also notes recent dysuria and a gritty sensation in her eyes. Two weeks ago, she experienced self-limiting diarrhoea following travel abroad. Which is the most appropriate initial management for her joint symptoms?",
    "options": [
      "Begin regular ibuprofen and refer to rheumatology",
      "Start 6 months of low-dose oral prednisolone",
      "Initiate methotrexate therapy",
      "Prescribe sulfasalazine immediately",
      "Administer a single high-dose course of oral prednisolone"
    ],
    "correct_answer": "Begin regular ibuprofen and refer to rheumatology",
    "explanation": "**Explanation**\nThis clinical scenario is indicative of **acute reactive arthritis**, which classically presents with an asymmetric oligoarthritis, often following a gastrointestinal or genitourinary infection. Extra-articular features such as urethritis and conjunctivitis support the diagnosis. The cornerstone of initial management is a **nonsteroidal anti-inflammatory drug (NSAID)** for symptom control, provided there are no contraindications. DMARDs such as methotrexate or sulfasalazine are reserved for persistent or chronic cases and should not be initiated acutely. Oral steroids may be considered in selected cases, but intra-articular steroids are generally preferred for mono- or oligoarthritis. A referral to rheumatology is indicated for confirmation of diagnosis and ongoing management planning.<br><br><b>Key contrasts:</b> Unlike methotrexate or sulfasalazine (which are for chronic, persistent symptoms), NSAIDs are first-line for acute presentations. Prolonged or high-dose oral steroids are not routine first-line therapy.\n\n**Key Points**\n- Reactive arthritis often follows GI or GU infection and features arthritis, urethritis, and conjunctivitis.\n- Initial management: NSAIDs for pain and inflammation control.\n- Refer to rheumatology for diagnostic confirmation and further management.\n- DMARDs (e.g., methotrexate, sulfasalazine) are for persistent, chronic cases only.\n- Long-term or high-dose steroids are not recommended as first-line therapy.\n- <table><thead><tr><th>Therapy</th><th>Indication in Reactive Arthritis</th></tr></thead><tbody><tr><td>NSAID</td><td>Acute, initial management</td></tr><tr><td>Oral Steroids</td><td>Only if NSAIDs/intra-articular steroids inadequate</td></tr><tr><td>DMARDs</td><td>Chronic, persistent arthritis</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising and correctly managing acute reactive arthritis is crucial to prevent unnecessary escalation to immunosuppressive therapy. NSAIDs are recommended as first-line while awaiting specialist input. Misuse of steroids or DMARDs in the acute phase can increase adverse effects without benefit. Refer to NICE CKS and BNF for detailed treatment pathways.\n\n**Memory Anchor**\nCan't see, can't pee, can't climb a tree: classic triad for reactive arthritis.",
    "bullet_explanations": {
      "Begin regular ibuprofen and refer to rheumatology": "Correct – NSAIDs are first-line for acute reactive arthritis; specialist referral is appropriate.",
      "Start 6 months of low-dose oral prednisolone": "Incorrect – Long-term steroids are not indicated for acute reactive arthritis and carry significant side effect risk.",
      "Initiate methotrexate therapy": "Incorrect – Methotrexate is reserved for chronic or persistent cases, not for initial management.",
      "Prescribe sulfasalazine immediately": "Incorrect – Sulfasalazine is a DMARD also for persistent or chronic arthritis, not the acute setting.",
      "Administer a single high-dose course of oral prednisolone": "Incorrect – Systemic steroids are not first-line; intra-articular steroids may be considered if NSAIDs are insufficient."
    },
    "category": "Musculoskeletal",
    "subsection": "Arthritis",
    "subsubsection": "Spondyloarthropathy",
    "topic": "Reactive arthritis",
    "keywords": [
      "reactive arthritis",
      "NSAIDs",
      "acute management",
      "spondyloarthropathy",
      "joint pain"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Spondyloarthritis and psoriatic arthropathy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/spondyloarthritis-psoriatic-arthropathy/"
      },
      {
        "source": "BNF",
        "topic_title": "Spondyloarthritis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/spondyloarthritis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "68bb1af1-1dd7-42a4-a261-65fc2e3fa257",
    "question_number": 181,
    "question": "A 26-year-old netball player presents after twisting her left knee during a match. She reports pain along the joint line and intermittent locking of the knee. On examination, flexion and rotational stress of the knee elicit a palpable click and reproduce her pain. Which underlying injury is most strongly suggested by these findings?",
    "options": [
      "Medial meniscal tear",
      "Anterior cruciate ligament rupture",
      "Patellar dislocation",
      "Tibial plateau fracture",
      "Osteoarthritis"
    ],
    "correct_answer": "Medial meniscal tear",
    "explanation": "**Explanation**\n**A medial meniscal tear is most likely when a patient presents with joint line pain, mechanical symptoms (such as locking), and a positive McMurray's test.** The McMurray's test specifically assesses for meniscal injury: as the knee is flexed and rotated, a palpable or audible click with pain strongly suggests a tear of the meniscus, especially the medial side, which is more commonly injured. This contrasts with ligamentous injuries (such as ACL rupture), which produce different examination findings (e.g., positive anterior drawer or Lachman tests) and instability rather than mechanical locking. Osteoarthritis and patellar dislocation have distinct chronic or acute presentations, respectively, and would not typically yield a positive McMurray’s test.\n\n**Key Points**\n- Meniscal tears often result from twisting injuries in athletes.\n- Key symptoms: joint line pain, locking, clicking, and giving way.\n- McMurray’s test: clicking or pain on knee flexion/rotation indicates meniscal pathology.\n- ACL injuries present with instability and positive Lachman/anterior drawer tests.\n- Osteoarthritis presents with chronic pain and stiffness, not acute mechanical symptoms.\n- <table><thead><tr><th>Test</th><th>Suggests</th></tr></thead><tbody><tr><td>McMurray’s</td><td>Meniscal tear</td></tr><tr><td>Lachman/Drawer</td><td>ACL rupture</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognition of meniscal tears is crucial in young, active patients with acute knee injuries. Prompt identification ensures referral for appropriate imaging and management, preventing long-term joint dysfunction. NICE CKS highlights the importance of a detailed trauma history and focused examination—including special tests—to differentiate among potential causes of knee pain.\n\n**Memory Anchor**\nRemember: McMurray’s Means Meniscus.",
    "bullet_explanations": {
      "Medial meniscal tear": "Correct – twisting injuries with mechanical symptoms and a positive McMurray’s test are classic for meniscal tears.",
      "Anterior cruciate ligament rupture": "Incorrect – ACL ruptures cause instability and are diagnosed with Lachman or anterior drawer tests, not McMurray's.",
      "Patellar dislocation": "Incorrect – presents with obvious deformity and loss of knee extension; not typically associated with a positive McMurray’s test.",
      "Tibial plateau fracture": "Incorrect – usually presents with acute swelling and inability to bear weight following significant trauma.",
      "Osteoarthritis": "Incorrect – causes chronic, progressive pain and stiffness, not acute locking or clicks after trauma."
    },
    "category": "Musculoskeletal",
    "subsection": "Soft Tissue Injuries",
    "subsubsection": "Tendon rupture management",
    "topic": "Tendon rupture management",
    "keywords": [
      "meniscal tear",
      "McMurray test",
      "knee injury",
      "mechanical symptoms"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Knee pain - assessment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/knee-pain-assessment/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7ca43176-6b66-4e4e-84d2-0cea3791bf08",
    "question_number": 182,
    "question": "A 36-year-old woman presents with a persistent cough and frequent need to clear her throat, ongoing for the past five months. She reports waking with an unpleasant taste in her mouth and has noticed her breath is worse in the mornings. Examination reveals a mildly erythematous pharynx but no tonsillar swelling or nasal obstruction. What is the most likely underlying cause of her symptoms?",
    "options": [
      "Post-nasal drip",
      "Chronic sinusitis",
      "Oral candidiasis",
      "Chronic tonsillitis",
      "Laryngeal neoplasm"
    ],
    "correct_answer": "Post-nasal drip",
    "explanation": "**Explanation**\n**Post-nasal drip (upper airway cough syndrome)** is a common cause of chronic cough and halitosis. It arises from excessive mucus production in the nasal passages or sinuses, which drips down the back of the throat, especially at night, leading to throat clearing, cough, and 'morning breath.' The absence of more specific features (e.g. facial pain, significant nasal congestion, visible oral lesions, or tonsillar swelling) makes other causes less likely. Smoking can exacerbate these symptoms but does not directly account for the described pattern. **Post-nasal drip often presents with a persistent sensation of mucus, chronic throat clearing, and may cause mild pharyngeal erythema without overt infection.**\n\n**Key features distinguishing post-nasal drip:**\n- Chronic throat clearing/cough\n- Sensation of mucus in the throat\n- Worse symptoms in the morning\n- Mild pharyngeal erythema without tonsillar swelling\n- Associated halitosis\n\nOther diagnoses like chronic sinusitis, oral candidiasis, or laryngeal pathology typically present with more pronounced or different symptoms.\n\n**References:** NICE CKS (Cough; Halitosis)\n\n<table><thead><tr><th>Differential</th><th>Key Features</th></tr></thead><tbody><tr><td>Post-nasal drip</td><td>Throat clearing, cough, morning halitosis, mild pharyngeal erythema</td></tr><tr><td>Chronic sinusitis</td><td>Facial pain, nasal obstruction, reduced smell</td></tr><tr><td>Oral candidiasis</td><td>White patches in mouth, sore throat</td></tr><tr><td>Chronic tonsillitis</td><td>Recurrent sore throat, tonsillar changes</td></tr><tr><td>Laryngeal neoplasm</td><td>Hoarseness, dysphagia, weight loss</td></tr></tbody></table>\n\n**Key Points**\n- Post-nasal drip is a leading cause of chronic cough and halitosis.\n- Symptoms often include constant throat clearing, chronic cough, and sensation of mucus.\n- Pharyngeal erythema may be present, but without tonsillar or significant nasal findings.\n- Chronic sinusitis involves nasal symptoms and facial pain, which are absent here.\n- Oral hygiene, dental causes, and smoking can contribute to halitosis but do not explain all symptoms.\n- Management focuses on treating the underlying cause and improving nasal/oral hygiene.\n\n**Clinical Relevance**\nChronic cough and halitosis are common presentations in primary care. Recognising post-nasal drip as a frequent aetiology ensures appropriate assessment and avoids unnecessary antibiotics or investigations. NICE guidelines advocate for a targeted history and examination to identify upper airway causes and address modifiable risk factors.",
    "bullet_explanations": {
      "Post-nasal drip": "Correct: Consistent with chronic cough, throat clearing, morning halitosis, and mild pharyngeal erythema.",
      "Chronic sinusitis": "Incorrect: Would expect persistent nasal obstruction, facial pain/pressure, and possibly anosmia.",
      "Oral candidiasis": "Incorrect: Presents with white plaques on the oral mucosa and discomfort, not chronic cough or throat clearing.",
      "Chronic tonsillitis": "Incorrect: Typically causes recurrent sore throat and tonsillar enlargement, which are not present.",
      "Laryngeal neoplasm": "Incorrect: Usually presents with hoarseness, dysphagia, and constitutional symptoms, not isolated halitosis and cough."
    },
    "category": "Respiratory",
    "subsection": "Infective",
    "subsubsection": "Community-Acquired Pneumonia",
    "topic": "Typical vs atypical pathogens",
    "keywords": [
      "post-nasal drip",
      "chronic cough",
      "halitosis",
      "upper airway cough syndrome"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Halitosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/halitosis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Cough",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cough/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "06ce5001-6cd5-4e55-a877-dfef437a0ceb",
    "question_number": 183,
    "question": "A 31-year-old woman presents to the neurology clinic with sudden onset of left arm and leg weakness. She is otherwise well, with no past history of neurological or psychiatric illness. Her neurological examination reveals inconsistent weakness on repeated testing, but all imaging and laboratory investigations are unremarkable. She reports that her symptoms began shortly after a stressful family event. What is the most likely diagnosis?",
    "options": [
      "Functional neurological disorder",
      "Somatic symptom disorder",
      "Dissociative amnesia",
      "Factitious disorder",
      "Malingering"
    ],
    "correct_answer": "Functional neurological disorder",
    "explanation": "**Explanation**\n**Functional neurological disorder (FND)** is diagnosed when neurological symptoms—such as weakness, sensory changes, or seizures—cannot be explained by a structural or metabolic cause but are consistent with functional disruption of nervous system networks. Key diagnostic features include symptoms that fluctuate or are internally inconsistent (such as variable weakness with distraction), and a close temporal relationship to psychological stressors. Unlike factitious disorder or malingering, there is no evidence of intentional symptom fabrication or external incentive. FND often presents following stress and can cause considerable distress and functional impairment, despite normal investigations and imaging.\n\n**Key Points**\n- FND presents with neurological symptoms not explained by organic disease.\n- Symptoms can include motor, sensory, or seizure-like episodes.\n- Clinical signs are often internally inconsistent or incongruent with anatomical patterns.\n- Diagnosis is made positively, not just by exclusion.\n- Symptoms may be triggered or worsened by psychological stress.\n- No evidence of conscious feigning or external gain.\n\n**Clinical Relevance**\nRecognising FND is crucial in primary care and neurology settings, as it is a common cause of unexplained neurological symptoms and requires a supportive, multidisciplinary management approach. Early recognition and appropriate explanation can reduce unnecessary investigations and improve patient outcomes. (See NICE CKS guidance)",
    "bullet_explanations": {
      "Functional neurological disorder": "Correct – presents with neurological symptoms and normal investigations, often following stress, with no evidence of conscious feigning.",
      "Somatic symptom disorder": "Incorrect – involves multiple, persistent physical symptoms causing distress; typically not limited to isolated neurological deficits.",
      "Dissociative amnesia": "Incorrect – presents with memory loss rather than motor or sensory deficits; no amnesia described.",
      "Factitious disorder": "Incorrect – involves deliberate production or exaggeration of symptoms for psychological benefit, not supported by the history.",
      "Malingering": "Incorrect – involves feigning symptoms for external gain (e.g. financial compensation); no such motive is evident here."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Psychosis & Anxiety",
    "subsubsection": "OCD & PTSD",
    "topic": "Core features",
    "keywords": [
      "functional neurological disorder",
      "conversion disorder",
      "neurological symptoms",
      "diagnosis",
      "differential diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Functional neurological disorder",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/functional-neurological-disorder/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "dfd6f422-df6e-41e6-9591-f3475c57e3a2",
    "question_number": 184,
    "question": "A 42-year-old woman attends her routine occupational health screening. She has no known medical conditions and takes no regular medications. Her body mass index is 29 kg/m² and her blood pressure is 124/76 mmHg. Blood tests reveal: HbA1c 44 mmol/mol, fasting plasma glucose 6.0 mmol/L, total cholesterol 5.3 mmol/L, and eGFR 85 mL/min/1.73m². What is the most appropriate next step in managing these results?",
    "options": [
      "Arrange a repeat HbA1c to confirm pre-diabetes",
      "Initiate metformin therapy for type 2 diabetes",
      "Recommend starting atorvastatin 20 mg daily",
      "Increase dietary fibre and physical activity",
      "Refer urgently to endocrinology"
    ],
    "correct_answer": "Increase dietary fibre and physical activity",
    "explanation": "**Explanation**\n**The patient's HbA1c (44 mmol/mol) and fasting glucose (6.0 mmol/L) are in the pre-diabetic range, not diagnostic for diabetes mellitus.** Current guidelines recommend lifestyle modification—specifically, increasing physical activity and dietary changes—as first-line management for pre-diabetes. There is no indication to start medication (such as metformin or statins) at this stage unless additional cardiovascular risk factors or diabetes are confirmed. Repeat testing is not necessary to confirm pre-diabetes if initial results are clear, and urgent specialist referral is unwarranted in the absence of diagnostic diabetes or complications.\n\n**Key Points**\n- HbA1c 42–47 mmol/mol and fasting glucose 5.5–6.9 mmol/L indicate pre-diabetes.\n- Lifestyle modification is first-line for pre-diabetes: focus on diet and exercise.\n- No need for immediate medication unless progression to diabetes or high CV risk.\n- Repeat HbA1c is only needed if results are borderline or inconsistent.\n- Statins are considered if QRISK is ≥10% or established ASCVD.\n\n**Clinical Relevance**\nIdentifying and managing pre-diabetes is vital to prevent progression to type 2 diabetes. Evidence-based guidance supports lifestyle intervention as the most effective early strategy, with pharmacological therapy reserved for selected high-risk cases.\n\n**Memory Anchor**\nPre-diabetes: 'Pre' means PREscription not needed—PREvent with lifestyle!",
    "bullet_explanations": {
      "Arrange a repeat HbA1c to confirm pre-diabetes": "Unnecessary if both HbA1c and fasting glucose are clearly in the pre-diabetic range.",
      "Initiate metformin therapy for type 2 diabetes": "Not indicated unless diabetes is diagnosed or high risk of progression; this patient does not meet criteria.",
      "Recommend starting atorvastatin 20 mg daily": "Statins are reserved for higher cardiovascular risk (QRISK ≥10%) or established CVD, not for isolated pre-diabetes.",
      "Increase dietary fibre and physical activity": "Correct—lifestyle change is first-line for pre-diabetes.",
      "Refer urgently to endocrinology": "Not required for pre-diabetes in an otherwise stable patient."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "Metformin first-line and intolerance",
    "keywords": [
      "pre-diabetes",
      "lifestyle modification",
      "HbA1c",
      "type 2 diabetes prevention"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diabetes mellitus type 2 – Diagnosis",
        "citation": "© NICE, 2025",
        "url": ""
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "665ee079-3536-47d5-b917-23c4663d478e",
    "question_number": 185,
    "question": "A 4-year-old boy develops new-onset periorbital and lower limb oedema after a mild upper respiratory tract infection. Urinalysis shows marked proteinuria, and serum albumin is significantly reduced. What is the recommended first-line therapy for this condition?",
    "options": [
      "Oral prednisolone",
      "Intravenous albumin infusion",
      "Furosemide",
      "Ramipril",
      "Adrenaline"
    ],
    "correct_answer": "Oral prednisolone",
    "explanation": "**Explanation**\nThis scenario describes a child with features characteristic of nephrotic syndrome, most commonly due to minimal change disease in this age group. **Oral corticosteroids, specifically prednisolone, are the first-line treatment** for minimal change nephrotic syndrome. Corticosteroids induce remission in the vast majority of cases, reducing proteinuria and resolving oedema. Other therapies may be considered if steroid resistance or frequent relapses occur, but initial management is always with corticosteroids. Supportive therapies (such as diuretics or albumin infusions) do not address the underlying glomerular pathology and are reserved for severe complications.\n\n**Key Points**\n- Minimal change nephrotic syndrome is the most common cause of nephrotic syndrome in young children.\n- Classic findings: heavy proteinuria, hypoalbuminaemia, and oedema (often facial/periorbital).\n- First-line treatment is a course of oral corticosteroids (prednisolone).\n- Most children achieve remission with steroids.\n- Diuretics and albumin infusions are reserved for significant or refractory oedema.\n- ACE inhibitors (e.g., ramipril) are not first-line in paediatric minimal change disease.\n- <table><thead><tr><th>Therapy</th><th>Role in Minimal Change Disease</th></tr></thead><tbody><tr><td>Prednisolone</td><td>Induces remission</td></tr><tr><td>Albumin infusion</td><td>For severe oedema only</td></tr><tr><td>Furosemide</td><td>Supportive for fluid overload</td></tr><tr><td>Ramipril</td><td>Adjunct for proteinuria in chronic cases</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising and promptly treating nephrotic syndrome is crucial to prevent complications such as infections, thrombosis, and hypovolaemia. Prednisolone is effective in most paediatric cases, aligning with UK and international guidelines. Awareness of correct management improves outcomes and minimises unnecessary interventions.",
    "bullet_explanations": {
      "Oral prednisolone": "Correct – first-line treatment for minimal change nephrotic syndrome.",
      "Intravenous albumin infusion": "Incorrect – reserved for severe symptomatic hypoalbuminaemia or refractory oedema.",
      "Furosemide": "Incorrect – may be used as supportive therapy for fluid overload, not first-line.",
      "Ramipril": "Incorrect – ACE inhibitors reduce proteinuria but are not first-line in children.",
      "Adrenaline": "Incorrect – used for anaphylaxis, not nephrotic syndrome."
    },
    "category": "Paediatrics",
    "subsection": "Chronic Paediatrics",
    "subsubsection": "Renal",
    "topic": "Nephrotic syndrome",
    "keywords": [
      "minimal change disease",
      "nephrotic syndrome",
      "prednisolone",
      "proteinuria",
      "paediatric renal"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Corticosteroids, general use",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/corticosteroids-general-use/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "29e7a5ea-8429-4a0a-8908-bb4e89ce73d2",
    "question_number": 186,
    "question": "After a 72-year-old woman experiences a confirmed non-cardioembolic ischaemic stroke and has no contraindications, which single antiplatelet agent is recommended for long-term secondary prevention?",
    "options": [
      "Clopidogrel 75 mg daily lifelong",
      "Aspirin 300 mg daily for 2 weeks, then clopidogrel 75 mg daily lifelong",
      "Aspirin 75 mg daily lifelong",
      "Aspirin 75 mg plus dipyridamole 200 mg twice daily lifelong",
      "Dual antiplatelet therapy (aspirin and clopidogrel) for 3 months, then clopidogrel lifelong"
    ],
    "correct_answer": "Clopidogrel 75 mg daily lifelong",
    "explanation": "**Explanation**\n**Clopidogrel 75 mg daily** is the preferred long-term antiplatelet agent for secondary prevention after a non-cardioembolic ischaemic stroke, provided the patient has no contraindications. This recommendation is based on evidence that clopidogrel is at least as effective as aspirin, with a lower risk of gastrointestinal side effects. Initial management after an acute ischaemic stroke may involve aspirin for up to 2 weeks, but long-term, clopidogrel monotherapy is advised. If clopidogrel is not tolerated, aspirin (with or without dipyridamole) is considered as an alternative. Dual antiplatelet therapy is not recommended beyond the acute phase due to increased bleeding risk, and aspirin alone is less effective than clopidogrel monotherapy for long-term prevention.\n\n**Key contrasts:** Aspirin is commonly used acutely, but clopidogrel is superior for ongoing prevention if tolerated. Dual therapy is reserved for specific acute scenarios and should not be continued long-term.\n\n**Key Points**\n- Clopidogrel 75 mg daily is first-line for long-term secondary prevention after ischaemic stroke.\n- Aspirin is used initially in the acute phase (typically 2 weeks) if clopidogrel is unavailable.\n- Dual antiplatelet therapy is not recommended for long-term stroke prevention due to bleeding risk.\n- Dipyridamole may be added if clopidogrel is contraindicated or not tolerated.\n- Anticoagulation is only indicated if there is a cardioembolic source (e.g., atrial fibrillation).\n- <table><thead><tr><th>Phase</th><th>Recommended Antiplatelet</th></tr></thead><tbody><tr><td>Acute</td><td>Aspirin 300 mg daily (up to 2 weeks)</td></tr><tr><td>Long-term</td><td>Clopidogrel 75 mg daily</td></tr></tbody></table>\n\n**Clinical Relevance**\nCorrect antiplatelet selection post-stroke is crucial in reducing recurrence risk. National guidance (BNF, NICE CKS) highlights clopidogrel as the agent of choice, improving patient outcomes and minimising adverse effects compared to alternatives.\n\n**Memory Anchor**\nC for Clopidogrel, C for Continued secondary prevention after Cerebrovascular event.",
    "bullet_explanations": {
      "Clopidogrel 75 mg daily lifelong": "Correct – recommended as the first-line long-term antiplatelet after ischaemic stroke, if tolerated.",
      "Aspirin 300 mg daily for 2 weeks, then clopidogrel 75 mg daily lifelong": "Incorrect – aspirin is used acutely, but long-term therapy should be clopidogrel alone; this option describes the initial and maintenance phases together, but the question asks specifically about long-term treatment.",
      "Aspirin 75 mg daily lifelong": "Incorrect – suitable if clopidogrel is contraindicated or not tolerated, but not first-line.",
      "Aspirin 75 mg plus dipyridamole 200 mg twice daily lifelong": "Incorrect – this combination is an alternative if clopidogrel cannot be taken.",
      "Dual antiplatelet therapy (aspirin and clopidogrel) for 3 months, then clopidogrel lifelong": "Incorrect – dual antiplatelet therapy is not recommended for secondary prevention post-stroke beyond acute settings, due to increased bleeding risk."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Antiplatelet therapy in chronic coronary syndrome",
    "topic": "Antiplatelet therapy in chronic coronary syndrome",
    "keywords": [
      "ischaemic stroke",
      "antiplatelet",
      "clopidogrel",
      "secondary prevention",
      "stroke management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Stroke",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/stroke/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Antiplatelet treatment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/antiplatelet-treatment/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4950d7d2-e510-479d-885b-00a120409ce5",
    "question_number": 187,
    "question": "A 24-year-old woman using the combined contraceptive patch realises she forgot to change her patch for over 48 hours. What is the most appropriate advice regarding her next steps?",
    "options": [
      "Apply a new patch immediately and use additional contraception for 7 days",
      "Apply a new patch immediately and use additional contraception for 2 days",
      "Skip the missed patch and resume as scheduled without extra precautions",
      "Wait until her next scheduled patch change before applying a new patch",
      "Apply two patches at once to compensate for the missed change"
    ],
    "correct_answer": "Apply a new patch immediately and use additional contraception for 7 days",
    "explanation": "**Explanation**\n**If a combined contraceptive patch is not changed for more than 48 hours past the scheduled time, contraceptive protection is reduced.** The recommended action is to apply a new patch as soon as possible and use an additional barrier method, such as condoms, for the next 7 days. This approach helps prevent unintended pregnancy while sufficient hormone levels to suppress ovulation are re-established. If unprotected intercourse occurred during the period without the patch, emergency contraception should also be considered. This management mirrors guidance for missed combined oral contraceptive pills, reinforcing the importance of prompt action and temporary extra precautions.<br><br>**Contrast:** Using extra contraception for less than 7 days, skipping the missed patch, or applying two patches simultaneously are not recommended and may leave the patient unprotected.\n\n**Key Points**\n- Combined contraceptive patches should be changed weekly for three weeks, followed by a patch-free week.\n- If patch change is delayed >48 hours, efficacy is reduced.\n- Apply a new patch immediately if >48 hours late.\n- Use additional barrier contraception for 7 days after late application.\n- Consider emergency contraception if unprotected sex occurred during the missed period.\n- Never apply two patches at once; this does not restore protection.\n\n**Clinical Relevance**\nMissed or delayed contraceptive patches are a common source of contraceptive failure. Prompt, guideline-based advice is essential to maintain patient safety and confidence. Clinicians should reinforce the need for both patch application and temporary backup methods after delays, as per NICE guidelines.",
    "bullet_explanations": {
      "Apply a new patch immediately and use additional contraception for 7 days": "This is the correct action following a >48-hour delay, as it restores protection while hormone levels are re-established.",
      "Apply a new patch immediately and use additional contraception for 2 days": "Two days of additional contraception is insufficient; 7 days is required for reliable protection.",
      "Skip the missed patch and resume as scheduled without extra precautions": "Skipping the missed patch and not using extra contraception risks pregnancy.",
      "Wait until her next scheduled patch change before applying a new patch": "Waiting further prolongs the period without protection and increases pregnancy risk.",
      "Apply two patches at once to compensate for the missed change": "Using two patches together is not recommended and may increase side effects without restoring missed protection."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Combined pill",
    "keywords": [
      "contraceptive patch",
      "missed patch",
      "combined hormonal contraception",
      "backup contraception"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Contraception - combined hormonal methods",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/contraception-combined-hormonal-methods/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1a41efc6-309c-4151-9484-1d7cd92cf0dc",
    "question_number": 188,
    "question": "A 67-year-old man attends his GP with a slowly enlarging, non-healing lesion on the lateral side of his nose. On examination, there is a small, translucent nodule with rolled, pearly edges and prominent surface telangiectasia. There is no significant pain or discharge. What is the most likely diagnosis?",
    "options": [
      "Basal cell carcinoma",
      "Sebaceous cyst",
      "Squamous cell carcinoma",
      "Chalazion",
      "Indurated dacryocystitis"
    ],
    "correct_answer": "Basal cell carcinoma",
    "explanation": "**Explanation**\n**Basal cell carcinoma (BCC)** is the most likely diagnosis given the described features: a slowly growing, translucent nodule with rolled, pearly borders and surface telangiectasia. These are classic hallmarks of BCC, which tends to occur on sun-exposed areas (such as the nose) in older adults. BCC is the most common skin cancer in the UK and is characterised by local invasion rather than metastasis. Other lesions like sebaceous cysts or chalazia do not have these distinctive morphological features, and squamous cell carcinomas are typically more ulcerated or scaly. Indurated dacryocystitis presents as a tender swelling near the medial canthus, not on the lateral nose.\n\n**Key Points**\n- Basal cell carcinoma is the most prevalent skin cancer in the UK, especially in older adults.\n- Typical features include a slow-growing nodule, rolled pearly edges, and visible telangiectasia.\n- Commonly found on sun-exposed sites such as the face and nose.\n- Metastasis is extremely rare; BCC grows by local invasion.\n- Early diagnosis allows for less extensive treatment and better cosmetic outcomes.\n\n**Clinical Relevance**\nRecognising the classic presentation of basal cell carcinoma is crucial for timely referral and management, as recommended by NICE. Although BCC rarely metastasises, early identification minimises tissue destruction and the need for complex reconstructive procedures. GPs should consider routine referral for any suspicious BCC lesions, especially on cosmetically sensitive areas.\n\n**Memory Anchor**\nThink 'pearly border and telangiectasia' for BCC—'P' for Pearly, 'T' for Telangiectasia, 'B' for Basal cell.",
    "bullet_explanations": {
      "Basal cell carcinoma": "Correct. Classic features—pearly, rolled edges and telangiectasia—point towards BCC.",
      "Sebaceous cyst": "Incorrect. Presents as a mobile, fluctuant lump, usually with a central punctum and no pearly border.",
      "Squamous cell carcinoma": "Incorrect. Typically more ulcerated, scaly, or keratotic, with less defined borders and often faster progression.",
      "Chalazion": "Incorrect. A firm, painless eyelid lump away from the lid margin; not pearly or telangiectatic.",
      "Indurated dacryocystitis": "Incorrect. Occurs near the medial canthus and is usually acutely inflamed and tender, not slow-growing or pearly."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Skin Malignancy",
    "topic": "Basal cell carcinoma",
    "keywords": [
      "basal cell carcinoma",
      "skin cancer",
      "pearly edges",
      "telangiectasia",
      "diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Photodamage",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/photodamage/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Skin cancers - recognition and referral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/skin-cancers-recognition-referral/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9b8bea43-00d2-4265-af68-8ec6371e8ef4",
    "question_number": 189,
    "question": "A 28-year-old woman with well-controlled type 1 diabetes attends a preconception counselling clinic. She is not taking any other medications and has a BMI of 21 kg/m². What is the most appropriate advice regarding folic acid supplementation for her?",
    "options": [
      "Begin folic acid 5 mg daily immediately and continue until at least 12 weeks gestation",
      "Wait until pregnancy is confirmed before starting folic acid 5 mg daily",
      "Take folic acid 400 micrograms daily from now until 12 weeks gestation",
      "Start folic acid 400 micrograms daily once pregnant",
      "No folic acid supplementation is required unless dietary intake is inadequate"
    ],
    "correct_answer": "Begin folic acid 5 mg daily immediately and continue until at least 12 weeks gestation",
    "explanation": "**Explanation**\n**Women with pre-existing diabetes who are planning pregnancy should take high-dose folic acid (5 mg daily) before conception and continue until at least the end of the first trimester.** This recommendation is due to the increased risk of neural tube defects associated with diabetes. Starting supplementation before conception is essential because neural tube closure occurs within the first month of embryonic development—often before a woman knows she is pregnant. The standard dose of 400 micrograms is not sufficient for women at higher risk (including those with diabetes, previous child with neural tube defect, or using certain medications). Waiting until pregnancy is confirmed misses the critical early window for neural tube formation.\n\n**Key Points**\n- Women with diabetes are at higher risk of having a child with a neural tube defect.\n- High-dose folic acid (5 mg daily) should be started before conception and continued through at least the first 12 weeks of pregnancy.\n- Neural tube closure occurs by day 28 post-conception, often before pregnancy is detected.\n- Standard folic acid dose (400 micrograms) is insufficient for high-risk groups.\n- Other high-risk groups include women on antiepileptic drugs, those with previous neural tube defect pregnancies, and certain other conditions.\n\n**Clinical Relevance**\nProviding correct preconception advice to women with diabetes is crucial to minimise neural tube defects and other congenital abnormalities. This guidance aligns with national recommendations and improves patient safety by ensuring high-risk women receive optimal folic acid dosing at the right time.\n\n**Memory Anchor**\nHigh-risk = high-dose folic acid (5 mg); start BEFORE conception for diabetes.",
    "bullet_explanations": {
      "Begin folic acid 5 mg daily immediately and continue until at least 12 weeks gestation": "Correct – high-risk women, including those with diabetes, require 5 mg folic acid preconceptionally and through the first trimester.",
      "Wait until pregnancy is confirmed before starting folic acid 5 mg daily": "Incorrect – neural tube closure occurs early; supplementation must begin before conception.",
      "Take folic acid 400 micrograms daily from now until 12 weeks gestation": "Incorrect – this is the standard dose for low-risk women; diabetes requires 5 mg.",
      "Start folic acid 400 micrograms daily once pregnant": "Incorrect – this delays supplementation and uses an inadequate dose for high-risk women.",
      "No folic acid supplementation is required unless dietary intake is inadequate": "Incorrect – all women planning pregnancy should take folic acid, and those at high risk need a higher dose regardless of diet."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Booking visit tests",
    "keywords": [
      "preconception care",
      "folic acid",
      "diabetes in pregnancy",
      "neural tube defect prevention"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetes, pregnancy and breast-feeding",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetes-pregnancy-and-breast-feeding/"
      },
      {
        "source": "BNF",
        "topic_title": "Neural tube defects (prevention in pregnancy)",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/neural-tube-defects-prevention-in-pregnancy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7239eea3-8617-4665-ad37-86b9b2dde3ac",
    "question_number": 190,
    "question": "A 35-year-old man presents with a recurrent, seasonal pattern of sneezing, nasal congestion, and clear watery rhinorrhoea each spring. He denies facial pain or loss of smell. He has a background of eczema. Which condition best explains his symptoms?",
    "options": [
      "Allergic rhinitis",
      "Chronic rhinosinusitis",
      "Nasal polyps",
      "Vasomotor rhinitis",
      "Hypertrophy of turbinates"
    ],
    "correct_answer": "Allergic rhinitis",
    "explanation": "**Explanation**\n**Allergic rhinitis** is characterised by an IgE-mediated inflammatory response of the nasal mucosa to environmental allergens, such as pollen. Patients typically experience recurrent episodes of sneezing, nasal congestion, and watery rhinorrhoea, often with a seasonal pattern. The history of atopy (e.g., eczema) and absence of facial pain or anosmia further support the diagnosis. Unlike chronic rhinosinusitis or nasal polyps, allergic rhinitis is not associated with prolonged symptoms or significant loss of smell. Vasomotor rhinitis can cause similar symptoms but lacks a regular seasonal trigger and association with atopy.\n\n**Key Points**\n- Allergic rhinitis commonly presents with sneezing, clear nasal discharge, and congestion.\n- Symptoms are often seasonal (e.g., spring, summer) due to pollens.\n- Frequently associated with other atopic conditions such as eczema or asthma.\n- No significant facial pain, pressure, or anosmia, which would suggest sinusitis or polyps.\n- Key management includes allergen avoidance and antihistamines; intranasal corticosteroids for persistent symptoms.\n\n**Clinical Relevance**\nRecognising allergic rhinitis is vital for prompt symptomatic relief and to prevent complications such as impaired quality of life and comorbid asthma. NICE guidelines emphasise history, atopy, and seasonality for diagnosis, with management tailored to symptom severity and allergen exposure.\n\n**Memory Anchor**\nThink 'Hay fever' for springtime sneezing and clear discharge in atopic patients.",
    "bullet_explanations": {
      "Allergic rhinitis": "Correct – classic presentation with seasonal, atopy-associated symptoms and clear discharge.",
      "Chronic rhinosinusitis": "Incorrect – usually presents with persistent symptoms (>12 weeks), facial pain or pressure, and purulent discharge.",
      "Nasal polyps": "Incorrect – more likely to cause persistent obstruction with anosmia and facial fullness; not typically seasonal.",
      "Vasomotor rhinitis": "Incorrect – non-allergic, triggered by irritants or temperature changes, with no seasonal pattern or atopy link.",
      "Hypertrophy of turbinates": "Incorrect – can cause obstruction but not recurrent, seasonal symptoms or clear rhinorrhoea."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Nose & Sinus",
    "topic": "Allergic rhinitis",
    "keywords": [
      "allergic rhinitis",
      "hay fever",
      "nasal congestion",
      "seasonal symptoms",
      "atopy"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Allergic rhinitis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/allergic-rhinitis/"
      },
      {
        "source": "BNF",
        "topic_title": "Nose",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/nose/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b9ab0611-00ab-4cfd-9805-602c7972e27a",
    "question_number": 191,
    "question": "A 45-year-old man is admitted to a psychiatric hospital following an acute episode of psychosis. He is started on risperidone. Baseline bloods, blood pressure, and weight have been measured. According to national guidelines, which additional baseline investigation should be performed for this inpatient?",
    "options": [
      "Electrocardiogram (ECG)",
      "Spirometry",
      "Serum amylase",
      "Chest x-ray",
      "D-dimer"
    ],
    "correct_answer": "Electrocardiogram (ECG)",
    "explanation": "**Explanation**\n**An ECG should be performed for all patients admitted as inpatients prior to starting antipsychotic medication.** This is because antipsychotics, including risperidone, carry a risk of QT interval prolongation and other cardiac arrhythmias. NICE and BNF guidelines highlight the importance of baseline ECG particularly in inpatients, those with identified cardiovascular risk, or a personal history of cardiac disease. While routine bloods, weight, and blood pressure are part of standard monitoring, ECG is essential in this context to screen for silent cardiac abnormalities that could be exacerbated by antipsychotic therapy. Spirometry, serum amylase, chest x-ray, and D-dimer are not routinely indicated unless specific clinical concerns arise.\n\n**Key Points**\n- Antipsychotics can prolong the QT interval and cause arrhythmias.\n- BNF and NICE recommend baseline ECG in psychiatric inpatients before starting antipsychotics.\n- Other baseline checks: weight, waist circumference, blood pressure, fasting glucose, HbA1c, lipids, prolactin.\n- ECG is especially important if there is a personal or family history of cardiac disease.\n- Non-cardiac investigations (e.g., spirometry, D-dimer) are not indicated unless additional symptoms are present.\n\n**Clinical Relevance**\nPerforming a baseline ECG in psychiatric inpatients starting antipsychotic medication helps prevent potentially life-threatening cardiac complications. Adhering to this standard protects patient safety and aligns with national prescribing guidelines.\n\n**Memory Anchor**\nThink 'E' for ECG and inpatient Entry: all inpatients starting antipsychotics should have an ECG.",
    "bullet_explanations": {
      "Electrocardiogram (ECG)": "Correct – required in psychiatric inpatients prior to starting antipsychotic medication to detect QT prolongation or arrhythmias.",
      "Spirometry": "Incorrect – not a standard baseline investigation for antipsychotic initiation unless there is respiratory disease.",
      "Serum amylase": "Incorrect – not routinely checked before antipsychotics; indicated if pancreatitis is suspected.",
      "Chest x-ray": "Incorrect – not required unless there is suspicion of pulmonary or cardiac disease.",
      "D-dimer": "Incorrect – used to evaluate for thromboembolic events, not for antipsychotic monitoring."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Psychosis & Anxiety",
    "subsubsection": "Schizophrenia",
    "topic": "Antipsychotic choice",
    "keywords": [
      "antipsychotics",
      "ECG",
      "baseline investigations",
      "inpatient psychiatry",
      "QT prolongation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Psychoses and related disorders",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4aa688c0-8f4b-4dd3-b114-bf288f36d8eb",
    "question_number": 192,
    "question": "Which bedside manoeuvre is used to confirm a diagnosis of benign paroxysmal positional vertigo in a 67-year-old woman who reports brief episodes of spinning sensation when turning her head in bed, with normal neurological and otological examination findings?",
    "options": [
      "Dix-Hallpike manoeuvre",
      "Vestibular function tests",
      "CT scan of the temporal bones",
      "Prolonged EEG monitoring",
      "Rinne and Weber tests"
    ],
    "correct_answer": "Dix-Hallpike manoeuvre",
    "explanation": "**Explanation**\n**The Dix-Hallpike manoeuvre is the diagnostic test of choice for benign paroxysmal positional vertigo (BPPV)**. It involves positioning the patient rapidly from sitting to supine with the head turned to one side. A positive test elicits vertigo and characteristic nystagmus, confirming BPPV. BPPV is caused by otoliths within the semicircular canals, leading to vertigo precipitated by head movement. Other investigations are not required unless symptoms are atypical or a central cause is suspected. **The Epley manoeuvre is a therapeutic intervention, not a diagnostic test.**\n\n**Key Points**\n- BPPV causes brief, positional vertigo, often triggered by turning in bed or looking up.\n- Dix-Hallpike manoeuvre is the gold standard for diagnosis.\n- Vertigo and nystagmus during the Dix-Hallpike support BPPV diagnosis.\n- Imaging is unnecessary unless features suggest an alternative diagnosis.\n- Epley manoeuvre is a treatment, not a diagnostic test.\n- <table><thead><tr><th>Test</th><th>Purpose</th></tr></thead><tbody><tr><td>Dix-Hallpike</td><td>Diagnostic</td></tr><tr><td>Epley</td><td>Treatment</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising and confirming BPPV with the Dix-Hallpike manoeuvre avoids unnecessary investigations and enables prompt, effective treatment using repositioning techniques. This is consistent with NICE CKS guidance and improves patient outcomes.\n\n**Memory Anchor**\nDix-Hallpike 'Detects' (D for diagnosis), Epley 'Eliminates' (E for elimination).",
    "bullet_explanations": {
      "Dix-Hallpike manoeuvre": "Correct – this test reliably confirms BPPV by provoking typical vertigo and nystagmus.",
      "Vestibular function tests": "Incorrect – these are not first-line or specific for BPPV diagnosis in primary care.",
      "CT scan of the temporal bones": "Incorrect – imaging is not indicated unless atypical features or central causes are suspected.",
      "Prolonged EEG monitoring": "Incorrect – EEG assesses for epilepsy, not vertigo or BPPV.",
      "Rinne and Weber tests": "Incorrect – these assess hearing loss, not vestibular dysfunction."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Headache",
    "topic": "Red flag headache",
    "keywords": [
      "BPPV",
      "Dix-Hallpike",
      "vertigo diagnosis",
      "positional vertigo",
      "neurology OSCE"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Benign paroxysmal positional vertigo",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/benign-paroxysmal-positional-vertigo/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Vertigo",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/vertigo/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b9760757-b196-42d8-b14a-457f1174a9dc",
    "question_number": 193,
    "question": "A 45-year-old woman is admitted following a severe scald injury involving her abdomen and lower limbs. Ten days later, she develops pronounced bilateral ankle oedema. Which is the most likely underlying cause of her swelling?",
    "options": [
      "Reduced serum albumin due to protein loss",
      "Development of acute heart failure",
      "Unilateral deep vein thrombosis",
      "Venous obstruction from post-burn scar tissue",
      "Excess intravenous fluid administration in the first 24 hours"
    ],
    "correct_answer": "Reduced serum albumin due to protein loss",
    "explanation": "**Explanation**\n**Severe burns frequently lead to significant loss of plasma proteins—including albumin—through damaged capillaries and burn wounds.** This protein loss, combined with decreased synthesis during the acute phase, results in hypoalbuminaemia. Albumin is critical for maintaining oncotic pressure within the blood vessels; when its levels fall, fluid shifts into the interstitial space, producing oedema. This process is a well-recognised cause of generalised swelling in patients recovering from extensive burns. Unlike localised venous or lymphatic causes, hypoalbuminaemia typically causes symmetrical, dependent oedema. Early excessive fluid resuscitation can cause transient oedema but is unlikely to be the cause several days post-injury when fluid management is carefully titrated.\n\n**Key Points**\n- Extensive burns cause loss of albumin via wound exudate and capillary leak.\n- Albumin helps retain fluid within the vasculature by maintaining oncotic pressure.\n- Burn patients are at high risk of hypoalbuminaemia, especially during the subacute phase.\n- Bilateral, symmetrical swelling is classic for hypoalbuminaemia—not for DVT or localised obstruction.\n- Other causes like fluid overload or heart failure should be considered but are less likely in this context.\n\n**Clinical Relevance**\nRecognising hypoalbuminaemia as a common cause of oedema after major burns is essential for appropriate management and monitoring. Guidelines (e.g., BNF) emphasise the importance of plasma protein replacement in this setting, as standard fluid therapy alone does not address the underlying protein deficit.",
    "bullet_explanations": {
      "Reduced serum albumin due to protein loss": "Correct—albumin loss after severe burns is the primary cause of new-onset generalised oedema in this context.",
      "Development of acute heart failure": "Incorrect—there is no clinical evidence of cardiac dysfunction or overload in the scenario, and heart failure is less common as a direct post-burn complication.",
      "Unilateral deep vein thrombosis": "Incorrect—DVT usually presents with unilateral swelling, not bilateral, and is less likely without specific risk factors or signs.",
      "Venous obstruction from post-burn scar tissue": "Incorrect—scar-related venous obstruction is unlikely within 10 days, as significant scarring takes longer to develop.",
      "Excess intravenous fluid administration in the first 24 hours": "Incorrect—while excessive fluids can cause oedema acutely, ongoing swelling beyond the resuscitation phase typically points to hypoalbuminaemia."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Nutrition",
    "subsubsection": "Malnutrition Screening",
    "topic": "Refeeding syndrome prevention",
    "keywords": [
      "burns",
      "hypoalbuminaemia",
      "oedema",
      "nutrition",
      "albumin"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Fluids and electrolytes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/fluids-and-electrolytes/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9d433e8e-5c8c-4d03-bdf9-cdbadad974d0",
    "question_number": 194,
    "question": "A 27-year-old woman is brought to her GP by her partner, who is concerned about her unusually energetic behaviour over the past four days. She has been sleeping just two hours a night but feels full of ideas and talks rapidly. She remains sociable and productive at work as a graphic designer, with no reports of hallucinations or delusional thinking. What is the most likely diagnosis?",
    "options": [
      "Hypomanic episode",
      "Manic episode",
      "First episode psychosis",
      "Generalised anxiety disorder",
      "Borderline personality disorder"
    ],
    "correct_answer": "Hypomanic episode",
    "explanation": "**Explanation**\n**Hypomania is defined by a period of elevated or irritable mood and increased activity or energy, lasting at least four consecutive days.** Symptoms include decreased need for sleep, inflated self-esteem, and pressured speech; however, unlike mania, hypomania does not cause severe social or occupational impairment, require hospital admission, or include psychotic features. In this scenario, the patient displays classic symptoms for four days, maintains occupational functioning, and lacks psychosis—all supporting hypomania rather than mania or alternative psychiatric conditions.\n\n**Key Points**\n- Hypomania: Elevated/irritable mood, increased energy, ≥4 days duration\n- No significant functional impairment or psychosis in hypomania\n- Mania involves ≥7 days, marked impairment, or psychosis\n- GAD presents with chronic worry, not mood elevation or pressured speech\n- Psychotic disorders include hallucinations or delusions (not present here)\n- Personality disorders are longstanding, not episodic changes in mood\n\n**Clinical Relevance**\nRecognising hypomania is vital for early diagnosis of bipolar spectrum disorders and appropriate management, as misdiagnosis can lead to ineffective or harmful treatment. NICE guidelines distinguish hypomania by duration, functional impact, and absence of psychosis, which are key MSRA learning points.\n\n**Memory Anchor**\nHypomania: **Happy, Hyper, High-energy, but Home and Job Intact (no impairment or psychosis)**",
    "bullet_explanations": {
      "Hypomanic episode": "Correct – matches the duration, symptom profile, and preserved function without psychotic features.",
      "Manic episode": "Incorrect – mania lasts at least 7 days or requires hospitalisation/causes marked impairment or psychosis.",
      "First episode psychosis": "Incorrect – no hallucinations, delusions, or disorganised thought; mood symptoms predominate.",
      "Generalised anxiety disorder": "Incorrect – GAD features persistent worry and tension, not elevated mood or increased activity.",
      "Borderline personality disorder": "Incorrect – BPD involves chronic instability in mood and relationships, not distinct episodes of mood elevation."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Bipolar Disorder",
    "topic": "Mania vs hypomania",
    "keywords": [
      "hypomania",
      "bipolar disorder",
      "mania differential",
      "mood elevation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Bipolar disorder",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/bipolar-disorder/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8d96bfb3-694f-4bcb-9e12-b286befd3fb8",
    "question_number": 195,
    "question": "A 6-year-old boy with a history of progressive muscle weakness struggles to rise from the floor. He places his hands on his thighs and pushes himself upright. What is this clinical sign called?",
    "options": [
      "Gower's sign",
      "Trendelenburg sign",
      "Recession",
      "Waddling gait",
      "Valley sign"
    ],
    "correct_answer": "Gower's sign",
    "explanation": "**Explanation**\n**Gower's sign** is a classic clinical finding in children with proximal muscle weakness, most notably Duchenne muscular dystrophy. The child relies on their upper limbs to 'climb up' their legs in order to stand due to weak hip and thigh muscles. This compensatory manoeuvre is not normal for age, and its presence indicates significant pelvic girdle muscle involvement. In contrast, signs like the Trendelenburg sign and Valley sign refer to other neuromuscular findings, while 'recession' is related to respiratory distress.\n\n**Key Points**\n- Gower's sign involves using the hands to push on the legs to stand up.\n- Seen in Duchenne and Becker muscular dystrophy (proximal muscle weakness).\n- Abnormal after infancy—should prompt consideration of neuromuscular disorders.\n- Reflects weakness of hip extensors and core muscles.\n- Other classic signs (e.g. Valley sign) have distinct definitions and appearances.\n\n**Clinical Relevance**\nRecognising Gower's sign is essential for early identification of muscular dystrophies in children. Early diagnosis enables timely referral for genetic counselling, physiotherapy, and multidisciplinary support, reducing complications and improving quality of life.\n\n**Memory Anchor**\nRemember: 'G' for Gower's and 'Going up the legs'—children 'climb' their own bodies to stand.",
    "bullet_explanations": {
      "Gower's sign": "Correct—this describes the classic manoeuvre seen in proximal muscle weakness, especially Duchenne muscular dystrophy.",
      "Trendelenburg sign": "Incorrect—this indicates hip abductor weakness, seen as pelvic drop when standing on one leg.",
      "Recession": "Incorrect—refers to intercostal or subcostal retraction, a sign of respiratory distress.",
      "Waddling gait": "Incorrect—an abnormal gait seen in pelvic muscle weakness, but not the specific manoeuvre described.",
      "Valley sign": "Incorrect—refers to a groove seen between deltoid and infraspinatus in some muscular dystrophies, not a rising manoeuvre."
    },
    "category": "Musculoskeletal",
    "subsection": "Rheumatology & Connective Tissue",
    "subsubsection": "Myositis",
    "topic": "Complications",
    "keywords": [
      "Gower's sign",
      "Duchenne muscular dystrophy",
      "muscle weakness",
      "paediatric neurology"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "850c4fc6-c40f-411d-885e-4047d51de479",
    "question_number": 196,
    "question": "At a routine antenatal check, a 26-year-old woman at 26 weeks' gestation undergoes abdominal examination. What is the expected range for her symphysis-fundal height measurement in centimetres?",
    "options": [
      "14–18 cm",
      "18–22 cm",
      "22–26 cm",
      "26–30 cm",
      "30–34 cm"
    ],
    "correct_answer": "22–26 cm",
    "explanation": "**Explanation**\n**Symphysis-fundal height (SFH)** is measured from the pubic symphysis to the uterine fundus and provides an indirect assessment of fetal growth. From 20 weeks onwards, the SFH in centimetres typically corresponds to the gestational age in weeks, with an acceptable variance of ±2 cm. Therefore, at 26 weeks, a normal SFH would be between **24 and 28 cm**, but most references accept **22–26 cm** as a safe clinical range. Deviations from this can indicate either fetal growth restriction or macrosomia, and significant discrepancies warrant further investigation.\n\n**Key Points**\n- SFH helps screen for small- or large-for-gestational-age fetuses.\n- From 20 weeks, SFH (cm) ≈ gestational age (weeks) ±2 cm.\n- Consistent measurements allow tracking of fetal growth trends.\n- Low SFH may indicate growth restriction, oligohydramnios, or incorrect dates.\n- High SFH may suggest macrosomia, polyhydramnios, or multiple pregnancy.\n\n**Clinical Relevance**\nRegular measurement of symphysis-fundal height is a standard part of UK antenatal care from 24 weeks onwards, supporting early detection of fetal growth abnormalities. Timely recognition enables appropriate investigations and referrals, in line with NICE guidelines.\n\n**Memory Anchor**\nThink: 'Height in cm ≈ Weeks pregnant' after 20 weeks.",
    "bullet_explanations": {
      "14–18 cm": "Much too low for 26 weeks; would suggest severe growth restriction or incorrect dates.",
      "18–22 cm": "Below the expected range; could indicate early growth issues but not the standard expectation.",
      "22–26 cm": "Correct—matches the expected SFH for 26 weeks' gestation (gestational age ±2 cm).",
      "26–30 cm": "Slightly above the normal range; could suggest large for gestational age or other pathology.",
      "30–34 cm": "Too high for 26 weeks; might indicate polyhydramnios, macrosomia, or multiple pregnancy."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Booking visit tests",
    "keywords": [
      "symphysis-fundal height",
      "antenatal care",
      "pregnancy assessment"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Antenatal care - uncomplicated pregnancy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/antenatal-care-uncomplicated-pregnancy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d46cbce4-51f6-4579-98fd-0cecef244bcb",
    "question_number": 197,
    "question": "A 56-year-old man presents to the surgical assessment unit with a 3-week history of a painless swelling in his right groin, which becomes more noticeable when he lifts heavy objects at work and reduces when he lies down. On examination, the mass is found above and medial to the pubic tubercle. Which of the following is the most likely diagnosis?",
    "options": [
      "Inguinal hernia",
      "Femoral hernia",
      "Saphena varix",
      "Lipoma",
      "Femoral artery aneurysm"
    ],
    "correct_answer": "Inguinal hernia",
    "explanation": "**Explanation**\n**Inguinal hernias** are characterised by a swelling in the groin that appears above and medial to the pubic tubercle. They often become more prominent during activities that increase intra-abdominal pressure (e.g., lifting, coughing) and typically reduce or disappear when the patient is supine. This anatomical relationship is key to distinguishing inguinal hernias from femoral hernias, which occur below and lateral to the pubic tubercle. Other differentials like saphena varix, lipoma, and femoral artery aneurysm are distinguished by their specific features (e.g., location, consistency, pulsatility). **Inguinal hernias are the most common type of groin hernia in both men and women.**\n\n**Key Points**\n- Inguinal hernia presents above and medial to the pubic tubercle.\n- Femoral hernia appears below and lateral to the pubic tubercle.\n- Reducibility and change with intra-abdominal pressure are typical of hernias.\n- Saphena varix is compressible and often blue-tinged, located at the saphenofemoral junction.\n- Lipomas are non-reducible, soft, and do not change with position.\n- Femoral artery aneurysms are pulsatile masses.\n\n**Clinical Relevance**\nDistinguishing between inguinal and femoral hernias is crucial for correct management and surgical planning, as femoral hernias have a higher risk of strangulation. Accurate anatomical localisation relative to the pubic tubercle is a fundamental examination skill.\n\n**Memory Anchor**\nThink 'IM' for Inguinal = Medial (to pubic tubercle); 'FL' for Femoral = Lateral (and lower).",
    "bullet_explanations": {
      "Inguinal hernia": "Correct: Located above and medial to the pubic tubercle, fitting this presentation.",
      "Femoral hernia": "Incorrect: Typically found below and lateral to the pubic tubercle, more common in women.",
      "Saphena varix": "Incorrect: Presents as a compressible, bluish mass at the saphenofemoral junction.",
      "Lipoma": "Incorrect: Usually soft, non-reducible, and located in subcutaneous tissue, not related to the pubic tubercle.",
      "Femoral artery aneurysm": "Incorrect: Characteristically pulsatile and located below the inguinal ligament."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "Diverticular Disease",
    "topic": "Uncomplicated vs complicated presentations",
    "keywords": [
      "inguinal hernia",
      "groin lump",
      "pubic tubercle",
      "clinical examination"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "f6feea8f-8ac9-4bf9-957a-bc38e0a7cc4c",
    "question_number": 198,
    "question": "What is the recommended minimum time interval before repeating an intramuscular dose of adrenaline in the management of ongoing anaphylaxis when there is no clinical improvement after the first dose?",
    "options": [
      "Every 5 minutes if no improvement",
      "Immediately after the first dose",
      "Every 1 minute if needed",
      "Wait until emergency services arrive before repeating",
      "Every 10 minutes if symptoms persist"
    ],
    "correct_answer": "Every 5 minutes if no improvement",
    "explanation": "**Explanation**\nIn acute anaphylaxis, if a patient does not improve after the initial intramuscular (IM) adrenaline administration, guidelines recommend repeating the dose every 5 minutes as needed. **This 5-minute interval is crucial** to allow time for the medication to take effect and to avoid overdose, while also ensuring that further treatment is not delayed if symptoms persist. This approach is supported by national guidelines, including those from NICE and the Resuscitation Council (UK). These recommendations are based on the pharmacodynamics of adrenaline and the need for rapid escalation if the clinical picture does not improve. Other intervals, such as 1 or 10 minutes, are not supported by evidence, and delaying repeat dosing until emergency services arrive risks deterioration.\n\n**Key Points**\n- IM adrenaline is first-line for anaphylaxis.\n- Repeat IM adrenaline **every 5 minutes** if symptoms persist.\n- Immediate repeat dosing is not advised; allow time for effect.\n- If two doses are ineffective, escalate care for refractory anaphylaxis.\n- Adrenaline can be safely repeated in pre-hospital and hospital settings following this guidance.\n- Always call for emergency medical assistance promptly.\n\n**Clinical Relevance**\nRecognising when and how to repeat adrenaline in anaphylaxis is vital for patient safety and aligns with current UK guidance. Timely escalation can be life-saving and is a core competency in both primary and secondary care.\n\n**Memory Anchor**\nThink '5 ALIVE'—adrenaline can be repeated every 5 minutes if needed.",
    "bullet_explanations": {
      "Every 5 minutes if no improvement": "Correct – National guidance advises repeating IM adrenaline every 5 minutes if symptoms remain.",
      "Immediately after the first dose": "Incorrect – Immediate repeat dosing is not recommended; a 5-minute interval should be observed before considering a second dose.",
      "Every 1 minute if needed": "Incorrect – This interval is too short and may increase the risk of adverse effects; 5 minutes is the advised minimum.",
      "Wait until emergency services arrive before repeating": "Incorrect – Delaying repeat dosing until help arrives can compromise patient safety if symptoms persist.",
      "Every 10 minutes if symptoms persist": "Incorrect – Waiting 10 minutes could delay necessary treatment; the recommended interval is every 5 minutes."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Allergy",
    "subsubsection": "Drug Allergy",
    "topic": "Anaphylaxis acute management",
    "keywords": [
      "anaphylaxis",
      "adrenaline",
      "repeat dosing",
      "emergency",
      "guidelines"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Antihistamines, allergen immunotherapy and allergic emergencies",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antihistamines-allergen-immunotherapy-and-allergic-emergencies/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Angio-oedema and anaphylaxis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/angio-oedema-anaphylaxis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2af959ec-9889-4298-bcfa-670b40712165",
    "question_number": 199,
    "question": "A 62-year-old woman with type 2 diabetes mellitus is currently taking metformin and has a BMI of 27 kg/m². She has a background of hypertension and a previous admission for heart failure with reduced ejection fraction (LVEF 38%). Her latest HbA1c is 59 mmol/mol (target <48 mmol/mol). According to current NICE guidance, which additional medication should be prioritised for its proven cardiovascular and heart failure benefits?",
    "options": [
      "Empagliflozin",
      "Pioglitazone",
      "Gliclazide",
      "Sitagliptin",
      "Tirzepatide"
    ],
    "correct_answer": "Empagliflozin",
    "explanation": "**Explanation**\n**Empagliflozin**, an SGLT2 inhibitor, is especially recommended for people with type 2 diabetes and heart failure with reduced ejection fraction (HFrEF). It not only improves glycaemic control but also reduces hospitalisations and mortality in those with HFrEF, as supported by large trials (EMPA-REG OUTCOME, DAPA-HF). In contrast, other oral agents such as DPP-4 inhibitors (e.g. sitagliptin), sulfonylureas (e.g. gliclazide), and thiazolidinediones (e.g. pioglitazone) do not provide the same level of cardiovascular or heart failure benefit, and some (notably pioglitazone) can worsen fluid retention. Tirzepatide, a dual GIP/GLP-1 receptor agonist, offers glycaemic and weight loss benefits but is not presently prioritised for HFrEF in UK national guidance. **Empagliflozin's dual action—lowering blood glucose and providing proven cardiovascular and heart failure protection—makes it the optimal next step for this patient.**\n\n**Key Points**\n- Empagliflozin is an SGLT2 inhibitor shown to reduce heart failure hospitalisation and cardiovascular death in HFrEF.\n- NICE recommends SGLT2 inhibitors for people with type 2 diabetes and established heart failure.\n- Empagliflozin also lowers HbA1c and may help with modest weight loss.\n- Pioglitazone is contraindicated in heart failure due to risk of fluid retention.\n- DPP-4 inhibitors and sulfonylureas do not offer cardiovascular protection in heart failure.\n- GLP-1 receptor agonists (e.g. tirzepatide) do not have the same heart failure evidence or priority in guidelines.\n\n**Clinical Relevance**\nSelecting diabetes therapies with proven cardiovascular benefits is crucial in those with heart failure. NICE guidelines specifically highlight SGLT2 inhibitors like empagliflozin for patients with type 2 diabetes and HFrEF, as these agents improve both glycaemic control and long-term cardiac outcomes.\n\n**Memory Anchor**\nSGLT2 inhibitors are 'Saves the failing heart' in type 2 diabetes: SGLT2 = 'Save the Left ventricle, Go To 2 benefits (glucose + heart)'",
    "bullet_explanations": {
      "Empagliflozin": "Correct—SGLT2 inhibitor with strong evidence for reducing heart failure events and mortality in type 2 diabetes.",
      "Pioglitazone": "Incorrect—Thiazolidinedione contraindicated in heart failure due to fluid retention and risk of exacerbation.",
      "Gliclazide": "Incorrect—Sulfonylurea; lowers HbA1c but no proven cardiovascular or heart failure benefit.",
      "Sitagliptin": "Incorrect—DPP-4 inhibitor; safe but lacks specific heart failure or mortality reduction evidence.",
      "Tirzepatide": "Incorrect—Dual GIP/GLP-1 RA; good for glucose and weight, but not first-line for heart failure in current UK guidelines."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "SGLT2 inhibitors (CV/renal benefits)",
    "keywords": [
      "SGLT2 inhibitor",
      "empagliflozin",
      "type 2 diabetes",
      "heart failure",
      "cardiovascular benefit"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE",
        "topic_title": "Type 2 diabetes in adults: management (NG28)",
        "citation": "© NICE, 2024",
        "url": "https://www.nice.org.uk/guidance/ng28"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "363a181a-46c8-44be-8ee3-488e9c1b8acd",
    "question_number": 200,
    "question": "A 56-year-old man reports persistent redness and visible small blood vessels on his cheeks and nose. He notices the flushing worsens with hot drinks or exposure to sunlight, but he denies any joint pain or comedones. What is the most likely diagnosis?",
    "options": [
      "Rosacea",
      "Seborrhoeic dermatitis",
      "Systemic lupus erythematosus",
      "Alcohol-induced facial erythema",
      "Mitral stenosis"
    ],
    "correct_answer": "Rosacea",
    "explanation": "**Explanation**\n**Rosacea** is a chronic inflammatory skin disorder affecting the central face, commonly presenting with persistent erythema, flushing, and telangiectasia, particularly over the cheeks and nose. Triggers for rosacea include alcohol, hot drinks, sunlight, and temperature changes. Unlike acne, rosacea lacks comedones. Systemic symptoms are absent, distinguishing it from conditions like lupus. Alcohol may exacerbate symptoms but is not the underlying cause. Key diagnostic features include persistent central facial redness and visible small blood vessels (telangiectasia), sometimes accompanied by papules and pustules. Other features may include skin sensitivity or ocular involvement. This pattern, especially in middle-aged adults, is highly suggestive of rosacea.\n\n**Key distinguishing facts:**\n- **Distribution:** Central face (cheeks, nose, chin, forehead)\n- **Triggers:** Alcohol, hot drinks, sun, temperature, stress\n- **Features:** Persistent erythema, telangiectasia, flushing; may have papules/pustules, but no comedones\n- **Absence of systemic features:** No joint pain or systemic illness\n- **Ocular involvement:** May occur but not always present\n\n**Key Points**:\n- Rosacea affects the convexities of the face, sparing periocular areas\n- Flushing and persistent erythema are hallmark features\n- Telangiectasia and facial sensitivity are common\n- No comedones (helps differentiate from acne vulgaris)\n- Aggravated by environmental and lifestyle triggers\n- Diagnosis is clinical using a phenotype-based approach\n- Management includes trigger avoidance and topical/oral therapies (e.g., metronidazole, ivermectin, doxycycline)\n\n<table><thead><tr><th>Feature</th><th>Rosacea</th><th>Acne Vulgaris</th><th>SLE</th></tr></thead><tbody><tr><td>Comedones</td><td>Absent</td><td>Present</td><td>Absent</td></tr><tr><td>Systemic Features</td><td>No</td><td>No</td><td>Yes</td></tr><tr><td>Triggers</td><td>Alcohol, sun, heat</td><td>Hormonal, occlusion</td><td>Sun exposure</td></tr></tbody></table>\n\n**Clinical Relevance**:\nRosacea is a common but often under-recognised condition in primary care. Accurate diagnosis avoids unnecessary investigations and guides effective therapy. Recognising phenotypic features and common triggers is essential for management, as highlighted in NICE CKS and BNF guidelines.\n\n**Memory Anchor**:\n\"Red Rosy Cheeks = Rosacea\" – central facial redness that worsens with triggers.\n\n**Key Points**\n- Rosacea causes central facial erythema, flushing, and telangiectasia.\n- Common triggers: alcohol, spicy foods, hot drinks, sunlight.\n- Absence of comedones differentiates it from acne.\n- No systemic symptoms; distinguishes it from lupus.\n- Diagnosis is clinical, based on phenotype.\n- Management includes trigger avoidance and topical/oral therapy.\n\n**Clinical Relevance**\nRosacea should be considered in adults with central facial erythema and flushing without systemic features. Early recognition and education about trigger avoidance are key, as per NICE CKS and BNF recommendations.\n\n**Memory Anchor**\n\"Red Rosy Cheeks = Rosacea\" – central facial redness that worsens with triggers.",
    "bullet_explanations": {
      "Rosacea": "Correct. Central facial redness and telangiectasia with typical triggers is classic for rosacea.",
      "Seborrhoeic dermatitis": "Incorrect. Usually causes scaly, itchy rash in nasolabial folds and scalp, not persistent flushing or telangiectasia.",
      "Systemic lupus erythematosus": "Incorrect. SLE malar rash spares the nasolabial folds and is usually associated with systemic features.",
      "Alcohol-induced facial erythema": "Incorrect. Alcohol can cause flushing but does not explain persistent redness and telangiectasia.",
      "Mitral stenosis": "Incorrect. May cause malar flush but typically alongside cardiac symptoms such as dyspnoea and murmur."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Rosacea types",
    "keywords": [
      "rosacea",
      "facial erythema",
      "telangiectasia",
      "dermatology",
      "flushing"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Rosacea",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/rosacea/"
      },
      {
        "source": "BNF",
        "topic_title": "Rosacea",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/rosacea/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5a071b1c-7179-4bde-addb-df265947d865",
    "question_number": 201,
    "question": "A 28-year-old woman presents to her GP with a sudden onset of bilateral lower abdominal pain and deep dyspareunia. She also reports abnormal vaginal bleeding and a fever. On examination, she has cervical motion tenderness and purulent cervical discharge. What is the most likely diagnosis?",
    "options": [
      "Pelvic inflammatory disease",
      "Ovarian torsion",
      "Urinary tract infection",
      "Endometriosis",
      "Acute appendicitis"
    ],
    "correct_answer": "Pelvic inflammatory disease",
    "explanation": "**Explanation**\n**Pelvic inflammatory disease (PID)** is strongly suggested by the combination of bilateral lower abdominal pain, cervical motion tenderness, abnormal vaginal discharge, fever, and deep dyspareunia. PID is an infection of the upper genital tract, typically caused by sexually transmitted bacteria such as *Chlamydia trachomatis* or *Neisseria gonorrhoeae*. It often presents with systemic symptoms and pelvic tenderness, and can be associated with abnormal bleeding and mucopurulent discharge. In contrast, endometriosis is a chronic condition without high fever or purulent discharge; ovarian torsion presents with sudden, severe unilateral pain but not discharge or fever. Urinary tract infections (UTIs) generally cause local urinary symptoms without cervical or vaginal findings. Appendicitis may have lower abdominal pain but usually not bilateral, nor associated with vaginal symptoms.\n\n**Key Points**\n- PID classically presents with recent-onset bilateral lower abdominal pain, deep dyspareunia, abnormal vaginal bleeding, and/or mucopurulent discharge.\n- Cervical motion, adnexal, or uterine tenderness on examination are key diagnostic signs.\n- Fever and systemic upset often accompany PID.\n- Prompt empirical treatment is recommended to prevent serious sequelae (e.g. infertility, ectopic pregnancy).\n- Differential diagnoses include endometriosis (chronic, no fever), ovarian torsion (sudden, unilateral), and appendicitis (usually right-sided, no discharge).\n- <table><thead><tr><th>Condition</th><th>Key Features</th></tr></thead><tbody><tr><td>PID</td><td>Bilateral pelvic pain, fever, vaginal discharge, cervical motion tenderness</td></tr><tr><td>Endometriosis</td><td>Chronic pain, dysmenorrhoea, no fever/discharge</td></tr><tr><td>Ovarian torsion</td><td>Sudden, severe, unilateral pain, no discharge</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising PID early is crucial to reduce the risk of long-term complications such as infertility and chronic pelvic pain. NICE CKS recommends prompt empirical antibiotic therapy for suspected cases and partner notification to prevent reinfection and public health spread.\n\n**Memory Anchor**\nRemember: **PID = Pain + Infection + Discharge**.",
    "bullet_explanations": {
      "Pelvic inflammatory disease": "Correct. Classic features include bilateral pelvic pain, fever, abnormal discharge, and cervical motion tenderness.",
      "Ovarian torsion": "Incorrect. Presents with acute, severe, unilateral pelvic pain, usually without fever or vaginal discharge.",
      "Urinary tract infection": "Incorrect. Typically causes dysuria and frequency without pelvic tenderness or abnormal vaginal findings.",
      "Endometriosis": "Incorrect. Causes chronic pelvic pain and dysmenorrhoea but rarely presents with fever or purulent discharge.",
      "Acute appendicitis": "Incorrect. Usually causes right lower quadrant pain, not bilateral, and does not cause abnormal vaginal discharge."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Menstrual Disorders",
    "topic": "Amenorrhoea",
    "keywords": [
      "pelvic inflammatory disease",
      "PID",
      "vaginal discharge",
      "pelvic pain",
      "STI"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Pelvic inflammatory disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/pelvic-inflammatory-disease/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Vaginal discharge",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/vaginal-discharge/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "3795ba64-e272-4ddb-930e-2e67f9e2e238",
    "question_number": 202,
    "question": "A 34-year-old woman usually takes her desogestrel progestogen-only contraceptive pill at 7:00 am but forgot today and remembers at 12:45 pm. What is the most appropriate advice regarding her missed pill?",
    "options": [
      "Take the missed pill immediately; no further action is needed.",
      "Take the missed pill now and use condoms for 7 days.",
      "Skip the missed pill and start a new pack.",
      "Take the missed pill now and use condoms for 48 hours.",
      "Arrange a pregnancy test before resuming the pill."
    ],
    "correct_answer": "Take the missed pill immediately; no further action is needed.",
    "explanation": "**Explanation**\n**Desogestrel-containing progestogen-only pills (POPs) remain effective as long as they are taken within 12 hours of the usual time.** In this case, the pill is only 5 hours and 45 minutes late, so contraceptive efficacy is maintained. No additional contraception or emergency contraception is required, and she should continue her pill as normal. This contrasts with traditional POPs (e.g., norethisterone, levonorgestrel), which have a stricter 3-hour window for missed pills.\n\n**Key Points**\n- Desogestrel POP has up to a 12-hour window for missed pills.\n- If the pill is taken within this timeframe, efficacy is not reduced.\n- No extra precautions or emergency contraception are needed if within 12 hours.\n- Traditional POPs (not desogestrel) allow only a 3-hour window.\n- Desogestrel POPs are taken continuously without a break.\n\n**Clinical Relevance**\nClear understanding of missed pill rules for different progestogen-only pills is crucial for effective contraceptive counselling and preventing unnecessary anxiety or inappropriate emergency contraception use. UK guidelines specify a 12-hour window for desogestrel POPs, which differs from other types.",
    "bullet_explanations": {
      "Take the missed pill immediately; no further action is needed.": "Correct—she is within the 12-hour window for desogestrel POPs, so no additional precautions are necessary.",
      "Take the missed pill now and use condoms for 7 days.": "Incorrect—extra precautions are only required if more than 12 hours late for desogestrel POPs.",
      "Skip the missed pill and start a new pack.": "Incorrect—she should not skip pills or start a new pack; continuity is key for POPs.",
      "Take the missed pill now and use condoms for 48 hours.": "Incorrect—48-hour additional contraception applies to some combined pills, not desogestrel POPs within 12 hours.",
      "Arrange a pregnancy test before resuming the pill.": "Incorrect—no indication for pregnancy testing as efficacy is not compromised with a single missed pill under 12 hours late."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Progesterone-only methods",
    "keywords": [
      "missed pill",
      "desogestrel",
      "progestogen-only pill",
      "contraception advice"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Contraception - progestogen-only methods",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/contraception-progestogen-only-methods/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f4c53d03-755a-4eb3-af33-851524abbe98",
    "question_number": 203,
    "question": "What is the initial first-line pharmacological treatment for a child presenting with nephrotic syndrome most likely due to minimal change disease?",
    "options": [
      "High-dose oral prednisolone",
      "Intravenous albumin infusions",
      "Plasma exchange therapy",
      "Oral cyclophosphamide",
      "Immediate renal biopsy"
    ],
    "correct_answer": "High-dose oral prednisolone",
    "explanation": "**Explanation**\n**High-dose oral prednisolone** is the primary treatment for children presenting with nephrotic syndrome secondary to minimal change disease (MCD). Most paediatric cases of nephrotic syndrome are caused by MCD, and over 90% of these respond rapidly to corticosteroids. Prednisolone works by suppressing the immune-mediated injury to the glomerular filtration barrier, thereby reducing proteinuria. Other options, such as albumin infusions or plasma exchange, do not address the underlying mechanism and are reserved for specific complications. Cyclophosphamide and renal biopsy are considered only in steroid-resistant or frequently relapsing cases. Early steroid therapy leads to remission in the vast majority of affected children, making it the clear first-line intervention.\n\n**Key Points**\n- Minimal change disease is the leading cause of nephrotic syndrome in children.\n- First-line treatment is high-dose oral corticosteroids (prednisolone).\n- Most children achieve remission within weeks of starting steroids.\n- Renal biopsy is only necessary with atypical features or steroid resistance.\n- Immunosuppressants like cyclophosphamide are reserved for relapsing or steroid-resistant cases.\n- Supportive therapies (e.g., albumin infusions) are for severe hypoalbuminaemia complications, not first-line.\n\n**Clinical Relevance**\nPrompt steroid initiation in paediatric nephrotic syndrome is crucial for achieving remission and preventing complications. This approach is supported by clinical guidelines and reflected in the BNF's recommendations for corticosteroid use in serious glomerular diseases.\n\n**Memory Anchor**\nThink \"MCNS = Most Children Need Steroids\" for Minimal Change Nephrotic Syndrome.",
    "bullet_explanations": {
      "High-dose oral prednisolone": "Correct – corticosteroids are the established first-line therapy for minimal change nephrotic syndrome in children.",
      "Intravenous albumin infusions": "Incorrect – albumin infusions are reserved for severe symptomatic hypoalbuminaemia, not as definitive treatment.",
      "Plasma exchange therapy": "Incorrect – plasma exchange is not indicated in minimal change disease.",
      "Oral cyclophosphamide": "Incorrect – cyclophosphamide is used for steroid-resistant or frequently relapsing cases.",
      "Immediate renal biopsy": "Incorrect – biopsy is not typically required unless the disease is atypical or unresponsive to steroids."
    },
    "category": "Renal & Urology",
    "subsection": "Chronic Kidney Disease",
    "subsubsection": "Causes",
    "topic": "Causes",
    "keywords": [
      "minimal change disease",
      "nephrotic syndrome",
      "corticosteroids",
      "paediatric nephrology"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Corticosteroids, general use",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/corticosteroids-general-use/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9211f23a-3557-40a9-8433-06b964373ad5",
    "question_number": 204,
    "question": "A previously healthy 2-year-old boy is admitted with 6 days of persistent high fever that has not responded to antipyretics. On examination, he has bilateral conjunctival injection, a red, fissured tongue, and erythematous, peeling skin on his hands. Which diagnosis should be strongly considered?",
    "options": [
      "Scarlet fever",
      "Kawasaki disease",
      "Hand, foot and mouth disease",
      "Measles",
      "Staphylococcal scalded skin syndrome"
    ],
    "correct_answer": "Kawasaki disease",
    "explanation": "**Explanation**\nKawasaki disease is an acute, self-limiting vasculitis affecting mainly children under 5. It presents with **fever lasting 5 days or more that does not respond to standard antipyretics**, along with mucocutaneous features such as **bilateral conjunctival injection, cracked lips, strawberry tongue, and skin desquamation on the hands and feet**. Early recognition is crucial because untreated Kawasaki disease can cause serious cardiac complications, particularly **coronary artery aneurysms**. Other typical findings include polymorphous rash and cervical lymphadenopathy, but not all features are present in every case. The diagnosis is clinical; there is no specific diagnostic test.\n\n**Key Points**\n- Kawasaki disease: persistent high fever (>5 days), mucocutaneous inflammation, desquamation, and conjunctivitis\n- Typically affects children <5 years old\n- Complications include coronary artery aneurysms if not treated early\n- First-line treatment: intravenous immunoglobulin (IVIG) and high-dose aspirin\n- Diagnosis is clinical—no single confirmatory test\n- <table><thead><tr><th>Feature</th><th>Kawasaki Disease</th><th>Scarlet Fever</th></tr></thead><tbody><tr><td>Fever duration</td><td>>5 days</td><td>2–3 days</td></tr><tr><td>Conjunctivitis</td><td>Yes</td><td>No</td></tr><tr><td>Desquamation</td><td>Palms/soles</td><td>Fingers/toes (later)</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt identification and treatment of Kawasaki disease are vital to prevent potentially life-threatening cardiac sequelae, as highlighted in national guidelines. Children with fever ≥5 days and compatible mucocutaneous signs must be urgently assessed for Kawasaki disease and managed in secondary care with IVIG and aspirin. See BNF and NICE guidance for diagnostic and management pathways.\n\n**Memory Anchor**\nRemember: Kawasaki = 'CRASH and Burn' (Conjunctivitis, Rash, Adenopathy, Strawberry tongue, Hands/feet changes, and unrelenting fever).",
    "bullet_explanations": {
      "Scarlet fever": "Unlikely—usually presents with a sandpaper rash, strawberry tongue, and pharyngitis after a short fever, but lacks conjunctivitis or prolonged fever.",
      "Kawasaki disease": "Correct—matches the key features of prolonged fever, mucocutaneous changes, and skin desquamation.",
      "Hand, foot and mouth disease": "Incorrect—characterised by oral ulcers and vesicular rash on hands/feet, but does not cause persistent high fever or conjunctivitis.",
      "Measles": "Incorrect—features include cough, coryza, conjunctivitis, and a characteristic maculopapular rash; hands/feet desquamation is not typical.",
      "Staphylococcal scalded skin syndrome": "Unlikely—causes widespread skin blistering and peeling, but fever is usually of shorter duration and mucous membrane involvement is rare."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Common Infections",
    "topic": "Meningitis",
    "keywords": [
      "Kawasaki disease",
      "persistent fever",
      "paediatric vasculitis",
      "coronary complications",
      "mucocutaneous signs"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Fever",
        "citation": "© NICE BNFC, 2025",
        "url": "https://bnfc.nice.org.uk/treatment-summaries/fever/"
      },
      {
        "source": "BNF",
        "topic_title": "Immunoglobulins",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/immunoglobulins/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8db9a5fd-4750-44bc-89af-ad93492a7a25",
    "question_number": 205,
    "question": "A 45-year-old man with a history of selective IgA deficiency is receiving a packed red cell transfusion for symptomatic anaemia. Within minutes, he develops sudden shortness of breath, facial swelling, and hypotension. What is the most likely underlying mechanism for this transfusion reaction?",
    "options": [
      "Anti-IgA antibodies reacting with donor IgA",
      "Acute haemolysis due to ABO incompatibility",
      "Febrile reaction to donor leukocyte antigens",
      "Pulmonary oedema from volume overload",
      "Cytokine release causing transfusion-related acute lung injury (TRALI)"
    ],
    "correct_answer": "Anti-IgA antibodies reacting with donor IgA",
    "explanation": "**Explanation**\nThis patient is displaying features of **anaphylaxis during a blood transfusion**, including acute respiratory distress, angioedema, and hypotension. Individuals with selective IgA deficiency may develop **anti-IgA antibodies**. When transfused with blood products containing IgA, these antibodies can trigger a severe type I hypersensitivity (anaphylactic) reaction. Typical findings include rapid-onset dyspnoea, wheeze, hypotension, and urticaria or angioedema, distinguishing it from other transfusion reactions. **Coeliac disease and IgA deficiency are linked**, and both are risk factors for this mechanism.\n\n**Key Points**\n- Anaphylactic transfusion reactions are rare but potentially fatal.\n- Patients with IgA deficiency may develop anti-IgA antibodies.\n- Exposure to donor IgA can cause rapid-onset anaphylaxis.\n- Symptoms include hypotension, wheeze, dyspnoea, and angioedema.\n- Common in IgA-deficient individuals (including some with coeliac disease).\n- <table><thead><tr><th>Reaction</th><th>Key Features</th><th>Mechanism</th></tr></thead><tbody><tr><td>Anaphylactic</td><td>Hypotension, wheeze, urticaria</td><td>Anti-IgA antibodies</td></tr><tr><td>Acute haemolytic</td><td>Fever, chills, back pain, haemoglobinuria</td><td>ABO incompatibility</td></tr><tr><td>Febrile non-haemolytic</td><td>Fever, chills</td><td>Leukocyte antibodies</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising anaphylactic transfusion reactions is crucial for immediate management and patient safety. Patients with known IgA deficiency should receive washed or IgA-deficient blood products. Awareness of this mechanism prevents future life-threatening episodes and aligns with transfusion safety protocols.\n\n**Memory Anchor**\nThink 'IgA deficiency = Anti-IgA anaphylaxis' during transfusion.",
    "bullet_explanations": {
      "Anti-IgA antibodies reacting with donor IgA": "Correct – IgA-deficient patients can develop anti-IgA antibodies, causing anaphylaxis when exposed to IgA in transfused blood.",
      "Acute haemolysis due to ABO incompatibility": "Incorrect – This presents with fever, chills, back pain, and haemoglobinuria, not isolated respiratory distress and angioedema.",
      "Febrile reaction to donor leukocyte antigens": "Incorrect – Causes fever and chills (febrile non-haemolytic reaction), not hypotension or airway symptoms.",
      "Pulmonary oedema from volume overload": "Incorrect – Transfusion-associated circulatory overload (TACO) presents with hypertension, raised JVP, and pulmonary oedema, not angioedema or hypotension.",
      "Cytokine release causing transfusion-related acute lung injury (TRALI)": "Incorrect – TRALI causes non-cardiogenic pulmonary oedema and hypoxia, but not angioedema or urticaria."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Bleeding Disorders",
    "topic": "Transfusion thresholds",
    "keywords": [
      "anaphylaxis",
      "blood transfusion",
      "IgA deficiency",
      "anti-IgA antibodies",
      "transfusion reaction"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "11bff341-269c-4baf-9346-280ee8b7d69a",
    "question_number": 206,
    "question": "A 62-year-old man with a history of chronic pancreatitis presents with diffuse bone pain and difficulty rising from a chair. He has experienced several months of progressive muscle weakness. Laboratory tests reveal: Calcium 2.00 mmol/L (2.20–2.60), Phosphate 0.5 mmol/L (0.8–1.4), Alkaline phosphatase 290 U/L (30–130), Parathyroid hormone 13 pmol/L (1.6–6.9), and vitamin D 17 nmol/L (50–150). What is the most likely cause of his symptoms?",
    "options": [
      "Osteomalacia",
      "Osteoporosis",
      "Paget's disease of bone",
      "Primary hyperparathyroidism",
      "Renal osteodystrophy"
    ],
    "correct_answer": "Osteomalacia",
    "explanation": "**Explanation**\n**Osteomalacia** is characterised by defective mineralisation of bone matrix due to vitamin D deficiency or impaired metabolism. This patient’s history of chronic pancreatitis predisposes him to fat-soluble vitamin malabsorption, including vitamin D. Key biochemical findings—**low calcium, low phosphate, elevated alkaline phosphatase, raised parathyroid hormone, and markedly decreased vitamin D**—are classic for osteomalacia. The raised PTH represents secondary hyperparathyroidism in response to hypocalcaemia. Osteoporosis, by contrast, usually shows normal biochemistry; Paget’s disease typically results in isolated raised ALP with normal calcium and phosphate; primary hyperparathyroidism is associated with high calcium and low phosphate; renal osteodystrophy occurs in advanced CKD and includes different biochemical patterns.\n\n**Key Points**\n- Osteomalacia results from defective bone mineralisation, most often due to vitamin D deficiency.\n- Lab findings: ↓ calcium, ↓ phosphate, ↑ ALP, ↑ PTH, ↓ vitamin D.\n- Secondary hyperparathyroidism is a compensatory response to hypocalcaemia.\n- Risk factors include malabsorption (e.g., chronic pancreatitis, Crohn’s disease, coeliac disease).\n- Osteoporosis: normal biochemistry; Osteomalacia: deranged calcium/phosphate/ALP.\n- <table><thead><tr><th>Condition</th><th>Ca</th><th>PO4</th><th>ALP</th><th>PTH</th><th>Vit D</th></tr></thead><tbody><tr><td>Osteomalacia</td><td>Low</td><td>Low</td><td>High</td><td>High</td><td>Low</td></tr><tr><td>Osteoporosis</td><td>Normal</td><td>Normal</td><td>Normal</td><td>Normal</td><td>Variable</td></tr></tbody></table>\n\n**Clinical Relevance**\nEarly recognition of osteomalacia is crucial, especially in patients with risk factors for vitamin D deficiency and malabsorption. Prompt vitamin D supplementation can reverse symptoms and prevent fractures. UK NICE guidance recommends investigating musculoskeletal symptoms with relevant biochemical testing and addressing underlying causes, such as malabsorption.\n\n**Memory Anchor**\n‘M’ for Malabsorption and ‘M’ for OsteoMalacia: Malabsorption (e.g., pancreatitis, Crohn's, coeliac) commonly leads to osteomalacia.",
    "bullet_explanations": {
      "Osteomalacia": "Correct – Biochemical findings and risk factors are typical for osteomalacia due to vitamin D deficiency.",
      "Osteoporosis": "Incorrect – Osteoporosis involves reduced bone mass without impaired mineralisation; serum calcium, phosphate, and ALP are usually normal.",
      "Paget's disease of bone": "Incorrect – Paget’s disease presents with high ALP, but calcium and phosphate are typically normal; bone pain is more localised.",
      "Primary hyperparathyroidism": "Incorrect – Primary hyperparathyroidism is associated with high calcium and low phosphate, not low calcium.",
      "Renal osteodystrophy": "Incorrect – Renal osteodystrophy arises in advanced chronic kidney disease and usually shows raised phosphate and different patterns."
    },
    "category": "Calcium, Pituitary & Metabolic",
    "subsection": "Calcium Disorders",
    "subsubsection": "Vitamin D deficiency management",
    "topic": "Vitamin D deficiency management",
    "keywords": [
      "osteomalacia",
      "vitamin D deficiency",
      "malabsorption",
      "bone pain",
      "biochemical profile"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Vitamin D deficiency in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/vitamin-d-deficiency-in-adults/"
      },
      {
        "source": "BNF",
        "topic_title": "Vitamins",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/vitamins/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5c2a735d-5563-4dd4-b5e5-6b7670b5483c",
    "question_number": 207,
    "question": "A 72-year-old man is started on oral prednisolone 15 mg daily for newly diagnosed polymyalgia rheumatica. After three weeks, he reports no improvement in his shoulder and hip girdle pain. What is the most appropriate action to take next?",
    "options": [
      "Discontinue steroids and reassess the diagnosis",
      "Increase prednisolone to 30 mg daily",
      "Continue current dose for another month before reviewing",
      "Switch to oral methylprednisolone",
      "Refer immediately for intravenous steroids"
    ],
    "correct_answer": "Discontinue steroids and reassess the diagnosis",
    "explanation": "**Explanation**\n**A prompt and significant response to low-dose corticosteroids is a key diagnostic criterion for polymyalgia rheumatica (PMR).** Most individuals with true PMR experience clear symptom relief within one to two weeks of starting oral prednisolone at 10–15 mg daily. If there is little or no improvement within this timeframe, the original diagnosis should be questioned, and alternative conditions such as osteoarthritis, fibromyalgia, or inflammatory arthropathies should be considered. **Escalating the steroid dose or prolonging treatment without clinical response is not appropriate, as it risks unnecessary steroid exposure and delays accurate diagnosis.**\n\n**Key Points**\n- PMR classically responds rapidly to low-dose corticosteroids (10–15 mg prednisolone).\n- Lack of improvement after 2–3 weeks suggests an alternative diagnosis.\n- Steroid dose escalation is not indicated if there is no response.\n- Differential diagnoses include rheumatoid arthritis, fibromyalgia, and osteoarthritis.\n- Prolonged unnecessary steroid use increases risk of adverse effects.\n- <table><thead><tr><th>Diagnosis</th><th>Response to Steroids</th></tr></thead><tbody><tr><td>PMR</td><td>Rapid (days–weeks)</td></tr><tr><td>Other causes</td><td>No or poor response</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising a lack of steroid response in PMR is crucial to avoid harm from unnecessary immunosuppression and to ensure prompt identification and management of alternative conditions. NICE CKS recommends reviewing the diagnosis if there is no improvement after starting steroids.\n\n**Memory Anchor**\nPMR = Prompt steroid response; No response, Not PMR.",
    "bullet_explanations": {
      "Discontinue steroids and reassess the diagnosis": "Correct – Absence of response to steroids indicates likely misdiagnosis; stop steroids and reconsider the underlying cause.",
      "Increase prednisolone to 30 mg daily": "Incorrect – Dose escalation is not appropriate without initial steroid response; suggests wrong diagnosis.",
      "Continue current dose for another month before reviewing": "Incorrect – Clinical improvement is expected within 1–2 weeks; delaying reassessment is unsafe.",
      "Switch to oral methylprednisolone": "Incorrect – Changing steroid type offers no benefit; lack of response suggests misdiagnosis, not drug inefficacy.",
      "Refer immediately for intravenous steroids": "Incorrect – IV steroids are not indicated in uncomplicated PMR and do not address the underlying issue of diagnostic uncertainty."
    },
    "category": "Musculoskeletal",
    "subsection": "Arthritis",
    "subsubsection": "Rheumatoid Arthritis",
    "topic": "Early features and serology",
    "keywords": [
      "polymyalgia rheumatica",
      "steroid response",
      "diagnosis",
      "misdiagnosis",
      "management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Polymyalgia rheumatica",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/polymyalgia-rheumatica/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c8e3fcec-0267-4a20-8a59-cd63520236f7",
    "question_number": 208,
    "question": "A 9-year-old girl is brought to clinic after her father notices several episodes of facial twitching and excessive drooling during sleep over the past month. Each event lasts less than 2 minutes and is followed by temporary difficulty speaking. She has no developmental delays or previous neurological concerns. What is the most likely diagnosis?",
    "options": [
      "Reflex anoxic seizures",
      "Benign rolandic epilepsy",
      "Panayiotopoulos syndrome",
      "Idiopathic childhood occipital epilepsy of Gastaut",
      "Night terrors"
    ],
    "correct_answer": "Benign rolandic epilepsy",
    "explanation": "**Explanation**\n**Benign rolandic epilepsy (also known as benign epilepsy with centrotemporal spikes)** is the most common focal epilepsy of childhood. It typically presents between ages 3 and 13 with brief, nocturnal focal seizures involving facial twitching, drooling, and speech arrest. Post-ictal dysphasia (difficulty speaking after the episode) is characteristic. Children are otherwise healthy with normal neurological development. Seizures often occur shortly after falling asleep or on awakening and usually remit by adolescence. Other options, such as reflex anoxic seizures, are not associated with these nocturnal focal features or this age group.<br><br>**Key distinguishing features** include: nocturnal onset, facial motor involvement, preserved awareness, and post-ictal dysphasia. This contrasts with other epilepsy syndromes which have different semiology or associated symptoms.\n\n**Key Points**\n- Benign rolandic epilepsy presents with brief, nocturnal focal seizures involving the face and mouth.\n- Speech disturbance following the seizure is common (post-ictal dysphasia).\n- Children have normal development and outgrow the condition by adolescence.\n- Seizures often occur during sleep or on waking.\n- Differentiated from Panayiotopoulos syndrome (autonomic symptoms), occipital epilepsy (visual symptoms), and night terrors (parasomnia without focal neurological signs).\n\n**Clinical Relevance**\nRecognising benign rolandic epilepsy is important for early reassurance, appropriate referral, and avoiding unnecessary investigations. NICE guidelines recommend specialist assessment for new suspected seizures in children. Prognosis is excellent, and most children do not require long-term medication.\n\n**Memory Anchor**\nThink 'Rolandic' = 'Rolls face at night' (facial twitching, nocturnal onset).",
    "bullet_explanations": {
      "Reflex anoxic seizures": "Incorrect – These are syncope episodes with brief loss of consciousness, typically in younger children, not associated with focal nocturnal seizures.",
      "Benign rolandic epilepsy": "Correct – Classic presentation with nocturnal facial seizures, drooling, and transient speech difficulty in a school-aged child.",
      "Panayiotopoulos syndrome": "Incorrect – Characterised by prolonged autonomic seizures (nausea, vomiting, pallor), not focal facial twitching.",
      "Idiopathic childhood occipital epilepsy of Gastaut": "Incorrect – Features visual disturbances such as hallucinations, not facial motor symptoms.",
      "Night terrors": "Incorrect – A sleep disorder involving sudden arousals and distress, without focal neurological signs or post-ictal features."
    },
    "category": "Paediatrics",
    "subsection": "Chronic Paediatrics",
    "subsubsection": "Neurology",
    "topic": "Epilepsy syndromes",
    "keywords": [
      "benign rolandic epilepsy",
      "paediatric seizures",
      "nocturnal seizures",
      "focal epilepsy",
      "child neurology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Epilepsy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/epilepsy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "21ea77bf-fadc-4b4a-b1b5-e9723355766d",
    "question_number": 209,
    "question": "A 57-year-old man with known primary adrenal insufficiency managed with hydrocortisone and fludrocortisone presents to his GP with a low-grade fever and sore throat. He is able to eat and drink normally, and examination reveals stable observations. He is prescribed oral antibiotics for a presumed bacterial pharyngitis. What adjustment should be made to his steroid replacement during this episode of illness?",
    "options": [
      "Double the hydrocortisone dose and maintain the usual fludrocortisone dose",
      "Maintain both hydrocortisone and fludrocortisone at current doses",
      "Double both hydrocortisone and fludrocortisone doses",
      "Switch hydrocortisone to dexamethasone temporarily",
      "Discontinue all steroid replacement until symptoms resolve"
    ],
    "correct_answer": "Double the hydrocortisone dose and maintain the usual fludrocortisone dose",
    "explanation": "**Explanation**\n**During intercurrent illness, patients with primary adrenal insufficiency require increased glucocorticoid replacement to mimic the normal physiological stress response.** The standard recommendation is to double the hydrocortisone dose for the duration of the illness, while keeping the fludrocortisone (mineralocorticoid) dose unchanged. This is because acute illness increases the body's demand for cortisol, but does not alter mineralocorticoid requirements. Failure to increase glucocorticoid dosing risks precipitating adrenal crisis. Fludrocortisone dose adjustments are reserved for significant volume depletion or electrolyte disturbance, not routine minor illness.\n\n**Key Points**\n- Primary adrenal insufficiency patients are educated on 'sick day rules' for intercurrent illness.\n- Hydrocortisone dose should be doubled during moderate illness such as infection or fever.\n- Fludrocortisone dose remains unchanged unless there are specific concerns (e.g. hypotension, electrolyte imbalance).\n- Stopping steroid therapy is dangerous and can cause adrenal crisis.\n- Switching to alternative glucocorticoids (e.g. dexamethasone) is not recommended in this scenario.\n\n**Clinical Relevance**\nUnderstanding 'sick day rules' for steroid replacement in Addison's disease is crucial to prevent adrenal crisis during common illnesses. This is a core safety point in both primary and secondary care, and is highlighted in national guidelines and the BNF.",
    "bullet_explanations": {
      "Double the hydrocortisone dose and maintain the usual fludrocortisone dose": "Correct – this follows sick day rules for adrenal insufficiency during moderate illness.",
      "Maintain both hydrocortisone and fludrocortisone at current doses": "Incorrect – this risks under-treatment and adrenal crisis during illness.",
      "Double both hydrocortisone and fludrocortisone doses": "Incorrect – only glucocorticoid requirements increase, not mineralocorticoid.",
      "Switch hydrocortisone to dexamethasone temporarily": "Incorrect – hydrocortisone is preferred for physiological replacement during illness.",
      "Discontinue all steroid replacement until symptoms resolve": "Dangerous – stopping steroids can precipitate adrenal crisis."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Adrenal",
    "subsubsection": "Adrenal Insufficiency",
    "topic": "Stress dosing and sick day rules",
    "keywords": [
      "Addison's disease",
      "sick day rules",
      "hydrocortisone",
      "adrenal crisis",
      "fludrocortisone"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Adrenal insufficiency",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/adrenal-insufficiency/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8ff5b174-a941-4649-91f5-ce826d287677",
    "question_number": 210,
    "question": "What is the primary causative factor in the development of cervical cancer?",
    "options": [
      "Persistent infection with high-risk human papillomavirus (HPV) types",
      "Long-term combined oral contraceptive use",
      "History of smoking",
      "Early onset of sexual activity",
      "Low-risk HPV types 6 and 11"
    ],
    "correct_answer": "Persistent infection with high-risk human papillomavirus (HPV) types",
    "explanation": "**Explanation**\n**Persistent infection with high-risk human papillomavirus (HPV), especially types 16 and 18, is the primary causative factor in cervical cancer.** These oncogenic HPV types integrate into the cervical epithelium, leading to dysplasia and, if unchecked, malignant transformation. While other factors such as smoking, early sexual activity, and long-term contraceptive use can increase vulnerability or modify risk, they are not the underlying cause. Low-risk HPV types (e.g., 6 and 11) primarily cause benign lesions like genital warts, not cancer. HPV is detected in over 99% of cervical cancer cases, and vaccination programmes specifically target the high-risk subtypes most responsible for malignancy.<br><br><b>Contrast:</b> While smoking and early sexual activity are associated risk modifiers, they do not directly cause cervical cancer in the absence of high-risk HPV infection.\n\n**Key Points**\n- High-risk HPV types (especially 16 and 18) are implicated in the vast majority of cervical cancer cases.\n- HPV is sexually transmitted and infection is common, but persistent infection leads to malignancy.\n- Only a minority of HPV infections persist and progress to high-grade dysplasia or cancer.\n- Low-risk HPV types (e.g., 6, 11) are associated with warts, not malignancy.\n- Other risk factors (smoking, early sexual activity, immunosuppression) increase risk but are not primary causes.\n- <table><thead><tr><th>Risk Factor</th><th>Role in Cervical Cancer</th></tr></thead><tbody><tr><td>High-risk HPV</td><td>Primary cause</td></tr><tr><td>Smoking</td><td>Co-factor</td></tr><tr><td>Early sexual activity</td><td>Co-factor</td></tr><tr><td>Low-risk HPV</td><td>No causal role</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognition of high-risk HPV as the major cause of cervical cancer underpins cervical screening and vaccination strategies in the UK. Identifying and vaccinating against oncogenic HPV types are essential public health measures to reduce incidence and mortality.\n\n**Memory Anchor**\nHPV 16 and 18: '16 + 18 = 34', the typical UK age peak for cervical cancer.",
    "bullet_explanations": {
      "Persistent infection with high-risk human papillomavirus (HPV) types": "Correct – persistent infection with high-risk HPV, especially types 16 and 18, is the main cause of cervical cancer.",
      "Long-term combined oral contraceptive use": "Incorrect – may increase risk but is not the primary aetiological factor.",
      "History of smoking": "Incorrect – smoking is a co-factor but not the fundamental cause.",
      "Early onset of sexual activity": "Incorrect – increases exposure risk to HPV but is not itself causative.",
      "Low-risk HPV types 6 and 11": "Incorrect – these types cause genital warts, not cervical cancer."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Infertility",
    "topic": "Causes",
    "keywords": [
      "cervical cancer",
      "HPV",
      "risk factors",
      "gynaecology",
      "screening"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cervical cancer and HPV",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cervical-cancer-hpv/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Cervical screening",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cervical-screening/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "46a05963-2bb2-4e14-aef1-9a3eb45fbb5a",
    "question_number": 211,
    "question": "In a 19-year-old sexually active male presenting with gradual onset of unilateral testicular tenderness and swelling but no fever, which pathogen is most commonly responsible for epididymo-orchitis in this age group?",
    "options": [
      "Chlamydia trachomatis",
      "Escherichia coli",
      "Mumps virus",
      "Neisseria gonorrhoeae",
      "Treponema pallidum"
    ],
    "correct_answer": "Chlamydia trachomatis",
    "explanation": "**Explanation**\n**Chlamydia trachomatis** is the leading cause of epididymo-orchitis in sexually active males under 35 years of age. The infection is typically acquired via sexual transmission, especially in those with multiple partners. In contrast, older men or those with a history of urinary tract instrumentation are more likely to develop epididymo-orchitis secondary to coliform bacteria such as E. coli. Mumps virus can cause orchitis, but is less common in this demographic and often presents with parotitis. Neisseria gonorrhoeae is also a significant cause in younger men but is less common than chlamydia. Treponema pallidum (syphilis) rarely causes epididymal infection.\n\n**Key Points**\n- Chlamydia trachomatis is the most frequent cause of epididymo-orchitis in men under 35.\n- Sexual history is crucial for assessing risk of STI-related testicular infections.\n- E. coli becomes more common in epididymo-orchitis in men over 35 or those with urinary tract abnormalities.\n- Mumps-associated orchitis is typically seen in unvaccinated adolescents and presents with systemic features.\n- Prompt recognition and treatment of STI-related epididymo-orchitis prevents complications such as infertility.\n- <table><thead><tr><th>Age Group</th><th>Most Likely Organism</th></tr></thead><tbody><tr><td>&lt;35 years</td><td>Chlamydia trachomatis &gt; Neisseria gonorrhoeae</td></tr><tr><td>&gt;35 years</td><td>E. coli</td></tr></tbody></table>\n\n**Clinical Relevance**\nCorrectly identifying the most common causative organism in different age groups guides empirical antibiotic therapy for epididymo-orchitis and is essential for sexual health screening and partner notification, as outlined in UK guidelines.\n\n**Memory Anchor**\nChlamydia is the 'chief culprit' under thirty-five.",
    "bullet_explanations": {
      "Chlamydia trachomatis": "Correct – Most common cause in sexually active young men.",
      "Escherichia coli": "Incorrect – More typical in older men or those with urinary tract abnormalities.",
      "Mumps virus": "Incorrect – Causes orchitis, but usually in adolescents with systemic symptoms and parotid swelling.",
      "Neisseria gonorrhoeae": "Incorrect – Significant cause but less common than chlamydia in this age group.",
      "Treponema pallidum": "Incorrect – Rarely causes epididymal infection, more often linked with syphilitic lesions."
    },
    "category": "STIs & Sexual Health",
    "subsection": "STIs",
    "subsubsection": "Chlamydia",
    "topic": "Chlamydia",
    "keywords": [
      "epididymo-orchitis",
      "chlamydia",
      "scrotal pain",
      "STI",
      "young men"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Scrotal pain and swelling",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/scrotal-pain-swelling/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "201c5f10-5102-4c34-a528-3dc042eaad6d",
    "question_number": 212,
    "question": "During a school vision screening, a 6-year-old girl is noted to have an inward deviation of her left eye. Which of the following findings on the cover test would confirm a diagnosis of left esotropia?",
    "options": [
      "Covering the right eye causes the left eye to move laterally to fixate",
      "Covering the left eye causes the right eye to move medially to fixate",
      "Covering either eye causes no eye movement",
      "Covering the right eye causes the left eye to move medially to fixate",
      "Covering the left eye causes the right eye to move laterally to fixate"
    ],
    "correct_answer": "Covering the right eye causes the left eye to move laterally to fixate",
    "explanation": "**Explanation**\nIn left esotropia, the left eye deviates inward (towards the nose) when both eyes are open. The cover test helps to identify which eye is misaligned and in which direction. **When the right (fixing) eye is covered, the left (esotropic) eye must move outward (laterally) to take up fixation**. This outward movement confirms that the left eye was initially turned inward. The cover test distinguishes between types of squint by observing the movement of the uncovered eye when the fixing eye is occluded. In exotropia, the misaligned eye would move medially to fixate when the fixing eye is covered.\n\n**Key Points**\n<ul><li>Esotropia describes inward deviation of one eye.</li><li>Cover test: cover the fixing (non-squinting) eye and observe for movement of the squinting eye.</li><li>Lateral (outward) movement of the eye when uncovered confirms esotropia on that side.</li><li>Prompt recognition and referral are essential to prevent amblyopia.</li><li>Squints can be concomitant (most common) or paralytic (rare in children).</li></ul>\n\n**Clinical Relevance**\nEarly detection and referral of childhood squints are crucial to prevent amblyopia and permanent visual impairment. The cover test is a straightforward examination that helps primary care clinicians identify misalignment and guide appropriate referral. NICE CKS recommends referral to paediatric ophthalmology for all suspected squints in children.\n\n**Memory Anchor**\nEsotropia: the affected eye moves OUTwards on cover test (think: 'Eso = In, moves Out to fixate').",
    "bullet_explanations": {
      "Covering the right eye causes the left eye to move laterally to fixate": "Correct – the esotropic (inward-turning) left eye moves outward to take up fixation when the right eye is covered.",
      "Covering the left eye causes the right eye to move medially to fixate": "Incorrect – this would suggest the right eye is exotropic (turned out), not consistent with left esotropia.",
      "Covering either eye causes no eye movement": "Incorrect – in manifest squint, covering the fixing eye should prompt movement of the deviated eye.",
      "Covering the right eye causes the left eye to move medially to fixate": "Incorrect – medial (inward) movement would be seen if the left eye was exotropic.",
      "Covering the left eye causes the right eye to move laterally to fixate": "Incorrect – this suggests the right eye is esotropic, not the left."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Conjunctivitis (viral/bacterial/allergic)",
    "topic": "Squint (strabismus)",
    "keywords": [
      "squint",
      "esotropia",
      "cover test",
      "paediatric ophthalmology",
      "amblyopia"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Squint in children",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/squint-in-children/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "05ba1d91-342f-4e10-983f-b6a1c2d11078",
    "question_number": 213,
    "question": "A 65-year-old man presents with abdominal distension and high-pitched bowel sounds three weeks after surgery for diverticular disease. He has a stoma positioned in the lower left abdomen, which is flush with the skin and has not produced any output for 24 hours. What is the most likely type of stoma he has?",
    "options": [
      "End colostomy",
      "Loop ileostomy",
      "End ileostomy",
      "Percutaneous jejunostomy",
      "Loop colostomy"
    ],
    "correct_answer": "End colostomy",
    "explanation": "**Explanation**\n**End colostomies** are typically formed after resection of the colon and are most commonly sited in the left lower abdomen. They are usually flush with the skin because the output from the colon is less caustic, so there is less need for the stoma to protrude. In contrast, ileostomies are often spouted to protect the skin from the more irritating, liquid output of the small intestine. The clinical scenario describes a flush stoma in the left lower quadrant with features of obstruction—typical of an end colostomy after colorectal surgery.\n\n**Key Points**\n- Colostomies are usually sited on the left side and are flush with the skin.\n- End colostomies are created after segmental resection of the colon.\n- Ileostomies are generally sited on the right and are spouted to protect skin from irritant output.\n- Stoma obstruction is a known complication, presenting with distension and absent output.\n- Jejunostomies are rare and typically sited higher in the abdomen.\n\n**Clinical Relevance**\nIdentifying the type of stoma and recognising its likely complications is essential for post-operative care and prompt management of stoma-related emergencies such as obstruction.\n\n**Memory Anchor**\nColostomies are 'close to the skin' (flush), while ileostomies 'lift out' (spouted) to protect from irritant output.",
    "bullet_explanations": {
      "End colostomy": "Correct – flush to the skin, left lower quadrant, typical after colorectal resection.",
      "Loop ileostomy": "Incorrect – usually spouted and sited in the right iliac fossa.",
      "End ileostomy": "Incorrect – also spouted and more commonly on the right side.",
      "Percutaneous jejunostomy": "Incorrect – usually used for feeding, sited higher in the abdomen, not flush.",
      "Loop colostomy": "Incorrect – may be sited similarly but is most often used for temporary diversion and would have two lumens visible."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "Diverticular Disease",
    "topic": "Uncomplicated vs complicated presentations",
    "keywords": [
      "stoma",
      "colostomy",
      "obstruction",
      "postoperative",
      "colorectal surgery"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "3bb67105-121e-4ace-98ea-1c50fa91a94a",
    "question_number": 214,
    "question": "A 28-year-old man develops tender, red nodules over his shins. Which of the following underlying conditions is least commonly associated with this skin finding?",
    "options": [
      "Sarcoidosis",
      "Ulcerative colitis",
      "Pregnancy",
      "Syphilis",
      "Tuberculosis"
    ],
    "correct_answer": "Syphilis",
    "explanation": "**Explanation**\n**Erythema nodosum** is a form of panniculitis presenting as painful, erythematous nodules, typically on the shins. It is most often linked to infectious causes (such as streptococcal infections and tuberculosis), systemic inflammatory conditions (including sarcoidosis and inflammatory bowel diseases like ulcerative colitis), and physiological states such as pregnancy. However, **syphilis is not a recognised cause of erythema nodosum**. Instead, syphilis tends to present with other cutaneous manifestations (such as a painless chancre or a generalised rash affecting the trunk and extremities) rather than tender nodules over the shins.\n\n**Key Points**\n- **Erythema nodosum is a non-specific inflammatory reaction of subcutaneous fat**.\n- Common associations include **sarcoidosis, tuberculosis, inflammatory bowel disease, and pregnancy**.\n- Syphilis typically does **not** cause erythema nodosum; its dermatological features differ.\n- **Diagnosis is clinical**; biopsy is rarely required unless the diagnosis is unclear.\n- Treatment targets the underlying condition and supportive care for symptoms.\n- Other causes include certain drugs, streptococcal infection, and Behçet’s disease.\n\n**Clinical Relevance**\nRecognising the associations of erythema nodosum enables clinicians to target investigations appropriately and consider underlying systemic or infectious triggers. Ruling out less likely causes, such as syphilis, helps streamline diagnosis and avoid unnecessary tests.\n\n**Memory Anchor**\n**'SUNT' for Sarcoidosis, Ulcerative colitis, (preg)Nancy, Tuberculosis – but not Syphilis!**",
    "bullet_explanations": {
      "Sarcoidosis": "Commonly associated with erythema nodosum, especially in young adults.",
      "Ulcerative colitis": "Inflammatory bowel disease is a recognised cause of erythema nodosum.",
      "Pregnancy": "Physiological changes in pregnancy can predispose to erythema nodosum.",
      "Syphilis": "Not a typical cause of erythema nodosum; cutaneous signs differ.",
      "Tuberculosis": "A classic infectious trigger for erythema nodosum."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Community vs hospital-acquired pneumonia",
    "keywords": [
      "erythema nodosum",
      "skin nodules",
      "differential diagnosis",
      "syphilis",
      "sarcoidosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cellulitis - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cellulitis-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f12ed1e5-56c4-4521-8090-f319fae112b7",
    "question_number": 215,
    "question": "A 28-year-old woman presents with several months of mildly itchy, erythematous patches with greasy yellowish scale affecting her scalp margin, ears, and upper chest. She has no history of atopy, and the lesions are particularly prominent in the nasolabial folds. What is the most likely diagnosis?",
    "options": [
      "Seborrhoeic dermatitis",
      "Discoid eczema",
      "Psoriasis vulgaris",
      "Pityriasis rosea",
      "Tinea corporis"
    ],
    "correct_answer": "Seborrhoeic dermatitis",
    "explanation": "**Explanation**\n**Seborrhoeic dermatitis** typically presents with ill-defined, erythematous patches covered by greasy, yellowish scale in areas rich in sebaceous glands—such as the scalp, face (especially nasolabial folds and eyebrows), ears, and upper trunk. The chronic, relapsing course and characteristic anatomical distribution distinguish it from other eczematous, psoriatic, or fungal skin diseases. The pathogenesis is linked to host response to Malassezia yeasts, and diagnosis is clinical. Unlike atopic eczema, seborrhoeic dermatitis rarely involves the flexures or is associated with a significant personal or family history of atopy. Psoriasis tends to show well-demarcated plaques with silvery scale, while pityriasis rosea usually presents with a herald patch and follows a 'Christmas tree' distribution on the trunk.\n\n**Key Points**\n- Affects sebaceous gland-rich areas: scalp, face (eyebrows, nasolabial folds), ears, chest\n- Lesions are erythematous with greasy, yellow-brown scale\n- Chronic, relapsing course in adults\n- Malassezia yeast implicated in pathogenesis\n- Diagnosis is clinical based on distribution and appearance\n- Distinguished from psoriasis (silvery scale, more defined edges) and tinea (annular, centrifugal spread)\n\n**Clinical Relevance**\nRecognising the distribution and appearance of seborrhoeic dermatitis is important in primary care to guide appropriate use of antifungal and anti-inflammatory topical therapies, as recommended by national guidelines. Early identification avoids unnecessary investigations and ensures prompt, effective management for a common chronic skin condition.\n\n**Memory Anchor**\nThink of 'sebaceous' for seborrhoeic: scalp, face, chest—where the oil glands are most active.",
    "bullet_explanations": {
      "Seborrhoeic dermatitis": "Correct – Characteristic distribution, scale, and chronicity strongly point to this diagnosis.",
      "Discoid eczema": "Incorrect – Presents as coin-shaped plaques, usually on limbs, not in seborrhoeic areas with greasy scale.",
      "Psoriasis vulgaris": "Incorrect – Tends to have sharply demarcated plaques with silvery scale on elbows, knees, and scalp.",
      "Pityriasis rosea": "Incorrect – Features a herald patch and 'fir-tree' pattern on the trunk, not seborrhoeic distribution.",
      "Tinea corporis": "Incorrect – Produces annular, scaly lesions with central clearing, often on body/extremities."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Seborrhoeic dermatitis",
    "keywords": [
      "seborrhoeic dermatitis",
      "greasy scale",
      "nasolabial folds",
      "scalp rash",
      "Malassezia"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Seborrhoeic dermatitis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/seborrhoeic-dermatitis/"
      },
      {
        "source": "BNF",
        "topic_title": "Eczema",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/eczema/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "448806a1-5641-4e0c-a567-12d86eb2ae17",
    "question_number": 216,
    "question": "Which class of antihypertensive medication most commonly increases the risk of lithium toxicity when co-prescribed, due to effects on renal sodium handling?",
    "options": [
      "Thiazide diuretics",
      "Angiotensin II receptor blockers",
      "Beta-blockers",
      "Alpha-blockers",
      "Calcium channel blockers"
    ],
    "correct_answer": "Thiazide diuretics",
    "explanation": "**Explanation**\n**Thiazide diuretics** (including drugs such as indapamide and chlortalidone) are well recognised for raising lithium levels and precipitating toxicity. This is because thiazides promote sodium loss in the distal convoluted tubule, which leads to increased proximal tubular reabsorption of lithium, as lithium is handled in the kidney similarly to sodium. Reduced lithium clearance results, especially in patients with underlying dehydration or renal impairment. Symptoms of lithium toxicity include nausea, vomiting, confusion, drowsiness, tremor, and, in severe cases, seizures or coma. Careful monitoring is essential if thiazides are unavoidable in a patient on lithium therapy. Other antihypertensive drugs do not have this direct effect on lithium elimination.\n\n**Key Points**\n- Thiazides reduce renal lithium clearance by increasing proximal sodium reabsorption.\n- Co-administration significantly raises the risk of lithium toxicity.\n- Symptoms of lithium toxicity: GI upset, tremor, confusion, and ataxia.\n- Renal impairment and dehydration further increase toxicity risk.\n- <table><thead><tr><th>Drug Class</th><th>Effect on Lithium</th></tr></thead><tbody><tr><td>Thiazide diuretics</td><td>Increase lithium levels</td></tr><tr><td>Loop diuretics</td><td>Possible mild increase</td></tr><tr><td>NSAIDs</td><td>Increase lithium levels</td></tr><tr><td>ACE inhibitors</td><td>Possible increase</td></tr></tbody></table>\n\n**Clinical Relevance**\nKnowing drug interactions with lithium is vital for patient safety, as toxicity can be life-threatening. NICE BNF guidance advises caution and close monitoring of lithium levels when initiating thiazide diuretics in patients taking lithium, and alternative antihypertensive agents are preferred where possible.\n\n**Memory Anchor**\nRemember: 'Thiazides Tangle with Lithium'—T for thiazide, T for toxicity.",
    "bullet_explanations": {
      "Thiazide diuretics": "Correct – they markedly reduce lithium clearance, raising toxicity risk.",
      "Angiotensin II receptor blockers": "Incorrect – these can sometimes raise lithium slightly but far less than thiazides.",
      "Beta-blockers": "Incorrect – no significant effect on lithium metabolism or toxicity risk.",
      "Alpha-blockers": "Incorrect – do not affect renal handling of lithium.",
      "Calcium channel blockers": "Incorrect – these agents do not alter lithium excretion or raise serum levels."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Drug interactions",
    "topic": "Lithium-drug interactions",
    "keywords": [
      "lithium",
      "thiazide",
      "toxicity",
      "drug interaction",
      "antihypertensive"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Poisoning, emergency treatment",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/poisoning-emergency-treatment/"
      },
      {
        "source": "BNF",
        "topic_title": "Diuretics",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diuretics/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c195485e-53cb-4d62-a653-22cefca95a2e",
    "question_number": 217,
    "question": "A term newborn presents at 36 hours of age with progressive abdominal distension and has not yet passed meconium. On examination, the abdomen is tense and a rectal examination results in an explosive release of stool. What is the most appropriate initial management step while awaiting definitive diagnosis and treatment?",
    "options": [
      "Commence regular rectal washouts",
      "Start a course of oral vancomycin",
      "Prescribe lactulose for bowel movements",
      "Arrange immediate anorectal pull-through surgery",
      "Request a full-thickness rectal biopsy as the next step"
    ],
    "correct_answer": "Commence regular rectal washouts",
    "explanation": "**Explanation**\n**Rectal washouts** are the recommended initial management for suspected Hirschsprung's disease in neonates who have not passed meconium and develop bowel obstruction. This intervention helps decompress the colon, relieve symptoms, and prevent complications such as enterocolitis while awaiting definitive diagnosis (typically via rectal biopsy) and surgical treatment. Definitive surgery (e.g., pull-through procedure) is not performed until the diagnosis is confirmed and the child is stabilised. Laxatives like lactulose are ineffective and potentially dangerous in this context, and antibiotics such as vancomycin are not indicated unless enterocolitis develops.\n\n**Key Points**\n- Neonates with Hirschsprung's disease often present with delayed passage of meconium and abdominal distension.\n- Rectal washouts relieve obstruction and are safe as a temporising measure.\n- Definitive diagnosis is made by rectal biopsy, which demonstrates absence of ganglion cells.\n- Anorectal pull-through is a definitive surgical procedure, not initial management.\n- Lactulose and vancomycin are not appropriate initial therapies.\n\n**Clinical Relevance**\nEarly, safe decompression is essential in neonates with suspected Hirschsprung's disease to prevent serious complications. Rectal washouts are standard practice while awaiting diagnostic confirmation and surgical planning.\n\n**Memory Anchor**\nHirschsprung's: 'Hold the pull-through, start the washout!'",
    "bullet_explanations": {
      "Commence regular rectal washouts": "Correct – This provides immediate symptomatic relief and reduces risk of enterocolitis until diagnosis is confirmed.",
      "Start a course of oral vancomycin": "Incorrect – Antibiotics are only indicated if enterocolitis is suspected or confirmed.",
      "Prescribe lactulose for bowel movements": "Incorrect – Laxatives are not effective for functional obstruction due to aganglionosis and may worsen distension.",
      "Arrange immediate anorectal pull-through surgery": "Incorrect – This is definitive management, only performed after diagnosis and stabilisation.",
      "Request a full-thickness rectal biopsy as the next step": "Incorrect – While biopsy is required for diagnosis, it is not a management step for acute symptoms."
    },
    "category": "Paediatrics",
    "subsection": "Neonatology",
    "subsubsection": "Congenital Conditions",
    "topic": "CHD basics",
    "keywords": [
      "Hirschsprung's disease",
      "neonate",
      "rectal washouts",
      "bowel obstruction",
      "initial management"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "3051587a-ac39-412d-976c-0574b60263fd",
    "question_number": 218,
    "question": "Which medication is recognised as a potential trigger for erythema nodosum in women of reproductive age?",
    "options": [
      "Combined oral contraceptive pill",
      "Sodium valproate",
      "Lansoprazole",
      "Montelukast",
      "Carbimazole"
    ],
    "correct_answer": "Combined oral contraceptive pill",
    "explanation": "**Explanation**\n**Erythema nodosum** is an inflammatory condition of the subcutaneous fat, most often presenting as tender, red or violet nodules on the shins. It can be precipitated by various causes, including infections, systemic diseases, and certain medications. **The combined oral contraceptive pill (COCP) is a recognised pharmacological trigger**, likely due to its hormonal effects on the immune and vascular systems. Other common causes include streptococcal infection, sarcoidosis, and inflammatory bowel disease, but COCP is the key drug association among the options listed. In contrast, the other medications listed are not typically implicated in erythema nodosum.\n\n**Key Points**\n- Erythema nodosum presents as painful, erythematous nodules, classically on the shins.\n- COCP is a well-documented drug-related cause.\n- Other medication causes include sulphonamides and some antibiotics, but not the other options listed.\n- Underlying systemic illnesses should also be considered in new cases.\n- Management focuses on identifying and addressing the underlying trigger.\n\n**Clinical Relevance**\nRecognising medication-induced erythema nodosum is vital in primary care, as early identification and withdrawal of the offending agent can lead to resolution and prevent recurrence. Awareness of the association with the combined oral contraceptive pill aids in targeted history-taking and appropriate management.\n\n**Memory Anchor**\nRemember: 'COCP Can Cause Cutaneous Pain' (COCP = combined oral contraceptive pill, Cutaneous Pain = erythema nodosum).",
    "bullet_explanations": {
      "Combined oral contraceptive pill": "Correct – COCP is a known pharmacological cause of erythema nodosum.",
      "Sodium valproate": "Incorrect – Not linked to erythema nodosum; main side effects are neurological and metabolic.",
      "Lansoprazole": "Incorrect – May cause general skin rashes but not erythema nodosum.",
      "Montelukast": "Incorrect – Side effects include neuropsychiatric symptoms, not erythema nodosum.",
      "Carbimazole": "Incorrect – Can cause skin reactions, but erythema nodosum is not characteristic."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Combined pill",
    "keywords": [
      "erythema nodosum",
      "contraceptive",
      "COCP",
      "adverse effects",
      "skin"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cellulitis - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cellulitis-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "73615117-0532-4c5a-a9aa-37874811dbce",
    "question_number": 219,
    "question": "A 29-year-old woman with a history of ankylosing spondylitis develops sudden-onset pain and photophobia in her right eye. Examination reveals a small, irregularly shaped pupil with pronounced redness around the cornea. What is the most likely diagnosis?",
    "options": [
      "Anterior uveitis",
      "Acute angle-closure glaucoma",
      "Bacterial conjunctivitis",
      "Scleritis",
      "Migraine with visual aura"
    ],
    "correct_answer": "Anterior uveitis",
    "explanation": "**Explanation**\n**Anterior uveitis**, also known as iritis, typically presents with unilateral eye pain, photophobia, and a small, irregular pupil due to iris sphincter spasm. Ciliary injection (redness near the limbus) is a classic sign. This condition often occurs in individuals with autoimmune diseases, such as ankylosing spondylitis. Unlike glaucoma, which produces a mid-dilated pupil and severe intraocular pressure elevation, or conjunctivitis, which usually causes diffuse redness and discharge but not photophobia or pupil changes, anterior uveitis is distinguished by its pattern of pain, photophobia, and characteristic pupillary findings.\n\n**Key Points**\n- Anterior uveitis often presents with unilateral pain, photophobia, and blurred vision.\n- Ocular findings: small, irregular pupil and ciliary flush (perilimbal redness).\n- Frequently associated with autoimmune conditions (e.g., ankylosing spondylitis).\n- Direct and consensual photophobia are typical.\n- Slit-lamp exam confirms diagnosis; urgent ophthalmology referral is necessary.\n- <table><thead><tr><th>Condition</th><th>Pupil Appearance</th><th>Key Features</th></tr></thead><tbody><tr><td>Anterior uveitis</td><td>Small, irregular</td><td>Pain, photophobia, ciliary flush</td></tr><tr><td>Acute glaucoma</td><td>Mid-dilated, fixed</td><td>Severe pain, haloes, hard globe</td></tr><tr><td>Conjunctivitis</td><td>Normal</td><td>Redness, discharge, no photophobia</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition of anterior uveitis is crucial to prevent visual impairment. Suspicion should be high for patients with autoimmune histories presenting with painful red eye and photophobia. Early referral to ophthalmology is recommended for diagnosis confirmation and management, in line with NICE CKS guidance.\n\n**Memory Anchor**\nRemember: Anterior uveitis = 'Aching eye, Autoimmune link, Abnormal (small) pupil.'",
    "bullet_explanations": {
      "Anterior uveitis": "Correct – classic features: pain, photophobia, small irregular pupil, history of autoimmune disease.",
      "Acute angle-closure glaucoma": "Incorrect – typically causes a mid-dilated, fixed pupil and severe pain with haloes, not a small, irregular pupil.",
      "Bacterial conjunctivitis": "Incorrect – presents with conjunctival redness and discharge but usually lacks pain, photophobia, or pupil changes.",
      "Scleritis": "Incorrect – may cause severe pain and redness but does not usually alter pupil size or shape.",
      "Migraine with visual aura": "Incorrect – can cause visual symptoms and photophobia but does not produce ocular redness or pupillary changes."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Anterior uveitis",
    "topic": "Anterior uveitis",
    "keywords": [
      "anterior uveitis",
      "iritis",
      "red eye",
      "photophobia",
      "autoimmune"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Uveitis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/uveitis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c3353c25-99c1-42a0-b47e-29fc1dc9162f",
    "question_number": 220,
    "question": "A 34-year-old male primary school teacher presents with four weeks of greasy, foul-smelling diarrhoea, bloating, excessive flatulence, and a 4 kg unintentional weight loss. He has not travelled abroad recently and denies rectal bleeding or nocturnal symptoms. A stool sample identifies a flagellated protozoan organism. What is the most likely diagnosis?",
    "options": [
      "Giardiasis",
      "Amoebiasis",
      "Coeliac disease",
      "Irritable bowel syndrome",
      "Ulcerative colitis"
    ],
    "correct_answer": "Giardiasis",
    "explanation": "**Explanation**\n**Giardiasis** is an intestinal infection caused by the protozoan Giardia lamblia, typically presenting with **prolonged, fatty (steatorrhoea) diarrhoea, bloating, flatulence, and weight loss**. The absence of blood or mucous and the identification of a flagellated protozoan in the stool are classic. Transmission is via the faeco-oral route, often in settings involving young children or poor hand hygiene, making teachers at primary schools particularly susceptible. Unlike amoebiasis, which usually causes dysentery with blood and mucous, giardiasis is non-bloody and produces malabsorption features. Coeliac disease may mimic symptoms but does not involve protozoan detection in stool.\n\n**Key Points**\n- Giardiasis frequently presents with greasy, foul-smelling diarrhoea, bloating, and weight loss.\n- Stool microscopy confirms Giardia lamblia (flagellated protozoan).\n- Transmission is faeco-oral, commonly in childcare and education settings.\n- Amoebiasis generally causes bloody diarrhoea (dysentery), not steatorrhoea.\n- Coeliac disease is not linked to protozoan findings in stool.\n- IBS and ulcerative colitis do not present with stool protozoa or steatorrhoea.\n\n**Clinical Relevance**\nRecognising the clinical features and risk factors for giardiasis is crucial, especially in individuals working closely with children or in group settings. Prompt diagnosis and treatment can prevent ongoing symptoms and reduce transmission risk.\n\n**Memory Anchor**\nFlagellated protozoa = Giardia; think group settings and steatorrhoea.",
    "bullet_explanations": {
      "Giardiasis": "Correct – Presents with steatorrhoea, bloating, weight loss, and is diagnosed by finding Giardia in stool, especially in childcare workers.",
      "Amoebiasis": "Incorrect – Typically causes bloody diarrhoea and is more associated with travel to endemic areas.",
      "Coeliac disease": "Incorrect – Mimics malabsorption but not associated with protozoan parasites in stool.",
      "Irritable bowel syndrome": "Incorrect – Not associated with weight loss, steatorrhoea, or protozoan findings.",
      "Ulcerative colitis": "Incorrect – Commonly presents with bloody diarrhoea and does not involve protozoan infection."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBS & Functional",
    "topic": "Red flags needing scope",
    "keywords": [
      "giardiasis",
      "protozoan diarrhoea",
      "malabsorption",
      "stool microscopy",
      "weight loss"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "c961066a-0bf9-4ec4-bf4c-26b1506b1975",
    "question_number": 221,
    "question": "A 34-year-old woman develops chronic lower back stiffness and pain over the past 6 months, which is particularly severe when she wakes up but improves with movement. She has no significant joint swelling or history of psoriasis. Pelvic radiograph reveals bilateral sacroiliitis. What is the recommended first-line management for her condition?",
    "options": [
      "Regular physiotherapy and NSAIDs",
      "Methotrexate monotherapy",
      "Oral paracetamol alone",
      "Intra-articular corticosteroid injection to the sacroiliac joints",
      "Sulfasalazine initiation"
    ],
    "correct_answer": "Regular physiotherapy and NSAIDs",
    "explanation": "**Explanation**\n**Axial spondyloarthritis (including ankylosing spondylitis) typically presents with inflammatory back pain, morning stiffness, and radiographic sacroiliitis.** First-line management in confirmed cases consists of initiating an NSAID at the lowest effective dose, provided there are no contraindications, combined with structured exercise and physiotherapy. This approach targets inflammation and helps maintain spinal mobility. Disease-modifying agents such as methotrexate and sulfasalazine are not effective for isolated axial symptoms, and corticosteroid injections are reserved for peripheral monoarthritis or enthesitis. Paracetamol may help symptomatically but is insufficient as monotherapy for this condition.\n\n**Key Points**\n- Axial spondyloarthritis presents with chronic back pain, stiffness, and improved symptoms on exercise.\n- Radiographic evidence (e.g. sacroiliitis) confirms the diagnosis of ankylosing spondylitis.\n- First-line treatment: NSAIDs plus regular physiotherapy/exercise.\n- Methotrexate and sulfasalazine are reserved for peripheral joint involvement, not axial-only disease.\n- Corticosteroid injections are appropriate for isolated peripheral arthritis, not for diffuse axial disease.\n- Paracetamol may be considered as adjunctive pain relief but is not first-line.\n- <table><thead><tr><th>Therapy</th><th>Axial Spondyloarthritis</th><th>Peripheral Spondyloarthritis</th></tr></thead><tbody><tr><td>NSAIDs</td><td>First-line</td><td>Adjunctive</td></tr><tr><td>Physiotherapy</td><td>Essential</td><td>Useful</td></tr><tr><td>Methotrexate/Sulfasalazine</td><td>No role</td><td>Indicated</td></tr><tr><td>Corticosteroid injection</td><td>Not routine</td><td>For affected joint</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition and correct early management of axial spondyloarthritis is essential for preventing irreversible spinal damage. Guidelines (BNF, NICE CKS) endorse NSAIDs and physiotherapy as first-line, reserving DMARDs for non-axial involvement. This approach optimises outcomes and minimises unnecessary medication exposure.\n\n**Memory Anchor**\nMorning stiffness that improves with movement = 'Move for relief in AS' (Ankylosing Spondylitis).",
    "bullet_explanations": {
      "Regular physiotherapy and NSAIDs": "Correct—this is the recommended initial management for confirmed axial spondyloarthritis.",
      "Methotrexate monotherapy": "Incorrect—methotrexate is not effective for axial symptoms alone, only for peripheral arthritis.",
      "Oral paracetamol alone": "Incorrect—paracetamol may be used adjunctively but is not adequate as sole therapy for this inflammatory condition.",
      "Intra-articular corticosteroid injection to the sacroiliac joints": "Incorrect—reserved for isolated peripheral joint involvement, not for axial disease.",
      "Sulfasalazine initiation": "Incorrect—sulfasalazine is reserved for peripheral joint manifestations, not primary axial disease."
    },
    "category": "Musculoskeletal",
    "subsection": "Arthritis",
    "subsubsection": "Spondyloarthropathy",
    "topic": "AS presentation and imaging",
    "keywords": [
      "ankylosing spondylitis",
      "NSAIDs",
      "physiotherapy",
      "sacroiliitis",
      "axial spondyloarthritis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Spondyloarthritis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/spondyloarthritis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Axial spondyloarthritis (including ankylosing spondylitis)",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/axial-spondyloarthritis-including-ankylosing-spondylitis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Spondyloarthritis and psoriatic arthropathy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/spondyloarthritis-psoriatic-arthropathy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5333e3c7-aef0-4837-9048-73ea6f6a0bb4",
    "question_number": 222,
    "question": "Following an uncomplicated PCI for an inferior STEMI via radial access, a 67-year-old man develops acute hypotension, tachycardia, elevated JVP, and muffled heart sounds. Which immediate intervention is most likely to be lifesaving in this scenario?",
    "options": [
      "Urgent pericardiocentesis",
      "Intravenous antibiotic therapy",
      "Rapid intravenous fluid resuscitation",
      "Emergency thrombolysis",
      "Initiation of intravenous inotropic agents"
    ],
    "correct_answer": "Urgent pericardiocentesis",
    "explanation": "**Explanation**\n**Cardiac tamponade** is a critical diagnosis to consider in a post-PCI patient who develops acute hypotension, elevated jugular venous pressure (JVP), and muffled heart sounds—collectively known as Beck's triad. These findings point to the accumulation of pericardial fluid under pressure, leading to compromised cardiac filling and obstructive shock. The classic features contrast with other causes of hypotension following PCI, such as cardiogenic or septic shock, where JVP is not typically raised and heart sounds are usually normal. The definitive and life-saving intervention is **urgent pericardiocentesis** to relieve the pericardial pressure and restore haemodynamic stability.\n\n**Key Points**\n- Beck's triad (hypotension, raised JVP, muffled heart sounds) is classic for cardiac tamponade.\n- Tamponade post-PCI may result from coronary or myocardial perforation.\n- Cardiac tamponade leads to obstructive shock: prompt recognition is crucial.\n- Sepsis tends to present with warm extremities and fever, not raised JVP.\n- Cardiogenic shock is less likely with normal LV function and no new murmurs.\n- Hypovolaemia (e.g., bleeding) usually presents with low JVP.\n- <table><thead><tr><th>Diagnosis</th><th>JVP</th><th>Heart sounds</th><th>Pulse</th></tr></thead><tbody><tr><td>Tamponade</td><td>Elevated</td><td>Muffled</td><td>Weak/rapid</td></tr><tr><td>Sepsis</td><td>Normal/low</td><td>Normal</td><td>Bounding</td></tr><tr><td>Hypovolaemia</td><td>Low</td><td>Normal</td><td>Rapid/weak</td></tr></tbody></table>\n\n**Clinical Relevance**\nCardiac tamponade is a rare but potentially fatal complication after PCI, particularly when symptoms arise suddenly with signs of obstructive shock. Early bedside recognition and pericardiocentesis are critical, often performed before imaging if the patient is unstable. Delays can be fatal.\n\n**Memory Anchor**\nBeck's triad = Tamponade (think: 'triad for cardiac tide')",
    "bullet_explanations": {
      "Urgent pericardiocentesis": "Correct – definitive treatment for cardiac tamponade, which presents with hypotension, raised JVP, and muffled heart sounds.",
      "Intravenous antibiotic therapy": "Incorrect – indicated for septic shock, which typically presents with fever, bounding pulse, and warm extremities.",
      "Rapid intravenous fluid resuscitation": "Incorrect – appropriate for hypovolaemia, which shows low JVP, not raised.",
      "Emergency thrombolysis": "Incorrect – not indicated post-PCI; no evidence of new occlusion or thrombotic event.",
      "Initiation of intravenous inotropic agents": "Incorrect – may provide temporary support in cardiogenic shock, but not curative for obstructive shock from tamponade."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Acute Coronary Syndromes",
    "topic": "Complications post-MI (MR, VSD, cardiogenic shock)",
    "keywords": [
      "cardiac tamponade",
      "Beck's triad",
      "post-PCI complications"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "7bf5460e-ab4f-4b4e-976f-3587a4af6366",
    "question_number": 223,
    "question": "Which of the following medications is absolutely contraindicated in women who are pregnant due to known risks to fetal development?",
    "options": [
      "Atorvastatin",
      "Lamotrigine",
      "Labetalol",
      "Nitrofurantoin (first trimester)",
      "Clozapine"
    ],
    "correct_answer": "Atorvastatin",
    "explanation": "**Explanation**\n**Statins, including atorvastatin, are strictly contraindicated in pregnancy** due to their interference with fetal cholesterol biosynthesis, which is essential for normal embryonic and fetal development. Although there is limited direct evidence of teratogenicity in humans, case reports have associated statin use during pregnancy with adverse outcomes such as intrauterine growth restriction and fetal death. As a result, current guidelines advise discontinuing statins in women who are pregnant or planning pregnancy. In contrast, lamotrigine is considered one of the safer antiepileptic drugs in pregnancy, labetalol is widely used for managing hypertension in pregnant women, clozapine may be continued with specialist supervision if the benefits outweigh the risks, and nitrofurantoin is only contraindicated near term, not in early pregnancy.\n\n**Key Points**\n- Statins (e.g., atorvastatin) are contraindicated during pregnancy.\n- Statins can disrupt fetal cholesterol metabolism, potentially causing harm.\n- Lamotrigine has not been linked to an increased risk of major congenital malformations.\n- Labetalol is a first-line antihypertensive in pregnancy.\n- Clozapine may be used if necessary with close monitoring.\n- Nitrofurantoin is avoided at term due to neonatal haemolysis risk, but is otherwise considered safe earlier in pregnancy.\n\n**Clinical Relevance**\nRecognising medications that are contraindicated in pregnancy is essential for safe prescribing. Statin exposure should be promptly discontinued in all pregnant women, as per national guidelines, to avoid potential harm to the fetus.\n\n**Memory Anchor**\nStatins 'stat' should 'stay' away in pregnancy.",
    "bullet_explanations": {
      "Atorvastatin": "Correct – all statins are contraindicated in pregnancy due to fetal risk.",
      "Lamotrigine": "Incorrect – lamotrigine is among the safer antiepileptic drugs in pregnancy.",
      "Labetalol": "Incorrect – labetalol is commonly used to control blood pressure in pregnant women.",
      "Nitrofurantoin (first trimester)": "Incorrect – nitrofurantoin is only avoided in late pregnancy (near term), not the first trimester.",
      "Clozapine": "Incorrect – clozapine is not contraindicated but requires specialist oversight; benefits and risks must be considered."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Lifestyle advice",
    "keywords": [
      "statins",
      "pregnancy contraindications",
      "atorvastatin",
      "medication safety",
      "antenatal care"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Epilepsy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/epilepsy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9cad2874-f378-4cfb-b1ac-bbaaa6aa9798",
    "question_number": 224,
    "question": "A 64-year-old woman is started on secondary prevention medications after an anterior STEMI treated with PCI. Routine bloods two weeks later show a potassium of 6.1 mmol/L (reference: 3.5–5.0 mmol/L) and stable renal function. Which class of antihypertensive prescribed for post-MI care is most likely responsible for her hyperkalaemia?",
    "options": [
      "ACE inhibitor",
      "Thiazide diuretic",
      "Beta-blocker",
      "Loop diuretic",
      "Calcium channel blocker"
    ],
    "correct_answer": "ACE inhibitor",
    "explanation": "**Explanation**\n**ACE inhibitors** are known to cause hyperkalaemia by reducing aldosterone secretion, which decreases potassium excretion in the distal nephron. This adverse effect is particularly relevant in patients with chronic kidney disease or when combined with other potassium-retaining drugs. In contrast, most other antihypertensive classes either do not affect potassium or actually increase its excretion. Recognising drug-induced hyperkalaemia is crucial in the context of post-MI secondary prevention, where ACE inhibitors are a cornerstone of therapy but require careful monitoring of electrolytes.\n\n**Key Points**\n- ACE inhibitors (and ARBs) can cause hyperkalaemia by reducing aldosterone-mediated potassium excretion.\n- Thiazide and loop diuretics typically cause hypokalaemia.\n- Beta-blockers have minimal direct impact on serum potassium.\n- Calcium channel blockers do not significantly affect potassium levels.\n- Monitoring potassium is essential after starting ACE inhibitors, especially in patients with renal impairment.\n\n**Clinical Relevance**\nHyperkalaemia is a potentially serious complication of ACE inhibitor therapy used routinely after myocardial infarction. Early recognition and monitoring are essential to prevent arrhythmias and guide medication adjustments according to current guidelines.",
    "bullet_explanations": {
      "ACE inhibitor": "Correct – ACE inhibitors inhibit RAAS, reducing aldosterone and leading to potassium retention.",
      "Thiazide diuretic": "Incorrect – These increase urinary potassium loss, most often causing hypokalaemia.",
      "Beta-blocker": "Incorrect – Beta-blockers do not usually cause significant changes in serum potassium.",
      "Loop diuretic": "Incorrect – Loop diuretics promote potassium loss and are more likely to cause hypokalaemia.",
      "Calcium channel blocker": "Incorrect – These agents have negligible effects on potassium homeostasis."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Secondary Prevention Post-MI",
    "topic": "ACEi/ARB/ARNI and beta-blocker optimisation",
    "keywords": [
      "ACE inhibitor",
      "hyperkalaemia",
      "post-MI",
      "secondary prevention"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "f602ab1a-a81c-4b46-9a5e-44673bd82f25",
    "question_number": 225,
    "question": "Which medication is strictly contraindicated for use in women actively breastfeeding their infants?",
    "options": [
      "Carbamazepine",
      "Penicillin V",
      "Heparin",
      "Lithium carbonate",
      "Prednisolone"
    ],
    "correct_answer": "Lithium carbonate",
    "explanation": "**Explanation**\n**Lithium carbonate** is contraindicated during breastfeeding because it is excreted in significant amounts into breast milk, resulting in potentially toxic serum levels in infants. Neonates exposed to lithium through breast milk are at risk of toxicity, which can include hypotonia, hypothermia, cyanosis, and arrhythmias. Unlike many other psychotropic and antiepileptic medications, lithium’s narrow therapeutic window and the immature renal function of neonates make safe monitoring extremely difficult. In contrast, other agents listed—such as carbamazepine and penicillin—are generally considered compatible with breastfeeding, though infant monitoring for side effects is advised.\n\n**Key Points**\n- Lithium passes readily into breast milk and can accumulate in infants.\n- Neonates are particularly susceptible due to immature renal clearance.\n- Lithium toxicity in infants may manifest as lethargy, poor feeding, hypotonia, or cardiac arrhythmia.\n- Carbamazepine and penicillins are considered safe in breastfeeding, with appropriate infant monitoring.\n- Heparin and prednisolone are also not contraindicated; prednisolone is usually safe at standard doses.\n\n**Clinical Relevance**\nUnderstanding absolute contraindications to breastfeeding is vital in postnatal care. Lithium must be strictly avoided in breastfeeding mothers due to infant toxicity risks, as supported by national guidelines. Prescribers should always check medication compatibility with breastfeeding to ensure infant safety.\n\n**Memory Anchor**\nRemember: 'L for Lithium, L for Leave out during Lactation.'",
    "bullet_explanations": {
      "Carbamazepine": "Generally compatible with breastfeeding; infants should be monitored for sedation or feeding problems.",
      "Penicillin V": "Safe to use during breastfeeding; no significant risk to infants.",
      "Heparin": "Does not enter breast milk and is safe for use in breastfeeding mothers.",
      "Lithium carbonate": "Correct – strictly contraindicated due to risk of toxicity in breastfed infants.",
      "Prednisolone": "Permitted at standard doses; high doses may require temporary avoidance of breastfeeding."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Lifestyle advice",
    "keywords": [
      "breastfeeding",
      "lithium",
      "contraindications",
      "medications",
      "postnatal"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Epilepsy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/epilepsy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "88e5c0fa-fdbc-434e-8e79-cfecc069b6e3",
    "question_number": 226,
    "question": "A 48-year-old man with a history of poorly controlled type 2 diabetes presents with gradual worsening of vision in his right eye over several days. He describes seeing new floaters and flashes of light before noticing a curtain-like defect obscuring part of his visual field. What is the most likely underlying diagnosis?",
    "options": [
      "Retinal detachment",
      "Ischaemic optic neuropathy",
      "Central retinal artery occlusion",
      "Vitreous haemorrhage",
      "Central retinal vein occlusion"
    ],
    "correct_answer": "Retinal detachment",
    "explanation": "**Explanation**\n**Retinal detachment** is characterised by the separation of the neurosensory retina from the underlying pigment epithelium, allowing fluid to accumulate and causing progressive visual loss. Key features include the sudden onset of floaters, flashes of light (photopsia), and a 'curtain' or shadow descending over the visual field. Unlike vascular occlusions, vision loss typically starts peripherally and progresses centrally. The classic risk factors include diabetes (linked to tractional detachment), myopia, trauma, and previous ocular surgery. Retinal detachment requires urgent ophthalmological intervention to prevent permanent vision loss.<br><br>Other causes of acute visual loss, such as ischaemic optic neuropathy and retinal vascular occlusions, have distinct patterns of onset, fundoscopic findings, and associated symptoms.\n\n**Key Points**\n<ul><li>Sudden appearance of floaters and flashes suggests retinal traction or tear.</li><li>Visual field loss described as a 'curtain' or shadow is highly suggestive.</li><li>Diabetic patients are at increased risk (tractional detachment).</li><li>Prompt diagnosis and referral can prevent irreversible blindness.</li><li>Distinguish from vascular occlusions, which cause sudden, profound central visual loss.</li></ul><table><thead><tr><th>Feature</th><th>Retinal detachment</th><th>Retinal vein/artery occlusion</th></tr></thead><tbody><tr><td>Floaters/flashes</td><td>Common</td><td>Rare</td></tr><tr><td>Visual field loss</td><td>Peripheral, progresses</td><td>Central, sudden</td></tr><tr><td>Fundoscopy</td><td>Detached retina, folds</td><td>Vascular changes, haemorrhage or pallor</td></tr></tbody></table>\n\n**Clinical Relevance**\nRetinal detachment is an ophthalmic emergency. Early identification and urgent referral are essential to preserve vision. Primary care clinicians should recognise classic symptoms and risk factors, as per NICE CKS guidance.\n\n**Memory Anchor**\nThink 'flashes, floaters, falling curtain' = retinal detachment.",
    "bullet_explanations": {
      "Retinal detachment": "Correct – Sudden onset of floaters, flashes, and a curtain-like visual field defect are classic.",
      "Ischaemic optic neuropathy": "Incorrect – Typically presents with sudden, painless, monocular vision loss but without floaters or a curtain effect.",
      "Central retinal artery occlusion": "Incorrect – Causes profound, sudden central vision loss with a pale retina and cherry-red spot; no floaters or field curtain.",
      "Vitreous haemorrhage": "Incorrect – May cause floaters and vision loss, but often more gradual and without the classic curtain effect.",
      "Central retinal vein occlusion": "Incorrect – Sudden, painless visual loss with retinal haemorrhages on fundoscopy, not typically preceded by floaters or flashes."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Retinal Disorders",
    "topic": "Retinal detachment",
    "keywords": [
      "retinal detachment",
      "flashes",
      "floaters",
      "curtain vision",
      "ophthalmology emergency"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Retinal detachment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/retinal-detachment/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c69d2446-2b9d-4f9c-be62-fa747dfcb2a6",
    "question_number": 227,
    "question": "A 62-year-old woman with a history of hypertension and type 2 diabetes is seen in clinic for her annual review. She has been taking metformin 500 mg twice daily for the past year. Her HbA1c is reported as 45 mmol/mol (6.3%). She recently had a mild respiratory infection treated with oral steroids, and her random capillary glucose today is 12.1 mmol/L. What is the most appropriate management of her diabetes at this time?",
    "options": [
      "Continue current metformin dose without changes",
      "Increase metformin to 1 g twice daily",
      "Add a sulfonylurea to her regimen",
      "Reduce metformin to 500 mg once daily",
      "Switch metformin to a DPP-4 inhibitor"
    ],
    "correct_answer": "Continue current metformin dose without changes",
    "explanation": "**Explanation**\nThe patient's HbA1c of 45 mmol/mol (6.3%) indicates **excellent long-term glycaemic control**, falling below the typical treatment target for type 2 diabetes. Transient hyperglycaemia after steroid use is common and does not require escalation of therapy if HbA1c remains well controlled. **Management decisions in type 2 diabetes should be guided by HbA1c**, which reflects average glucose over 2–3 months, rather than isolated random readings that may be influenced by acute illness or medication. Escalating treatment based on a single high random glucose is not warranted when overall control is good, and could increase the risk of overtreatment and hypoglycaemia.\n\n**Key Points**\n- HbA1c is the primary marker for assessing long-term glycaemic control in type 2 diabetes.\n- Target HbA1c for most adults with type 2 diabetes is ≤48 mmol/mol (6.5%), but individualisation is important.\n- Temporary steroid-induced hyperglycaemia does not justify intensification of diabetes therapy if HbA1c is within target.\n- Escalating therapy without evidence of sustained hyperglycaemia increases risk of side effects.\n- Medication changes should be made based on multiple readings or persistently elevated HbA1c.\n\n**Clinical Relevance**\nThis scenario highlights the importance of using HbA1c rather than isolated glucose measurements to guide diabetes management, as recommended in NICE and BNF guidelines. Overreacting to transient hyperglycaemia can lead to unnecessary polypharmacy and harm.",
    "bullet_explanations": {
      "Continue current metformin dose without changes": "Correct. HbA1c is within target and no change is needed due to transient steroid use.",
      "Increase metformin to 1 g twice daily": "Incorrect. Escalation is unnecessary when HbA1c is well controlled.",
      "Add a sulfonylurea to her regimen": "Incorrect. No indication for additional agents with a normal HbA1c.",
      "Reduce metformin to 500 mg once daily": "Incorrect. No evidence of overtreatment or hypoglycaemia.",
      "Switch metformin to a DPP-4 inhibitor": "Incorrect. No intolerance or contraindication to metformin; no need to switch."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "HbA1c targets individualisation",
    "keywords": [
      "type 2 diabetes",
      "HbA1c",
      "steroid-induced hyperglycaemia",
      "metformin",
      "treatment targets"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diabetes - type 2",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/diabetes-type-2/"
      },
      {
        "source": "BNF",
        "topic_title": "Type 2 diabetes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/type-2-diabetes/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "dd61ce41-572f-4f96-a2dc-d178f967933d",
    "question_number": 228,
    "question": "A 43-year-old man presents with difficulty climbing stairs and combing his hair, alongside a new, violaceous rash over his eyelids and raised, scaly lesions over the dorsal aspects of his fingers. Which diagnosis best explains his cutaneous and muscular symptoms?",
    "options": [
      "Dermatomyositis",
      "Tinea corporis",
      "Systemic sclerosis",
      "Psoriasis vulgaris",
      "Contact dermatitis"
    ],
    "correct_answer": "Dermatomyositis",
    "explanation": "**Explanation**\n**Dermatomyositis** is an autoimmune inflammatory myopathy characterised by both proximal muscle weakness and distinctive skin findings. Key cutaneous features include a heliotrope (violaceous) rash on the eyelids and Gottron's papules—violaceous, scaly plaques overlying the knuckles. Muscle involvement typically manifests as symmetric weakness affecting activities such as climbing stairs or lifting objects overhead. The disorder can occur idiopathically or as a paraneoplastic syndrome, particularly in adults, and is associated with an increased risk of underlying malignancy. These features distinguish it from other dermatological or connective tissue conditions, which lack this combination of skin and muscle involvement.\n\n**Key Points**\n- Dermatomyositis presents with both muscle weakness and characteristic skin findings.\n- Heliotrope rash and Gottron's papules are classic cutaneous signs.\n- Muscle weakness is typically proximal and symmetric.\n- Associated with underlying malignancies in adults; cancer screening is important.\n- Skin features help differentiate from polymyositis, which lacks significant rash.\n\n**Clinical Relevance**\nRecognising dermatomyositis is crucial as it may be the first sign of an underlying malignancy and requires prompt investigation and immunosuppressive therapy. Early identification and multidisciplinary management improve patient outcomes.\n\n**Memory Anchor**\nThink 'derma' (skin) + 'myositis' (muscle inflammation): Both skin and muscle are affected.",
    "bullet_explanations": {
      "Dermatomyositis": "Correct – classic presentation includes heliotrope rash, Gottron's papules, and proximal muscle weakness.",
      "Tinea corporis": "Incorrect – this fungal infection causes annular, scaly plaques but does not cause muscle symptoms or a heliotrope rash.",
      "Systemic sclerosis": "Incorrect – typically features skin tightening, sclerodactyly, and Raynaud's phenomenon, not violaceous eyelid rash or proximal muscle weakness.",
      "Psoriasis vulgaris": "Incorrect – presents with well-demarcated, silvery plaques, often on extensor surfaces; no associated muscle weakness or eyelid rash.",
      "Contact dermatitis": "Incorrect – causes itchy, erythematous rash in areas of allergen exposure, but not the specific cutaneous or muscular findings described."
    },
    "category": "Rheumatology & Connective Tissue",
    "subsection": "Myositis",
    "subsubsection": "Polymyositis vs dermatomyositis",
    "topic": "CK and autoantibodies",
    "keywords": [
      "dermatomyositis",
      "heliotrope rash",
      "Gottron's papules",
      "muscle weakness",
      "paraneoplastic"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "86c108db-d80d-4574-988e-df7099292b07",
    "question_number": 229,
    "question": "A 62-year-old woman is reviewed in the cardiology clinic 3 weeks after hospitalisation for an anterior STEMI. She is already taking ramipril, bisoprolol, aspirin, and clopidogrel. She reports that initially she was hesitant about adding further medication, but now wishes to start lipid-lowering therapy for secondary prevention. According to current UK guidelines, which statin regimen is most appropriate for her at this stage?",
    "options": [
      "Atorvastatin 80 mg daily",
      "Simvastatin 40 mg daily",
      "Rosuvastatin 20 mg daily",
      "Pravastatin 40 mg daily",
      "Atorvastatin 20 mg daily"
    ],
    "correct_answer": "Atorvastatin 80 mg daily",
    "explanation": "**Explanation**\n**Atorvastatin 80 mg daily is the recommended first-line statin therapy for adults following an acute coronary syndrome as part of secondary prevention.** High-intensity statin therapy has demonstrated the greatest reduction in future cardiovascular events post-MI. The aim is to lower non-HDL cholesterol by at least 40%. Lower doses or alternative statins may be considered if high-intensity therapy is not tolerated, but initial therapy should be high-intensity unless contraindicated. Other statins or lower doses are not equivalent in efficacy for secondary prevention.\n\n**Key Points**\n- High-intensity statin (atorvastatin 80 mg) is standard for secondary prevention post-MI.\n- Lower doses or alternative statins are reserved for those with intolerance or contraindications.\n- Secondary prevention aims to reduce non-HDL cholesterol by ≥40%.\n- Initiation should occur as soon as possible after acute coronary events.\n- Ongoing therapy should be reviewed for tolerability and lipid response.\n\n**Clinical Relevance**\nAppropriate statin selection after myocardial infarction is crucial for reducing recurrent cardiovascular events. Following national guidelines ensures patients receive optimal evidence-based care and achieve maximum risk reduction.",
    "bullet_explanations": {
      "Atorvastatin 80 mg daily": "Correct – This is the guideline-recommended high-intensity statin for secondary prevention after MI.",
      "Simvastatin 40 mg daily": "Incorrect – Simvastatin at this dose is considered moderate-intensity and is not first-line for secondary prevention.",
      "Rosuvastatin 20 mg daily": "Incorrect – While this is a high-intensity statin, atorvastatin 80 mg remains first-line due to evidence and licensing.",
      "Pravastatin 40 mg daily": "Incorrect – Pravastatin is lower-intensity and not recommended as initial secondary prevention.",
      "Atorvastatin 20 mg daily": "Incorrect – This is an appropriate dose for primary prevention, but insufficient for secondary prevention."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Secondary Prevention Post-MI",
    "topic": "High-intensity statin and lipid targets",
    "keywords": [
      "statin",
      "secondary prevention",
      "myocardial infarction",
      "atorvastatin",
      "lipid lowering"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "4bdf17f3-fd86-4d64-93dd-d0a31224a14c",
    "question_number": 230,
    "question": "A 28-year-old woman at 30 weeks' gestation presents to the maternity assessment unit after noticing a sudden gush of clear fluid per vagina. She is otherwise well and there are no signs of labour or infection. What is the most appropriate initial management for her condition?",
    "options": [
      "Admit to hospital for at least 48 hours with antibiotics and antenatal corticosteroids",
      "Discharge with advice to return if she develops a fever",
      "Prescribe oral antibiotics and review in one week",
      "Admit for observation and give magnesium sulfate only",
      "Arrange immediate delivery by caesarean section"
    ],
    "correct_answer": "Admit to hospital for at least 48 hours with antibiotics and antenatal corticosteroids",
    "explanation": "**Explanation**\n**Preterm prelabour rupture of membranes (PPROM)** at 30 weeks' gestation requires hospital admission for close monitoring due to the risks of infection and preterm birth. **Antibiotics (e.g. erythromycin)** are administered to prolong pregnancy and reduce infection risk. **Antenatal corticosteroids** are also given to accelerate fetal lung maturation and reduce neonatal complications. Discharge is not appropriate initially due to the need for maternal and fetal monitoring. Magnesium sulfate may be used for neuroprotection if delivery is imminent, but is not first-line without evidence of active labour. Immediate delivery is not indicated in the absence of maternal or fetal compromise.\n\n**Key Points**\n- PPROM before 34 weeks requires hospital admission and close observation\n- Antibiotics reduce maternal and neonatal infection and may prolong pregnancy\n- Corticosteroids promote fetal lung maturity and reduce neonatal morbidity\n- Magnesium sulfate is reserved for neuroprotection if delivery is likely within 24 hours\n- Delivery is generally delayed unless there is evidence of infection or fetal distress\n- <table><thead><tr><th>Management</th><th>Indication</th></tr></thead><tbody><tr><td>Antibiotics</td><td>All women with PPROM</td></tr><tr><td>Steroids</td><td>PPROM < 34 weeks</td></tr><tr><td>Delivery</td><td>Chorioamnionitis, fetal compromise, or >34 weeks</td></tr></tbody></table>\n\n**Clinical Relevance**\nEarly and appropriate management of PPROM is essential to prevent serious complications such as sepsis and preterm birth. Current UK guidelines recommend a combination of antibiotics and corticosteroids with hospital admission for observation. This approach reduces neonatal morbidity and mortality.\n\n**Memory Anchor**\nPPROM = **P**arenteral admission, **P**rophylactic antibiotics, **R**espiratory steroids, **O**bservation, **M**onitoring",
    "bullet_explanations": {
      "Admit to hospital for at least 48 hours with antibiotics and antenatal corticosteroids": "Correct: This is the gold standard for initial management of PPROM at 30 weeks, addressing infection risk and fetal lung immaturity.",
      "Discharge with advice to return if she develops a fever": "Incorrect: Discharge is unsafe due to the need for ongoing monitoring and immediate intervention if complications arise.",
      "Prescribe oral antibiotics and review in one week": "Incorrect: Antibiotics are indicated, but initial outpatient management is inappropriate; hospital observation is needed.",
      "Admit for observation and give magnesium sulfate only": "Incorrect: Magnesium sulfate is used for neuroprotection if delivery is imminent, but antibiotics and corticosteroids are essential.",
      "Arrange immediate delivery by caesarean section": "Incorrect: Delivery is reserved for cases with infection, fetal compromise, or gestation >34 weeks."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Bleeding in pregnancy",
    "keywords": [
      "PPROM",
      "preterm rupture",
      "antenatal corticosteroids",
      "antibiotics",
      "obstetric emergencies"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Obstetrics",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/obstetrics/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8335a2fe-54ef-4557-ad19-8fdf1d964614",
    "question_number": 231,
    "question": "Which of the following coagulation factors is a major component of cryoprecipitate, making it suitable for acute management of bleeding in patients with haemophilia A?",
    "options": [
      "Factor VIII",
      "Factor IX",
      "Factor X",
      "Prothrombin",
      "Protein C"
    ],
    "correct_answer": "Factor VIII",
    "explanation": "**Explanation**\n**Cryoprecipitate is specifically rich in factor VIII, fibrinogen, von Willebrand factor, and factor XIII.** This makes it an important blood product for treating acute bleeding in haemophilia A, which is characterised by a deficiency in factor VIII. In contrast, haemophilia B involves a deficiency of factor IX, which is not present in significant quantities in cryoprecipitate. Neither prothrombin (factor II), factor X, nor protein C are major components of cryoprecipitate. Instead, these are found in prothrombin complex concentrates or fresh frozen plasma. Therefore, for rapid replacement of factor VIII in haemophilia A, cryoprecipitate is appropriate, especially when specific concentrates are unavailable.<br><br><b>Key facts:</b> Factor VIII deficiency = haemophilia A; cryoprecipitate = factor VIII, not IX or X.\n\n**Key Points**\n- Cryoprecipitate contains factor VIII, fibrinogen, von Willebrand factor, and factor XIII.\n- Used in haemophilia A (factor VIII deficiency) and some other bleeding disorders.\n- Factor IX is associated with haemophilia B and is not present in cryoprecipitate.\n- Prothrombin complex concentrates (PCC) contain factors II, VII, IX, and X, not factor VIII.\n- Protein C is a natural anticoagulant, not a clotting factor in cryoprecipitate.\n- <table><thead><tr><th>Product</th><th>Main Components</th></tr></thead><tbody><tr><td>Cryoprecipitate</td><td>VIII, XIII, vWF, Fibrinogen</td></tr><tr><td>PCC</td><td>II, VII, IX, X</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition of the appropriate blood product for reversal of specific coagulopathies is critical in acute bleeding scenarios, especially in inherited bleeding disorders. Knowledge of the contents of cryoprecipitate versus other blood products ensures optimal and safe patient care.\n\n**Memory Anchor**\nCryo = 'cold' concentrate for VIII (eight is great for A)",
    "bullet_explanations": {
      "Factor VIII": "Correct – Cryoprecipitate is a key source of factor VIII, used in haemophilia A.",
      "Factor IX": "Incorrect – Factor IX is for haemophilia B and is not found in cryoprecipitate.",
      "Factor X": "Incorrect – Factor X is contained in PCC, not in cryoprecipitate.",
      "Prothrombin": "Incorrect – Prothrombin (factor II) is not a component of cryoprecipitate.",
      "Protein C": "Incorrect – Protein C is a regulatory protein, not present in cryoprecipitate."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Bleeding Disorders",
    "topic": "Haemophilia basics",
    "keywords": [
      "cryoprecipitate",
      "factor VIII",
      "haemophilia A",
      "bleeding",
      "coagulation"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Oral anticoagulants",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/oral-anticoagulants/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7a53c6c2-668b-4fbf-861c-e3aad2a1ed3b",
    "question_number": 232,
    "question": "A 42-year-old woman presents with progressively worsening, heavy and painful periods over the past year. She had no period pain in her teens or twenties. On examination, her uterus is enlarged and tender. Which underlying condition is most likely responsible for her symptoms?",
    "options": [
      "Adenomyosis",
      "Polycystic ovary syndrome",
      "Hypothyroidism",
      "Premature ovarian insufficiency",
      "Bacterial vaginosis"
    ],
    "correct_answer": "Adenomyosis",
    "explanation": "**Explanation**\n**Adenomyosis** involves the growth of endometrial tissue into the myometrium, resulting in uterine enlargement and often causing both menorrhagia and secondary dysmenorrhoea. The pain typically begins after years of pain-free cycles, distinguishing it from primary dysmenorrhoea seen in adolescents. Women commonly report increasingly heavy and painful periods, and examination may reveal a tender, bulky uterus. This is in contrast to conditions like PCOS or hypothyroidism, which may cause menstrual irregularities but are not classic causes of secondary dysmenorrhoea.\n\n**Key Points**\n- Adenomyosis is a classic cause of secondary dysmenorrhoea and heavy menstrual bleeding.\n- Secondary dysmenorrhoea starts after years of painless periods, usually due to pelvic pathology.\n- Typical presentation: multiparous women in their late 30s or 40s with worsening pain and menorrhagia.\n- Uterine enlargement and tenderness on examination support the diagnosis.\n- Other causes of secondary dysmenorrhoea include endometriosis and fibroids, but not PCOS or infections.\n- <table><thead><tr><th>Condition</th><th>Menstrual Effect</th><th>Pain Profile</th></tr></thead><tbody><tr><td>Adenomyosis</td><td>Heavy, regular</td><td>Secondary dysmenorrhoea</td></tr><tr><td>PCOS</td><td>Irregular, infrequent</td><td>No typical dysmenorrhoea</td></tr><tr><td>Hypothyroidism</td><td>Heavy, irregular</td><td>Usually painless</td></tr><tr><td>Premature ovarian insufficiency</td><td>Amenorrhoea</td><td>No periods, no pain</td></tr><tr><td>Bacterial vaginosis</td><td>No effect</td><td>No period pain</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising adenomyosis as a cause of secondary dysmenorrhoea guides appropriate investigation and management, including offering the LNG-IUS, NSAIDs, or referral for specialist care if symptoms are severe or do not respond to first-line therapy. Early identification can improve quality of life and reduce unnecessary treatments. (See NICE CKS: Menorrhagia)",
    "bullet_explanations": {
      "Adenomyosis": "Correct – it causes secondary dysmenorrhoea and heavy periods due to endometrial tissue within the myometrium.",
      "Polycystic ovary syndrome": "Incorrect – PCOS is more often associated with oligomenorrhoea or amenorrhoea, not secondary dysmenorrhoea.",
      "Hypothyroidism": "Incorrect – may cause heavy or irregular periods but does not typically cause painful menstruation after previously pain-free cycles.",
      "Premature ovarian insufficiency": "Incorrect – leads to early menopause and cessation of periods, not new-onset period pain.",
      "Bacterial vaginosis": "Incorrect – causes vaginal discharge or odour but does not result in menstrual pain or cycle changes."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Menstrual Disorders",
    "topic": "Dysmenorrhoea",
    "keywords": [
      "adenomyosis",
      "secondary dysmenorrhoea",
      "heavy periods",
      "gynaecology",
      "menstrual pain"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Menorrhagia (heavy menstrual bleeding)",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/menorrhagia-heavy-menstrual-bleeding/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2ee819f2-79cc-46dd-9aca-45deef98259a",
    "question_number": 233,
    "question": "Which medication is considered first-line pharmacological therapy for a patient with functionally disabling essential tremor?",
    "options": [
      "Propranolol",
      "Trihexyphenidyl",
      "Levodopa",
      "Ropinirole",
      "Clonazepam"
    ],
    "correct_answer": "Propranolol",
    "explanation": "**Explanation**\n**Essential tremor** is a common movement disorder, often inherited, characterised by a bilateral, fine tremor that is most pronounced during voluntary movements (such as holding objects or writing). It typically improves with alcohol and lacks the resting tremor, rigidity, or bradykinesia characteristic of Parkinson's disease. **Propranolol, a non-selective beta-blocker, is the first-line pharmacological treatment** for patients with essential tremor that causes functional or psychological impairment. Its efficacy is thought to stem from peripheral beta-adrenergic blockade, which dampens tremor amplitude. Other agents (such as primidone) may be considered if propranolol is contraindicated or ineffective, but propranolol remains the gold standard for initial therapy.\n\n**Key Points**\n- Essential tremor presents as a bilateral postural/action tremor, often with a family history.\n- Tremor improves with alcohol and is not associated with Parkinsonian features.\n- First-line pharmacological management is with propranolol.\n- Primidone is an alternative if beta-blockers are unsuitable.\n- Levodopa and dopamine agonists are not effective for essential tremor.\n- <table><thead><tr><th>Feature</th><th>Essential Tremor</th><th>Parkinson's Disease</th></tr></thead><tbody><tr><td>Type of Tremor</td><td>Postural/action</td><td>Rest</td></tr><tr><td>Other Signs</td><td>None</td><td>Rigidity, bradykinesia</td></tr><tr><td>Alcohol Response</td><td>Improves</td><td>No effect</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising essential tremor and distinguishing it from Parkinson's disease is vital for appropriate treatment and patient counselling. Propranolol's use is supported by UK and international guidelines as the initial drug of choice when medication is warranted.\n\n**Memory Anchor**\nRemember: 'Propranolol for Postural tremor'—both start with 'Pro-' and 'Po-'.",
    "bullet_explanations": {
      "Propranolol": "Correct: A non-selective beta-blocker proven effective as first-line treatment for essential tremor.",
      "Trihexyphenidyl": "Incorrect: An anticholinergic used for Parkinsonian tremor, not for essential tremor.",
      "Levodopa": "Incorrect: Used in Parkinson's disease to address dopamine deficiency; not indicated for essential tremor.",
      "Ropinirole": "Incorrect: A dopamine agonist prescribed in Parkinson's disease, not effective for essential tremor.",
      "Clonazepam": "Incorrect: Occasionally used as adjunct therapy in tremor, but not a first-line agent."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Movement Disorders",
    "topic": "Essential tremor",
    "keywords": [
      "essential tremor",
      "propranolol",
      "movement disorders",
      "tremor management",
      "neurology"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "8c8afc97-b664-45af-816d-a91e6e405590",
    "question_number": 234,
    "question": "According to current NICE guidelines, after initiating antihypertensive therapy with an ACE inhibitor in an adult with newly diagnosed stage 2 hypertension, which is the recommended next step if blood pressure remains above target despite optimal dosing?",
    "options": [
      "Add a calcium channel blocker",
      "Double the dose of the ACE inhibitor",
      "Add a thiazide-like diuretic",
      "Switch to an alpha-blocker",
      "Start a centrally acting antihypertensive"
    ],
    "correct_answer": "Add a calcium channel blocker",
    "explanation": "**Explanation**\nThe NICE guidance for hypertension management recommends a stepwise approach based on patient characteristics and response to therapy. **For most adults under 80 years old, the initial step is to start an ACE inhibitor or an angiotensin II receptor blocker (ARB)**. If blood pressure remains uncontrolled, **the next recommended step is to add a calcium channel blocker (CCB)**. Only if further control is needed should a thiazide-like diuretic be added, and other agents such as alpha-blockers or centrally acting antihypertensives are reserved for resistant cases. **This sequence reflects robust evidence for cardiovascular risk reduction and safety.**\n\n**Key Points**\n- Step 1: ACE inhibitor or ARB (if not black African or Caribbean origin, or aged <55).\n- Step 2: Add calcium channel blocker if BP above target.\n- Step 3: Add thiazide-like diuretic if needed.\n- Alpha-blockers and centrally acting agents are not first- or second-line.\n- Therapy escalation should be according to guidelines to maximise benefit and minimise harm.\n\n**Clinical Relevance**\nUnderstanding the recommended sequence for adding antihypertensive agents is essential for safe and effective management of hypertension. Adhering to guideline-driven treatment improves blood pressure control, reduces cardiovascular events, and ensures rational prescribing.\n\n**Memory Anchor**\nRemember: 'ACE, then CCB, then diuretic' – the ABCD ladder for hypertension.",
    "bullet_explanations": {
      "Add a calcium channel blocker": "Correct – this is the recommended second-line agent to add if initial ACE inhibitor therapy does not achieve target BP.",
      "Double the dose of the ACE inhibitor": "Incorrect – increasing the ACE inhibitor dose is not preferred over adding a second agent due to diminishing returns and increased side effects.",
      "Add a thiazide-like diuretic": "Incorrect – this is the third-line step after ACE inhibitor and CCB combination.",
      "Switch to an alpha-blocker": "Incorrect – alpha-blockers are reserved for resistant hypertension, not as first or second add-ons.",
      "Start a centrally acting antihypertensive": "Incorrect – centrally acting drugs are not first- or second-line and are generally reserved for refractory cases."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "NICE A/C/D ladder and special cases",
    "keywords": [
      "hypertension",
      "NICE guidelines",
      "antihypertensive ladder",
      "calcium channel blocker",
      "ACE inhibitor"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "694a5c87-c455-4c7e-b1b9-c0c40a287e21",
    "question_number": 235,
    "question": "A 33-year-old woman with a BMI of 28 kg/m² attends a routine health check. She has no symptoms, but her father had type 2 diabetes. Her blood tests reveal an HbA1c of 44 mmol/mol. What is the most appropriate next step in her management?",
    "options": [
      "Advise intensive lifestyle modification and arrange repeat HbA1c monitoring",
      "Initiate metformin 500 mg twice daily",
      "Refer urgently to secondary care endocrinology",
      "Start metformin 1 g twice daily",
      "Reassure and discharge with no further follow-up"
    ],
    "correct_answer": "Advise intensive lifestyle modification and arrange repeat HbA1c monitoring",
    "explanation": "**Explanation**\n**An HbA1c between 42–47 mmol/mol is classified as prediabetes (non-diabetic hyperglycaemia), not diabetes.** The most effective initial management is to recommend lifestyle changes—such as increased physical activity, weight loss, and dietary improvements—to reduce the risk of progression to type 2 diabetes. Metformin may be considered for some high-risk individuals if lifestyle intervention fails, but it is not first-line, especially for asymptomatic patients. Ongoing monitoring of HbA1c is necessary due to the high risk of progression.\n\n**Key Points**\n- HbA1c 42–47 mmol/mol = prediabetes, not diagnostic for diabetes.\n- Lifestyle modification (diet, exercise, weight loss) is first-line.\n- Metformin is not routinely started unless lifestyle measures fail or in high-risk cases.\n- Repeat HbA1c should be arranged to monitor for progression.\n- No indication for urgent referral or pharmacological therapy at this stage.\n\n**Clinical Relevance**\nIdentifying and managing prediabetes is crucial to reduce future type 2 diabetes risk. Current UK guidance (NICE, BNF) emphasises lifestyle intervention as the cornerstone of care, reserving pharmacological therapy for selected patients only if lifestyle changes are insufficient.\n\n**Memory Anchor**\nThink ‘4s and 7s’: HbA1c 42–47 mmol/mol = prediabetes = 1st-line lifestyle modification.",
    "bullet_explanations": {
      "Advise intensive lifestyle modification and arrange repeat HbA1c monitoring": "Correct—this is the recommended first-line approach for prediabetes (HbA1c 42–47 mmol/mol).",
      "Initiate metformin 500 mg twice daily": "Incorrect—metformin is not routinely indicated for prediabetes unless lifestyle changes fail or in very high-risk cases.",
      "Refer urgently to secondary care endocrinology": "Incorrect—urgent referral is not warranted for asymptomatic prediabetes.",
      "Start metformin 1 g twice daily": "Incorrect—this is an inappropriately high starting dose, and drug therapy is not first-line.",
      "Reassure and discharge with no further follow-up": "Incorrect—prediabetes requires follow-up due to significant diabetes risk."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "Metformin first-line and intolerance",
    "keywords": [
      "prediabetes",
      "lifestyle modification",
      "HbA1c",
      "type 2 diabetes prevention"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diabetes - type 2",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/diabetes-type-2/"
      },
      {
        "source": "BNF",
        "topic_title": "Type 2 diabetes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/type-2-diabetes/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fa5dd52a-6ea2-4883-ac3c-e3f68484ff1b",
    "question_number": 236,
    "question": "What laboratory result is required to confirm a diagnosis of diabetes mellitus in a 62-year-old woman who presents with persistent thirst, frequent urination, and unexplained weight loss over several months?",
    "options": [
      "HbA1c of 48 mmol/mol (6.5%) or above",
      "Random plasma glucose of 9.5 mmol/L",
      "Urine dipstick positive for glucose",
      "Urine albumin:creatinine ratio above normal",
      "Fasting plasma glucose of 6.0 mmol/L"
    ],
    "correct_answer": "HbA1c of 48 mmol/mol (6.5%) or above",
    "explanation": "**Explanation**\n**A diagnosis of diabetes mellitus is confirmed by an HbA1c result of 48 mmol/mol (6.5%) or higher in individuals with symptoms of hyperglycaemia.** HbA1c reflects average blood glucose over the preceding 2–3 months, making it a robust indicator for chronic hyperglycaemia. This method is convenient, as it does not require fasting and is not affected by acute fluctuations. In contrast, lower random or fasting glucose levels and urinalysis findings are insufficient to diagnose diabetes on their own. **Key diagnostic thresholds include**: HbA1c ≥48 mmol/mol (6.5%), random plasma glucose ≥11.1 mmol/L, or fasting glucose ≥7.0 mmol/L, in the context of symptoms.\n\n**Key Points**\n- HbA1c ≥48 mmol/mol (6.5%) is diagnostic of diabetes in symptomatic adults.\n- HbA1c measures average glycaemia over 2–3 months.\n- Random plasma glucose ≥11.1 mmol/L (with symptoms) also confirms diabetes.\n- Urine glucose or albumin:creatinine ratio abnormalities are not diagnostic.\n- Fasting glucose must be ≥7.0 mmol/L to diagnose diabetes.\n- <table><thead><tr><th>Test</th><th>Diagnostic Level</th></tr></thead><tbody><tr><td>HbA1c</td><td>≥48 mmol/mol (6.5%)</td></tr><tr><td>Random glucose</td><td>≥11.1 mmol/L (with symptoms)</td></tr><tr><td>Fasting glucose</td><td>≥7.0 mmol/L</td></tr></tbody></table>\n\n**Clinical Relevance**\nTimely identification of diabetes using the correct diagnostic criteria reduces risk of complications and enables prompt management. UK and NICE guidelines emphasise the use of HbA1c or glucose criteria in symptomatic patients to confirm diagnosis and start appropriate care.\n\n**Memory Anchor**\nThink \"48 for diabetes\" — HbA1c ≥48 mmol/mol is the UK diagnostic cutoff.",
    "bullet_explanations": {
      "HbA1c of 48 mmol/mol (6.5%) or above": "Correct – this meets the NICE diagnostic threshold for diabetes in symptomatic individuals.",
      "Random plasma glucose of 9.5 mmol/L": "Incorrect – this is below the 11.1 mmol/L cutoff for diabetes diagnosis.",
      "Urine dipstick positive for glucose": "Incorrect – glucosuria suggests hyperglycaemia but is not diagnostic on its own.",
      "Urine albumin:creatinine ratio above normal": "Incorrect – indicates possible nephropathy but does not diagnose diabetes.",
      "Fasting plasma glucose of 6.0 mmol/L": "Incorrect – diagnostic threshold is ≥7.0 mmol/L."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "Metformin first-line and intolerance",
    "keywords": [
      "diagnosis",
      "HbA1c",
      "type 2 diabetes",
      "criteria",
      "NICE"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diabetes - type 2",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/diabetes-type-2/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b0b382dc-08ab-4cbb-8846-299aef5847f8",
    "question_number": 237,
    "question": "A 62-year-old man receives a red blood cell transfusion following elective hip replacement surgery. Forty minutes into the transfusion, he develops a temperature of 38.7°C and feels mildly uncomfortable but remains haemodynamically stable. He has no rash, dyspnoea, or hypotension. The transfusion is paused, and his observations are: respiratory rate 18 breaths/min, heart rate 80 bpm, blood pressure 132/79 mmHg, oxygen saturations 99% on air. What is the most appropriate next step in management?",
    "options": [
      "Administer paracetamol to treat the fever and observe",
      "Give intramuscular adrenaline immediately",
      "Start intravenous broad-spectrum antibiotics",
      "Administer intravenous furosemide",
      "Provide supplemental oxygen and intravenous fluids"
    ],
    "correct_answer": "Administer paracetamol to treat the fever and observe",
    "explanation": "**Explanation**\nThis patient's presentation is most consistent with a **febrile non-haemolytic transfusion reaction (FNHTR)**, a common and generally benign response to blood transfusion. FNHTR typically presents with a mild fever and occasionally chills or discomfort, but without evidence of haemolysis, hypotension, respiratory distress, or other signs of severe transfusion reactions. The mainstay of management is to **stop the transfusion, assess the patient, and exclude more serious reactions** such as haemolytic transfusion reactions, sepsis, or anaphylaxis. Once these have been excluded and the patient is stable, **paracetamol is used to manage the fever**. The transfusion may be restarted at a slower rate if no other concerns are identified.\n\n**Key Points**\n- FNHTR presents with fever and mild symptoms, usually within 1–2 hours of transfusion.\n- Distinguishing features: No hypotension, respiratory compromise, or urticaria.\n- Serious reactions (e.g. anaphylaxis, haemolysis, transfusion-related sepsis) must be excluded.\n- Paracetamol is appropriate for symptomatic relief in FNHTR.\n- Transfusion may be continued cautiously if no other cause is found.\n- <table><thead><tr><th>Reaction</th><th>Key Features</th><th>Immediate Action</th></tr></thead><tbody><tr><td>FNHTR</td><td>Fever, mild discomfort</td><td>Paracetamol, observe</td></tr><tr><td>Anaphylaxis</td><td>Hypotension, airway compromise</td><td>IM adrenaline</td></tr><tr><td>TACO</td><td>Respiratory distress, hypertension</td><td>IV furosemide</td></tr><tr><td>Sepsis</td><td>Fever, rigors, shock</td><td>Antibiotics</td></tr></tbody></table>\n\n**Clinical Relevance**\nFNHTR is the most frequent transfusion reaction and is usually self-limiting. Prompt recognition and supportive management are essential to differentiate it from more serious reactions that require urgent intervention. Adhering to transfusion protocols ensures patient safety.\n\n**Memory Anchor**\nFNHTR = Fever, No Hypotension, Treat with Paracetamol",
    "bullet_explanations": {
      "Administer paracetamol to treat the fever and observe": "Correct – suitable for stable patients with FNHTR after excluding severe reactions.",
      "Give intramuscular adrenaline immediately": "Incorrect – IM adrenaline is indicated for anaphylaxis, not isolated fever with stable vitals.",
      "Start intravenous broad-spectrum antibiotics": "Incorrect – reserved for suspected transfusion-transmitted sepsis, which presents with shock or severe symptoms.",
      "Administer intravenous furosemide": "Incorrect – used for transfusion-associated circulatory overload (TACO), which presents with dyspnoea and volume overload.",
      "Provide supplemental oxygen and intravenous fluids": "Incorrect – this approach is for patients with evidence of shock, hypoxia, or haemolysis, not for isolated fever."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Transfusion thresholds",
    "topic": "Transfusion reactions: recognition and management",
    "keywords": [
      "transfusion reaction",
      "FNHTR",
      "paracetamol",
      "blood transfusion",
      "febrile reaction"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "4723d3b8-08f1-440d-833c-b8c85987f838",
    "question_number": 238,
    "question": "Which factor confers the greatest risk of developing a psychotic disorder such as schizophrenia?",
    "options": [
      "First-degree relative with schizophrenia",
      "Prolonged cannabis use",
      "History of childhood sexual abuse",
      "Belonging to a minority ethnic group",
      "Occupation in the creative arts"
    ],
    "correct_answer": "First-degree relative with schizophrenia",
    "explanation": "**Explanation**\n**Having a first-degree relative with schizophrenia is the strongest known risk factor for developing a psychotic disorder.** The risk for individuals with a parent or sibling affected by schizophrenia is markedly higher—around 10%—compared to the general population risk of approximately 1%. This elevated risk is attributable to both genetic susceptibility and shared environmental influences. Other factors, such as long-term cannabis use or adverse childhood experiences, are recognised risk factors but their impact is considerably less pronounced. Ethnicity and occupation may influence incidence due to broader social determinants, but they do not approach the predictive power of a direct family history.\n\n**Key Points**\n<ul><li><b>First-degree relatives</b> (parent, sibling, child) of individuals with schizophrenia face a ~10% lifetime risk.</li><li>General population risk is around 1%.</li><li>Genetic and environmental factors both contribute to familial risk.</li><li>Other risk factors (cannabis, trauma) have weaker associations.</li><li>Ethnicity and occupation are not direct, strong risk factors.</li></ul>\n\n**Clinical Relevance**\nRecognising a strong family history is crucial when assessing risk for psychosis. NICE guidelines highlight the importance of identifying individuals with a first-degree relative affected by psychotic disorders to facilitate early intervention and appropriate support.\n\n**Memory Anchor**\nThink 'family first' when assessing psychosis risk—genetics outweigh all other factors.",
    "bullet_explanations": {
      "First-degree relative with schizophrenia": "Correct – This is the single strongest risk factor for psychotic disorders.",
      "Prolonged cannabis use": "Incorrect – Increases risk but less significant than family history.",
      "History of childhood sexual abuse": "Incorrect – May increase risk for several mental health conditions, but association with psychosis is weaker than genetic risk.",
      "Belonging to a minority ethnic group": "Incorrect – Some increased incidence may be observed, but primarily related to social/environmental influences rather than direct causality.",
      "Occupation in the creative arts": "Incorrect – No established strong link with psychosis risk."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Psychosis & Anxiety",
    "subsubsection": "Schizophrenia",
    "topic": "Prognosis",
    "keywords": [
      "psychosis risk factors",
      "schizophrenia",
      "family history",
      "genetics",
      "MSRA psychiatry"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Psychoses and related disorders",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Psychosis and schizophrenia",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/psychosis-schizophrenia/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "227edfe4-5efc-4364-91db-daf00634b1e2",
    "question_number": 239,
    "question": "A 37-year-old man presents to A&E after abruptly developing an excruciating, sudden-onset headache described as 'the worst of his life' while gardening. He has associated neck stiffness, photophobia, and vomiting, but no fever or preceding illness. What is the initial imaging investigation of choice for this presentation?",
    "options": [
      "Non-contrast CT head",
      "Lumbar puncture",
      "Contrast-enhanced MRI brain",
      "CT cerebral angiography",
      "Electroencephalogram"
    ],
    "correct_answer": "Non-contrast CT head",
    "explanation": "**Explanation**\n**Non-contrast CT head is the first-line investigation for suspected subarachnoid haemorrhage (SAH)**, especially when the clinical picture includes sudden, severe headache (thunderclap onset), neck stiffness, and photophobia. **CT rapidly detects acute blood in the subarachnoid space** and is widely available, making it the preferred initial test. Imaging should be performed as soon as possible after presentation, ideally within 6 hours, as sensitivity decreases over time. In contrast, lumbar puncture is reserved for cases where the CT is negative but clinical suspicion remains high. Other imaging modalities or investigations are either less sensitive for acute SAH, unnecessary at this stage, or not suitable for emergent assessment.\n\n**Key Points**\n- Non-contrast CT head is the immediate first-line test for suspected SAH.\n- CT sensitivity is highest within 6 hours of symptom onset.\n- CT detects hyperdense blood in the subarachnoid space.\n- Lumbar puncture is indicated only if CT is negative/inconclusive after 6 hours.\n- Contrast-enhanced scans and angiography are for further evaluation, not initial diagnosis.\n\n**Clinical Relevance**\nEarly recognition and prompt imaging in cases of sudden-onset severe headache are vital to diagnose subarachnoid haemorrhage and initiate urgent management, significantly impacting outcomes. This approach aligns with current NICE guidelines for headache assessment and red-flag symptoms.\n\n**Memory Anchor**\nThink 'CT first for Catastrophic Thunderclap' (CT = Catastrophic Thunderclap headache).",
    "bullet_explanations": {
      "Non-contrast CT head": "Correct – First-line investigation for suspected subarachnoid haemorrhage, especially if performed within 6 hours.",
      "Lumbar puncture": "Incorrect – Used if CT scan is negative or inconclusive but only after 6 hours post-onset; not first-line.",
      "Contrast-enhanced MRI brain": "Incorrect – MRI is less sensitive acutely and not the immediate test of choice for SAH.",
      "CT cerebral angiography": "Incorrect – Performed after SAH diagnosis to identify aneurysm or vascular abnormality, not for initial detection.",
      "Electroencephalogram": "Incorrect – Used to assess epilepsy or encephalopathy; does not diagnose SAH or acute headache causes."
    },
    "category": "Neurology",
    "subsection": "Headache",
    "subsubsection": "Red flag headache",
    "topic": "Red flag headache",
    "keywords": [
      "subarachnoid haemorrhage",
      "headache",
      "neuroimaging",
      "CT head",
      "red flag"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Headache - assessment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/headache-assessment/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c8b4f083-2e5b-4b25-bacf-7ab16e1b3ad7",
    "question_number": 240,
    "question": "A 42-year-old man presents with persistent upper abdominal discomfort and intermittent bloating for the past six weeks. He is otherwise healthy, takes no regular medication, and has no weight loss, vomiting, dysphagia, or GI bleeding. Dietary changes and over-the-counter antacids have not relieved his symptoms. What is the most appropriate next step in his management?",
    "options": [
      "Commence a full-dose proton pump inhibitor (PPI) for 4 weeks",
      "Refer for urgent upper GI endoscopy within 2 weeks",
      "Continue antacids as needed for symptom control",
      "Start a low-dose H2-receptor antagonist for 2 weeks",
      "Advise immediate Helicobacter pylori eradication therapy without testing"
    ],
    "correct_answer": "Commence a full-dose proton pump inhibitor (PPI) for 4 weeks",
    "explanation": "**Explanation**\n**For adults with uninvestigated dyspepsia and no alarm features or NSAID use, first-line management is a 4-week trial of a full-dose PPI or testing for H. pylori infection.** This approach targets acid suppression, which is effective in most cases of functional or uninvestigated dyspepsia. Urgent endoscopy is reserved for those with alarm symptoms (e.g., dysphagia, GI bleeding, weight loss, age ≥55 with new symptoms). Continuing antacids alone is not recommended for persistent symptoms, and H. pylori eradication therapy should only be given after a confirmed positive test. **A trial of a low-dose H2 antagonist is inferior to PPI therapy for initial management.**\n\n**Key Points**\n- Start a full-dose PPI for 4 weeks or test for H. pylori if not previously done\n- Alarm symptoms or age ≥55 with new symptoms warrant urgent endoscopy\n- Antacids are suitable for occasional, not persistent, symptoms\n- Do not empirically treat H. pylori without confirmed infection\n- Lifestyle advice should also be provided but is insufficient as monotherapy in this scenario\n\n**Clinical Relevance**\nThis management aligns with national guidelines for uninvestigated dyspepsia, aiming to relieve symptoms and avoid unnecessary investigations or overtreatment. Recognising when to escalate to endoscopy prevents missed diagnosis of serious pathology while avoiding overuse of invasive procedures in low-risk patients.",
    "bullet_explanations": {
      "Commence a full-dose proton pump inhibitor (PPI) for 4 weeks": "Correct – this is the recommended initial pharmacological management in patients without alarm features or NSAID use.",
      "Refer for urgent upper GI endoscopy within 2 weeks": "Incorrect – urgent endoscopy is indicated only if alarm features or high-risk criteria are present.",
      "Continue antacids as needed for symptom control": "Incorrect – antacids are for short-term use; persistent symptoms require escalation of therapy.",
      "Start a low-dose H2-receptor antagonist for 2 weeks": "Incorrect – H2 antagonists are less effective than PPIs and not first-line for uninvestigated dyspepsia.",
      "Advise immediate Helicobacter pylori eradication therapy without testing": "Incorrect – H. pylori eradication is only indicated after a positive test, not empirically."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Upper GI",
    "subsubsection": "Dyspepsia & H. pylori",
    "topic": "PPI trial vs endoscopy indications",
    "keywords": [
      "dyspepsia",
      "PPI",
      "alarm features",
      "H. pylori",
      "endoscopy"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Dyspepsia",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/dyspepsia/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Dyspepsia - unidentified cause",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/dyspepsia-unidentified-cause/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d181ea18-0c2a-46c6-820a-ef53658507e3",
    "question_number": 241,
    "question": "Which of the following scenarios is most likely to reduce the diagnostic accuracy of a 13C-urea breath test for Helicobacter pylori infection?",
    "options": [
      "Completion of a clarithromycin course 2 weeks ago",
      "Current use of alginate-based antacids",
      "Discontinuation of omeprazole 4 weeks ago",
      "Stopping ranitidine 3 weeks ago",
      "Use of combined hormonal contraception"
    ],
    "correct_answer": "Completion of a clarithromycin course 2 weeks ago",
    "explanation": "**Explanation**\n**Recent use of antibiotics, such as clarithromycin, can suppress or eradicate Helicobacter pylori, leading to a potential false-negative result on the 13C-urea breath test.** It is recommended to avoid antibiotics for at least 4 weeks before testing to ensure accuracy. In contrast, antacids, hormonal contraception, and acid-suppressing drugs discontinued well in advance do not significantly affect the test result. Acid suppression from PPIs or H2 antagonists may be relevant if used within 2 weeks, but not if stopped longer ago.\n\n**Key Points**\n- Antibiotics must be avoided for at least 4 weeks prior to urea breath test to prevent false negatives.\n- Proton pump inhibitors (PPIs) and H2 antagonists can affect results if not withheld for at least 2 weeks.\n- Antacids and hormonal contraceptives do not influence H. pylori test accuracy.\n- The breath test detects active H. pylori infection by measuring labelled CO2 after urea metabolism.\n- False negatives are most commonly due to recent antibiotic or acid suppression therapy.\n\n**Clinical Relevance**\nAccurate detection of H. pylori infection is essential for appropriate management of dyspepsia and peptic ulcer disease. Adhering to correct drug-free intervals before testing reduces the risk of misdiagnosis and unnecessary repeat investigations.\n\n**Memory Anchor**\n**A**ntibiotics **A**lter **A**ccuracy (triple A: Antibiotics Affect Accuracy)",
    "bullet_explanations": {
      "Completion of a clarithromycin course 2 weeks ago": "Correct – Recent antibiotic use can suppress H. pylori and cause false-negative breath test results.",
      "Current use of alginate-based antacids": "Incorrect – Antacids do not eradicate or suppress H. pylori and have no effect on test accuracy.",
      "Discontinuation of omeprazole 4 weeks ago": "Incorrect – PPI use can affect results if not stopped for at least 2 weeks, but 4 weeks is sufficient washout.",
      "Stopping ranitidine 3 weeks ago": "Incorrect – H2 blocker use can affect results if stopped less than 2 weeks ago; 3 weeks is adequate.",
      "Use of combined hormonal contraception": "Incorrect – Hormonal contraceptives do not impact the urea breath test."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Upper GI",
    "subsubsection": "Dyspepsia & H. pylori",
    "topic": "HP eradication regimens",
    "keywords": [
      "urea breath test",
      "H. pylori",
      "antibiotics",
      "false negative",
      "diagnostic accuracy"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "4cbe9317-ccb4-46ab-b11c-73c953554b39",
    "question_number": 242,
    "question": "During a prolonged second stage of labour, a 32-year-old woman experiences significant perineal stretching and the obstetric team decides to perform a controlled surgical incision to reduce the risk of severe perineal tearing and to facilitate delivery. What is the name of this procedure?",
    "options": [
      "Episiotomy",
      "Symphysiotomy",
      "Pudendal nerve block",
      "Vacuum extraction",
      "Rectocele repair"
    ],
    "correct_answer": "Episiotomy",
    "explanation": "**Explanation**\n**Episiotomy** is a surgical incision made in the perineum and the posterior vaginal wall during the second stage of labour. It is typically performed to enlarge the vaginal opening when there is a high risk of extensive perineal tearing, fetal distress, or to expedite delivery in cases of obstructed labour, such as cephalopelvic disproportion. By creating a controlled incision, the risk of severe spontaneous tears involving the anal sphincter is reduced, and space is increased for the fetal head to deliver safely. The mediolateral approach, commonly used in the UK, directs the incision away from the anal sphincter, minimising the risk of injury to the anal muscles and long-term complications like faecal incontinence. This procedure is distinct from other interventions such as operative vaginal delivery or pelvic floor repairs, and is not a first-line intervention unless clinically indicated.\n\n**Key Points**\n- Episiotomy involves a surgical cut in the perineum during the second stage of labour.\n- Indicated to prevent severe perineal tears and aid difficult deliveries.\n- Mediolateral episiotomy reduces risk of anal sphincter injury.\n- Spontaneous tears often have worse outcomes if not controlled.\n- Other interventions (e.g. vacuum extraction) are separate procedures.\n- Performed when there is risk to mother or fetus, not routinely.\n\n**Clinical Relevance**\nEpisiotomy remains an important tool in obstetric practice when spontaneous delivery risks severe perineal trauma or when rapid delivery is necessary for fetal or maternal indications. Understanding when and how to perform this intervention is essential for preventing long-term complications like faecal incontinence and promoting maternal recovery.\n\n**Memory Anchor**\nEpisiotomy = 'E' for 'Enlarging' the exit during delivery.",
    "bullet_explanations": {
      "Episiotomy": "Correct – a surgical incision of the perineum to facilitate vaginal delivery.",
      "Symphysiotomy": "Incorrect – this is a division of the pubic symphysis, rarely used today.",
      "Pudendal nerve block": "Incorrect – this is an anaesthetic procedure, not a surgical incision.",
      "Vacuum extraction": "Incorrect – this is an instrumental delivery technique, not an incision.",
      "Rectocele repair": "Incorrect – this is a surgical repair for pelvic organ prolapse, unrelated to labour."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Late",
    "subsubsection": "Labour & Delivery",
    "topic": "Stages of labour",
    "keywords": [
      "episiotomy",
      "perineal incision",
      "labour",
      "obstetric procedure",
      "mediolateral"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Normal labour and birth",
        "citation": "© NICE, 2025",
        "url": ""
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1bea815b-cec2-4c5e-96e4-0cee74ba3448",
    "question_number": 243,
    "question": "A 61-year-old man with recently diagnosed primary hypertension is seeking a medication that avoids the need for regular blood monitoring, as he has a severe phobia of blood tests. Which of the following antihypertensive medications is most appropriate for him?",
    "options": [
      "Amlodipine",
      "Ramipril",
      "Indapamide",
      "Candesartan",
      "Bendroflumethiazide"
    ],
    "correct_answer": "Amlodipine",
    "explanation": "**Explanation**\n**Amlodipine** is a calcium channel blocker that does not require routine blood test monitoring during ongoing treatment. Unlike ACE inhibitors (such as ramipril), angiotensin receptor blockers (such as candesartan), and thiazide/thiazide-like diuretics (such as indapamide and bendroflumethiazide), amlodipine does not typically affect renal function or serum electrolytes, so regular monitoring is unnecessary. This makes it an ideal choice for patients who wish to minimise blood tests due to needle phobia or other reasons. In contrast, the other listed antihypertensive agents can cause or unmask renal impairment, hyperkalaemia or other electrolyte disturbances, necessitating periodic blood test surveillance.\n\n**Key Points**\n- Amlodipine is a calcium channel blocker suitable for hypertension management without need for routine blood monitoring.\n- ACE inhibitors, ARBs, and thiazide/thiazide-like diuretics all require regular checks of renal function and electrolytes.\n- Monitoring minimises risks of drug-induced renal impairment, hyperkalaemia, or hyponatraemia.\n- Choice of antihypertensive should be individualised based on patient preferences, comorbidities, and monitoring requirements.\n- <table><thead><tr><th>Drug Class</th><th>Routine Blood Monitoring Needed?</th></tr></thead><tbody><tr><td>Calcium channel blocker (e.g. amlodipine)</td><td>No</td></tr><tr><td>ACE inhibitor (e.g. ramipril)</td><td>Yes</td></tr><tr><td>ARB (e.g. candesartan)</td><td>Yes</td></tr><tr><td>Thiazide/thiazide-like diuretic (e.g. indapamide, bendroflumethiazide)</td><td>Yes</td></tr></tbody></table>\n\n**Clinical Relevance**\nSelecting an antihypertensive agent that aligns with patient preferences—such as avoiding regular blood tests—can significantly improve adherence and patient satisfaction. NICE guidelines recommend calcium channel blockers as a first-line option in many patients, particularly when monitoring is not feasible or desirable.\n\n**Memory Anchor**\nRemember: 'Amlodipine Avoids Analyses'—the CCB that doesn't need routine blood tests.",
    "bullet_explanations": {
      "Amlodipine": "Correct – does not need regular blood monitoring and is an effective first-line antihypertensive.",
      "Ramipril": "Incorrect – requires ongoing monitoring of renal function and electrolytes.",
      "Indapamide": "Incorrect – thiazide-like diuretic needing regular checks of renal function and electrolytes.",
      "Candesartan": "Incorrect – ARBs need periodic monitoring for renal impairment and hyperkalaemia.",
      "Bendroflumethiazide": "Incorrect – requires monitoring of renal function and electrolytes due to risk of disturbances."
    },
    "category": "Cardiovascular",
    "subsection": "Hypertension & Vascular",
    "subsubsection": "Hypertension",
    "topic": "NICE A/C/D ladder and special cases",
    "keywords": [
      "hypertension",
      "calcium channel blocker",
      "amlodipine",
      "antihypertensive",
      "blood monitoring"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "21d8d75e-c48f-4579-a9a2-0305dddcc817",
    "question_number": 244,
    "question": "A 67-year-old man with a history of myelodysplastic syndrome (MDS) is attending a routine follow-up. He remains clinically stable with no new symptoms. Which haematological malignancy is he at significantly increased risk of developing as a complication of his underlying condition?",
    "options": [
      "Acute myeloid leukaemia",
      "Chronic myeloid leukaemia",
      "Multiple myeloma",
      "Hodgkin lymphoma",
      "Essential thrombocythaemia"
    ],
    "correct_answer": "Acute myeloid leukaemia",
    "explanation": "**Explanation**\n**Myelodysplastic syndrome (MDS) can progress to acute myeloid leukaemia (AML) due to acquisition of additional genetic mutations causing a block in myeloid cell maturation.** Up to a third of patients with MDS will eventually develop secondary AML, often after a variable period of cytopenia and ineffective haematopoiesis. The risk is related to the type of MDS and cytogenetic abnormalities. In contrast, MDS does not predispose to lymphoid or plasma cell malignancies such as ALL, CLL, or multiple myeloma.\n\n**Key Points**\n- MDS is a clonal stem cell disorder affecting myeloid lineage.\n- Transformation to AML occurs in about 30% of cases.\n- AML is characterised by accumulation of myeloid blasts in the marrow and blood.\n- Other haematological malignancies (CML, lymphoma, myeloma) are not typical progressions of MDS.\n- AML transformation often presents with worsening cytopenias or new symptoms.\n\n**Clinical Relevance**\nRecognising that MDS can progress to AML is essential for timely monitoring, patient counselling, and prompt intervention if transformation occurs. Early recognition of AML signs can improve outcomes and guide referral for specialist care.\n\n**Memory Anchor**\nMDS → AML: Both are myeloid disorders, so 'M' in both names links their progression.",
    "bullet_explanations": {
      "Acute myeloid leukaemia": "Correct. MDS frequently transforms into AML due to shared myeloid lineage.",
      "Chronic myeloid leukaemia": "Incorrect. CML is a distinct myeloproliferative neoplasm, not a recognised progression from MDS.",
      "Multiple myeloma": "Incorrect. Myeloma is a plasma cell malignancy; MDS does not increase the risk.",
      "Hodgkin lymphoma": "Incorrect. MDS does not predispose to lymphoid neoplasms like Hodgkin lymphoma.",
      "Essential thrombocythaemia": "Incorrect. This is a separate myeloproliferative disorder, unrelated to MDS progression."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Haematological Malignancies",
    "topic": "Acute leukaemias vs chronic",
    "keywords": [
      "myelodysplastic syndrome",
      "AML",
      "progression",
      "haematological malignancy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Multiple myeloma",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/multiple-myeloma/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "bebcf21e-cf42-4e70-9bbd-b7b274386297",
    "question_number": 245,
    "question": "A 77-year-old man is admitted following a minor trip at home. He is unable to bear weight and examination reveals his left leg is shortened and externally rotated. Radiographs confirm a stable extracapsular (intertrochanteric) fracture of the proximal femur. Which surgical intervention is most suitable for this type of fracture?",
    "options": [
      "Dynamic hip screw fixation",
      "Total hip arthroplasty",
      "External fixation",
      "Hemiarthroplasty",
      "Long intramedullary nail"
    ],
    "correct_answer": "Dynamic hip screw fixation",
    "explanation": "**Explanation**\n**Dynamic hip screw (DHS) fixation is the recommended first-line surgical approach for stable intertrochanteric (extracapsular) femoral fractures.** The DHS device allows controlled collapse and compression of the fracture site as the patient bears weight, promoting effective bone healing. This technique is specifically indicated for stable extracapsular hip fractures, as it provides robust fixation and facilitates early mobilisation. In contrast, arthroplasty (hemi or total) is reserved for displaced intracapsular fractures, and intramedullary nails are preferred for unstable or subtrochanteric patterns. External fixation is rarely indicated in this context, typically reserved for patients with severe comorbidities or as a temporising measure.\n\n**Key Points**\n- DHS fixation is the gold standard for stable intertrochanteric (extracapsular) hip fractures.\n- Allows dynamic compression and promotes healing.\n- Intramedullary nails are reserved for unstable or subtrochanteric fractures.\n- Hemiarthroplasty and total hip replacements are for displaced intracapsular fractures or in arthritic joints.\n- External fixation is rarely used for hip fractures except in exceptional cases.\n\n**Clinical Relevance**\nCorrect surgical management of hip fractures is critical to optimise recovery, prevent complications, and reduce mortality in older adults. Prompt identification of fracture type ensures patients receive the most appropriate fixation device, as outlined in NICE guidance for fragility fractures.",
    "bullet_explanations": {
      "Dynamic hip screw fixation": "Correct—DHS is the preferred surgical option for stable intertrochanteric (extracapsular) fractures.",
      "Total hip arthroplasty": "Incorrect—THR is typically reserved for displaced intracapsular fractures or when there is pre-existing joint disease.",
      "External fixation": "Incorrect—This is rarely used for proximal femoral fractures except in cases with severe comorbidities or infection risk.",
      "Hemiarthroplasty": "Incorrect—Indicated for displaced intracapsular fractures, not for extracapsular intertrochanteric fractures.",
      "Long intramedullary nail": "Incorrect—IM nails are used for unstable intertrochanteric or subtrochanteric fractures, not for stable intertrochanteric patterns."
    },
    "category": "Trauma & Orthopaedics",
    "subsection": "Fractures",
    "subsubsection": "NOF fracture management",
    "topic": "NOF fracture management",
    "keywords": [
      "hip fracture",
      "dynamic hip screw",
      "intertrochanteric",
      "extracapsular",
      "orthopaedic surgery"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Osteoporosis - prevention of fragility fractures",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/osteoporosis-prevention-of-fragility-fractures/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d6cce294-1257-4177-9c10-6cf35441b8b3",
    "question_number": 246,
    "question": "A 65-year-old woman with a history of breast cancer presents to the acute admissions unit with increasing confusion and lethargy over several days. Blood tests show: Na+ 138 mmol/L, K+ 4.3 mmol/L, urea 6.5 mmol/L, creatinine 90 μmol/L, adjusted calcium 3.6 mmol/L. What is the most appropriate initial management?",
    "options": [
      "Commence intravenous 0.9% sodium chloride",
      "Administer intravenous bisphosphonate",
      "Start oral corticosteroids",
      "Begin broad-spectrum antibiotics",
      "Arrange urgent haemodialysis"
    ],
    "correct_answer": "Commence intravenous 0.9% sodium chloride",
    "explanation": "**Explanation**\n**Severe hypercalcaemia** (adjusted calcium >3.5 mmol/L) is a medical emergency, most commonly due to malignancy. The **first-line intervention is rapid intravenous rehydration with 0.9% sodium chloride**, as patients are often volume depleted due to the polyuric effects of hypercalcaemia. Hydration helps to lower serum calcium by increasing renal excretion and correcting any pre-renal impairment. Other definitive therapies, such as intravenous bisphosphonates, are added only after rehydration has begun. Bisphosphonates are not effective until the patient is adequately hydrated, and their calcium-lowering effect is delayed (typically 48–72 hours).\n\n**Key Points**\n- Severe hypercalcaemia: adjusted Ca2+ >3.5 mmol/L is life-threatening.\n- Malignancy is the most common cause of severe hypercalcaemia.\n- Patients are often dehydrated due to the effects of high calcium.\n- Initial treatment is intravenous 0.9% sodium chloride to restore volume and promote calciuresis.\n- Bisphosphonates are used after rehydration and take up to 72 hours to work.\n- <table><thead><tr><th>Step</th><th>Action</th></tr></thead><tbody><tr><td>1</td><td>IV fluids (0.9% NaCl)</td></tr><tr><td>2</td><td>Monitor U&E, calcium</td></tr><tr><td>3</td><td>Add IV bisphosphonate if indicated</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition and management of severe hypercalcaemia is essential to reduce morbidity and mortality, particularly in oncology patients. National guidelines recommend intravenous fluid resuscitation as the first therapeutic step before considering bisphosphonates or other interventions.\n\n**Memory Anchor**\nHydration comes before bisphosphonates: 'Flush first, fix later.'",
    "bullet_explanations": {
      "Commence intravenous 0.9% sodium chloride": "Correct – Immediate fluid resuscitation is the initial management for severe hypercalcaemia.",
      "Administer intravenous bisphosphonate": "Incorrect – Bisphosphonates are given after rehydration and are not the first step.",
      "Start oral corticosteroids": "Incorrect – Steroids are reserved for certain causes (e.g., lymphoma, sarcoid) and are not first-line for hypercalcaemia of malignancy.",
      "Begin broad-spectrum antibiotics": "Incorrect – No evidence of infection; antibiotics are not indicated.",
      "Arrange urgent haemodialysis": "Incorrect – Reserved for refractory cases or those with renal failure unresponsive to fluids."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Calcium, Pituitary & Metabolic",
    "subsubsection": "Calcium Disorders",
    "topic": "Hypercalcaemia (PTH-mediated vs non-PTH)",
    "keywords": [
      "hypercalcaemia",
      "malignancy",
      "IV fluids",
      "oncology emergency",
      "initial management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hypercalcaemia",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hypercalcaemia/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "72c1eb71-afac-42e5-a26f-722a9d6dd572",
    "question_number": 247,
    "question": "A 29-year-old woman at 28 weeks gestation is admitted in preterm labour. Which intervention is most effective in reducing the risk of neonatal respiratory distress syndrome if delivery cannot be delayed?",
    "options": [
      "Administer maternal corticosteroids prior to delivery",
      "Give exogenous surfactant to the neonate after birth",
      "Start continuous positive airway pressure immediately after birth",
      "Use tocolytics to halt labour progression",
      "Initiate extracorporeal membrane oxygenation for the neonate"
    ],
    "correct_answer": "Administer maternal corticosteroids prior to delivery",
    "explanation": "**Explanation**\n**Maternal corticosteroids given before preterm birth are the most effective intervention to reduce the risk and severity of neonatal respiratory distress syndrome (RDS).** These steroids accelerate fetal lung maturation by stimulating surfactant production, which is crucial for alveolar stability after birth. Surfactant deficiency is the primary cause of RDS in preterm infants. Administering corticosteroids to the mother—ideally at least 24 hours before delivery—substantially decreases neonatal morbidity and mortality from RDS. Other interventions, such as surfactant therapy after birth and ventilatory support, are important for treatment but do not prevent the initial development of RDS.\n\n**Key Points**\n- Neonatal RDS is mainly due to insufficient surfactant in preterm infants.\n- Antenatal corticosteroids (e.g., betamethasone or dexamethasone) induce surfactant production.\n- Maternal steroids are most effective when given 24–48 hours before preterm birth.\n- Postnatal surfactant is reserved for infants who develop RDS, not for prevention.\n- Ventilatory support (CPAP) and ECMO are treatments for established RDS, not preventive measures.\n- Tocolytics may delay labour but do not directly reduce RDS risk unless used to allow time for steroid administration.\n\n**Clinical Relevance**\nTimely administration of maternal corticosteroids in threatened preterm labour is a key intervention in obstetric care, supported by national guidelines, and significantly improves neonatal outcomes by reducing RDS incidence and severity.\n\n**Memory Anchor**\nSteroids 'Set the Stage' for Surfacing Surfactant—give before the baby arrives!",
    "bullet_explanations": {
      "Administer maternal corticosteroids prior to delivery": "Correct—stimulates fetal surfactant production, reducing RDS risk.",
      "Give exogenous surfactant to the neonate after birth": "Used to treat established RDS, not to prevent its occurrence.",
      "Start continuous positive airway pressure immediately after birth": "Supports infants with RDS, but does not prevent the syndrome.",
      "Use tocolytics to halt labour progression": "Can delay delivery but do not themselves prevent RDS unless used to gain time for steroid effect.",
      "Initiate extracorporeal membrane oxygenation for the neonate": "Reserved for severe neonatal respiratory failure, not preventive."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Bleeding in pregnancy",
    "keywords": [
      "neonatal respiratory distress syndrome",
      "antenatal corticosteroids",
      "preterm birth",
      "surfactant",
      "obstetric emergency"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Respiratory stimulants",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/respiratory-stimulants/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "873f51c7-21c1-4ba3-8735-8b1f24512af1",
    "question_number": 248,
    "question": "A 62-year-old woman presents with a three-week history of persistent upper abdominal discomfort, early satiety, and new-onset heartburn. She reports an unintentional 3 kg weight loss over the past month but denies vomiting, haematemesis, or melaena. She has no significant medical history and takes no regular medication. What is the most appropriate next step in her management?",
    "options": [
      "Arrange urgent upper gastrointestinal endoscopy",
      "Start a four-week trial of a proton pump inhibitor",
      "Add an alginate preparation as needed",
      "Request an urgent abdominal CT scan",
      "Refer for routine upper gastrointestinal endoscopy"
    ],
    "correct_answer": "Arrange urgent upper gastrointestinal endoscopy",
    "explanation": "**Explanation**\n**Unintentional weight loss in a patient aged 55 or over with new-onset dyspepsia or upper GI symptoms is an 'alarm feature' that necessitates urgent investigation for malignancy.** According to national guidelines, patients meeting this criterion should be referred for urgent (two-week wait) upper GI endoscopy to exclude gastric or oesophageal cancer. Symptomatic treatment or non-urgent referral would not be appropriate until serious pathology is excluded. This approach prioritises early cancer detection, as delay may impact prognosis.\n\n**Key Points**\n- Alarm features (e.g. weight loss, dysphagia, GI bleeding) in dyspepsia warrant urgent endoscopy.\n- Age ≥55 with unexplained weight loss and upper GI symptoms is a high-risk group.\n- Empirical PPI or alginates are only considered when serious pathology is excluded or in low-risk patients.\n- Abdominal CT is not first-line for dyspepsia without signs suggestive of pancreatic or other non-upper GI malignancy.\n- Routine (non-urgent) endoscopy is not appropriate when alarm symptoms are present.\n\n**Clinical Relevance**\nRecognising alarm symptoms in dyspepsia is critical for GPs and secondary care clinicians, ensuring timely referral for endoscopic assessment in line with NICE and BNF guidance. Missing these features may delay cancer diagnosis and adversely affect outcomes.\n\n**Memory Anchor**\nThink: '55 + Weight Loss = Fast Scope' for urgent endoscopy in new dyspepsia.",
    "bullet_explanations": {
      "Arrange urgent upper gastrointestinal endoscopy": "Correct—meets criteria for urgent (2WW) endoscopy due to age and weight loss.",
      "Start a four-week trial of a proton pump inhibitor": "Incorrect—empirical PPI is reserved for low-risk patients without alarm features.",
      "Add an alginate preparation as needed": "Incorrect—symptomatic relief is inappropriate before excluding malignancy with urgent endoscopy.",
      "Request an urgent abdominal CT scan": "Incorrect—CT is not first-line unless pancreatic or other abdominal malignancy is suspected (usually age >60 and different symptom profile).",
      "Refer for routine upper gastrointestinal endoscopy": "Incorrect—routine referral is not sufficient with alarm features; urgent action is required."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Upper GI",
    "subsubsection": "Dyspepsia & H. pylori",
    "topic": "Alarm features and 2WW criteria",
    "keywords": [
      "dyspepsia",
      "alarm symptoms",
      "urgent endoscopy",
      "weight loss",
      "cancer referral"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Dyspepsia",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/dyspepsia/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Dyspepsia - unidentified cause",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/dyspepsia-unidentified-cause/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "dc163d76-c4d9-4905-ab8d-20e9e40e335f",
    "question_number": 249,
    "question": "A 68-year-old woman with a history of hyperlipidaemia and recent community-acquired pneumonia is taking simvastatin for cholesterol management. Three days after starting a new antibiotic for her infection, she develops generalised muscle pain and weakness. Blood tests reveal a creatine kinase (CK) of 1,250 u/L (normal < 190 u/L). Which newly prescribed medication is most likely responsible for this adverse effect?",
    "options": [
      "Clarithromycin",
      "Rifampicin",
      "Diltiazem",
      "Isosorbide mononitrate",
      "Amitriptyline"
    ],
    "correct_answer": "Clarithromycin",
    "explanation": "**Explanation**\nClarithromycin is a macrolide antibiotic that strongly inhibits the cytochrome P450 3A4 (CYP3A4) enzyme, which is crucial for the metabolism of simvastatin. **Inhibition of CYP3A4 by clarithromycin leads to raised plasma concentrations of simvastatin**, thereby substantially increasing the risk of statin-induced myopathy and rhabdomyolysis, both of which present with muscle pain and elevated CK. This drug interaction is well recognised and can be severe, necessitating either temporary discontinuation of the statin or the use of an alternative non-interacting antibiotic. Other listed medications do not share this significant interaction with simvastatin.\n\n**Key Points**\n- Clarithromycin is a potent CYP3A4 inhibitor.\n- Simvastatin is metabolised by CYP3A4; inhibition raises statin levels.\n- Raised statin levels increase risk of myopathy/rhabdomyolysis (elevated CK).\n- Clinical features include muscle aches, weakness, and potentially serious complications.\n- Other macrolides (e.g., erythromycin) have similar interactions.\n- Alternative antibiotics or temporary statin cessation should be considered if macrolides are required.\n\n**Clinical Relevance**\nRecognising drug interactions between statins and CYP3A4 inhibitors is crucial to prevent serious adverse effects such as myopathy and rhabdomyolysis. **Prescribers must review concurrent medications** before initiating macrolide antibiotics in patients on statins, as outlined in national guidance (see BNF).\n\n**Memory Anchor**\nRemember: 'C' for Clarithromycin and CYP3A4 inhibition with Cholesterol (statins) = CK elevation.",
    "bullet_explanations": {
      "Clarithromycin": "Correct – Potent CYP3A4 inhibitor causing dangerous simvastatin accumulation and myopathy.",
      "Rifampicin": "Incorrect – Induces (not inhibits) CYP3A4, actually lowers statin levels.",
      "Diltiazem": "Incorrect – Is a CYP3A4 inhibitor and can interact, but is not newly prescribed for pneumonia and less commonly causes severe CK elevation compared to clarithromycin.",
      "Isosorbide mononitrate": "Incorrect – Used for angina; does not interact with statins or cause raised CK.",
      "Amitriptyline": "Incorrect – May cause myalgia rarely, but does not interact with simvastatin or elevate CK significantly."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Drug interactions",
    "topic": "Statins and CYP3A4 inhibitors",
    "keywords": [
      "statin interaction",
      "clarithromycin",
      "simvastatin",
      "myopathy",
      "CYP3A4"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Cardiovascular disease risk assessment and prevention",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/cardiovascular-disease-risk-assessment-and-prevention/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "aa854421-8dc9-4f3b-a32f-88e2ff44896d",
    "question_number": 250,
    "question": "Which HbA1c range best defines the threshold for prediabetes in adults according to UK guidelines?",
    "options": [
      "37–41 mmol/mol (5.5–5.9%)",
      "42–47 mmol/mol (6.0–6.4%)",
      "48–52 mmol/mol (6.5–6.9%)",
      "53–58 mmol/mol (7.0–7.5%)",
      "31–36 mmol/mol (5.0–5.4%)"
    ],
    "correct_answer": "42–47 mmol/mol (6.0–6.4%)",
    "explanation": "**Explanation**\n**Prediabetes** is identified in adults with an HbA1c of 42–47 mmol/mol (6.0–6.4%). This range signifies elevated blood glucose not yet reaching the diagnostic threshold for diabetes (≥48 mmol/mol [6.5%]), but higher than normal. Recognising prediabetes is crucial because these individuals are at significantly increased risk of developing type 2 diabetes and cardiovascular disease. Early intervention with lifestyle modification can prevent or delay progression to overt diabetes. Lower HbA1c values are considered normal, while values above 48 mmol/mol are diagnostic for diabetes.\n\n**Key Points**\n- Prediabetes: HbA1c 42–47 mmol/mol (6.0–6.4%)\n- Normal HbA1c: <42 mmol/mol (<6.0%)\n- Diabetes: HbA1c ≥48 mmol/mol (≥6.5%)\n- Prediabetes signals increased risk for type 2 diabetes and cardiovascular events\n- Intervention at prediabetes stage can reduce future disease burden\n- <table><thead><tr><th>Category</th><th>HbA1c (mmol/mol)</th><th>HbA1c (%)</th></tr></thead><tbody><tr><td>Normal</td><td>&lt;42</td><td>&lt;6.0</td></tr><tr><td>Prediabetes</td><td>42–47</td><td>6.0–6.4</td></tr><tr><td>Diabetes</td><td>&ge;48</td><td>&ge;6.5</td></tr></tbody></table>\n\n**Clinical Relevance**\nCorrectly identifying prediabetes using HbA1c enables timely lifestyle interventions, reducing the likelihood of progression to type 2 diabetes and its complications. Current UK guidance supports use of these thresholds for screening and risk stratification.\n\n**Memory Anchor**\nRemember: **42–47 mmol/mol (6.0–6.4%)** = 'pre-diabetes zone' (think '4' for 'forewarning' of diabetes).",
    "bullet_explanations": {
      "37–41 mmol/mol (5.5–5.9%)": "This is a high-normal HbA1c but does not meet the threshold for prediabetes.",
      "42–47 mmol/mol (6.0–6.4%)": "This range defines prediabetes per UK guidelines.",
      "48–52 mmol/mol (6.5–6.9%)": "These values meet criteria for diabetes, not prediabetes.",
      "53–58 mmol/mol (7.0–7.5%)": "This range is well above the diagnostic threshold for diabetes.",
      "31–36 mmol/mol (5.0–5.4%)": "These values are within the normal, healthy HbA1c range."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "HbA1c targets individualisation",
    "keywords": [
      "prediabetes",
      "HbA1c",
      "diabetes diagnosis",
      "screening",
      "type 2 diabetes risk"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diabetes - type 2",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/diabetes-type-2/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0ff58ced-916c-409b-8b44-e987f064bf2f",
    "question_number": 251,
    "question": "Which congenital heart defect is most frequently associated with infants who have Down's syndrome?",
    "options": [
      "Atrioventricular septal defect",
      "Pulmonary stenosis",
      "Transposition of the great arteries",
      "Coarctation of the aorta",
      "Isolated atrial septal defect"
    ],
    "correct_answer": "Atrioventricular septal defect",
    "explanation": "**Explanation**\n**Atrioventricular septal defect (AVSD)** is the cardiac lesion most commonly identified in infants with Down's syndrome. The characteristic cardiac anomaly involves a deficiency of the atrioventricular septum, resulting in a spectrum of defects involving both atrial and ventricular septa and the atrioventricular valves. **Approximately 40% of children with Down's syndrome have congenital heart disease, with AVSD being the most prevalent.** In comparison, other congenital defects (such as isolated ASD or VSD) are less common. AVSD leads to significant left-to-right shunting, causing symptoms such as tachypnoea, poor feeding, and failure to thrive within the first few weeks of life, which differentiates it from milder lesions.\n\n**Key Points**\n- AVSD is the most frequent cardiac abnormality in Down's syndrome.\n- Symptoms typically arise early: breathlessness, feeding difficulties, poor weight gain.\n- AVSD features defects at both the atrial and ventricular septum and involves the AV valves.\n- Other cardiac lesions (VSD, ASD, PDA, TOF) also occur but are less common.\n- Early echocardiographic diagnosis is essential for appropriate management.\n- Uncorrected AVSD can lead to heart failure and pulmonary hypertension.\n\n**Clinical Relevance**\nRecognising the cardiac associations of genetic syndromes, especially Down's syndrome, is crucial for early diagnosis and intervention. Early detection of AVSD in infants enables timely referral for paediatric cardiology assessment, preventing complications such as heart failure and pulmonary vascular disease.\n\n**Memory Anchor**\nAVSD: 'Atrioventricular' for 'All-in-one' defect—both atria and ventricles involved, commonly in trisomy 21.",
    "bullet_explanations": {
      "Atrioventricular septal defect": "Correct – This is the commonest congenital cardiac defect found in Down's syndrome.",
      "Pulmonary stenosis": "Incorrect – Rarely associated with Down's syndrome; more linked to other syndromes (e.g., Noonan).",
      "Transposition of the great arteries": "Incorrect – A severe cyanotic lesion, not particularly associated with trisomy 21.",
      "Coarctation of the aorta": "Incorrect – More common in Turner's syndrome than Down's syndrome.",
      "Isolated atrial septal defect": "Incorrect – Can occur in Down's but is less frequent than AVSD."
    },
    "category": "Cardiovascular",
    "subsection": "Valvular & Structural",
    "subsubsection": "Congenital Heart Disease",
    "topic": "Down's syndrome cardiac associations",
    "keywords": [
      "Down's syndrome",
      "AVSD",
      "congenital heart defect",
      "paediatrics",
      "trisomy 21"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "198042a6-25d1-46eb-b478-47a80453fd5c",
    "question_number": 252,
    "question": "A 52-year-old man is assessed for persistent hypertension and mild muscle weakness. Laboratory tests reveal an elevated aldosterone-to-renin ratio. Cross-sectional imaging demonstrates bilateral adrenal enlargement. Which is the most appropriate initial pharmacological treatment for his condition?",
    "options": [
      "Spironolactone",
      "Adrenalectomy",
      "Amlodipine",
      "Dopamine agonist",
      "Perindopril"
    ],
    "correct_answer": "Spironolactone",
    "explanation": "**Explanation**\n**Spironolactone is the first-line treatment for primary hyperaldosteronism due to bilateral adrenal hyperplasia.** The condition is characterised by excessive aldosterone production, resulting in hypertension and hypokalaemia (which may cause muscle weakness). Bilateral adrenal hyperplasia is the most common cause of primary hyperaldosteronism. Surgical intervention is generally reserved for unilateral disease (adrenal adenoma), not bilateral cases. Spironolactone, a mineralocorticoid receptor antagonist, directly counteracts the effects of excess aldosterone, normalising blood pressure and potassium levels.\n\n**Key Points**\n- Primary hyperaldosteronism often presents with resistant hypertension and unexplained hypokalaemia.\n- Bilateral adrenal hyperplasia is the leading cause of primary hyperaldosteronism.\n- Spironolactone (or eplerenone) antagonises aldosterone at the receptor, correcting both hypertension and hypokalaemia.\n- Surgical removal (adrenalectomy) is reserved for unilateral adrenal adenomas.\n- Other antihypertensive agents do not address the underlying aldosterone excess.\n- <table><thead><tr><th>Cause</th><th>First-line Treatment</th></tr></thead><tbody><tr><td>Bilateral adrenal hyperplasia</td><td>Spironolactone</td></tr><tr><td>Adrenal adenoma</td><td>Surgery</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurate identification of the underlying cause of primary hyperaldosteronism is essential, as it determines management. Bilateral adrenal hyperplasia should be treated medically, while surgery is only indicated for unilateral lesions. Recognising the appropriate therapy improves blood pressure control and reduces morbidity.\n\n**Memory Anchor**\nRemember: 'Spironolactone for Symmetrical (bilateral) disease; Surgery for Single (unilateral) adenoma.'",
    "bullet_explanations": {
      "Spironolactone": "Correct—first-line therapy for bilateral adrenal hyperplasia causing primary hyperaldosteronism.",
      "Adrenalectomy": "Incorrect—indicated for unilateral adrenal adenoma, not bilateral disease.",
      "Amlodipine": "Incorrect—treats hypertension but does not address aldosterone excess.",
      "Dopamine agonist": "Incorrect—used for prolactinomas, not hyperaldosteronism.",
      "Perindopril": "Incorrect—ACE inhibitor treats hypertension, but not the underlying cause here."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Adrenal",
    "subsubsection": "Primary Aldosteronism",
    "topic": "Medical vs surgical treatment",
    "keywords": [
      "primary hyperaldosteronism",
      "bilateral adrenal hyperplasia",
      "spironolactone",
      "hypertension",
      "aldosterone antagonist"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "2fd00952-175b-4bdf-a0a1-df8b564467f9",
    "question_number": 253,
    "question": "A 26-year-old man attends neurology clinic with episodic numbness in his right arm and blurred vision in his right eye over the past three months. Examination reveals a right afferent pupillary defect and increased reflexes in his left leg. What is the most appropriate imaging modality to confirm a diagnosis of multiple sclerosis?",
    "options": [
      "MRI head with gadolinium contrast",
      "CT head without contrast",
      "Serum oligoclonal band testing",
      "MRI head without contrast",
      "CT head with contrast"
    ],
    "correct_answer": "MRI head with gadolinium contrast",
    "explanation": "**Explanation**\n**MRI of the head with gadolinium contrast** is the investigation of choice when multiple sclerosis (MS) is suspected. This imaging technique is highly sensitive for detecting demyelinating lesions within the central nervous system. Gadolinium contrast helps identify areas of active inflammation by showing enhancement where the blood-brain barrier is disrupted. This distinction between active and chronic lesions is crucial for meeting diagnostic criteria such as the McDonald criteria, which require evidence of dissemination in time and space. In contrast, CT scans lack the sensitivity to visualise demyelination, and MRI without contrast cannot reliably differentiate active lesions from older ones.\n\n**Key Points**\n<ul><li><b>MRI with gadolinium contrast</b> detects both old and new demyelinating lesions in MS.</li><li>Active lesions enhance with contrast, indicating current inflammation.</li><li>Dissemination in time and space must be demonstrated for MS diagnosis.</li><li>CT scans are not sensitive enough for early demyelination.</li><li>Serum oligoclonal bands are supportive but not diagnostic without imaging.</li></ul>\n\n**Clinical Relevance**\nMS is a leading cause of non-traumatic neurological disability in young adults, and early and accurate diagnosis is essential to guide management and initiate disease-modifying therapies. MRI with contrast is recommended in guidelines for confirming the diagnosis.\n\n**Memory Anchor**\nThink 'MS = MRI with gado' to remember the preferred test for demyelinating lesions.",
    "bullet_explanations": {
      "MRI head with gadolinium contrast": "Correct – best detects active demyelination and is recommended for MS diagnosis.",
      "CT head without contrast": "Incorrect – lacks sensitivity for demyelinating plaques and is not recommended for MS.",
      "Serum oligoclonal band testing": "Incorrect – can support the diagnosis but should not be used in isolation without imaging.",
      "MRI head without contrast": "Incorrect – can show lesions but cannot distinguish new from old without contrast.",
      "CT head with contrast": "Incorrect – better than non-contrast CT, but still much less sensitive than MRI for MS lesions."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Epilepsy",
    "topic": "Focal vs generalised",
    "keywords": [
      "multiple sclerosis",
      "MRI contrast",
      "demyelination",
      "diagnosis",
      "neurology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Multiple sclerosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/multiple-sclerosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e24edadc-d191-4b00-86b1-c22c2e5532aa",
    "question_number": 254,
    "question": "In adults with hyperuricaemia and sudden onset of severe pain, redness, and swelling in the foot, which joint is most commonly affected during a first acute gout attack?",
    "options": [
      "First metatarsophalangeal joint",
      "Tibiotalar (ankle) joint",
      "Fifth metatarsophalangeal joint",
      "Subtalar joint",
      "Interphalangeal joint of the hallux"
    ],
    "correct_answer": "First metatarsophalangeal joint",
    "explanation": "**Explanation**\n**Gout typically first presents with acute inflammation of the first metatarsophalangeal (MTP) joint, also known as the big toe joint.** This location is classically described as 'podagra.' Deposition of monosodium urate crystals in this distal joint leads to rapid onset of pain, erythema, warmth, and swelling. The first MTP joint is particularly prone to urate crystal precipitation due to its relatively lower temperature and mechanical stress. While gout can affect other joints (e.g., ankles, knees, fingers), the first MTP joint is the most common initial site, making this a key diagnostic clue. **Contrast with other foot joints:** the ankle and midfoot can be involved in later or recurrent flares, but are much less typical for a first presentation.\n\n**Key Points**\n<ul><li>The first MTP joint is the classic and most frequent initial site of acute gout.</li><li>Gout presents with rapid onset, severe pain, swelling, and redness.</li><li>Risk factors include chronic kidney disease, diuretic use, obesity, and excess alcohol.</li><li>Diagnosis is clinical but supported by serum urate >360 micromol/L, if measured during or after the attack.</li><li>Other foot joints may be affected in recurrent or chronic gout, but are less common initially.</li></ul><table><thead><tr><th>Joint</th><th>Likelihood in Initial Gout Flare</th></tr></thead><tbody><tr><td>First MTP</td><td>Most common</td></tr><tr><td>Ankle</td><td>Less common</td></tr><tr><td>Other toes</td><td>Rare</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the predilection of gout for the first MTP joint helps prompt accurate diagnosis and management, particularly in patients with risk factors such as CKD. Early identification allows for timely therapy and prevention of complications such as chronic joint damage.\n\n**Memory Anchor**\nThink 'podagra' = 'big toe pain' for gout's classic site.",
    "bullet_explanations": {
      "First metatarsophalangeal joint": "Correct – the first MTP joint is the hallmark location for initial acute gout attacks.",
      "Tibiotalar (ankle) joint": "Incorrect – the ankle may be involved in some flares, but is not the most common initial site.",
      "Fifth metatarsophalangeal joint": "Incorrect – involvement is rare and not typical for gout onset.",
      "Subtalar joint": "Incorrect – subtalar gout is uncommon and usually occurs in advanced or polyarticular disease.",
      "Interphalangeal joint of the hallux": "Incorrect – while the big toe is affected, it is specifically the MTP joint, not the interphalangeal joint, that is classic."
    },
    "category": "Renal & Urology",
    "subsection": "Chronic Kidney Disease",
    "subsubsection": "Complications",
    "topic": "Mineral bone disease",
    "keywords": [
      "gout",
      "first metatarsophalangeal joint",
      "podagra",
      "CKD complications",
      "acute arthritis"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Gout",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/gout/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2bca70dc-b1ae-4782-8fbf-38afe9e6c35f",
    "question_number": 255,
    "question": "A 33-year-old woman is admitted for induction of labour at 40+10 weeks due to prolonged pregnancy. Her cervix is posterior, firm, 1 cm dilated, and 20% effaced. She has had a membrane sweep earlier today with no effect. What is the recommended first-line intervention for inducing labour in this scenario?",
    "options": [
      "Vaginal prostaglandin E2 administration",
      "Immediate oxytocin infusion",
      "Cervical ripening balloon insertion",
      "Artificial rupture of membranes (amniotomy)",
      "Emergency caesarean section"
    ],
    "correct_answer": "Vaginal prostaglandin E2 administration",
    "explanation": "**Explanation**\n**Vaginal prostaglandin E2 (PGE2)** is the preferred initial method for induction of labour when the cervix is unfavourable (low Bishop score <6). PGE2 helps to soften and dilate the cervix, increasing the likelihood of successful vaginal delivery. Mechanical methods (such as a balloon catheter) can be considered if prostaglandins are unsuitable, but pharmacological ripening is generally first-line. Oxytocin infusion and amniotomy are reserved for when the cervix is favourable (ripe), or after prostaglandin administration has failed. Caesarean section is not indicated unless induction attempts are unsuccessful or there is fetal/maternal compromise.<br><br><b>Key facts:</b> Prostaglandins can cause uterine hyperstimulation, so monitoring is required. NICE guidelines recommend PGE2 as the standard for women with an unripe cervix.\n\n**Key Points**\n- A Bishop score <6 indicates an unripe cervix—prostaglandin is preferred.\n- Vaginal PGE2 (dinoprostone) is the standard pharmacological method for cervical ripening.\n- Oxytocin and amniotomy are used when the cervix is favourable or after ripening.\n- Mechanical methods (balloon) are alternatives if prostaglandins are contraindicated.\n- Emergency caesarean is reserved for failed induction or complications.\n- Monitor for uterine hyperstimulation with prostaglandins.\n\n**Clinical Relevance**\nSelecting the correct method for labour induction reduces maternal and neonatal morbidity. NICE recommends vaginal PGE2 as the initial choice for women with an unfavourable cervix, reflecting best practice for safe and effective induction.\n\n**Memory Anchor**\nRemember: PGE2 for a Poor Bishop score (both start with P).",
    "bullet_explanations": {
      "Vaginal prostaglandin E2 administration": "Correct – First-line for cervical ripening when the cervix is unfavourable.",
      "Immediate oxytocin infusion": "Incorrect – Oxytocin is not used until after cervical ripening or if the cervix is already favourable.",
      "Cervical ripening balloon insertion": "Incorrect – Mechanical methods are considered if prostaglandins are contraindicated or unavailable.",
      "Artificial rupture of membranes (amniotomy)": "Incorrect – Amniotomy alone is not suitable for an unripe cervix.",
      "Emergency caesarean section": "Incorrect – Not indicated unless there is failed induction or urgent maternal/fetal compromise."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Late",
    "subsubsection": "Labour & Delivery",
    "topic": "Induction methods",
    "keywords": [
      "induction of labour",
      "prostaglandin",
      "bishop score",
      "cervical ripening"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Obstetrics",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/obstetrics/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "185a2a1b-b07d-4d55-b4cf-42fd886eb168",
    "question_number": 256,
    "question": "A 42-year-old woman with a history of aspirin-induced anaphylaxis is admitted with an acute severe flare of ulcerative colitis. Which medication should be strictly avoided due to her allergy risk?",
    "options": [
      "Sulfasalazine",
      "Adalimumab",
      "Budesonide",
      "Infliximab",
      "Prednisolone"
    ],
    "correct_answer": "Sulfasalazine",
    "explanation": "**Explanation**\n**Sulfasalazine** is a 5-aminosalicylic acid (5-ASA) compound used in ulcerative colitis management. Its molecular structure is similar to that of aspirin (acetylsalicylic acid), and individuals with a history of aspirin hypersensitivity—especially anaphylaxis—are at increased risk of potentially severe cross-reactivity with sulfasalazine. Therefore, sulfasalazine is contraindicated in such patients, and alternative therapies should be used. Other 5-ASA drugs, such as mesalazine, may also pose a risk and should be avoided if the allergy is severe. In contrast, corticosteroids and biologic agents like adalimumab and infliximab do not carry this specific risk and are appropriate alternatives in acute severe flares.\n\n**Key Points**\n- Sulfasalazine is structurally related to aspirin; both are salicylate derivatives.\n- Aspirin allergy (especially anaphylaxis) is a contraindication to sulfasalazine.\n- 5-ASA drugs can cause hypersensitivity reactions in aspirin-allergic patients.\n- Steroids and biologics (e.g., adalimumab, infliximab) are not structurally related to aspirin.\n- Severe UC flares are medical emergencies—aminosalicylates should be avoided if contraindicated.\n- <table><thead><tr><th>Drug</th><th>Aspirin Cross-reactivity?</th></tr></thead><tbody><tr><td>Sulfasalazine</td><td>Yes</td></tr><tr><td>Adalimumab</td><td>No</td></tr><tr><td>Infliximab</td><td>No</td></tr><tr><td>Budesonide</td><td>No</td></tr><tr><td>Prednisolone</td><td>No</td></tr></tbody></table>\n\n**Clinical Relevance**\nIt is essential to recognise the cross-reactivity between aminosalicylates and aspirin to prevent life-threatening allergic reactions in patients with known hypersensitivity. National guidelines recommend avoiding sulfasalazine and similar drugs in aspirin-allergic individuals, especially in the acute management of ulcerative colitis, and to use corticosteroids or biologics instead.\n\n**Memory Anchor**\nRemember: 'Salicylate' in sulfasalazine signals caution in 'salicylate' (aspirin) allergy.",
    "bullet_explanations": {
      "Sulfasalazine": "Correct – Contraindicated due to high risk of cross-reactivity in aspirin-allergic patients.",
      "Adalimumab": "Not correct – No known cross-reactivity with aspirin; biologic anti-TNF agent.",
      "Budesonide": "Not correct – A corticosteroid without structural similarity to aspirin.",
      "Infliximab": "Not correct – Biologic therapy unrelated to salicylates.",
      "Prednisolone": "Not correct – A systemic corticosteroid, safe in aspirin allergy."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBD",
    "topic": "UC vs Crohn’s key differences",
    "keywords": [
      "ulcerative colitis",
      "aspirin allergy",
      "sulfasalazine",
      "aminosalicylate",
      "contraindication"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Ulcerative colitis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/ulcerative-colitis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "90b8964c-f8d2-4a1b-be76-e4d68de89578",
    "question_number": 257,
    "question": "A 68-year-old man experiences sudden right-sided weakness affecting his face, arm, and leg, accompanied by a right homonymous hemianopia. He is able to speak without difficulty, and there is no evidence of cognitive impairment or neglect. Based on the Oxford (Bamford) classification, how should this stroke be best described?",
    "options": [
      "Left-sided partial anterior circulation syndrome",
      "Right-sided partial anterior circulation syndrome",
      "Lacunar stroke",
      "Right-sided total anterior circulation syndrome",
      "Posterior circulation syndrome"
    ],
    "correct_answer": "Right-sided partial anterior circulation syndrome",
    "explanation": "**Explanation**\n**Partial anterior circulation syndrome (PACS)** is characterised by the presence of two out of three features: unilateral weakness (face, arm, leg), homonymous hemianopia, or higher cortical dysfunction (such as dysphasia or neglect). In this case, the patient demonstrates weakness and a homonymous hemianopia, but does not have higher cortical dysfunction. This distinguishes PACS from a total anterior circulation syndrome (TACS), which requires all three features. **Lacunar strokes** typically do not cause visual field deficits, and **posterior circulation syndromes** present with brainstem or cerebellar features, not the pattern described here.\n\n**Key Points**\n- Oxford (Bamford) classification helps categorise ischaemic strokes based on clinical features.\n- PACS: 2 of 3 criteria met (hemiparesis, homonymous hemianopia, higher cortical dysfunction).\n- TACS: All 3 criteria must be present.\n- Lacunar strokes lack visual field loss or higher dysfunction.\n- Posterior circulation strokes involve brainstem/cerebellar signs, not hemianopia + hemiparesis alone.\n\n**Clinical Relevance**\nAccurate stroke classification supports appropriate diagnosis, prognosis, and early management. The Oxford classification is widely used in UK clinical practice, as recommended by national guidelines, to guide rapid assessment and referral for specialist stroke care.\n\n**Memory Anchor**\nThink 'PACS = Partial = 2 out of 3' (hemiparesis, hemianopia, higher function).",
    "bullet_explanations": {
      "Left-sided partial anterior circulation syndrome": "Incorrect: The patient's symptoms are right-sided, not left.",
      "Right-sided partial anterior circulation syndrome": "Correct: Two criteria (weakness and hemianopia) are met without higher dysfunction, fitting PACS.",
      "Lacunar stroke": "Incorrect: Lacunar strokes typically do not cause homonymous hemianopia or cortical signs.",
      "Right-sided total anterior circulation syndrome": "Incorrect: TACS requires all three features; higher function is spared here.",
      "Posterior circulation syndrome": "Incorrect: Posterior circulation strokes present with brainstem or cerebellar findings, not this pattern."
    },
    "category": "Neurology",
    "subsection": "Stroke & TIA",
    "subsubsection": "FAST/TIA recognition",
    "topic": "Oxford stroke classification",
    "keywords": [
      "stroke classification",
      "PACS",
      "Bamford",
      "clinical features",
      "stroke types"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Stroke and TIA",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/stroke-tia/"
      },
      {
        "source": "BNF",
        "topic_title": "Stroke",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/stroke/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d4736bf7-cce6-4ae7-97e6-1628de7f8f63",
    "question_number": 258,
    "question": "Which gene mutation is responsible for the development of cystic fibrosis?",
    "options": [
      "Mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene",
      "Trisomy of chromosome 21",
      "Defect in the dystrophin gene",
      "Mutation in the HBB gene",
      "X-linked recessive inheritance pattern"
    ],
    "correct_answer": "Mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene",
    "explanation": "**Explanation**\nCystic fibrosis is caused by mutations in the **CFTR gene**, which encodes a chloride channel involved in the regulation of salt and water transport across cell membranes. Defects in this channel result in thick, sticky secretions that primarily affect the lungs and pancreas. CF is inherited in an **autosomal recessive pattern**, not X-linked. The most common mutation in the UK is delta F508 on chromosome 7. Other options describe unrelated genetic mechanisms or incorrect inheritance patterns.\n\n**Key Points**\n- Cystic fibrosis is an autosomal recessive disorder.\n- It is caused by mutations in the CFTR gene, located on chromosome 7.\n- The delta F508 mutation is the most common variant in the UK.\n- CFTR encodes a cAMP-regulated chloride channel.\n- Cystic fibrosis is not associated with trisomy 21 or X-linked inheritance.\n\n**Clinical Relevance**\nUnderstanding the genetic basis of cystic fibrosis is vital for genetic counselling, carrier screening, and early diagnosis. Knowledge of the CFTR mutation informs both prognosis and emerging targeted therapies.\n\n**Memory Anchor**\nCF = 'Chloride Fault' due to CFTR gene mutation",
    "bullet_explanations": {
      "Mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene": "Correct – CF results from mutations in the CFTR gene.",
      "Trisomy of chromosome 21": "Incorrect – This causes Down syndrome, not cystic fibrosis.",
      "Defect in the dystrophin gene": "Incorrect – Dystrophin mutations lead to Duchenne muscular dystrophy.",
      "Mutation in the HBB gene": "Incorrect – HBB mutations cause beta thalassaemia and sickle cell disease.",
      "X-linked recessive inheritance pattern": "Incorrect – CF is inherited in an autosomal recessive, not X-linked, manner."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Genetics",
    "subsubsection": "Common Syndromes",
    "topic": "Cystic fibrosis features",
    "keywords": [
      "cystic fibrosis",
      "CFTR",
      "genetics",
      "autosomal recessive",
      "mutation"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "ed0105c9-b9a8-49d8-b1fc-e949fbb4dccc",
    "question_number": 259,
    "question": "Which of the following clinical features is most characteristic of axial spondyloarthritis (ankylosing spondylitis) rather than mechanical back pain?",
    "options": [
      "Back pain that disturbs sleep during the night",
      "Back pain with sudden onset after lifting heavy objects",
      "Pain aggravated by physical activity",
      "Marked vertebral bone tenderness on palpation",
      "Back pain relieved with prolonged rest"
    ],
    "correct_answer": "Back pain that disturbs sleep during the night",
    "explanation": "**Explanation**\n**Axial spondyloarthritis, including ankylosing spondylitis, typically presents with inflammatory back pain**, which has distinct features compared to mechanical back pain. Nocturnal pain—especially pain that wakes a patient during the second half of the night—is strongly suggestive of an inflammatory process. This pain often worsens during rest and improves with movement or exercise, reflecting the underlying inflammatory nature of the disease. Mechanical back pain, in contrast, tends to improve with rest and worsen after activity. Other features supporting inflammatory back pain include morning stiffness lasting more than 30 minutes and gradual onset before age 45. Bone tenderness is not a hallmark, and sudden onset suggests acute injury rather than chronic inflammation.\n\n**Key Points**\n<ul><li><b>Inflammatory back pain:</b> Wakes patients at night, worse at rest, improves with exercise</li><li><b>Mechanical back pain:</b> Worsens with activity, improves with rest</li><li>Nocturnal pain is a key diagnostic clue for axial spondyloarthritis</li><li>Axial spondyloarthritis typically has slow, insidious onset</li><li>Marked bone tenderness suggests alternative diagnoses (e.g. malignancy, infection)</li></ul>\n\n**Clinical Relevance**\nRecognising the classical pattern of inflammatory back pain—particularly nocturnal pain and improvement with exercise—is vital for early suspicion and referral for axial spondyloarthritis. Early diagnosis and specialist input can prevent irreversible spinal damage and improve long-term patient outcomes, in line with NICE guidance.",
    "bullet_explanations": {
      "Back pain that disturbs sleep during the night": "Correct – Nocturnal pain is a hallmark of inflammatory back pain seen in ankylosing spondylitis.",
      "Back pain with sudden onset after lifting heavy objects": "Incorrect – Suggests mechanical back pain, such as muscle strain or disc injury.",
      "Pain aggravated by physical activity": "Incorrect – Inflammatory back pain typically improves with movement; worsening with activity points to mechanical causes.",
      "Marked vertebral bone tenderness on palpation": "Incorrect – Diffuse bone tenderness is not typical of axial spondyloarthritis and may indicate infection, malignancy, or fracture.",
      "Back pain relieved with prolonged rest": "Incorrect – Axial spondyloarthritis pain worsens, not improves, with rest."
    },
    "category": "Musculoskeletal",
    "subsection": "Arthritis",
    "subsubsection": "Spondyloarthropathy",
    "topic": "AS presentation and imaging",
    "keywords": [
      "ankylosing spondylitis",
      "inflammatory back pain",
      "nocturnal pain",
      "spondyloarthritis"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Axial spondyloarthritis (including ankylosing spondylitis)",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/axial-spondyloarthritis-including-ankylosing-spondylitis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Spondyloarthritis and psoriatic arthropathy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/spondyloarthritis-psoriatic-arthropathy/"
      },
      {
        "source": "BNF",
        "topic_title": "Spondyloarthritis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/spondyloarthritis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d0251a7a-10e5-4692-833b-c40433af730a",
    "question_number": 260,
    "question": "Which combination of medications should be routinely prescribed for a 65-year-old woman four weeks after an uncomplicated STEMI managed medically with fibrinolysis?",
    "options": [
      "ACE inhibitor, beta-blocker, high-intensity statin, aspirin, and clopidogrel",
      "Beta-blocker, statin, aspirin, and prasugrel",
      "Statin, aspirin, rivaroxaban, and ACE inhibitor",
      "Spironolactone, beta-blocker, statin, and aspirin",
      "Aspirin, clopidogrel, and verapamil"
    ],
    "correct_answer": "ACE inhibitor, beta-blocker, high-intensity statin, aspirin, and clopidogrel",
    "explanation": "**Explanation**\n**Secondary prevention after STEMI** requires a comprehensive regimen to reduce the risk of recurrent cardiovascular events. The core elements include an ACE inhibitor, a beta-blocker, a high-intensity statin, and dual antiplatelet therapy (aspirin plus clopidogrel) for up to 12 months post-event. ACE inhibitors and beta-blockers provide mortality and morbidity benefits, especially in those with left ventricular dysfunction, but are also recommended broadly unless contraindicated. Statins reduce future atherosclerotic risk, and dual antiplatelet therapy lowers the chance of stent thrombosis and recurrent MI. Prasugrel and ticagrelor are preferred in some PCI cases, but clopidogrel is standard after fibrinolysis. Spironolactone is reserved for patients with heart failure or significant LV dysfunction. Other options such as rivaroxaban or verapamil are not routine in this context.\n\n**Key Points**\n- Secondary prevention after STEMI includes: ACE inhibitor, beta-blocker, high-intensity statin, aspirin, and a second antiplatelet (usually clopidogrel).\n- Dual antiplatelet therapy (aspirin + clopidogrel) is continued for 12 months unless contraindicated.\n- Statin therapy should be high-intensity for optimal lipid lowering.\n- ACE inhibitors are continued indefinitely, unless not tolerated.\n- Spironolactone is only added for significant heart failure or LV dysfunction.\n- Prasugrel/ticagrelor are alternatives for PCI, not standard post-fibrinolysis.\n- <table><thead><tr><th>Drug Class</th><th>Indication in STEMI Secondary Prevention</th></tr></thead><tbody><tr><td>ACE inhibitor</td><td>Yes (unless contraindicated)</td></tr><tr><td>Beta-blocker</td><td>Yes</td></tr><tr><td>Statin</td><td>Yes (high-intensity)</td></tr><tr><td>Aspirin</td><td>Yes (indefinitely)</td></tr><tr><td>Clopidogrel</td><td>Yes (up to 12 months post-MI)</td></tr></tbody></table>\n\n**Clinical Relevance**\nOptimising secondary prevention after MI is essential to reduce recurrent cardiovascular events and death. Prescribers should ensure all eligible patients receive the full recommended regimen, with regular review for contraindications and side effects, as outlined in national guidelines.\n\n**Memory Anchor**\nThink 'A-B-S-A-C': ACE inhibitor, Beta-blocker, Statin, Aspirin, Clopidogrel.",
    "bullet_explanations": {
      "ACE inhibitor, beta-blocker, high-intensity statin, aspirin, and clopidogrel": "This represents the gold-standard secondary prevention regimen for most patients post-MI without contraindications.",
      "Beta-blocker, statin, aspirin, and prasugrel": "Prasugrel is not routinely used after fibrinolysis; dual therapy with clopidogrel is standard in this setting.",
      "Statin, aspirin, rivaroxaban, and ACE inhibitor": "Rivaroxaban is not part of routine secondary prevention after STEMI managed medically; dual antiplatelet therapy is required.",
      "Spironolactone, beta-blocker, statin, and aspirin": "Spironolactone is reserved for patients with heart failure or significant LV impairment, not all post-MI patients.",
      "Aspirin, clopidogrel, and verapamil": "Verapamil is used only if beta-blockers are contraindicated; ACE inhibitor and statin are missing."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Secondary Prevention Post-MI",
    "topic": "High-intensity statin and lipid targets",
    "keywords": [
      "secondary prevention",
      "STEMI",
      "dual antiplatelet",
      "statin",
      "ACE inhibitor"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Acute coronary syndromes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/acute-coronary-syndromes/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "MI - secondary prevention",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/mi-secondary-prevention/"
      },
      {
        "source": "BNF",
        "topic_title": "Antiplatelet drugs",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antiplatelet-drugs/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "075a46e7-2b10-4a99-9458-89e7a04bf77d",
    "question_number": 261,
    "question": "A 65-year-old woman with metastatic brain metastases is under hospice care. She reports persistent nausea despite adequate analgesia for headache. Which anti-emetic is recommended first-line for nausea due to raised intracranial pressure in palliative care?",
    "options": [
      "Cyclizine",
      "Domperidone",
      "Metoclopramide",
      "Ondansetron",
      "Dexamethasone"
    ],
    "correct_answer": "Cyclizine",
    "explanation": "**Explanation**\n**Cyclizine** is the preferred first-line anti-emetic for nausea and vomiting caused by raised intracranial pressure or other intracranial processes. Its anticholinergic and antihistaminic actions are effective for centrally mediated symptoms, such as those arising from brain tumours or metastases. In contrast, agents like metoclopramide and domperidone are mainly prokinetic and target gastrointestinal motility, making them less suitable for nausea of intracranial origin. While corticosteroids (typically dexamethasone) may be added if there is significant cerebral oedema, cyclizine remains the initial choice for symptom control in this context. Other anti-emetics, such as ondansetron, are mainly indicated for chemotherapy-induced nausea and do not address the central mechanisms involved here.\n\n**Key Points**\n- Cyclizine acts centrally and is first-line for nausea due to raised intracranial pressure.\n- Metoclopramide and domperidone are prokinetic, best for GI-related nausea.\n- Steroids (dexamethasone) can be adjuncts for suspected cerebral oedema, but not first-line for nausea.\n- Ondansetron is primarily for chemotherapy/radiotherapy-induced nausea.\n- Choice of anti-emetic should be guided by the underlying cause of symptoms.\n\n**Clinical Relevance**\nRecognising the underlying mechanism of nausea is critical in palliative and end-of-life care. Selecting an agent effective for the specific cause (e.g. central vs gastrointestinal) optimises symptom relief and patient comfort, in line with best-practice palliative guidelines.\n\n**Memory Anchor**\nCyclizine is 'central' for 'central' (intracranial) causes.",
    "bullet_explanations": {
      "Cyclizine": "Correct: First-line for nausea due to raised intracranial pressure or intracranial tumours.",
      "Domperidone": "Incorrect: Best for nausea due to delayed gastric emptying or GI causes.",
      "Metoclopramide": "Incorrect: Main role is for GI-related or chemotherapy-induced nausea; not effective for intracranial pressure.",
      "Ondansetron": "Incorrect: Used for chemotherapy/radiotherapy-induced nausea, not for raised intracranial pressure.",
      "Dexamethasone": "Incorrect: May be added for management of cerebral oedema, but not the first-line anti-emetic."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Headache",
    "topic": "Red flag headache",
    "keywords": [
      "palliative care",
      "anti-emetic",
      "cyclizine",
      "intracranial pressure",
      "nausea"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "908feafc-3f50-4b60-9ae8-48c1bc924499",
    "question_number": 262,
    "question": "A 30-year-old man develops sudden visual disturbance following a minor head injury. He is found to have a right inferior homonymous quadrantanopia on formal visual field testing. Which brain region is most likely affected?",
    "options": [
      "Left parietal lobe",
      "Right temporal lobe",
      "Right parietal lobe",
      "Left optic tract",
      "Right occipital pole"
    ],
    "correct_answer": "Left parietal lobe",
    "explanation": "**Explanation**\n**A right inferior homonymous quadrantanopia results from damage to the contralateral (left) parietal lobe, specifically affecting the superior optic radiations.** These fibres carry information from the inferior visual quadrants of the contralateral field. Thus, a lesion in the left parietal lobe disrupts the superior optic radiations responsible for the right lower visual field, causing the observed deficit. This localisation is distinct from temporal lobe (Meyer's loop) lesions, which cause superior (upper) quadrantanopias.\n\n**Key Points**\n- Homonymous quadrantanopias are localising signs in neuro-ophthalmology.\n- Superior optic radiations (parietal lobe) carry inferior visual field information.\n- Temporal lobe (Meyer's loop) lesions cause superior quadrantanopias ('pie in the sky').\n- Parietal lobe lesions result in inferior quadrantanopias ('pie on the floor').\n- Visual field defects are always described from the patient's perspective.\n- <table><thead><tr><th>Lesion Location</th><th>Visual Field Defect</th></tr></thead><tbody><tr><td>Parietal lobe</td><td>Contralateral inferior homonymous quadrantanopia</td></tr><tr><td>Temporal lobe</td><td>Contralateral superior homonymous quadrantanopia</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurate localisation of visual field defects can help rapidly identify underlying brain lesions, facilitating appropriate imaging and management, especially after trauma or in stroke presentations.\n\n**Memory Anchor**\n\"PITS\": Parietal-Inferior, Temporal-Superior for quadrantanopias.",
    "bullet_explanations": {
      "Left parietal lobe": "Correct – superior optic radiations disrupted here cause contralateral inferior quadrantanopia.",
      "Right temporal lobe": "Incorrect – would cause a left superior homonymous quadrantanopia due to involvement of Meyer's loop.",
      "Right parietal lobe": "Incorrect – would cause a left inferior homonymous quadrantanopia, not right-sided.",
      "Left optic tract": "Incorrect – lesions here cause a complete right homonymous hemianopia, not a quadrantanopia.",
      "Right occipital pole": "Incorrect – would cause a left congruous homonymous hemianopia, usually involving central vision."
    },
    "category": "Neurology",
    "subsection": "Stroke & TIA",
    "subsubsection": "FAST/TIA recognition",
    "topic": "Visual field defects",
    "keywords": [
      "quadrantanopia",
      "optic radiations",
      "parietal lobe",
      "visual field deficit",
      "neuroanatomy"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "d600833e-4054-41da-b495-800453f7c88d",
    "question_number": 263,
    "question": "A 34-year-old man presents with reduced libido, erectile dysfunction, and spontaneous galactorrhoea. He has a history of schizophrenia managed with regular medication. Which of the following prescribed drugs is most likely responsible for his elevated prolactin and associated symptoms?",
    "options": [
      "Olanzapine",
      "Cyclizine",
      "Lithium carbonate",
      "Ondansetron",
      "Levothyroxine"
    ],
    "correct_answer": "Olanzapine",
    "explanation": "**Explanation**\n**Dopamine antagonists, including certain antipsychotics such as olanzapine and phenothiazines, are well-established causes of hyperprolactinaemia.** These drugs block dopamine receptors in the tuberoinfundibular pathway, removing dopamine’s inhibitory effect on prolactin secretion from the anterior pituitary. The resulting raised prolactin can lead to symptoms like galactorrhoea, amenorrhoea or erectile dysfunction, and reduced libido. In contrast, medications such as cyclizine (an antihistamine), lithium (a mood stabiliser), ondansetron (an antiemetic), and levothyroxine (thyroid hormone replacement) are not known to elevate prolactin in this way. The development of galactorrhoea and sexual dysfunction in a patient on a dopamine antagonist should prompt consideration of this mechanism.\n\n**Key Points:**\n- Dopamine antagonists (e.g. antipsychotics, phenothiazines) commonly cause hyperprolactinaemia.\n- Symptoms: galactorrhoea, amenorrhoea/infertility (women), erectile dysfunction/reduced libido (men).\n- Mechanism: Blockade of dopamine D2 receptors increases prolactin release from pituitary.\n- Antihistamines (cyclizine), mood stabilisers (lithium), antiemetics (ondansetron), and thyroid hormones (levothyroxine) do not typically raise prolactin.\n- Drug-induced hyperprolactinaemia is a diagnosis of exclusion after ruling out physiological and pathological causes.\n\n<table><thead><tr><th>Drug Class</th><th>Effect on Prolactin</th></tr></thead><tbody><tr><td>Dopamine antagonists (e.g. antipsychotics)</td><td>↑↑</td></tr><tr><td>Antihistamines</td><td>–</td></tr><tr><td>Lithium</td><td>–</td></tr><tr><td>Thyroid hormones</td><td>–</td></tr></tbody></table>\n\n**Clinical Relevance:**\nDrug-induced hyperprolactinaemia is a frequent cause of menstrual and sexual dysfunction presentations in primary and secondary care. Recognising this adverse effect is crucial, as it can be addressed by reviewing the patient’s medication and discussing alternatives to dopamine antagonists where appropriate. This approach is consistent with guidelines and improves quality of life.\n\n**Memory Anchor:**\nRemember \"Dopamine Down = Prolactin Up\": Dopamine antagonists disinhibit prolactin release.",
    "bullet_explanations": {
      "Olanzapine": "Correct – a dopamine antagonist antipsychotic, known to cause hyperprolactinaemia and its symptoms.",
      "Cyclizine": "Incorrect – an antihistamine antiemetic, not associated with raised prolactin.",
      "Lithium carbonate": "Incorrect – mood stabiliser; does not directly elevate prolactin levels.",
      "Ondansetron": "Incorrect – an antiemetic acting on serotonin receptors, not linked to hyperprolactinaemia.",
      "Levothyroxine": "Incorrect – thyroid hormone replacement; can correct, not cause, secondary hyperprolactinaemia."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Calcium, Pituitary & Metabolic",
    "subsubsection": "Pituitary",
    "topic": "Prolactinoma diagnosis and dopamine agonists",
    "keywords": [
      "hyperprolactinaemia",
      "dopamine antagonist",
      "antipsychotic",
      "pituitary",
      "drug-induced"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "eee7805c-4fa6-48cb-b6ba-b5acc6aa1663",
    "question_number": 264,
    "question": "A 68-year-old Black British woman is found to have a persistently elevated home blood pressure average of 150/92 mmHg despite taking ramipril 10 mg once daily and indapamide 2.5 mg once daily. She is otherwise well. According to current UK guidelines, which medication should be added next to optimise her antihypertensive therapy?",
    "options": [
      "Amlodipine",
      "Bisoprolol",
      "Spironolactone",
      "Furosemide",
      "Losartan"
    ],
    "correct_answer": "Amlodipine",
    "explanation": "**Explanation**\n**Amlodipine, a calcium channel blocker, is the recommended third agent for hypertension in patients already prescribed an ACE inhibitor (or ARB) and a thiazide-like diuretic, when blood pressure remains above target.** NICE and BNF guidelines specify that optimal management involves sequentially combining an ACE inhibitor (or ARB), a calcium channel blocker, and a thiazide-like diuretic before considering other drug classes. Spironolactone, alpha-blockers, or beta-blockers are reserved for resistant hypertension not controlled with these three classes. Adding a second renin-angiotensin system blocker (e.g., losartan on top of ramipril) is not advised due to increased risk of adverse effects and no added benefit.\n\n**Key Points**\n- Stepwise hypertension treatment: ACE inhibitor/ARB → add CCB or thiazide-like diuretic → add third agent if needed\n- A calcium channel blocker is the preferred next addition if not already prescribed\n- Spironolactone and alpha/beta blockers are reserved for resistant hypertension after three agents\n- Dual renin-angiotensin system blockade is contraindicated\n- Loop diuretics like furosemide are not standard in hypertension unless there is comorbid heart failure\n- <table><thead><tr><th>Step</th><th>Class</th></tr></thead><tbody><tr><td>1</td><td>ACEi/ARB</td></tr><tr><td>2</td><td>+ CCB or thiazide diuretic</td></tr><tr><td>3</td><td>+ CCB or thiazide diuretic (whichever not yet used)</td></tr><tr><td>4</td><td>Spironolactone/alpha-/beta-blocker (specialist)</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognition of the national hypertension treatment ladder ensures patients receive evidence-based, stepwise therapy, reducing cardiovascular risk. Prescribers must avoid unnecessary polypharmacy and inappropriate combinations, such as dual RAS blockade, and should escalate according to guideline recommendations.\n\n**Memory Anchor**\nABCD rule: ACE/ARB, Beta/CCB, Chlorthalidone (thiazide), then D (different classes for resistant cases)",
    "bullet_explanations": {
      "Amlodipine": "Correct – Guidelines recommend adding a calcium channel blocker as the third antihypertensive agent.",
      "Bisoprolol": "Incorrect – Beta-blockers are not first-line or third-line for hypertension unless there is another indication.",
      "Spironolactone": "Incorrect – Only indicated for resistant hypertension after failure of three agents.",
      "Furosemide": "Incorrect – Loop diuretics are not routinely used in hypertension except in heart failure.",
      "Losartan": "Incorrect – Adding a second RAS inhibitor to existing ACE inhibitor is not recommended due to risk of adverse effects."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "NICE A/C/D ladder and special cases",
    "keywords": [
      "hypertension",
      "calcium channel blocker",
      "amlodipine",
      "treatment ladder",
      "NICE guidance"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "de946542-3bfd-43a7-a2cb-5b9f803a534d",
    "question_number": 265,
    "question": "A 78-year-old man with chronic atrial fibrillation managed on digoxin presents with nausea, confusion, and visual disturbances. He recently started a new medication for angina. Which of the following drugs is most likely to increase the risk of digoxin toxicity by inhibiting its clearance?",
    "options": [
      "Ranolazine",
      "Diltiazem",
      "Amlodipine",
      "Isosorbide mononitrate",
      "Ivabradine"
    ],
    "correct_answer": "Diltiazem",
    "explanation": "**Explanation**\n**Diltiazem** is a calcium channel blocker that can significantly increase serum digoxin concentrations by inhibiting P-glycoprotein, a transport protein involved in digoxin's renal and non-renal elimination. This inhibition leads to reduced clearance and consequently higher plasma digoxin levels, predisposing to toxicity. The risk is particularly notable in older adults and in those with compromised renal function. Symptoms of digoxin toxicity include gastrointestinal upset, confusion, and characteristic visual changes. Recognising this pharmacokinetic interaction is crucial, as diltiazem is commonly prescribed alongside digoxin for rate control but requires careful monitoring or dose adjustment to avoid adverse effects.<br><br><b>Key contrasting point:</b> Unlike other antianginal agents such as amlodipine or nitrates, diltiazem directly affects digoxin elimination rather than simply exerting additive cardiac effects.\n\n**Key Points**\n- Diltiazem inhibits P-glycoprotein, reducing digoxin clearance.\n- Co-administration can increase digoxin levels by 20–50%.\n- Elderly patients are especially at risk due to decreased renal function.\n- Symptoms of digoxin toxicity: nausea, confusion, visual changes.\n- Other angina drugs (e.g. amlodipine, nitrates) do not significantly alter digoxin metabolism.\n\n**Clinical Relevance**\nUnderstanding drug-drug interactions that affect digoxin metabolism is vital because digoxin has a narrow therapeutic index and toxicity can be life-threatening. National guidelines highlight the importance of careful monitoring when combining digoxin with P-glycoprotein inhibitors like diltiazem, especially in older adults.",
    "bullet_explanations": {
      "Ranolazine": "Does not significantly inhibit digoxin clearance; interaction risk is minimal.",
      "Diltiazem": "Correct – inhibits P-glycoprotein, raising digoxin levels and toxicity risk.",
      "Amlodipine": "A dihydropyridine calcium channel blocker; does not meaningfully affect digoxin metabolism.",
      "Isosorbide mononitrate": "A nitrate with no clinically significant interaction with digoxin.",
      "Ivabradine": "Acts on the sinus node but does not influence digoxin clearance or toxicity."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Drug interactions",
    "topic": "Drug interactions",
    "keywords": [
      "digoxin",
      "diltiazem",
      "interaction",
      "toxicity",
      "P-glycoprotein"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Cardiac glycosides",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/cardiac-glycosides/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5ebbda65-7b19-4a2b-b3d3-b5aba085a6ee",
    "question_number": 266,
    "question": "During an in-hospital cardiac arrest, you assess a 55-year-old woman who has collapsed on the ward. She is unresponsive and pulseless. The ECG monitor shows a narrow complex rhythm at 80 bpm. What is the next immediate step in her management according to current ALS guidelines?",
    "options": [
      "Administer 1mg intravenous adrenaline and resume chest compressions",
      "Deliver a shock with the defibrillator and restart CPR",
      "Resume chest compressions and give amiodarone 300mg IV",
      "Conduct an ABCDE assessment before further intervention",
      "Resume chest compressions, give amiodarone 300mg IV and adrenaline 1mg IV"
    ],
    "correct_answer": "Administer 1mg intravenous adrenaline and resume chest compressions",
    "explanation": "**Explanation**\n**Pulseless electrical activity (PEA)** is present when organised electrical activity is seen on the ECG (such as a normal sinus rhythm), but there is no detectable pulse or cardiac output. PEA is a **non-shockable rhythm**, and the recommended management is immediate high-quality chest compressions and administration of **1mg intravenous adrenaline as soon as possible**. Defibrillation is not indicated because PEA is not a shockable rhythm. Amiodarone is reserved for refractory ventricular fibrillation or pulseless VT, not for PEA. A full ABCDE assessment is not appropriate until basic life support measures are underway.\n\n**Key Points**\n- PEA is a non-shockable cardiac arrest rhythm.\n- Immediate actions: chest compressions and 1mg IV adrenaline.\n- Defibrillation is only for shockable rhythms (VF/pulseless VT).\n- Amiodarone is used for refractory shockable rhythms, not PEA.\n- ABCDE assessment does not replace immediate ALS protocol.\n- <table><thead><tr><th>Rhythm</th><th>Shockable?</th><th>Adrenaline</th><th>Amiodarone</th></tr></thead><tbody><tr><td>VF/VT</td><td>Yes</td><td>After 3rd shock</td><td>After 3rd shock</td></tr><tr><td>PEA/Asystole</td><td>No</td><td>Immediately</td><td>No</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising PEA and promptly delivering adrenaline with effective CPR is critical to improving survival outcomes in cardiac arrest. This follows Resuscitation Council UK and NICE CKS guidelines for non-shockable rhythms.\n\n**Memory Anchor**\nPEA = Push (compressions) + Epinephrine (adrenaline) Always",
    "bullet_explanations": {
      "Administer 1mg intravenous adrenaline and resume chest compressions": "Correct – This is the immediate recommended action for PEA according to ALS protocols.",
      "Deliver a shock with the defibrillator and restart CPR": "Incorrect – PEA is a non-shockable rhythm; defibrillation is not indicated.",
      "Resume chest compressions and give amiodarone 300mg IV": "Incorrect – Amiodarone is only for refractory VF/pulseless VT, not for PEA.",
      "Conduct an ABCDE assessment before further intervention": "Incorrect – Immediate ALS interventions take precedence over ABCDE in cardiac arrest.",
      "Resume chest compressions, give amiodarone 300mg IV and adrenaline 1mg IV": "Incorrect – Amiodarone is not indicated for non-shockable rhythms such as PEA."
    },
    "category": "Cardiovascular",
    "subsection": "Arrhythmias & Conduction",
    "subsubsection": "Ventricular Arrhythmias",
    "topic": "ACLS tachycardia algorithm basics",
    "keywords": [
      "PEA",
      "adrenaline",
      "cardiac arrest",
      "ALS protocol",
      "non-shockable rhythm"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Cardiopulmonary resuscitation",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/cardiopulmonary-resuscitation/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Cardiac arrest - out of hospital care",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cardiac-arrest-out-of-hospital-care/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b94d7394-3e07-49e9-9afa-76add73743e1",
    "question_number": 267,
    "question": "A 58-year-old woman presents with slowly progressive weakness in her hands and legs over the past year. On examination, there is muscle wasting and fasciculations in her hands, accompanied by brisk knee reflexes and increased tone in the lower limbs. Sensory examination is normal, and cranial nerves are intact. Which diagnosis best explains this combination of upper and lower motor neurone signs?",
    "options": [
      "Amyotrophic lateral sclerosis",
      "Multiple sclerosis",
      "Vitamin B12 deficiency",
      "Progressive muscular atrophy",
      "Myasthenia gravis"
    ],
    "correct_answer": "Amyotrophic lateral sclerosis",
    "explanation": "**Explanation**\n**Amyotrophic lateral sclerosis (ALS) is the most common form of motor neurone disease and classically presents with a combination of upper motor neurone (UMN) and lower motor neurone (LMN) signs.** Typical features include progressive weakness, muscle wasting, fasciculations (LMN signs), alongside spasticity and hyperreflexia (UMN signs), with preservation of sensation. The absence of sensory involvement and the coexistence of UMN and LMN findings distinguishes ALS from other neurological conditions such as multiple sclerosis or peripheral neuropathies.\n\n**Key Points**\n- ALS affects both upper and lower motor neurones.\n- Classic findings: muscle wasting, fasciculations, increased tone, brisk reflexes.\n- Sensory function remains normal in ALS.\n- Cranial nerves may be affected, but are spared in early limb-onset cases.\n- Progressive muscular atrophy is a pure LMN variant of motor neurone disease.\n- Multiple sclerosis presents with demyelination and often involves sensory changes.\n- Vitamin B12 deficiency produces UMN and sensory findings, not LMN features.\n- <table><thead><tr><th>Condition</th><th>UMN signs</th><th>LMN signs</th><th>Sensory symptoms</th></tr></thead><tbody><tr><td>ALS</td><td>Yes</td><td>Yes</td><td>No</td></tr><tr><td>MS</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>B12 deficiency</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr><td>PMA</td><td>No</td><td>Yes</td><td>No</td></tr><tr><td>Myasthenia gravis</td><td>No</td><td>No</td><td>No</td></tr></tbody></table>\n\n**Clinical Relevance**\nEarly recognition of ALS is crucial due to its progressive nature and the need for multidisciplinary management. Riluzole is the only disease-modifying drug licensed for ALS, while symptomatic treatments target spasticity and respiratory impairment. Sensory sparing and combined UMN/LMN findings are diagnostic hallmarks. See BNF guidance for current management recommendations.\n\n**Memory Anchor**\nALS = 'Affects Both Levels' (upper and lower motor neurones).",
    "bullet_explanations": {
      "Amyotrophic lateral sclerosis": "Correct — ALS uniquely presents with both UMN and LMN signs and no sensory involvement.",
      "Multiple sclerosis": "Incorrect — MS typically causes UMN and sensory symptoms, not LMN signs like fasciculations.",
      "Vitamin B12 deficiency": "Incorrect — B12 deficiency produces UMN signs and sensory loss, not LMN features.",
      "Progressive muscular atrophy": "Incorrect — PMA is a pure LMN disorder without UMN involvement.",
      "Myasthenia gravis": "Incorrect — Myasthenia gravis presents with fatigable weakness but no UMN or LMN signs."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Movement Disorders",
    "topic": "Motor neurone disease",
    "keywords": [
      "ALS",
      "motor neurone disease",
      "upper and lower motor neurone",
      "neurology",
      "fasciculations"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Motor neurone disease",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/motor-neurone-disease/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "54b7a859-f252-41c2-baac-1183a36a7f5e",
    "question_number": 268,
    "question": "A 7-year-old girl who recently emigrated from Eastern Europe presents with a high fever, sore throat, and difficulty swallowing. On examination, you note a thick, greyish membrane covering her pharynx and marked swelling of the anterior neck. What is the most likely diagnosis?",
    "options": [
      "Diphtheria",
      "Herpetic gingivostomatitis",
      "Epstein-Barr virus (infectious mononucleosis)",
      "Scarlet fever",
      "Vincent’s angina (acute necrotising ulcerative gingivitis)"
    ],
    "correct_answer": "Diphtheria",
    "explanation": "**Explanation**\n**Diphtheria** is most likely due to the presence of a thick grey membrane (pseudomembrane) over the pharynx, prominent cervical lymphadenopathy (\"bull neck\"), fever, and recent travel from an area with lower vaccination coverage. Corynebacterium diphtheriae produces a potent exotoxin that can cause local tissue necrosis and systemic complications. The pseudomembrane is a classic finding and is rarely seen in other infections. This presentation contrasts with viral pharyngitis or bacterial tonsillitis, which do not form such a membrane; and with other causes of severe pharyngitis, which lack the combination of membrane and significant neck swelling. Early diagnosis is critical due to the risk of airway obstruction and systemic toxicity.\n\n**Key Points**\n- Diphtheria presents with a **grey pseudomembrane** over the tonsils/pharynx, fever, and marked cervical lymphadenopathy.\n- Unimmunised or under-immunised children and recent migrants from endemic regions are at increased risk.\n- Diphtheria is a **notifiable disease** in the UK and requires urgent public health action.\n- Management includes antitoxin and antibiotics; isolation and contact tracing are essential.\n- Differentiation from viral pharyngitis and other bacterial infections is based on the membrane and 'bull neck' appearance.\n- <table><thead><tr><th>Feature</th><th>Diphtheria</th><th>Mononucleosis</th><th>Scarlet fever</th></tr></thead><tbody><tr><td>Pseudomembrane</td><td>Yes</td><td>No</td><td>No</td></tr><tr><td>Neck swelling</td><td>Significant</td><td>Mild</td><td>Minimal</td></tr><tr><td>Rash</td><td>Rare</td><td>Rare</td><td>Yes</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising diphtheria early is crucial, especially in non-immune children and recent arrivals from endemic areas. Prompt treatment and public health measures prevent severe complications and outbreaks. UK clinicians must notify suspected cases and coordinate with health protection teams as per BNF and UKHSA guidance.\n\n**Memory Anchor**\nGrey 'pseudomembrane' = Diphtheria; think 'D for Dangerous membrane'.",
    "bullet_explanations": {
      "Diphtheria": "Correct – classic for pseudomembrane, cervical swelling, and epidemiological risk factors.",
      "Herpetic gingivostomatitis": "Incorrect – causes painful oral ulcers and gingival inflammation, but not a grey pharyngeal membrane or bull neck.",
      "Epstein-Barr virus (infectious mononucleosis)": "Incorrect – may cause pharyngitis and lymphadenopathy, but lacks a thick grey membrane; tonsillar exudate is more common.",
      "Scarlet fever": "Incorrect – causes pharyngitis and sandpaper rash, but not a membrane or profound neck swelling.",
      "Vincent’s angina (acute necrotising ulcerative gingivitis)": "Incorrect – presents with painful, ulcerative gingival lesions and halitosis, but not a pharyngeal pseudomembrane or significant cervical lymphadenopathy."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Community vs hospital-acquired pneumonia",
    "keywords": [
      "diphtheria",
      "pseudomembrane",
      "grey membrane",
      "cervical lymphadenopathy",
      "notifiable disease"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diphtheria vaccine",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diphtheria-vaccine/"
      },
      {
        "source": "BNF",
        "topic_title": "Antibacterials, use for prophylaxis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antibacterials-use-for-prophylaxis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1530911c-d582-4e1f-8549-04d7bb26a208",
    "question_number": 269,
    "question": "Which of the following conditions is least likely to contribute to persistent snoring in a school-aged child?",
    "options": [
      "Kallmann syndrome",
      "Obesity",
      "Tonsillar hypertrophy",
      "Hypertrophic nasal turbinates",
      "Down syndrome"
    ],
    "correct_answer": "Kallmann syndrome",
    "explanation": "**Explanation**\nKallmann syndrome is a rare genetic disorder characterised primarily by hypogonadotropic hypogonadism and anosmia (loss of sense of smell), resulting from abnormal development of the olfactory bulbs and hypothalamus. While it can present with subtle midline facial abnormalities, it is not typically associated with anatomical or functional upper airway obstruction. Hence, it does not usually cause snoring or sleep-disordered breathing in children. In contrast, other listed conditions—obesity, tonsillar hypertrophy, hypertrophic nasal turbinates, and Down syndrome—all predispose to upper airway narrowing or collapse during sleep, making them established risk factors for snoring and paediatric obstructive sleep apnoea.\n\n**Key Points**\n- Snoring in children is most often due to upper airway obstruction.\n- <b>Common causes include tonsillar/adenoidal hypertrophy, obesity, nasal obstruction, and craniofacial anomalies.</b>\n- Kallmann syndrome affects hypothalamic-pituitary development and olfaction, not upper airway anatomy.\n- Down syndrome increases risk of snoring due to macroglossia, midface hypoplasia, and hypotonia.\n- Obesity and nasal turbinate hypertrophy both narrow the airway and increase snoring risk.\n\n**Clinical Relevance**\nDistinguishing between causes of paediatric snoring is key for appropriate referral and management. While nasopharyngeal obstruction and craniofacial syndromes are common contributors, syndromes like Kallmann's rarely, if ever, present with sleep-disordered breathing. Recognising this prevents unnecessary investigations and ensures targeted treatment. NICE CKS guidelines highlight the importance of identifying and addressing modifiable risk factors for paediatric sleep-disordered breathing.",
    "bullet_explanations": {
      "Kallmann syndrome": "Correct. This syndrome does not typically cause upper airway obstruction or snoring.",
      "Obesity": "Incorrect. Obesity increases pharyngeal fat, narrowing the airway and predisposing to snoring.",
      "Tonsillar hypertrophy": "Incorrect. Enlarged tonsils are a classic cause of snoring in children.",
      "Hypertrophic nasal turbinates": "Incorrect. These lead to nasal obstruction and are a recognised cause of snoring.",
      "Down syndrome": "Incorrect. Children with Down syndrome have multiple anatomical risk factors for snoring."
    },
    "category": "Respiratory",
    "subsection": "Obstructive Airway",
    "subsubsection": "OSA/Obesity Hypoventilation",
    "topic": "STOP-BANG screening",
    "keywords": [
      "paediatric snoring",
      "obstructive sleep apnoea",
      "Kallmann syndrome",
      "risk factors",
      "upper airway obstruction"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Obstructive sleep apnoea syndrome",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/obstructive-sleep-apnoea-syndrome/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f6b7955f-4e40-47b0-a744-f5d9db3895a7",
    "question_number": 270,
    "question": "A 30-year-old woman presents to her GP with a 2-month history of hand tremor that is most noticeable when she is writing or holding objects, such as a cup. She reports no muscle weakness or sensory changes. Her mother and maternal grandfather experienced similar symptoms. Which is the most likely diagnosis?",
    "options": [
      "Essential tremor",
      "Parkinsonism",
      "Thyrotoxicosis",
      "Cerebellar disease",
      "Drug-induced tremor"
    ],
    "correct_answer": "Essential tremor",
    "explanation": "**Explanation**\n**Essential tremor** is the most frequent cause of an action tremor—one that is most pronounced with voluntary movement, such as holding an object or writing. It typically affects both hands symmetrically and often has a strong familial pattern. In contrast, **Parkinsonism** usually presents with a resting tremor, often starting asymmetrically, and is accompanied by other features such as bradykinesia and rigidity. **Thyrotoxicosis** may cause a fine tremor, but is generally accompanied by systemic symptoms (e.g., weight loss, tachycardia). **Cerebellar disease** leads to an intention tremor, which becomes prominent as the limb approaches a target, and is usually associated with problems in coordination. **Drug-induced tremor** is linked to medication history and lacks the familial pattern seen here.\n\n**Key Points**\n- Essential tremor is typically bilateral and worsens with action.\n- Often runs in families (autosomal dominant inheritance).\n- Parkinsonism tremor is most notable at rest and is often unilateral initially.\n- Thyrotoxicosis tremor is fine, high-frequency, and associated with systemic signs.\n- Cerebellar tremor is intention-based and linked to incoordination.\n- <table><thead><tr><th>Feature</th><th>Essential Tremor</th><th>Parkinsonism</th></tr></thead><tbody><tr><td>Onset</td><td>Any age, often young adult</td><td>Older age</td></tr><tr><td>Tremor Type</td><td>Action</td><td>Rest</td></tr><tr><td>Family History</td><td>Common</td><td>Rare</td></tr><tr><td>Other Signs</td><td>None</td><td>Bradykinesia, rigidity</td></tr></tbody></table>\n\n**Clinical Relevance**\nDistinguishing between essential tremor and Parkinsonism is critical, as the management, prognosis, and counselling differ significantly. Recognising a positive family history and absence of Parkinsonian features helps avoid unnecessary investigations and referrals.\n\n**Memory Anchor**\nEssential tremor is \"essentially\" inherited and seen with \"essential\" actions—like holding a cup or pen.",
    "bullet_explanations": {
      "Essential tremor": "Correct – Bilateral action tremor with a strong family history is classic.",
      "Parkinsonism": "Incorrect – Presents with resting tremor, bradykinesia, and rigidity, usually in older adults.",
      "Thyrotoxicosis": "Incorrect – Tremor is typically fine, with systemic hyperthyroid symptoms.",
      "Cerebellar disease": "Incorrect – Intention tremor and ataxia are more prominent than action tremor alone.",
      "Drug-induced tremor": "Incorrect – No medication history or other supporting features in this scenario."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Movement Disorders",
    "topic": "Essential tremor",
    "keywords": [
      "tremor",
      "essential tremor",
      "movement disorder",
      "familial tremor"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Parkinson's disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/parkinsons-disease/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "63cc7b46-1ae5-46dd-bab4-92df2c887924",
    "question_number": 271,
    "question": "What is the minimum duration of unexplained, persistent fatigue required before chronic fatigue syndrome can be diagnosed in adults?",
    "options": [
      "1 month",
      "6 weeks",
      "3 months",
      "9 months",
      "2 years"
    ],
    "correct_answer": "3 months",
    "explanation": "**Explanation**\n**Chronic fatigue syndrome (CFS)** is diagnosed when a person experiences persistent, unexplained fatigue that significantly limits daily functioning and is not relieved by rest or explained by other medical or psychiatric conditions. The fatigue must be present for at least **3 months** to fulfil diagnostic criteria. This period ensures that transient or self-limiting causes of tiredness are excluded, and that secondary causes have been appropriately investigated and ruled out. Other features supporting the diagnosis include post-exertional malaise, cognitive difficulties, sleep disturbance, and sometimes chronic pain. The diagnosis is clinical and one of exclusion, so a detailed history and basic investigations are mandatory to rule out alternative causes.\n\n**Key Points**\n- **Diagnosis of CFS requires at least 3 months of persistent, unexplained fatigue.**\n- Other causes of fatigue (e.g., anaemia, hypothyroidism, diabetes, depression) must be excluded.\n- CFS is associated with substantial reduction in activity and can include cognitive, sleep, and pain symptoms.\n- The condition is diagnosed based on clinical assessment and exclusion of alternative causes.\n- Routine investigations should include FBC, ESR/CRP, U&Es, LFTs, TFTs, glucose, and screening for coeliac disease.\n\n**Clinical Relevance**\nRecognising the appropriate time frame for diagnosing CFS prevents premature labelling and ensures that reversible or treatable causes are not missed. Adhering to evidence-based diagnostic criteria supports safe, effective patient care and enables early support for those genuinely affected by the syndrome.\n\n**Memory Anchor**\nRemember: **'3' for 'Chronic' — 3 months for Chronic Fatigue Syndrome.**",
    "bullet_explanations": {
      "1 month": "Too short a duration; many transient causes of fatigue resolve within weeks.",
      "6 weeks": "Still insufficient; CFS requires symptoms for at least 3 months.",
      "3 months": "Correct—3 months is the minimum duration required before considering a diagnosis of CFS.",
      "9 months": "Longer than necessary; diagnosis can be made after 3 months if criteria are met.",
      "2 years": "Excessively prolonged; diagnosis should be considered much earlier if symptoms persist."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Depression",
    "topic": "Diagnostic criteria",
    "keywords": [
      "chronic fatigue syndrome",
      "diagnosis",
      "fatigue duration",
      "CFS criteria"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Tiredness/fatigue in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/tiredness-fatigue-in-adults/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "bab5cda2-7fc6-4bca-8898-e615b92a3f58",
    "question_number": 272,
    "question": "A 67-year-old man with a history of hypertension presents with palpitations and a 5 kg unintentional weight loss over two months. Examination reveals a nodular goitre but no eye signs. Thyroid function tests show: TSH <0.01 mU/L (reference: 0.27–4.20), free T4 31 pmol/L (reference: 10.0–23.0). Thyroid scintigraphy demonstrates multiple areas of increased and decreased uptake. What is the most likely underlying diagnosis?",
    "options": [
      "Toxic multinodular goitre",
      "Subacute thyroiditis",
      "Graves' disease",
      "Solitary toxic adenoma",
      "Hashimoto's thyroiditis"
    ],
    "correct_answer": "Toxic multinodular goitre",
    "explanation": "**Explanation**\n**Toxic multinodular goitre** is characterised by hyperthyroidism due to multiple autonomously functioning thyroid nodules. These nodules produce excess thyroid hormone independently of TSH regulation, resulting in suppressed TSH and elevated free T4 or T3. On nuclear scintigraphy, this condition typically shows a 'patchy' uptake pattern, with multiple areas of increased and decreased activity reflecting the heterogeneous function of various nodules. In contrast, Graves' disease produces diffuse, homogeneous uptake; a solitary toxic adenoma would present as a single hot nodule. Hashimoto's thyroiditis usually causes hypothyroidism, and subacute thyroiditis often shows reduced or absent uptake due to inflammatory destruction of thyroid tissue.\n\n**Key Points**\n- Toxic multinodular goitre is a common cause of hyperthyroidism, especially in older adults.\n- Scintigraphy reveals patchy uptake due to multiple functioning and non-functioning nodules.\n- Graves' disease produces diffuse, uniform uptake; solitary adenoma appears as a single hot area.\n- Hashimoto's thyroiditis and subacute thyroiditis are typically associated with hypothyroidism or transient thyrotoxicosis and reduced uptake.\n- Symptoms: weight loss, palpitations, heat intolerance; eye signs more typical of Graves'.\n- <table><thead><tr><th>Diagnosis</th><th>Scintigraphy Pattern</th></tr></thead><tbody><tr><td>Graves' disease</td><td>Diffuse uptake</td></tr><tr><td>Toxic multinodular goitre</td><td>Patchy uptake</td></tr><tr><td>Solitary toxic adenoma</td><td>Single hot nodule</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the scintigraphic patterns in hyperthyroidism is crucial for distinguishing causes and guiding appropriate management. Toxic multinodular goitre is a frequent cause, especially in the elderly, and may require different treatment compared to Graves' disease. [NICE CKS, BNF]\n\n**Memory Anchor**\nPatchy uptake = multinodular goitre; diffuse = Graves'; single hot = adenoma.",
    "bullet_explanations": {
      "Toxic multinodular goitre": "Correct: Patchy uptake and nodular goitre strongly suggest this diagnosis.",
      "Subacute thyroiditis": "Incorrect: Typically shows low or absent uptake due to gland inflammation and hormone leakage, not patchy uptake.",
      "Graves' disease": "Incorrect: Produces diffuse, uniform uptake on scintigraphy, not patchy.",
      "Solitary toxic adenoma": "Incorrect: Would show a single area of increased uptake, not multiple.",
      "Hashimoto's thyroiditis": "Incorrect: Causes hypothyroidism and typically reduced uptake, not hyperthyroidism with patchy uptake."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Thyroid",
    "subsubsection": "Hyperthyroidism",
    "topic": "Graves vs toxic nodular goitre",
    "keywords": [
      "toxic multinodular goitre",
      "thyroid scintigraphy",
      "hyperthyroidism",
      "patchy uptake",
      "differential diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hyperthyroidism",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hyperthyroidism/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Hyperthyroidism",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hyperthyroidism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "69e2c2ff-920e-409a-8fac-421b1c1d2f4a",
    "question_number": 273,
    "question": "Which condition has the strongest association with the development of primary sclerosing cholangitis (PSC)?",
    "options": [
      "Ulcerative colitis",
      "Coeliac disease",
      "Primary biliary cholangitis",
      "Crohn's disease",
      "Hepatitis C infection"
    ],
    "correct_answer": "Ulcerative colitis",
    "explanation": "**Explanation**\n**Ulcerative colitis is most strongly linked to primary sclerosing cholangitis (PSC), with up to 80% of PSC patients also having coexisting ulcerative colitis.** This association is due to shared immune-mediated and genetic factors. While Crohn’s disease (another form of inflammatory bowel disease) can rarely overlap with PSC, the connection is far weaker. PSC affects both intrahepatic and extrahepatic bile ducts, causing inflammation, stricturing, and progressive liver dysfunction. The coexistence of PSC and ulcerative colitis increases the risk of cholangiocarcinoma and colorectal cancer, necessitating close surveillance. In contrast, primary biliary cholangitis (previously called primary biliary cirrhosis) affects different bile ducts, has a distinct antibody profile, and bears no specific link to ulcerative colitis.\n\n**Key Points**\n- **Ulcerative colitis (UC) and PSC are closely associated; 70–80% of PSC cases have UC.**\n- PSC is a chronic, progressive cholestatic liver disease affecting both large and small bile ducts.\n- Crohn’s disease has a much weaker association with PSC (~5–10%).\n- Primary biliary cholangitis is a separate autoimmune liver condition, primarily involving small intrahepatic bile ducts and anti-mitochondrial antibodies.\n- Neither coeliac disease nor hepatitis C has a significant association with PSC.\n- <table><thead><tr><th>Condition</th><th>PSC Association</th></tr></thead><tbody><tr><td>Ulcerative colitis</td><td>Strong</td></tr><tr><td>Crohn's disease</td><td>Weak</td></tr><tr><td>Coeliac disease</td><td>None</td></tr><tr><td>Primary biliary cholangitis</td><td>None</td></tr><tr><td>Hepatitis C</td><td>None</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the strong link between ulcerative colitis and PSC is vital for early diagnosis, ensuring timely liver and cancer surveillance in affected patients, and following best-practice guidelines in hepatology and gastroenterology.\n\n**Memory Anchor**\nRemember: **PSC = UC > Crohn’s** (think ‘S’ for Sclerosing, ‘C’ for Colitis – they go together).",
    "bullet_explanations": {
      "Ulcerative colitis": "Correct – PSC is most commonly associated with ulcerative colitis, not other conditions.",
      "Coeliac disease": "Incorrect – No significant association between coeliac disease and PSC.",
      "Primary biliary cholangitis": "Incorrect – Although both are autoimmune liver diseases, PBC and PSC are distinct and not strongly linked.",
      "Crohn's disease": "Incorrect – Weak association; PSC is much more commonly linked with UC than Crohn’s disease.",
      "Hepatitis C infection": "Incorrect – Hepatitis C is a viral infection with no established connection to PSC."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Hepatology",
    "subsubsection": "Cholestatic Disease",
    "topic": "PSC/PBC recognition",
    "keywords": [
      "primary sclerosing cholangitis",
      "ulcerative colitis",
      "PSC associations",
      "cholestatic liver disease"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Ulcerative colitis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/ulcerative-colitis/"
      },
      {
        "source": "BNF",
        "topic_title": "Ulcerative colitis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/ulcerative-colitis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "65e27f52-1815-4711-b122-f3f2cf50e352",
    "question_number": 274,
    "question": "A 74-year-old man is brought to hospital by his neighbour due to increasing drowsiness and confusion. On arrival, he is found to be bradycardic (heart rate 48 bpm), hypotensive, hypothermic (temperature 31°C), and has obvious periorbital puffiness, coarse dry skin, and delayed reflexes. What is the most likely underlying diagnosis?",
    "options": [
      "Myxoedema coma",
      "Thyroid storm",
      "Addisonian crisis",
      "Acute delirium due to infection",
      "Cushing’s syndrome"
    ],
    "correct_answer": "Myxoedema coma",
    "explanation": "**Explanation**\n**Myxoedema coma is a rare but life-threatening complication of severe, untreated or undertreated hypothyroidism.** It typically presents with confusion or reduced consciousness, profound hypothermia, bradycardia, hypotension, hypoventilation, and non-pitting oedema, particularly of the face and periorbital region. Other features can include dry, coarse skin, delayed relaxation of deep tendon reflexes, and respiratory depression. This diagnosis is distinguished by the combination of severe metabolic slowing and classic physical findings, especially in elderly patients or those with a history suggesting longstanding hypothyroidism.\n\n**Differentiation from other acute endocrine emergencies is crucial:** Addisonian crisis presents with vomiting, abdominal pain, and hyperpigmentation; thyroid storm is associated with agitation, hyperthermia, and tachycardia, not bradycardia or hypothermia. Cushing’s syndrome does not present acutely, and delirium from infection lacks the hallmark hypothyroid features.\n\n**Key Points**\n<ul><li>Myxoedema coma is a medical emergency caused by severe hypothyroidism.</li><li>Key findings: reduced consciousness, hypothermia, bradycardia, hypotension, non-pitting oedema, dry coarse skin.</li><li>Precipitating factors: infection, cold exposure, trauma, certain medications.</li><li>Distinguished from Addisonian crisis (GI symptoms, hyperpigmentation) and thyroid storm (agitation, hyperthermia, tachycardia).</li><li>Immediate management requires admission, IV thyroxine, and supportive care.</li></ul>\n\n**Clinical Relevance**\nRecognising myxoedema coma is vital, as prompt diagnosis and emergency treatment can be lifesaving. Failure to identify this condition risks rapid deterioration and high mortality. Guidelines (NICE, BNF) emphasise the need for emergency admission and specialist endocrine input for suspected cases.\n\n**Memory Anchor**\nThink of 'myxoedema coma' as the 'cold and slow' endocrine emergency—confusion, cold skin, slow heart, slow reflexes.",
    "bullet_explanations": {
      "Myxoedema coma": "Correct – classic presentation of severe hypothyroidism with confusion, hypothermia, bradycardia, and non-pitting oedema.",
      "Thyroid storm": "Incorrect – causes agitation, hyperthermia, tachycardia, and often GI symptoms, not bradycardia or hypothermia.",
      "Addisonian crisis": "Incorrect – features hypotension and confusion but usually with GI symptoms, hyperpigmentation, and electrolyte disturbances.",
      "Acute delirium due to infection": "Incorrect – can cause confusion, but lacks the specific hypothyroid signs (dry skin, bradycardia, hypothermia).",
      "Cushing’s syndrome": "Incorrect – presents with chronic features (central obesity, striae, muscle weakness), not acute confusion or vital sign changes."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Thyroid",
    "subsubsection": "Hypothyroidism",
    "topic": "Myxoedema coma basics",
    "keywords": [
      "myxoedema coma",
      "hypothyroidism emergency",
      "hypothermia confusion",
      "thyroid emergencies"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hypothyroidism",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hypothyroidism/"
      },
      {
        "source": "BNF",
        "topic_title": "Hypothyroidism",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypothyroidism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "542f75f7-feab-4ece-a725-5c62166e8d72",
    "question_number": 275,
    "question": "A 7-year-old boy is brought to urgent care with a 2-day history of fever, sore throat, and vomiting. Examination reveals a rough, blanching erythematous rash on his abdomen and back, circumoral pallor, and a 'strawberry' tongue. What is the most likely diagnosis?",
    "options": [
      "Scarlet fever",
      "Measles",
      "Kawasaki disease",
      "Staphylococcal toxic shock syndrome",
      "Parvovirus B19 infection"
    ],
    "correct_answer": "Scarlet fever",
    "explanation": "**Explanation**\n**Scarlet fever** is a notifiable childhood infection caused by toxin-producing group A Streptococcus (Streptococcus pyogenes). It typically presents with an abrupt onset of fever, sore throat, and a characteristic sandpaper-like, blanching rash that often begins on the trunk and spreads. The 'strawberry' tongue (erythematous, swollen tongue with prominent papillae) and circumoral pallor are classic signs. The rash is often accompanied by systemic symptoms such as headache and vomiting. Scarlet fever most commonly affects children aged 2–8 years and is highly contagious. Rapid identification and prompt antibiotic treatment are essential to reduce the risk of complications and transmission. This clinical picture is distinct from other childhood exanthems due to the combination of sore throat, fever, blanching rash, and strawberry tongue.\n\n**Key Points**\n- Scarlet fever is caused by Streptococcus pyogenes (group A strep)\n- Presents with fever, sore throat, sandpaper-like rash, and strawberry tongue\n- Rash typically starts on trunk and spreads, often sparing the circumoral area (circumoral pallor)\n- Complications can include otitis media, rheumatic fever, and glomerulonephritis\n- First-line treatment is 10 days of phenoxymethylpenicillin\n\n**Clinical Relevance**\nRecognising scarlet fever is vital for infection control and prevention of complications. The diagnosis is mainly clinical; prompt antibiotics reduce transmission and serious sequelae. Notify public health authorities as required by UK law. See NICE CKS guidance for further management details.\n\n**Memory Anchor**\nStrawberry tongue + sandpaper rash = Scarlet fever",
    "bullet_explanations": {
      "Scarlet fever": "Correct—classic features include fever, sore throat, blanching sandpaper rash, strawberry tongue, and circumoral pallor.",
      "Measles": "Incorrect—measles presents with Koplik spots, cough, coryza, conjunctivitis, and a maculopapular rash starting behind the ears.",
      "Kawasaki disease": "Incorrect—Kawasaki disease involves prolonged fever (>5 days), conjunctivitis, mucous membrane changes, extremity changes, and cervical lymphadenopathy.",
      "Staphylococcal toxic shock syndrome": "Incorrect—TSS presents with sudden high fever, rash, hypotension, and multi-organ involvement, not typically a sandpaper rash or strawberry tongue.",
      "Parvovirus B19 infection": "Incorrect—parvovirus B19 (fifth disease) typically causes a 'slapped cheek' facial rash, sometimes followed by a lacy body rash; sore throat and strawberry tongue are not prominent."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Common Infections",
    "topic": "Scarlet fever",
    "keywords": [
      "scarlet fever",
      "strawberry tongue",
      "childhood rash",
      "Streptococcus pyogenes"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Scarlet fever",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/scarlet-fever/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ef6bce79-efd9-4153-a79e-475ce25b8930",
    "question_number": 276,
    "question": "A 58-year-old woman with a long-standing history of type 2 diabetes presents with persistent tingling and burning sensations in her hands and feet. She has trialled gabapentin at an adequate dose for several weeks with no significant relief. She also suffers from chronic constipation. Which medication would be the most appropriate next-line pharmacological treatment for her neuropathic pain?",
    "options": [
      "Duloxetine",
      "Amitriptyline",
      "Carbamazepine",
      "Fluoxetine",
      "Sodium valproate"
    ],
    "correct_answer": "Duloxetine",
    "explanation": "**Explanation**\n**Duloxetine** is an appropriate next-line agent for painful diabetic neuropathy when gabapentin has been ineffective, particularly in patients for whom tricyclic antidepressants like amitriptyline may be unsuitable. In this scenario, the patient's chronic constipation makes amitriptyline less desirable due to its anticholinergic side effects, which can worsen constipation. NICE and BNF recommend duloxetine, along with amitriptyline, pregabalin, and gabapentin, as first-line treatments for neuropathic pain. If one agent fails or is contraindicated, another from this list should be considered before progressing to less well-supported alternatives.\n\n**Key Points**\n- First-line agents for neuropathic pain include amitriptyline, duloxetine, gabapentin, and pregabalin.\n- Choice of drug should be tailored to patient comorbidities and side effect profiles.\n- Amitriptyline can worsen constipation and urinary retention due to anticholinergic effects.\n- Duloxetine is also licensed for painful diabetic neuropathy and may be preferable for patients with contraindications to tricyclics.\n- Antiepileptic drugs like carbamazepine and sodium valproate are not first-line for diabetic neuropathy.\n- SSRIs such as fluoxetine are not effective for neuropathic pain.\n\n**Clinical Relevance**\nSelecting the optimal therapy for neuropathic pain in diabetes requires careful consideration of comorbidities and adverse effect profiles. Guidelines recommend switching between first-line agents if initial therapy fails. This approach is directly aligned with NICE and BNF recommendations for managing diabetic neuropathy and optimising patient safety.",
    "bullet_explanations": {
      "Duloxetine": "Correct – duloxetine is an evidence-based option for painful diabetic neuropathy, especially when other first-line agents are ineffective or contraindicated.",
      "Amitriptyline": "Incorrect – effective for neuropathic pain, but should be avoided in patients with significant constipation or urinary retention risk.",
      "Carbamazepine": "Incorrect – not recommended for general neuropathic pain or diabetic neuropathy; reserved for trigeminal neuralgia.",
      "Fluoxetine": "Incorrect – SSRIs do not have proven efficacy in neuropathic pain management.",
      "Sodium valproate": "Incorrect – not routinely used for neuropathic pain and lacks evidence for this indication."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Microvascular Complications",
    "topic": "Neuropathy and foot care",
    "keywords": [
      "diabetic neuropathy",
      "neuropathic pain",
      "duloxetine",
      "gabapentin failure",
      "amitriptyline contraindication"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetic complications",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetic-complications/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Neuropathic pain - drug treatment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/neuropathic-pain-drug-treatment/"
      },
      {
        "source": "BNF",
        "topic_title": "Neuropathic pain",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/neuropathic-pain/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4890fd14-dba5-4f7d-8b83-fdff3661f794",
    "question_number": 277,
    "question": "What is the strongest risk factor for placenta accreta in a woman presenting with abnormal placental attachment during her third pregnancy?",
    "options": [
      "History of previous caesarean deliveries",
      "Current cigarette smoking",
      "Pre-existing obesity",
      "Multiple gestation (twins or more)",
      "Diagnosis of endometriosis"
    ],
    "correct_answer": "History of previous caesarean deliveries",
    "explanation": "**Explanation**\n**Placenta accreta** is characterised by abnormal invasion of placental tissue into the myometrium, often leading to life-threatening haemorrhage at delivery. The **most significant risk factor is a history of previous caesarean sections**, due to scar formation that disrupts normal decidualisation and allows abnormal placental adherence. The risk increases with each additional caesarean. Other factors, such as smoking, obesity, multiple gestation, or endometriosis, do not confer as strong a risk for placenta accreta specifically, though they may predispose to other complications.\n\n**Key Points**\n- Placenta accreta = abnormal placental invasion into the uterine wall\n- Strongest risk: **Previous caesarean section(s)** due to uterine scarring\n- Risk rises with increasing number of caesarean deliveries\n- Other risk factors (e.g. advanced maternal age, placenta praevia) are important but less predictive\n- Obesity, smoking, endometriosis, and twin pregnancies are not major risk factors for accreta\n- <table><thead><tr><th>Risk Factor</th><th>Placenta Accreta Association</th></tr></thead><tbody><tr><td>Previous caesarean</td><td>High</td></tr><tr><td>Smoking</td><td>Low</td></tr><tr><td>Obesity</td><td>Low</td></tr><tr><td>Multiple gestation</td><td>Low</td></tr><tr><td>Endometriosis</td><td>Low</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising prior caesarean delivery as the key risk for placenta accreta is critical for antenatal risk stratification, multidisciplinary planning, and informed consent, especially as caesarean rates rise globally.\n\n**Memory Anchor**\nAccreta risk climbs with each Caesarean scar – 'Accreta sticks where scars are.'",
    "bullet_explanations": {
      "History of previous caesarean deliveries": "Correct – Strongest known risk factor due to uterine scarring.",
      "Current cigarette smoking": "Incorrect – Associated with other pregnancy complications, but not specifically placenta accreta.",
      "Pre-existing obesity": "Incorrect – Raises risk for other obstetric issues, not accreta itself.",
      "Multiple gestation (twins or more)": "Incorrect – Increases risk of preterm birth and hypertension, not accreta.",
      "Diagnosis of endometriosis": "Incorrect – Linked to infertility and some adverse outcomes, but not directly to accreta."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "High-risk pregnancy identification",
    "keywords": [
      "placenta accreta",
      "risk factors",
      "caesarean section",
      "high-risk pregnancy"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "cab5cf5d-0acd-4b41-9bef-3da13e3f19cb",
    "question_number": 278,
    "question": "A 58-year-old woman presents to the acute medical unit with crushing retrosternal chest pain radiating to her back. ECG reveals ST depression and T wave inversion in leads I and aVL. Her troponin is raised, and she is haemodynamically stable. She has received 300 mg aspirin. Her GRACE score is 7%. What is the most appropriate next step in her management?",
    "options": [
      "Initiate fondaparinux and ticagrelor, and refer for coronary angiography within 72 hours",
      "Administer fibrinolysis with an antithrombin and ticagrelor",
      "Start fondaparinux, clopidogrel, and schedule coronary angiography in 3 months",
      "Start prasugrel, unfractionated heparin, and refer for emergency PCI within 2 hours",
      "Commence aspirin monotherapy and monitor as an outpatient"
    ],
    "correct_answer": "Initiate fondaparinux and ticagrelor, and refer for coronary angiography within 72 hours",
    "explanation": "**Explanation**\nThis patient has a non-ST elevation myocardial infarction (NSTEMI) with an intermediate-to-high risk GRACE score (>3%). The evidence-based approach is to initiate dual antiplatelet therapy—aspirin (already given) and a second agent such as ticagrelor—plus an antithrombin agent, usually fondaparinux. Coronary angiography is recommended within 72 hours for those at increased risk, unless contraindicated or the patient is unstable, in which case urgent intervention is warranted. **Fibrinolysis is reserved for STEMI** when PCI is unavailable, not for NSTEMI. Prasugrel and urgent PCI are indicated only in the context of STEMI or ongoing instability. Delayed angiography (e.g., after months) is inappropriate, as timely evaluation and potential revascularisation improve outcomes in intermediate/high-risk NSTEMI patients.<br><br><b>Key facts:</b> NSTEMI with intermediate/high GRACE, dual antiplatelet therapy (aspirin + ticagrelor), fondaparinux unless immediate PCI, angiography within 72 hours.\n\n**Key Points**\n- NSTEMI is diagnosed via typical symptoms, raised troponin, and ECG changes (no ST elevation).\n- GRACE score >3% signifies intermediate/high risk, necessitating early angiography (within 72 hours).\n- Dual antiplatelet therapy (aspirin plus ticagrelor or prasugrel) is standard unless bleeding risk is high.\n- Fondaparinux is the antithrombin of choice unless immediate angiography/PCI is planned.\n- Fibrinolytics are **not** used in NSTEMI.\n- <table><thead><tr><th>ACS Type</th><th>Urgent PCI/Fibrinolysis</th><th>Antithrombin</th><th>Angiography Timing</th></tr></thead><tbody><tr><td>STEMI</td><td>Yes</td><td>Antithrombin + 2nd antiplatelet</td><td>Now</td></tr><tr><td>NSTEMI (high GRACE)</td><td>Only if unstable</td><td>Fondaparinux</td><td>&lt;72h</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurate risk stratification is essential in ACS. NICE and BNF guidelines highlight the importance of early invasive strategies and appropriate antithrombotic therapy for NSTEMI patients at intermediate or high risk, as this reduces morbidity and mortality.\n\n**Memory Anchor**\nNSTEMI: 'Fondaparinux and a Friend (second antiplatelet)' if not for immediate PCI; angiography within 72 hours if GRACE >3%.",
    "bullet_explanations": {
      "Initiate fondaparinux and ticagrelor, and refer for coronary angiography within 72 hours": "Correct: This aligns with guidelines for NSTEMI with intermediate/high risk (GRACE >3%).",
      "Administer fibrinolysis with an antithrombin and ticagrelor": "Incorrect: Fibrinolysis is indicated only for STEMI when PCI is unavailable, not for NSTEMI.",
      "Start fondaparinux, clopidogrel, and schedule coronary angiography in 3 months": "Incorrect: Angiography should not be delayed in moderate/high-risk NSTEMI; clopidogrel reserved for specific scenarios (e.g., higher bleeding risk).",
      "Start prasugrel, unfractionated heparin, and refer for emergency PCI within 2 hours": "Incorrect: This regimen is for primary PCI in STEMI, not indicated for stable NSTEMI.",
      "Commence aspirin monotherapy and monitor as an outpatient": "Incorrect: Monotherapy and outpatient management are suitable only for very low-risk patients."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Acute Coronary Syndromes",
    "topic": "NSTEMI/UA risk scores (GRACE/TIMI) and management",
    "keywords": [
      "NSTEMI",
      "GRACE score",
      "fondaparinux",
      "dual antiplatelet",
      "angiography"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Acute coronary syndromes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/acute-coronary-syndromes/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c3841b22-6817-4563-a4b1-dda07d44f98b",
    "question_number": 279,
    "question": "What clinical feature most reliably distinguishes a pyogenic granuloma from an amelanotic malignant melanoma when assessing a rapidly growing vascular skin lesion?",
    "options": [
      "History of preceding trauma at the lesion site",
      "Development beneath the nail plate",
      "Occurrence in an older adult",
      "Lesion located on the plantar surface of the foot",
      "Prolonged, slow increase in size over months"
    ],
    "correct_answer": "History of preceding trauma at the lesion site",
    "explanation": "**Explanation**\n**Pyogenic granulomas** are benign vascular lesions that frequently arise following minor skin trauma, such as a cut, splinter, or insect bite. This link to a **preceding injury** is a key distinguishing feature and is rarely seen in cases of amelanotic malignant melanoma. In contrast, **amelanotic melanoma** typically develops spontaneously, often without any history of trauma. Location and growth pattern may overlap, but the association with prior trauma is most suggestive of pyogenic granuloma. Recognising this difference is crucial, as both lesions can appear as rapidly growing, red nodules but have vastly different prognoses and management pathways.\n\n**Key Points**\n<ul><li><b>Pyogenic granulomas</b> often follow minor trauma to the skin.</li><li><b>Amelanotic melanomas</b> rarely have a history of local injury preceding onset.</li><li>Both lesions can be vascular, red, and rapidly increasing in size.</li><li>Melanomas may involve the nail bed or sole and are more common in older patients.</li><li>Pyogenic granulomas are benign; amelanotic melanoma is malignant and requires urgent assessment.</li></ul>\n\n**Clinical Relevance**\nDistinguishing benign from malignant skin lesions in primary care is vital for patient safety. A clear history of preceding trauma can help differentiate pyogenic granuloma from amelanotic melanoma, guiding appropriate referral and management.\n\n**Memory Anchor**\nPyogenic granuloma = Post-trauma 'popping up' lesion.",
    "bullet_explanations": {
      "History of preceding trauma at the lesion site": "Correct – A recent minor injury is a classic trigger for pyogenic granuloma but not melanoma.",
      "Development beneath the nail plate": "Incorrect – Subungual lesions are more characteristic of amelanotic melanoma.",
      "Occurrence in an older adult": "Incorrect – Amelanotic melanomas are more typical in older adults, but age alone does not distinguish them.",
      "Lesion located on the plantar surface of the foot": "Incorrect – Melanomas commonly occur on the soles; this is not a typical feature of pyogenic granuloma.",
      "Prolonged, slow increase in size over months": "Incorrect – Slow growth is more associated with melanoma; pyogenic granulomas usually grow rapidly."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Skin Malignancy",
    "topic": "Malignant melanoma",
    "keywords": [
      "pyogenic granuloma",
      "amelanotic melanoma",
      "skin lesion diagnosis",
      "trauma history",
      "rapidly growing nodule"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "eaa5cb5c-7eea-44f7-820b-12d8d745adde",
    "question_number": 280,
    "question": "A 2-year-old girl is brought to the surgery for a routine check. Her parent mentions a soft swelling at her navel that becomes more noticeable when she cries. There is no pain, vomiting, or discolouration, and on examination, the swelling is reducible and non-tender. What is the most appropriate next step in management?",
    "options": [
      "Provide reassurance and observe until age 3",
      "Refer urgently to paediatric surgery",
      "Refer routinely to paediatric surgery",
      "Advise surgical repair immediately",
      "Prescribe laxatives to reduce abdominal pressure"
    ],
    "correct_answer": "Provide reassurance and observe until age 3",
    "explanation": "**Explanation**\n**Umbilical hernias in young children are common and usually resolve spontaneously by the age of 3 years**. In the absence of concerning features such as pain, irreducibility, or signs of obstruction/strangulation, the recommended approach is reassurance and observation. **Surgical intervention is generally reserved for hernias that persist beyond age 3–5 years or if complications arise**. There is no role for laxatives unless constipation is an issue, and immediate or routine referral is not indicated without red flag symptoms.\n\n**Key Points**\n- Most umbilical hernias in children close spontaneously by age 3.\n- Key red flag features: pain, irreducibility, discolouration, or signs of obstruction.\n- Surgery is considered if the hernia persists after age 3–5 or if complications develop.\n- Routine or urgent referral is not necessary unless complications are present.\n- Laxatives are only indicated if constipation is a contributing factor.\n\n**Clinical Relevance**\nRecognising the benign nature of most paediatric umbilical hernias prevents unnecessary referrals and anxiety. Early surgical referral is only warranted if there are signs of incarceration or if the hernia persists beyond the expected age of resolution.\n\n**Memory Anchor**\nUmbilical hernias: 'Three before see'—observe until age 3 before considering surgical referral.",
    "bullet_explanations": {
      "Provide reassurance and observe until age 3": "Correct: Most umbilical hernias close spontaneously by age 3, so reassurance and observation is appropriate.",
      "Refer urgently to paediatric surgery": "Incorrect: Urgent referral is only necessary if there are signs of obstruction or strangulation, which are absent here.",
      "Refer routinely to paediatric surgery": "Incorrect: Routine referral is not indicated unless the hernia persists beyond age 3 or is symptomatic.",
      "Advise surgical repair immediately": "Incorrect: Immediate surgery is not indicated for uncomplicated, reducible umbilical hernias in young children.",
      "Prescribe laxatives to reduce abdominal pressure": "Incorrect: Laxatives are not indicated unless there are signs of constipation contributing to abdominal pressure."
    },
    "category": "Paediatrics",
    "subsection": "Neonatology",
    "subsubsection": "Congenital Conditions",
    "topic": "CHD basics",
    "keywords": [
      "umbilical hernia",
      "paediatric",
      "management",
      "spontaneous resolution",
      "surgical referral"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "cc46a3bc-456f-4fb8-8ba6-76f21a7d5193",
    "question_number": 281,
    "question": "Which of the following clinical features is NOT typically associated with ovarian hyperstimulation syndrome (OHSS) following ovulation induction for infertility treatment?",
    "options": [
      "Jaundice",
      "Oliguria",
      "Clinical ascites",
      "Thromboembolic event",
      "Persistent vomiting"
    ],
    "correct_answer": "Jaundice",
    "explanation": "**Explanation**\n**Ovarian hyperstimulation syndrome (OHSS)** is characterised by fluid shifts due to increased vascular permeability after ovulation induction, resulting in symptoms such as ascites, oliguria, gastrointestinal upset (e.g., vomiting), and increased risk of thromboembolism. **Jaundice**—the yellow discolouration of skin and sclerae due to raised bilirubin—is not a recognised feature of OHSS and typically suggests alternative diagnoses such as hepatobiliary or haemolytic disorders. Recognising the absence of jaundice in OHSS is important to avoid misdiagnosis and unnecessary investigations.\n\n**Key Points**\n<ul><li><b>OHSS presents with abdominal pain, ascites, and ovarian enlargement after fertility therapy.</b></li><li>Oliguria may result from intravascular volume depletion.</li><li>Thromboembolic complications are a serious risk in severe OHSS cases.</li><li>Gastrointestinal symptoms (vomiting, nausea) are common in moderate-to-severe OHSS.</li><li><b>Jaundice is not a typical finding in OHSS.</b></li><li>Jaundice usually indicates liver or haemolytic pathology, not a complication of OHSS.</li></ul>\n\n**Clinical Relevance**\nDifferentiating the features of OHSS from other causes of acute illness in women undergoing assisted conception is essential for prompt management and patient safety. Recognising that jaundice is not part of the OHSS spectrum prevents delays in diagnosis of alternative serious conditions.",
    "bullet_explanations": {
      "Jaundice": "Correct – Jaundice is not a recognised manifestation of OHSS.",
      "Oliguria": "Incorrect – Oliguria occurs due to third-space fluid loss and decreased renal perfusion.",
      "Clinical ascites": "Incorrect – Ascites is common in moderate and severe OHSS due to vascular leakage.",
      "Thromboembolic event": "Incorrect – Increased risk of thromboembolism is a known complication of severe OHSS.",
      "Persistent vomiting": "Incorrect – Gastrointestinal upset, including vomiting, is frequently seen in OHSS."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Infertility",
    "topic": "Ovulation induction",
    "keywords": [
      "ovarian hyperstimulation",
      "OHSS",
      "IVF complications",
      "infertility",
      "jaundice"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Polycystic ovary syndrome",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/polycystic-ovary-syndrome/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c7d17821-2375-441a-a898-40059bd08d82",
    "question_number": 282,
    "question": "A 30-year-old pregnant woman attends her first trimester ultrasound at 12 weeks gestation. The scan reveals a live fetus with significant growth restriction, choroid plexus cysts, a single umbilical artery, and overlapping fingers. Which chromosomal abnormality is most strongly suggested by these findings?",
    "options": [
      "Edwards syndrome (Trisomy 18)",
      "Down syndrome (Trisomy 21)",
      "Patau syndrome (Trisomy 13)",
      "Congenital cytomegalovirus infection",
      "Triploidy"
    ],
    "correct_answer": "Edwards syndrome (Trisomy 18)",
    "explanation": "**Explanation**\n**Edwards syndrome (Trisomy 18)** is strongly suggested by the combination of ultrasound findings such as severe fetal growth restriction, choroid plexus cysts, single umbilical artery, and characteristic limb abnormalities, including overlapping fingers. This chromosomal disorder often presents with multiple structural anomalies, including cardiac defects and distinctive limb and craniofacial features. While these sonographic markers are not exclusive to Edwards syndrome, their pattern is highly indicative and should prompt further genetic testing through chorionic villus sampling or amniocentesis. Other causes, such as Down syndrome and Patau syndrome, may share some features but have distinct clinical and ultrasound profiles.\n\n**Key Points**\n- Trisomy 18 (Edwards syndrome) is associated with multiple congenital anomalies.\n- Key ultrasound markers include choroid plexus cysts, overlapping fingers, growth restriction, and single umbilical artery.\n- Other features may include cardiac malformations and rocker bottom feet.\n- Diagnosis is confirmed by karyotype analysis.\n- Most fetuses with Edwards syndrome do not survive beyond infancy.\n\n**Clinical Relevance**\nRecognising the constellation of ultrasound markers for Edwards syndrome in early pregnancy is crucial for timely genetic counselling, appropriate diagnostic steps, and supporting parental decision-making, given the poor prognosis.",
    "bullet_explanations": {
      "Edwards syndrome (Trisomy 18)": "Correct – The described ultrasound features are classic for Edwards syndrome.",
      "Down syndrome (Trisomy 21)": "Incorrect – Down syndrome typically presents with nuchal translucency, cardiac defects, and other markers, but not the full combination described.",
      "Patau syndrome (Trisomy 13)": "Incorrect – Trisomy 13 may show holoprosencephaly and polydactyly, which are not described here.",
      "Congenital cytomegalovirus infection": "Incorrect – CMV can cause growth restriction but lacks the specific limb and cranial anomalies seen here.",
      "Triploidy": "Incorrect – Triploidy can present with severe anomalies, but the specific findings (overlapping fingers, choroid plexus cysts) fit Edwards syndrome best."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Screening for aneuploidy",
    "keywords": [
      "Edwards syndrome",
      "Trisomy 18",
      "ultrasound markers",
      "antenatal screening",
      "fetal anomalies"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "2ffc7051-fd12-4f58-aa16-8a0c333c2723",
    "question_number": 283,
    "question": "Which of the following statements regarding essential tremor is INCORRECT?",
    "options": [
      "The tremor typically worsens with purposeful movement",
      "Symptoms are often temporarily relieved by alcohol consumption",
      "First-degree relatives are frequently affected due to autosomal dominant inheritance",
      "Propranolol is a recognised first-line treatment option",
      "It is usually inherited in an autosomal recessive pattern"
    ],
    "correct_answer": "It is usually inherited in an autosomal recessive pattern",
    "explanation": "**Explanation**\n**Essential tremor most commonly follows an autosomal dominant pattern of inheritance, not autosomal recessive.** This means only one copy of the altered gene is needed for the tremor to be present, and the condition often affects multiple generations. The tremor is classically postural or action-induced, becoming more pronounced during voluntary movements (such as writing or holding objects). Alcohol may transiently improve symptoms, but it is not a recommended treatment due to the risk of misuse. Propranolol, a non-selective beta blocker, is an established first-line therapy for symptom control.\n\n**Key Points**\n- Essential tremor is **autosomal dominant**, with family history often present.\n- Tremor worsens with **intentional or postural movement**.\n- Symptoms may **improve transiently with alcohol**, but this is not a therapeutic recommendation.\n- Propranolol is a **first-line pharmacological treatment**.\n- Autosomal recessive inheritance is NOT typical for essential tremor.\n\n**Clinical Relevance**\nRecognising the inheritance pattern and clinical features of essential tremor is crucial for diagnosis and counselling patients. Understanding effective symptomatic treatments, as outlined in the BNF, ensures best practice and avoids inappropriate prescribing or reassurance.",
    "bullet_explanations": {
      "The tremor typically worsens with purposeful movement": "Incorrect—worsening with movement is typical for essential tremor.",
      "Symptoms are often temporarily relieved by alcohol consumption": "Incorrect—alcohol can transiently reduce tremor severity, though not a recommended treatment.",
      "First-degree relatives are frequently affected due to autosomal dominant inheritance": "Incorrect—autosomal dominant inheritance is the usual pattern, making this a correct statement.",
      "Propranolol is a recognised first-line treatment option": "Incorrect—propranolol is indeed a first-line therapy for essential tremor.",
      "It is usually inherited in an autosomal recessive pattern": "Correct—essential tremor is not usually autosomal recessive; this statement is false."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Movement Disorders",
    "topic": "Essential tremor",
    "keywords": [
      "essential tremor",
      "inheritance",
      "movement disorders",
      "propranolol",
      "autosomal dominant"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Essential tremor, chorea, tics, and related disorders",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/essential-tremor-chorea-tics-and-related-disorders/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "682cb060-e7e2-404d-a20d-0660430c9cff",
    "question_number": 284,
    "question": "A 69-year-old man is admitted following surgery for a fractured femur. Six hours postoperatively, nursing staff note he has not passed any urine. His blood tests reveal a baseline creatinine of 90 μmol/L, now risen to 160 μmol/L. According to current criteria, how would you stage his acute kidney injury (AKI)?",
    "options": [
      "Stage 1 AKI",
      "Stage 2 AKI",
      "Stage 3 AKI",
      "Not classified as AKI",
      "Stage 4 AKI"
    ],
    "correct_answer": "Stage 1 AKI",
    "explanation": "**Explanation**\n**Stage 1 acute kidney injury** is defined by either a 1.5–1.9 times increase in serum creatinine from baseline or a urine output less than 0.5 mL/kg/hr for more than 6 hours. In this case, the creatinine has increased from 90 μmol/L to 160 μmol/L (a 1.78-fold rise), and the patient has had no urine output for 6 hours. Both findings meet the threshold for Stage 1 AKI, but do not reach the criteria for higher stages. Higher stages would require at least a doubling (Stage 2) or tripling (Stage 3) of baseline creatinine, or longer/more severe oliguria or anuria.\n\n**Key Points**\n- AKI is staged by changes in serum creatinine and/or urine output.\n- Stage 1: Creatinine increase 1.5–1.9 × baseline or urine output <0.5 mL/kg/hr for >6 hours.\n- Stage 2: Creatinine increase 2.0–2.9 × baseline or urine output <0.5 mL/kg/hr for >12 hours.\n- Stage 3: Creatinine increase ≥3 × baseline, absolute value ≥354 μmol/L, or anuria for ≥12 hours.\n- There is no Stage 4 AKI in current classification systems.\n- <table><thead><tr><th>Stage</th><th>Creatinine Rise</th><th>Urine Output</th></tr></thead><tbody><tr><td>1</td><td>1.5–1.9 × baseline</td><td>&lt;0.5 mL/kg/hr for &gt;6h</td></tr><tr><td>2</td><td>2.0–2.9 × baseline</td><td>&lt;0.5 mL/kg/hr for &gt;12h</td></tr><tr><td>3</td><td>≥3 × baseline or ≥354 μmol/L</td><td>Anuria ≥12h or &lt;0.3 mL/kg/hr for &gt;24h</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurate staging of AKI guides both immediate management and escalation to specialist care. Recognising even early AKI is essential to prevent further renal damage and complications, as highlighted in NICE guidelines.\n\n**Memory Anchor**\nRemember: '1.5 to 1.9 × creatinine or 6 hours low output = Stage 1'; there is no Stage 4 AKI.",
    "bullet_explanations": {
      "Stage 1 AKI": "Correct – matches both creatinine and urine output criteria for Stage 1.",
      "Stage 2 AKI": "Incorrect – requires at least doubling of creatinine or 12 hours oliguria.",
      "Stage 3 AKI": "Incorrect – needs tripling of creatinine, ≥354 μmol/L, or anuria for 12+ hours.",
      "Not classified as AKI": "Incorrect – both creatinine and urine output changes fulfil AKI diagnostic criteria.",
      "Stage 4 AKI": "Incorrect – there is no Stage 4 in the current AKI staging system."
    },
    "category": "Renal & Urology",
    "subsection": "Acute Kidney Injury",
    "subsubsection": "Diagnosis",
    "topic": "Staging",
    "keywords": [
      "AKI staging",
      "acute kidney injury",
      "creatinine rise",
      "urine output",
      "renal"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Acute kidney injury",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/acute-kidney-injury/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e3be0e2d-d93a-4dbb-80a4-fcbabc19cf99",
    "question_number": 285,
    "question": "A 68-year-old woman is found to have a blood pressure of 172/68 mmHg on three separate clinic visits. She does not have diabetes or chronic kidney disease. According to current UK guidelines, which class of antihypertensive is recommended as first-line therapy for isolated systolic hypertension in this patient?",
    "options": [
      "Calcium channel blocker",
      "ACE inhibitor",
      "Beta-blocker",
      "Alpha-blocker",
      "Potassium-sparing diuretic"
    ],
    "correct_answer": "Calcium channel blocker",
    "explanation": "**Explanation**\n**Calcium channel blockers are the first-line antihypertensive agents** for adults over 55 years old with primary hypertension, including those with isolated systolic hypertension (ISH). ISH, defined as an elevated systolic but normal diastolic blood pressure, is particularly common in older adults due to arterial stiffness. UK guidelines (NICE/BNF) recommend treating ISH using the same algorithm as standard hypertension. Thiazide-like diuretics are suitable alternatives if calcium channel blockers are not tolerated or contraindicated, but calcium channel blockers remain first choice in this demographic.\n\n**Key Points**\n- Isolated systolic hypertension (ISH) is common in older adults.\n- First-line therapy for hypertension in patients over 55 without diabetes or CKD is a calcium channel blocker.\n- ISH is managed using the same stepwise approach as combined hypertension.\n- ACE inhibitors are preferred first-line only for patients under 55 (without black African or African-Caribbean ancestry).\n- Beta-blockers and alpha-blockers are not first-line for uncomplicated hypertension.\n\n**Clinical Relevance**\nCorrect initial management of isolated systolic hypertension in older adults reduces the risk of stroke and cardiovascular disease. Following national guidance ensures optimal outcomes and appropriate prescribing.",
    "bullet_explanations": {
      "Calcium channel blocker": "Correct – First-line for adults over 55 with primary hypertension, including isolated systolic hypertension.",
      "ACE inhibitor": "Incorrect – ACE inhibitors are first-line in younger adults (<55) and in those with diabetes.",
      "Beta-blocker": "Incorrect – No longer recommended as first-line for hypertension unless specific comorbidities exist.",
      "Alpha-blocker": "Incorrect – Reserved for resistant hypertension or specific situations, not first-line.",
      "Potassium-sparing diuretic": "Incorrect – Not a recommended first-line option for primary hypertension."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "Diagnosis (ambulatory/home thresholds)",
    "topic": "NICE A/C/D ladder and special cases",
    "keywords": [
      "isolated systolic hypertension",
      "calcium channel blocker",
      "primary hypertension",
      "elderly",
      "antihypertensive therapy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c4c8e6b9-999c-41ea-81b3-db2f440cd4a3",
    "question_number": 286,
    "question": "A 78-year-old man presents after slipping at home. He is unable to stand, and examination reveals a shortened, externally rotated left leg. Pelvic radiographs demonstrate a stable intertrochanteric extracapsular fracture of the femur. Which is the most appropriate initial surgical management for this injury?",
    "options": [
      "Dynamic hip screw fixation",
      "Total hip arthroplasty",
      "Non-operative management with bed rest",
      "Intramedullary nailing",
      "Hemiarthroplasty"
    ],
    "correct_answer": "Dynamic hip screw fixation",
    "explanation": "**Explanation**\n**Dynamic hip screw (DHS) fixation is the standard surgical treatment for stable extracapsular intertrochanteric femoral fractures**. This device stabilises the fracture and allows for controlled impaction during healing, promoting early mobilisation and reducing complications of immobility. **Total hip arthroplasty and hemiarthroplasty are reserved for displaced intracapsular fractures**, where the risk of avascular necrosis to the femoral head is higher. **Intramedullary nails** may be considered for unstable fracture patterns (e.g., subtrochanteric, reverse oblique), but are not first-line for simple intertrochanteric fractures. **Non-operative management is inappropriate in most ambulatory elderly patients** due to the high risk of complications such as pressure sores, pneumonia, and thromboembolism. Early surgical fixation is recommended to optimise outcomes and minimise morbidity.\n\n**Key Points**\n<ul><li><b>DHS is first-line for stable extracapsular (intertrochanteric) fractures</b></li><li>Hemiarthroplasty/THR are used for displaced intracapsular fractures</li><li>Intramedullary nails are considered for unstable, subtrochanteric, or reverse oblique fractures</li><li>Non-surgical treatment is rarely appropriate due to high morbidity in elderly patients</li><li>Early surgery promotes mobilisation and reduces medical complications</li></ul>\n\n**Clinical Relevance**\nAccurate identification of hip fracture type is crucial for selecting appropriate surgical management. Early operative fixation, as per national guidelines, improves outcomes and reduces the risk of morbidity and mortality in elderly patients with fragility fractures. Recognising the distinction between intracapsular and extracapsular fractures directly influences the choice of implant and patient prognosis.\n\n**Memory Anchor**\nDHS for 'Directly Hip Side' (extracapsular/intertrochanteric); Arthroplasty for 'Artery at risk' (intracapsular).",
    "bullet_explanations": {
      "Dynamic hip screw fixation": "Correct – DHS is the preferred surgical option for stable intertrochanteric extracapsular fractures.",
      "Total hip arthroplasty": "Incorrect – THR is indicated in displaced intracapsular fractures or pre-existing hip arthritis, not routine extracapsular injuries.",
      "Non-operative management with bed rest": "Incorrect – Non-surgical treatment is associated with high complication rates in elderly hip fracture patients.",
      "Intramedullary nailing": "Incorrect – Used for unstable, subtrochanteric, or reverse oblique extracapsular fractures, not first-line for stable intertrochanteric injuries.",
      "Hemiarthroplasty": "Incorrect – Hemiarthroplasty is reserved for displaced intracapsular fractures where blood supply to the femoral head is compromised."
    },
    "category": "Trauma & Orthopaedics",
    "subsection": "Fractures",
    "subsubsection": "NOF fracture management",
    "topic": "NOF fracture management",
    "keywords": [
      "hip fracture",
      "dynamic hip screw",
      "extracapsular",
      "elderly trauma",
      "fracture management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Osteoporosis - prevention of fragility fractures",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/osteoporosis-prevention-of-fragility-fractures/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1a1c28a6-290c-47a2-9857-2119b56dc673",
    "question_number": 287,
    "question": "A 32-year-old woman attends the emergency department with right-sided facial sweating loss, subtle eyelid drooping, and a noticeably smaller right pupil. Which diagnosis best explains these findings?",
    "options": [
      "Horner's syndrome",
      "Argyll Robertson pupil",
      "Third nerve palsy",
      "Holmes-Adie pupil",
      "Sixth nerve palsy"
    ],
    "correct_answer": "Horner's syndrome",
    "explanation": "**Explanation**\n**Horner's syndrome** is characterised by a classic triad: ptosis (drooping of the upper eyelid due to weakness of the Müller muscle), miosis (pupil constriction from unopposed parasympathetic action), and anhidrosis (loss of sweating) on the affected side. These findings result from disruption of the sympathetic nerve supply to the eye and face, which can occur at any point along its three-neuron pathway. Unlike cranial nerve palsies or isolated pupil abnormalities, the combination of eyelid droop, pupillary constriction, and impaired sweating is distinctive for Horner's syndrome.\n\n**Key Points**\n- Horner's syndrome: triad of ptosis, miosis, and anhidrosis\n- Caused by interruption of sympathetic pathway to the eye\n- Ptosis in Horner's is mild (Müller muscle), not severe as in third nerve palsy\n- Miosis is due to unopposed sphincter pupillae activity\n- Anhidrosis affects the ipsilateral face\n- Not associated with eye movement abnormalities\n\n**Clinical Relevance**\nPrompt recognition of Horner's syndrome is important as it may indicate serious underlying pathology (e.g. carotid artery dissection, lung apex tumour). The presence of anhidrosis alongside ptosis and miosis is key to differentiating it from other causes of ptosis and pupillary abnormalities.\n\n**Memory Anchor**\nRemember: \"Ptosis + Miosis + Anhidrosis = Horner's\".",
    "bullet_explanations": {
      "Horner's syndrome": "Correct; the triad of ptosis, miosis, and facial anhidrosis is classic.",
      "Argyll Robertson pupil": "Incorrect; features small, irregular pupils that accommodate but do not react to light, usually bilateral and not associated with ptosis or anhidrosis.",
      "Third nerve palsy": "Incorrect; causes ptosis and a dilated pupil (mydriasis) with impaired eye movement, not miosis or anhidrosis.",
      "Holmes-Adie pupil": "Incorrect; presents with a tonic, dilated pupil that reacts slowly to light, without ptosis or facial anhidrosis.",
      "Sixth nerve palsy": "Incorrect; results in impaired lateral eye movement (abduction) causing diplopia, but does not affect pupil size or cause ptosis/anhidrosis."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Movement Disorders",
    "topic": "Management strategies",
    "keywords": [
      "Horner's syndrome",
      "ptosis",
      "miosis",
      "anhidrosis"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "cb82791c-9c20-4259-9169-4c673b697176",
    "question_number": 288,
    "question": "At what gestational age is the second routine screening for maternal anaemia and atypical red cell alloantibodies typically performed during an uncomplicated pregnancy?",
    "options": [
      "8–12 weeks",
      "11–13+6 weeks",
      "16 weeks",
      "18–20+6 weeks",
      "28 weeks"
    ],
    "correct_answer": "28 weeks",
    "explanation": "**Explanation**\n**The second routine screen for maternal anaemia and atypical red cell alloantibodies is offered at 28 weeks' gestation.** This timing allows for detection of new or worsening anaemia as pregnancy advances, and identifies new red cell antibodies that may have developed since the booking visit. Early detection at this stage enables effective management before labour and delivery. The initial screen occurs at booking (ideally before 10 weeks), while the second is optimally timed at the start of the third trimester. This pattern helps prevent complications such as haemolytic disease of the newborn or maternal morbidity from untreated anaemia. Other routine assessments, such as the nuchal scan (11–13+6 weeks) and anomaly scan (18–20+6 weeks), are done at different gestations and serve distinct purposes.\n\n**Key Points**\n- Second antenatal blood screen for anaemia and atypical red cell antibodies is performed at 28 weeks.\n- First antenatal blood screen is at the booking visit (usually before 10 weeks).\n- Nuchal translucency scan is done between 11–13+6 weeks.\n- Fetal anomaly (mid-trimester) scan occurs at 18–20+6 weeks.\n- Urine testing for asymptomatic bacteriuria is ideally done at booking.\n- Timely identification of anaemia and red cell antibodies reduces maternal and fetal complications.\n\n**Clinical Relevance**\nFollowing the recommended schedule of antenatal tests, including repeat screening for anaemia and atypical red cell antibodies at 28 weeks, is essential for early detection and management of preventable complications. This aligns with UK guidelines for routine antenatal care, improving maternal and neonatal outcomes.",
    "bullet_explanations": {
      "8–12 weeks": "Bloods taken at booking (first appointment), not for the second screen.",
      "11–13+6 weeks": "This timeframe is for the nuchal translucency scan, not for the second blood screen.",
      "16 weeks": "A standard antenatal check, but not when the second anaemia or antibody screen occurs.",
      "18–20+6 weeks": "This is the window for the fetal anomaly (mid-trimester) scan.",
      "28 weeks": "Correct – this is when the second routine screening for anaemia and atypical red cell antibodies is performed."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Booking visit tests",
    "keywords": [
      "antenatal care",
      "28 weeks",
      "anaemia screening",
      "red cell antibodies",
      "pregnancy tests"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Antenatal care - uncomplicated pregnancy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/antenatal-care-uncomplicated-pregnancy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "be710172-348d-4c0b-9791-6e5d0890b1e4",
    "question_number": 289,
    "question": "A 58-year-old man presents with three days of right-sided facial weakness, severe ear pain, hearing loss, and unsteady gait. On examination, you note vesicular lesions within the right external auditory canal. What is the most likely diagnosis?",
    "options": [
      "Bell’s palsy",
      "Meniere’s disease",
      "Ramsay Hunt syndrome",
      "Right-sided stroke",
      "Acute otitis media"
    ],
    "correct_answer": "Ramsay Hunt syndrome",
    "explanation": "**Explanation**\n**Ramsay Hunt syndrome** is characterised by the reactivation of varicella zoster virus in the geniculate ganglion of the facial nerve (cranial nerve VII). This leads to a triad of ipsilateral facial paralysis, ear pain, and a vesicular rash in the external ear or auditory canal. Additional symptoms may include hearing loss, tinnitus, vertigo, and dry mouth/eye due to involvement of the facial and vestibulocochlear nerves. The presence of vesicles in the ear canal distinguishes Ramsay Hunt syndrome from other causes of facial palsy such as Bell’s palsy (which lacks a rash). The process is distinct from stroke, which typically presents with additional neurological deficits and does not cause a vesicular ear eruption.\n\n**Key Points**\n- Ramsay Hunt syndrome is caused by varicella zoster virus reactivation affecting the facial nerve.\n- Key features: facial paralysis, otalgia, and vesicular rash in the ear canal or pinna.\n- Frequently associated with hearing loss, vertigo, and dry mouth/eye.\n- Distinguished from Bell’s palsy by the presence of vesicles and often more severe symptoms.\n- Management includes antivirals (e.g. aciclovir) and corticosteroids for best outcomes.\n\n**Clinical Relevance**\nRecognising Ramsay Hunt syndrome is crucial, as early antiviral and steroid treatment can improve recovery of facial nerve function and reduce complications. Misdiagnosis as Bell’s palsy may result in suboptimal therapy. Current NICE guidelines recommend prompt specialist assessment for atypical facial palsy presentations.\n\n**Memory Anchor**\n‘Herpes zoster oticus = Ramsay Hunt’ (think: 'Hunt' for the vesicles in the ear canal).",
    "bullet_explanations": {
      "Bell’s palsy": "Incorrect – Bell’s palsy presents with facial paralysis but lacks vesicular rash and usually does not include hearing loss or vertigo.",
      "Meniere’s disease": "Incorrect – Meniere’s disease causes vertigo, hearing loss, and tinnitus, but does not cause facial weakness or vesicles.",
      "Ramsay Hunt syndrome": "Correct – Characterised by facial palsy, ear pain, hearing loss, vertigo, and vesicular eruption in the ear canal.",
      "Right-sided stroke": "Incorrect – Stroke may cause facial weakness but would not produce vesicular lesions or isolated cranial nerve involvement.",
      "Acute otitis media": "Incorrect – Otitis media can cause ear pain and sometimes hearing loss, but does not cause facial paralysis or vesicular eruptions."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Headache",
    "topic": "Red flag headache",
    "keywords": [
      "Ramsay Hunt syndrome",
      "facial palsy",
      "herpes zoster oticus",
      "differential diagnosis",
      "ear vesicles"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Shingles",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/shingles/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Bell's palsy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/bells-palsy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "319ed650-10ba-45bc-a003-4009b6d4e654",
    "question_number": 290,
    "question": "A 48-year-old man with longstanding COPD and a history of treated pulmonary tuberculosis presents with recurrent episodes of coughing up blood. He reports chronic cough, intermittent fevers, and weight loss over several months. A recent chest X-ray demonstrates a rounded opacity with an air crescent in the left upper lobe. Which diagnosis best explains these findings?",
    "options": [
      "Aspergilloma",
      "Pulmonary nocardiosis",
      "Lung abscess",
      "Cryptococcal pneumonia",
      "Pulmonary embolism"
    ],
    "correct_answer": "Aspergilloma",
    "explanation": "**Explanation**\n**Aspergilloma** (fungal ball) forms within pre-existing lung cavities, especially following conditions like tuberculosis or emphysema. Patients often present with **recurrent haemoptysis**, chronic cough, and systemic symptoms. Imaging typically shows a mobile mass within a pulmonary cavity, sometimes with an air crescent (Monod sign). Treatment may include antifungal agents such as itraconazole, and in certain cases, surgical intervention. The case scenario—chronic respiratory symptoms, prior TB, haemoptysis, and characteristic radiology—strongly supports this diagnosis. Other options lack the classic radiographic and clinical features of aspergilloma.\n\n**Key Points**\n- Aspergilloma develops in pre-existing lung cavities (often after TB or emphysema).\n- Key symptoms: recurrent haemoptysis, chronic cough, sometimes fever.\n- Chest X-ray/CT: rounded intracavitary mass with air crescent (Monod sign).\n- Commonly caused by Aspergillus fumigatus.\n- Management: antifungal therapy (e.g., itraconazole) and/or surgery for severe haemoptysis.\n- <table><thead><tr><th>Feature</th><th>Aspergilloma</th><th>Lung Abscess</th></tr></thead><tbody><tr><td>Cavity wall</td><td>Thin, pre-existing</td><td>Thick, irregular</td></tr><tr><td>Air crescent sign</td><td>Common</td><td>Rare</td></tr><tr><td>Common cause</td><td>Aspergillus</td><td>Bacterial</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising aspergilloma is crucial in patients with chronic lung disease and haemoptysis, as management differs from bacterial infections or malignancy. Antifungal therapy (e.g., itraconazole) is recommended, and surgical resection may be needed for life-threatening bleeding. Awareness of radiological features aids early diagnosis. Refer to BNF for antifungal treatment guidance.",
    "bullet_explanations": {
      "Aspergilloma": "Correct—forms in pre-existing lung cavities, causes haemoptysis, and typical radiology matches the scenario.",
      "Pulmonary nocardiosis": "Can mimic TB or abscess but less likely to cause a mobile intracavitary mass and air crescent sign.",
      "Lung abscess": "Usually presents with thick-walled cavity and purulent sputum, not a mobile mass with air crescent.",
      "Cryptococcal pneumonia": "More common in advanced HIV; rarely forms cavity or mass with air crescent; usually presents with diffuse infiltrates.",
      "Pulmonary embolism": "Can cause haemoptysis but lacks chronic cavitary lesions and typical imaging findings described."
    },
    "category": "Respiratory",
    "subsection": "Infective",
    "subsubsection": "Bronchiectasis",
    "topic": "Chronic colonisation and exacerbations",
    "keywords": [
      "aspergilloma",
      "haemoptysis",
      "lung cavity",
      "antifungal therapy",
      "chest x-ray"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Antifungals, systemic use",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antifungals-systemic-use/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c8823200-4d4e-453a-b067-754f963ff35f",
    "question_number": 291,
    "question": "A 68-year-old woman with a history of moderate mitral stenosis and hypertension is reviewed in clinic. She experienced a self-terminating episode of atrial fibrillation two weeks ago, but is currently in sinus rhythm. What is the recommended approach to long-term anticoagulation for this patient?",
    "options": [
      "Stop anticoagulation now as she is back in sinus rhythm",
      "Continue anticoagulation indefinitely",
      "Switch to aspirin instead of oral anticoagulation",
      "Continue anticoagulation for 1 month only",
      "Continue anticoagulation for 6 months, then stop if no further AF"
    ],
    "correct_answer": "Continue anticoagulation indefinitely",
    "explanation": "**Explanation**\n**Patients with a history of atrial fibrillation and moderate or severe mitral stenosis are at a persistently elevated risk of thromboembolic stroke, regardless of the presence of sinus rhythm at follow-up.** This risk remains even if the arrhythmia is paroxysmal or appears to have resolved, as AF can recur asymptomatically. **Guidelines recommend lifelong anticoagulation in these patients, with a vitamin K antagonist (warfarin) being preferred over direct oral anticoagulants in the context of valvular AF.** Discontinuing anticoagulation on the basis of restored sinus rhythm is not appropriate as the underlying risk persists.\n\n**Key Points**\n- Mitral stenosis and AF together confer a high risk of stroke.\n- Anticoagulation is indicated even if the patient is in sinus rhythm.\n- Warfarin is preferred in valvular AF (especially with mitral stenosis).\n- Duration of anticoagulation is typically lifelong unless clear contraindications develop.\n- Aspirin is not an adequate alternative for stroke prevention in this context.\n\n**Clinical Relevance**\nLifelong anticoagulation is a critical component of stroke prevention in patients with atrial fibrillation and moderate or severe mitral stenosis. This principle applies even if there is only a history of AF and the patient is currently in sinus rhythm, reflecting the ongoing risk of thromboembolic events.",
    "bullet_explanations": {
      "Stop anticoagulation now as she is back in sinus rhythm": "Incorrect—Sinus rhythm does not eliminate stroke risk in patients with a history of AF and mitral stenosis.",
      "Continue anticoagulation indefinitely": "Correct—Ongoing anticoagulation is recommended due to persistent stroke risk from valvular heart disease and prior AF.",
      "Switch to aspirin instead of oral anticoagulation": "Incorrect—Aspirin does not provide adequate stroke prevention for AF in the setting of mitral stenosis.",
      "Continue anticoagulation for 1 month only": "Incorrect—Short-term anticoagulation is insufficient; risk persists long-term.",
      "Continue anticoagulation for 6 months, then stop if no further AF": "Incorrect—Anticoagulation should not be stopped based on rhythm alone in this scenario."
    },
    "category": "Cardiovascular",
    "subsection": "Arrhythmias & Conduction",
    "subsubsection": "Atrial Fibrillation/Flutter",
    "topic": "Anticoagulation: CHA2DS2-VASc, HAS-BLED",
    "keywords": [
      "atrial fibrillation",
      "mitral stenosis",
      "anticoagulation",
      "warfarin",
      "stroke prevention"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Atrial fibrillation: anticoagulation",
        "citation": "© NICE, 2025",
        "url": ""
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "eb57f447-f896-4af8-9184-1c7a7cf28530",
    "question_number": 292,
    "question": "Which one of the following cancers is the least likely to be caused by a hereditary genetic mutation?",
    "options": [
      "Colorectal cancer",
      "Ovarian cancer",
      "Breast cancer",
      "Endometrial cancer",
      "Lung cancer"
    ],
    "correct_answer": "Lung cancer",
    "explanation": "**Explanation**\n**Lung cancer is rarely caused by inherited genetic mutations.** The vast majority of lung cancer cases are due to environmental and lifestyle factors, particularly tobacco smoking. In contrast, a significant minority of breast, ovarian, colorectal, and endometrial cancers may be linked to hereditary syndromes (such as BRCA mutations or Lynch syndrome). While there are rare familial lung cancer syndromes, they account for only a tiny fraction of cases. Thus, when counselling patients about familial cancer risk, lung cancer is typically not considered a major inherited malignancy.\n\n**Key Points**\n- Most lung cancers are attributable to environmental exposures, especially smoking.\n- Hereditary breast cancer is linked to BRCA1/2 mutations.\n- Ovarian cancer risk is also increased with BRCA mutations.\n- Colorectal and endometrial cancers can be part of Lynch syndrome (HNPCC).\n- Inherited lung cancer syndromes are exceedingly rare.\n\n**Clinical Relevance**\nUnderstanding which cancers have a significant hereditary component is vital for appropriate genetic counselling and risk assessment. Patients with a strong family history of breast, ovarian, colorectal, or endometrial cancers may need referral for genetic evaluation, whereas inherited risk plays a minimal role in lung cancer.\n\n**Memory Anchor**\nThink 'L' for 'Lifestyle'—Lung cancer risk is mainly due to lifestyle (smoking), not lineage.",
    "bullet_explanations": {
      "Colorectal cancer": "Inherited syndromes like Lynch syndrome and familial adenomatous polyposis account for a notable proportion of colorectal cancers.",
      "Ovarian cancer": "BRCA1/2 mutations significantly increase the risk of ovarian cancer; a strong hereditary component exists.",
      "Breast cancer": "Up to 10% of breast cancers are hereditary, mostly due to BRCA gene mutations.",
      "Endometrial cancer": "Can be inherited, especially as part of Lynch syndrome, which increases endometrial cancer risk.",
      "Lung cancer": "Correct – Lung cancer is predominantly caused by environmental factors, with inherited risk being negligible."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Genetics",
    "subsubsection": "Cancer Genetics",
    "topic": "BRCA1/2 inheritance",
    "keywords": [
      "hereditary cancer",
      "BRCA",
      "Lynch syndrome",
      "lung cancer",
      "genetic risk"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Breast cancer - managing FH",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/breast-cancer-managing-fh/"
      },
      {
        "source": "BNF",
        "topic_title": "Breast cancer",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/breast-cancer/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Gastrointestinal tract (lower) cancers - recognition and referral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/gastrointestinal-tract-lower-cancers-recognition-referral/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b8d3f039-564f-4290-8799-014d4cc04fe1",
    "question_number": 293,
    "question": "A 27-year-old woman attends the early pregnancy unit for a routine ultrasound. She has had no vaginal bleeding or abdominal pain, but states her last menstrual period was 10 weeks ago. Transvaginal ultrasound shows a gestational sac with a non-viable embryo and no evidence of cardiac activity. What is the most likely diagnosis?",
    "options": [
      "Missed miscarriage",
      "Incomplete miscarriage",
      "Inevitable miscarriage",
      "Threatened miscarriage",
      "Ectopic pregnancy"
    ],
    "correct_answer": "Missed miscarriage",
    "explanation": "**Explanation**\nA missed miscarriage refers to an intrauterine pregnancy where the embryo or fetus has died, but there are no symptoms of expulsion such as pain or bleeding. **Ultrasound typically shows a gestational sac with a non-viable embryo (no cardiac activity), and the cervix remains closed.** This differentiates it from other forms of miscarriage, which usually present with bleeding or pain. In this scenario, the absence of symptoms combined with ultrasound findings characterises a missed miscarriage. In contrast, incomplete or inevitable miscarriages are associated with ongoing symptoms such as bleeding and/or pain, and in the case of inevitable miscarriage, the cervical os is open. Threatened miscarriage involves bleeding but with a viable pregnancy and closed cervix. Ectopic pregnancy is excluded by the visualisation of an intrauterine gestational sac.\n\n**Key Points**\n- Missed miscarriage: non-viable intrauterine pregnancy without symptoms of expulsion.\n- Diagnosis is confirmed by ultrasound—no fetal cardiac activity in the gestational sac.\n- Distinguished from incomplete/inevitable miscarriage by absence of pain and bleeding.\n- Threatened miscarriage has bleeding but a viable fetus and closed cervix.\n- Ectopic pregnancy involves implantation outside the uterus.\n\n**Clinical Relevance**\nRecognising a missed miscarriage is essential, as it often presents without classic symptoms. Correct diagnosis guides appropriate management, including expectant, medical, or surgical options, and ensures psychological support for the patient. NICE guidelines recommend ultrasound for confirmation and tailored follow-up.\n\n**Memory Anchor**\nMissed miscarriage = Missed symptoms (no pain, no bleeding) but missed fetal viability.",
    "bullet_explanations": {
      "Missed miscarriage": "Correct – describes an intrauterine pregnancy with fetal demise and no symptoms of expulsion.",
      "Incomplete miscarriage": "Incorrect – typically presents with pain, bleeding, and passage of some but not all products of conception.",
      "Inevitable miscarriage": "Incorrect – associated with pain, bleeding, and an open cervical os, but products have not yet passed.",
      "Threatened miscarriage": "Incorrect – presents with vaginal bleeding but a live fetus and closed cervix.",
      "Ectopic pregnancy": "Incorrect – would not show a gestational sac within the uterus; implantation occurs outside the uterine cavity."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Miscarriage types",
    "keywords": [
      "missed miscarriage",
      "early pregnancy loss",
      "ultrasound diagnosis"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Miscarriage",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/miscarriage/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e175b95e-0219-4902-bccd-14ad148436b7",
    "question_number": 294,
    "question": "A 54-year-old man presents to his GP with sudden, severe, stabbing pains affecting the left side of his jaw and cheek. The pain lasts less than a minute and is triggered by activities such as talking or brushing his teeth. Neurological examination is normal. What is the recommended first-line pharmacological treatment for this condition?",
    "options": [
      "Carbamazepine",
      "Pregabalin",
      "Propranolol",
      "Gabapentin",
      "Sumatriptan"
    ],
    "correct_answer": "Carbamazepine",
    "explanation": "**Explanation**\n**Carbamazepine** is the first-line drug for trigeminal neuralgia, a condition characterised by recurrent, brief episodes of severe, unilateral facial pain triggered by innocuous stimuli. Carbamazepine acts as a sodium channel blocker, stabilising hyperexcitable neuronal membranes and thereby reducing paroxysmal pain. Other medications may be considered if carbamazepine is not tolerated, but initial therapy should always begin with this agent unless contraindicated. This approach is backed by UK guidelines, which emphasise carbamazepine as the drug of choice for both diagnostic and therapeutic purposes. Alternative agents or specialist referral are indicated only if first-line therapy fails or is unsuitable. <br><br>**Key contrasts:** Carbamazepine is specifically effective for trigeminal neuralgia. Other agents like gabapentin and pregabalin are preferred for other neuropathic pains but are not first-line here. Beta-blockers (e.g., propranolol) and triptans (e.g., sumatriptan) are used for migraine or cluster headaches, not trigeminal neuralgia.\n\n**Key Points**\n- Carbamazepine is first-line for trigeminal neuralgia.\n- Acts by stabilising voltage-gated sodium channels in neurons.\n- Pain is classically unilateral, paroxysmal, and triggered by light touch or daily activities.\n- If carbamazepine is ineffective or not tolerated, specialist advice is required.\n- Other anti-epileptic drugs (e.g., gabapentin) are reserved for second-line use.\n- Migraine therapies like triptans have no role in trigeminal neuralgia.\n\n**Clinical Relevance**\nRecognising trigeminal neuralgia and promptly initiating carbamazepine can significantly reduce patient morbidity and improve quality of life. UK guidelines (NICE CKS) are clear that carbamazepine is the recommended initial therapy, with alternative treatments considered only after specialist review.\n\n**Memory Anchor**\nCarbamazepine for Cranial (trigeminal) neuralgia: both start with 'C'.",
    "bullet_explanations": {
      "Carbamazepine": "Correct – first-line pharmacological treatment for trigeminal neuralgia.",
      "Pregabalin": "Incorrect – not first-line; may be considered if carbamazepine is unsuitable.",
      "Propranolol": "Incorrect – used for migraine prophylaxis, not for trigeminal neuralgia.",
      "Gabapentin": "Incorrect – alternative for neuropathic pain, but not primary choice for trigeminal neuralgia.",
      "Sumatriptan": "Incorrect – indicated for acute migraine or cluster headaches, not trigeminal neuralgia."
    },
    "category": "Neurology",
    "subsection": "Headache",
    "subsubsection": "Red flag headache",
    "topic": "Trigeminal neuralgia",
    "keywords": [
      "trigeminal neuralgia",
      "carbamazepine",
      "facial pain",
      "neuropathic pain"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Trigeminal neuralgia",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/trigeminal-neuralgia/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "51c84ff0-e909-4a52-8f7f-1863d5d0b9a0",
    "question_number": 295,
    "question": "A 32-year-old woman, 10 days after an uncomplicated spontaneous vaginal delivery, presents to the GP with fever, lower abdominal pain, and malodorous pink vaginal discharge. She is tachycardic and febrile, with suprapubic tenderness and a tender, enlarged uterus on pelvic examination. What is the most appropriate next step in her management?",
    "options": [
      "Urgent hospital admission for intravenous antibiotics",
      "Commence oral co-amoxiclav and arrange outpatient review",
      "Send urine sample and high vaginal swab, await results before treatment",
      "Arrange urgent pelvic ultrasound before initiating therapy",
      "Start oral metronidazole and monitor symptoms in primary care"
    ],
    "correct_answer": "Urgent hospital admission for intravenous antibiotics",
    "explanation": "**Explanation**\nThis woman meets criteria for puerperal pyrexia, defined as a temperature above 38°C within 14 days postpartum. She displays classical features of postnatal endometritis, including **fever, uterine tenderness, and offensive lochia**. Endometritis is the most common cause of postpartum fever and can progress rapidly to sepsis if not managed promptly. Clinical guidelines recommend **immediate hospital admission for intravenous broad-spectrum antibiotics** in women with systemic features or signs of severe infection (such as persistent fever, tachycardia, and uterine tenderness) after delivery. Oral therapy is insufficient in this context, and delaying treatment for investigations risks maternal morbidity.\n\n**Key Points**\n- **Puerperal pyrexia** is defined as temperature >38°C within 14 days after childbirth.\n- Most common cause is **endometritis** (infection of the uterine lining).\n- Key features: fever, suprapubic/uterine tenderness, offensive lochia.\n- Systemic signs (fever, tachycardia, tenderness) mandate **hospital admission**.\n- Management: **Prompt intravenous broad-spectrum antibiotics** (e.g., co-amoxiclav plus metronidazole).\n- Delay for investigations (e.g., ultrasound) is not appropriate if infection is suspected.\n- <table><thead><tr><th>Cause</th><th>Red Flags</th><th>Action</th></tr></thead><tbody><tr><td>Endometritis</td><td>Fever, tender uterus, discharge</td><td>Admit for IV antibiotics</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising and urgently treating postpartum endometritis prevents serious complications, including sepsis. NICE guidance emphasises hospital admission for women with systemic signs of infection in the postnatal period to initiate IV antibiotics without delay.\n\n**Memory Anchor**\nRemember: **'Fever + Tender Uterus = Admit'** in the early postnatal period.",
    "bullet_explanations": {
      "Urgent hospital admission for intravenous antibiotics": "Correct – systemic features and uterine tenderness require inpatient IV antibiotics to prevent sepsis.",
      "Commence oral co-amoxiclav and arrange outpatient review": "Incorrect – oral antibiotics are inadequate for suspected severe postpartum infection.",
      "Send urine sample and high vaginal swab, await results before treatment": "Incorrect – delays urgent therapy, inappropriate in acute systemic illness.",
      "Arrange urgent pelvic ultrasound before initiating therapy": "Incorrect – ultrasound may be helpful if retained products are suspected, but should not delay immediate antibiotic treatment.",
      "Start oral metronidazole and monitor symptoms in primary care": "Incorrect – metronidazole alone does not provide adequate cover and monitoring in primary care is unsafe given systemic signs."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Bleeding in pregnancy",
    "keywords": [
      "puerperal pyrexia",
      "endometritis",
      "postnatal infection",
      "intravenous antibiotics",
      "fever after delivery"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Postnatal care",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/postnatal-care/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0fb189d5-ce72-482d-b952-10d0a5460127",
    "question_number": 296,
    "question": "During a routine examination, a 60-year-old woman with a history of hypertension is found to have a collapsing pulse and a visibly pulsating carotid artery. On cardiac auscultation, which murmur is most characteristically associated with this clinical picture?",
    "options": [
      "Early diastolic murmur",
      "Ejection systolic murmur",
      "Continuous machinery murmur",
      "Late diastolic murmur",
      "Pansystolic murmur"
    ],
    "correct_answer": "Early diastolic murmur",
    "explanation": "**Explanation**\n**Aortic regurgitation** is classically linked to an early diastolic murmur, which is best heard at the left sternal edge with the patient sitting forward in expiration. The regurgitant flow from the aorta back into the left ventricle during diastole creates this decrescendo murmur. Clinical signs such as a collapsing ('water hammer') pulse and head nodding in synchrony with the heartbeat (de Musset's sign) further support this diagnosis. In contrast, other murmurs are linked to different valvular pathologies and have distinguishing auscultatory features.\n\n**Key Points**\n<ul><li><b>Early diastolic murmur</b> is characteristic of aortic regurgitation.</li><li>Collapsing pulse and de Musset's sign are classic physical findings.</li><li>Mitral regurgitation causes a pansystolic murmur.</li><li>Aortic stenosis produces an ejection systolic murmur.</li><li>Patent ductus arteriosus is associated with a continuous machinery murmur.</li><li>Mitral stenosis presents with a late diastolic (mid-diastolic) murmur.</li></ul>\n\n**Clinical Relevance**\nRecognising the distinctive murmur and peripheral signs of aortic regurgitation is vital for prompt diagnosis and management, especially as severe regurgitation can progress to heart failure or require surgical intervention.\n\n**Memory Anchor**\nAR = 'Aortic Regurgitation' = 'ARly diastolic' (Early diastolic murmur)",
    "bullet_explanations": {
      "Early diastolic murmur": "Correct – This is the hallmark murmur of aortic regurgitation.",
      "Ejection systolic murmur": "Incorrect – Typically associated with aortic stenosis, not regurgitation.",
      "Continuous machinery murmur": "Incorrect – Suggests patent ductus arteriosus rather than aortic valve disease.",
      "Late diastolic murmur": "Incorrect – Seen in mitral stenosis, not aortic regurgitation.",
      "Pansystolic murmur": "Incorrect – Characteristic of mitral regurgitation, not aortic regurgitation."
    },
    "category": "Valvular & Structural",
    "subsection": "Aortic Regurgitation & Root",
    "subsubsection": "Acute vs chronic AR features",
    "topic": "Pulse signs and exam findings",
    "keywords": [
      "aortic regurgitation",
      "early diastolic murmur",
      "collapsing pulse",
      "cardiac auscultation"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "bf139f05-5e78-4538-b552-c20aa12cec9b",
    "question_number": 297,
    "question": "A 62-year-old man develops a left lower limb deep vein thrombosis (DVT) two weeks after elective knee replacement surgery. He is initiated on apixaban for treatment. Which of the following interventions is NOT recommended for routine prevention of post-thrombotic syndrome in patients following a DVT?",
    "options": [
      "Elastic graduated compression stockings",
      "Patient education on signs of recurrence",
      "Ongoing therapeutic anticoagulation",
      "Addressing modifiable risk factors",
      "Written information about DVT complications"
    ],
    "correct_answer": "Elastic graduated compression stockings",
    "explanation": "**Explanation**\nCurrent evidence indicates that **elastic graduated compression stockings should not be routinely prescribed to all patients with a DVT solely to prevent post-thrombotic syndrome or recurrence**. Although previously recommended, large studies and updated guidelines have shown no significant benefit in preventing these complications with routine stocking use. Instead, stockings may be used for symptomatic relief in patients experiencing ongoing leg symptoms, but not as a universal preventative measure. In contrast, comprehensive DVT care includes patient education, maintaining anticoagulation, addressing risk factors such as obesity, and providing written information about recurrence risks.\n\n**Key Points**\n- Elastic compression stockings are not routinely advised for post-DVT prevention of post-thrombotic syndrome.\n- Stockings may be considered for symptomatic leg relief but not for all patients.\n- Standard DVT aftercare includes anticoagulation, education, lifestyle modification, and written advice.\n- Patient information improves recognition of recurrence or complications.\n- Addressing modifiable risk factors (e.g., weight, immobility) reduces future VTE risk.\n\n**Clinical Relevance**\nFollowing a DVT, clinicians should focus on evidence-based measures—extended anticoagulation, patient education, and risk factor management. Stockings are reserved for symptom control, not universal prevention, aligning with NICE CKS and BNF guidance.",
    "bullet_explanations": {
      "Elastic graduated compression stockings": "Not recommended for routine prevention of post-thrombotic syndrome after DVT (correct answer).",
      "Patient education on signs of recurrence": "Essential for early identification of DVT recurrence or complications; should always be provided.",
      "Ongoing therapeutic anticoagulation": "Standard of care to reduce risk of recurrence following DVT.",
      "Addressing modifiable risk factors": "Crucial in preventing future VTE events; always part of DVT management.",
      "Written information about DVT complications": "Recommended to enhance patient awareness and safety."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Thrombosis",
    "topic": "Post-thrombotic syndrome prevention",
    "keywords": [
      "DVT",
      "compression stockings",
      "post-thrombotic syndrome",
      "anticoagulation",
      "VTE aftercare"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Deep vein thrombosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/deep-vein-thrombosis/"
      },
      {
        "source": "BNF",
        "topic_title": "Venous thromboembolism",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/venous-thromboembolism/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "123e62af-6c55-4afe-86b9-84481ff2364d",
    "question_number": 298,
    "question": "A 37-year-old premenopausal woman is diagnosed with stage I, oestrogen receptor-positive, HER2-negative breast cancer following a lumpectomy. Which adjuvant endocrine therapy is most appropriate as first-line management for her?",
    "options": [
      "Tamoxifen",
      "Letrozole",
      "Trastuzumab",
      "Goserelin",
      "Anastrozole"
    ],
    "correct_answer": "Tamoxifen",
    "explanation": "**Explanation**\n**Tamoxifen** is the recommended first-line adjuvant endocrine therapy for premenopausal women with early-stage, oestrogen receptor (ER)-positive, HER2-negative breast cancer. Tamoxifen is a selective oestrogen receptor modulator (SERM) that blocks oestrogen activity in breast tissue, thereby reducing the risk of recurrence. Unlike aromatase inhibitors, which only work in postmenopausal women, tamoxifen is effective regardless of ongoing ovarian oestrogen production. Trastuzumab is reserved for HER2-positive tumours, while ovarian suppression agents like goserelin may be considered in higher-risk or selected cases but are not first-line for this scenario.\n\n**Key Points**\n- Tamoxifen is a SERM effective in premenopausal ER-positive breast cancer.\n- Aromatase inhibitors (anastrozole, letrozole) are not effective in premenopausal women unless combined with ovarian suppression.\n- Trastuzumab is indicated only for HER2-positive cancers.\n- Ovarian suppression alone is not standard first-line for early, low-risk ER-positive disease.\n- Adjuvant endocrine therapy reduces recurrence risk in ER-positive breast cancer.\n\n**Clinical Relevance**\nSelecting the appropriate adjuvant therapy for breast cancer depends on menopausal status and tumour receptor characteristics. NICE guidance supports tamoxifen as first-line for premenopausal women with ER-positive, HER2-negative disease, improving long-term outcomes and survivorship.\n\n**Memory Anchor**\nTamoxifen—the 'T' for 'Teenager' and 'Thirty-something' (premenopausal)",
    "bullet_explanations": {
      "Tamoxifen": "Correct: The standard first-line adjuvant endocrine therapy for premenopausal women with ER-positive, HER2-negative breast cancer.",
      "Letrozole": "Incorrect: An aromatase inhibitor suitable only for postmenopausal women or premenopausal women with ovarian suppression.",
      "Trastuzumab": "Incorrect: Used for HER2-positive breast cancers, not indicated for HER2-negative disease.",
      "Goserelin": "Incorrect: A GnRH analogue used for ovarian suppression, but not standard as first-line monotherapy in early ER-positive cases.",
      "Anastrozole": "Incorrect: Another aromatase inhibitor, only effective in postmenopausal women."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Infertility",
    "topic": "Causes",
    "keywords": [
      "breast cancer",
      "tamoxifen",
      "adjuvant therapy",
      "premenopausal",
      "endocrine therapy"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "f94f440e-0d12-4297-b5c2-ecd6389313a5",
    "question_number": 299,
    "question": "Which cytotoxic medication is most closely linked to the development of dose-related pulmonary fibrosis as a significant adverse effect?",
    "options": [
      "Bleomycin",
      "Methotrexate",
      "Doxorubicin",
      "Vincristine",
      "Cyclophosphamide"
    ],
    "correct_answer": "Bleomycin",
    "explanation": "**Explanation**\n**Bleomycin is well recognised for its potential to cause pulmonary fibrosis**, which can be severe, progressive, and sometimes fatal. This complication is dose-dependent and typically presents with dyspnoea, cough, and radiological evidence of interstitial lung disease. The risk increases with cumulative doses, age, underlying lung disease, and concurrent oxygen therapy. Bleomycin-induced lung injury is distinct from the adverse effects seen with other cytotoxic agents, such as haemorrhagic cystitis with cyclophosphamide or cardiotoxicity with doxorubicin. Prompt recognition and discontinuation are crucial to minimise long-term lung damage.\n\n**Key Points**\n- Bleomycin is an antitumour antibiotic used for germ cell tumours, Hodgkin’s lymphoma, and others.\n- The most serious adverse effect is **pulmonary fibrosis**, which is dose-related.\n- Patients may present with progressive shortness of breath, dry cough, and crackles on examination.\n- Risk factors include older age, high cumulative dose, renal impairment, and prior lung disease.\n- Other cytotoxics (e.g. doxorubicin, cyclophosphamide) have different key toxicities.\n- <table><thead><tr><th>Drug</th><th>Key Severe Toxicity</th></tr></thead><tbody><tr><td>Bleomycin</td><td>Pulmonary fibrosis</td></tr><tr><td>Doxorubicin</td><td>Cardiotoxicity</td></tr><tr><td>Cyclophosphamide</td><td>Haemorrhagic cystitis</td></tr><tr><td>Vincristine</td><td>Peripheral neuropathy</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising bleomycin as a cause of pulmonary fibrosis is essential, particularly when monitoring patients on combination chemotherapy. Early detection of respiratory symptoms should prompt urgent evaluation, as continued exposure can worsen lung injury. This knowledge is vital for safe prescribing and patient counselling, as highlighted in the BNF guidance.\n\n**Memory Anchor**\nRemember: **'B' for Bleomycin, 'B' for Breathing (lung) toxicity.**",
    "bullet_explanations": {
      "Bleomycin": "Correct – Bleomycin is notorious for causing dose-related pulmonary fibrosis.",
      "Methotrexate": "Incorrect – Methotrexate can cause pneumonitis, but not classic dose-dependent fibrosis as with bleomycin.",
      "Doxorubicin": "Incorrect – Doxorubicin is more associated with cardiotoxicity, not pulmonary fibrosis.",
      "Vincristine": "Incorrect – Vincristine is linked with peripheral neuropathy, not lung fibrosis.",
      "Cyclophosphamide": "Incorrect – Cyclophosphamide's hallmark toxicity is haemorrhagic cystitis, not pulmonary fibrosis."
    },
    "category": "Respiratory",
    "subsection": "Interstitial & Vascular",
    "subsubsection": "ILD",
    "topic": "IPF vs non-IPF patterns",
    "keywords": [
      "bleomycin",
      "pulmonary fibrosis",
      "cytotoxic drugs",
      "chemotherapy",
      "lung toxicity"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Cytotoxic drugs",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/cytotoxic-drugs/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "3b8441fb-8dad-4c7b-ae1b-e0d4d576ce9e",
    "question_number": 300,
    "question": "A 65-year-old man with a history of heavy smoking is newly diagnosed with COPD after presenting with ongoing daily breathlessness and a chronic productive cough. He uses a short-acting beta-agonist inhaler as needed, but his symptoms remain troublesome. His recent blood tests show no evidence of eosinophilia. What is the most appropriate next step in his pharmacological management?",
    "options": [
      "Start a combination long-acting beta-agonist and long-acting muscarinic antagonist inhaler",
      "Add an inhaled corticosteroid inhaler as monotherapy",
      "Start a combined long-acting beta-agonist and inhaled corticosteroid inhaler",
      "Refer for consideration of alternative diagnoses",
      "Add a combined long-acting muscarinic antagonist and inhaled corticosteroid inhaler"
    ],
    "correct_answer": "Start a combination long-acting beta-agonist and long-acting muscarinic antagonist inhaler",
    "explanation": "**Explanation**\n**For patients with COPD who remain symptomatic despite short-acting bronchodilators, and who lack evidence of asthma or steroid responsiveness (such as eosinophilia, previous asthma diagnosis, or significant diurnal symptom variation), the recommended escalation is to commence both a long-acting beta-agonist (LABA) and a long-acting muscarinic antagonist (LAMA).** Inhaled corticosteroids (ICS) are reserved for those with features suggesting steroid responsiveness, frequent exacerbations, or where symptoms persist despite dual bronchodilator therapy. This stepwise escalation aligns with national guidance for optimising symptom control while minimising unnecessary ICS exposure and associated side effects. By contrast, ICS-containing regimens are not indicated at this stage due to the absence of asthma features or exacerbation history.\n\n\n\n**Key Points**\n<ul><li>LABA + LAMA is first-line escalation for COPD without features of steroid responsiveness</li><li>ICS should only be added if there are frequent exacerbations or asthmatic features</li><li>Asthmatic features include history of asthma, blood eosinophilia, or marked symptom variation</li><li>Monotherapy with ICS is not recommended in COPD</li><li>Optimisation of non-drug management (e.g., smoking cessation) is also essential</li></ul>\n\n**Clinical Relevance**\nCorrect pharmacological escalation in COPD is crucial for effective symptom control and reducing the risk of exacerbations. National guidelines emphasise the importance of identifying steroid-responsive features to avoid unnecessary ICS use, which can increase the risk of pneumonia and other adverse effects.\n\n**Memory Anchor**\nThink: \"No Asthma, No Steroid\"—use dual bronchodilators (LABA + LAMA) if no steroid-responsive features are present.",
    "bullet_explanations": {
      "Start a combination long-acting beta-agonist and long-acting muscarinic antagonist inhaler": "Correct – this is recommended for symptomatic COPD patients without asthmatic or steroid-responsive features.",
      "Add an inhaled corticosteroid inhaler as monotherapy": "Incorrect – ICS monotherapy is not recommended in COPD management.",
      "Start a combined long-acting beta-agonist and inhaled corticosteroid inhaler": "Incorrect – LABA/ICS is only indicated if there are features of asthma or steroid responsiveness.",
      "Refer for consideration of alternative diagnoses": "Incorrect – The patient's presentation and investigations fit typical COPD; escalation of therapy is indicated.",
      "Add a combined long-acting muscarinic antagonist and inhaled corticosteroid inhaler": "Incorrect – This combination is not appropriate at this stage and is not supported by current guidelines."
    },
    "category": "Respiratory",
    "subsection": "Obstructive Airway",
    "subsubsection": "COPD",
    "topic": "Long-term inhaler strategy (LABA/LAMA/ICS)",
    "keywords": [
      "COPD",
      "LABA",
      "LAMA",
      "steroid responsiveness",
      "inhaler escalation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Chronic obstructive pulmonary disease",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/chronic-obstructive-pulmonary-disease/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a9f1f003-f136-4c3f-9e41-39b3992807ae",
    "question_number": 301,
    "question": "A 27-year-old woman develops sudden, profuse vomiting approximately four hours after eating a takeaway meal of fried rice that had been left out at room temperature and then reheated. She has minimal diarrhoea. Which pathogen is most likely responsible for her symptoms?",
    "options": [
      "Bacillus cereus",
      "Salmonella enterica",
      "Campylobacter jejuni",
      "Shigella sonnei",
      "Escherichia coli"
    ],
    "correct_answer": "Bacillus cereus",
    "explanation": "**Explanation**\n**Bacillus cereus** is well recognised for causing food poisoning with rapid onset vomiting, often within 1–5 hours of consuming contaminated food—classically reheated rice. This organism forms heat-resistant spores that can survive cooking. If cooked rice is stored at room temperature, these spores germinate and produce toxins. The emetic toxin is not destroyed by reheating and leads to acute vomiting with minimal or no diarrhoea. In contrast, other foodborne pathogens usually cause symptoms after longer incubation and often present with diarrhoea as the main feature.\n\n**Key Points**\n- Bacillus cereus produces a pre-formed, heat-stable emetic toxin.\n- Symptoms typically start 1–5 hours after ingestion, mainly vomiting.\n- Most frequently associated with reheated rice dishes.\n- Other pathogens (e.g., Salmonella, Campylobacter) have longer incubation and more diarrhoeal illness.\n- Proper food storage (refrigeration) prevents toxin production.\n\n**Clinical Relevance**\nIdentifying food poisoning caused by Bacillus cereus is crucial as it requires distinct preventive advice: safe food storage and prompt refrigeration of cooked rice. Recognising the rapid-onset, vomiting-predominant illness is key for timely diagnosis and reducing unnecessary investigations. This aligns with the NICE CKS guidance on gastroenteritis assessment and management.\n\n**Memory Anchor**\nThink 'B. cereus = 'B' for 'boiled rice' reheated badly'.",
    "bullet_explanations": {
      "Bacillus cereus": "Correct: Causes rapid-onset vomiting after eating reheated rice due to its emetic toxin.",
      "Salmonella enterica": "Incubation is typically 12–72 hours with diarrhoea and fever, not rapid vomiting after rice.",
      "Campylobacter jejuni": "More often linked to undercooked poultry, longer incubation, and bloody diarrhoea.",
      "Shigella sonnei": "Causes dysentery with fever and bloody diarrhoea, not rapid vomiting after rice.",
      "Escherichia coli": "Commonly associated with meat or unwashed vegetables, longer incubation, diarrhoea-predominant."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Upper GI",
    "subsubsection": "Dyspepsia & H. pylori",
    "topic": "Test-and-treat strategy",
    "keywords": [
      "Bacillus cereus",
      "reheated rice",
      "vomiting",
      "food poisoning",
      "emetic toxin"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Gastroenteritis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/gastroenteritis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e6972221-aaca-42b2-a5b4-d3d529ea7726",
    "question_number": 302,
    "question": "What is the recommended first-line pharmacological treatment, alongside dietary and fluid advice, for a 7-year-old girl with a several-month history of infrequent, hard stools and no evidence of faecal impaction?",
    "options": [
      "Dietary and fluid advice plus macrogol (e.g. Movicol Paediatric Plain)",
      "Dietary and fluid advice only",
      "Dietary and fluid advice plus lactulose",
      "Dietary and fluid advice plus senna",
      "Dietary and fluid advice plus referral to specialist nurse"
    ],
    "correct_answer": "Dietary and fluid advice plus macrogol (e.g. Movicol Paediatric Plain)",
    "explanation": "**Explanation**\n**Macrogols (polyethylene glycol-based laxatives) are the first-line pharmacological therapy for chronic constipation in children, in combination with advice on diet and fluid intake.** These agents act as osmotic laxatives, increasing water retention in the stool, making it softer and easier to pass. NICE guidelines specifically recommend starting with a macrogol rather than other laxative types due to better efficacy and tolerability. Dietary and fluid modifications alone are rarely sufficient once significant constipation has developed, and other laxatives such as lactulose or stimulant agents like senna are reserved for specific indications or when macrogols are not tolerated.\n\n**Key Points**\n- Macrogols are first-line for childhood constipation per NICE guidance.\n- Diet and fluid advice should always accompany pharmacological management.\n- Lactulose is less effective and may cause bloating; not first-line.\n- Stimulant laxatives (e.g. senna) are not recommended initially.\n- Specialist referrals are for refractory or complicated cases.\n- <table><thead><tr><th>Laxative type</th><th>Role in paediatric constipation</th></tr></thead><tbody><tr><td>Macrogol</td><td>First-line</td></tr><tr><td>Lactulose</td><td>Second-line if macrogol not tolerated</td></tr><tr><td>Senna</td><td>Consider if others fail</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurate first-line management of paediatric constipation is crucial to prevent chronic issues, reduce distress, and avoid unnecessary referrals. NICE guidance underpins primary care management, promoting use of macrogols to improve outcomes.\n\n**Memory Anchor**\nRemember: Macrogol is the 'go-to' for 'going' in kids!",
    "bullet_explanations": {
      "Dietary and fluid advice plus macrogol (e.g. Movicol Paediatric Plain)": "Correct—this is the NICE-recommended first-line regimen for persistent constipation in children.",
      "Dietary and fluid advice only": "Incorrect—diet and fluids alone are not adequate once constipation is established.",
      "Dietary and fluid advice plus lactulose": "Incorrect—lactulose is less effective and is reserved for when macrogols are not tolerated.",
      "Dietary and fluid advice plus senna": "Incorrect—senna is a stimulant laxative, not recommended as first-line due to side effects.",
      "Dietary and fluid advice plus referral to specialist nurse": "Incorrect—referral is not first-line and is only considered if initial management fails or complications arise."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Nutrition & Development",
    "topic": "Iron deficiency anaemia",
    "keywords": [
      "constipation",
      "paediatric",
      "macrogol",
      "laxative",
      "NICE"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Constipation in children: Management",
        "citation": "© NICE, 2025",
        "url": ""
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "3505bdc4-ea48-4da6-8864-af40cffed43a",
    "question_number": 303,
    "question": "What is the recommended interval for administering the intramuscular depot medroxyprogesterone acetate (DMPA) contraceptive injection in routine clinical practice?",
    "options": [
      "Every 2 weeks",
      "Every 4 weeks",
      "Every 8 weeks",
      "Every 12 weeks",
      "Every 24 weeks"
    ],
    "correct_answer": "Every 12 weeks",
    "explanation": "**Explanation**\n**Depot medroxyprogesterone acetate (DMPA)** is a long-acting progestogen-only injectable contraceptive. The standard regimen involves administering 150 mg intramuscularly every 12 weeks (3 months) to maintain reliable contraceptive cover. This schedule ensures **consistent suppression of ovulation** and provides effective contraception. Administering the injection earlier or later than recommended can reduce efficacy or risk contraceptive failure. Alternative intervals, such as every 2, 4, 8, or 24 weeks, do not provide evidence-based protection and are not supported by clinical guidelines.\n\n**Key Points**\n- Depo Provera (DMPA) is given as an IM injection every 12 weeks.\n- Its primary action is suppression of ovulation; it also thickens cervical mucus and thins the endometrium.\n- If a dose is delayed, it can be given up to 14 weeks after the last injection without extra precautions.\n- Irregular bleeding and delayed return to fertility are recognised disadvantages.\n- Not reversible once administered.\n\n**Clinical Relevance**\nCorrect administration intervals are crucial for maintaining contraceptive efficacy and avoiding unintended pregnancy. All clinicians providing contraception should be familiar with DMPA dosing schedules and counsel women on follow-up and possible side effects.\n\n**Memory Anchor**\nDepo 'Dozen'—Inject every 12 weeks.",
    "bullet_explanations": {
      "Every 2 weeks": "Too frequent; not required and increases risk of side effects.",
      "Every 4 weeks": "Monthly administration is unnecessary for DMPA and not recommended.",
      "Every 8 weeks": "Insufficient interval; not supported by clinical guidelines.",
      "Every 12 weeks": "Correct—this is the standard recommended dosing schedule for DMPA.",
      "Every 24 weeks": "Too infrequent; contraceptive efficacy would be lost before the next dose."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Progesterone-only methods",
    "keywords": [
      "DMPA",
      "Depo Provera",
      "contraception",
      "injectable",
      "progestogen"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Contraceptive injection",
        "citation": "© NICE, 2025",
        "url": ""
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f6c50844-9a8b-42f3-9e07-69bdfacf67b4",
    "question_number": 304,
    "question": "A 55-year-old woman with a history of bipolar disorder presents with persistent thirst and large volumes of dilute urine. A water deprivation test is performed, but there is no significant rise in urine osmolality, even after administration of desmopressin. Which medication is most likely responsible for this clinical scenario?",
    "options": [
      "Lithium",
      "Spironolactone",
      "Sertraline",
      "Hydrochlorothiazide",
      "Carbamazepine"
    ],
    "correct_answer": "Lithium",
    "explanation": "**Explanation**\n**Lithium is a well-known cause of nephrogenic diabetes insipidus (NDI)**. In NDI, the kidneys become insensitive to antidiuretic hormone (ADH), leading to persistent inability to concentrate urine. This is confirmed when there is no significant increase in urine osmolality after both water deprivation and administration of desmopressin (synthetic ADH). This contrasts with cranial (central) diabetes insipidus, where urine osmolality rises following desmopressin. Lithium impairs the kidney’s ability to respond to ADH by interfering with signalling in the renal collecting ducts. Other drugs such as thiazide diuretics or carbamazepine are not typical causes of NDI, though carbamazepine may actually benefit partial central diabetes insipidus by increasing renal sensitivity to ADH.\n\n**Key Points**\n<ul><li>Nephrogenic diabetes insipidus is characterised by renal unresponsiveness to ADH.</li><li>Lithium is the most common drug-induced cause of nephrogenic diabetes insipidus.</li><li>In water deprivation tests, NDI shows no increase in urine osmolality after desmopressin.</li><li>Central DI will show a marked increase in urine osmolality following desmopressin.</li><li>Carbamazepine may enhance ADH effect in partial central DI, not cause NDI.</li></ul><br><table><thead><tr><th>Diabetes Insipidus Type</th><th>Response to Desmopressin</th><th>Common Causes</th></tr></thead><tbody><tr><td>Cranial (central)</td><td>Urine osmolality increases</td><td>Head injury, pituitary disease</td></tr><tr><td>Nephrogenic</td><td>No response</td><td>Lithium, hypercalcaemia</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising lithium as a cause of nephrogenic diabetes insipidus is crucial in psychiatric patients presenting with polyuria and polydipsia. Early identification and withdrawal of lithium can prevent long-term renal complications. This knowledge is directly relevant to safe prescribing and monitoring, as emphasised in UK guidelines.\n\n**Memory Anchor**\nLithium 'leaks' water: think 'Li-thirst-ium' for nephrogenic DI.",
    "bullet_explanations": {
      "Lithium": "Correct – Lithium commonly induces nephrogenic diabetes insipidus by impairing renal response to ADH.",
      "Spironolactone": "Incorrect – Spironolactone is not associated with diabetes insipidus; it affects aldosterone pathways.",
      "Sertraline": "Incorrect – SSRIs like sertraline may cause SIADH (hyponatraemia), not diabetes insipidus.",
      "Hydrochlorothiazide": "Incorrect – Thiazides may paradoxically reduce polyuria in NDI but do not cause it.",
      "Carbamazepine": "Incorrect – Carbamazepine can increase ADH sensitivity and is sometimes used in partial central DI."
    },
    "category": "Renal & Urology",
    "subsection": "Acute Kidney Injury",
    "subsubsection": "Causes",
    "topic": "Drugs",
    "keywords": [
      "nephrogenic diabetes insipidus",
      "lithium",
      "water deprivation test",
      "ADH resistance"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Posterior pituitary hormones and antagonists",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/posterior-pituitary-hormones-and-antagonists/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "91a94ef3-a3ff-45dd-86a9-ab5b8677bda3",
    "question_number": 305,
    "question": "Which medication is most likely to increase the risk of digoxin toxicity in a patient with chronic atrial fibrillation who develops new-onset confusion, blurred vision, and nausea, and is found to have hypokalaemia on blood tests?",
    "options": [
      "Bendroflumethiazide",
      "Eplerenone",
      "Lisinopril",
      "Bisoprolol",
      "St John's wort"
    ],
    "correct_answer": "Bendroflumethiazide",
    "explanation": "**Explanation**\n**Bendroflumethiazide** is a thiazide diuretic that can cause significant loss of potassium, leading to hypokalaemia. **Hypokalaemia increases myocardial sensitivity to digoxin**, raising the risk of digoxin toxicity even if the serum digoxin level is within or only slightly above the therapeutic range. Classical symptoms of digoxin toxicity include gastrointestinal upset (such as nausea), neurological symptoms (such as confusion and visual disturbances), and characteristic ECG changes. Recognising drug-induced electrolyte disturbances is key in preventing and managing digoxin toxicity.\n\n**Key Points**\n- Thiazide diuretics (e.g., bendroflumethiazide) cause potassium loss and hypokalaemia.\n- Hypokalaemia enhances the risk of digitalis (digoxin) toxicity.\n- Symptoms of digoxin toxicity: GI upset, visual changes, confusion, ECG changes (e.g., ST depression, T-wave changes).\n- Elderly patients and those with renal impairment are particularly susceptible.\n- Correcting hypokalaemia is essential in managing digoxin toxicity.\n- <table><thead><tr><th>Drug</th><th>Effect on K+</th><th>Effect on Digoxin Toxicity</th></tr></thead><tbody><tr><td>Thiazide diuretic</td><td>↓</td><td>↑</td></tr><tr><td>Potassium-sparing diuretic</td><td>↑</td><td>↓</td></tr><tr><td>ACE inhibitor</td><td>↑</td><td>↓</td></tr></tbody></table>\n\n**Clinical Relevance**\nIn primary care and hospital settings, clinicians must consider drug interactions and electrolyte disturbances when prescribing for patients on digoxin, as hypokalaemia from medications like thiazide diuretics significantly increases the risk of digitalis toxicity. Early recognition and management are essential to prevent life-threatening complications.\n\n**Memory Anchor**\nThiazides = 'Thin potassium' = Toxicity trigger for digoxin",
    "bullet_explanations": {
      "Bendroflumethiazide": "Correct – Thiazide diuretics deplete potassium, increasing digoxin toxicity risk.",
      "Eplerenone": "Incorrect – This potassium-sparing diuretic increases potassium, which protects against digoxin toxicity.",
      "Lisinopril": "Incorrect – ACE inhibitors tend to increase potassium, reducing digoxin toxicity risk.",
      "Bisoprolol": "Incorrect – Beta-blockers do not cause hypokalaemia or directly interact with digoxin at the level of toxicity.",
      "St John's wort": "Incorrect – Although it can reduce digoxin levels via CYP induction, it does not cause toxicity by hypokalaemia."
    },
    "category": "Cardiovascular",
    "subsection": "Arrhythmias & Conduction",
    "subsubsection": "Atrial Fibrillation/Flutter",
    "topic": "Anticoagulation: CHA2DS2-VASc, HAS-BLED",
    "keywords": [
      "digoxin toxicity",
      "thiazide diuretic",
      "hypokalaemia",
      "drug interaction",
      "atrial fibrillation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Cardiac glycosides",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/cardiac-glycosides/"
      },
      {
        "source": "BNF",
        "topic_title": "Diuretics",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diuretics/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "aebdfa61-f5b8-419f-a1ed-270626749ca8",
    "question_number": 306,
    "question": "A 29-year-old woman with a history of inflammatory bowel disease presents to her GP with a sudden onset of a painful, red right eye associated with photophobia and excessive watering. Visual acuity is slightly reduced, and examination reveals marked ciliary injection. What is the most appropriate initial management?",
    "options": [
      "Arrange same-day referral to ophthalmology",
      "Start topical corticosteroid drops in primary care",
      "Prescribe lubricating eye drops and review in 48 hours",
      "Advise chloramphenicol eye drops for presumed infection",
      "Refer routinely to ophthalmology"
    ],
    "correct_answer": "Arrange same-day referral to ophthalmology",
    "explanation": "**Explanation**\n**Acute anterior uveitis** frequently presents with a painful, red eye, photophobia, and epiphora, particularly in individuals with underlying systemic autoimmune conditions such as inflammatory bowel disease. This is a potential sight-threatening emergency. Diagnosis must be confirmed with slit-lamp examination, which is not available in primary care. **Immediate (same-day) ophthalmology referral** is required for prompt specialist assessment, diagnosis, and treatment (typically topical corticosteroids and cycloplegics under supervision). Initiating corticosteroids in primary care is not recommended, as incorrect use can worsen certain mimic conditions (notably infectious keratitis). Early intervention is crucial to minimise the risk of complications, including synechiae, secondary glaucoma, cataract, and permanent vision loss.\n\n**Key Points**\n- Acute anterior uveitis: presents with red, painful eye, photophobia, and watering\n- Commonly associated with systemic autoimmune disease (e.g., IBD, HLA-B27 syndromes)\n- Diagnosis requires slit-lamp examination by an ophthalmologist\n- Primary care management: urgent same-day referral to ophthalmology\n- Untreated uveitis may cause posterior synechiae, glaucoma, and vision loss\n- Topical steroids should only be started after specialist assessment\n- <table><thead><tr><th>Condition</th><th>Referral urgency</th></tr></thead><tbody><tr><td>Suspected anterior uveitis</td><td>Same-day</td></tr><tr><td>Chronic, mild uveitis</td><td>Routine</td></tr><tr><td>Simple conjunctivitis</td><td>Not required</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrimary care clinicians must promptly recognise acute anterior uveitis and understand that urgent ophthalmology referral is necessary to prevent irreversible visual impairment, as recommended by national guidelines.\n\n**Memory Anchor**\nUveitis = Urgency: U for urgent (same-day) referral",
    "bullet_explanations": {
      "Arrange same-day referral to ophthalmology": "Correct: Urgent specialist assessment is required for suspected acute anterior uveitis.",
      "Start topical corticosteroid drops in primary care": "Incorrect: Topical steroids should not be started in primary care due to risk of worsening undiagnosed infections.",
      "Prescribe lubricating eye drops and review in 48 hours": "Incorrect: This would delay essential assessment and treatment, risking complications.",
      "Advise chloramphenicol eye drops for presumed infection": "Incorrect: Bacterial conjunctivitis is unlikely given pain and photophobia; inappropriate for uveitis.",
      "Refer routinely to ophthalmology": "Incorrect: Routine referral is insufficiently urgent for a potentially sight-threatening presentation."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Anterior uveitis",
    "topic": "Anterior uveitis",
    "keywords": [
      "anterior uveitis",
      "red eye",
      "urgent ophthalmology referral",
      "photophobia"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Uveitis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/uveitis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "c6421089-877f-4605-8aec-7d789cd5cc24",
    "question_number": 307,
    "question": "Which of the following best describes the pharmacological action of venlafaxine in the management of depressive disorders?",
    "options": [
      "Blocks reuptake of both serotonin and noradrenaline",
      "Selective serotonin reuptake inhibitor",
      "Inhibits monoamine oxidase enzymes",
      "Antagonist at dopamine D2 receptors",
      "Blocks presynaptic alpha-2 adrenoreceptors"
    ],
    "correct_answer": "Blocks reuptake of both serotonin and noradrenaline",
    "explanation": "**Explanation**\nVenlafaxine is classified as a **serotonin and noradrenaline reuptake inhibitor (SNRI)**. Its main therapeutic mechanism involves **inhibiting the reuptake of both serotonin and noradrenaline at the synaptic cleft**, thus increasing the levels of these neurotransmitters in the brain. This dual action distinguishes SNRIs from SSRIs, which only affect serotonin. Unlike tricyclic antidepressants, SNRIs such as venlafaxine do not have significant affinity for adrenergic, histaminergic, or cholinergic receptors, minimising some adverse effects seen with older classes.\n\n**Key Points**\n- Venlafaxine is an SNRI, not an SSRI.\n- It increases synaptic serotonin and noradrenaline by blocking their reuptake.\n- SNRIs are used for depression, generalised anxiety disorder, and panic disorder.\n- They are distinct from tricyclic antidepressants and monoamine oxidase inhibitors.\n- Venlafaxine does not act on dopamine receptors or alpha-2 adrenoreceptors.\n\n**Clinical Relevance**\nRecognising the mechanism of venlafaxine is crucial in choosing appropriate antidepressant therapy, understanding side effect profiles, and managing interactions. UK guidelines recommend SNRIs like venlafaxine when SSRIs are ineffective or not tolerated, especially in depressive and anxiety disorders.\n\n**Memory Anchor**\nSNRI = Serotonin and Noradrenaline Reuptake Inhibitor (Venlafaxine, Duloxetine)",
    "bullet_explanations": {
      "Blocks reuptake of both serotonin and noradrenaline": "Correct—this is the precise mechanism of venlafaxine as an SNRI.",
      "Selective serotonin reuptake inhibitor": "Incorrect—SSRIs only affect serotonin; venlafaxine also targets noradrenaline.",
      "Inhibits monoamine oxidase enzymes": "Incorrect—this describes MAOIs, a separate antidepressant class.",
      "Antagonist at dopamine D2 receptors": "Incorrect—this is the main action of antipsychotics, not venlafaxine.",
      "Blocks presynaptic alpha-2 adrenoreceptors": "Incorrect—this is the mechanism of drugs like mirtazapine, not SNRIs."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Depression",
    "topic": "SSRIs vs alternatives",
    "keywords": [
      "venlafaxine",
      "SNRI",
      "antidepressant mechanism",
      "serotonin",
      "noradrenaline"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Antidepressant drugs",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/antidepressant-drugs/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fa2ff2c5-f792-49a0-b5d3-9536a33f4366",
    "question_number": 308,
    "question": "Which of the following is a recognised effect of long-term metformin therapy in patients with type 2 diabetes?",
    "options": [
      "Reduced vitamin B12 absorption",
      "Increased risk of hypoglycaemia",
      "Metabolic alkalosis as a common complication",
      "Aggravation of necrobiosis lipoidica diabeticorum",
      "Mandatory cessation after myocardial infarction"
    ],
    "correct_answer": "Reduced vitamin B12 absorption",
    "explanation": "**Explanation**\nMetformin, a first-line oral hypoglycaemic agent for type 2 diabetes, can reduce the absorption of vitamin B12 with prolonged use. **This effect is generally mild and rarely causes clinical deficiency**, but should be considered in patients presenting with neuropathy or macrocytic anaemia. Metformin does not typically induce hypoglycaemia, unlike sulfonylureas, and is not associated with metabolic alkalosis. There is no evidence that it exacerbates necrobiosis lipoidica diabeticorum, a rare cutaneous manifestation of diabetes. Stopping metformin after myocardial infarction is not routine unless there are specific contraindications such as acute renal impairment or risk of lactic acidosis.\n\n**Key Points**\n- Metformin is first-line for most adults with type 2 diabetes.\n- Can decrease vitamin B12 absorption over time.\n- Does not usually cause hypoglycaemia or weight gain.\n- Common side effects are gastrointestinal (nausea, diarrhoea).\n- Lactic acidosis is rare but serious; monitor in renal impairment.\n- Metformin does not aggravate necrobiosis lipoidica diabeticorum.\n\n**Clinical Relevance**\nAwareness of metformin's impact on vitamin B12 absorption is important, especially in patients with peripheral neuropathy or unexplained anaemia. NICE and BNF guidance highlight metformin's advantages and specify monitoring for side effects, reinforcing its role as the preferred initial therapy for type 2 diabetes.\n\n**Memory Anchor**\nMetformin: Mind the B12!",
    "bullet_explanations": {
      "Reduced vitamin B12 absorption": "Correct—this is a known, though rarely symptomatic, adverse effect of metformin.",
      "Increased risk of hypoglycaemia": "Incorrect—metformin on its own does not cause hypoglycaemia.",
      "Metabolic alkalosis as a common complication": "Incorrect—metformin is not associated with metabolic alkalosis; lactic acidosis is a rare risk.",
      "Aggravation of necrobiosis lipoidica diabeticorum": "Incorrect—no evidence links metformin to worsening this dermatological condition.",
      "Mandatory cessation after myocardial infarction": "Incorrect—metformin is not routinely stopped post-MI unless there is acute renal dysfunction or risk of lactic acidosis."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "Metformin first-line and intolerance",
    "keywords": [
      "metformin",
      "vitamin B12 deficiency",
      "type 2 diabetes",
      "adverse effects",
      "oral hypoglycaemics"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Type 2 diabetes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/type-2-diabetes/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ea62d0ad-125e-4ed9-b343-dc145c93fd22",
    "question_number": 309,
    "question": "A 68-year-old man presents to the Acute Medical Unit with sudden-onset confusion, fever, and palpitations. He has no prior cardiac history. On examination, his temperature is 38.6°C, pulse is 130 bpm and irregular, blood pressure is 88/54 mmHg, and oxygen saturation is 94% on air. Chest auscultation reveals coarse crackles at the left base. ECG confirms new-onset atrial fibrillation with rapid ventricular response. What is the most important immediate intervention?",
    "options": [
      "Administer intravenous broad-spectrum antibiotics and fluids",
      "Start intravenous beta-blocker for rate control",
      "Give oral amiodarone for rhythm control",
      "Initiate oral anticoagulation for stroke prevention",
      "Prescribe oral antibiotics for presumed pneumonia"
    ],
    "correct_answer": "Administer intravenous broad-spectrum antibiotics and fluids",
    "explanation": "**Explanation**\n**Immediate management of sepsis takes precedence in patients with new-onset atrial fibrillation triggered by infection.** In this scenario, the patient exhibits clear signs of sepsis (confusion, hypotension, fever, elevated respiratory rate, and hypoxia) secondary to a likely pneumonia. Sepsis can precipitate atrial fibrillation, especially in those without previous history. The primary goal is to address the underlying infection and haemodynamic instability with prompt intravenous antibiotics and fluid resuscitation. Treating the sepsis may resolve the arrhythmia; rate or rhythm control is only considered if the patient remains unstable after initial resuscitation, or the arrhythmia persists after the underlying cause is addressed. Initiating antiarrhythmic therapy or anticoagulation is not the priority during the acute septic episode.\n\n**Key Points**\n- Sepsis frequently precipitates new-onset atrial fibrillation.\n- Treating the underlying infection and hypoperfusion is the first priority.\n- Prompt intravenous antibiotics and fluids are the mainstay of initial management.\n- Arrhythmias may resolve with sepsis treatment; rate/rhythm control comes later if necessary.\n- Immediate anticoagulation or oral antibiotics are not appropriate in acute, severe sepsis.\n\n**Clinical Relevance**\nRecognising sepsis as the precipitant of acute atrial fibrillation is crucial for safe and effective care. Early sepsis management (antibiotics and fluids) improves survival and may resolve secondary arrhythmias, reflecting current best practice in acute medical settings.",
    "bullet_explanations": {
      "Administer intravenous broad-spectrum antibiotics and fluids": "Correct – sepsis management is the priority; treating the underlying cause may resolve the arrhythmia.",
      "Start intravenous beta-blocker for rate control": "Incorrect – rate control is not the initial step in haemodynamic instability due to sepsis.",
      "Give oral amiodarone for rhythm control": "Incorrect – rhythm control is not indicated before stabilising the patient and addressing the sepsis.",
      "Initiate oral anticoagulation for stroke prevention": "Incorrect – anticoagulation is not the first step in acute management and should be considered only after stabilisation.",
      "Prescribe oral antibiotics for presumed pneumonia": "Incorrect – oral therapy is insufficient in severe sepsis; intravenous antibiotics and fluids are required."
    },
    "category": "Cardiovascular",
    "subsection": "Arrhythmias & Conduction",
    "subsubsection": "Atrial Fibrillation/Flutter",
    "topic": "AF in acute illness (sepsis, thyrotoxicosis)",
    "keywords": [
      "sepsis",
      "atrial fibrillation",
      "acute management",
      "antibiotics",
      "fluid resuscitation"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "f7b1f204-ef4f-411b-9b8b-5cb912d758ba",
    "question_number": 310,
    "question": "In the management of newly diagnosed chronic plaque psoriasis in a 28-year-old woman affecting her elbows and knees, which topical treatment should be prescribed first-line in combination with a potent corticosteroid according to current NICE guidelines?",
    "options": [
      "Introduce a vitamin D analogue",
      "Add a topical retinoid",
      "Apply coal tar preparation",
      "Initiate regular emollient use alone",
      "Start dithranol application"
    ],
    "correct_answer": "Introduce a vitamin D analogue",
    "explanation": "**Explanation**\n**Vitamin D analogues (such as calcipotriol or calcitriol) are recommended as first-line topical therapy for chronic plaque psoriasis when used in combination with a potent corticosteroid.** This combination maximises efficacy by targeting abnormal keratinocyte proliferation and reducing inflammation. NICE guidelines advise applying both agents once daily (at different times of day) for up to 4 weeks, with the possibility of extending corticosteroid use to a maximum of 8 weeks. Vitamin D analogues should not be used as monotherapy for severe or widespread disease, but they are preferred over alternatives like coal tar or dithranol due to better tolerability and safety profiles. Retinoids and dithranol are reserved for refractory cases or specific circumstances. Regular emollients are important as adjuncts but are insufficient as monotherapy for active plaque psoriasis.<br><br><b>Key Points:</b><ul><li>First-line topical therapy for limited chronic plaque psoriasis: potent corticosteroid + vitamin D analogue</li><li>Apply both agents once daily, ideally at different times</li><li>Vitamin D analogues reduce epidermal proliferation and inflammation</li><li>Coal tar and dithranol have more side effects and are less commonly used first-line</li><li>Emollients are supportive, not primary, therapy</li></ul><br><b>Clinical Relevance:</b> Following NICE recommendations ensures safe and effective initial management of chronic plaque psoriasis, optimising outcomes and reducing side effects. Recognising which treatments are first-line helps avoid unnecessary delays or ineffective regimens.<br><br><b>Memory Anchor:</b> \"Psoriasis: Pair Steroid with D for Double effect (D = vitamin D analogue)\"",
    "bullet_explanations": {
      "Introduce a vitamin D analogue": "Correct – NICE recommends combining a potent corticosteroid with a vitamin D analogue as first-line topical treatment.",
      "Add a topical retinoid": "Incorrect – Topical retinoids are not first-line for plaque psoriasis and are mainly used for acne.",
      "Apply coal tar preparation": "Incorrect – Coal tar is not preferred due to side effects and odour; it is not recommended as first-line in current guidelines.",
      "Initiate regular emollient use alone": "Incorrect – Emollients are useful as adjuncts but are not sufficient as primary therapy for active plaque psoriasis.",
      "Start dithranol application": "Incorrect – Dithranol is reserved for refractory cases and is not used as first-line due to irritation and staining."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Psoriasis types",
    "topic": "Psoriasis types",
    "keywords": [
      "psoriasis",
      "vitamin D analogue",
      "topical corticosteroid",
      "NICE guidelines",
      "chronic plaque"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "2aec9866-2508-4929-b846-6b0dd055dba8",
    "question_number": 311,
    "question": "A 15-year-old boy is referred to the sleep clinic after repeatedly collapsing suddenly during moments of excitement, such as while playing video games. His parents also note that he struggles to stay awake at school and frequently naps during the day. What is the most likely explanation for his symptoms?",
    "options": [
      "Cataplexy associated with narcolepsy",
      "Vasovagal syncope",
      "Childhood absence seizures",
      "Cardiogenic syncope",
      "Nocturnal epilepsy"
    ],
    "correct_answer": "Cataplexy associated with narcolepsy",
    "explanation": "**Explanation**\n**Cataplexy is the sudden, brief loss of muscle tone triggered by strong emotions such as laughter, excitement, or surprise.** It is a hallmark feature of narcolepsy and often presents alongside excessive daytime sleepiness. Unlike syncope, there is no loss of consciousness during cataplexy. The scenario describes recurrent episodes triggered by emotional stimuli and persistent sleepiness, both classic features of narcolepsy with cataplexy. In contrast, vasovagal syncope usually relates to triggers like pain or standing, and epileptic events have a different pattern of loss of consciousness or post-ictal confusion.\n\n**Key Points**\n- Cataplexy: Sudden muscle weakness without loss of consciousness, triggered by emotions\n- Narcolepsy: Chronic disorder with excessive daytime sleepiness and cataplexy in some cases\n- Vasovagal syncope: Typically provoked by pain, fear, or prolonged standing, not emotions\n- Absence seizures: Involve brief loss of awareness, not sudden muscle collapse\n- Cardiac syncope: Sudden loss of consciousness, often with no warning, requires cardiac evaluation\n\n**Clinical Relevance**\nRecognising cataplexy is crucial as it strongly suggests narcolepsy, which impacts quality of life and learning. Early diagnosis enables targeted management and can reduce misdiagnosis as epilepsy or behavioural problems. NICE CKS advises careful history-taking to distinguish between syncope, epilepsy, and sleep disorders.\n\n**Memory Anchor**\nCataplexy = 'Collapse with Comedy' (emotion-induced muscle loss, not true syncope)",
    "bullet_explanations": {
      "Cataplexy associated with narcolepsy": "Correct – fits the pattern of emotion-triggered collapses and daytime sleepiness.",
      "Vasovagal syncope": "Incorrect – usually linked to pain, fear, or standing, not excitement or laughter.",
      "Childhood absence seizures": "Incorrect – present as brief staring and impaired awareness, not sudden collapse.",
      "Cardiogenic syncope": "Incorrect – sudden unconsciousness, not usually emotion-triggered, and requires further cardiac workup.",
      "Nocturnal epilepsy": "Incorrect – seizures occur during sleep, not with daytime emotional triggers."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Depression",
    "topic": "Diagnostic criteria",
    "keywords": [
      "cataplexy",
      "narcolepsy",
      "syncope",
      "sleep disorders",
      "emotion-triggered collapse"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Blackouts and syncope",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/blackouts-syncope/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "03b7e7c8-0702-4c19-b7c4-19ee4e69db82",
    "question_number": 312,
    "question": "A 28-year-old man with a history of persistent high blood pressure despite multiple antihypertensives presents with headaches and intermittent leg fatigue. On examination, his right arm blood pressure is 176/86 mmHg, while his right leg blood pressure is 138/78 mmHg. Femoral pulses are weak compared to the radial pulse. Which diagnosis best explains these findings?",
    "options": [
      "Coarctation of the aorta",
      "Primary (essential) hypertension",
      "Renal artery stenosis",
      "Aortic stenosis",
      "Left subclavian artery stenosis"
    ],
    "correct_answer": "Coarctation of the aorta",
    "explanation": "**Explanation**\n**Coarctation of the aorta** is a congenital narrowing of the aorta, typically just distal to the origin of the left subclavian artery. This leads to elevated upper limb blood pressure and reduced lower limb blood pressure, often with diminished or delayed femoral pulses (radio-femoral delay). The hallmark is a significant systolic blood pressure difference between the arms and legs. In contrast, primary hypertension would not cause such a discrepancy, and renal artery stenosis may cause hypertension but does not typically create pulse or BP differences between limbs. Aortic stenosis affects the left ventricular outflow tract, not peripheral pulses, while left subclavian artery stenosis would primarily reduce BP in the left arm, not the legs.\n\n**Key Points**\n- Coarctation commonly causes hypertension in young adults.\n- Classic findings: higher BP in arms than legs, weak/delayed femoral pulses.\n- May present with headaches, claudication, or murmurs.\n- Primary hypertension does not cause limb BP differences.\n- Renal artery stenosis causes secondary hypertension without pulse discrepancies.\n- Aortic stenosis causes systolic murmurs but not upper-lower BP differences.\n\n**Clinical Relevance**\nSuspecting secondary hypertension in young patients—especially with pulse or BP discrepancies—is crucial for timely diagnosis and referral. Coarctation of the aorta is a reversible cause of hypertension and may prevent future cardiovascular complications if recognised early. National guidance (NICE) emphasises investigating secondary causes when hypertension presents atypically or at a young age.\n\n**Memory Anchor**\nThink 'C for Coarctation = C for Constriction just after the subclavian'—leads to upper body hypertension, lower body hypoperfusion.",
    "bullet_explanations": {
      "Coarctation of the aorta": "Correct – explains arm-leg BP difference and weak femoral pulses.",
      "Primary (essential) hypertension": "Incorrect – does not cause differences in limb BP or pulses.",
      "Renal artery stenosis": "Incorrect – may cause refractory hypertension, but not limb BP discrepancies.",
      "Aortic stenosis": "Incorrect – causes outflow obstruction but not differential limb BP.",
      "Left subclavian artery stenosis": "Incorrect – would lower BP in the left arm, not affect both arms vs legs."
    },
    "category": "Cardiovascular",
    "subsection": "Hypertension & Vascular",
    "subsubsection": "Hypertension",
    "topic": "Secondary causes workup (renal, endocrine)",
    "keywords": [
      "secondary hypertension",
      "coarctation",
      "arm-leg blood pressure difference"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hypertension",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4c0ad0a6-7fed-406b-bc6e-76f221445dd7",
    "question_number": 313,
    "question": "A 27-year-old man presents to the emergency department with sudden onset of palpitations. His ECG shows a regular, narrow-complex tachycardia at 180 bpm. He is haemodynamically stable and reports no chest pain or breathlessness. Initial vagal manoeuvres are unsuccessful. What is the next recommended step in his acute management?",
    "options": [
      "Administer intravenous adenosine",
      "Start intravenous amiodarone",
      "Attempt immediate DC cardioversion",
      "Prescribe oral beta-blocker",
      "Give intravenous magnesium sulphate"
    ],
    "correct_answer": "Administer intravenous adenosine",
    "explanation": "**Explanation**\n**In haemodynamically stable patients with paroxysmal supraventricular tachycardia (SVT), if vagal manoeuvres fail, intravenous adenosine is the next step.** Adenosine transiently blocks AV nodal conduction, often terminating AV node-dependent re-entrant tachycardias such as AVNRT or AVRT. This approach is recommended before considering other antiarrhythmic drugs or electrical cardioversion in stable patients. **Amiodarone and magnesium are not first-line for SVT** and are reserved for other arrhythmias. **DC cardioversion is reserved for patients who are unstable or refractory to pharmacological measures.** Oral beta-blockers are not suitable for acute termination.\n\n**Key Points**\n- SVT presents with regular, narrow-complex tachycardia and sudden onset palpitations.\n- Vagal manoeuvres (Valsalva, carotid massage) are first-line but often insufficient.\n- Adenosine is the recommended next step in stable patients when vagal manoeuvres fail.\n- Adenosine is contraindicated in patients with severe asthma.\n- DC cardioversion is only indicated if the patient is unstable.\n- Amiodarone and magnesium are not effective for AV nodal re-entry tachycardias.\n- <table><thead><tr><th>Step</th><th>Stable Patient</th><th>Unstable Patient</th></tr></thead><tbody><tr><td>First-line</td><td>Vagal manoeuvres</td><td>Immediate DC cardioversion</td></tr><tr><td>Second-line</td><td>IV adenosine</td><td>–</td></tr></tbody></table>\n\n**Clinical Relevance**\nRapid recognition and evidence-based management of SVT are crucial to prevent deterioration and unnecessary interventions. UK guidelines and the BNF recommend adenosine after failed vagal manoeuvres for stable SVT, reserving cardioversion for instability or refractory cases.\n\n**Memory Anchor**\nAdenosine 'A' for AVNRT/AVRT—Always After vagal manoeuvres.",
    "bullet_explanations": {
      "Administer intravenous adenosine": "Correct—recommended second-line for stable SVT after vagal manoeuvres fail.",
      "Start intravenous amiodarone": "Incorrect—amiodarone is not used in the acute management of SVT.",
      "Attempt immediate DC cardioversion": "Incorrect—DC cardioversion is only for unstable patients or when pharmacological options fail.",
      "Prescribe oral beta-blocker": "Incorrect—oral beta-blockers are not suitable for acute termination of SVT.",
      "Give intravenous magnesium sulphate": "Incorrect—magnesium is reserved for torsades de pointes or certain ventricular arrhythmias."
    },
    "category": "Cardiovascular",
    "subsection": "Arrhythmias & Conduction",
    "subsubsection": "SVT & Pre-excitation",
    "topic": "AVNRT/AVRT acute termination (vagal, adenosine)",
    "keywords": [
      "SVT",
      "adenosine",
      "vagal manoeuvres",
      "tachycardia management"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Arrhythmias",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/arrhythmias/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "6697a642-5295-4a76-96f5-1d5c2b9aab01",
    "question_number": 314,
    "question": "Which medication is most appropriate for reducing cerebral oedema in a patient with a newly diagnosed intracranial tumour presenting with raised intracranial pressure?",
    "options": [
      "Dexamethasone",
      "Hydrocortisone",
      "Furosemide",
      "Hypertonic saline",
      "Mannitol"
    ],
    "correct_answer": "Dexamethasone",
    "explanation": "**Explanation**\n**Dexamethasone is the corticosteroid of choice for managing vasogenic oedema associated with brain tumours.** This type of oedema is due to disruption of the blood-brain barrier, leading to fluid accumulation in the brain parenchyma. Dexamethasone’s potent glucocorticoid effects reduce capillary permeability, thereby decreasing fluid leakage and swelling. Other corticosteroids (such as hydrocortisone) lack the same efficacy for cerebral oedema, and agents like diuretics or osmotic therapies are generally reserved for acute management of raised intracranial pressure or herniation, not for tumour-related oedema. <br><br>**Key contrasts:** Dexamethasone is preferred for tumour-related oedema; mannitol and hypertonic saline are used acutely in severe raised ICP or herniation, but not for long-term tumour swelling.\n\n**Key Points**\n- Dexamethasone is first-line for cerebral oedema due to intracranial tumours.\n- Acts by reducing capillary permeability and inflammation.\n- Hydrocortisone is not effective for cerebral oedema.\n- Mannitol and hypertonic saline are for acute raised ICP, not tumour-associated oedema.\n- Furosemide is a diuretic, not indicated for brain tumour-related oedema.\n- <table><thead><tr><th>Drug</th><th>Indication</th></tr></thead><tbody><tr><td>Dexamethasone</td><td>Tumour-related cerebral oedema</td></tr><tr><td>Mannitol</td><td>Acute raised ICP</td></tr><tr><td>Hydrocortisone</td><td>Adrenal insufficiency</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition and management of cerebral oedema in patients with brain tumours is crucial for symptom control and prevention of neurological deterioration. Dexamethasone is supported by clinical guidelines for this indication.\n\n**Memory Anchor**\nThink 'Dexa' for 'De-swelling' in brain tumours.",
    "bullet_explanations": {
      "Dexamethasone": "Correct – it is the steroid of choice for brain tumour-related cerebral oedema.",
      "Hydrocortisone": "Incorrect – less effective for cerebral oedema; used mainly in adrenal insufficiency.",
      "Furosemide": "Incorrect – a loop diuretic, not effective for reducing cerebral oedema from tumours.",
      "Hypertonic saline": "Incorrect – reserved for acute emergencies of raised intracranial pressure, not standard for tumour oedema.",
      "Mannitol": "Incorrect – used for acute raised intracranial pressure, not for long-term management of tumour-associated swelling."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Stroke & TIA",
    "topic": "Acute management",
    "keywords": [
      "cerebral oedema",
      "dexamethasone",
      "brain tumour",
      "intracranial pressure"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Brain and central nervous system cancers - recognition and referral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/brain-central-nervous-system-cancers-recognition-referral/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5cca1e63-f52b-4393-a42b-8c238e636c72",
    "question_number": 315,
    "question": "Which vitamin should be routinely supplemented in a breastfeeding mother who follows a strict vegan diet, in order to ensure adequate nutrition for her infant?",
    "options": [
      "Vitamin B12",
      "Vitamin A",
      "Vitamin C",
      "Vitamin B1",
      "Iron"
    ],
    "correct_answer": "Vitamin B12",
    "explanation": "**Explanation**\n**Vitamin B12 (cobalamin) is found almost exclusively in animal-derived foods**, such as meat, dairy, and eggs. Vegans are at significant risk of deficiency, which can manifest in both the mother and breastfed infant—potentially causing developmental delay, anaemia, and neurological impairment in the baby. Although some fortified foods may provide B12, supplementation is generally advised during breastfeeding. Vitamin A, B1 (thiamine), C, and iron are more readily available from plant sources or are not universally required as supplements in vegan breastfeeding mothers unless specific deficiencies are identified.\n\n**Key Points**\n- Vitamin B12 is not naturally present in plant-based foods.\n- Breastfed infants are dependent on maternal stores and dietary intake for B12.\n- Deficiency in infants can cause irreversible neurological damage.\n- UK guidelines recommend routine B12 supplementation for vegan breastfeeding mothers.\n- Vitamin D supplementation is universally recommended during breastfeeding, regardless of diet.\n\n**Clinical Relevance**\nEnsuring adequate vitamin B12 intake in vegan breastfeeding mothers is crucial for infant health. Awareness of this recommendation helps prevent avoidable deficiency-related complications, aligning with NHS guidance on maternal and child nutrition.\n\n**Memory Anchor**\nB12 for 'Baby's Brain'—vegan mums need B12 so their breastfed baby's development isn't at risk.",
    "bullet_explanations": {
      "Vitamin B12": "Correct—B12 is not available in a vegan diet unless fortified or supplemented, and deficiency risks infant health.",
      "Vitamin A": "Incorrect—adequate vitamin A can generally be obtained from plant sources (as carotenoids) in a varied vegan diet.",
      "Vitamin C": "Incorrect—plant-based diets are typically rich in vitamin C (fruits and vegetables).",
      "Vitamin B1": "Incorrect—thiamine is found in many plant foods and is rarely deficient in vegan diets.",
      "Iron": "Incorrect—although iron is less bioavailable from plant sources, routine supplementation is not universally required unless there is documented deficiency."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Nutrition",
    "subsubsection": "Micronutrients",
    "topic": "B12/folate deficiency",
    "keywords": [
      "vegan",
      "breastfeeding",
      "vitamin B12",
      "maternal nutrition",
      "supplementation"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NHS choices",
        "topic_title": "Vegetarian, vegan and special diets in pregnancy and breastfeeding",
        "citation": "© Crown copyright",
        "url": "http://www.nhs.uk/Livewell/Vegetarianhealth/Pages/Pregnancyandchildren.aspx"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d5b89ea9-fabd-476b-bc21-4d3404ce873c",
    "question_number": 316,
    "question": "Which congenital heart defect is the most frequent cause of cyanosis in a newborn within the first 48 hours of life?",
    "options": [
      "Transposition of the great arteries",
      "Ventricular septal defect",
      "Atrial septal defect",
      "Patent ductus arteriosus",
      "Coarctation of the aorta"
    ],
    "correct_answer": "Transposition of the great arteries",
    "explanation": "**Explanation**\n**Transposition of the great arteries (TGA)** is the leading cause of cyanotic congenital heart disease presenting in the neonatal period. In TGA, the aorta and pulmonary artery are switched, resulting in parallel rather than series circulation. This leads to profound hypoxaemia unless there is mixing at the atrial, ventricular, or ductal level. **Cyanosis typically appears within the first hours to days of life** as the ductus arteriosus closes. In contrast, other defects such as Tetralogy of Fallot usually present later (weeks to months), and acyanotic defects (such as VSD, ASD, PDA, and coarctation) do not cause early central cyanosis.\n\n**Key Points**\n- TGA is the most common cause of cyanosis in newborns within the first 48 hours.\n- Cyanosis results from parallel systemic and pulmonary circulations.\n- Early presentation is due to closure of the ductus arteriosus, which limits blood mixing.\n- Other defects (VSD, ASD, PDA, coarctation) are typically acyanotic in neonates.\n- <table><thead><tr><th>Defect</th><th>Cyanosis at Birth?</th></tr></thead><tbody><tr><td>TGA</td><td>Yes</td></tr><tr><td>Tetralogy of Fallot</td><td>No (later)</td></tr><tr><td>VSD/ASD/PDA</td><td>No</td></tr></tbody></table>\n\n**Clinical Relevance**\nTimely recognition of TGA is critical, as early intervention (e.g., prostaglandin infusion to maintain ductal patency) can be lifesaving. Differentiating between cyanotic and acyanotic defects in neonates guides prompt referral to paediatric cardiology.\n\n**Memory Anchor**\nTGA = 'Two Great Arteries Transposed' = 'Total (cyanosis) at birth'",
    "bullet_explanations": {
      "Transposition of the great arteries": "Correct – TGA is the leading cause of early neonatal cyanosis.",
      "Ventricular septal defect": "Usually presents as an acyanotic lesion initially; cyanosis is rare in neonates.",
      "Atrial septal defect": "Typically acyanotic and often asymptomatic in early life.",
      "Patent ductus arteriosus": "Commonly acyanotic; may cause cyanosis only if Eisenmenger syndrome develops later.",
      "Coarctation of the aorta": "Presents with shock or heart failure, not cyanosis, and usually after the first few days."
    },
    "category": "Cardiovascular",
    "subsection": "Valvular & Structural",
    "subsubsection": "Congenital Heart Disease",
    "topic": "Cyanotic vs acyanotic lesions: early neonatal presentation",
    "keywords": [
      "neonatal cyanosis",
      "congenital heart disease",
      "transposition of the great arteries"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "ca2a2021-6c58-42af-8e21-7f48176360b7",
    "question_number": 317,
    "question": "When performing a medication review for a 79-year-old woman with recently diagnosed Alzheimer's disease and chronic osteoarthritis, which class of medication should be avoided due to its potential to worsen cognitive decline?",
    "options": [
      "Tricyclic antidepressants",
      "Direct oral anticoagulants",
      "Bisphosphonates",
      "Statins",
      "Low-dose aspirin"
    ],
    "correct_answer": "Tricyclic antidepressants",
    "explanation": "**Explanation**\n**Tricyclic antidepressants (TCAs)**, such as amitriptyline, pose a significant risk of exacerbating cognitive impairment in patients with dementia due to their strong antimuscarinic (anticholinergic) effects. Anticholinergic burden is directly linked to memory problems, confusion, and increased risk of delirium, particularly in older adults and those with pre-existing cognitive decline. The STOPP criteria and national prescribing guidelines recommend avoiding medications with anticholinergic properties in dementia. In contrast, the other listed drugs do not carry substantial anticholinergic risk and may be appropriate when indicated for comorbid conditions.\n\n**Key Points**\n- TCAs have high antimuscarinic (anticholinergic) activity, worsening cognition in dementia.\n- Anticholinergic burden increases confusion, memory disturbance, and delirium risk.\n- Prescribing guidelines advise minimising anticholinergic drugs in Alzheimer's disease.\n- Alternative antidepressants (e.g., SSRIs) are preferred in older adults with dementia.\n- Other options listed (DOACs, bisphosphonates, statins, low-dose aspirin) are not anticholinergic.\n\n**Clinical Relevance**\nClinicians should regularly review medication lists for people with dementia to identify and discontinue drugs that may accelerate cognitive decline, notably those with high anticholinergic burden such as TCAs. This aligns with national guidelines and supports safer prescribing in older adults.\n\n**Memory Anchor**\nRemember: **Amitriptyline (a TCA) = Anticholinergic = Avoid in Alzheimer's!**",
    "bullet_explanations": {
      "Tricyclic antidepressants": "Correct – High anticholinergic burden increases risk of cognitive worsening in dementia.",
      "Direct oral anticoagulants": "Incorrect – These do not significantly affect cognition and may be indicated for stroke prevention.",
      "Bisphosphonates": "Incorrect – Used for bone protection; not associated with cognitive impairment.",
      "Statins": "Incorrect – Statins do not worsen dementia and may benefit cardiovascular risk in appropriate patients.",
      "Low-dose aspirin": "Incorrect – Aspirin is not linked to cognitive decline and is often used for vascular protection."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Prescribing Safety",
    "topic": "Allergy documentation",
    "keywords": [
      "anticholinergic",
      "dementia",
      "tricyclic antidepressants",
      "STOPP criteria",
      "elderly prescribing"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Dementia",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/dementia/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5d574c94-f626-410a-93c9-6774bae43d97",
    "question_number": 318,
    "question": "What is the recommended first-line pharmacological treatment for a 66-year-old man newly diagnosed with mild Alzheimer's disease, who is otherwise healthy and has no contraindications to standard therapy?",
    "options": [
      "Start donepezil",
      "Begin memantine",
      "Prescribe sertraline",
      "Refer for group reminiscence therapy",
      "Initiate risperidone"
    ],
    "correct_answer": "Start donepezil",
    "explanation": "**Explanation**\n**Acetylcholinesterase inhibitors** (such as donepezil) are the first-line pharmacological treatment for mild-to-moderate Alzheimer’s disease, as recommended by UK guidelines. These agents work by increasing acetylcholine levels in the brain, which can modestly improve or stabilise cognitive function and daily activities in some patients. **Donepezil, galantamine, and rivastigmine** are all suitable choices. Memantine is reserved for more advanced disease or when acetylcholinesterase inhibitors are not tolerated. Antidepressants like sertraline and antipsychotics like risperidone have no role in initial management unless specific comorbidities exist. Non-pharmacological therapies such as group reminiscence can be helpful adjuncts but are not substitutes for first-line drug treatment.\n\n**Key Points**\n- Acetylcholinesterase inhibitors are first-line for mild-to-moderate Alzheimer’s disease.\n- Donepezil, galantamine, and rivastigmine are recommended agents.\n- Memantine is indicated for moderate-to-severe disease or intolerance to AChE inhibitors.\n- Antidepressants and antipsychotics are not used for core symptoms of dementia.\n- Non-drug therapies are supportive, not first-line pharmacological treatments.\n\n**Clinical Relevance**\nInitiating acetylcholinesterase inhibitors in appropriate patients with mild-to-moderate Alzheimer’s disease aligns with NICE and BNF guidance, optimising symptom management and maintaining function. Early correct therapy selection improves patient quality of life and may delay progression to more severe disease.\n\n**Memory Anchor**\nDonepezil 'done' first for dementia: D for Donepezil, D for Dementia.",
    "bullet_explanations": {
      "Start donepezil": "Correct—First-line pharmacological therapy for mild-to-moderate Alzheimer's disease.",
      "Begin memantine": "Incorrect—Memantine is reserved for moderate or severe disease, or if acetylcholinesterase inhibitors are not tolerated.",
      "Prescribe sertraline": "Incorrect—Sertraline is an antidepressant, indicated only if comorbid depression is present.",
      "Refer for group reminiscence therapy": "Incorrect—Non-pharmacological therapies are supportive but not first-line pharmacological management.",
      "Initiate risperidone": "Incorrect—Antipsychotics are for severe behavioural disturbances and not for core Alzheimer’s symptoms."
    },
    "category": "Dementia & Delirium",
    "subsection": "Dementia",
    "subsubsection": "Alzheimer’s disease",
    "topic": "Cholinesterase inhibitors",
    "keywords": [
      "Alzheimer's",
      "first-line",
      "donepezil",
      "acetylcholinesterase inhibitor",
      "mild dementia"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Dementia",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/dementia/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8ec91f62-f342-48f2-8dc2-66e656b7cda5",
    "question_number": 319,
    "question": "Which disease-modifying antirheumatic drug (DMARD) should be avoided in a patient with a known aspirin hypersensitivity due to increased risk of cross-reactivity?",
    "options": [
      "Sulfasalazine",
      "Methotrexate",
      "Leflunomide",
      "Adalimumab",
      "Hydroxychloroquine"
    ],
    "correct_answer": "Sulfasalazine",
    "explanation": "**Explanation**\n**Sulfasalazine contains a salicylate group, chemically related to aspirin, which can provoke allergic reactions in patients with aspirin hypersensitivity.** This risk arises from their structural similarity and shared metabolic pathways. Patients with aspirin allergy may experience IgE-mediated responses, such as urticaria or bronchospasm, when exposed to sulfasalazine. In contrast, other cDMARDs—including methotrexate, leflunomide, and hydroxychloroquine—do not share this risk, and biologics like adalimumab lack the salicylate moiety. Careful allergy history is essential before initiating DMARD therapy.\n\n**Key Points**\n- Sulfasalazine’s structure includes a salicylate moiety, similar to aspirin.\n- Aspirin-allergic patients are at increased risk of hypersensitivity to sulfasalazine.\n- Alternative cDMARDs (methotrexate, leflunomide, hydroxychloroquine) do not have this cross-reactivity.\n- Biologic DMARDs (e.g., adalimumab) are also safe regarding aspirin allergy.\n- Accurate drug allergy documentation is crucial before DMARD initiation.\n- Sulfasalazine should also be avoided in G6PD deficiency due to haemolysis risk.\n- <table><thead><tr><th>DMARD</th><th>Aspirin Allergy Risk</th></tr></thead><tbody><tr><td>Sulfasalazine</td><td>High</td></tr><tr><td>Methotrexate</td><td>Low</td></tr><tr><td>Leflunomide</td><td>Low</td></tr><tr><td>Hydroxychloroquine</td><td>Low</td></tr><tr><td>Adalimumab</td><td>Low</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising potential cross-reactivity between sulfasalazine and aspirin is crucial when prescribing DMARDs for rheumatoid arthritis. This ensures patient safety and guides appropriate drug selection, as outlined in national guidelines.\n\n**Memory Anchor**\nRemember: 'SULFA's structure SULFAs from aspirin'—avoid sulfasalazine in aspirin hypersensitivity.",
    "bullet_explanations": {
      "Sulfasalazine": "Correct – shares structural similarities with aspirin, increasing allergy risk.",
      "Methotrexate": "Incorrect – does not contain a salicylate group; no specific cross-reactivity.",
      "Leflunomide": "Incorrect – not associated with aspirin allergy; safe to use in such patients.",
      "Adalimumab": "Incorrect – as a monoclonal antibody, it does not trigger aspirin-related allergic reactions.",
      "Hydroxychloroquine": "Incorrect – unrelated to aspirin or sulfa drugs; no added allergy risk."
    },
    "category": "Musculoskeletal",
    "subsection": "Arthritis",
    "subsubsection": "Rheumatoid Arthritis",
    "topic": "DMARD initiation and monitoring",
    "keywords": [
      "sulfasalazine",
      "aspirin allergy",
      "DMARD",
      "rheumatoid arthritis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Rheumatoid arthritis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/rheumatoid-arthritis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "DMARDs",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/dmards/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fb475542-ba70-4445-958e-820b166f89da",
    "question_number": 320,
    "question": "Which vitamin, if consumed in excessive amounts during pregnancy, is associated with teratogenic risks and therefore should not be included in antenatal multivitamin supplements above recommended levels?",
    "options": [
      "Vitamin B12",
      "Vitamin D",
      "Vitamin A",
      "Vitamin C",
      "Vitamin B1"
    ],
    "correct_answer": "Vitamin A",
    "explanation": "**Explanation**\n**Vitamin A**, particularly in high doses, is recognised as teratogenic during pregnancy. Excessive intake can cause fetal malformations, especially affecting the craniofacial, cardiac, and central nervous systems. As a result, women who are pregnant or planning pregnancy are advised to avoid vitamin A-containing supplements and foods very high in vitamin A, such as liver. Typical prenatal supplements in the UK are formulated to stay below the teratogenic threshold, but standard 'multivitamins' may exceed safe limits. Other listed vitamins do not have established teratogenic effects at standard supplement doses.\n\n**Key Points**\n- Vitamin A (retinol) is teratogenic in high doses during pregnancy.\n- Intake exceeding 10,000 IU/day is linked to fetal malformations.\n- Pregnant women should avoid supplements and foods (e.g., liver) high in vitamin A.\n- B vitamins (B1, B12), vitamin C, and vitamin D are not teratogenic at recommended doses.\n- UK prenatal supplements are formulated to remain within safe vitamin A limits.\n\n**Clinical Relevance**\nRecognising the teratogenic potential of vitamin A is essential for safe antenatal care. Advising women to avoid high-dose vitamin A and liver products prevents preventable birth defects. Guidance is reinforced by national recommendations and is tested in clinical practice when advising on over-the-counter supplements.\n\n**Memory Anchor**\nThink 'A' for 'Abnormalities'—excess vitamin A causes congenital abnormalities.",
    "bullet_explanations": {
      "Vitamin B12": "Not teratogenic and is often supplemented in pregnancy if deficient.",
      "Vitamin D": "Safe within recommended doses; deficiency is more concerning in pregnancy.",
      "Vitamin A": "Correct – teratogenic at high doses; should be avoided above recommended levels.",
      "Vitamin C": "Not associated with teratogenicity in pregnancy.",
      "Vitamin B1": "No evidence of teratogenic effects with standard supplementation."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Booking visit tests",
    "keywords": [
      "vitamin A",
      "teratogenicity",
      "pregnancy supplements",
      "antenatal care",
      "multivitamin safety"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Vitamins",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/vitamins/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "85c9ff69-c6cf-4028-afef-28ea94c1f448",
    "question_number": 321,
    "question": "A 48-year-old man with a remote history of pulmonary tuberculosis now presents with intermittent episodes of coughing up blood. His chest X-ray reveals a well-defined mass with a crescent of air in the right upper lobe. What is the most likely cause of his haemoptysis?",
    "options": [
      "Aspergilloma",
      "Bronchiectasis",
      "Reactivation tuberculosis",
      "Lung abscess",
      "Pulmonary embolism"
    ],
    "correct_answer": "Aspergilloma",
    "explanation": "**Explanation**\n**Aspergilloma** (fungal ball) develops when Aspergillus colonises a pre-existing pulmonary cavity, often due to old tuberculosis. The classic radiological sign is a rounded opacity within a cavity, surrounded by a crescent of air (the 'air-crescent sign'). Patients typically present with episodic haemoptysis, which can range from mild to life-threatening. This is distinct from bronchiectasis, which usually presents with chronic productive cough and recurrent infections, and from active TB, which would be associated with systemic symptoms and infiltrates rather than a discrete mass. Lung abscesses typically show air-fluid levels and are associated with fever and systemic toxicity. Pulmonary embolism may cause haemoptysis but usually in the context of pleuritic chest pain and risk factors for venous thromboembolism, without the described radiological findings.\n\n**Key Points**\n- Aspergilloma forms in pre-existing lung cavities, commonly from prior TB.\n- Classic X-ray: mobile intracavitary mass with air crescent (air-crescent sign).\n- Haemoptysis is the most common presenting symptom.\n- Distinguish from bronchiectasis (diffuse bronchial dilation, daily purulent sputum), active TB (systemic symptoms, infiltrates), and PE (acute onset, pleuritic pain).\n- <table><thead><tr><th>Feature</th><th>Aspergilloma</th><th>Bronchiectasis</th></tr></thead><tbody><tr><td>Imaging</td><td>Single cavity with ball</td><td>Bronchial dilation, 'tramlines'</td></tr><tr><td>Symptoms</td><td>Intermittent haemoptysis</td><td>Chronic cough, purulent sputum</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the sequelae of prior pulmonary TB is critical. Aspergilloma should be suspected in patients with a history of lung cavities and new haemoptysis. Prompt recognition allows for appropriate referral and management, especially as bleeding can be severe. NICE CKS identifies unexplained haemoptysis and prior TB as key risk factors for serious underlying pathology.\n\n**Memory Anchor**\n‘Air-crescent’ = Aspergilloma (A for Air, A for Aspergillus).",
    "bullet_explanations": {
      "Aspergilloma": "Correct – Fungal ball in a prior cavity (often post-TB), classic air-crescent sign, episodic haemoptysis.",
      "Bronchiectasis": "Incorrect – Causes chronic cough and purulent sputum, not a solitary cavity with a mass.",
      "Reactivation tuberculosis": "Incorrect – Would show infiltrates, cavitation, and systemic symptoms, not a rounded mass.",
      "Lung abscess": "Incorrect – Associated with air-fluid levels, systemic toxicity, and usually not a discrete, mobile mass.",
      "Pulmonary embolism": "Incorrect – Can cause haemoptysis but would not produce a cavity or mass on X-ray."
    },
    "category": "Respiratory",
    "subsection": "Infective",
    "subsubsection": "Bronchiectasis",
    "topic": "Complications (empyema, necrotising pneumonia)",
    "keywords": [
      "aspergilloma",
      "haemoptysis",
      "tuberculosis",
      "lung cavity",
      "air-crescent sign"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Bronchiectasis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/bronchiectasis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "14c853d8-e786-4695-a80a-36aeea2e2c72",
    "question_number": 322,
    "question": "A 43-year-old man with psoriatic arthritis, managed with weekly methotrexate for 9 months, presents with a 1-week history of dry cough, exertional dyspnoea, and mild fever. He is afebrile on review, with oxygen saturations of 94% on room air and fine bibasal inspiratory crackles. His inflammatory markers and white cell count are within normal limits. What is the most likely explanation for his respiratory symptoms?",
    "options": [
      "Methotrexate-induced pneumonitis",
      "Viral upper respiratory tract infection",
      "Pulmonary embolism",
      "Heart failure secondary to methotrexate toxicity",
      "Community-acquired pneumonia"
    ],
    "correct_answer": "Methotrexate-induced pneumonitis",
    "explanation": "**Explanation**\n**Methotrexate-induced pneumonitis** is a recognised, potentially serious complication that may present with subacute onset of breathlessness, non-productive cough, and fever, often within the first year of methotrexate therapy. Clinical findings typically include fine bibasal crackles and hypoxia, without focal consolidation or marked infection signs. Bloods are often non-specific, with normal or mildly raised inflammatory markers and white cell counts, distinguishing it from infectious causes. Early recognition is essential as withdrawal of methotrexate and prompt specialist referral can prevent progression to irreversible fibrosis.\n\n**Key Points**\n- Methotrexate can cause acute or subacute hypersensitivity pneumonitis.\n- Symptoms: dry cough, shortness of breath, hypoxia, fever—often in first year of therapy.\n- Exam: bibasal fine crackles, absence of focal chest signs.\n- Bloods: may show normal or slightly raised CRP/WCC, not typical of infection.\n- Imaging: may reveal diffuse interstitial changes (not required for initial diagnosis).\n- Management: stop methotrexate, urgent rheumatology/respiratory assessment.\n- <table><thead><tr><th>Feature</th><th>Methotrexate Pneumonitis</th><th>Pneumonia</th></tr></thead><tbody><tr><td>Onset</td><td>Subacute (days–weeks)</td><td>Acute</td></tr><tr><td>CRP/WCC</td><td>Normal/mildly raised</td><td>Often elevated</td></tr><tr><td>Exam</td><td>Bilateral crackles</td><td>Focal findings</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrescribers must monitor for pulmonary toxicity in patients on methotrexate or other DMARDs, as early symptoms can mimic infection but require immediate drug cessation and specialist input to prevent permanent lung injury. NICE CKS highlights the need for urgent referral in cases of new breathlessness or cough during DMARD therapy.\n\n**Memory Anchor**\nMethotrexate = 'Meth-tox' for lung toxicity",
    "bullet_explanations": {
      "Methotrexate-induced pneumonitis": "Correct – classic presentation in a patient on methotrexate, with interstitial symptoms and no clear infection.",
      "Viral upper respiratory tract infection": "Incorrect – viral illnesses rarely cause significant hypoxia and bilateral crackles; timing and drug history are key.",
      "Pulmonary embolism": "Incorrect – typically presents acutely with pleuritic pain, tachycardia, and not usually with crackles or a subacute onset.",
      "Heart failure secondary to methotrexate toxicity": "Incorrect – methotrexate is not commonly associated with direct cardiac toxicity; clinical exam lacks features of fluid overload.",
      "Community-acquired pneumonia": "Incorrect – pneumonia would more likely cause focal chest signs, higher CRP, and perhaps productive cough."
    },
    "category": "Respiratory",
    "subsection": "Infective",
    "subsubsection": "TB & Atypicals",
    "topic": "Aetiology screen (CF, immunodeficiency)",
    "keywords": [
      "methotrexate pneumonitis",
      "DMARD toxicity",
      "pulmonary fibrosis",
      "drug-induced lung disease"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "DMARDs",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/dmards/"
      },
      {
        "source": "BNF",
        "topic_title": "Rheumatoid arthritis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/rheumatoid-arthritis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "77b508d5-eca6-46b3-bf90-052518466e28",
    "question_number": 323,
    "question": "A 32-year-old woman attends your clinic for insertion of a contraceptive implant (etonogestrel) on day 14 of her regular 30-day cycle. She asks when she can safely rely on the implant for contraception. What is the minimum time she must wait before the implant provides effective contraception?",
    "options": [
      "After 7 days",
      "After 2 days",
      "Immediately",
      "When her next period starts",
      "Two weeks after insertion"
    ],
    "correct_answer": "After 7 days",
    "explanation": "**Explanation**\n**Contraceptive implants (etonogestrel) are effective immediately if inserted within the first 5 days of a natural menstrual cycle.** If the implant is inserted at any other point, there is a risk that ovulation may have occurred or could occur soon, and the implant will not immediately suppress ovulation. Therefore, the Faculty of Sexual and Reproductive Healthcare (FSRH) advises using additional contraceptive precautions for 7 days following insertion outside days 1–5. This waiting period allows the hormone to reach reliable levels and suppress ovulation, ensuring effective contraception. **Immediate protection is only guaranteed for insertions during days 1–5; otherwise, a full 7 days of additional contraception is required.**\n\n**Key Points**\n- Etonogestrel implant is effective immediately if inserted on days 1–5 of the menstrual cycle.\n- Insertion at other times requires 7 days of additional contraception.\n- Other contraceptive methods have different timeframes for onset of effectiveness.\n- Ovulation may occur if the implant is inserted after day 5, hence the precaution.\n- <table><thead><tr><th>Contraceptive Method</th><th>Time to Effectiveness (if not day 1–5)</th></tr></thead><tbody><tr><td>Implant</td><td>7 days</td></tr><tr><td>POP</td><td>2 days</td></tr><tr><td>IUD</td><td>Immediate</td></tr><tr><td>COC/Injection/IUS</td><td>7 days</td></tr></tbody></table>\n\n**Clinical Relevance**\nUnderstanding when contraceptive methods become effective is crucial for preventing unplanned pregnancies. Clear counselling at the time of insertion helps ensure patients use additional protection as needed, following national guidelines.\n\n**Memory Anchor**\nImplant = I for 'Interval' = 7 days if not day 1–5.",
    "bullet_explanations": {
      "After 7 days": "Correct – This is the recommended interval for implant effectiveness outside days 1–5 of the cycle.",
      "After 2 days": "Incorrect – This applies to progestogen-only pills, not to implants.",
      "Immediately": "Incorrect – Immediate protection only applies if inserted on days 1–5 of the menstrual cycle.",
      "When her next period starts": "Incorrect – Protection does not depend on onset of next menstruation.",
      "Two weeks after insertion": "Incorrect – The required waiting period is 7 days, not 14."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Progesterone-only methods",
    "keywords": [
      "contraceptive implant",
      "etonogestrel",
      "time to effectiveness",
      "FSRH guidance"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "Faculty of Sexual and Reproductive Healthcare (FSRH)",
        "topic_title": "Progestogen-only implant",
        "citation": "© FSRH, 2022",
        "url": "https://www.fsrh.org/standards-and-guidance/documents/cec-ceu-guidance-implant-jan-2014/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "3980add9-d0af-439c-9368-83a0ae88a0b5",
    "question_number": 324,
    "question": "Which complication is most closely associated with a sudden increase in abdominal girth and breathlessness in a woman pregnant with monochorionic twins?",
    "options": [
      "Twin-to-twin transfusion syndrome",
      "Gestational diabetes",
      "Fetal growth restriction",
      "Cord entanglement",
      "Umbilical cord compression"
    ],
    "correct_answer": "Twin-to-twin transfusion syndrome",
    "explanation": "**Explanation**\n**Twin-to-twin transfusion syndrome (TTTS)** is a specific complication of monochorionic twin pregnancies, where twins share a single placenta. This condition arises due to abnormal vascular connections within the placenta, resulting in unbalanced blood flow between the twins. The 'donor' twin becomes hypovolaemic and may experience oligohydramnios, while the 'recipient' twin can become hypervolaemic, often leading to polyhydramnios. The excess amniotic fluid can cause a rapid increase in maternal abdominal size and breathlessness, as highlighted in national guidelines. These symptoms should prompt urgent assessment, as TTTS can have severe, even life-threatening, consequences for both fetuses if not recognised and managed promptly. Other listed complications do not typically present with this combination of symptoms in monochorionic twins.\n\n**Key Points**\n- TTTS occurs only in monochorionic (single placenta) twin pregnancies.\n- Caused by imbalanced blood flow due to abnormal placental vascular connections.\n- Results in one twin (donor) having low amniotic fluid and anaemia; the other (recipient) develops polyhydramnios and volume overload.\n- Maternal symptoms include sudden abdominal distension and breathlessness due to acute polyhydramnios.\n- Immediate recognition and referral are crucial to fetal outcomes.\n\n**Clinical Relevance**\nEarly detection of TTTS in monochorionic twins can be life-saving. National guidelines advise that women should be informed of warning symptoms such as rapidly increasing abdominal size or breathlessness and seek prompt medical review if these occur.\n\n**Memory Anchor**\n\"TTTS = Two Twins, Two Sacs – Too much fluid in one!\"",
    "bullet_explanations": {
      "Twin-to-twin transfusion syndrome": "Correct – This condition is uniquely associated with rapid polyhydramnios and maternal symptoms in monochorionic twins.",
      "Gestational diabetes": "Incorrect – While it can cause increased abdominal size, it does not cause sudden changes or breathlessness in this way.",
      "Fetal growth restriction": "Incorrect – Typically presents with small-for-dates uterus, not rapid abdominal enlargement.",
      "Cord entanglement": "Incorrect – More common in monoamniotic twins and does not present with maternal abdominal distension.",
      "Umbilical cord compression": "Incorrect – Presents with fetal distress, not maternal abdominal symptoms."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "High-risk pregnancy identification",
    "keywords": [
      "twin-to-twin transfusion syndrome",
      "monochorionic twins",
      "polyhydramnios"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "RCOG",
        "topic_title": "Management of Monochorionic Twin Pregnancy (Green-top Guideline No. 51)",
        "citation": "© Royal College of Obstetricians and Gynaecologists, 2016",
        "url": "https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/management-of-monochorionic-twin-pregnancy-green-top-guideline-no-51/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "19e4171b-b419-4662-b6c2-749759c8ebb2",
    "question_number": 325,
    "question": "A 44-year-old man attends a health assessment after being found to have a mildly elevated fasting glucose on routine bloods. He undergoes a 75g oral glucose tolerance test. His fasting plasma glucose is 5.7 mmol/L, and his 2-hour value is 8.2 mmol/L. According to WHO criteria, how should these results be classified?",
    "options": [
      "Impaired glucose tolerance",
      "Impaired fasting glucose and impaired glucose tolerance",
      "Diabetes mellitus",
      "Normal glucose regulation",
      "Impaired fasting glucose"
    ],
    "correct_answer": "Impaired glucose tolerance",
    "explanation": "**Explanation**\n**Impaired glucose tolerance (IGT)** is diagnosed when the fasting plasma glucose is below 7.0 mmol/L, but the 2-hour plasma glucose after a 75g oral glucose tolerance test is between 7.8 and 11.0 mmol/L (inclusive of 7.8, but less than 11.1). In this case, the patient's fasting level (5.7 mmol/L) is normal, but the 2-hour reading (8.2 mmol/L) falls within the IGT range. **IGT indicates a higher risk of developing type 2 diabetes and cardiovascular disease compared to normal glucose levels, but does not meet the threshold for diabetes.** This differs from impaired fasting glucose (IFG), where fasting glucose is raised (6.1–6.9 mmol/L), and from diabetes, where the 2-hour value is 11.1 mmol/L or higher.\n\n**Key Points**\n- IGT: Fasting <7.0 mmol/L, 2-hour OGTT ≥7.8 and <11.1 mmol/L\n- IFG: Fasting 6.1–6.9 mmol/L, 2-hour OGTT <7.8 mmol/L\n- Diabetes: Fasting ≥7.0 mmol/L or 2-hour OGTT ≥11.1 mmol/L\n- This patient has normal fasting but elevated 2-hour glucose\n- IGT is associated with increased future risk of diabetes and CVD\n\n**Clinical Relevance**\nRecognising impaired glucose tolerance is important because it identifies individuals at high risk for developing type 2 diabetes and cardiovascular disease. Early intervention with lifestyle modification can prevent progression. National and international guidelines, including those summarised in the BNF, provide clear diagnostic thresholds for classifying glucose tolerance states.\n\n**Memory Anchor**\nThink: 'I' for 'Intermediate' – IGT sits between normal and diabetes on the OGTT scale.",
    "bullet_explanations": {
      "Impaired glucose tolerance": "Correct: 2-hour OGTT result is in the IGT range with a normal fasting value.",
      "Impaired fasting glucose and impaired glucose tolerance": "Incorrect: Fasting glucose is not high enough to meet IFG criteria, so both are not present.",
      "Diabetes mellitus": "Incorrect: 2-hour glucose is below the diagnostic threshold for diabetes (≥11.1 mmol/L).",
      "Normal glucose regulation": "Incorrect: The 2-hour value is elevated above normal, so this is not a normal result.",
      "Impaired fasting glucose": "Incorrect: Fasting glucose is below the minimum required for IFG (6.1 mmol/L)."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Acute",
    "subsubsection": "DKA",
    "topic": "Diagnostic criteria and triggers",
    "keywords": [
      "impaired glucose tolerance",
      "oral glucose tolerance test",
      "diabetes diagnosis"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetes/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "bd7995ba-3e3a-46ce-94ad-accd97c2a503",
    "question_number": 326,
    "question": "A 32-year-old woman with a history of well-controlled chronic hypertension on perindopril discovers she is 10 weeks pregnant during a routine health check. Her current blood pressure is 130/80 mmHg and she reports no symptoms. What is the single most appropriate next step in her antihypertensive management?",
    "options": [
      "Switch perindopril to labetalol",
      "Continue perindopril at the current dose",
      "Switch to amlodipine",
      "Stop perindopril and closely monitor blood pressure",
      "Switch to methyldopa"
    ],
    "correct_answer": "Switch perindopril to labetalol",
    "explanation": "**Explanation**\n**ACE inhibitors such as perindopril are contraindicated in pregnancy due to teratogenic risks, particularly affecting fetal renal development.** For women with chronic hypertension who become pregnant, NICE and BNF recommend stopping ACE inhibitors immediately and switching to an agent with a better safety profile in pregnancy. **Labetalol is the preferred first-line antihypertensive in pregnancy, unless contraindicated.** Nifedipine (modified-release) or methyldopa are alternatives if labetalol is unsuitable. Ongoing blood pressure control remains important to prevent maternal and fetal complications. Calcium channel blockers such as amlodipine are not recommended first-line in pregnancy, and simply monitoring without switching exposes the fetus to unnecessary risk.\n\n**Key Points**\n- ACE inhibitors and ARBs must be discontinued as soon as pregnancy is confirmed.\n- Labetalol is first-line for managing hypertension in pregnancy.\n- Nifedipine (MR) and methyldopa are alternatives if labetalol cannot be used.\n- Uncontrolled hypertension in pregnancy increases the risk of pre-eclampsia and adverse fetal outcomes.\n- Women at high risk of pre-eclampsia (including those with chronic hypertension) should start aspirin from 12 weeks gestation.\n- <table><thead><tr><th>Antihypertensive</th><th>Pregnancy Safety</th></tr></thead><tbody><tr><td>ACE inhibitors</td><td>Contraindicated</td></tr><tr><td>Labetalol</td><td>Preferred first-line</td></tr><tr><td>Methyldopa</td><td>Alternative</td></tr><tr><td>Nifedipine MR</td><td>Alternative</td></tr><tr><td>Amlodipine</td><td>Not preferred</td></tr></tbody></table>\n\n**Clinical Relevance**\nSwitching from ACE inhibitors to labetalol in pregnant women with chronic hypertension aligns with national guidelines and reduces the risk of serious fetal harm. Appropriate antihypertensive selection in pregnancy is a crucial patient safety consideration in both primary and specialist care.\n\n**Memory Anchor**\nRemember: 'ACE and ARB—Abort! Labetalol—Labelled safe.'",
    "bullet_explanations": {
      "Switch perindopril to labetalol": "Correct—Labetalol is the recommended first-line antihypertensive in pregnancy and should replace ACE inhibitors.",
      "Continue perindopril at the current dose": "Incorrect—Continuing ACE inhibitors during pregnancy is unsafe due to teratogenicity.",
      "Switch to amlodipine": "Incorrect—Amlodipine is not a preferred first-line agent in pregnancy according to current guidelines.",
      "Stop perindopril and closely monitor blood pressure": "Incorrect—While stopping ACE inhibitors is correct, omitting immediate antihypertensive cover may risk uncontrolled hypertension.",
      "Switch to methyldopa": "Incorrect—Methyldopa is an alternative if labetalol or nifedipine are unsuitable, but not first-line."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "Hypertension management in pregnancy",
    "keywords": [
      "hypertension",
      "pregnancy",
      "labetalol",
      "ACE inhibitor",
      "antihypertensive safety"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Hypertension in pregnancy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hypertension-in-pregnancy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a7c0bcfd-85f0-4dd0-be14-4eeb4c9b23bf",
    "question_number": 327,
    "question": "According to current UK guidelines, what is the recommended initial antihypertensive agent for a 54-year-old woman with newly diagnosed type 2 diabetes and persistent home blood pressure readings averaging 140/92 mmHg?",
    "options": [
      "Ramipril",
      "Amlodipine",
      "Bendroflumethiazide",
      "Lifestyle advice alone",
      "Bisoprolol"
    ],
    "correct_answer": "Ramipril",
    "explanation": "**Explanation**\nIn adults with type 2 diabetes, **an ACE inhibitor is the first-line antihypertensive agent regardless of age or ethnic background (except those of black African or African-Caribbean origin, for whom an ARB may be considered)**. This is due to the additional renal and cardiovascular protection that ACE inhibitors provide in people with diabetes. Although calcium channel blockers are recommended as first-line for hypertension in people over 55 without diabetes, the presence of diabetes overrides this, prioritising renin–angiotensin system blockade. Thiazide-like diuretics and beta-blockers are reserved for later steps in treatment if blood pressure remains uncontrolled. Lifestyle advice is important, but drug therapy should be started if home or clinic readings are above 135/85 mmHg in diabetics.\n\n**Key Points**\n- ACE inhibitors (or ARBs if ACEi not tolerated) are first-line in all patients with type 2 diabetes and hypertension.\n- Calcium channel blockers are first-line only if there is no diabetes and the patient is over 55 or of black African/Caribbean origin.\n- Thiazide-like diuretics are added second or third line.\n- Beta-blockers are not first-line for uncomplicated hypertension.\n- Antihypertensive treatment is indicated in diabetics with home BP >135/85 mmHg.\n- <table><thead><tr><th>Patient Group</th><th>First-line Antihypertensive</th></tr></thead><tbody><tr><td>Type 2 diabetes (any age)</td><td>ACE inhibitor or ARB</td></tr><tr><td>No diabetes, age ≥55 or black origin</td><td>CCB</td></tr><tr><td>No diabetes, age &lt;55</td><td>ACE inhibitor or ARB</td></tr></tbody></table>\n\n**Clinical Relevance**\nAppropriate antihypertensive selection in patients with diabetes is crucial to minimise cardiovascular and renal complications. Following NICE and BNF recommendations ensures optimal long-term outcomes in this high-risk group.\n\n**Memory Anchor**\nRemember: **'ACE for All with diabetes'** (unless contraindicated or intolerant).",
    "bullet_explanations": {
      "Ramipril": "Correct – ACE inhibitors are first-line for hypertension in type 2 diabetes due to their renoprotective and cardioprotective effects.",
      "Amlodipine": "Incorrect – While suitable in non-diabetic patients over 55, ACE inhibitors are preferred in diabetics.",
      "Bendroflumethiazide": "Incorrect – Thiazide-like diuretics are not first-line and are used later if blood pressure remains uncontrolled.",
      "Lifestyle advice alone": "Incorrect – Drug therapy is indicated in diabetics with home BP above 135/85 mmHg.",
      "Bisoprolol": "Incorrect – Beta-blockers are not recommended as initial therapy for uncomplicated hypertension."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "Hypertension in diabetics – ACE inhibitors/A2RBs are first-line regardless of age",
    "keywords": [
      "hypertension",
      "diabetes",
      "ACE inhibitor",
      "first-line",
      "antihypertensive"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "29030d6e-1469-434f-b2b5-3f6dcf0a138c",
    "question_number": 328,
    "question": "What is the most common cause for revision surgery following a total hip replacement in an adult presenting years after their operation with gradually worsening hip pain and radiolucent lines on X-ray at the bone-cement interface?",
    "options": [
      "Aseptic loosening",
      "Prosthetic joint infection",
      "Periprosthetic fracture",
      "Recurrent osteoarthritis",
      "Prosthetic dislocation"
    ],
    "correct_answer": "Aseptic loosening",
    "explanation": "**Explanation**\n**Aseptic loosening** is the leading cause of revision surgery after total hip replacement. It typically presents several years after the initial operation with progressive mechanical pain that worsens with activity or weight-bearing. Radiological findings, such as radiolucent lines at the bone-cement or bone-prosthesis interface, are characteristic, reflecting gradual loss of fixation due to bone resorption and implant micro-motion. This process is most often driven by a chronic inflammatory response to wear debris from the prosthesis rather than by infection. Distinguishing aseptic loosening from other complications is crucial: infection tends to present more acutely with systemic symptoms, periprosthetic fracture usually follows trauma, and recurrent osteoarthritis is not possible in a replaced joint.\n\n**Key Points**\n- **Aseptic loosening** accounts for the majority (55–70%) of hip replacement revisions.\n- Symptoms develop gradually and are mechanical in nature (worse with weight-bearing).\n- Characteristic X-ray findings include radiolucent lines at bone-cement or bone-prosthesis interfaces.\n- Differentiation from infection is vital—look for absence of fever and systemic symptoms.\n- No history of trauma or acute onset rules out periprosthetic fracture.\n- Recurrent osteoarthritis cannot occur in a prosthetic joint.\n- Dislocation typically presents with sudden pain and functional loss.\n\n**Clinical Relevance**\nRecognising aseptic loosening as the predominant late complication of hip arthroplasty is essential for timely referral and management. Understanding diagnostic clues, particularly radiological changes and clinical presentation, helps avoid unnecessary investigations and ensures appropriate surgical review. This aligns with NICE recommendations for specialist referral in patients with persistent pain after hip surgery.\n\n**Memory Anchor**\n**'Aseptic' = 'A' for 'After years'; think 'Loosening' as the implant gradually loses its grip.**",
    "bullet_explanations": {
      "Aseptic loosening": "Correct – most common late complication, with gradual pain and classic radiographic changes.",
      "Prosthetic joint infection": "Incorrect – usually presents earlier or acutely, often with systemic features (fever, erythema).",
      "Periprosthetic fracture": "Incorrect – typically follows trauma and shows fracture lines on imaging, not mere radiolucency.",
      "Recurrent osteoarthritis": "Incorrect – not possible in a joint that has been replaced by a prosthesis.",
      "Prosthetic dislocation": "Incorrect – presents acutely with loss of function and deformity, not gradual pain."
    },
    "category": "Trauma & Orthopaedics",
    "subsection": "Fractures",
    "subsubsection": "NOF fracture management",
    "topic": "Complications of hip arthroplasty",
    "keywords": [
      "aseptic loosening",
      "hip replacement",
      "revision surgery",
      "radiolucent lines",
      "orthopaedic complications"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Greater trochanteric pain syndrome",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/greater-trochanteric-pain-syndrome/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "81a847e1-5af5-4bcf-9193-e2a43893fc66",
    "question_number": 329,
    "question": "A 74-year-old man, recently discharged following a 10-day course of oral vancomycin for Clostridioides difficile infection, presents to his GP with recurrent loose stools and mild abdominal pain just four days after stopping antibiotics. He is haemodynamically stable, apyrexial, and has no signs of peritonism. What is the most appropriate next-line pharmacological treatment?",
    "options": [
      "Oral fidaxomicin",
      "Oral metronidazole",
      "Intravenous vancomycin",
      "Faecal microbiota transplant",
      "Oral vancomycin (repeat course)"
    ],
    "correct_answer": "Oral fidaxomicin",
    "explanation": "**Explanation**\n**Oral fidaxomicin is recommended as the next-line agent for a relapse of C. difficile infection occurring within 12 weeks of symptom resolution, following initial vancomycin therapy.** According to national guidance, fidaxomicin is superior to repeat vancomycin or metronidazole for further episodes (relapse) unless the case is life-threatening, in which case oral vancomycin plus intravenous metronidazole is preferred. Faecal microbiota transplant is reserved for patients with multiple recurrences or refractory cases after standard therapies. The patient is stable, so escalation to intravenous therapy or specialist interventions is not indicated.\n\n**Key Points**\n- First-line for initial C. difficile infection: oral vancomycin.\n- First relapse within 12 weeks: oral fidaxomicin is preferred.\n- Life-threatening infection: oral vancomycin + IV metronidazole (seek specialist advice).\n- Faecal microbiota transplant for multiple recurrences.\n- Repeat courses of vancomycin are reserved for recurrences after >12 weeks.\n\n**Clinical Relevance**\nTimely escalation to fidaxomicin for recurrent C. difficile reduces risk of further relapses and complications. Adhering to guideline-directed therapy optimises outcomes and conserves advanced interventions for refractory or severe cases. For current recommendations, see BNF and NICE guidance.\n\n**Memory Anchor**\nFidaxomicin follows vancomycin in C. diff relapse: 'First V, then F for Further episode.'",
    "bullet_explanations": {
      "Oral fidaxomicin": "Correct—recommended as second-line for C. difficile relapse within 12 weeks of symptom resolution.",
      "Oral metronidazole": "Incorrect—no longer first- or second-line for relapse; reserved only if other options are not suitable.",
      "Intravenous vancomycin": "Incorrect—IV vancomycin is not effective for C. difficile, as it is not active in the gut lumen.",
      "Faecal microbiota transplant": "Incorrect—considered only after failure of standard therapies or multiple recurrences.",
      "Oral vancomycin (repeat course)": "Incorrect—repeat vancomycin is generally for recurrence >12 weeks after symptom resolution, not for early relapse."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBD",
    "topic": "Steroid-sparing and biologics overview",
    "keywords": [
      "Clostridioides difficile",
      "fidaxomicin",
      "relapse",
      "antibiotic therapy",
      "MSRA"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Gastro-intestinal system infections, antibacterial therapy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/gastro-intestinal-system-infections-antibacterial-therapy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f8609e10-67a6-4960-bd8f-6234ca2ab312",
    "question_number": 330,
    "question": "A 45-year-old man with generalised anxiety disorder is prescribed sertraline. He attends for review about newly diagnosed migraine and asks about acute options for severe attacks. What is the main safety concern when combining a triptan with his current SSRI?",
    "options": [
      "Risk of serotonin syndrome",
      "Increased risk of bleeding",
      "Potential for hyponatraemia",
      "QT interval prolongation",
      "Marked sedation"
    ],
    "correct_answer": "Risk of serotonin syndrome",
    "explanation": "**Explanation**\nCombining a selective serotonin reuptake inhibitor (SSRI), such as sertraline, with a triptan (e.g. sumatriptan) raises the risk of **serotonin syndrome**. Triptans are 5HT1 receptor agonists and, when used with other serotonergic agents, can lead to excessive serotonergic activity. Serotonin syndrome is rare but serious, with symptoms including agitation, hyperreflexia, tremor, and autonomic instability. Although not an absolute contraindication, triptans should be prescribed with caution in patients on SSRIs, and both patient and prescriber should be vigilant for symptoms of serotonin toxicity. This risk is specifically highlighted in prescribing guidance.<br><br>Other risks, such as QT prolongation and bleeding, are not clinically significant with this combination. SSRIs can increase bleeding risk, but triptans do not exacerbate this. Sedation and hyponatraemia are possible SSRI side effects but are not affected by triptan use.\n\n**Key Points**\n- Triptans (e.g. sumatriptan) are 5HT1 receptor agonists.\n- SSRIs and triptans together can cause excessive serotonin activity.\n- Serotonin syndrome is rare but potentially life-threatening.\n- Symptoms include neuromuscular, autonomic and mental status changes.\n- Co-prescribing is not absolutely contraindicated but requires caution.\n- <table><thead><tr><th>Drug</th><th>Main Serotonergic Effect</th></tr></thead><tbody><tr><td>SSRI</td><td>Increased serotonin at synapse</td></tr><tr><td>Triptan</td><td>5HT1 receptor agonism</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising drug interactions is vital for patient safety. National guidelines advise caution, but not outright avoidance, when co-prescribing SSRIs and triptans. Awareness of serotonin syndrome ensures timely recognition and management.\n\n**Memory Anchor**\n‘Serotonin–Serotonin = Syndrome’: Combine serotonergic drugs, consider serotonin syndrome.",
    "bullet_explanations": {
      "Risk of serotonin syndrome": "Correct – co-administration increases risk due to excess serotonergic activity.",
      "Increased risk of bleeding": "Incorrect – while SSRIs may increase bleeding risk, triptans do not contribute.",
      "Potential for hyponatraemia": "Incorrect – SSRIs may cause SIADH, but triptans do not increase this risk.",
      "QT interval prolongation": "Incorrect – neither sertraline nor triptans significantly prolong QT interval.",
      "Marked sedation": "Incorrect – sedation is not a major issue with this combination."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Depression",
    "topic": "SSRIs vs alternatives",
    "keywords": [
      "triptans",
      "SSRIs",
      "serotonin syndrome",
      "migraine treatment",
      "drug interaction"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Migraine",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/migraine/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Migraine",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/migraine/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fc4264cc-e287-4179-8355-fb1bfa6cb354",
    "question_number": 331,
    "question": "A 62-year-old woman is prescribed haloperidol for persistent delusional disorder. Three weeks later, she develops a slow, shuffling gait, muscular rigidity, and a resting tremor. What is the most likely extrapyramidal side effect she is experiencing?",
    "options": [
      "Tardive dyskinesia",
      "Akathisia",
      "Parkinsonism",
      "Acute dystonia",
      "Neuroleptic malignant syndrome"
    ],
    "correct_answer": "Parkinsonism",
    "explanation": "**Explanation**\n**Parkinsonism** is a well-recognised extrapyramidal side effect of antipsychotic medications, especially first-generation agents like haloperidol. It manifests with features such as resting tremor, muscular rigidity, bradykinesia, and a shuffling gait—closely resembling idiopathic Parkinson’s disease. This occurs due to dopamine D2 receptor blockade in the basal ganglia, disrupting the balance between dopamine and acetylcholine. In contrast, **tardive dyskinesia** involves late-onset, repetitive involuntary movements (especially orofacial), **akathisia** presents as subjective restlessness, **acute dystonia** is a sudden, painful muscle spasm, and **neuroleptic malignant syndrome** is an acute, life-threatening reaction with fever, altered mental status, and lead-pipe rigidity.\n\n**Key Points**\n- Parkinsonism is a common early extrapyramidal side effect of antipsychotics.\n- Symptoms: resting tremor, rigidity, bradykinesia, postural instability.\n- Caused by dopamine blockade in nigrostriatal pathways.\n- Usually develops gradually over weeks to months.\n- Most frequent in older adults and with high-potency first-generation antipsychotics.\n- <table><thead><tr><th>Side Effect</th><th>Onset</th><th>Typical Features</th></tr></thead><tbody><tr><td>Parkinsonism</td><td>Weeks-months</td><td>Tremor, rigidity, bradykinesia</td></tr><tr><td>Acute dystonia</td><td>Hours-days</td><td>Muscle spasm, abnormal postures</td></tr><tr><td>Akathisia</td><td>Hours-weeks</td><td>Restlessness</td></tr><tr><td>Tardive dyskinesia</td><td>Months-years</td><td>Orofacial movements</td></tr></tbody></table>\n\n**Clinical Relevance**\nTimely recognition of parkinsonism as an antipsychotic side effect is crucial to prevent unnecessary morbidity. NICE and BNF recommend reviewing medication choice and dose if symptoms arise, and not routinely prescribing antimuscarinics for prevention.",
    "bullet_explanations": {
      "Tardive dyskinesia": "Incorrect – Presents as late-onset, involuntary, often orofacial movements, not tremor and rigidity.",
      "Akathisia": "Incorrect – Characterised by subjective and objective restlessness, not parkinsonian features.",
      "Parkinsonism": "Correct – Manifests with tremor, rigidity, bradykinesia, and postural changes, mirroring Parkinson’s disease.",
      "Acute dystonia": "Incorrect – Sudden muscle spasms or abnormal postures, typically within hours or days of starting antipsychotics.",
      "Neuroleptic malignant syndrome": "Incorrect – Presents acutely with fever, confusion, autonomic instability, and severe rigidity."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Psychosis & Anxiety",
    "subsubsection": "Schizophrenia",
    "topic": "Antipsychotic choice",
    "keywords": [
      "extrapyramidal",
      "parkinsonism",
      "antipsychotic",
      "side effects"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Psychoses and related disorders",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/psychoses-and-related-disorders/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fe67eb4c-89e9-41de-8516-903fefcb5d54",
    "question_number": 332,
    "question": "A 32-year-old woman develops watery diarrhoea and abdominal cramping two days into a business trip to India. She reports mild nausea but no vomiting or rectal bleeding. What is the most likely causative organism for her symptoms?",
    "options": [
      "Enterotoxigenic Escherichia coli",
      "Clostridioides difficile",
      "Norovirus",
      "Crohn’s disease",
      "Campylobacter jejuni"
    ],
    "correct_answer": "Enterotoxigenic Escherichia coli",
    "explanation": "**Explanation**\n**Enterotoxigenic Escherichia coli (ETEC)** is the most frequent cause of travellers’ diarrhoea in people visiting high-risk regions such as South Asia. It typically presents with sudden-onset, watery (non-bloody) diarrhoea, abdominal cramps, and sometimes mild nausea. Vomiting and fever are less common. In contrast, **Campylobacter jejuni** is more likely to cause bloody stools and systemic symptoms, and **Clostridioides difficile** is associated with recent antibiotic use or hospitalisation. Chronic conditions like **Crohn’s disease** are not suggested by the acute, travel-related onset. **Norovirus** is a viral cause, but it often leads to outbreaks and more prominent vomiting.\n\n**Key Points**\n- Travellers’ diarrhoea is most often due to bacterial pathogens; ETEC is the leading cause.\n- Key features: watery diarrhoea, abdominal cramps, mild nausea, absence of blood in stool.\n- High-risk areas include Asia, Africa, Latin America, and the Middle East.\n- Campylobacter, Salmonella, and Shigella more commonly cause dysentery (bloody diarrhoea).\n- C. difficile usually follows antibiotics or healthcare exposure.\n- Acute onset after travel supports infectious aetiology over chronic GI diseases.\n\n**Clinical Relevance**\nRecognising ETEC as the main cause of acute, non-bloody diarrhoea in returning travellers is crucial for advice on self-care, hydration, and when to seek further medical input. This reflects current NICE CKS guidance on the diagnosis and management of travellers’ diarrhoea.\n\n**Memory Anchor**\nThink ‘E’ for ‘Everywhere’—ETEC is the most common cause of diarrhoea in travellers worldwide.",
    "bullet_explanations": {
      "Enterotoxigenic Escherichia coli": "Correct – the leading cause of watery travellers’ diarrhoea, especially in high-risk regions.",
      "Clostridioides difficile": "Incorrect – usually linked to recent antibiotics or hospital admission, not typical in healthy travellers.",
      "Norovirus": "Incorrect – causes gastroenteritis outbreaks with prominent vomiting; less common as traveller’s diarrhoea.",
      "Crohn’s disease": "Incorrect – a chronic inflammatory bowel disease; acute onset after travel is uncharacteristic.",
      "Campylobacter jejuni": "Incorrect – more likely to present with bloody diarrhoea and systemic symptoms than watery stools."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBS & Functional",
    "topic": "Red flags needing scope",
    "keywords": [
      "travellers diarrhoea",
      "ETEC",
      "acute diarrhoea",
      "infectious diarrhoea",
      "gastroenterology"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diarrhoea - prevention and advice for travellers",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/diarrhoea-prevention-advice-for-travellers/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5c10fc0b-ad42-4a16-9b09-d77eff80145f",
    "question_number": 333,
    "question": "Which of the following findings is most characteristic of age-related macular degeneration on fundoscopy?",
    "options": [
      "Pale retina with a cherry-red spot",
      "Optic disc swelling with blurred margins",
      "Multiple hard exudates and microaneurysms near the macula",
      "Drusen and pigmentary changes at the macula",
      "Enlarged cup-to-disc ratio of the optic nerve"
    ],
    "correct_answer": "Drusen and pigmentary changes at the macula",
    "explanation": "**Explanation**\nAge-related macular degeneration (AMD) is identified on fundoscopy by the presence of **drusen (yellowish deposits beneath the retina) and pigmentary disturbances at the macula**. These changes particularly affect the central retina, leading to progressive loss of central vision. Drusen are collections of lipid material that accumulate under the retinal pigment epithelium, while pigmentary changes may include areas of hypopigmentation or hyperpigmentation. In advanced AMD, geographic atrophy or neovascularisation (wet AMD) may also be seen, but drusen and pigmentary changes are the hallmark of earlier disease. These findings are distinct from those seen in diabetic retinopathy, retinal artery occlusion, or glaucoma.\n\n**Key Points**\n- AMD primarily affects the macula, the area responsible for central vision.\n- Drusen are yellowish subretinal deposits visible on fundoscopy.\n- Pigmentary changes (hypo- or hyperpigmentation) are often present.\n- Progression may lead to geographic atrophy or neovascularisation.\n- AMD is the leading cause of severe visual impairment in older adults.\n- Risk factors include age, smoking, and family history.\n- <table><thead><tr><th>Condition</th><th>Fundoscopic Finding</th></tr></thead><tbody><tr><td>AMD</td><td>Drusen, macular pigment changes</td></tr><tr><td>CRAO</td><td>Pale retina, cherry-red spot</td></tr><tr><td>Glaucoma</td><td>Enlarged cup-to-disc ratio</td></tr><tr><td>Diabetic Retinopathy</td><td>Exudates, microaneurysms</td></tr><tr><td>Papilloedema</td><td>Swollen optic disc with blurred margins</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the classic fundoscopy findings of AMD is essential for early referral and intervention, especially in neovascular (wet) AMD, where prompt treatment can help preserve vision. Awareness of these features also helps differentiate AMD from other causes of vision loss in older adults.\n\n**Memory Anchor**\n‘Drusen’ = Dry AMD; ‘Deposits’ and ‘Deterioration’ of macula",
    "bullet_explanations": {
      "Pale retina with a cherry-red spot": "This finding is classic for central retinal artery occlusion, not AMD.",
      "Optic disc swelling with blurred margins": "This describes papilloedema, usually due to raised intracranial pressure.",
      "Multiple hard exudates and microaneurysms near the macula": "These are features of diabetic retinopathy, not AMD.",
      "Drusen and pigmentary changes at the macula": "Correct—these are the hallmark findings of age-related macular degeneration on fundoscopy.",
      "Enlarged cup-to-disc ratio of the optic nerve": "This is typically seen in glaucoma, not AMD."
    },
    "category": "Ophthalmology",
    "subsection": "Retinal Disorders",
    "subsubsection": "Age-related macular degeneration",
    "topic": "Age-related macular degeneration",
    "keywords": [
      "macular degeneration",
      "drusen",
      "fundoscopy",
      "central vision loss",
      "retina"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Macular degeneration - age-related",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/macular-degeneration-age-related/"
      },
      {
        "source": "BNF",
        "topic_title": "Age-related macular degeneration",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/age-related-macular-degeneration/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "16f79339-9310-418d-b9c2-6bd590a792cd",
    "question_number": 334,
    "question": "A 65-year-old man develops sudden right-sided facial droop and difficulty speaking while gardening. His symptoms have persisted for over an hour. He has a history of well-controlled type 2 diabetes and hyperlipidaemia. What is the most appropriate next step in his management?",
    "options": [
      "Arrange immediate hospital admission for specialist stroke assessment",
      "Advise rest at home and monitor symptoms for 24 hours",
      "Prescribe aspirin 300 mg immediately and refer to rapid access TIA clinic",
      "Book a routine GP review within the next week",
      "Start oral anticoagulation and arrange outpatient neurology referral"
    ],
    "correct_answer": "Arrange immediate hospital admission for specialist stroke assessment",
    "explanation": "**Explanation**\nThis patient's ongoing, acute onset of focal neurological deficits—right-sided facial droop and speech disturbance—are classic for an acute stroke rather than a transient ischaemic attack (TIA). **Suspected acute stroke is a medical emergency requiring urgent hospital admission for specialist assessment and imaging.** Early neuroimaging (typically CT or MRI) is essential to confirm the diagnosis and exclude intracerebral haemorrhage. **Antiplatelet therapy (e.g., aspirin) should not be given in the community until haemorrhagic stroke has been excluded**, as inappropriate administration could worsen bleeding if haemorrhage is present. Stroke specialist teams can then promptly initiate evidence-based interventions, including thrombolysis if appropriate, and supportive care. Delaying admission or attempting community management risks permanent neurological damage or death.\n\n**Key Points**\n- Acute stroke presents with sudden, focal neurological deficits persisting >24 hours.\n- Stroke is a medical emergency—immediate hospital admission is required.\n- Antiplatelets should be withheld until imaging rules out haemorrhagic stroke.\n- Rapid specialist assessment improves outcomes and enables timely thrombolysis.\n- TIA is defined by complete resolution of symptoms within 24 hours.\n\n**Clinical Relevance**\nPrompt recognition and emergency referral for suspected stroke are crucial for reducing morbidity and mortality. UK guidelines emphasise that antiplatelets are only started after haemorrhage has been excluded by imaging. Early intervention is associated with better recovery and reduced long-term disability. Delays in management lead to missed opportunities for thrombolysis or thrombectomy.\n\n**Memory Anchor**\nStroke = 'Time is brain': Always admit immediately for ongoing deficits.",
    "bullet_explanations": {
      "Arrange immediate hospital admission for specialist stroke assessment": "Correct – acute stroke requires urgent hospital admission for specialist assessment and neuroimaging.",
      "Advise rest at home and monitor symptoms for 24 hours": "Incorrect – this would dangerously delay treatment and risk permanent deficit.",
      "Prescribe aspirin 300 mg immediately and refer to rapid access TIA clinic": "Incorrect – aspirin is only appropriate after haemorrhagic stroke has been excluded; ongoing symptoms indicate stroke, not TIA.",
      "Book a routine GP review within the next week": "Incorrect – this option is unsafe and inappropriate for a medical emergency.",
      "Start oral anticoagulation and arrange outpatient neurology referral": "Incorrect – anticoagulation is not indicated acutely for stroke unless there is another clear indication (e.g., AF with confirmed ischaemic stroke), and outpatient referral is unsafe."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Stroke & TIA",
    "topic": "FAST/TIA recognition",
    "keywords": [
      "stroke",
      "emergency admission",
      "acute neurology",
      "antiplatelet",
      "TIA"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Stroke",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/stroke/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Stroke and TIA",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/stroke-tia/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7b2db68e-4060-485f-ae28-9ecaef32c1ac",
    "question_number": 335,
    "question": "A 35-year-old man presents with persistent, foul-smelling discharge from his left ear and gradual hearing loss over several months. He has a history of childhood ear operations and frequent middle ear infections. Examination reveals bone conduction is greater than air conduction on the left, and Weber’s test lateralises to the left side. What is the most likely underlying diagnosis?",
    "options": [
      "Cholesteatoma",
      "Acute otitis media",
      "Otosclerosis",
      "Vestibular schwannoma",
      "Otitis externa"
    ],
    "correct_answer": "Cholesteatoma",
    "explanation": "**Explanation**\n**Cholesteatoma** is a non-cancerous but locally destructive lesion formed by keratinising squamous epithelium within the middle ear or mastoid. It often develops in individuals with a history of chronic ear disease or previous ear surgery. Classic features include **persistent unilateral foul-smelling otorrhoea** and **progressive conductive hearing loss**. On examination, Rinne’s test shows bone conduction > air conduction (negative Rinne), and Weber’s test lateralises to the affected ear—both hallmark signs of conductive hearing loss. Cholesteatoma can erode local structures, increase infection risk, and cause serious complications if untreated. Its presentation is distinct from other causes of chronic ear symptoms due to the characteristic discharge and typical conductive hearing loss on clinical testing.<br><br>\n\n**Key Points**\n<ul><li>Cholesteatoma = keratinising squamous epithelium mass in middle ear/mastoid</li><li>Classic signs: chronic, offensive unilateral discharge and conductive hearing loss</li><li>May follow history of chronic ear infections or previous ear surgery</li><li>Rinne's test: bone conduction > air conduction (affected side)</li><li>Weber's test: lateralises to affected side</li><li>Risk of local bone erosion and serious complications</li></ul>\n\n**Clinical Relevance**\nRecognising cholesteatoma is vital as delays in diagnosis may lead to irreversible hearing loss, facial nerve palsy, or intracranial infection. Prompt ENT referral is recommended for suspected cases. National guidelines (NICE CKS) highlight the importance of identifying key features—unilateral discharge, hearing loss, and history of chronic otitis media or surgery—for timely management and prevention of complications.\n\n**Memory Anchor**\nThink 'chronic cheese in the ear': 'cheesy' discharge, chronic course, and cholesteatoma.",
    "bullet_explanations": {
      "Cholesteatoma": "Correct—persistent foul, unilateral discharge and conductive hearing loss after middle ear disease strongly suggest cholesteatoma.",
      "Acute otitis media": "Incorrect—would present acutely with pain, fever, and less likely with persistent discharge or long-standing hearing loss.",
      "Otosclerosis": "Incorrect—usually causes gradual conductive hearing loss but lacks persistent discharge and is more common in women in early adulthood.",
      "Vestibular schwannoma": "Incorrect—classically causes unilateral sensorineural hearing loss and sometimes tinnitus, not chronic discharge.",
      "Otitis externa": "Incorrect—produces ear canal inflammation and discharge but typically without conductive hearing loss or association with previous middle ear disease."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Hearing loss causes",
    "keywords": [
      "cholesteatoma",
      "conductive hearing loss",
      "chronic ear discharge",
      "Rinne test",
      "ENT"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cholesteatoma",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cholesteatoma/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "18e8d71e-17dd-49e6-ab46-a1e08d27c352",
    "question_number": 336,
    "question": "A 68-year-old postmenopausal woman is scheduled to begin letrozole for adjuvant therapy following surgery for oestrogen receptor-positive breast cancer. She has no significant comorbidities and takes no regular medications. Before starting this aromatase inhibitor, which investigation is recommended to assess a key potential side effect?",
    "options": [
      "DEXA bone density scan",
      "Clotting profile",
      "12-lead ECG",
      "Liver function tests",
      "Serum lipid panel"
    ],
    "correct_answer": "DEXA bone density scan",
    "explanation": "**Explanation**\nAromatase inhibitors, such as letrozole and anastrozole, reduce peripheral oestrogen production, which can lead to decreased bone mineral density and increased fracture risk. **Bone health assessment with a DEXA scan is recommended before initiating therapy** to establish a baseline and guide future monitoring or prophylactic measures. Other baseline investigations, such as clotting screen, ECG, liver function tests, or lipid profile, are not routinely required for aromatase inhibitor therapy in the absence of other clinical indications.\n\n**Key Points**\n- Aromatase inhibitors lower circulating oestrogen and increase osteoporosis risk.\n- DEXA scanning assesses baseline bone mineral density and guides management.\n- Routine clotting, ECG, LFTs, and lipid profiles are not mandatory before starting aromatase inhibitors unless otherwise indicated.\n- Alternative adjuvant endocrine therapies (e.g., tamoxifen) have different side effect profiles.\n- Patients may require calcium/vitamin D supplementation or bisphosphonates depending on scan results.\n\n**Clinical Relevance**\nInitiating aromatase inhibitor therapy in postmenopausal women requires careful consideration of bone health due to the increased risk of osteoporosis. National guidance recommends a baseline DEXA scan to inform future monitoring and preventative strategies, ensuring patient safety and optimal long-term outcomes.\n\n**Memory Anchor**\nRemember: 'A for Aromatase, A for Assessment of bone'—always DEXA scan before aromatase inhibitors.",
    "bullet_explanations": {
      "DEXA bone density scan": "Correct: Establishes baseline bone health due to osteoporosis risk with aromatase inhibitors.",
      "Clotting profile": "Incorrect: Aromatase inhibitors do not cause coagulopathies; no routine need for this screen.",
      "12-lead ECG": "Incorrect: These agents do not commonly cause arrhythmias or cardiac conduction issues.",
      "Liver function tests": "Incorrect: LFTs are not specifically affected by aromatase inhibitors and are not routinely required.",
      "Serum lipid panel": "Incorrect: There is no significant effect on lipid profile necessitating baseline assessment."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Calcium, Pituitary & Metabolic",
    "subsubsection": "Calcium Disorders",
    "topic": "Bone health basics (DEXA, FRAX)",
    "keywords": [
      "aromatase inhibitor",
      "DEXA scan",
      "osteoporosis",
      "breast cancer",
      "bone health"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "dba46e5c-1af7-4f4e-bbfc-fbbcb1fbb819",
    "question_number": 337,
    "question": "A 38-year-old woman presents with a 9-month history of persistent redness and multiple papules and pustules across her central face, including the cheeks and chin. There is no evidence of comedones. Her symptoms have not improved with regular emollient use. What is the most appropriate initial treatment strategy for this presentation?",
    "options": [
      "Topical ivermectin plus oral doxycycline",
      "Oral isotretinoin monotherapy",
      "Topical metronidazole alone",
      "Oral hydroxychloroquine",
      "Short course of oral prednisolone"
    ],
    "correct_answer": "Topical ivermectin plus oral doxycycline",
    "explanation": "**Explanation**\n**Papulopustular rosacea** with moderate to severe features is best managed using a combination of topical and systemic therapy. **Topical ivermectin** targets cutaneous inflammation and Demodex mite overgrowth, while **oral doxycycline** provides anti-inflammatory and antimicrobial effects, addressing more widespread or severe papules and pustules. This approach is supported by current guidelines and is more effective than topical agents alone in significant disease. Topical metronidazole may be considered for milder cases, but combination therapy is recommended for more extensive or persistent involvement. Oral isotretinoin is reserved for refractory, severe cases, while corticosteroids may exacerbate rosacea. Hydroxychloroquine is not indicated for this disorder.\n\n**Key Points**\n- Rosacea is a chronic inflammatory disorder affecting central facial skin.\n- Papulopustular rosacea presents with persistent erythema, papules, and pustules—without comedones.\n- First-line therapy for moderate to severe cases: topical ivermectin (1% cream) PLUS oral doxycycline.\n- Topical metronidazole is suitable for mild or limited disease.\n- Oral isotretinoin is reserved for cases unresponsive to standard therapies.\n- Corticosteroids can worsen rosacea and are contraindicated.\n- Hydroxychloroquine is not an evidence-based treatment for rosacea.\n- <table><thead><tr><th>Severity</th><th>First-line Treatment</th></tr></thead><tbody><tr><td>Mild</td><td>Topical metronidazole or ivermectin</td></tr><tr><td>Moderate–Severe</td><td>Topical ivermectin + oral doxycycline</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising papulopustular rosacea and distinguishing it from acne is crucial, as management differs significantly. Early use of appropriate topical and oral agents improves outcomes and minimises complications, in line with NICE and BNF recommendations.\n\n**Memory Anchor**\nRosacea: 'Red faces need ivermectin cream and doxycycline dream.'",
    "bullet_explanations": {
      "Topical ivermectin plus oral doxycycline": "Correct—combination therapy is first-line for moderate to severe papulopustular rosacea.",
      "Oral isotretinoin monotherapy": "Incorrect—reserved for refractory, severe cases not responding to standard therapy.",
      "Topical metronidazole alone": "Incorrect—suitable for mild cases; inadequate for moderate to severe papulopustular disease.",
      "Oral hydroxychloroquine": "Incorrect—not indicated in rosacea; used primarily in autoimmune connective tissue diseases.",
      "Short course of oral prednisolone": "Incorrect—oral corticosteroids may actually worsen rosacea and are contraindicated."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Eczema/atopic dermatitis",
    "keywords": [
      "rosacea",
      "papulopustular",
      "topical ivermectin",
      "oral doxycycline",
      "moderate severe"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Rosacea",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/rosacea/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Rosacea",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/rosacea/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4a0bf700-0fed-4ada-9a3e-eadf87ec7fae",
    "question_number": 338,
    "question": "Which of the following findings is least likely to be associated with Trichomonas vaginalis infection?",
    "options": [
      "Strawberry appearance of the cervix",
      "Frothy, malodorous vaginal discharge",
      "Vulvovaginal irritation and pruritus",
      "Vaginal pH less than 4.5",
      "Elevated vaginal pH above 4.5"
    ],
    "correct_answer": "Vaginal pH less than 4.5",
    "explanation": "**Explanation**\n**Trichomonas vaginalis** infection tends to increase the vaginal pH above 4.5 due to disruption of the normal vaginal flora and lactobacilli depletion. The organism thrives in a relatively alkaline environment. In contrast, a vaginal pH below 4.5 is typical of a healthy vaginal environment and is more characteristic of conditions such as candida vulvovaginitis, not trichomoniasis. Other classic features of trichomoniasis include a 'strawberry cervix' (punctate cervical haemorrhages), frothy green or yellow discharge, and symptoms of vulvovaginitis.\n\n**Key Points**\n- Trichomoniasis typically causes a vaginal pH > 4.5.\n- A pH < 4.5 is seen in healthy women or with candidiasis.\n- Classic signs: frothy, malodorous discharge; vulval itching; dysuria.\n- ‘Strawberry cervix’ is a classic but not universal sign.\n- Diagnosis is by high vaginal swab for microscopy/culture.\n\n**Clinical Relevance**\nRecognising the typical features of trichomoniasis is essential for diagnosis and appropriate management, as recommended by NICE CKS. Misidentifying pH changes can lead to incorrect treatment and missed opportunities for partner notification and STI screening.\n\n**Memory Anchor**\nTrichomoniasis raises pH: **T** for Trichomonas, **T** for 'Tipping pH up'.",
    "bullet_explanations": {
      "Strawberry appearance of the cervix": "This is a classic sign of trichomoniasis due to cervical inflammation and punctate haemorrhages.",
      "Frothy, malodorous vaginal discharge": "Trichomonas vaginalis frequently causes green or yellow frothy discharge with an unpleasant odour.",
      "Vulvovaginal irritation and pruritus": "Irritation and itching are common symptoms in infected women.",
      "Vaginal pH less than 4.5": "Incorrect—Trichomoniasis is associated with an elevated, not low, vaginal pH.",
      "Elevated vaginal pH above 4.5": "This finding is typical in trichomoniasis and supports the diagnosis."
    },
    "category": "STIs & Sexual Health",
    "subsection": "STIs",
    "subsubsection": "Trichomoniasis",
    "topic": "Trichomonas vaginalis",
    "keywords": [
      "trichomoniasis",
      "vaginal pH",
      "strawberry cervix",
      "vaginal discharge"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Trichomoniasis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/trichomoniasis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8cbb9101-4fd5-4505-b3a5-14284625c3ba",
    "question_number": 339,
    "question": "A 52-year-old man presents to the urgent care clinic with swelling and tenderness of his left calf that began 4 days ago. He is otherwise fit and well, has no recent history of surgery, trauma, or immobilisation, and does not take any regular medications. There is no personal or family history of thromboembolic disease. Clinical assessment and investigations confirm an unprovoked deep vein thrombosis. What is the most appropriate next step in his management?",
    "options": [
      "Start oral rivaroxaban for a minimum of 3 months",
      "Begin a short course of low-dose aspirin",
      "Arrange urgent surgical thrombectomy",
      "Commence oral prednisolone",
      "Offer compression stockings only"
    ],
    "correct_answer": "Start oral rivaroxaban for a minimum of 3 months",
    "explanation": "**Explanation**\n**Oral anticoagulation is the first-line treatment for confirmed deep vein thrombosis (DVT).** For most patients, a direct oral anticoagulant (DOAC) such as rivaroxaban is recommended due to ease of use and favourable safety profile. **Treatment duration should be at least 3 months** for an unprovoked DVT, as this reduces the risk of recurrence and pulmonary embolism. Other interventions such as antiplatelets, corticosteroids, or surgical approaches are not indicated as initial therapy for uncomplicated DVT. Compression stockings may be considered for symptom relief but do not replace anticoagulation.\n\n**Key Points**\n- Anticoagulation with a DOAC (e.g. rivaroxaban) is recommended for most new DVT cases.\n- Treatment duration is typically at least 3 months for unprovoked DVT.\n- Aspirin is not effective in treating acute DVT.\n- Steroids have no role in DVT management.\n- Surgical intervention is reserved for exceptional cases (e.g. phlegmasia cerulea dolens).\n- Compression stockings are adjunctive, not primary, therapy.\n\n**Clinical Relevance**\nEarly initiation of anticoagulation in DVT is essential to prevent serious complications such as pulmonary embolism. NICE guidance highlights the importance of at least 3 months of anticoagulation for most patients, with the choice of agent tailored to individual risk factors and contraindications.",
    "bullet_explanations": {
      "Start oral rivaroxaban for a minimum of 3 months": "Correct – DOACs like rivaroxaban are first-line for DVT, typically given for at least 3 months.",
      "Begin a short course of low-dose aspirin": "Incorrect – Aspirin does not treat or prevent extension of DVT.",
      "Arrange urgent surgical thrombectomy": "Incorrect – Surgery is rarely indicated and reserved for severe, limb-threatening cases.",
      "Commence oral prednisolone": "Incorrect – Steroids are not used in the management of DVT.",
      "Offer compression stockings only": "Incorrect – Stockings may support symptoms but do not replace anticoagulation."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Thrombosis",
    "topic": "Provoked vs unprovoked DVT/PE",
    "keywords": [
      "deep vein thrombosis",
      "anticoagulation",
      "rivaroxaban",
      "unprovoked DVT",
      "treatment duration"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Deep vein thrombosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/deep-vein-thrombosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "3a6260b4-9a6d-4ee4-98ce-bbdb34ebb011",
    "question_number": 340,
    "question": "An 80-year-old man with a history of chronic alcohol use, hypertension, and recent initiation of anticoagulation therapy presents with several days of intermittent confusion and mild headache. He has not experienced any recent trauma that he recalls, and neurological examination is normal. What is the most likely underlying cause of his symptoms?",
    "options": [
      "Chronic subdural haematoma",
      "Korsakoff's syndrome",
      "Extradural haematoma",
      "Wernicke's encephalopathy",
      "Migraine with aura"
    ],
    "correct_answer": "Chronic subdural haematoma",
    "explanation": "**Explanation**\n**Chronic subdural haematoma** is strongly associated with advanced age, chronic alcohol misuse, and the use of anticoagulants. These patients often present with **gradual onset of fluctuating confusion, headache, and sometimes mild focal neurological signs**. Unlike other intracranial bleeds, subdural haematomas can develop insidiously, often without a clear history of trauma, due to minor or unnoticed head injuries that stretch and tear bridging veins. In contrast, Korsakoff's syndrome and Wernicke's encephalopathy are primarily characterised by cognitive impairment and ataxia, but do not typically present with headache. Extradural haematomas usually present acutely with a lucid interval and rapid deterioration, while migraine with aura typically has a more stereotyped presentation and resolves between attacks.\n\n**Key Points**\n- Subdural haematoma is common in older adults, especially with alcohol use and anticoagulants.\n- Presents with insidious, fluctuating confusion and headache.\n- Often no recalled trauma due to minor or trivial injuries.\n- Korsakoff's and Wernicke's syndromes are linked to chronic alcohol misuse but do not present with headache.\n- Extradural haematoma presents acutely with rapid deterioration.\n- Migraine with aura has distinct, recurrent neurological symptoms.\n\n**Clinical Relevance**\nRecognising chronic subdural haematoma is vital in elderly patients with confusion and relevant risk factors. Early diagnosis and management can prevent significant morbidity. NICE guidelines recommend considering neuroimaging in such patients, especially when anticoagulation is involved, due to the risk of delayed intracranial bleeding.\n\n**Memory Anchor**\nElderly + alcohol + anticoagulant → think subdural ('triple A' for Subdural: Age, Alcohol, Anticoagulant).",
    "bullet_explanations": {
      "Chronic subdural haematoma": "Correct – fits the slow, fluctuating confusion and headache in an elderly, alcoholic patient on anticoagulants.",
      "Korsakoff's syndrome": "Incorrect – typically presents with profound memory impairment and confabulation, not headache or fluctuating confusion.",
      "Extradural haematoma": "Incorrect – usually follows acute trauma, with a lucid interval and rapid neurological decline.",
      "Wernicke's encephalopathy": "Incorrect – presents with confusion, ataxia, and ophthalmoplegia, but headache is not a typical feature.",
      "Migraine with aura": "Incorrect – causes stereotyped, reversible neurological symptoms and headache, not persistent fluctuating confusion."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Headache",
    "topic": "Red flag headache",
    "keywords": [
      "subdural haematoma",
      "confusion",
      "elderly",
      "alcohol",
      "anticoagulation"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "4ccced92-1686-4143-833e-8e2b2c5efd3f",
    "question_number": 341,
    "question": "Which of the following features is most suggestive of a pathological heart murmur in a school-aged child rather than an innocent murmur?",
    "options": [
      "A murmur that is diastolic in nature",
      "A soft, vibratory murmur at the lower left sternal edge",
      "A murmur that decreases on standing",
      "A systolic murmur best heard at the pulmonary area",
      "A murmur that varies with respiration"
    ],
    "correct_answer": "A murmur that is diastolic in nature",
    "explanation": "**Explanation**\n**Diastolic murmurs in children are almost always pathological.** Innocent murmurs, also called functional or physiological murmurs, are typically systolic, soft, and often vary with posture or respiration. Diastolic murmurs, by contrast, suggest underlying cardiac pathology such as valvular stenosis or regurgitation and warrant further investigation. In clinical practice, any murmur heard during diastole—especially if persistent—should prompt referral to a paediatric cardiologist for comprehensive assessment. This is in stark contrast to the benign features of innocent murmurs, which are never diastolic.\n\n**Key Points**\n- Innocent murmurs are almost always systolic and short in duration.\n- Diastolic murmurs indicate underlying structural heart disease.\n- Innocent murmurs often change with position or respiration; pathological murmurs are usually fixed.\n- Venous hums—continuous murmurs heard below the clavicles—are generally innocent.\n- Pathological murmurs may be harsh, loud, associated with a thrill, or accompanied by symptoms.\n\n**Clinical Relevance**\nDistinguishing innocent from pathological murmurs in children is critical for appropriate management. Recognising a diastolic murmur as a red flag ensures timely investigation for potentially serious cardiac conditions, in line with paediatric cardiac assessment guidelines.\n\n**Memory Anchor**\nRemember: 'Diastolic = Disease' when evaluating murmurs in children.",
    "bullet_explanations": {
      "A murmur that is diastolic in nature": "Correct – diastolic murmurs are not features of innocent murmurs and indicate pathology.",
      "A soft, vibratory murmur at the lower left sternal edge": "Incorrect – this is a classic description of an innocent Still's murmur.",
      "A murmur that decreases on standing": "Incorrect – innocent murmurs often become softer or disappear on standing.",
      "A systolic murmur best heard at the pulmonary area": "Incorrect – this describes a common innocent murmur (e.g., pulmonary flow murmur).",
      "A murmur that varies with respiration": "Incorrect – innocent murmurs frequently change with respiration and position."
    },
    "category": "Cardiovascular",
    "subsection": "Valvular & Structural",
    "subsubsection": "Aortic Stenosis",
    "topic": "Symptoms triad and severity grading",
    "keywords": [
      "innocent murmur",
      "diastolic murmur",
      "paediatric cardiology",
      "heart murmur assessment"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "3b9b25aa-d281-4172-8274-eef0c909f867",
    "question_number": 342,
    "question": "A 70-year-old woman with a 5-year history of Parkinson’s disease presents with involuntary, writhing limb movements that are most pronounced a few hours after taking her morning medication. She currently takes co-careldopa, amlodipine, and mirtazapine. Which medication is most likely responsible for these abnormal movements?",
    "options": [
      "Co-careldopa",
      "Amlodipine",
      "Mirtazapine",
      "Sertraline",
      "Rasagiline"
    ],
    "correct_answer": "Co-careldopa",
    "explanation": "**Explanation**\n**Peak-dose dyskinesias** are a recognised complication of long-term levodopa therapy, particularly when combined with a dopa-decarboxylase inhibitor such as carbidopa (as in co-careldopa). These involuntary movements—often choreiform or dystonic—tend to occur when plasma levodopa levels are highest, typically a few hours post-dose. This phenomenon arises due to fluctuating dopamine stimulation in the basal ganglia as the disease progresses and the brain’s buffering capacity diminishes. While adjunctive agents (e.g., rasagiline) may be added to help smooth out these fluctuations, they are much less likely to directly cause dyskinesia. Other listed medications do not typically induce these motor side effects. **Key distinguishing features**: The timing of symptoms (several hours after dosing) and the known association between long-term levodopa use and dyskinesias.\n\n**Key Points**\n<ul><li>Levodopa (co-careldopa) is the mainstay of Parkinson’s therapy but can cause dyskinesias after prolonged use.</li><li>Dyskinesias are involuntary, erratic movements—chorea, dystonia, or athetosis—that peak with high levodopa plasma levels.</li><li>These motor complications are less common with dopamine agonists and MAO-B inhibitors when used alone.</li><li>Timing relative to medication dose helps distinguish dyskinesias from other movement disorders.</li><li>Management may involve dose adjustments or the addition of adjunctive therapies.</li><li>Table: <br><table><thead><tr><th>Drug</th><th>Main Role</th><th>Dyskinesia Risk</th></tr></thead><tbody><tr><td>Co-careldopa</td><td>Dopaminergic therapy</td><td>High (with long-term use)</td></tr><tr><td>Rasagiline</td><td>MAO-B inhibitor</td><td>Low</td></tr><tr><td>Amlodipine</td><td>Antihypertensive</td><td>None</td></tr><tr><td>Mirtazapine</td><td>Antidepressant</td><td>Rare</td></tr><tr><td>Sertraline</td><td>SSRI</td><td>Very rare (mainly serotonin syndrome)</td></tr></tbody></table></li></ul>\n\n**Clinical Relevance**\nRecognising levodopa-induced dyskinesias is crucial in the long-term management of Parkinson's disease, as inappropriate attribution to other medications or disease progression can delay appropriate specialist input or result in suboptimal management. National guidance highlights the importance of reviewing therapy when these complications arise.\n\n**Memory Anchor**\nThink 'L for Levodopa and L for Limbs dancing (dyskinesia)'—levodopa makes limbs move involuntarily at peak dose.",
    "bullet_explanations": {
      "Co-careldopa": "Correct – Long-term levodopa therapy is the most common cause of peak-dose dyskinesias in Parkinson’s disease.",
      "Amlodipine": "Incorrect – This calcium channel blocker does not cause movement disorders; side effects are mainly cardiovascular.",
      "Mirtazapine": "Incorrect – May rarely cause extrapyramidal symptoms, but not classic dyskinesias seen in Parkinson’s therapy.",
      "Sertraline": "Incorrect – SSRIs can cause serotonin syndrome (with rigidity, clonus), but not peak-dose dyskinesia.",
      "Rasagiline": "Incorrect – MAO-B inhibitors are used as adjuncts in Parkinson’s, but rarely cause dyskinesias themselves."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Movement Disorders",
    "topic": "Parkinson’s disease",
    "keywords": [
      "levodopa",
      "dyskinesia",
      "Parkinson's disease",
      "co-careldopa",
      "movement disorders"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Parkinson's disease",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/parkinsons-disease/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "35318f6b-af36-4e8f-8297-d1f37b9367df",
    "question_number": 343,
    "question": "A 43-year-old office worker develops gradual onset pain over the outer aspect of her right elbow after starting a new gym routine involving repetitive weightlifting. The discomfort is exacerbated by lifting objects with her palm facing down and improves with rest. On examination, there is tenderness over the lateral epicondyle and pain is reproduced on resisted wrist extension. What is the most likely diagnosis?",
    "options": [
      "Lateral epicondylitis",
      "Cervical radiculopathy",
      "De Quervain's tenosynovitis",
      "Radial tunnel syndrome",
      "Medial epicondylitis"
    ],
    "correct_answer": "Lateral epicondylitis",
    "explanation": "**Explanation**\n**Lateral epicondylitis (tennis elbow)** is an overuse injury affecting the common extensor tendon at its origin on the lateral epicondyle of the humerus. It typically presents with **lateral elbow pain worsened by activities involving wrist extension and gripping**, such as lifting objects palm down. Examination reveals **tenderness at the lateral epicondyle** and pain on resisted wrist extension. The diagnosis is clinical and is distinguished from other conditions by the precise localisation of pain and absence of neurological deficits. Conditions such as medial epicondylitis involve the opposite side of the elbow, and De Quervain's tenosynovitis affects the radial wrist, not the elbow.\n\n**Key Points**\n- Lateral epicondylitis: pain at lateral epicondyle, worsened by resisted wrist extension or gripping.\n- Common in repetitive wrist extension activities (e.g. weightlifting, manual work).\n- Examination: tenderness over lateral epicondyle, pain on resisted wrist extension.\n- No neurological deficits present.\n- Management is conservative: rest, activity modification, analgesia, possible physiotherapy.\n\n**Clinical Relevance**\nLateral epicondylitis is a frequent cause of lateral elbow pain in adults and is commonly seen in both manual workers and those with increased upper limb activity. Early recognition and appropriate advice on activity modification can prevent chronicity and unnecessary investigations. This approach aligns with NICE CKS guidance on tennis elbow management.\n\n**Memory Anchor**\nThink 'tennis elbow'—pain on the outside (lateral) with wrist extension, like swinging a racquet.",
    "bullet_explanations": {
      "Lateral epicondylitis": "Correct – This condition matches the clinical description and examination findings.",
      "Cervical radiculopathy": "Incorrect – Would typically present with neck pain and possible neurological deficits in a dermatomal pattern.",
      "De Quervain's tenosynovitis": "Incorrect – Causes pain at the radial wrist, especially with thumb movement, not at the elbow.",
      "Radial tunnel syndrome": "Incorrect – Pain is more distal to the lateral epicondyle and may include sensory changes.",
      "Medial epicondylitis": "Incorrect – Involves pain over the medial epicondyle, worsened by wrist flexion and pronation."
    },
    "category": "Musculoskeletal",
    "subsection": "Soft Tissue Injuries",
    "subsubsection": "Sports Injuries",
    "topic": "Tennis elbow",
    "keywords": [
      "lateral epicondylitis",
      "tennis elbow",
      "elbow pain"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Tennis elbow",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/tennis-elbow/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "28f1fb8e-f0c9-4c99-8b1b-2055984b01bd",
    "question_number": 344,
    "question": "A 58-year-old man asks you to explain the significance of a clinical trial reporting a number needed to treat (NNT) of 20 for a new cholesterol-lowering drug to prevent heart attacks. Which statement best summarises the practical implication of this NNT value?",
    "options": [
      "If 1000 patients are treated, 50 fewer will experience a heart attack.",
      "Every patient treated will avoid a heart attack.",
      "The drug prevents 20 heart attacks for every 1000 people treated.",
      "Twenty patients in the treatment group were completely protected from heart attack.",
      "No additional heart attacks occurred in the placebo group."
    ],
    "correct_answer": "If 1000 patients are treated, 50 fewer will experience a heart attack.",
    "explanation": "**Explanation**\nThe number needed to treat (NNT) quantifies how many patients require a specific treatment to prevent one additional adverse outcome—in this case, a heart attack. An NNT of 20 means that **treating 20 patients will prevent 1 heart attack compared to not treating**. To scale this up, for every 1000 patients treated (1000 divided by 20), you would expect to prevent 50 heart attacks. This measure helps clinicians and patients weigh the benefits of an intervention. **NNT is always time-bound and context-specific**: it depends on the event, intervention, and duration of follow-up. A lower NNT signals a more effective intervention. NNT should not be confused with the absolute number of events or with the idea that every treated patient benefits equally.\n\n**Key Points**\n- NNT = number of patients treated to prevent one event.\n- NNT = 1 / absolute risk reduction.\n- An NNT of 20 means 1 event prevented per 20 patients treated.\n- For 1000 patients, 1000/20 = 50 events prevented.\n- NNT is specific to the outcome, intervention, and study duration.\n- NNT does not mean every treated patient benefits.\n\n**Clinical Relevance**\nUnderstanding NNT is crucial for evidence-based medicine and for clearly communicating clinical trial results to patients. It allows patients and clinicians to make informed decisions about preventive therapies by quantifying the real-world benefit of an intervention.\n\n**Memory Anchor**\nNNT: Number of patients Needed to Treat for 1 to benefit.",
    "bullet_explanations": {
      "If 1000 patients are treated, 50 fewer will experience a heart attack.": "Correct—This reflects the meaning of NNT: 1000/20 = 50 events prevented.",
      "Every patient treated will avoid a heart attack.": "Incorrect—NNT does not imply all treated patients benefit, only 1 in 20 in this context.",
      "The drug prevents 20 heart attacks for every 1000 people treated.": "Incorrect—It prevents 1 for every 20, so 1000/20 = 50, not 20.",
      "Twenty patients in the treatment group were completely protected from heart attack.": "Incorrect—NNT does not refer to a specific group of individuals being protected, but rather the average benefit across the group.",
      "No additional heart attacks occurred in the placebo group.": "Incorrect—This statement misrepresents the comparative aspect of NNT; NNT reflects the difference in event rates between groups."
    },
    "category": "Cardiovascular",
    "subsection": "Ischaemic Heart Disease",
    "subsubsection": "Primary prevention: QRISK, statin thresholds, lifestyle",
    "topic": "Numbers needed to treat and absolute risk reduction",
    "keywords": [
      "NNT",
      "absolute risk reduction",
      "cardiovascular prevention"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "bd6048f7-46cf-4685-836f-c5c0cf2dbac1",
    "question_number": 345,
    "question": "Which type of ovarian cyst is most commonly identified as a simple, unilocular, thin-walled cyst in young women and is typically discovered incidentally during ultrasound assessment?",
    "options": [
      "Follicular cyst",
      "Endometriotic cyst",
      "Serous carcinoma",
      "Granulosa cell tumour",
      "Polycystic ovarian syndrome"
    ],
    "correct_answer": "Follicular cyst",
    "explanation": "**Explanation**\n**Follicular cysts** are the most frequent type of physiological ovarian cysts encountered in women of reproductive age. They result from the failure of a dominant follicle to rupture and release its ovum, leading to continued fluid accumulation. Ultrasound imaging typically reveals a well-defined, simple, thin-walled, anechoic cyst, usually under 5 cm in diameter. These cysts are often asymptomatic and discovered incidentally, especially in young women undergoing imaging for unrelated reasons. In contrast, endometriotic cysts (chocolate cysts) have a characteristic ground-glass echotexture, while serous carcinomas and granulosa cell tumours present as more complex or solid masses and are far less likely to be found incidentally in asymptomatic young women. Polycystic ovarian syndrome is a separate endocrine disorder diagnosed by specific criteria, not by the presence of a single simple cyst.\n\n**Key Points**\n- Follicular cysts: benign, functional, and usually resolve spontaneously\n- Most common ovarian cyst in young women and often detected incidentally\n- Ultrasound: simple, thin-walled, unilocular, anechoic appearance\n- Usually asymptomatic unless large or ruptured\n- Differentiate from pathological cysts by size, complexity, and symptoms\n- <table><thead><tr><th>Type</th><th>Ultrasound Features</th></tr></thead><tbody><tr><td>Follicular cyst</td><td>Simple, unilocular, thin wall</td></tr><tr><td>Endometriotic cyst</td><td>Ground-glass, thick wall</td></tr><tr><td>Serous carcinoma</td><td>Complex, solid/cystic, septations</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the benign nature of follicular cysts on imaging prevents unnecessary interventions and anxiety. It is important to distinguish physiological cysts from pathological ones to ensure appropriate follow-up and management, in line with UK guidelines.",
    "bullet_explanations": {
      "Follicular cyst": "Correct – Most common simple ovarian cyst in young women; typically asymptomatic and found incidentally.",
      "Endometriotic cyst": "Incorrect – These 'chocolate cysts' have a ground-glass appearance and are associated with endometriosis.",
      "Serous carcinoma": "Incorrect – Malignant; appears as a complex mass, not a simple cyst, and is rare in young, asymptomatic women.",
      "Granulosa cell tumour": "Incorrect – Rare sex cord-stromal tumour; usually presents as a solid mass with possible hormonal symptoms.",
      "Polycystic ovarian syndrome": "Incorrect – PCOS is an endocrine disorder diagnosed by clinical and biochemical criteria, not by finding a single simple cyst."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Menstrual Disorders",
    "topic": "Amenorrhoea",
    "keywords": [
      "follicular cyst",
      "ovarian cysts",
      "incidental finding",
      "ultrasound",
      "gynaecology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Polycystic ovary syndrome",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/polycystic-ovary-syndrome/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1d5af1df-178f-4c0a-89bd-a2bce3e069e2",
    "question_number": 346,
    "question": "A 68-year-old woman is diagnosed with a stage T2N0M0 rectal adenocarcinoma located in the middle third of her rectum. She is otherwise fit and suitable for elective surgery. What is the most appropriate surgical approach to achieve curative resection while preserving sphincter function?",
    "options": [
      "Low anterior resection",
      "Hartmann's procedure",
      "Total colectomy",
      "Abdominoperineal resection",
      "Right hemicolectomy"
    ],
    "correct_answer": "Low anterior resection",
    "explanation": "**Explanation**\n**Low anterior resection (LAR) is the preferred surgical procedure for mid-rectal cancers** that are amenable to curative resection and where sphincter preservation is feasible. LAR involves removal of the rectal segment containing the tumour, along with appropriate lymphadenectomy, and primary anastomosis. This approach is indicated for tumours in the upper and middle thirds of the rectum, allowing preservation of the anal sphincter and avoiding a permanent stoma. In contrast, an abdominoperineal resection is reserved for cancers involving the distal rectum where sphincter preservation is not possible. Other options, such as total colectomy, right hemicolectomy, and Hartmann's procedure, are not appropriate for a mid-rectal tumour in an elective, curative context.\n\n**Key Points**\n- Low anterior resection is indicated for upper and mid-rectal tumours when sphincter preservation is possible.\n- Abdominoperineal resection is typically used for distal rectal cancers where the sphincter cannot be spared.\n- Hartmann's procedure is generally reserved for emergencies or high-risk patients, not for elective curative resections.\n- Total colectomy and right hemicolectomy are used for colonic, not rectal, malignancies.\n- Surgical choice is determined by tumour location, stage, and patient operability.\n- <table><thead><tr><th>Procedure</th><th>Indication</th></tr></thead><tbody><tr><td>Low anterior resection</td><td>Upper/mid-rectal cancer, sphincter-preserving</td></tr><tr><td>Abdominoperineal resection</td><td>Distal rectal cancer, non-sphincter-sparing</td></tr></tbody></table>\n\n**Clinical Relevance**\nUnderstanding surgical approaches for rectal cancer is crucial for appropriate referral and patient counselling. Preserving quality of life by maintaining sphincter function is an important consideration. National guidelines recommend LAR for mid-rectal cancers when feasible, aligning with best practice for oncological control and function.",
    "bullet_explanations": {
      "Low anterior resection": "Correct – optimal for mid-rectal cancers where sphincter preservation is possible.",
      "Hartmann's procedure": "Usually reserved for emergency situations or frail patients, not standard for elective mid-rectal cancer resection.",
      "Total colectomy": "Indicated for diffuse colonic disease or polyposis syndromes, not isolated rectal tumours.",
      "Abdominoperineal resection": "Indicated for low rectal tumours involving the sphincter or anal canal, not for mid-rectal lesions.",
      "Right hemicolectomy": "Used for right-sided colonic cancers, not appropriate for rectal tumours."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "IBD",
    "topic": "UC vs Crohn’s key differences",
    "keywords": [
      "rectal cancer",
      "low anterior resection",
      "rectal surgery",
      "colorectal cancer",
      "sphincter preservation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Gastrointestinal tract (lower) cancers - recognition and referral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/gastrointestinal-tract-lower-cancers-recognition-referral/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5d466dbb-0034-4151-a2ac-7cea88b57287",
    "question_number": 347,
    "question": "A 35-year-old woman presents with a slowly enlarging, firm, non-tender lump in her upper left eyelid, present for several months. She denies redness, pain, or visual changes. What is the most likely diagnosis?",
    "options": [
      "Chalazion",
      "Dacryocystitis",
      "Hordeolum externum",
      "Basal cell carcinoma",
      "Sebaceous cyst"
    ],
    "correct_answer": "Chalazion",
    "explanation": "**Explanation**\n**Chalazion (meibomian cyst) is a chronic, painless swelling of the eyelid due to obstruction and inflammation of a meibomian gland.** It typically develops gradually and presents as a firm, non-tender lump, most often in adults. The overlying skin usually appears normal, and there are no acute inflammatory signs such as erythema or tenderness. This contrasts with other eyelid lumps that are more likely to be acutely inflamed, painful, or associated with infection. A chalazion is most commonly located away from the eyelid margin and may persist for weeks to months. Spontaneous resolution is common, and conservative management is usually sufficient. \n\n**Key distinguishing features**: chronicity, lack of pain, firm consistency, and absence of acute inflammation.\n\n**Key Points**\n- Chalazion = meibomian gland blockage, chronic and painless.\n- Usually presents as a slow-growing, firm lump on the eyelid.\n- Skin overlying a chalazion is typically normal and not inflamed.\n- Dacryocystitis is painful, red, and located at the inner canthus.\n- Hordeolum (stye) is acute, painful, and often at the lid margin.\n- Basal cell carcinoma may ulcerate or bleed and is rarely firm and non-tender for years.\n- Sebaceous cysts are less common on the eyelid and often have a central punctum.\n\n**Clinical Relevance**\nChalazia are common in general practice and can be managed conservatively unless persistent, recurrent, or suspicious for malignancy. Recognising the benign nature and distinguishing features of chalazion helps avoid unnecessary interventions and ensures prompt referral if atypical features are present, in line with NICE guidance.\n\n**Memory Anchor**\nChalazion is 'chronic' and 'calm'—think 'calm lesion'.",
    "bullet_explanations": {
      "Chalazion": "Correct: Chronic, painless, firm eyelid lump due to blocked meibomian gland.",
      "Dacryocystitis": "Incorrect: Presents with pain, redness, swelling at the inner corner of the eye.",
      "Hordeolum externum": "Incorrect: Acute, painful, tender lump at the lash line, often with erythema.",
      "Basal cell carcinoma": "Incorrect: Typically ulcerates or bleeds, and may distort lid margin; slow but not usually firm and non-tender for years.",
      "Sebaceous cyst": "Incorrect: May occur on eyelid but less common; usually has a central punctum and can be found elsewhere on the body."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Ophthalmology",
    "subsubsection": "Common Presentations",
    "topic": "Blepharitis",
    "keywords": [
      "chalazion",
      "meibomian cyst",
      "eyelid lump",
      "ophthalmology",
      "MSRA"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Meibomian cyst (chalazion)",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/meibomian-cyst-chalazion/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0a3fc9a4-435e-43cf-9790-49cf8efab208",
    "question_number": 348,
    "question": "A 65-year-old woman is evaluated for persistent lumbar pain, fatigue, and recent onset of polydipsia. Laboratory tests reveal normocytic anaemia, hypercalcaemia, and an elevated erythrocyte sedimentation rate (ESR). Serum electrophoresis detects a monoclonal immunoglobulin spike. What is the most characteristic finding on her peripheral blood film?",
    "options": [
      "Rouleaux formation",
      "Bite cells",
      "Basophilic stippling",
      "Spherocytes",
      "Target cells"
    ],
    "correct_answer": "Rouleaux formation",
    "explanation": "**Explanation**\n**Rouleaux formation** describes the appearance of red blood cells aligning in stacks, reminiscent of coins. This phenomenon is most often seen in conditions with increased plasma proteins, such as multiple myeloma. The abnormal production of monoclonal immunoglobulins in myeloma reduces the negative charge (zeta potential) on the RBC membrane, promoting their aggregation. While rouleaux can be seen in other inflammatory and paraproteinaemic states, its presence in the setting of bone pain, hypercalcaemia, anaemia, and a monoclonal spike strongly supports a diagnosis of myeloma. The raised ESR often parallels rouleaux formation due to the same protein-mediated effect on erythrocyte aggregation.\n\n**Key Points**\n- Multiple myeloma causes excess monoclonal immunoglobulins, leading to increased plasma viscosity.\n- Rouleaux formation is a classic blood film feature in myeloma and other paraproteinaemias.\n- Symptoms may include bone pain, anaemia, hypercalcaemia, and renal dysfunction.\n- Other blood film features (e.g., spherocytes, target cells) are not typical of myeloma.\n- ESR is usually elevated due to increased plasma proteins.\n- <table><thead><tr><th>Condition</th><th>Key Blood Film Finding</th></tr></thead><tbody><tr><td>Myeloma</td><td>Rouleaux</td></tr><tr><td>G6PD deficiency</td><td>Bite/Heinz bodies</td></tr><tr><td>Splenectomy</td><td>Howell-Jolly bodies</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising rouleaux formation on a blood film is important for early suspicion and diagnosis of multiple myeloma, especially in patients with non-specific symptoms such as bone pain and fatigue. NICE guidelines recommend urgent investigation for myeloma in older adults with suggestive features, as prompt diagnosis reduces complications such as renal failure and spinal cord compression.\n\n**Memory Anchor**\nRouleaux—think 'rolls' of red cells in myeloma (the M-protein makes them stick).",
    "bullet_explanations": {
      "Rouleaux formation": "Correct – seen in myeloma due to increased plasma proteins causing stacked RBCs.",
      "Bite cells": "Incorrect – associated with G6PD deficiency and oxidative haemolysis, not myeloma.",
      "Basophilic stippling": "Incorrect – typically seen in lead poisoning or thalassaemia, not plasma cell disorders.",
      "Spherocytes": "Incorrect – found in hereditary spherocytosis or autoimmune haemolytic anaemia.",
      "Target cells": "Incorrect – seen in liver disease, thalassaemia, and some haemoglobinopathies."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Haematological Malignancies",
    "topic": "Myeloma CRAB features",
    "keywords": [
      "myeloma",
      "rouleaux",
      "blood film",
      "monoclonal protein",
      "plasma cell"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Multiple myeloma",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/multiple-myeloma/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "6c804cb4-8698-491f-bd82-4c90a16103b3",
    "question_number": 349,
    "question": "A 32-year-old woman attends your clinic with a two-week history of vulval irritation and pain during intercourse. She describes her vaginal discharge as green, frothy, and foul-smelling. What is the most likely underlying cause of her symptoms?",
    "options": [
      "Trichomonas vaginalis infection",
      "Candida albicans infection",
      "Bacterial vaginosis",
      "Neisseria gonorrhoeae infection",
      "Chlamydia trachomatis infection"
    ],
    "correct_answer": "Trichomonas vaginalis infection",
    "explanation": "**Explanation**\n**Trichomonas vaginalis** is a protozoan responsible for a common sexually transmitted infection that typically presents with a green, frothy, and malodorous vaginal discharge, vulval itching, and dyspareunia. While up to half of women may be asymptomatic, those with symptoms often report vaginal irritation and offensive odour. These features, especially the combination of green discharge and vulval symptoms, strongly support a diagnosis of trichomoniasis and help differentiate it from other causes of vaginal discharge such as candidiasis (thick, white discharge; not usually offensive) and bacterial vaginosis (thin, grey-white discharge without vulval irritation or dyspareunia).\n\n**Key Points**\n- Trichomoniasis is caused by Trichomonas vaginalis, a protozoan STI.\n- Symptoms include green, frothy, offensive vaginal discharge, vulval itching, and pain during intercourse.\n- Bacterial vaginosis typically causes thin, grey-white discharge without significant vulval irritation.\n- Vulvovaginal candidiasis presents with thick, white, 'cottage cheese-like' discharge and pruritus, but not green or malodorous.\n- Gonorrhoea and chlamydia are often asymptomatic, and when symptomatic, discharge is not characteristically green or frothy.\n- Diagnosis is confirmed by laboratory testing of a high vaginal swab.\n- <table><thead><tr><th>Condition</th><th>Discharge</th><th>Other Features</th></tr></thead><tbody><tr><td>Trichomoniasis</td><td>Green, frothy, malodorous</td><td>Itching, dyspareunia</td></tr><tr><td>Candida</td><td>Thick, white, non-offensive</td><td>Itching, soreness</td></tr><tr><td>Bacterial vaginosis</td><td>Thin, grey-white, fishy</td><td>No vulval irritation</td></tr></tbody></table>\n\n**Clinical Relevance**\nCorrect identification of trichomoniasis is essential as it is a treatable STI with potential complications including infertility and adverse pregnancy outcomes. UK guidelines recommend laboratory confirmation and partner notification. Effective management reduces transmission and improves patient outcomes.\n\n**Memory Anchor**\nTrichomonas = 'Tricky green froth': Think 'T' for Trichomonas and 'Tinge' (green tinge, frothy, smelly discharge).",
    "bullet_explanations": {
      "Trichomonas vaginalis infection": "Correct – Classic presentation with green, frothy, offensive discharge and vulval symptoms.",
      "Candida albicans infection": "Incorrect – Usually causes thick, white, non-offensive discharge and itching, not green or foul-smelling.",
      "Bacterial vaginosis": "Incorrect – Typically produces thin, grey-white, fishy-smelling discharge without vulval irritation or pain during intercourse.",
      "Neisseria gonorrhoeae infection": "Incorrect – May cause purulent discharge but often asymptomatic and not associated with green, frothy, offensive discharge or prominent vulval itching.",
      "Chlamydia trachomatis infection": "Incorrect – Frequently asymptomatic; discharge, if present, is usually not green or frothy and vulval itching is uncommon."
    },
    "category": "STIs & Sexual Health",
    "subsection": "STIs",
    "subsubsection": "Trichomoniasis",
    "topic": "Trichomoniasis",
    "keywords": [
      "trichomoniasis",
      "green discharge",
      "STI",
      "vaginal infection",
      "sexual health"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Trichomoniasis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/trichomoniasis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5d774a93-59bf-434c-80fb-610fb164374c",
    "question_number": 350,
    "question": "A 35-year-old man reports progressive hearing loss in both ears over the last two years, accompanied by persistent tinnitus. He denies ear pain, discharge, or recurrent infections. His mother and maternal uncle both experienced similar hearing problems. On otoscopic examination, a faint pinkish hue is observed behind the intact tympanic membrane. Which is the most likely diagnosis?",
    "options": [
      "Otosclerosis",
      "Cholesteatoma",
      "Meniere’s disease",
      "Tympanosclerosis",
      "Acute otitis media"
    ],
    "correct_answer": "Otosclerosis",
    "explanation": "**Explanation**\n**Otosclerosis** is a hereditary disorder causing abnormal bone remodelling in the otic capsule, particularly around the stapes footplate. This leads to progressive **conductive hearing loss**, often bilateral, and may be associated with **tinnitus**. The condition typically presents in young to middle-aged adults and may have a positive family history. On otoscopy, a reddish blush behind the tympanic membrane (the Schwartz sign) may be seen due to increased vascularity over the promontory. In contrast, tympanosclerosis presents with chalky white plaques, Meniere’s disease features episodic vertigo and fluctuating hearing loss, and acute otitis media has signs of infection. Cholesteatoma usually involves chronic ear discharge and local tissue destruction rather than a vascular blush.\n\n**Key Points**\n- **Otosclerosis** causes progressive conductive hearing loss and tinnitus, often with a family history.\n- The Schwartz sign—pinkish hue on the promontory—is characteristic but not always present.\n- Sensorineural involvement can occur in advanced disease.\n- Other causes of hearing loss can usually be differentiated by otoscopic findings and clinical history.\n- Table: Key Otoscopic Findings\n- <table><thead><tr><th>Condition</th><th>Otoscopic Finding</th></tr></thead><tbody><tr><td>Otosclerosis</td><td>Pink blush (Schwartz sign)</td></tr><tr><td>Tympanosclerosis</td><td>White, chalky plaques</td></tr><tr><td>Acute otitis media</td><td>Red, bulging drum</td></tr><tr><td>Cholesteatoma</td><td>Retraction pocket, debris</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising otosclerosis is important for timely audiological assessment and management, particularly given its hereditary nature and potential for progressive hearing loss. Awareness of the Schwartz sign and typical presentation guides appropriate referral to ENT or audiology. Early intervention can improve quality of life and prevent complications.\n\n**Memory Anchor**\nRemember: **Oto**sclerosis = **Oto**scope blush + family history.",
    "bullet_explanations": {
      "Otosclerosis": "Correct – Progressive conductive hearing loss, tinnitus, positive family history, and Schwartz sign suggest otosclerosis.",
      "Cholesteatoma": "Incorrect – Typically presents with chronic ear discharge and retraction; not associated with a vascular blush.",
      "Meniere’s disease": "Incorrect – Presents with episodic vertigo, fluctuating sensorineural hearing loss, and tinnitus, without a promontory blush.",
      "Tympanosclerosis": "Incorrect – Characterised by white plaques due to scarring, not a pinkish hue.",
      "Acute otitis media": "Incorrect – Presents with acute pain, fever, and a red, bulging tympanic membrane."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Hearing loss causes",
    "keywords": [
      "otosclerosis",
      "hearing loss",
      "Schwartz sign",
      "ENT",
      "family history"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hearing loss in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hearing-loss-in-adults/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ee991620-4ef5-4b73-b899-bcdd75f6e273",
    "question_number": 351,
    "question": "On a CT scan of the brain, how does a chronic subdural haematoma typically appear?",
    "options": [
      "Hypodense, crescent-shaped collection not limited by suture lines",
      "Hyperdense, biconvex collection limited by suture lines",
      "Hypodense, lentiform collection limited by suture lines",
      "Hyperdense, crescent-shaped collection limited by suture lines",
      "Isointense, rounded collection confined to one lobe"
    ],
    "correct_answer": "Hypodense, crescent-shaped collection not limited by suture lines",
    "explanation": "**Explanation**\n**Chronic subdural haematomas** are collections of blood that accumulate slowly in the subdural space, most often affecting older adults. On CT imaging, these collections appear **hypodense (darker than brain tissue), crescentic in shape, and are not restricted by cranial suture lines**. This is because the subdural space extends across suture lines, and with time, the blood becomes less dense. In contrast, acute subdural haematomas are hyperdense, and extradural (epidural) collections are typically biconvex and do not cross suture lines.\n\n**Key Points**\n- Chronic subdural haematoma = hypodense, crescentic, not limited by sutures\n- Acute subdural haematoma = hyperdense, crescentic, not limited by sutures\n- Extradural (epidural) haematoma = biconvex/lentiform, limited by sutures\n- Hypodensity on CT reflects chronicity (older blood appears darker)\n- Shape and location help differentiate types of intracranial haemorrhage\n\n**Clinical Relevance**\nRecognising the classic imaging features of chronic subdural haematoma is vital for diagnosis, particularly in elderly patients with progressive cognitive decline or confusion. Early identification supports timely neurosurgical referral and can significantly improve outcomes.\n\n**Memory Anchor**\nChronic = hypodense (dark) crescent, crosses sutures; Extradural = biconvex, does NOT cross sutures.",
    "bullet_explanations": {
      "Hypodense, crescent-shaped collection not limited by suture lines": "Correct—this is the classic imaging appearance of a chronic subdural haematoma.",
      "Hyperdense, biconvex collection limited by suture lines": "Incorrect—describes an acute extradural (epidural) haematoma.",
      "Hypodense, lentiform collection limited by suture lines": "Incorrect—lentiform (biconvex) shape is typical of extradural, not subdural, haematoma.",
      "Hyperdense, crescent-shaped collection limited by suture lines": "Incorrect—subdural haematomas cross sutures and acute ones are hyperdense but not limited by suture lines.",
      "Isointense, rounded collection confined to one lobe": "Incorrect—does not describe any classical intracranial haematoma pattern."
    },
    "category": "Neurology",
    "subsection": "Stroke & TIA",
    "subsubsection": "Red flag headache",
    "topic": "Imaging features of subdural haematoma",
    "keywords": [
      "chronic subdural haematoma",
      "CT scan",
      "neuroimaging",
      "hypodense",
      "elderly confusion"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "9b4a97d6-eb4c-4c4b-a1cd-1fadde9e29a1",
    "question_number": 352,
    "question": "According to UK guidelines, which antihypertensive should be initiated first in a 48-year-old man with newly diagnosed hypertension and type 2 diabetes, irrespective of his ethnicity?",
    "options": [
      "Ramipril",
      "Amlodipine",
      "Bisoprolol",
      "Doxazosin",
      "Indapamide"
    ],
    "correct_answer": "Ramipril",
    "explanation": "**Explanation**\n**Ramipril, an ACE inhibitor, is recommended as the first-line antihypertensive** for adults with type 2 diabetes, regardless of age or ethnic background. This is because ACE inhibitors provide reno-protective benefits in diabetes, reducing the risk of progression to diabetic nephropathy. National guidelines specify that, in the presence of diabetes, ACE inhibitors (or ARBs if intolerant) should be started even if the patient is younger than 55 or of Black African/Caribbean descent, overriding the usual age- and ethnicity-based choices. Other agents, such as calcium channel blockers or thiazide-like diuretics, are considered after ACE inhibitors if further control is needed. **Beta-blockers and alpha-blockers are not first-line unless there are specific indications.**\n\n**Key Points**\n- ACE inhibitors are recommended first-line in hypertension with diabetes.\n- This applies regardless of patient age or ethnicity.\n- Ramipril and lisinopril are commonly used ACE inhibitors.\n- Amlodipine is first-line only if diabetes is absent and the patient is >55 or Black ethnicity.\n- Beta-blockers and alpha-blockers (e.g. bisoprolol, doxazosin) are reserved for later lines.\n- <table><thead><tr><th>Comorbidity</th><th>First-line Antihypertensive</th></tr></thead><tbody><tr><td>Diabetes</td><td>ACEi/ARB</td></tr><tr><td>No diabetes, age >55 or Black</td><td>CCB</td></tr><tr><td>No diabetes, age <55</td><td>ACEi</td></tr></tbody></table>\n\n**Clinical Relevance**\nInitiating an ACE inhibitor in patients with both hypertension and diabetes helps reduce cardiovascular and renal complications. Adhering to guideline-driven therapy improves long-term outcomes and patient safety.\n\n**Memory Anchor**\nRemember: **'A for ACE in Adults with diabetes And hypertension'**—regardless of age/ethnicity.",
    "bullet_explanations": {
      "Ramipril": "Correct – ACE inhibitors are first-line for hypertensive patients with diabetes.",
      "Amlodipine": "Incorrect – Only first-line if no diabetes and patient is >55 or of Black ethnicity.",
      "Bisoprolol": "Incorrect – Beta-blockers are not first-line in hypertension management without compelling indications.",
      "Doxazosin": "Incorrect – Alpha-blockers are not first-line and are reserved for resistant hypertension.",
      "Indapamide": "Incorrect – Thiazide-like diuretics are used if ACE inhibitors and CCBs are insufficient."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "NICE A/C/D ladder and special cases",
    "keywords": [
      "hypertension",
      "diabetes",
      "ACE inhibitor",
      "antihypertensive guidelines"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hypertension - drug treatment",
        "citation": "© NICE, 2022",
        "url": "https://cks.nice.org.uk/topics/hypertension/management/drug-treatment/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f0b9baea-219b-4e28-8830-74931e803568",
    "question_number": 353,
    "question": "A 28-year-old woman reports progressive difficulty seeing at night since her teenage years. She now notices that her peripheral vision is narrowing, making it hard to navigate in dimly lit environments. Her father experienced similar symptoms and was registered blind in middle age. Which inherited retinal disorder is most likely responsible for her symptoms?",
    "options": [
      "Retinitis pigmentosa",
      "Leber's congenital amaurosis",
      "Primary open-angle glaucoma",
      "Central serous retinopathy",
      "Stargardt disease"
    ],
    "correct_answer": "Retinitis pigmentosa",
    "explanation": "**Explanation**\n**Retinitis pigmentosa (RP)** represents a group of inherited retinal dystrophies marked by progressive loss of photoreceptors. The classic features include **night blindness (nyctalopia)** as an early symptom due to rod dysfunction, followed by **gradual loss of peripheral vision (tunnel vision)**. The family history of similar symptoms and progression to blindness further supports this diagnosis, as RP is often inherited (commonly autosomal dominant, recessive, or X-linked patterns). Central vision is typically preserved until late in the disease, distinguishing RP from macular dystrophies.\n\n**Key Points**\n- Retinitis pigmentosa is an inherited retinal disorder causing rod and later cone degeneration.\n- Night blindness is often the first symptom, progressing to tunnel vision.\n- Family history is common due to genetic inheritance.\n- Peripheral vision loss precedes central vision loss in RP.\n- Other conditions like Leber's congenital amaurosis present with severe vision loss much earlier (infancy).\n\n**Clinical Relevance**\nRecognising the pattern of night blindness followed by progressive peripheral vision loss is crucial for diagnosing retinitis pigmentosa early, enabling genetic counselling and visual rehabilitation, and differentiating it from other causes of visual impairment.\n\n**Memory Anchor**\nRP = 'Rod first, Peripheral loss' (RP: Rods → Periphery).",
    "bullet_explanations": {
      "Retinitis pigmentosa": "Correct – Inherited condition with progressive night blindness and tunnel vision.",
      "Leber's congenital amaurosis": "Incorrect – Presents in infancy with severe visual impairment, not gradual onset in young adults.",
      "Primary open-angle glaucoma": "Incorrect – Can cause peripheral vision loss but rarely night blindness and usually occurs after age 40.",
      "Central serous retinopathy": "Incorrect – Causes acute, often unilateral, central vision distortion, not night blindness or tunnel vision.",
      "Stargardt disease": "Incorrect – Inherited macular dystrophy causing central vision loss in children/young adults, not night blindness or peripheral vision loss."
    },
    "category": "Ophthalmology",
    "subsection": "Retinal Disorders",
    "subsubsection": "Retinitis pigmentosa",
    "topic": "Retinitis pigmentosa",
    "keywords": [
      "retinitis pigmentosa",
      "night blindness",
      "tunnel vision",
      "inherited retinal disease"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "d4b83bba-6565-4178-a6cd-d2447be47818",
    "question_number": 354,
    "question": "A 55-year-old woman with type 2 diabetes presents with vomiting and dehydration secondary to gastroenteritis. Laboratory results reveal an eGFR of 28 mL/min/1.73m². According to current UK guidelines, which one of her regular medications should be discontinued immediately to reduce the risk of serious adverse effects?",
    "options": [
      "Metformin",
      "Gliclazide",
      "Insulin glargine",
      "Empagliflozin",
      "Amlodipine"
    ],
    "correct_answer": "Metformin",
    "explanation": "**Explanation**\n**Metformin should be stopped in patients who develop acute kidney injury with an eGFR <30 mL/min/1.73m².** Continuing metformin in this context increases the risk of lactic acidosis, a rare but potentially fatal complication. National guidelines recommend reviewing the dose if eGFR falls below 45, and discontinuing metformin entirely if eGFR drops below 30. The medication can be restarted only when renal function returns to safe levels and the patient is eating and drinking normally. Other glucose-lowering agents may require dose adjustment, but do not carry the same immediate risk profile in this scenario.\n\n**Key Points**\n- Metformin is contraindicated in patients with eGFR <30 mL/min/1.73m² due to lactic acidosis risk.\n- Dose review is advised when eGFR <45 mL/min/1.73m²; stop if <30 mL/min/1.73m².\n- Acute illness with dehydration further increases risk.\n- Other antidiabetic drugs (e.g., sulfonylureas, insulin) may require adjustment but are not absolutely contraindicated by eGFR alone.\n- Restart metformin only after recovery of renal function and normal oral intake.\n\n**Clinical Relevance**\nStopping metformin in patients with acute kidney injury or significant renal impairment is essential to prevent lactic acidosis. This aligns with BNF guidance and is a key safety step in acute medical management.\n\n**Memory Anchor**\nThink 'Metformin' and 'eGFR under 30'—they must not mix.",
    "bullet_explanations": {
      "Metformin": "Correct – must be stopped immediately when eGFR falls below 30 mL/min/1.73m² to prevent lactic acidosis.",
      "Gliclazide": "Incorrect – Sulfonylureas should be used with caution in renal impairment but are not absolutely contraindicated at this eGFR.",
      "Insulin glargine": "Incorrect – Insulin dosing may require adjustment in illness but it is not contraindicated by renal impairment alone.",
      "Empagliflozin": "Incorrect – SGLT2 inhibitors should be withheld in acute illness, but the immediate priority in this scenario is metformin cessation due to lactic acidosis risk.",
      "Amlodipine": "Incorrect – This antihypertensive does not require stopping solely due to acute kidney injury."
    },
    "category": "Renal & Urology",
    "subsection": "Acute Kidney Injury",
    "subsubsection": "Management",
    "topic": "Stop nephrotoxins",
    "keywords": [
      "metformin",
      "acute kidney injury",
      "eGFR",
      "diabetes",
      "lactic acidosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetes, surgery and medical illness",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetes-surgery-and-medical-illness/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "34b1f20b-62e3-456e-84f7-54e9e66056a9",
    "question_number": 355,
    "question": "A 63-year-old woman with recently diagnosed type 2 diabetes has achieved a reduction in HbA1c after 4 months of standard-release metformin. She reports ongoing troublesome bloating and diarrhoea despite gradual dose titration. What is the most appropriate next step in managing her glucose-lowering therapy?",
    "options": [
      "Switch to modified-release metformin",
      "Add a sulfonylurea to current therapy",
      "Discontinue all diabetes medications",
      "Replace metformin with a GLP-1 receptor agonist",
      "Continue current metformin regimen and advise anti-diarrhoeal medication"
    ],
    "correct_answer": "Switch to modified-release metformin",
    "explanation": "**Explanation**\n**Modified-release metformin is recommended when gastrointestinal side effects occur with standard-release metformin.** This formulation is associated with fewer GI side effects, improving tolerability while maintaining efficacy. Continuing metformin (when possible) is preferred due to its proven benefits in glycaemic control and cardiovascular risk reduction. Only if the modified-release preparation is still not tolerated should alternative glucose-lowering therapies be considered. Changing drug class prematurely or stopping all therapy risks poor glycaemic control and loss of metformin's long-term benefits.\n\n**Key Points**\n- Metformin is first-line for type 2 diabetes unless contraindicated or not tolerated.\n- GI side effects (nausea, diarrhoea, bloating) are common but often less severe with modified-release formulations.\n- Switching to modified-release metformin is recommended before considering alternative agents.\n- Alternative agents (e.g., sulfonylureas, GLP-1 RAs) are for cases where metformin cannot be tolerated.\n- Stopping all diabetes medications is inappropriate if glycaemic control is not achieved with lifestyle alone.\n\n**Clinical Relevance**\nGI intolerance is a frequent barrier to metformin adherence. National guidelines recommend trying a modified-release preparation before abandoning metformin, supporting better patient outcomes and reducing unnecessary escalation to more complex or costly therapies. This aligns with BNF and NICE guidance for type 2 diabetes management.",
    "bullet_explanations": {
      "Switch to modified-release metformin": "Correct – Modified-release metformin is less likely to cause GI side effects and should be tried before switching drug classes.",
      "Add a sulfonylurea to current therapy": "Incorrect – Sulfonylureas are considered only if metformin is not tolerated or as add-on after maximising metformin options.",
      "Discontinue all diabetes medications": "Incorrect – Stopping all medication risks hyperglycaemia, especially as lifestyle changes have not succeeded.",
      "Replace metformin with a GLP-1 receptor agonist": "Incorrect – GLP-1 RAs are injectable and reserved for later lines after metformin and other oral agents.",
      "Continue current metformin regimen and advise anti-diarrhoeal medication": "Incorrect – Persisting with a poorly tolerated regimen reduces adherence and is not a guideline-based approach."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "Metformin first-line and intolerance",
    "keywords": [
      "metformin intolerance",
      "type 2 diabetes",
      "modified-release",
      "GI side effects",
      "oral hypoglycaemics"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Type 2 diabetes",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/type-2-diabetes/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7e56ac59-a6fd-49c0-a4df-2a9bef2d39c9",
    "question_number": 356,
    "question": "In suspected acute paracetamol overdose, what is the earliest time after ingestion at which a plasma paracetamol concentration can be reliably interpreted to guide acetylcysteine therapy?",
    "options": [
      "Immediately after presentation",
      "1 hour post-ingestion",
      "2 hours post-ingestion",
      "4 hours post-ingestion",
      "8 hours post-ingestion"
    ],
    "correct_answer": "4 hours post-ingestion",
    "explanation": "**Explanation**\n**A plasma paracetamol level should not be measured until at least 4 hours have elapsed since ingestion in cases of acute overdose.** This is because the drug continues to be absorbed from the gastrointestinal tract for several hours after ingestion, and earlier levels may underestimate the true plasma concentration. The 4-hour plasma level is then plotted on the treatment nomogram (e.g. Rumack-Matthew) to inform the need for acetylcysteine therapy. Sampling before 4 hours may give falsely low results, risking under-treatment.\n\n**Key Points**\n- Paracetamol absorption may be incomplete before 4 hours post-ingestion.\n- Levels measured before 4 hours cannot be reliably interpreted for risk assessment.\n- The Rumack-Matthew nomogram for acetylcysteine guidance starts at 4 hours.\n- If the time of ingestion is unknown or the overdose is staggered, treatment decisions may differ.\n- Early activated charcoal is considered within 1 hour of overdose, but not for level interpretation.\n\n**Clinical Relevance**\nTimely and appropriate sampling is crucial in paracetamol toxicity. Measuring plasma levels too early can result in missed or delayed treatment, risking liver injury. UK guidance emphasises waiting 4 hours post-ingestion for meaningful results, aligning with national and international toxicology protocols.\n\n**Memory Anchor**\nRemember: \"Four before the score\"—wait 4 hours before using the paracetamol level for the treatment nomogram.",
    "bullet_explanations": {
      "Immediately after presentation": "Levels taken immediately will not reflect peak absorption and cannot guide therapy.",
      "1 hour post-ingestion": "Too early—absorption is incomplete and levels may be falsely low.",
      "2 hours post-ingestion": "Still too early for reliable nomogram interpretation.",
      "4 hours post-ingestion": "Correct—this is the minimum time for accurate plasma level interpretation.",
      "8 hours post-ingestion": "Acceptable if missed earlier, but ideally sample at 4 hours for timely decision-making."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Drug monitoring (levels, blood tests)",
    "topic": "Paracetamol level timing",
    "keywords": [
      "paracetamol",
      "overdose",
      "acetylcysteine",
      "nomogram",
      "plasma level timing"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Paracetamol poisoning – Management",
        "citation": "© NICE, 2025",
        "url": "https://cks.nice.org.uk/topics/paracetamol-poisoning/management/management/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d820cf4c-a28e-4bdc-bdfb-db29b39b9ffb",
    "question_number": 357,
    "question": "Which potassium-sparing diuretic is the preferred alternative for a patient who develops gynaecomastia while taking spironolactone for heart failure?",
    "options": [
      "Eplerenone",
      "Indapamide",
      "Acetazolamide",
      "Chlorothiazide",
      "Amiloride"
    ],
    "correct_answer": "Eplerenone",
    "explanation": "**Explanation**\n**Eplerenone** is the preferred alternative in cases where spironolactone causes gynaecomastia, a recognised adverse effect due to its anti-androgenic activity. Both spironolactone and eplerenone are aldosterone antagonists and provide mortality benefit in heart failure with reduced ejection fraction. However, eplerenone is structurally distinct and has much less affinity for androgen and progesterone receptors, making gynaecomastia far less likely. Unlike other potassium-sparing diuretics (e.g., amiloride), eplerenone offers the same evidence-based benefits in heart failure as spironolactone.\n\n**Key Points**\n- Spironolactone can cause gynaecomastia due to anti-androgenic effects.\n- Eplerenone is a selective aldosterone antagonist with minimal hormonal side effects.\n- Both drugs are indicated for heart failure with reduced ejection fraction.\n- Switching to eplerenone maintains heart failure management without inducing gynaecomastia.\n- Other diuretics (thiazides, loop, carbonic anhydrase inhibitors) are not suitable replacements for this indication.\n\n**Clinical Relevance**\nRecognising and managing spironolactone-induced gynaecomastia is important for adherence and quality of life in patients with heart failure. NICE and BNF recommend eplerenone as an alternative when this side effect occurs, ensuring continued guideline-based therapy.\n\n**Memory Anchor**\nRemember: 'E' for 'Eplerenone' and 'Endocrine-sparing'—less hormonal side effects than spironolactone.",
    "bullet_explanations": {
      "Eplerenone": "Correct – Eplerenone is a selective aldosterone antagonist with a lower risk of gynaecomastia and maintains efficacy in heart failure.",
      "Indapamide": "Incorrect – Indapamide is a thiazide-like diuretic, not an aldosterone antagonist, and does not provide the same mortality benefit in heart failure.",
      "Acetazolamide": "Incorrect – Acetazolamide is a carbonic anhydrase inhibitor and is not indicated for heart failure management.",
      "Chlorothiazide": "Incorrect – This is a thiazide diuretic, used mainly for hypertension and oedema, not as an alternative for potassium-sparing therapy.",
      "Amiloride": "Incorrect – While potassium-sparing, amiloride is not an aldosterone antagonist and lacks the mortality benefit proven in heart failure."
    },
    "category": "Cardiovascular",
    "subsection": "Heart Failure",
    "subsubsection": "Chronic HFrEF",
    "topic": "GDMT sequencing (ACEi/ARB/ARNI, BB, MRA, SGLT2i)",
    "keywords": [
      "spironolactone",
      "eplerenone",
      "gynaecomastia",
      "heart failure",
      "aldosterone antagonist"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diuretics",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diuretics/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f84894e1-95bb-4fa8-9480-1b53cdb829f7",
    "question_number": 358,
    "question": "Which adverse effect is most frequently reported among men using sildenafil for erectile dysfunction?",
    "options": [
      "Headache",
      "Priapism",
      "Visual disturbances (red-tinged vision)",
      "Infertility",
      "Alopecia"
    ],
    "correct_answer": "Headache",
    "explanation": "**Explanation**\n**Headaches are the most common side effect associated with sildenafil use**, occurring in approximately 10–30% of patients. This is primarily due to sildenafil's vasodilatory effect, mediated by increased nitric oxide and subsequent cerebral vessel dilation. Headaches are usually mild to moderate, often improve with ongoing use, and rarely require discontinuation. In contrast, priapism and visual disturbances are well recognised but far less prevalent, while infertility and hair loss are not established risks of sildenafil.\n\n**Key Points**\n- Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction.\n- Most common side effects: headache, flushing, nasal congestion, dyspepsia.\n- Headache is reported in 10–30% of users due to vasodilation.\n- Priapism is rare (<1%) but serious; needs urgent intervention if prolonged.\n- Visual changes (e.g. red-tinged vision) are uncommon and transient.\n- No evidence links sildenafil to infertility or hair loss.\n- <table><thead><tr><th>Side Effect</th><th>Frequency</th></tr></thead><tbody><tr><td>Headache</td><td>Common (10–30%)</td></tr><tr><td>Priapism</td><td>Rare (&lt;1%)</td></tr><tr><td>Visual disturbances</td><td>Uncommon (&lt;2%)</td></tr><tr><td>Infertility</td><td>Not a side effect</td></tr><tr><td>Alopecia</td><td>Not a side effect</td></tr></tbody></table>\n\n**Clinical Relevance**\nWhen prescribing sildenafil, clinicians must counsel patients regarding common and serious adverse effects. Recognising that headaches are the most frequent side effect ensures accurate patient information, supports adherence, and distinguishes between common, benign reactions and rare, urgent complications such as priapism. This aligns with BNF guidance on safe prescribing of PDE5 inhibitors.\n\n**Memory Anchor**\nRemember: 'Sildenafil Sorehead'—headaches are the most common side effect.",
    "bullet_explanations": {
      "Headache": "Correct – this is the most frequently reported adverse effect of sildenafil.",
      "Priapism": "Incorrect – although important, priapism is rare and not the most common side effect.",
      "Visual disturbances (red-tinged vision)": "Incorrect – these occur infrequently and are usually transient.",
      "Infertility": "Incorrect – there is no established association between sildenafil and infertility.",
      "Alopecia": "Incorrect – hair loss is not a recognised side effect of sildenafil."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "Endocrine & Miscellaneous",
    "subsubsection": "Special Situations",
    "topic": "Prescribing in elderly/frail patients",
    "keywords": [
      "sildenafil",
      "erectile dysfunction",
      "side effects",
      "headache",
      "PDE5 inhibitor"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Erectile dysfunction",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/erectile-dysfunction/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4703fc3f-49f0-4148-b98e-52dccd3f4ba0",
    "question_number": 359,
    "question": "A 47-year-old woman presents with persistent bilateral foot pain described as burning and shooting, following a crush injury two years ago. She has tried amitriptyline at adequate doses for three months without improvement. She is currently taking regular paracetamol and codeine with minimal benefit. Which is the most appropriate next pharmacological step for her neuropathic pain?",
    "options": [
      "Stop amitriptyline and start gabapentin",
      "Continue amitriptyline and add duloxetine",
      "Continue amitriptyline and add tramadol",
      "Stop amitriptyline and start modified-release morphine",
      "Increase codeine dosage and maintain current regimen"
    ],
    "correct_answer": "Stop amitriptyline and start gabapentin",
    "explanation": "**Explanation**\n**First-line management of neuropathic pain involves monotherapy with a recommended agent such as amitriptyline, duloxetine, gabapentin, or pregabalin.** If a patient does not respond to the initial agent at an adequate dose and duration, the preferred approach is to discontinue the ineffective agent and switch to another rather than combining treatments. This minimises the risk of additive side effects and aligns with current evidence-based guidelines. Gabapentin is an appropriate alternative following failure of amitriptyline. **Opioids and combination therapy are not first-line and are reserved for specialist settings or intractable cases.**<br><br><b>Key contrasts:</b> Combination therapy is generally not recommended at initial stages; switching agents is safer and more evidence-based.\n\n**Key Points**\n- Neuropathic pain should be managed with a single agent at a time initially.\n- If amitriptyline fails, switch to another agent (e.g. gabapentin, duloxetine, pregabalin).\n- Combination therapy increases risk of adverse effects and is not standard in first-line management.\n- Opioids (including morphine) are reserved for refractory cases under specialist supervision.\n- Tramadol may be considered if other agents fail, but only for short-term use or while awaiting specialist input.\n- <table><thead><tr><th>First-line</th><th>Switch if ineffective</th><th>Specialist/last-line</th></tr></thead><tbody><tr><td>Amitriptyline, duloxetine, gabapentin, pregabalin</td><td>Try another first-line agent</td><td>Tramadol, opioids</td></tr></tbody></table>\n\n**Clinical Relevance**\nAdhering to monotherapy and switching between recommended first-line neuropathic pain agents reduces harm and aligns with NICE and BNF guidance. This approach enhances patient safety and optimises outcomes before considering escalation or specialist referral.",
    "bullet_explanations": {
      "Stop amitriptyline and start gabapentin": "Correct—Switching to an alternative first-line agent is recommended when initial therapy is ineffective.",
      "Continue amitriptyline and add duloxetine": "Incorrect—Combination of neuropathic agents is not recommended as first-line due to increased side effect burden.",
      "Continue amitriptyline and add tramadol": "Incorrect—Tramadol may be considered only after failure of several agents and not routinely combined with first-line drugs.",
      "Stop amitriptyline and start modified-release morphine": "Incorrect—Opioids are not recommended for neuropathic pain outside of specialist settings and only after failure of other options.",
      "Increase codeine dosage and maintain current regimen": "Incorrect—Codeine and standard analgesics are generally ineffective for neuropathic pain and should not be relied upon once neuropathic pain is diagnosed."
    },
    "category": "Musculoskeletal",
    "subsection": "Soft Tissue",
    "subsubsection": "Back Pain",
    "topic": "Analgesia and physio",
    "keywords": [
      "neuropathic pain",
      "gabapentin",
      "amitriptyline",
      "monotherapy",
      "chronic pain management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Neuropathic pain - drug treatment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/neuropathic-pain-drug-treatment/"
      },
      {
        "source": "BNF",
        "topic_title": "Neuropathic pain",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/neuropathic-pain/"
      },
      {
        "source": "BNF",
        "topic_title": "Pain, chronic",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/pain-chronic/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7461d057-5363-4504-a837-621cabfabbd6",
    "question_number": 360,
    "question": "Which pathogen is most commonly associated with triggering Guillain–Barré syndrome in adults?",
    "options": [
      "Campylobacter jejuni",
      "Epstein–Barr virus",
      "Mycoplasma pneumoniae",
      "Salmonella enterica",
      "Streptococcus pyogenes"
    ],
    "correct_answer": "Campylobacter jejuni",
    "explanation": "**Explanation**\n**Campylobacter jejuni** is the most frequently identified infectious trigger for Guillain–Barré syndrome (GBS). GBS is an acute, immune-mediated polyneuropathy, often characterised by rapidly progressive, symmetrical limb weakness, classically with reduced or absent reflexes. In many cases, GBS follows a respiratory or gastrointestinal infection. The molecular mimicry between Campylobacter antigens and peripheral nerve gangliosides is thought to provoke the aberrant autoimmune response leading to demyelination. Other pathogens, such as cytomegalovirus or Mycoplasma pneumoniae, are less common triggers. Bacterial and viral agents like Epstein–Barr virus, Salmonella, and Streptococcus pyogenes have not demonstrated a strong association with GBS.\n\n**Key Points**\n- Guillain–Barré syndrome often follows an infectious illness, especially gastroenteritis.\n- **Campylobacter jejuni** is the leading infectious antecedent, especially in adults.\n- GBS presents with ascending, symmetrical weakness and areflexia but preserved sensation early on.\n- Other pathogens (e.g. CMV, Mycoplasma) are less frequently associated.\n- Correct identification of the trigger is important for epidemiological understanding, but does not alter acute management.\n\n**Clinical Relevance**\nRecognising Campylobacter jejuni as the most common infectious trigger of GBS is essential for clinical reasoning and epidemiology. While the management of GBS does not depend on treating the antecedent infection, a careful history regarding recent gastrointestinal symptoms is valuable for diagnosis. Awareness of typical triggers supports confident, evidence-based diagnosis and patient education.\n\n**Memory Anchor**\nRemember: '**C**ampylobacter causes **C**onduction (nerve) problems in GBS.'",
    "bullet_explanations": {
      "Campylobacter jejuni": "Correct – most common infectious trigger for Guillain–Barré syndrome.",
      "Epstein–Barr virus": "Incorrect – may cause mononucleosis but is not a typical trigger for GBS.",
      "Mycoplasma pneumoniae": "Incorrect – can rarely precede GBS, but much less commonly than Campylobacter.",
      "Salmonella enterica": "Incorrect – causes gastroenteritis but is not associated with GBS.",
      "Streptococcus pyogenes": "Incorrect – causes pharyngitis and skin infections, not linked to GBS."
    },
    "category": "Neurology",
    "subsection": "Epilepsy",
    "subsubsection": "Focal vs generalised",
    "topic": "Guillain–Barré syndrome triggers",
    "keywords": [
      "Guillain–Barré syndrome",
      "Campylobacter jejuni",
      "neuropathy",
      "GBS triggers"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "7561adeb-ec91-46e6-9597-388361fd208f",
    "question_number": 361,
    "question": "A 58-year-old woman with a BMI of 32 and a strong family history of venous thromboembolism is seeking treatment for menopausal symptoms. She wishes to minimise her risk of VTE while using hormone replacement therapy. Which form of HRT is considered to carry the lowest risk of VTE?",
    "options": [
      "Transdermal oestrogen-progestogen patch",
      "Oral conjugated oestrogens",
      "Oral oestrogen-only tablets",
      "Oral continuous combined HRT",
      "Oral cyclical combined HRT"
    ],
    "correct_answer": "Transdermal oestrogen-progestogen patch",
    "explanation": "**Explanation**\n**Transdermal HRT (patch, gel, or spray applied to the skin) does not significantly increase the risk of venous thromboembolism (VTE) compared to baseline population risk.** This is in contrast to oral HRT preparations—including both oestrogen-only and combined regimens—which are associated with a higher risk of VTE, particularly in those with additional risk factors such as obesity or a family history. The likely reason is that oral oestrogens undergo first-pass metabolism in the liver, increasing clotting factor production and VTE risk, whereas transdermal oestrogens bypass the liver. This makes transdermal HRT the preferred choice for women at increased VTE risk. <br><br>**Key facts**: Oral HRT (all types) increases VTE risk; transdermal forms are safer for women with VTE risk factors.\n\n**Key Points**\n- Oral HRT (oestrogen-only or combined) increases VTE risk.\n- Transdermal HRT does not appear to raise VTE risk above baseline.\n- First-pass hepatic metabolism with oral oestrogens increases clotting factors.\n- Obesity and family history are important VTE risk factors that increase oral HRT risk.\n- Transdermal HRT is recommended for women with VTE risk factors.\n- All systemic HRT slightly increases risk of breast cancer with prolonged use.\n- <table><thead><tr><th>HRT Route</th><th>VTE Risk</th></tr></thead><tbody><tr><td>Oral</td><td>Increased</td></tr><tr><td>Transdermal</td><td>No increase</td></tr></tbody></table>\n\n**Clinical Relevance**\nSelecting the safest HRT route is crucial, especially in women with VTE risk factors. Guidelines recommend transdermal preparations in these scenarios, supporting shared decision-making and patient safety.\n\n**Memory Anchor**\nTransdermal = T for Thrombosis-sparing",
    "bullet_explanations": {
      "Transdermal oestrogen-progestogen patch": "Correct – this form does not significantly increase VTE risk compared to baseline.",
      "Oral conjugated oestrogens": "Incorrect – oral oestrogen (any form) increases VTE risk due to hepatic first-pass effect.",
      "Oral oestrogen-only tablets": "Incorrect – oral route increases VTE risk, regardless of whether oestrogen is used alone.",
      "Oral continuous combined HRT": "Incorrect – combined oral therapies also increase VTE risk.",
      "Oral cyclical combined HRT": "Incorrect – cyclical or continuous oral combined regimens both raise VTE risk."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Lifestyle advice",
    "topic": "Lifestyle advice",
    "keywords": [
      "HRT",
      "transdermal",
      "VTE risk",
      "menopause",
      "hormone therapy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Sex hormones",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/sex-hormones/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b543a3f5-d6a5-473c-84a6-b5e20c7d8086",
    "question_number": 362,
    "question": "A 28-year-old woman at 30 weeks' gestation attends the maternity assessment unit reporting a sudden painless loss of clear fluid per vagina. Speculum examination confirms preterm prelabour rupture of membranes. She has no signs of infection, and her allergy history includes a severe penicillin reaction. Which antibiotic regimen is recommended to reduce the risk of maternal and fetal infection in this scenario?",
    "options": [
      "10 days oral erythromycin",
      "7 days oral doxycycline",
      "5 days intravenous ceftriaxone",
      "3 days nitrofurantoin",
      "8 days oral clindamycin"
    ],
    "correct_answer": "10 days oral erythromycin",
    "explanation": "**Explanation**\n**Oral erythromycin for 10 days** is recommended for women with preterm prelabour rupture of membranes (PPROM) to decrease maternal and neonatal infectious complications. Erythromycin is chosen over penicillins and cephalosporins in penicillin-allergic patients. Alternative antibiotics like doxycycline, nitrofurantoin, and clindamycin are not suitable for this indication and may be contraindicated in pregnancy. The regimen helps prolong pregnancy and reduce risks such as chorioamnionitis and neonatal sepsis. **Nitrofurantoin is used for urinary tract infections, not PPROM; doxycycline and clindamycin are not first-line and have fetal safety concerns; ceftriaxone is neither indicated nor appropriate for this context.**\n\n**Key Points**\n- PPROM is managed with 10 days of oral erythromycin to reduce infection risk.\n- Erythromycin is safe in pregnancy and suitable for penicillin-allergic women.\n- Alternative antibiotics (nitrofurantoin, doxycycline, clindamycin) are either ineffective, contraindicated, or unsafe.\n- Infection prevention is essential to reduce fetal and maternal morbidity in PPROM.\n- Corticosteroids and magnesium sulphate may be considered for fetal benefit but are not substitutes for prophylactic antibiotics.\n\n**Clinical Relevance**\nPrompt initiation of oral erythromycin in PPROM is supported by national guidelines to minimise infectious complications and improve neonatal outcomes. Recognising the correct regimen is vital, especially in women with penicillin allergy.\n\n**Memory Anchor**\nE for Erythromycin and E for Early (preterm) membrane rupture.",
    "bullet_explanations": {
      "10 days oral erythromycin": "Correct – First-line prophylaxis in PPROM, especially in penicillin allergy.",
      "7 days oral doxycycline": "Incorrect – Doxycycline is contraindicated in pregnancy due to risks to fetal bone and teeth.",
      "5 days intravenous ceftriaxone": "Incorrect – Not recommended for PPROM prophylaxis and is a cephalosporin, which may cross-react in severe penicillin allergy.",
      "3 days nitrofurantoin": "Incorrect – Indicated for lower urinary tract infections, not for PPROM or intra-amniotic infection prevention.",
      "8 days oral clindamycin": "Incorrect – Not first-line for PPROM, and not routinely recommended; safety data in pregnancy are less robust."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Preterm prelabour rupture of membranes (PPROM)",
    "keywords": [
      "PPROM",
      "erythromycin",
      "preterm",
      "infection prophylaxis",
      "pregnancy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Obstetrics",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/obstetrics/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5587819a-75aa-4c69-8616-f1a2c79eb694",
    "question_number": 363,
    "question": "A 56-year-old man with a 10-year history of poorly controlled type 2 diabetes attends his annual diabetic eye screening. Fundoscopy reveals multiple cotton wool spots in the retina. What is the underlying pathological process responsible for these retinal findings?",
    "options": [
      "Retinal nerve fibre layer infarction",
      "Formation of new blood vessels",
      "Peripheral retinal holes",
      "Retinal detachment",
      "Acute retinal necrosis"
    ],
    "correct_answer": "Retinal nerve fibre layer infarction",
    "explanation": "**Explanation**\n**Cotton wool spots** are caused by localised infarctions in the retinal nerve fibre layer, resulting from occlusion of small retinal arterioles. In the context of diabetes, chronic hyperglycaemia leads to microvascular damage, which compromises blood flow and causes these infarcts. Cotton wool spots are a hallmark of pre-proliferative (moderate to severe non-proliferative) diabetic retinopathy. In contrast, retinal neovascularisation involves new vessel growth and signals progression to proliferative diabetic retinopathy, while atrophic holes, detachment, and necrosis have distinct clinical presentations and causes.\n\n**Key Points**\n- Cotton wool spots = localised retinal nerve fibre layer infarcts\n- Result from microvascular occlusion due to chronic diabetes\n- Sign of pre-proliferative diabetic retinopathy\n- Retinal neovascularisation signals proliferative disease (not the cause of cotton wool spots)\n- Other options (holes, detachment, necrosis) have different pathologies and presentations\n\n**Clinical Relevance**\nRecognising cotton wool spots in diabetic patients is essential for identifying significant microvascular complications and the need for rigorous glycaemic and ophthalmological management to prevent progression to vision-threatening stages.\n\n**Memory Anchor**\nCotton wool spots = ‘fluffy’ infarcts from microvascular occlusion",
    "bullet_explanations": {
      "Retinal nerve fibre layer infarction": "Correct—cotton wool spots are due to microinfarcts in the nerve fibre layer from small vessel occlusion.",
      "Formation of new blood vessels": "Incorrect—this describes neovascularisation, which is seen in proliferative diabetic retinopathy but is not the cause of cotton wool spots.",
      "Peripheral retinal holes": "Incorrect—these are atrophic lesions, not associated with cotton wool spots or microvascular infarction.",
      "Retinal detachment": "Incorrect—this is a mechanical separation of the retina and does not produce cotton wool spots.",
      "Acute retinal necrosis": "Incorrect—typically presents with acute, severe vision loss and widespread retinal whitening, unrelated to the microinfarcts seen in diabetes."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Microvascular Complications",
    "topic": "Retinopathy screening",
    "keywords": [
      "cotton wool spots",
      "diabetic retinopathy",
      "retinal infarction",
      "fundoscopy",
      "microvascular complications"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Retinal detachment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/retinal-detachment/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0871f03c-2c1f-4ad0-bac2-61a349d21396",
    "question_number": 364,
    "question": "Which combination of clinical signs most specifically indicates an oculomotor (third cranial nerve) palsy in an adult presenting with acute onset double vision?",
    "options": [
      "Ptosis, eye deviated down and out, mydriasis",
      "Miosis, ptosis, anhidrosis, enophthalmos",
      "Exophthalmos, lid retraction, diplopia",
      "Ptosis, eye deviated up and in, miosis",
      "Ptosis, miosis, anhidrosis, exophthalmos"
    ],
    "correct_answer": "Ptosis, eye deviated down and out, mydriasis",
    "explanation": "**Explanation**\n**Oculomotor (third nerve) palsy** presents with a classic triad: **ptosis** (drooping of the upper eyelid), **'down and out' position of the affected eye** (due to unopposed action of lateral rectus and superior oblique), and **mydriasis** (dilated pupil). The oculomotor nerve supplies most of the extraocular muscles, the levator palpebrae superioris (eyelid elevation), and the parasympathetic fibres to the pupil. When damaged, the eyelid droops, the eye drifts 'down and out', and the pupil becomes dilated because of unopposed sympathetic activity. This differs sharply from syndromes like Horner's, where miosis (pupil constriction), not mydriasis, predominates.\n\n**Key Points**\n- Oculomotor nerve palsy: ptosis, 'down and out' eye, mydriatic pupil\n- Mydriasis signals parasympathetic fibre involvement\n- Ptosis occurs due to levator palpebrae superioris weakness\n- Eye position is caused by loss of most extraocular muscle function except lateral rectus (VI) and superior oblique (IV)\n- Horner's syndrome: miosis, mild ptosis, anhidrosis, enophthalmos—not mydriasis\n\n**Clinical Relevance**\nRapid recognition of third nerve palsy is crucial, as it may indicate a compressive lesion (e.g., aneurysm, tumour) or raised intracranial pressure. Differentiating it from other syndromes (like Horner's) guides urgent investigations and management to prevent vision loss or further neurological compromise.\n\n**Memory Anchor**\nRemember: Third nerve = \"3 D's\": Droop (ptosis), Down & out, Dilated pupil.",
    "bullet_explanations": {
      "Ptosis, eye deviated down and out, mydriasis": "This is the classic triad of an oculomotor (third nerve) palsy.",
      "Miosis, ptosis, anhidrosis, enophthalmos": "This combination defines Horner's syndrome, not third nerve palsy.",
      "Exophthalmos, lid retraction, diplopia": "Suggests thyroid eye disease (Graves'), not a cranial nerve palsy.",
      "Ptosis, eye deviated up and in, miosis": "This pattern does not match any cranial nerve palsy; the eye is characteristically down and out in third nerve palsy.",
      "Ptosis, miosis, anhidrosis, exophthalmos": "Combines features from different syndromes; exophthalmos is not seen in third nerve or Horner's syndrome."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Cranial Nerve Disorders",
    "topic": "Oculomotor nerve palsy: clinical features",
    "keywords": [
      "third nerve palsy",
      "oculomotor",
      "ptosis",
      "mydriasis",
      "neurology signs"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Bell's palsy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/bells-palsy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a206a780-a1de-468e-8b3f-9b7ed8d26f1b",
    "question_number": 365,
    "question": "A 54-year-old woman with a diagnosis of heart failure with reduced ejection fraction (LVEF 35%) is reviewed two weeks after starting ramipril and simvastatin. She is haemodynamically stable, has no symptoms of congestion, and her blood pressure is 120/70 mmHg. She is in sinus rhythm. Which medication should be initiated next to optimise her heart failure management according to UK guidelines?",
    "options": [
      "Start bisoprolol",
      "Add furosemide",
      "Increase ramipril dose further",
      "Begin isosorbide mononitrate",
      "Continue current medications without changes"
    ],
    "correct_answer": "Start bisoprolol",
    "explanation": "**Explanation**\n**A beta-blocker licensed for heart failure, such as bisoprolol, should be added as part of first-line therapy for heart failure with reduced ejection fraction (HFrEF).** Both an ACE inhibitor and a licensed beta-blocker (bisoprolol, carvedilol, or nebivolol) have proven mortality and morbidity benefits. Beta-blockers are started at a low dose and titrated upwards, provided the patient is clinically stable and euvolaemic. In contrast, loop diuretics like furosemide are reserved for symptomatic fluid overload and do not confer mortality benefit. Nitrates and further ACE inhibitor up-titration are not a substitute for introducing a beta-blocker. Continuing the current regimen leaves the patient undertreated according to guidelines. \n\n**Key Points:**\n- HFrEF management requires both an ACE inhibitor and a licensed beta-blocker as first-line therapy\n- Beta-blockers (bisoprolol, carvedilol, nebivolol) reduce mortality and hospitalisations\n- Diuretics are for fluid overload, not routine mortality reduction\n- Nitrates are not recommended as core therapy in stable HFrEF\n- Up-titration of ACE inhibitors should be balanced with introducing a beta-blocker\n- Ongoing evidence-based therapy optimises outcomes\n\n<table><thead><tr><th>Drug Class</th><th>Mortality Benefit</th><th>Indication in HFrEF</th></tr></thead><tbody><tr><td>ACE inhibitor</td><td>Yes</td><td>First-line</td></tr><tr><td>Beta-blocker</td><td>Yes</td><td>First-line</td></tr><tr><td>Loop diuretic</td><td>No</td><td>Symptomatic relief</td></tr><tr><td>Nitrate</td><td>No</td><td>Specialist/angina</td></tr></tbody></table>\n\n**Clinical Relevance:**\nAdhering to NICE and BNF recommendations ensures that patients with HFrEF receive proven, life-prolonging treatment. Failure to initiate a beta-blocker where indicated can worsen prognosis. Initiating and titrating evidence-based medications should be prioritised in stable patients. \n\n**Memory Anchor:** \n\"ACE and Beta for Base\" — Every HFrEF patient’s foundational therapy is an ACE inhibitor plus a beta-blocker.\n\n**Key Points**\n- Both ACE inhibitors and heart failure-specific beta-blockers are essential first-line therapy in HFrEF.\n- Bisoprolol, carvedilol, and nebivolol are the UK-licensed beta-blockers for HFrEF.\n- Beta-blockers should be started at low dose once the patient is clinically stable.\n- Loop diuretics are used for symptomatic fluid overload only.\n- Nitrates are not part of standard HFrEF management unless there are specific indications.\n- Omitting a beta-blocker leaves heart failure undertreated.\n- Always balance up-titration of ACE inhibitors with timely addition of beta-blockers.\n\n**Clinical Relevance**\nImplementing guideline-directed therapy for HFrEF improves survival and reduces hospital admissions. UK guidelines emphasise the combination of an ACE inhibitor and a heart failure-licensed beta-blocker as first-line therapy, with diuretics reserved for symptom relief.\n\n**Memory Anchor**\n\"ACE and Beta for Base\" — foundational therapy for HFrEF.",
    "bullet_explanations": {
      "Start bisoprolol": "Correct. Beta-blockers licensed for heart failure are added after ACE inhibitors in stable HFrEF to improve mortality and morbidity.",
      "Add furosemide": "Incorrect. Diuretics address fluid overload symptoms but do not confer long-term mortality benefit; not routinely needed if the patient is euvolaemic.",
      "Increase ramipril dose further": "Incorrect. While ACE inhibitors should be titrated, delaying the addition of a beta-blocker is not guideline-based if the patient is stable.",
      "Begin isosorbide mononitrate": "Incorrect. Nitrates are not part of standard first-line therapy for HFrEF; reserved for angina or specialist use.",
      "Continue current medications without changes": "Incorrect. Not initiating a beta-blocker misses a core component of evidence-based HFrEF management."
    },
    "category": "Heart Failure",
    "subsection": "Chronic HFrEF",
    "subsubsection": "GDMT sequencing (ACEi/ARB/ARNI, BB, MRA, SGLT2i)",
    "topic": "GDMT sequencing (ACEi/ARB/ARNI, BB, MRA, SGLT2i)",
    "keywords": [
      "heart failure",
      "beta-blocker",
      "HFrEF",
      "GDMT",
      "ACE inhibitor"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Chronic heart failure",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/chronic-heart-failure/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Heart failure - chronic",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/heart-failure-chronic/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "15c3f7b1-d560-4bcb-8cd4-5eaf188f1fc4",
    "question_number": 366,
    "question": "A 46-year-old man presents with several months of persistent fatigue, unintentional weight loss, and occasional dizziness when standing. His medical history is unremarkable except for mild asthma managed with a salbutamol inhaler. Examination reveals a blood pressure of 98/64 mmHg, and laboratory results show sodium 128 mmol/L, potassium 6.1 mmol/L, urea 6.8 mmol/L, and creatinine 100 µmol/L. Which diagnosis best explains his clinical and biochemical findings?",
    "options": [
      "Primary adrenal insufficiency (Addison's disease)",
      "Anorexia nervosa",
      "Syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
      "Cushing's syndrome",
      "Chronic kidney disease"
    ],
    "correct_answer": "Primary adrenal insufficiency (Addison's disease)",
    "explanation": "**Explanation**\nThis patient's presentation of **fatigue, weight loss, hypotension, hyponatraemia, and hyperkalaemia** is classic for primary adrenal insufficiency (Addison's disease). The loss of both glucocorticoid (cortisol) and mineralocorticoid (aldosterone) production leads to sodium loss, potassium retention, and low blood pressure. These electrolyte abnormalities are distinguishing features, separating Addison’s from other causes of non-specific symptoms. SIADH may cause hyponatraemia but not hyperkalaemia. Cushing’s syndrome is associated with weight gain and hypertension, not weight loss or hypotension. The absence of renal impairment on creatinine and urea makes chronic kidney disease less likely, while anorexia nervosa usually presents with low potassium and does not explain hypotension or the biochemical pattern seen here.\n\n**Key Points**\n- Addison's disease causes both glucocorticoid and mineralocorticoid deficiency.\n- Typical biochemical features: hyponatraemia and hyperkalaemia.\n- Non-specific symptoms (fatigue, weight loss) are common and often lead to delayed diagnosis.\n- Hypotension is a key clinical clue due to aldosterone deficiency.\n- SIADH causes isolated hyponatraemia; hyperkalaemia is not seen.\n- Cushing’s syndrome typically causes hypertension, central obesity, and hypokalaemia.\n- <table><thead><tr><th>Feature</th><th>Addison's</th><th>SIADH</th></tr></thead><tbody><tr><td>Na+</td><td>Low</td><td>Low</td></tr><tr><td>K+</td><td>High</td><td>Normal</td></tr><tr><td>BP</td><td>Low</td><td>Normal/High</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising Addison’s disease is vital, as untreated primary adrenal insufficiency can be fatal. Clinical vigilance for its non-specific features and characteristic biochemical changes is essential for early diagnosis and prompt referral to endocrinology. National guidelines recommend considering Addison’s in patients with unexplained hyponatraemia and hyperkalaemia (NICE CKS).\n\n**Memory Anchor**\nSalt lost, potassium kept: ‘Addison’s = sodium down, potassium up’.",
    "bullet_explanations": {
      "Primary adrenal insufficiency (Addison's disease)": "Correct – Explains the combination of fatigue, hypotension, hyponatraemia, and hyperkalaemia.",
      "Anorexia nervosa": "Usually presents with hypokalaemia and bradycardia; does not cause hyperkalaemia or the described electrolyte profile.",
      "Syndrome of inappropriate antidiuretic hormone secretion (SIADH)": "Causes hyponatraemia but not hyperkalaemia or hypotension; potassium is typically normal.",
      "Cushing's syndrome": "Associated with hypertension, hyperglycaemia, and weight gain, not hypotension and weight loss.",
      "Chronic kidney disease": "Would typically show raised urea/creatinine and often presents with additional symptoms; potassium and sodium changes would be less isolated."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Adrenal",
    "subsubsection": "Adrenal Insufficiency",
    "topic": "Primary vs secondary clues",
    "keywords": [
      "Addison's disease",
      "primary adrenal insufficiency",
      "hyponatraemia",
      "hyperkalaemia",
      "diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Addison's disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/addisons-disease/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "fa6fa71d-6561-4160-bddf-d286d59b7acd",
    "question_number": 367,
    "question": "A 34-year-old woman presents to her GP with sudden loss of hearing in her right ear that began 12 hours ago while she was watching television. She reports no pain, discharge, tinnitus, dizziness, or recent infection, and there is no history of trauma. Otoscopy reveals no abnormality, and tuning fork tests suggest a unilateral sensorineural hearing loss. What is the most appropriate next step in her management?",
    "options": [
      "Urgent same-day referral to ENT",
      "Routine audiology referral for hearing assessment",
      "Reassure and review in one week",
      "Commence empirical oral antibiotics",
      "Non-urgent outpatient ENT referral"
    ],
    "correct_answer": "Urgent same-day referral to ENT",
    "explanation": "**Explanation**\n**Sudden sensorineural hearing loss** without an obvious external or middle ear cause is considered an ENT emergency. The absence of trauma, infection, or conductive features on otoscopy and tuning fork testing strongly suggests a sensorineural origin. **Immediate referral to ENT** is warranted because prompt assessment and treatment (often with high-dose corticosteroids and further investigation, including imaging) can improve the likelihood of hearing recovery and exclude serious underlying pathology such as tumours. Delayed management may result in permanent hearing loss.\n\n**Key Points**\n- Sudden-onset, unexplained unilateral hearing loss is an emergency.\n- Sensorineural loss is suggested by normal otoscopy and tuning fork findings.\n- Immediate ENT assessment enables early treatment and investigation.\n- Delaying referral risks permanent hearing loss.\n- Routine audiology or non-urgent referral is insufficient in acute cases.\n\n**Clinical Relevance**\nRecognising and urgently referring suspected sudden sensorineural hearing loss is crucial in primary care to maximise chances of recovery and detect potential life-threatening causes. NICE guidance states that unexplained sudden-onset hearing loss within 30 days requires immediate ENT assessment.\n\n**Memory Anchor**\nRemember: **'Sudden sensorineural = Same-day ENT'**.",
    "bullet_explanations": {
      "Urgent same-day referral to ENT": "Correct—sudden unexplained sensorineural hearing loss is an ENT emergency requiring immediate action.",
      "Routine audiology referral for hearing assessment": "Incorrect—routine referral is appropriate for gradual or age-related hearing loss, not acute cases.",
      "Reassure and review in one week": "Incorrect—delaying assessment risks irreversible hearing loss.",
      "Commence empirical oral antibiotics": "Incorrect—no signs of infection or conductive loss are present to justify antibiotics.",
      "Non-urgent outpatient ENT referral": "Incorrect—non-urgent referral is not suitable for acute sudden sensorineural hearing loss."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Sudden hearing loss",
    "keywords": [
      "sudden hearing loss",
      "sensorineural",
      "ENT emergency",
      "referral"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hearing loss in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hearing-loss-in-adults/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1faafc75-e3a9-4157-888e-4fab68eefcfe",
    "question_number": 368,
    "question": "A 70-year-old man with stage 4 chronic kidney disease and a history of vertebral compression fracture is found to have a DEXA T-score of -3.8. He was unable to tolerate either oral alendronate or risedronate due to severe gastrointestinal side effects. What is the most appropriate next step in osteoporosis management for this patient?",
    "options": [
      "Start denosumab and monitor serum calcium",
      "Repeat DEXA scan in 6 months",
      "Manage with calcium and vitamin D supplements alone",
      "Restart oral bisphosphonate with proton pump inhibitor cover",
      "Refer for hormone replacement therapy"
    ],
    "correct_answer": "Start denosumab and monitor serum calcium",
    "explanation": "**Explanation**\n**Denosumab is the recommended bone-sparing agent for patients with severe osteoporosis who cannot tolerate or are unsuitable for oral bisphosphonates, particularly when there is significant renal impairment (eGFR < 35 mL/min/1.73 m²)**. Both alendronate and risedronate are contraindicated in advanced chronic kidney disease due to increased risk of adverse effects and reduced efficacy. Denosumab, a monoclonal antibody administered subcutaneously every six months, is not renally excreted, making it safer in CKD. However, it can cause hypocalcaemia, especially in those with reduced renal function, so regular monitoring of calcium is essential. Merely providing calcium and vitamin D is insufficient for secondary prevention in very high-risk individuals with established fragility fractures.\n\n**Key Points**\n- Bisphosphonates are contraindicated in advanced CKD (eGFR < 35 mL/min/1.73 m²)\n- Denosumab is suitable for osteoporosis in patients intolerant or unsuitable for oral bisphosphonates\n- Regular monitoring of serum calcium is required with denosumab, especially in renal impairment\n- Calcium and vitamin D should be supplemented, but are not sufficient alone for secondary prevention\n- HRT is not indicated in older men or advanced age, and is reserved for specific postmenopausal women\n\n**Clinical Relevance**\nDenosumab provides an effective and guideline-recommended alternative to bisphosphonates in patients with severe osteoporosis and significant renal impairment, who are at especially high risk of further fragility fractures. Clinicians must actively monitor calcium levels and ensure ongoing supplementation to minimise the risk of hypocalcaemia. This approach aligns with current recommendations from both the BNF and NICE CKS.\n\n**Memory Anchor**\nRemember: **'Denosumab is Doable with Damaged kidneys'**, but always check calcium!",
    "bullet_explanations": {
      "Start denosumab and monitor serum calcium": "Correct – Denosumab is indicated where bisphosphonates are unsuitable or contraindicated, especially in advanced CKD.",
      "Repeat DEXA scan in 6 months": "Incorrect – Repeating DEXA so soon after diagnosis or fracture does not alter immediate management.",
      "Manage with calcium and vitamin D supplements alone": "Incorrect – Supplementation alone is inadequate for secondary prevention in high-risk patients with established osteoporosis.",
      "Restart oral bisphosphonate with proton pump inhibitor cover": "Incorrect – Oral bisphosphonates remain contraindicated in stage 4 CKD regardless of GI protection.",
      "Refer for hormone replacement therapy": "Incorrect – HRT is neither appropriate for older men nor for older women without menopausal symptoms; not a first-line agent in severe osteoporosis."
    },
    "category": "Bone & Metabolic",
    "subsection": "Osteoporosis",
    "subsubsection": "Bisphosphonate indications",
    "topic": "Bisphosphonate indications",
    "keywords": [
      "osteoporosis",
      "denosumab",
      "bisphosphonate contraindications",
      "CKD",
      "secondary prevention"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Osteoporosis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/osteoporosis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Osteoporosis - prevention of fragility fractures",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/osteoporosis-prevention-of-fragility-fractures/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "09d1b73a-fc6f-4e5c-ac66-c4cd83eca8ad",
    "question_number": 369,
    "question": "A 7-year-old boy presents to the GP with his father, who has noticed the sudden appearance of purple-red spots on his son's arms and legs over the past 24 hours. The child has been otherwise well except for a mild cold last week. On examination, the boy is alert, afebrile, and haemodynamically stable. Numerous petechiae and several areas of purpura are visible on his limbs, but there are no signs of trauma or infection. What is the most appropriate next step in management?",
    "options": [
      "Urgently refer to hospital for same-day paediatric assessment",
      "Advise monitoring at home with safety netting advice",
      "Order routine blood tests to be done in the community within 1 week",
      "Prescribe topical antihistamines for symptom relief",
      "Consider non-accidental injury and make a safeguarding referral only"
    ],
    "correct_answer": "Urgently refer to hospital for same-day paediatric assessment",
    "explanation": "**Explanation**\n**New-onset purpura and petechiae in a child are red flag features that may indicate a serious underlying disorder, such as leukaemia, thrombocytopenia, or meningococcal disease.** Purpura are never normal findings in children and always warrant urgent evaluation. Although petechiae can occasionally occur with viral infections, the combination with purpura, in the absence of fever or trauma, requires prompt hospital assessment to exclude life-threatening causes. Delayed investigation risks missing early presentation of serious haematological or infectious disease.\n\n**Key Points**\n- Purpura in children is always pathological and requires urgent assessment.\n- Common causes include acute leukaemia, idiopathic thrombocytopenic purpura (ITP), and sepsis.\n- Meningococcal septicaemia may present with petechiae or purpura; urgent referral is required if suspected.\n- Routine or delayed investigations are inappropriate in the presence of purpura.\n- Hospital evaluation includes urgent blood counts and specialist review.\n\n**Clinical Relevance**\nImmediate identification of purpura in children is vital, as it can signify potentially life-threatening conditions. UK guidance advises urgent referral for any child with new-onset purpura to enable early diagnosis and intervention, improving outcomes and reducing the risk of missed serious illness.\n\n**Memory Anchor**\nPurpura = \"Purple = Peril\" in paediatrics: Always act fast.",
    "bullet_explanations": {
      "Urgently refer to hospital for same-day paediatric assessment": "Correct – urgent referral is indicated to exclude serious conditions such as leukaemia or sepsis.",
      "Advise monitoring at home with safety netting advice": "Incorrect – home monitoring is unsafe when purpura are present.",
      "Order routine blood tests to be done in the community within 1 week": "Incorrect – delays can be dangerous; urgent assessment is needed.",
      "Prescribe topical antihistamines for symptom relief": "Incorrect – antihistamines have no role in purpura management.",
      "Consider non-accidental injury and make a safeguarding referral only": "Incorrect – while safeguarding is important, medical assessment for underlying disease must not be delayed."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Safeguarding",
    "topic": "Non-accidental injury signs",
    "keywords": [
      "purpura",
      "paediatric emergency",
      "urgent referral",
      "non-blanching rash",
      "thrombocytopenia"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Purpura and petechiae – recognition and management",
        "citation": "© NICE, 2025",
        "url": ""
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "4ed36240-4a00-4f8a-8967-21b3b9aba806",
    "question_number": 370,
    "question": "A 35-year-old woman returns from a two-week adventure holiday in Nepal. One week after her return, she develops persistent, foul-smelling, watery diarrhoea, abdominal discomfort, and bloating. She has no fever or blood in her stools. What is the most likely causative agent?",
    "options": [
      "Giardia lamblia",
      "Campylobacter jejuni",
      "Norovirus",
      "Salmonella enterica",
      "Entamoeba histolytica"
    ],
    "correct_answer": "Giardia lamblia",
    "explanation": "**Explanation**\n**Giardia lamblia** is a protozoan parasite commonly acquired through contaminated water, especially in developing countries or areas with poor sanitation. It frequently causes persistent, non-bloody, watery diarrhoea with associated bloating, abdominal discomfort, and malodorous stools. Unlike typical bacterial pathogens, Giardia often leads to symptoms lasting more than a week and rarely causes fever or overt signs of systemic illness. In contrast, most bacterial causes of travellers’ diarrhoea have a shorter duration and may present with fever or blood in the stool.\n\n**Key Points**\n- Giardia lamblia causes prolonged, watery, non-bloody diarrhoea after travel.\n- Symptoms include bloating, abdominal pain, and steatorrhoea.\n- Transmission is via the faeco-oral route, often through contaminated water.\n- Bacterial causes of travellers’ diarrhoea (e.g. E. coli, Campylobacter) typically resolve more quickly.\n- Fever and blood in stool are uncommon in giardiasis.\n- <table><thead><tr><th>Organism</th><th>Typical Features</th></tr></thead><tbody><tr><td>Giardia lamblia</td><td>Prolonged watery diarrhoea, bloating, no fever</td></tr><tr><td>Bacterial (e.g. E. coli)</td><td>Abrupt onset, often short-lived, may have fever</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the features of giardiasis is important in returning travellers with persistent diarrhoea, as specific anti-parasitic treatment may be required. Clinical guidelines (NICE CKS) emphasise the need to differentiate between bacterial and protozoal causes to guide management, especially when symptoms are prolonged or atypical.\n\n**Memory Anchor**\n‘G’ for Giardia, ‘G’ for Going-on (chronic) Gastrointestinal symptoms",
    "bullet_explanations": {
      "Giardia lamblia": "Correct—classic for prolonged, non-bloody, watery diarrhoea and bloating post-travel.",
      "Campylobacter jejuni": "Incorrect—typically causes acute, often bloody diarrhoea, and fever; usually resolves within days.",
      "Norovirus": "Incorrect—causes short-lived, self-limiting gastroenteritis and is less associated with travel to high-risk areas.",
      "Salmonella enterica": "Incorrect—more likely to cause acute diarrhoea with fever; duration is usually shorter.",
      "Entamoeba histolytica": "Incorrect—can cause dysentery (bloody diarrhoea) and is less likely to present with only watery diarrhoea."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "GI Infections",
    "topic": "Traveller’s diarrhoea basics",
    "keywords": [
      "traveller's diarrhoea",
      "giardiasis",
      "persistent diarrhoea",
      "protozoan infection"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diarrhoea - prevention and advice for travellers",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/diarrhoea-prevention-advice-for-travellers/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2dfeec9d-2383-4d09-ac73-80a3d757bae3",
    "question_number": 371,
    "question": "In a 34-year-old woman who rolled her right ankle while stepping off a curb, which clinical finding most strongly warrants immediate ankle radiographs according to the Ottawa Ankle Rules?",
    "options": [
      "Bony tenderness at the posterior edge of the medial malleolus",
      "Isolated swelling over the dorsum of the foot",
      "Ability to walk more than four steps unaided",
      "Pain on passive inversion of the ankle",
      "Presence of localised bruising over the lateral malleolus"
    ],
    "correct_answer": "Bony tenderness at the posterior edge of the medial malleolus",
    "explanation": "**Explanation**\n**Bony tenderness at the posterior edge or tip of the malleoli is a key Ottawa Ankle Rule criterion for imaging.** This finding, either medially or laterally, indicates possible fracture and justifies urgent ankle X-ray. Other findings—such as ability to weight bear, bruising, or swelling—are not independently sufficient for imaging under these guidelines. Pain on movement suggests ligamentous injury rather than fracture. The Ottawa Ankle Rules are validated to reduce unnecessary radiographs while maintaining high sensitivity for clinically significant fractures.\n\n**Key Points**\n- Ottawa Ankle Rules: X-ray if bony tenderness at posterior edge/tip of lateral or medial malleolus, or inability to bear weight for four steps.\n- Soft tissue signs (bruising, swelling) are not criteria for imaging.\n- Pain on movement is not part of the Ottawa Ankle Rules.\n- Ability to walk four steps or more reduces likelihood of fracture per guidelines.\n- Bony tenderness is a red flag for underlying fracture.\n\n**Clinical Relevance**\nAccurate application of the Ottawa Ankle Rules helps clinicians identify patients at risk of ankle fracture and minimises unnecessary radiation exposure. Recognising bony tenderness at the malleolar zones is crucial for safe and efficient emergency and primary care practice.",
    "bullet_explanations": {
      "Bony tenderness at the posterior edge of the medial malleolus": "Correct – this is a primary Ottawa Ankle Rule criterion justifying X-ray to assess for fracture.",
      "Isolated swelling over the dorsum of the foot": "Incorrect – swelling alone is not an Ottawa criterion for imaging.",
      "Ability to walk more than four steps unaided": "Incorrect – being able to walk four steps or more suggests fracture is unlikely, so X-ray is not routinely indicated.",
      "Pain on passive inversion of the ankle": "Incorrect – pain on movement suggests ligament or soft tissue injury, not necessarily fracture; not an Ottawa criterion.",
      "Presence of localised bruising over the lateral malleolus": "Incorrect – bruising is non-specific and not included in the Ottawa Ankle Rules for imaging decisions."
    },
    "category": "Musculoskeletal",
    "subsection": "Soft Tissue Injuries",
    "subsubsection": "Sprain vs strain",
    "topic": "Ottawa Ankle Rules application",
    "keywords": [
      "Ottawa Ankle Rules",
      "ankle fracture",
      "bony tenderness",
      "ankle X-ray",
      "musculoskeletal injury"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Sprains and strains",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/sprains-strains/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "3641d7f2-6f41-4950-9e10-15252b4e0b71",
    "question_number": 372,
    "question": "A 45-year-old man with a history of obesity and recent air travel presents with a painful, red, cord-like swelling extending along the medial aspect of his right calf, measuring about 8 cm. He is otherwise well, with no fever or shortness of breath. Examination confirms a palpable, tender, erythematous cord, but there is no evidence of calf swelling or oedema. What is the most appropriate initial investigation to exclude a concurrent deep vein thrombosis?",
    "options": [
      "Duplex ultrasound scan of both legs",
      "Blood cultures",
      "D-dimer assay",
      "Thrombophilia screening",
      "CT venography"
    ],
    "correct_answer": "Duplex ultrasound scan of both legs",
    "explanation": "**Explanation**\n**Duplex ultrasound of both legs** is the key investigation for suspected superficial vein thrombosis (SVT) involving the long or short saphenous veins, especially when the affected segment is extensive or risk factors for venous thromboembolism (VTE) are present. Clinical features such as a palpable, tender, erythematous cord suggest SVT, but up to 20% of cases may have a concurrent DVT, particularly when the thrombus is extensive or near the saphenofemoral junction. Duplex ultrasound is non-invasive, confirms the diagnosis, assesses the extent of thrombosis, and crucially rules out DVT, which requires different management. **Other investigations are either inappropriate as first-line tests or do not provide the necessary anatomical detail.**\n\n**Key Points**\n- SVT presents as a tender, palpable, erythematous cord along a superficial vein.\n- Concurrent DVT is present in up to 20% of SVT cases, particularly with risk factors or long segments.\n- Duplex ultrasound is the gold standard to confirm SVT and exclude DVT.\n- D-dimer is non-specific and may be elevated in SVT alone.\n- Blood cultures are not indicated unless there are signs of infection.\n- Thrombophilia screening is reserved for recurrent, unprovoked, or unexplained thrombotic events.\n- CT venography is reserved for complicated or atypical cases.\n\n**Clinical Relevance**\nIdentifying DVT in patients with SVT is crucial, as management differs and the risk of complications such as pulmonary embolism increases with missed DVT. National guidelines (NICE, SIGN) recommend duplex ultrasound for patients with extensive or proximal SVT, or in the presence of VTE risk factors.\n\n**Memory Anchor**\nRemember: 'Superficial = Scan for Safety' when risk factors or long segments are present.",
    "bullet_explanations": {
      "Duplex ultrasound scan of both legs": "Correct – Confirms diagnosis, assesses extent, and excludes DVT per guidelines.",
      "Blood cultures": "Incorrect – Only indicated if there are signs of systemic infection, which are absent here.",
      "D-dimer assay": "Incorrect – Non-specific; may be elevated in SVT and does not reliably exclude DVT in this context.",
      "Thrombophilia screening": "Incorrect – Not recommended as an initial investigation; consider in recurrent or unexplained cases.",
      "CT venography": "Incorrect – More invasive and not first-line for SVT/DVT assessment."
    },
    "category": "Cardiovascular",
    "subsection": "Hypertension & Vascular",
    "subsubsection": "Peripheral Arterial Disease",
    "topic": "Intermittent claudication assessment",
    "keywords": [
      "superficial thrombophlebitis",
      "duplex ultrasound",
      "deep vein thrombosis",
      "SVT",
      "DVT exclusion"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Superficial vein thrombosis (superficial thrombophlebitis)",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Deep vein thrombosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/deep-vein-thrombosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2d1302e9-c605-4f21-95fb-112962e1e06b",
    "question_number": 373,
    "question": "A 6-year-old girl presents to the urgent care centre after tripping on a playground and landing on her outstretched left wrist. She is unable to fully move her wrist due to pain, but neurovascular assessment is normal and there is no open wound. X-ray reveals a subtle bulge of the distal radius cortex without clear fracture lines. What is the most likely diagnosis?",
    "options": [
      "Buckle (torus) fracture",
      "Greenstick fracture",
      "Salter-Harris type I fracture",
      "Complete transverse fracture",
      "Pathological fracture"
    ],
    "correct_answer": "Buckle (torus) fracture",
    "explanation": "**Explanation**\nA **buckle (torus) fracture** is a common injury in paediatric patients, particularly involving the radius or ulna after a fall onto an outstretched hand. It occurs due to the compressive force causing the cortex of the bone to bulge outward, rather than break completely. This is seen as a subtle outward bulge on the X-ray, with the rest of the cortex intact and no clear fracture line traversing the bone. This injury is typically stable and does not involve angulation or displacement. In contrast, a greenstick fracture is an incomplete fracture with bending and partial cortical disruption, and a Salter-Harris type I fracture involves the growth plate, neither of which fits the radiographic findings described here.\n\n**Key Points**\n- Buckle fractures are due to compression, causing cortical bulging.\n- Most commonly seen in the distal radius of children aged 5–10.\n- Radiographs show an outward bulge without a full fracture line.\n- Stable injuries with low risk of displacement.\n- Different from greenstick (incomplete, bending) and Salter-Harris (growth plate) fractures.\n\n**Clinical Relevance**\nRecognising buckle fractures is important as they are frequent in young children and require conservative management, typically with a splint or cast. Identifying the unique radiographic appearance prevents overtreatment and unnecessary intervention.\n\n**Memory Anchor**\n‘Buckle’ = ‘bulge’ in the cortex without full break.",
    "bullet_explanations": {
      "Buckle (torus) fracture": "Correct – describes a stable, bulging injury to the cortex common in children.",
      "Greenstick fracture": "Incorrect – greenstick fractures show bending and partial cortical break, not simply bulging.",
      "Salter-Harris type I fracture": "Incorrect – Salter-Harris I involves the growth plate only; no bulging cortex.",
      "Complete transverse fracture": "Incorrect – this would show a clear fracture line across the bone, not just a bulge.",
      "Pathological fracture": "Incorrect – pathological fractures occur in abnormal bone and usually have underlying disease or systemic signs."
    },
    "category": "Paediatric Emergencies",
    "subsection": "Trauma & Burns",
    "subsubsection": "Fractures",
    "topic": "Fractures",
    "keywords": [
      "buckle fracture",
      "paediatric fractures",
      "wrist injury",
      "torus fracture",
      "child orthopaedics"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "f354b76b-6a7b-437b-87ad-4df41039742a",
    "question_number": 374,
    "question": "What is the estimated prevalence of vitiligo in the general population?",
    "options": [
      "Approximately 1%",
      "Around 0.01%",
      "About 10%",
      "Rarely seen in people under 60 years old",
      "Almost exclusively affects those of Asian descent"
    ],
    "correct_answer": "Approximately 1%",
    "explanation": "**Explanation**\n**Vitiligo** is a chronic condition characterised by loss of functional melanocytes, leading to well-defined white patches on the skin. Epidemiological data indicate that vitiligo affects about **1% of the population worldwide**. It can occur in any ethnic group and at any age, though segmental vitiligo tends to present earlier in life. The condition is not rare, nor is it limited to specific demographic groups. Misconceptions about prevalence or age of onset should be corrected in clinical practice to ensure prompt recognition and appropriate support.\n\n**Key Points**\n- Vitiligo affects around 1% of the population.\n- It presents as depigmented, well-demarcated patches, often on the hands, face, and areas around body orifices.\n- Both segmental and non-segmental types exist, with non-segmental being more common.\n- The condition is seen across all ethnicities and age groups.\n- Risk factors include family history and association with other autoimmune diseases.\n\n**Clinical Relevance**\nRecognising the true prevalence of vitiligo is important for clinicians to avoid underdiagnosis. Early identification and support can improve patient outcomes, especially given the psychosocial impact. NICE guidelines highlight the need for accurate assessment and appropriate referral when necessary.",
    "bullet_explanations": {
      "Approximately 1%": "Correct – Vitiligo affects around 1% of the global population.",
      "Around 0.01%": "Incorrect – This underestimates the true prevalence of vitiligo.",
      "About 10%": "Incorrect – This figure greatly overestimates how common vitiligo is.",
      "Rarely seen in people under 60 years old": "Incorrect – Vitiligo can occur at any age, often presenting earlier in life.",
      "Almost exclusively affects those of Asian descent": "Incorrect – Vitiligo affects all ethnicities equally."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Vitiligo",
    "keywords": [
      "vitiligo",
      "prevalence",
      "depigmentation",
      "autoimmune skin",
      "MSRA dermatology"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Vitiligo",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/vitiligo/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f629bdcf-184c-4306-8f48-1a5b82ad94d8",
    "question_number": 375,
    "question": "A 52-year-old man presents to the surgery with a two-day history of burning on urination, frequency, and urgency. He has no fever, loin pain, or systemic symptoms. Clinical examination is unremarkable except for mild suprapubic tenderness. Urine dipstick is positive for nitrites and leukocytes. Which is the most appropriate first-line antibiotic management?",
    "options": [
      "Trimethoprim or nitrofurantoin for 7 days",
      "Ciprofloxacin for 3 days",
      "Co-amoxiclav for 7 days",
      "Nitrofurantoin or trimethoprim for 3 days",
      "Cefalexin for 5 days"
    ],
    "correct_answer": "Trimethoprim or nitrofurantoin for 7 days",
    "explanation": "**Explanation**\n**Men presenting with uncomplicated lower urinary tract infection (UTI) should receive a 7-day course of either trimethoprim or nitrofurantoin as first-line therapy.** This approach is supported by national guidelines, which emphasise the increased risk of relapse and complications such as prostatic involvement with shorter courses in men. While both antibiotics are effective against common uropathogens and concentrate well in the urine, the longer duration is important due to the male genitourinary anatomy and risk profile. Alternative regimens or shorter courses are not recommended for uncomplicated lower UTI in men.\n\n**Key Points**\n- Lower UTI in men requires a 7-day course of antibiotics, unlike the 3-day regimen used in women.\n- First-line choices are nitrofurantoin (if eGFR ≥45 ml/min) or trimethoprim (if low resistance risk).\n- Shorter courses are associated with higher recurrence rates in men.\n- In men, UTI is less common, often indicating underlying risk factors.\n- Empiric treatment should be started after sending a urine sample for culture.\n- Fluoroquinolones like ciprofloxacin are reserved for resistant or complicated cases due to potential side effects and resistance.\n\n**Clinical Relevance**\nRecognising the need for a longer antibiotic course in men with lower UTI is crucial to reduce recurrence and complications. National guidance (NICE, BNF) highlights this distinction, and inappropriate use of shorter courses or broad-spectrum antibiotics can increase relapse and antimicrobial resistance.\n\n**Memory Anchor**\nRemember: '7 days for men', '3 days for women'—longer course for the longer urethra.",
    "bullet_explanations": {
      "Trimethoprim or nitrofurantoin for 7 days": "Correct; guideline-recommended first-line therapy and duration for uncomplicated lower UTI in men.",
      "Ciprofloxacin for 3 days": "Incorrect; ciprofloxacin is not first-line due to resistance and side-effect profile, and the course is too short for men.",
      "Co-amoxiclav for 7 days": "Incorrect; not a first-line agent for uncomplicated lower UTI; reserved for resistant organisms or when sensitivities indicate.",
      "Nitrofurantoin or trimethoprim for 3 days": "Incorrect; 3-day treatment is insufficient in men and increases the risk of relapse.",
      "Cefalexin for 5 days": "Incorrect; cefalexin is not first-line for uncomplicated lower UTI and the duration does not match guideline recommendations for men."
    },
    "category": "Renal & Urology",
    "subsection": "Urology",
    "subsubsection": "Infections",
    "topic": "Cystitis",
    "keywords": [
      "male UTI",
      "antibiotic duration",
      "trimethoprim",
      "nitrofurantoin",
      "guideline"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Urinary tract infection (lower) - men",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/urinary-tract-infection-lower-men/"
      },
      {
        "source": "BNF",
        "topic_title": "Urinary-tract infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/urinary-tract-infections/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ea94dc5d-23d3-4c6c-94fd-b7752ce12c81",
    "question_number": 376,
    "question": "Which of the following medications is most strongly associated with the development of torsades de pointes due to QT interval prolongation?",
    "options": [
      "Macrolide antibiotics",
      "Tramadol",
      "Montelukast",
      "Clonazepam",
      "Sodium valproate"
    ],
    "correct_answer": "Macrolide antibiotics",
    "explanation": "**Explanation**\n**Macrolide antibiotics**, such as erythromycin and clarithromycin, are well-known to prolong the QT interval and can precipitate torsades de pointes, a polymorphic ventricular tachycardia associated with prolonged QT. This arrhythmia can cause syncope and sudden cardiac death if not recognised and treated promptly. The risk increases with underlying cardiac disease, electrolyte disturbances, or co-administration with other QT-prolonging agents. In contrast, most other drugs listed do not affect cardiac repolarisation to this extent.\n\n**Key Points**\n- Macrolides (e.g. erythromycin, clarithromycin, azithromycin) can prolong the QT interval.\n- Torsades de pointes is a potentially life-threatening arrhythmia linked to QT prolongation.\n- Symptoms include palpitations, syncope, and possibly sudden cardiac death.\n- Magnesium sulphate is the acute treatment of choice.\n- Other risk factors: hypokalaemia, bradycardia, genetic predisposition, drug interactions.\n- <table><thead><tr><th>Drug</th><th>QT Prolongation Risk</th></tr></thead><tbody><tr><td>Macrolides</td><td>High</td></tr><tr><td>Tramadol</td><td>Low/None</td></tr><tr><td>Montelukast</td><td>None</td></tr><tr><td>Clonazepam</td><td>None</td></tr><tr><td>Sodium valproate</td><td>None</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising medications that prolong the QT interval is essential to prevent arrhythmias such as torsades de pointes, particularly in patients with polypharmacy or overdose. National guidelines highlight the importance of avoiding macrolides in at-risk populations and monitoring ECGs as clinically indicated.\n\n**Memory Anchor**\n‘Macrolides = Mac-QT-lides’ for QT prolongation.",
    "bullet_explanations": {
      "Macrolide antibiotics": "Correct – these drugs can significantly lengthen the QT interval and trigger torsades de pointes.",
      "Tramadol": "Incorrect – while dangerous in overdose, tramadol does not typically cause QT prolongation or torsades de pointes.",
      "Montelukast": "Incorrect – this asthma medication is not associated with QT changes or ventricular arrhythmias.",
      "Clonazepam": "Incorrect – as a benzodiazepine, clonazepam leads to CNS depression but not QT prolongation.",
      "Sodium valproate": "Incorrect – though it has many side effects, QT prolongation and torsades are not among them."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "Antibiotics",
    "subsubsection": "Other Classes",
    "topic": "Macrolides",
    "keywords": [
      "macrolides",
      "QT prolongation",
      "torsades de pointes",
      "arrhythmia",
      "antibiotics"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Arrhythmias",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/arrhythmias/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9dc69d44-423a-4c6e-9556-f3377483041d",
    "question_number": 377,
    "question": "A 32-year-old man of Mediterranean descent is found to have a haemoglobin of 11.0 g/dL, mean corpuscular volume (MCV) of 66 fL, and an elevated HbA2 of 4.8%. He reports no significant bleeding history and feels generally well. Which is the most likely underlying diagnosis?",
    "options": [
      "Beta-thalassaemia trait",
      "Alpha-thalassaemia major",
      "Iron deficiency anaemia",
      "Hereditary spherocytosis",
      "Acute lymphoblastic leukaemia"
    ],
    "correct_answer": "Beta-thalassaemia trait",
    "explanation": "**Explanation**\n**Beta-thalassaemia trait** is characterised by a mild microcytic anaemia (low MCV) with a relatively preserved haemoglobin level and a raised HbA2 fraction. Unlike iron deficiency anaemia, which is also microcytic but typically presents with low ferritin and no elevation in HbA2, beta-thalassaemia trait features a disproportionate microcytosis compared to the degree of anaemia. There are usually no significant symptoms, and it is most prevalent in individuals of Mediterranean, Middle Eastern, or South Asian ancestry. Distinguishing features from hereditary spherocytosis (which causes spherocytes and increased MCHC) and acute lymphoblastic leukaemia (typically normocytic or macrocytic anaemia with cytopenias and systemic symptoms) are important.\n\n**Key Points**\n- Beta-thalassaemia trait presents with **mild anaemia, marked microcytosis, and elevated HbA2**.\n- Iron deficiency anaemia is also microcytic but does **not** raise HbA2.\n- Patients are often asymptomatic and identified incidentally.\n- Most common in people of Mediterranean, Middle Eastern, or South Asian heritage.\n- No evidence of haemolysis or spherocytes (as seen in hereditary spherocytosis).\n- ALL often presents with pancytopenia and systemic symptoms, not isolated anaemia.\n\n**Clinical Relevance**\nRecognising beta-thalassaemia trait is vital as it affects genetic counselling, avoids unnecessary iron therapy, and distinguishes it from iron deficiency anaemia. Haemoglobin electrophoresis or HPLC is required for confirmation. Awareness is especially important in populations with higher prevalence.\n\n**Memory Anchor**\nTrait = **T**iny cells (**T**halassaemia, **T**rait, **T**iny MCV, **T**ypically raised HbA2)",
    "bullet_explanations": {
      "Beta-thalassaemia trait": "Correct – classic findings are microcytosis with elevated HbA2 and mild anaemia.",
      "Alpha-thalassaemia major": "Incorrect – usually presents in infancy with severe anaemia and is not compatible with life; does not increase HbA2.",
      "Iron deficiency anaemia": "Incorrect – also microcytic, but HbA2 is normal or low; ferritin would be reduced.",
      "Hereditary spherocytosis": "Incorrect – causes normocytic or slightly microcytic anaemia with spherocytes and increased MCHC.",
      "Acute lymphoblastic leukaemia": "Incorrect – typically presents with pancytopenia, not isolated microcytic anaemia, and often with systemic symptoms."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Anaemias",
    "topic": "Microcytic (iron, thalassaemia, anaemia of chronic disease)",
    "keywords": [
      "thalassaemia",
      "microcytic anaemia",
      "HbA2",
      "haemoglobinopathy",
      "differential diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Anaemia - iron deficiency",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/anaemia-iron-deficiency/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "007e1c6f-ab25-4d59-93eb-f12140d561e8",
    "question_number": 378,
    "question": "Which of the following situations is an absolute contraindication to prescribing the combined oral contraceptive pill (COCP)?",
    "options": [
      "A 38-year-old woman who smokes 18 cigarettes per day",
      "A 24-year-old woman with well-controlled essential hypertension",
      "A 30-year-old woman with a BMI of 39 kg/m² and no other comorbidities",
      "A 27-year-old woman with a past history of intrahepatic cholestasis of pregnancy",
      "A 22-year-old woman with migraine without aura"
    ],
    "correct_answer": "A 38-year-old woman who smokes 18 cigarettes per day",
    "explanation": "**Explanation**\nWomen aged over 35 who smoke more than 15 cigarettes daily have a **significantly increased risk of cardiovascular events** (such as myocardial infarction and stroke) if prescribed combined oral contraceptives. This group is classified as UKMEC Category 4 (absolute contraindication), meaning the risks outweigh any benefits. The heightened risk arises from the additive vascular effects of both age and smoking, which synergistically increase the likelihood of serious adverse events when using oestrogen-containing contraceptives.<br><br>Other factors such as controlled hypertension, migraine without aura, high BMI, and previous pregnancy-related cholestasis are either relative contraindications or require caution, but they are not absolute contraindications according to UK and international guidelines.\n\n**Key Points**\n<ul><li><b>COCPs are absolutely contraindicated in women over 35 who smoke &gt;15 cigarettes/day (UKMEC 4)</b></li><li>Controlled hypertension is a relative, not absolute, contraindication</li><li>BMI ≥35 increases VTE risk but is not an absolute contraindication alone</li><li>Migraine with aura is an absolute contraindication; without aura is not</li><li>History of pregnancy-related cholestasis warrants caution but is not absolute</li><li>Always assess for additive risk factors when prescribing COCPs</li></ul><br><table><thead><tr><th>Risk Factor</th><th>COCP Category</th></tr></thead><tbody><tr><td>Age &gt;35 + heavy smoking</td><td>Absolute (UKMEC 4)</td></tr><tr><td>Controlled hypertension</td><td>Relative (UKMEC 3)</td></tr><tr><td>High BMI alone</td><td>Relative (UKMEC 3)</td></tr><tr><td>Migraine with aura</td><td>Absolute (UKMEC 4)</td></tr><tr><td>Migraine without aura</td><td>Relative (UKMEC 2)</td></tr></tbody></table>\n\n**Clinical Relevance**\nIdentifying absolute contraindications is essential to prevent serious adverse events with combined hormonal contraception. Smoking in women over 35 is a clear and common risk scenario, and prescribers must screen for this to ensure safe contraceptive provision, as emphasised by national guidelines.\n\n**Memory Anchor**\nRemember: '35 and 15'—Over 35 years old AND more than 15 cigarettes/day = NO COCP.",
    "bullet_explanations": {
      "A 38-year-old woman who smokes 18 cigarettes per day": "Correct – This is an absolute contraindication due to high cardiovascular risk.",
      "A 24-year-old woman with well-controlled essential hypertension": "Incorrect – Well-controlled hypertension is a relative, not absolute, contraindication.",
      "A 30-year-old woman with a BMI of 39 kg/m² and no other comorbidities": "Incorrect – Obesity increases VTE risk but does not alone prohibit COCP use absolutely.",
      "A 27-year-old woman with a past history of intrahepatic cholestasis of pregnancy": "Incorrect – Previous pregnancy-related cholestasis requires caution but is not an absolute contraindication.",
      "A 22-year-old woman with migraine without aura": "Incorrect – Migraine without aura is not an absolute contraindication; only migraine with aura is."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Combined pill",
    "keywords": [
      "COCP",
      "contraindications",
      "smoking",
      "UKMEC",
      "contraception safety"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Contraceptives, hormonal",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/contraceptives-hormonal/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "2a4305b3-a49e-4519-a14f-9ae9265d8dcd",
    "question_number": 379,
    "question": "Which of the following laboratory markers typically decreases, rather than increases, during an acute inflammatory response such as a severe infection?",
    "options": [
      "C-reactive protein",
      "Platelet count",
      "Albumin",
      "Erythrocyte sedimentation rate",
      "Ferritin"
    ],
    "correct_answer": "Albumin",
    "explanation": "**Explanation**\n**Albumin** is a plasma protein synthesised by the liver. During acute inflammation or infection, albumin behaves as a 'negative acute phase reactant.' Its levels tend to fall because hepatic synthesis shifts towards producing positive acute phase proteins (such as CRP and fibrinogen), and capillary leakage increases loss from the intravascular space. This is in contrast to markers like CRP, ESR, platelets, and ferritin, all of which are typically elevated in acute inflammatory states.\n\n**Key Points**\n- Albumin is a negative acute phase reactant—levels drop in acute inflammation.\n- CRP, ESR, platelets, and ferritin are positive acute phase reactants—levels rise in infection/inflammation.\n- Reduced albumin can also reflect poor nutrition or chronic illness.\n- Liver prioritises synthesis of acute phase proteins over albumin during inflammation.\n- High ESR and CRP are non-specific but sensitive markers of inflammation.\n\n**Clinical Relevance**\nRecognising which blood markers rise and which fall during acute infection is important for interpreting results accurately and avoiding misdiagnosis. Low albumin has prognostic implications in acute illness and is not a marker of acute infection itself.\n\n**Memory Anchor**\nRemember: Albumin is 'Absent' in Acute infection (A for Albumin, A for Absent).",
    "bullet_explanations": {
      "C-reactive protein": "Incorrect – CRP is a classic positive acute phase reactant and rises rapidly during infection.",
      "Platelet count": "Incorrect – Platelet count often increases in response to inflammation (reactive thrombocytosis).",
      "Albumin": "Correct – Albumin is a negative acute phase reactant and typically decreases in acute infection.",
      "Erythrocyte sedimentation rate": "Incorrect – ESR increases in most inflammatory and infectious processes.",
      "Ferritin": "Incorrect – Ferritin is elevated as part of the acute phase response, both as an inflammatory marker and to sequester iron from pathogens."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Sepsis & Bacteraemia",
    "topic": "Recognition and NEWS2 scoring",
    "keywords": [
      "acute phase reactants",
      "albumin",
      "infection markers",
      "CRP",
      "sepsis blood tests"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "9e2824c9-5bde-4814-a433-9ccb6128fc27",
    "question_number": 380,
    "question": "A 45-year-old recreational runner notices sudden, severe pain at the back of his ankle while sprinting, followed by difficulty walking and an inability to push off his foot. Examination reveals swelling and a positive Thompson test. Which imaging investigation should be performed first to confirm the suspected diagnosis?",
    "options": [
      "Calf ultrasound",
      "MRI of the lower leg",
      "Foot x-ray",
      "Venous Doppler ultrasound",
      "CT scan of the ankle"
    ],
    "correct_answer": "Calf ultrasound",
    "explanation": "**Explanation**\n**Calf ultrasound is the preferred initial investigation for suspected Achilles tendon rupture** because it is highly sensitive, non-invasive, and readily accessible. It can reliably demonstrate discontinuity of tendon fibres, confirming the rupture. This approach is supported by current guidelines, which recommend ultrasound as the first-line imaging when clinical suspicion is high based on history (acute pain, loss of plantarflexion), examination (positive Thompson test), and risk factors (such as recent fluoroquinolone use). MRI may be used for complex cases or uncertain diagnoses, but is not required initially.\n\n**Key Points**\n- Achilles tendon rupture presents with sudden pain, loss of plantarflexion, and positive Thompson test.\n- Ultrasound is sensitive and specific for detecting Achilles tendon tears.\n- MRI is reserved for ambiguous cases or surgical planning.\n- X-rays are poor at visualising tendon injuries; their role is to exclude fractures.\n- Venous Doppler is for thrombosis, not tendon rupture.\n- CT is rarely indicated for soft tissue injuries of the ankle.\n\n**Clinical Relevance**\nPrompt diagnosis of Achilles tendon rupture is crucial to guide orthopaedic referral and to optimise outcomes. Ultrasound enables rapid confirmation and helps avoid unnecessary delays in management, as recommended by NICE CKS.",
    "bullet_explanations": {
      "Calf ultrasound": "Correct—first-line investigation for suspected Achilles tendon rupture due to high sensitivity and accessibility.",
      "MRI of the lower leg": "Incorrect—useful for complex or equivocal cases, but not required as an initial test.",
      "Foot x-ray": "Incorrect—cannot visualise tendon injuries; used only to rule out associated fractures.",
      "Venous Doppler ultrasound": "Incorrect—indicated for suspected DVT, not for tendon injury.",
      "CT scan of the ankle": "Incorrect—rarely used for soft tissue injuries; mainly for bone assessment."
    },
    "category": "Soft Tissue",
    "subsection": "Soft Tissue Injuries",
    "subsubsection": "Tendon rupture management",
    "topic": "Tendon rupture management",
    "keywords": [
      "Achilles tendon rupture",
      "ultrasound",
      "Thompson test",
      "soft tissue injury",
      "MSRA"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Achilles tendinopathy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/achilles-tendinopathy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b624d554-92ed-46cf-98e8-fe21baf35fa2",
    "question_number": 381,
    "question": "Which two vaccines are routinely recommended for all pregnant individuals in the UK to reduce the risk of serious infection in both mother and infant?",
    "options": [
      "Pertussis and influenza",
      "Rubella and pneumococcal",
      "Tetanus and MMR",
      "Pneumococcal and hepatitis B",
      "Varicella and measles"
    ],
    "correct_answer": "Pertussis and influenza",
    "explanation": "**Explanation**\n**Pertussis (whooping cough) and influenza vaccines are both recommended for all pregnant individuals in the UK as part of the routine antenatal immunisation programme.** The pertussis vaccine is offered in the third trimester (ideally between 16–32 weeks, but can be given later if missed), regardless of previous vaccination status, to protect newborns before their own immunisations. The influenza vaccine is offered during flu season, at any stage of pregnancy, to reduce the risk of severe flu-related complications in both mother and fetus. Other vaccines such as rubella, MMR, varicella, and pneumococcal are not routinely given during pregnancy—some are contraindicated due to live virus content (e.g. MMR, varicella), while others are reserved for specific risk groups.**\n\n**Key Points**\n- Pertussis vaccine: given each pregnancy, usually at 16–32 weeks, to protect newborns from whooping cough.\n- Influenza vaccine: recommended for all pregnant women during flu season, regardless of trimester.\n- Rubella (MMR) and varicella vaccines are live and contraindicated in pregnancy.\n- Pneumococcal and hepatitis B vaccines are not given routinely in pregnancy—reserved for selected risk groups.\n- Routine antenatal immunisation improves maternal and neonatal outcomes.\n\n**Clinical Relevance**\nRecognising which vaccines are safe and routinely recommended during pregnancy is vital for preventing severe complications in the mother and infant, and aligns with UK immunisation guidelines. Failure to offer these vaccines increases the risk of hospitalisation and death from preventable infections.\n\n**Memory Anchor**\nPregnant? Protect with 'Flu and Whoop' (Influenza and Pertussis).",
    "bullet_explanations": {
      "Pertussis and influenza": "Correct: These are the two vaccines recommended for all pregnant women in the UK to reduce maternal and neonatal morbidity.",
      "Rubella and pneumococcal": "Incorrect: Rubella vaccine (part of MMR) is live and contraindicated in pregnancy; pneumococcal is not routine unless specific risk factors exist.",
      "Tetanus and MMR": "Incorrect: MMR is live and contraindicated in pregnancy; tetanus is only given as part of the pertussis-containing combination.",
      "Pneumococcal and hepatitis B": "Incorrect: Neither is routine in pregnancy unless there is a specific risk (e.g., chronic disease, high prevalence areas).",
      "Varicella and measles": "Incorrect: Both are live vaccines and contraindicated in pregnant women due to risk to the fetus."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Influenza red flags and antivirals",
    "keywords": [
      "pregnancy",
      "vaccination",
      "influenza",
      "pertussis",
      "antenatal care"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Pertussis vaccine",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/pertussis-vaccine/"
      },
      {
        "source": "BNF",
        "topic_title": "Immunisation schedule",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/immunisation-schedule/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "66923dcd-b6a1-48fc-9b24-7e1b360b2e43",
    "question_number": 382,
    "question": "A 26-year-old woman with a documented latex allergy is seeking advice about contraception and STI prevention. She has multiple sexual partners and prefers a method she can use herself. Which barrier method would be most appropriate for her?",
    "options": [
      "Polyurethane condom",
      "Natural membrane (lambskin) condom",
      "Latex male condom",
      "Diaphragm with spermicide",
      "Cervical cap"
    ],
    "correct_answer": "Polyurethane condom",
    "explanation": "**Explanation**\n**Polyurethane condoms** are a suitable alternative for individuals with a latex allergy. Unlike latex condoms, they do not cause allergic reactions and are effective in preventing both pregnancy and sexually transmitted infections (STIs). Natural membrane condoms (such as lambskin) do not reliably protect against STIs as their pores may allow viruses to pass through. Diaphragms and cervical caps do not provide reliable STI protection and are less suitable for those prioritising STI prevention. Latex condoms are contraindicated in those with latex allergy.\n\n**Key Points**\n- Polyurethane condoms are latex-free and prevent both pregnancy and STIs.\n- Natural membrane condoms protect against pregnancy but not all STIs.\n- Diaphragms and cervical caps do not protect against STIs and are less ideal for patients at risk.\n- Latex allergy is a clear contraindication for latex-based barrier methods.\n- Barrier methods should be selected based on allergy status and risk of STIs.\n\n**Clinical Relevance**\nSelecting the appropriate barrier method in patients with latex allergy is critical to ensure both effective contraception and protection against STIs. National guidelines recommend polyurethane condoms in this context. Failure to provide an effective alternative can compromise patient safety and public health.\n\n**Memory Anchor**\nRemember: 'Poly' for 'poly-allergy'—polyurethane for those with latex allergy.",
    "bullet_explanations": {
      "Polyurethane condom": "Correct – provides both contraception and STI protection without latex.",
      "Natural membrane (lambskin) condom": "Incorrect – does not reliably prevent STIs despite preventing pregnancy.",
      "Latex male condom": "Incorrect – contraindicated in latex allergy and may cause allergic reaction.",
      "Diaphragm with spermicide": "Incorrect – provides contraception but not reliable STI protection.",
      "Cervical cap": "Incorrect – offers contraception but lacks adequate STI protection."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Barrier methods",
    "keywords": [
      "latex allergy",
      "condom",
      "polyurethane",
      "contraception",
      "STI prevention"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Contraception - barrier methods and spermicides",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/contraception-barrier-methods-spermicides/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e5c37cc7-9e08-4dcd-8b10-ed33fdcd14ad",
    "question_number": 383,
    "question": "A 68-year-old woman visits her optician for a routine eye examination. She reports no new visual symptoms. Fundoscopy reveals subretinal neovascular membranes with some haemorrhagic areas and the presence of exudates at the macula. What is the most likely diagnosis?",
    "options": [
      "Wet (neovascular) age-related macular degeneration",
      "Diabetic maculopathy",
      "Hypertensive retinopathy",
      "Retinal vein occlusion",
      "Central serous chorioretinopathy"
    ],
    "correct_answer": "Wet (neovascular) age-related macular degeneration",
    "explanation": "**Explanation**\n**Wet (neovascular) age-related macular degeneration (AMD)** is characterised by the growth of abnormal blood vessels beneath the macula, leading to leakage, haemorrhage, and rapid vision loss if untreated. Fundoscopic findings such as subretinal neovascular membranes, macular exudates, and haemorrhages are classic. This differentiates it from dry AMD, which is more slowly progressive and lacks neovascularisation. Diabetic maculopathy and hypertensive retinopathy may present with exudates and haemorrhages but typically have a different distribution and are associated with other systemic signs. Retinal vein occlusion often shows widespread retinal haemorrhages and cotton wool spots, while central serous chorioretinopathy is more likely in younger patients and presents with a localised serous retinal detachment without neovascularisation.\n\n**Key Points**\n- Wet AMD features new, fragile blood vessels under the macula (neovascularisation).\n- Fundoscopy shows macular exudates, subretinal haemorrhage, and possible scarring.\n- Common in patients over 55; key risk factors: age, smoking, family history.\n- Symptoms: painless, rapidly progressive central vision loss and distortion.\n- Prompt referral for anti-VEGF therapy can preserve vision.\n- <table><thead><tr><th>Condition</th><th>Key Fundoscopic Features</th></tr></thead><tbody><tr><td>Wet AMD</td><td>Subretinal neovascularisation, macular exudates, haemorrhage</td></tr><tr><td>Diabetic maculopathy</td><td>Hard exudates, microaneurysms near macula</td></tr><tr><td>Hypertensive retinopathy</td><td>AV nicking, flame haemorrhages, cotton wool spots</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising wet AMD is crucial, as early treatment with intravitreal anti-VEGF agents can significantly reduce the risk of severe, permanent central vision loss. NICE guidelines emphasise urgent referral for suspected wet AMD to optimise patient outcomes.\n\n**Memory Anchor**\nRemember 'wet' = 'weeping vessels': new vessels leak and bleed.",
    "bullet_explanations": {
      "Wet (neovascular) age-related macular degeneration": "Correct. Subretinal neovascularisation with exudates and haemorrhage is typical for wet AMD.",
      "Diabetic maculopathy": "Incorrect. While exudates can occur, neovascularisation at the macula is not a feature; usually associated with diabetes and microaneurysms.",
      "Hypertensive retinopathy": "Incorrect. Shows AV nicking, flame-shaped haemorrhages, and cotton wool spots; not specifically subretinal neovascularisation.",
      "Retinal vein occlusion": "Incorrect. Presents with widespread retinal haemorrhages ('blood and thunder' appearance), not localised macular findings.",
      "Central serous chorioretinopathy": "Incorrect. Causes serous retinal detachment in younger adults without neovascularisation or significant exudates."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Acute angle-closure glaucoma",
    "topic": "Acute angle-closure glaucoma",
    "keywords": [
      "wet AMD",
      "macular degeneration",
      "fundoscopy",
      "anti-VEGF",
      "vision loss"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Age-related macular degeneration",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/age-related-macular-degeneration/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Macular degeneration - age-related",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/macular-degeneration-age-related/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "6b028cc3-8d48-499e-9c38-5af0f54f5826",
    "question_number": 384,
    "question": "A 55-year-old man presents with sudden-onset right upper quadrant abdominal pain, high fever, and new-onset jaundice. His medical history includes type 2 diabetes and obesity. On examination, he is tachycardic and has marked tenderness in the right upper quadrant. Blood tests reveal a significantly raised bilirubin and neutrophilia. Which diagnosis is most strongly supported by these findings?",
    "options": [
      "Ascending cholangitis",
      "Acute cholecystitis",
      "Gilbert’s syndrome",
      "Ectopic pregnancy",
      "Uncomplicated biliary colic"
    ],
    "correct_answer": "Ascending cholangitis",
    "explanation": "**Explanation**\n**Ascending cholangitis** is characterised by a classic triad of fever, jaundice, and right upper quadrant pain (Charcot’s triad), often occurring in patients with risk factors such as obesity and diabetes. The presence of sepsis (fever, tachycardia), marked hyperbilirubinaemia, and evidence of biliary obstruction make this diagnosis much more likely than simple cholecystitis. While cholecystitis may cause right upper quadrant pain and fever, significant jaundice is uncommon unless there is concurrent biliary obstruction. Gilbert’s syndrome presents with isolated, mild jaundice, typically without pain, fever, or systemic upset. Ectopic pregnancy does not present with this symptom constellation, especially in a male patient. Uncomplicated biliary colic causes episodic pain without systemic features or jaundice.\n\n**Key facts:**\n- **Charcot’s triad:** Fever, jaundice, right upper quadrant pain (highly suggestive of cholangitis)\n- **Cholangitis** is a medical emergency due to risk of sepsis and multi-organ failure\n- Cholecystitis: RUQ pain and fever, rarely accompanied by significant jaundice\n- Gilbert’s syndrome: Benign, isolated hyperbilirubinaemia, no pain or fever\n- Biliary colic: Transient pain, no fever or jaundice\n\n<table><thead><tr><th>Feature</th><th>Cholangitis</th><th>Cholecystitis</th></tr></thead><tbody><tr><td>Fever</td><td>Yes</td><td>Yes</td></tr><tr><td>RUQ pain</td><td>Yes</td><td>Yes</td></tr><tr><td>Jaundice</td><td>Yes</td><td>No or mild</td></tr><tr><td>Sepsis risk</td><td>High</td><td>Moderate</td></tr></tbody></table>\n\n**Clinical relevance:** Recognising ascending cholangitis promptly is crucial, as delayed intervention can lead to septic shock and death. Early identification and escalation are aligned with national and international guidelines.\n\n**Memory anchor:** Charcot’s triad—think “Charcot’s Cholangitis” for fever, jaundice, and RUQ pain.\n\n**Key Points**\n- Charcot’s triad (fever, jaundice, RUQ pain) is highly specific for ascending cholangitis.\n- Cholangitis is a medical emergency requiring urgent treatment.\n- Cholecystitis presents with pain and fever but rarely with marked jaundice.\n- Gilbert’s syndrome causes isolated, mild jaundice without systemic symptoms.\n- Biliary colic does not cause fever or jaundice.\n- Prompt recognition and intervention are essential to prevent complications.\n\n**Clinical Relevance**\nIdentifying ascending cholangitis in patients with sepsis and obstructive jaundice is essential for rapid treatment and prevention of life-threatening complications. National guidelines highlight the need for urgent biliary decompression and antibiotics.\n\n**Memory Anchor**\nCharcot’s triad—'Charcot’s Cholangitis' for fever, jaundice, RUQ pain.",
    "bullet_explanations": {
      "Ascending cholangitis": "Correct—The combination of fever, jaundice, and right upper quadrant pain strongly supports this diagnosis.",
      "Acute cholecystitis": "Incorrect—While it presents with pain and fever, significant jaundice is uncommon unless there is Mirizzi's syndrome.",
      "Gilbert’s syndrome": "Incorrect—This is a benign condition with isolated, mild, intermittent jaundice and no systemic symptoms.",
      "Ectopic pregnancy": "Incorrect—Not applicable in a male patient and does not present with this symptom constellation.",
      "Uncomplicated biliary colic": "Incorrect—Typically presents with episodic pain but no fever or jaundice."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Biliary & Pancreas",
    "subsubsection": "Gallstone Disease",
    "topic": "Biliary colic vs cholecystitis vs choledocholithiasis",
    "keywords": [
      "ascending cholangitis",
      "Charcot's triad",
      "biliary disease",
      "jaundice",
      "RUQ pain"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cholecystitis - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cholecystitis-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d77cb596-676c-48e5-aeae-4eaf24a7cef9",
    "question_number": 385,
    "question": "A 30-year-old primigravida at 18 weeks' gestation is informed that her partner has developed shingles. She has no recollection of prior chickenpox infection and is uncertain about her immunisation status. She is currently asymptomatic. What is the most appropriate first step in her management?",
    "options": [
      "Send blood sample to check varicella-zoster IgG antibody status",
      "Administer varicella-zoster immunoglobulin immediately",
      "Refer for urgent obstetric review",
      "Reassure and discharge with no further action",
      "Advise her to see her midwife in one week"
    ],
    "correct_answer": "Send blood sample to check varicella-zoster IgG antibody status",
    "explanation": "**Explanation**\n**Women exposed to varicella-zoster virus during pregnancy who are unsure of their immunity should have their varicella-zoster IgG status checked.** If serology confirms non-immunity, post-exposure prophylaxis (such as varicella-zoster immunoglobulin) is considered. There is no role for immediate immunoglobulin administration without confirming susceptibility, as many adults are immune even without a clear history of infection. **This approach minimises unnecessary treatment and targets prophylaxis only to those at genuine risk.** Immediate reassurance without investigation could miss susceptible individuals, while urgent specialist referral or delayed review does not address the risk of maternal and fetal complications from varicella exposure.\n\n**Key Points**\n- Check varicella-zoster IgG in pregnant women with possible exposure and uncertain immunity.\n- Post-exposure prophylaxis is only indicated if serology shows no immunity.\n- Chickenpox in pregnancy increases risk of maternal and fetal complications.\n- Most adults without a history of chickenpox are still likely to be immune.\n- Immediate immunoglobulin is not indicated unless non-immunity is confirmed.\n\n**Clinical Relevance**\nAssessing varicella immunity following exposure in pregnancy is vital to prevent severe maternal illness and rare but serious fetal complications. Following this approach is consistent with national guidelines and aids in targeting immunoglobulin to those who truly need it.\n\n**Memory Anchor**\nVZV exposure in pregnancy: 'Check IgG before IG.'",
    "bullet_explanations": {
      "Send blood sample to check varicella-zoster IgG antibody status": "Correct – establishes immunity status and identifies those needing prophylaxis.",
      "Administer varicella-zoster immunoglobulin immediately": "Incorrect – immunoglobulin is only given if serology confirms lack of immunity.",
      "Refer for urgent obstetric review": "Incorrect – urgent referral is not required at this stage; immunity status should be established first.",
      "Reassure and discharge with no further action": "Incorrect – immunity status must be confirmed before reassurance.",
      "Advise her to see her midwife in one week": "Incorrect – this may delay identification and management of varicella susceptibility."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "High-risk pregnancy identification",
    "keywords": [
      "varicella",
      "pregnancy",
      "immunity",
      "antenatal",
      "chickenpox exposure"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "e45a37cd-ee5c-40d7-80c9-72459756a3d0",
    "question_number": 386,
    "question": "A 50-year-old man with a history of asthma is prescribed inhaled fluticasone and salmeterol. He presents with a one-week history of painful swallowing but no weight loss or fever. On examination, his oral cavity appears normal. What is the most likely diagnosis?",
    "options": [
      "Oesophageal candidiasis",
      "Oesophageal carcinoma",
      "Drug-induced oesophagitis",
      "Plummer-Vinson syndrome",
      "Myasthenia gravis"
    ],
    "correct_answer": "Oesophageal candidiasis",
    "explanation": "**Explanation**\n**Oesophageal candidiasis** should be suspected in patients using inhaled corticosteroids who develop odynophagia (painful swallowing), particularly in the absence of visible oral lesions. Inhaled steroids can locally suppress immunity, allowing overgrowth of Candida albicans along the oropharynx and oesophagus. This typically presents with pain on swallowing (odynophagia) rather than non-painful dysphagia. Lack of oral thrush does not exclude oesophageal involvement. Other causes such as malignancy or drug-induced oesophagitis usually present with additional symptoms or different risk factors.\n\n**Key Points**\n- Inhaled corticosteroids are a well-recognised risk factor for oropharyngeal and oesophageal candidiasis.\n- Oesophageal candidiasis often presents with odynophagia, not always accompanied by oral thrush.\n- Risk increases if the inhaler technique is suboptimal or mouth is not rinsed post-inhalation.\n- Painful swallowing (odynophagia) is the hallmark, distinguishing it from most causes of dysphagia.\n- Other risk factors: immunosuppression, diabetes, recent antibiotics.\n- <table><thead><tr><th>Condition</th><th>Main Symptom</th><th>Key Risk Factor</th></tr></thead><tbody><tr><td>Oesophageal candidiasis</td><td>Odynophagia</td><td>Inhaled steroids</td></tr><tr><td>Oesophageal carcinoma</td><td>Progressive dysphagia</td><td>Age, smoking</td></tr><tr><td>Plummer-Vinson</td><td>Intermittent dysphagia</td><td>Iron deficiency</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising oesophageal candidiasis as a complication of inhaled corticosteroid use is important for prompt management and prevention, as highlighted in BNF and NICE CKS guidance. Advising proper inhaler technique, mouth rinsing, and considering antifungal treatment can prevent complications and unnecessary investigations.\n\n**Memory Anchor**\nThink 'Candida can creep down the oesophagus' when steroids are involved, even if the mouth looks normal.",
    "bullet_explanations": {
      "Oesophageal candidiasis": "Correct—Classic cause of odynophagia in patients using inhaled corticosteroids.",
      "Oesophageal carcinoma": "Unlikely without progressive dysphagia, weight loss, or other red flag symptoms.",
      "Drug-induced oesophagitis": "Usually presents with retrosternal pain, often in patients taking bisphosphonates, NSAIDs, or tetracyclines.",
      "Plummer-Vinson syndrome": "Typically causes painless, intermittent dysphagia associated with iron deficiency anaemia.",
      "Myasthenia gravis": "Primarily presents with muscle weakness, ptosis, and sometimes dysphagia, but not isolated odynophagia."
    },
    "category": "Respiratory",
    "subsection": "Obstructive Airway",
    "subsubsection": "Asthma",
    "topic": "ICS-formoterol as MART",
    "keywords": [
      "inhaled corticosteroids",
      "oesophageal candidiasis",
      "odynophagia",
      "asthma",
      "fungal infection"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Oropharyngeal fungal infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/oropharyngeal-fungal-infections/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Candida - oral",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/candida-oral/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5d8a62be-e0d5-449e-921c-e33c77948aaa",
    "question_number": 387,
    "question": "A preterm female neonate, delivered at 32 weeks via spontaneous vaginal birth, initially feeds and breathes well. On the second day of life, she suddenly develops apnoea and decreased tone. What is the most likely neurological cause of her deterioration?",
    "options": [
      "Intraventricular haemorrhage",
      "Subdural haemorrhage",
      "Subarachnoid haemorrhage",
      "Perinatal arterial stroke",
      "Neonatal meningitis"
    ],
    "correct_answer": "Intraventricular haemorrhage",
    "explanation": "**Explanation**\n**Intraventricular haemorrhage (IVH)** is the most common neurological complication in premature infants, especially those born before 34 weeks gestation. The germinal matrix in preterm neonates contains fragile blood vessels prone to rupture, often triggered by fluctuations in cerebral blood flow. IVH typically presents within the first few days of life and can cause acute neurological decline, including apnoea, hypotonia, and seizures. In contrast, other intracranial bleeds are less likely in the absence of birth trauma or infection. Early detection is crucial as IVH can lead to long-term sequelae such as hydrocephalus and neurodevelopmental impairment.\n\n**Key Points**\n- IVH is most common in neonates born <34 weeks gestation.\n- Presents acutely with neurological signs (apnoea, hypotonia, seizures).\n- Caused by rupture of fragile vessels in the germinal matrix.\n- Less likely with term infants or in the absence of trauma.\n- May lead to complications such as hydrocephalus and cerebral palsy.\n\n**Clinical Relevance**\nRecognising IVH in premature infants is vital for prompt management and monitoring. Early neuroimaging and supportive care can improve outcomes. This scenario highlights the importance of surveillance for neurological deterioration in preterm neonates.\n\n**Memory Anchor**\nPremature = 'Paper-thin' vessels = Prone to IVH",
    "bullet_explanations": {
      "Intraventricular haemorrhage": "Correct – most common cause of acute neurological decline in preterm infants due to germinal matrix vessel fragility.",
      "Subdural haemorrhage": "Incorrect – more likely with traumatic delivery or asphyxia, less typical in stable preterm infants.",
      "Subarachnoid haemorrhage": "Incorrect – rare in neonates without trauma or vascular malformations.",
      "Perinatal arterial stroke": "Incorrect – can cause focal deficits but less likely to cause sudden global neurological deterioration in this context.",
      "Neonatal meningitis": "Incorrect – usually presents with fever, irritability, and systemic signs; onset is rarely this sudden and specific."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Neurology",
    "subsubsection": "Stroke & TIA",
    "topic": "FAST/TIA recognition",
    "keywords": [
      "intraventricular haemorrhage",
      "premature infant",
      "neonatal neurology"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "886303af-aa12-4034-9246-9520ecf6793c",
    "question_number": 388,
    "question": "A 63-year-old woman presents for review of routine blood tests. She reports feeling well, with no new symptoms or chronic illnesses. She recently completed a 7-day course of antibiotics for a urinary tract infection. Her renal function is normal. Her results are: Hb 110 g/L, MCV 76 fL, platelets 540 x 10^9/L, WBC 13 x 10^9/L, and ferritin 330 µg/L. Her last full blood count, performed one year ago, was entirely normal. What is the most likely cause of her current anaemia?",
    "options": [
      "Iron deficiency anaemia",
      "Anaemia of chronic disease",
      "Thalassaemia trait",
      "Vitamin B12 deficiency",
      "Hypothyroidism"
    ],
    "correct_answer": "Iron deficiency anaemia",
    "explanation": "**Explanation**\n**Iron deficiency anaemia** is the most likely diagnosis in this scenario. The patient has developed a new microcytic anaemia (low Hb, low MCV) with thrombocytosis and mild leukocytosis, all emerging after a recent infection. **Ferritin can be falsely elevated in the context of infection or inflammation**, as it is an acute phase reactant. Therefore, a normal or raised ferritin does not reliably exclude iron deficiency when inflammation is present. Thalassaemia trait would usually be present lifelong and not have a previously normal blood count. Anaemia of chronic disease is more often normocytic and requires a chronic underlying inflammatory process, which is not evident here. Both B12 deficiency and hypothyroidism typically cause macrocytic anaemia, not microcytic. Further iron studies are warranted to confirm iron deficiency, but in this clinical context, it remains the most likely explanation.\n\n**Key Points**\n- Microcytic anaemia in adults is most often due to iron deficiency, especially with new onset and no chronic disease\n- Ferritin is an acute phase protein; infection or inflammation can mask true iron deficiency by increasing ferritin\n- Anaemia of chronic disease is usually normocytic and associated with chronic illness, not isolated recent infection\n- Thalassaemia trait is lifelong and would not present with previously normal bloods\n- Macrocytic anaemia (high MCV) is suggestive of B12/folate deficiency or hypothyroidism, not seen here\n\n<table><thead><tr><th>Condition</th><th>MCV</th><th>Ferritin</th><th>Typical Setting</th></tr></thead><tbody><tr><td>Iron deficiency</td><td>Low</td><td>Low (may be normal/high in inflammation)</td><td>Diet, GI loss</td></tr><tr><td>Anaemia of chronic disease</td><td>Normal/Low</td><td>Normal/High</td><td>Chronic illness</td></tr><tr><td>B12/Folate deficiency</td><td>High</td><td>N/A</td><td>Malabsorption, diet</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising that ferritin can be misleadingly elevated during acute illness is vital for accurate diagnosis of iron deficiency. NICE guidelines recommend not excluding iron deficiency in the presence of infection and suggest further iron studies or repeat testing after recovery. Early identification ensures appropriate investigation for underlying causes and timely management.\n\n**Memory Anchor**\nFerritin 'fools' in fever—infection can raise ferritin, masking iron deficiency.",
    "bullet_explanations": {
      "Iron deficiency anaemia": "Correct: Most likely due to new microcytic anaemia and misleading ferritin in setting of recent infection.",
      "Anaemia of chronic disease": "Incorrect: More commonly normocytic and linked to chronic, not acute, illness.",
      "Thalassaemia trait": "Incorrect: Would cause lifelong microcytosis, not new onset in previously normal patient.",
      "Vitamin B12 deficiency": "Incorrect: Causes macrocytic, not microcytic, anaemia.",
      "Hypothyroidism": "Incorrect: Also typically leads to macrocytic anaemia, not microcytic."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Anaemias",
    "topic": "Microcytic (iron, thalassaemia, anaemia of chronic disease)",
    "keywords": [
      "iron deficiency",
      "microcytic anaemia",
      "ferritin",
      "acute phase",
      "diagnosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Anaemia - iron deficiency",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/anaemia-iron-deficiency/"
      },
      {
        "source": "BNF",
        "topic_title": "Anaemia, iron deficiency",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/anaemia-iron-deficiency/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Anaemia - B12 and folate deficiency",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/anaemia-b12-folate-deficiency/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5f46ae7c-eab8-4e57-83a5-fdafb1934e72",
    "question_number": 389,
    "question": "Which medication is known to delay the healing process of bone fractures?",
    "options": [
      "Non-steroidal anti-inflammatory drugs",
      "Metformin",
      "Proton pump inhibitors",
      "Selective serotonin reuptake inhibitors",
      "Beta blockers"
    ],
    "correct_answer": "Non-steroidal anti-inflammatory drugs",
    "explanation": "**Explanation**\n**Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with delayed bone healing.** NSAIDs inhibit cyclooxygenase enzymes, leading to reduced prostaglandin synthesis, which is crucial for the inflammatory phase of bone repair. This impedes the normal cascade of events required for effective fracture union. Other medications, such as corticosteroids and some immunosuppressants, also impair bone healing, but among the options listed, NSAIDs are the most well-established cause. In contrast, medications like metformin, PPIs, SSRIs, and beta blockers do not have a significant direct effect on fracture healing rates.\n\n**Key Points**\n<ul><li>NSAIDs can impair fracture healing by inhibiting prostaglandin-mediated bone repair.</li><li>Prostaglandins play an essential role in bone regeneration and remodelling.</li><li>Other negative factors for bone healing include corticosteroids, smoking, and poor nutrition.</li><li>Metformin, PPIs, SSRIs, and beta blockers are not strongly linked to delayed bone union.</li><li>Advising patients to avoid NSAIDs after a fracture may support optimal healing.</li></ul>\n\n**Clinical Relevance**\nRecognising the impact of NSAIDs on bone repair is crucial in both primary and secondary care, as inappropriate use in fracture patients may prolong recovery or increase the risk of non-union. This aligns with guidance to assess all modifiable risk factors for poor bone health, especially in patients susceptible to osteoporosis or impaired healing.",
    "bullet_explanations": {
      "Non-steroidal anti-inflammatory drugs": "Correct – NSAIDs delay bone healing by inhibiting prostaglandin synthesis necessary for fracture repair.",
      "Metformin": "Incorrect – Metformin does not have a clinically significant effect on bone healing.",
      "Proton pump inhibitors": "Incorrect – While long-term use may impact bone health via calcium absorption, they do not directly slow fracture healing.",
      "Selective serotonin reuptake inhibitors": "Incorrect – SSRIs may affect bone density long-term, but are not linked to delayed healing of acute fractures.",
      "Beta blockers": "Incorrect – Beta blockers have no established role in impairing bone healing."
    },
    "category": "Musculoskeletal",
    "subsection": "Bone & Metabolic",
    "subsubsection": "Osteoporosis",
    "topic": "Bisphosphonate indications",
    "keywords": [
      "fracture healing",
      "NSAIDs",
      "bone repair",
      "risk factors",
      "medication effects"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Osteoporosis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/osteoporosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9113c088-aa23-4b16-b29c-b3dee14118db",
    "question_number": 390,
    "question": "A 22-year-old woman with a history of primary adrenal insufficiency is newly registered with a UK GP after immigrating from Brazil. She is stable on daily hydrocortisone and fludrocortisone, with no current symptoms of adrenal under- or over-replacement. What essential emergency medication should her GP prescribe to ensure she is prepared for potential adrenal crisis?",
    "options": [
      "Hydrocortisone injection kit",
      "Oral codeine phosphate",
      "Fludrocortisone ampoules for injection",
      "Rescue pack of oral antibiotics",
      "Prednisolone tablets for self-medication"
    ],
    "correct_answer": "Hydrocortisone injection kit",
    "explanation": "**Explanation**\n**All patients with Addison’s disease (primary adrenal insufficiency) should have access to an intramuscular hydrocortisone injection kit** to use in case of adrenal crisis or when oral medications cannot be absorbed, such as during vomiting. This is a critical safety measure to prevent life-threatening adrenal crisis, characterised by hypotension, shock, and possible death if not treated promptly. Oral hydrocortisone, while suitable for daily management, is ineffective in emergencies involving gastrointestinal upset. **High-dose hydrocortisone provides both glucocorticoid and sufficient mineralocorticoid effect**, so separate fludrocortisone injections are not necessary in acute settings. Analgesics and antibiotics are not routinely indicated as emergency standby medication in adrenal insufficiency.\n\n**Key Points**\n- Adrenal crisis is a medical emergency requiring urgent parenteral glucocorticoid administration.\n- Hydrocortisone injection kits should be supplied to all patients at risk of adrenal crisis.\n- High-dose hydrocortisone covers both glucocorticoid and mineralocorticoid needs during crisis.\n- Fludrocortisone injection is not indicated in emergencies.\n- Routine provision of antibiotics or analgesics is not recommended unless other comorbidities exist.\n- Education on the use of emergency hydrocortisone and sick day rules is essential.\n\n**Clinical Relevance**\nEnsuring patients with Addison's disease have access to an emergency hydrocortisone injection kit is a key safety recommendation in UK guidelines. GPs must also educate patients and their families on recognising adrenal crisis and administering the injection, as delayed treatment can be fatal. This is supported by NICE and BNF guidance.\n\n**Memory Anchor**\nRemember: 'Hydro for crisis'—hydrocortisone injection is the emergency standby for Addison's.",
    "bullet_explanations": {
      "Hydrocortisone injection kit": "Correct – Provides immediate glucocorticoid replacement during adrenal crisis or if oral therapy is not tolerated.",
      "Oral codeine phosphate": "Incorrect – Analgesia is not routinely supplied for Addison’s disease emergency management.",
      "Fludrocortisone ampoules for injection": "Incorrect – Emergency mineralocorticoid is not required, as high-dose hydrocortisone suffices in crisis situations.",
      "Rescue pack of oral antibiotics": "Incorrect – Not indicated unless there is a specific risk of infection; not standard for adrenal insufficiency.",
      "Prednisolone tablets for self-medication": "Incorrect – Oral steroids are not suitable for acute crisis if the patient cannot tolerate oral medication; IM hydrocortisone is preferred."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Adrenal",
    "subsubsection": "Adrenal Insufficiency",
    "topic": "Adrenal crisis emergency management",
    "keywords": [
      "Addison's disease",
      "adrenal crisis",
      "hydrocortisone injection",
      "emergency kit",
      "primary adrenal insufficiency"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Addison's disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/addisons-disease/"
      },
      {
        "source": "BNF",
        "topic_title": "Adrenal insufficiency",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/adrenal-insufficiency/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "40b152d4-8848-40ba-92f2-a887d69438c0",
    "question_number": 391,
    "question": "A 31-year-old woman with a history of bipolar disorder is planning a pregnancy and asks her GP about the risks of continuing her current medication. She is taking lithium as a mood stabiliser. What is the most significant congenital abnormality associated with lithium use during pregnancy?",
    "options": [
      "Ebstein's anomaly",
      "Cleft palate",
      "Neural tube defects",
      "Sensorineural deafness",
      "Grey baby syndrome"
    ],
    "correct_answer": "Ebstein's anomaly",
    "explanation": "**Explanation**\n**Ebstein's anomaly is a rare congenital cardiac defect** that is characteristically associated with maternal lithium use during pregnancy. The anomaly involves **malformation of the tricuspid valve and right ventricle**, leading to abnormal heart function in the newborn. While lithium is an effective mood stabiliser, it carries a recognised teratogenic risk, most notably the development of Ebstein's anomaly. This is distinct from the teratogenic risks posed by other psychotropic drugs, such as neural tube defects with valproate or carbamazepine, or craniofacial abnormalities with certain antiepileptics and alcohol. Lithium's cardiac-specific risk is a key consideration in the preconception counselling of women with bipolar disorder.\n\n**Key Points**\n- Lithium is associated with an increased risk of Ebstein's anomaly, a cardiac defect.\n- Ebstein's anomaly affects the tricuspid valve and right ventricle.\n- Other teratogenic risks (e.g., neural tube defects, craniofacial abnormalities) are linked to different drugs.\n- Pre-pregnancy medication review is essential in women of childbearing age taking mood stabilisers.\n- Alternative mood stabilisers may be considered if pregnancy is planned.\n\n**Clinical Relevance**\nIdentifying the teratogenic risks of psychotropic medications is crucial in preconception care for women with mental health conditions. Lithium's association with Ebstein's anomaly informs both patient counselling and multidisciplinary management, reducing the risk of preventable congenital heart defects.\n\n**Memory Anchor**\nThink 'L' for Lithium and 'L' for Leak (tricuspid valve leaks in Ebstein’s anomaly).",
    "bullet_explanations": {
      "Ebstein's anomaly": "Correct – Lithium is specifically linked to this congenital heart defect.",
      "Cleft palate": "Incorrect – Associated more commonly with antiepileptics and alcohol, not lithium.",
      "Neural tube defects": "Incorrect – Linked to valproate and carbamazepine, not lithium.",
      "Sensorineural deafness": "Incorrect – Associated with aminoglycosides, not lithium.",
      "Grey baby syndrome": "Incorrect – Seen with chloramphenicol use, not lithium."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Mood Disorders",
    "subsubsection": "Bipolar Disorder",
    "topic": "Mood stabilisers",
    "keywords": [
      "lithium",
      "Ebstein's anomaly",
      "teratogenicity",
      "bipolar disorder",
      "pregnancy"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Bipolar disorder – Management",
        "citation": "© NICE, 2025",
        "url": "https://cks.nice.org.uk/topics/bipolar-disorder/management/"
      },
      {
        "source": "BNF",
        "topic_title": "Lithium: Pregnancy and breastfeeding",
        "citation": "© NICE, 2025",
        "url": "https://bnf.nice.org.uk/drug/lithium-hydroxide.html"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7a854ea2-4a0d-4a47-a4ab-369c63bf6440",
    "question_number": 392,
    "question": "A term male infant is born with severe central cyanosis and oxygen saturations persistently below 80% despite supplemental oxygen. Echocardiography confirms transposition of the great arteries. What is the most appropriate medication to administer immediately to stabilise the neonate prior to surgical intervention?",
    "options": [
      "Prostaglandin E1 infusion",
      "Adenosine bolus",
      "Indomethacin oral",
      "Captopril oral",
      "Prostaglandin F2 alpha injection"
    ],
    "correct_answer": "Prostaglandin E1 infusion",
    "explanation": "**Explanation**\n**Transposition of the great arteries (TGA) creates two parallel circulatory circuits, which are incompatible with life unless mixing occurs between them.** The ductus arteriosus is a vital channel that allows oxygenated and deoxygenated blood to mix in duct-dependent congenital heart diseases such as TGA. **Prostaglandin E1 (alprostadil) infusion is used to maintain ductal patency by relaxing vascular smooth muscle, ensuring ongoing mixing until definitive surgical correction is possible.** Closure of the duct in these neonates can rapidly lead to profound hypoxaemia and cardiovascular collapse. Prostaglandin E1 is administered intravenously and requires close monitoring for side effects such as apnoea and hypotension.<br><br>Other agents in the options either close the ductus arteriosus or have unrelated mechanisms, making them inappropriate for initial stabilisation in this context.\n\n**Key Points**\n- TGA is a duct-dependent congenital heart defect requiring prompt stabilisation.\n- Prostaglandin E1 maintains patency of the ductus arteriosus to allow blood mixing.\n- Immediate prostaglandin E1 infusion is life-saving until surgical correction.\n- Indomethacin and NSAIDs close the ductus arteriosus—contraindicated in this setting.\n- Adenosine is an antiarrhythmic, not used in duct-dependent lesions.\n- Captopril is for chronic heart failure, not acute cyanotic collapse.\n- <table><thead><tr><th>Drug</th><th>Main Action on Ductus Arteriosus</th></tr></thead><tbody><tr><td>Prostaglandin E1</td><td>Keeps ductus open</td></tr><tr><td>Indomethacin</td><td>Closes ductus</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising and urgently treating duct-dependent congenital heart disease is essential in neonatal emergencies. Prostaglandin E1 infusion stabilises affected infants by preserving ductal patency, buying time for surgical or catheter-based intervention, as reinforced by national guidelines.\n\n**Memory Anchor**\nProstaglandin 'E' for 'Emergency ductus patency'.",
    "bullet_explanations": {
      "Prostaglandin E1 infusion": "Correct. Keeps the ductus arteriosus open in duct-dependent lesions such as TGA, preventing rapid decompensation.",
      "Adenosine bolus": "Incorrect. Used for acute termination of supraventricular tachycardias, not for duct-dependent cyanotic heart disease.",
      "Indomethacin oral": "Incorrect. NSAID that promotes closure of the ductus arteriosus, which would worsen cyanosis in TGA.",
      "Captopril oral": "Incorrect. An ACE inhibitor used in chronic heart failure, not indicated for acute management of duct-dependent lesions.",
      "Prostaglandin F2 alpha injection": "Incorrect. Not used for maintaining ductal patency; prostaglandin E1 is the agent of choice."
    },
    "category": "Cardiovascular",
    "subsection": "Valvular & Structural",
    "subsubsection": "Congenital Heart Disease (Not listed in taxonomy; mapped to best fit: Aortic Stenosis > Endocarditis prophylaxis basics)",
    "topic": "Endocarditis prophylaxis basics",
    "keywords": [
      "transposition of the great arteries",
      "ductus arteriosus",
      "prostaglandin E1",
      "cyanotic heart disease"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Drugs affecting the ductus arteriosus",
        "citation": "© NICE BNFC, 2025",
        "url": "https://bnfc.nice.org.uk/treatment-summaries/drugs-affecting-the-ductus-arteriosus/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "845d8e51-d902-492a-81c6-e2a04ec1c6cf",
    "question_number": 393,
    "question": "A 52-year-old man with recently diagnosed primary adrenal insufficiency is maintained on hydrocortisone 20 mg daily and fludrocortisone 100 micrograms daily. According to 'sick day rules', what adjustment should he make to his medication if he develops a moderate infection requiring oral antibiotics?",
    "options": [
      "Double the hydrocortisone dose; keep fludrocortisone unchanged",
      "Increase both hydrocortisone and fludrocortisone doses by 50%",
      "Continue regular doses of both medications",
      "Triple the hydrocortisone dose; stop fludrocortisone",
      "Halve the hydrocortisone dose and increase fludrocortisone"
    ],
    "correct_answer": "Double the hydrocortisone dose; keep fludrocortisone unchanged",
    "explanation": "**Explanation**\n**Hydrocortisone dose should be doubled during episodes of illness or stress** in patients with adrenal insufficiency, as the body cannot mount a physiological increase in cortisol production. The fludrocortisone dose remains unchanged because high-dose hydrocortisone provides sufficient mineralocorticoid activity during these periods. This approach helps prevent adrenal crisis, a potentially fatal complication. In contrast, fludrocortisone adjustment is not required for intercurrent illness, unless specifically advised by an endocrinologist.\n\n**Key Points**\n- Primary adrenal insufficiency requires lifelong glucocorticoid and mineralocorticoid replacement.\n- During intercurrent illness, **'sick day rules'** advise patients to double their usual glucocorticoid (hydrocortisone) dose.\n- Fludrocortisone dose should remain the same during illness, as increased hydrocortisone provides adequate mineralocorticoid effect.\n- Failure to increase glucocorticoids during stress can precipitate **adrenal crisis** (hypotension, shock, death).\n- Patient education and provision of a **Steroid Emergency Card** are essential.\n\n**Clinical Relevance**\nUnderstanding and applying 'sick day rules' is vital in general practice and acute care to prevent adrenal crisis in patients with Addison's disease or other causes of adrenal insufficiency. National guidelines emphasise patient education and prompt glucocorticoid dose escalation during any physiological stress such as infection, surgery, or injury.\n\n**Memory Anchor**\n'Double the steroids, keep the salt'—double hydrocortisone, fludrocortisone unchanged during illness.",
    "bullet_explanations": {
      "Double the hydrocortisone dose; keep fludrocortisone unchanged": "Correct—this is the recommended adjustment for intercurrent illness to prevent adrenal crisis.",
      "Increase both hydrocortisone and fludrocortisone doses by 50%": "Incorrect—increasing fludrocortisone is unnecessary; high hydrocortisone covers mineralocorticoid needs.",
      "Continue regular doses of both medications": "Incorrect—this risks under-treatment and adrenal crisis during illness.",
      "Triple the hydrocortisone dose; stop fludrocortisone": "Incorrect—triple dosing is excessive and stopping fludrocortisone is not advised.",
      "Halve the hydrocortisone dose and increase fludrocortisone": "Incorrect—this would greatly increase the risk of adrenal crisis."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Adrenal",
    "subsubsection": "Adrenal Insufficiency",
    "topic": "Stress dosing and sick day rules",
    "keywords": [
      "Addison's disease",
      "sick day rules",
      "hydrocortisone",
      "adrenal crisis",
      "fludrocortisone"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Addison's disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/addisons-disease/"
      },
      {
        "source": "BNF",
        "topic_title": "Adrenal insufficiency",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/adrenal-insufficiency/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "532e69ac-6965-4bc2-9fe9-39b9fe91401e",
    "question_number": 394,
    "question": "A 29-year-old woman with newly diagnosed gestational diabetes mellitus has optimised her diet and reached the maximum tolerated dose of metformin over the past fortnight. Despite these measures, her fasting capillary blood glucose remains at 6.0 mmol/L and her 1-hour postprandial readings consistently exceed 8 mmol/L. Serial fetal scans are normal. What is the next best step in her management?",
    "options": [
      "Add insulin therapy to her regimen",
      "Switch metformin to gliclazide",
      "Introduce sitagliptin",
      "Reduce the metformin dose",
      "Continue current approach and reassess after delivery"
    ],
    "correct_answer": "Add insulin therapy to her regimen",
    "explanation": "**Explanation**\n**Insulin should be added when dietary modification and the maximum tolerated dose of metformin fail to achieve blood glucose targets in gestational diabetes.** Target levels are typically fasting <5.3 mmol/L and 1-hour postprandial <7.8 mmol/L. Oral agents other than metformin are generally not recommended in pregnancy due to insufficient safety data and lack of robust evidence. Sulfonylureas (other than glibenclamide, which is rarely used) and DPP-4 inhibitors like sitagliptin are not advised. Insulin is safe and effective for glycaemic control during pregnancy and should be offered to women whose glucose targets are not met with current therapy. Continuing suboptimal therapy risks fetal and maternal complications.\n\n**Key Points**\n- Insulin is indicated if blood glucose targets are not reached with diet and metformin in gestational diabetes.\n- Pregnancy glycaemic targets: fasting <5.3 mmol/L, 1-hour postprandial <7.8 mmol/L.\n- Metformin is the only oral agent routinely recommended in gestational diabetes.\n- Sulfonylureas (except glibenclamide in select cases) and DPP-4 inhibitors are not first-line in pregnancy.\n- Achieving optimal glycaemic control reduces risks of macrosomia, polyhydramnios, and pre-eclampsia.\n\n**Clinical Relevance**\nNational guidelines advise prompt escalation to insulin when non-insulin therapies fail to control gestational diabetes. This protects both maternal and fetal health and aligns with safety data and best practice recommendations.",
    "bullet_explanations": {
      "Add insulin therapy to her regimen": "Correct — Insulin is the recommended next step if targets are not met with diet and metformin in gestational diabetes.",
      "Switch metformin to gliclazide": "Incorrect — Gliclazide is not recommended in pregnancy due to safety concerns; metformin is the only oral agent routinely used.",
      "Introduce sitagliptin": "Incorrect — Sitagliptin (a DPP-4 inhibitor) is not approved for use in pregnancy.",
      "Reduce the metformin dose": "Incorrect — Lowering the metformin dose would worsen glycaemic control.",
      "Continue current approach and reassess after delivery": "Incorrect — Persistently elevated glucose requires timely intervention to prevent fetal and maternal complications."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Acute",
    "subsubsection": "Perioperative Glycaemia",
    "topic": "Sick-day rules",
    "keywords": [
      "gestational diabetes",
      "insulin",
      "pregnancy",
      "metformin",
      "glycaemic targets"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetes, pregnancy and breast-feeding",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetes-pregnancy-and-breast-feeding/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "72cf8af9-bd6e-4dff-8e99-e96fd9a6d86a",
    "question_number": 395,
    "question": "A 68-year-old man with a history of chronic lymphocytic leukaemia presents with four days of profuse, bloody diarrhoea, fever, and abdominal pain. Stool culture identifies Campylobacter jejuni. What is the most appropriate next step in his management?",
    "options": [
      "Initiate oral clarithromycin plus supportive rehydration",
      "Supportive care and oral rehydration only",
      "Start oral mebendazole with fluids",
      "Administer intravenous metronidazole",
      "Prescribe loperamide as needed"
    ],
    "correct_answer": "Initiate oral clarithromycin plus supportive rehydration",
    "explanation": "**Explanation**\n**Immunocompromised patients or those with severe Campylobacter infections (bloody diarrhoea, fever, systemic symptoms) require antibiotic therapy, rather than supportive care alone.** Clarithromycin is the recommended first-line antibiotic for severe or high-risk Campylobacter enteritis, as it is effective against this pathogen. Supportive rehydration is also essential to prevent dehydration and complications. In contrast, mild cases in immunocompetent individuals are typically managed with fluids alone, as most infections are self-limiting. Metronidazole and mebendazole are not appropriate for Campylobacter, and antimotility agents like loperamide are contraindicated in dysenteric or febrile presentations due to risk of complications.\n\n**Key Points**\n- Campylobacter is a common bacterial cause of bloody diarrhoea in the UK.\n- Most cases resolve without antibiotics in immunocompetent individuals.\n- Antibiotics (macrolides such as clarithromycin) are indicated in severe disease, prolonged symptoms, or immunocompromised hosts.\n- Supportive care includes oral rehydration therapy.\n- Loperamide should be avoided in cases with systemic symptoms or dysentery.\n- <table><thead><tr><th>Scenario</th><th>Recommended Management</th></tr></thead><tbody><tr><td>Immunocompetent, mild</td><td>Supportive care only</td></tr><tr><td>Severe/Immunocompromised</td><td>Clarithromycin + fluids</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising when to escalate from supportive to antibiotic therapy in Campylobacter infections is crucial for patient safety, particularly in those with immunosuppression or severe symptoms, in line with NICE guidance.\n\n**Memory Anchor**\nCampylobacter: Clarithromycin for Complications",
    "bullet_explanations": {
      "Initiate oral clarithromycin plus supportive rehydration": "Correct—macrolide antibiotics are first-line in severe or immunocompromised cases of Campylobacter enteritis.",
      "Supportive care and oral rehydration only": "Incorrect—suitable for mild, self-limiting cases in healthy individuals, but not for severe or immunocompromised presentations.",
      "Start oral mebendazole with fluids": "Incorrect—mebendazole treats helminthic infections, not bacterial gastroenteritis.",
      "Administer intravenous metronidazole": "Incorrect—metronidazole is not effective against Campylobacter; used mainly for anaerobic or protozoal infections.",
      "Prescribe loperamide as needed": "Incorrect—antimotility agents are contraindicated in bloody diarrhoea or systemic illness."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "GI Infections",
    "topic": "Food poisoning organisms",
    "keywords": [
      "Campylobacter",
      "immunocompromised diarrhoea",
      "clarithromycin",
      "bloody diarrhoea",
      "GI infection"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Gastroenteritis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/gastroenteritis/"
      },
      {
        "source": "BNF",
        "topic_title": "Quinolones",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/quinolones/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f06ee407-56e2-4db1-ad6e-05381cac07ab",
    "question_number": 396,
    "question": "A 55-year-old man of Black African descent is newly diagnosed with essential hypertension following ambulatory blood pressure monitoring (average 153/96 mmHg). He has no history of diabetes, renal disease, or cardiovascular events, and his kidney function is normal. According to UK guidelines, which class of antihypertensive medication should be offered first-line?",
    "options": [
      "Calcium channel blocker",
      "Angiotensin-converting enzyme inhibitor",
      "Thiazide-like diuretic",
      "Beta-blocker",
      "Angiotensin II receptor blocker"
    ],
    "correct_answer": "Calcium channel blocker",
    "explanation": "**Explanation**\n**Calcium channel blockers are the recommended initial therapy for adults of Black African or African-Caribbean family origin with newly diagnosed hypertension, in the absence of diabetes or evidence of chronic kidney disease.** This guideline reflects observed differences in hypertension pathophysiology, notably lower renin levels, which make ACE inhibitors and ARBs less effective as monotherapy in this group. Thiazide-like diuretics are an alternative only if calcium channel blockers are contraindicated or not tolerated. Beta-blockers are not first-line unless there are additional indications (such as angina or post-MI). ACE inhibitors and ARBs are reserved for later steps or for specific comorbidities.\n\n**Key Points**\n- Black African or African-Caribbean patients: calcium channel blockers first-line unless specific comorbidities.\n- Lower renin hypertension responds less well to ACE inhibitors and ARBs.\n- Thiazide-like diuretics are second-line if CCBs are not suitable.\n- ACE inhibitors are first-line in younger, non-Black patients or those with diabetes/CKD.\n- Beta-blockers are not routinely first-line for uncomplicated hypertension.\n\n**Clinical Relevance**\nCorrect first-line antihypertensive selection is crucial for effective blood pressure control and reducing cardiovascular risk, especially in populations with different treatment responses. NICE and BNF guidelines specifically address these differences to improve patient outcomes.\n\n**Memory Anchor**\nThink 'C' for 'Calcium channel blocker' and 'Caribbean' as first-line.",
    "bullet_explanations": {
      "Calcium channel blocker": "Correct – recommended as first-line in Black African/African-Caribbean patients with uncomplicated hypertension.",
      "Angiotensin-converting enzyme inhibitor": "Incorrect – less effective as initial monotherapy in this group without diabetes or CKD.",
      "Thiazide-like diuretic": "Incorrect – considered if calcium channel blocker is contraindicated or not tolerated.",
      "Beta-blocker": "Incorrect – not first-line for hypertension unless there are other compelling indications.",
      "Angiotensin II receptor blocker": "Incorrect – similar limitations as ACE inhibitors for initial therapy in this population."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "NICE A/C/D ladder and special cases",
    "keywords": [
      "hypertension",
      "African-Caribbean",
      "calcium channel blocker",
      "antihypertensive guidelines"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "aaa6438a-e861-46eb-90c5-417fa012bafa",
    "question_number": 397,
    "question": "A 48-year-old man with a history of poorly controlled type 2 diabetes and stage 4 chronic kidney disease presents with sudden onset palpitations and muscle weakness. His ECG shows tall, peaked T waves, broad QRS complexes, and a sine-wave appearance. What is the most likely underlying electrolyte abnormality?",
    "options": [
      "Hyperkalaemia",
      "Hypocalcaemia",
      "Digoxin toxicity",
      "Beta-blocker overdose",
      "Hypomagnesaemia"
    ],
    "correct_answer": "Hyperkalaemia",
    "explanation": "**Explanation**\n**Hyperkalaemia is the most likely cause of the described ECG changes: tall, peaked T waves, progressively broadening QRS, and a sine-wave pattern.** These findings are classic for severe potassium elevation, particularly in patients with advanced chronic kidney disease, where potassium excretion is compromised. Other electrolyte disturbances or drug toxicities (e.g., digoxin) can cause arrhythmias but do not produce this specific ECG signature. Early recognition is crucial, as hyperkalaemia can rapidly progress to ventricular fibrillation or asystole if untreated.\n\n**Key Points**\n- Hyperkalaemia: Causes tall, peaked T waves, widened QRS, sine-wave ECG at high levels.\n- CKD patients are at increased risk due to reduced renal potassium clearance.\n- Severe hyperkalaemia is life-threatening and requires urgent management.\n- Other causes of broad QRS (e.g., sodium channel blockade) do not feature peaked T waves.\n- <table><thead><tr><th>ECG Feature</th><th>Electrolyte Disturbance</th></tr></thead><tbody><tr><td>Tall, peaked T waves</td><td>Hyperkalaemia</td></tr><tr><td>Prolonged QT, Torsades</td><td>Hypocalcaemia, Hypomagnesaemia</td></tr><tr><td>Arrhythmias, scooped ST</td><td>Digoxin toxicity</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising hyperkalaemia on ECG is essential for timely intervention, especially in patients with renal impairment. UK guidelines recommend urgent treatment of severe hyperkalaemia to prevent fatal arrhythmias.\n\n**Memory Anchor**\nRemember: 'Tall T, Terrible Trouble' for hyperkalaemia ECG.",
    "bullet_explanations": {
      "Hyperkalaemia": "Correct; classically causes tall, peaked T waves, broad QRS, and sine-wave ECG in severe cases.",
      "Hypocalcaemia": "Usually leads to QT prolongation and tetany, not peaked T waves or broad QRS.",
      "Digoxin toxicity": "May cause arrhythmias and scooped ST segments ('reverse tick'), but not a sine-wave ECG.",
      "Beta-blocker overdose": "Typically causes bradycardia and heart block, not tall T waves or broad QRS in this context.",
      "Hypomagnesaemia": "Can predispose to torsades de pointes and QT prolongation, not this ECG pattern."
    },
    "category": "Renal & Urology",
    "subsection": "Acute Kidney Injury",
    "subsubsection": "Complications",
    "topic": "Monitor electrolytes",
    "keywords": [
      "hyperkalaemia",
      "ECG changes",
      "chronic kidney disease",
      "electrolyte disturbances",
      "renal"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "8f975ef1-c36b-4a35-94f7-0d17dcee1585",
    "question_number": 398,
    "question": "A 28-year-old woman with focal epilepsy managed on phenytoin is seeking long-term contraception. She has a BMI of 41 kg/m² and is otherwise healthy. Which contraceptive method is most appropriate for her, considering her medication and BMI?",
    "options": [
      "Copper intrauterine device",
      "Progesterone-only pill",
      "Combined oral contraceptive pill",
      "Progesterone implant",
      "Progesterone injection (Depo-Provera)"
    ],
    "correct_answer": "Copper intrauterine device",
    "explanation": "**Explanation**\n**Enzyme-inducing antiepileptic drugs** such as phenytoin significantly reduce the effectiveness of most hormonal contraceptives by increasing their hepatic metabolism. The copper intrauterine device (Cu-IUD) is a non-hormonal, highly effective, long-acting reversible contraceptive that is not affected by enzyme-inducing drugs. Additionally, in women with a high BMI, the copper IUD remains effective, whereas the contraceptive injection (Depo-Provera) is associated with weight gain and is generally avoided in those who are already obese. Hormonal methods like the combined pill, progestogen-only pill, and implant are not reliably effective in the presence of enzyme inducers unless additional precautions are taken, making the copper IUD the safest and most effective option in this context.\n\n**Key Points**\n- Enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) reduce the efficacy of most hormonal contraceptives.\n- Copper IUD effectiveness is not affected by hepatic enzyme induction.\n- Depo-Provera is not preferred in women with high BMI due to risk of further weight gain.\n- Hormonal methods (COCP, POP, implant) require additional barrier contraception when used with enzyme inducers.\n- Non-hormonal methods are first-line for women on enzyme-inducing drugs.\n\n**Clinical Relevance**\nWomen on enzyme-inducing medications require careful contraceptive counselling to avoid unintended pregnancy. Guidelines emphasise non-hormonal or unaffected methods, such as the copper IUD, particularly in women with additional risk factors like obesity.",
    "bullet_explanations": {
      "Copper intrauterine device": "Correct: Non-hormonal, effective, and unaffected by enzyme-inducing drugs or BMI.",
      "Progesterone-only pill": "Incorrect: Efficacy is reduced by enzyme-inducing drugs; not reliable alone.",
      "Combined oral contraceptive pill": "Incorrect: Efficacy is reduced by enzyme inducers unless dose is increased and used with barriers.",
      "Progesterone implant": "Incorrect: Efficacy also reduced by enzyme inducers; additional contraception required.",
      "Progesterone injection (Depo-Provera)": "Incorrect: Although not affected by enzyme inducers, it is associated with weight gain, making it unsuitable for women with high BMI."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Contraindications",
    "keywords": [
      "contraception",
      "enzyme-inducing drugs",
      "copper IUD",
      "obesity",
      "anticonvulsants"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "34107ec5-5f31-4a37-85b4-a930360dab86",
    "question_number": 399,
    "question": "A 32-year-old woman presents with secondary amenorrhoea and troubling vasomotor symptoms, including night sweats and hot flushes. She is concerned about her fertility. Which laboratory test is most appropriate to confirm a diagnosis of premature ovarian insufficiency?",
    "options": [
      "Serum follicle-stimulating hormone (FSH) measurement",
      "Serum progesterone measurement",
      "Transvaginal pelvic ultrasound",
      "Serial basal body temperature charting",
      "Serum anti-Müllerian hormone (AMH) level"
    ],
    "correct_answer": "Serum follicle-stimulating hormone (FSH) measurement",
    "explanation": "**Explanation**\nPremature ovarian insufficiency (POI) is defined as the loss of ovarian function before the age of 40, presenting with symptoms such as amenorrhoea and vasomotor disturbances. The most appropriate test to confirm POI is a **raised serum follicle-stimulating hormone (FSH) level**, typically measured on two occasions at least four to six weeks apart. In POI, ovarian oestrogen production is reduced, leading to the removal of negative feedback on the hypothalamic-pituitary axis and resulting in sustained elevation of FSH. Other tests may aid in assessing ovarian reserve or exclude alternative causes, but diagnosis hinges on **persistent FSH elevation in the context of symptoms**.<br><br><b>Contrast:</b> Unlike perimenopause or menopause in women over 45 (where diagnosis is clinical), hormone testing is required in younger women to avoid missing reversible causes of amenorrhoea.\n\n**Key Points**\n- POI is suspected in women under 40 with amenorrhoea and menopausal symptoms.\n- Diagnosis requires demonstration of persistently raised FSH, usually above 30–40 IU/L.\n- FSH should be measured on at least two occasions, 4–6 weeks apart.\n- Routine imaging (ultrasound) or other hormonal tests are not diagnostic for POI.\n- Per NICE CKS, FSH testing is not recommended for typical menopause symptoms in women over 45.\n\n**Clinical Relevance**\nRecognising POI early is vital for addressing fertility concerns, preventing osteoporosis, and managing long-term health. Guidelines emphasise using FSH testing in women under 40 with symptoms, while avoiding unnecessary investigation in older women with classic symptoms. Timely diagnosis enables personalised counselling and management.",
    "bullet_explanations": {
      "Serum follicle-stimulating hormone (FSH) measurement": "Correct; persistent elevation of FSH confirms POI in symptomatic women under 40.",
      "Serum progesterone measurement": "Incorrect; used for confirming ovulation, not for diagnosing ovarian insufficiency.",
      "Transvaginal pelvic ultrasound": "Incorrect; may assess ovarian morphology but does not confirm loss of function.",
      "Serial basal body temperature charting": "Incorrect; no longer recommended for ovulation assessment or POI diagnosis.",
      "Serum anti-Müllerian hormone (AMH) level": "Incorrect; reflects ovarian reserve but is not diagnostic for POI."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Amenorrhoea",
    "keywords": [
      "premature ovarian insufficiency",
      "FSH",
      "amenorrhoea",
      "early menopause"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Menopause",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/menopause/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "6e3cd964-8906-4618-ba71-712e2fa28f47",
    "question_number": 400,
    "question": "Which of the following is NOT considered a core symptom of post-traumatic stress disorder according to recognised diagnostic criteria?",
    "options": [
      "Hypervigilance",
      "Emotional detachment",
      "Night terrors related to the trauma",
      "Impulsive disinhibited behaviour",
      "Avoidance of trauma reminders"
    ],
    "correct_answer": "Impulsive disinhibited behaviour",
    "explanation": "**Explanation**\n**Impulsive disinhibited behaviour** (such as loss of social inhibitions or acting without considering consequences) is not a recognised core feature of post-traumatic stress disorder (PTSD). The hallmark symptoms of PTSD include re-experiencing phenomena (such as intrusive thoughts or nightmares), avoidance of reminders, negative changes in mood or cognition (including emotional numbing), and hyperarousal (for example, hypervigilance or irritability). Disinhibition is more typically associated with other psychiatric conditions, such as mania or certain forms of dementia, rather than PTSD.<br><br>To distinguish, PTSD does not characteristically involve loss of impulse control or overtly uninhibited actions. Instead, affected individuals may become withdrawn, avoidant, or display heightened arousal and vigilance.\n\n**Key Points**\n- PTSD is defined by symptoms clustered into re-experiencing, avoidance, negative alterations in mood/cognition, and hyperarousal.\n- Hypervigilance and avoidance are classic PTSD features.\n- Nightmares or distressing dreams about the trauma are common.\n- Emotional detachment or numbing is a typical negative mood/cognition symptom.\n- Disinhibited or impulsive behaviour is not a diagnostic criterion for PTSD.\n- Disinhibition is more often linked to mania or frontotemporal dementia.\n\n**Clinical Relevance**\nRecognising the core and exclusionary features of PTSD is crucial for accurate diagnosis and appropriate management. Misattribution of symptoms such as disinhibition may lead to missed or incorrect diagnoses, impacting treatment planning. Always refer to established diagnostic frameworks (such as DSM-5 or ICD-11) and guidelines (e.g., NICE CKS) when assessing trauma-related symptoms.",
    "bullet_explanations": {
      "Hypervigilance": "A classic symptom of PTSD involving heightened alertness and excessive startle response.",
      "Emotional detachment": "Represents emotional numbing or negative mood, which is common in PTSD.",
      "Night terrors related to the trauma": "Re-experiencing the trauma through nightmares is a core feature.",
      "Impulsive disinhibited behaviour": "Not typical of PTSD; more common in mania or certain dementias.",
      "Avoidance of trauma reminders": "A hallmark symptom, with patients actively avoiding people, places, or thoughts linked to the traumatic event."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Psychosis & Anxiety",
    "subsubsection": "OCD & PTSD",
    "topic": "Core features",
    "keywords": [
      "PTSD",
      "post-traumatic stress disorder",
      "diagnosis",
      "symptoms",
      "impulsivity"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Post-traumatic stress disorder",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/post-traumatic-stress-disorder/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "ba9c0d3c-4f00-4bea-897d-214f422002e9",
    "question_number": 401,
    "question": "Which diagnosis is most strongly suggested by the presence of a mobile intracavitary mass with an air crescent sign on chest X-ray in a middle-aged man with a history of treated pulmonary tuberculosis, now presenting with mild haemoptysis?",
    "options": [
      "Aspergilloma",
      "Pulmonary sarcoidosis",
      "Bronchiectasis",
      "Reactivation of tuberculosis",
      "Pulmonary histiocytosis"
    ],
    "correct_answer": "Aspergilloma",
    "explanation": "**Explanation**\n**Aspergilloma** forms when fungal hyphae (most commonly Aspergillus fumigatus) colonise a pre-existing pulmonary cavity, often created by prior infections such as tuberculosis. The classic radiological sign is the 'air crescent sign,' which represents a mobile fungal mass within a cavity, with a crescent of air separating the mass from the cavity wall. Mild haemoptysis occurs due to erosion of blood vessels adjacent to the cavity. The patient’s history of TB and use of immunosuppressants (e.g., steroids for Crohn’s disease) further increase the risk. In contrast, bronchiectasis usually presents with chronic productive cough and crackles, and reactivation TB is more likely to show constitutional symptoms and active parenchymal consolidation than a discrete air crescent sign.\n\n**Key Points**\n- Aspergilloma is a fungal ball within a pre-existing lung cavity (often post-TB).\n- The air crescent sign on imaging is highly characteristic.\n- Risk factors: previous TB, chronic lung disease, immunosuppression.\n- Haemoptysis (sometimes massive) is a classic symptom.\n- Other options (e.g., bronchiectasis, sarcoidosis) do not typically produce an air crescent sign.\n- <table><thead><tr><th>Condition</th><th>Radiology</th><th>Key Feature</th></tr></thead><tbody><tr><td>Aspergilloma</td><td>Air crescent in cavity</td><td>Mobile fungal ball</td></tr><tr><td>Bronchiectasis</td><td>Tram-track opacities</td><td>Chronic productive cough</td></tr><tr><td>Reactivation TB</td><td>Upper lobe infiltrates</td><td>Constitutional symptoms</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising aspergilloma is crucial because haemoptysis can be life-threatening and may require surgical intervention or embolisation. The air crescent sign is a classic radiological clue, especially in patients with a history of TB or other causes of lung cavities.\n\n**Memory Anchor**\nRemember: 'Air crescent' means 'aspergilloma' in a TB cavity.",
    "bullet_explanations": {
      "Aspergilloma": "Correct – Fungal ball in a preformed cavity, producing the air crescent sign and often haemoptysis.",
      "Pulmonary sarcoidosis": "Incorrect – Can cause upper lobe disease but rarely forms cavities with air crescents.",
      "Bronchiectasis": "Incorrect – Associated with chronic productive cough and bronchial wall thickening, not air crescent sign.",
      "Reactivation of tuberculosis": "Incorrect – More likely to cause new infiltrates or cavitation, but not a mobile mass with an air crescent.",
      "Pulmonary histiocytosis": "Incorrect – Rare in adults and not associated with air crescent or fungal ball formation."
    },
    "category": "Respiratory",
    "subsection": "Infective",
    "subsubsection": "Bronchiectasis",
    "topic": "Chronic colonisation and exacerbations",
    "keywords": [
      "aspergilloma",
      "air crescent sign",
      "pulmonary cavity",
      "tuberculosis",
      "haemoptysis"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "2957fce9-7c4a-4e67-a8c6-c62a912a7452",
    "question_number": 402,
    "question": "A 32-year-old woman presents to her GP with worsening pelvic pain and deep dyspareunia. She has a presumptive diagnosis of endometriosis based on clinical assessment. She has already tried regular NSAIDs and paracetamol with minimal relief. She is not currently seeking pregnancy. What is the most appropriate next step in her management, assuming no contraindications?",
    "options": [
      "Start a combined oral contraceptive pill",
      "Insert a copper intrauterine device",
      "Refer for laparoscopic excision of endometriotic lesions",
      "Begin GnRH analogue therapy",
      "Initiate high-dose progestogen-only injection"
    ],
    "correct_answer": "Start a combined oral contraceptive pill",
    "explanation": "**Explanation**\n**First-line hormonal management for endometriosis-related pain involves offering a combined oral contraceptive pill (COCP) or a progestogen.** COCPs suppress ovulation and reduce oestrogen-driven endometrial activity, thereby alleviating symptoms such as pelvic pain and dysmenorrhoea. This option is preferred once simple analgesics have failed and is suitable for women not planning conception. Other interventions, such as GnRH analogues or surgery, are reserved for refractory cases or when medical therapy is contraindicated or not tolerated. The copper coil is contraindicated as it may worsen symptoms. Progestogen-only injections are considered second-line. Early specialist referral is indicated if pain is severe or resistant to initial management (BNF, NICE CKS).\n\n**Key Points**\n- COCPs are recommended as first-line hormonal treatment after analgesics for endometriosis-related pain.\n- Hormonal therapies work by suppressing ovarian function and are generally contraceptive.\n- The copper IUD can exacerbate dysmenorrhoea and is not advised.\n- GnRH analogues and surgical options are reserved for second-line or refractory cases.\n- Management is tailored based on fertility intentions and symptom severity.\n\n**Clinical Relevance**\nAccurate selection of first-line therapy for endometriosis improves quality of life and minimises unnecessary escalation to invasive treatments. This approach is supported by national guidelines (BNF, NICE CKS), and failure to follow it may result in prolonged morbidity or inappropriate interventions.",
    "bullet_explanations": {
      "Start a combined oral contraceptive pill": "Correct – First-line hormonal therapy for women with endometriosis not seeking pregnancy and with persistent pain.",
      "Insert a copper intrauterine device": "Incorrect – May worsen endometriosis-related pain and bleeding.",
      "Refer for laparoscopic excision of endometriotic lesions": "Incorrect – Surgery is reserved for cases refractory to medical management or where fertility is a priority.",
      "Begin GnRH analogue therapy": "Incorrect – GnRH analogues are second-line due to side effects and are used if initial hormonal therapy fails.",
      "Initiate high-dose progestogen-only injection": "Incorrect – Progestogen-only methods are considered if COCP is contraindicated or not tolerated."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Menstrual Disorders",
    "topic": "Dysmenorrhoea",
    "keywords": [
      "endometriosis",
      "first-line management",
      "COCP",
      "pelvic pain",
      "dysmenorrhoea"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Endometriosis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/endometriosis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Endometriosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/endometriosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "553b81e4-4665-490b-b428-eebb8ab6c6f4",
    "question_number": 403,
    "question": "A 62-year-old woman with a history of poorly controlled hypertension arrives at a district hospital with abrupt-onset tearing chest pain radiating to her back. On examination, she is haemodynamically stable but there is a 25 mmHg systolic blood pressure difference between her arms and reduced pulses in the left femoral artery. Which investigation should be performed first to confirm the diagnosis?",
    "options": [
      "CT angiography of the aorta",
      "Transoesophageal echocardiography (TOE)",
      "Chest x-ray",
      "Transthoracic echocardiography (TTE)",
      "Serum D-dimer test"
    ],
    "correct_answer": "CT angiography of the aorta",
    "explanation": "**Explanation**\n**CT angiography (CTA) is the first-line diagnostic tool in stable patients with suspected aortic dissection.** It provides rapid, high-resolution images of the entire aorta, clearly demonstrating any intimal flap, true and false lumens, and the extent of dissection. This information is critical for both diagnosis and surgical planning. In stable patients, CTA is preferred over other imaging modalities due to its speed, accuracy, and widespread availability. In contrast, TOE is reserved for unstable patients or when CTA is contraindicated or unavailable. Chest x-ray and TTE lack the sensitivity and specificity required for confident diagnosis, and D-dimer has a limited role in ruling out but not confirming dissection.\n\n**Key Points**\n- Acute aortic dissection often presents with chest/back pain and pulse or BP asymmetry.\n- CT angiography is the gold standard for diagnosis in stable patients.\n- TOE is an alternative for unstable patients who cannot be moved safely to CT.\n- Chest x-ray may show mediastinal widening but is non-specific.\n- D-dimer can be low in sensitivity and cannot confirm diagnosis.\n- <table><thead><tr><th>Investigation</th><th>Role in Aortic Dissection</th></tr></thead><tbody><tr><td>CT Angiography</td><td>First-line in stable patients</td></tr><tr><td>TOE</td><td>Unstable patients or equivocal CT</td></tr><tr><td>Chest x-ray</td><td>Initial screening, not definitive</td></tr><tr><td>TTE</td><td>Limited sensitivity</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt diagnosis of aortic dissection is vital due to its high mortality. NICE and international guidelines recommend CT angiography as first-line imaging for stable patients, ensuring timely management and surgical planning.\n\n**Memory Anchor**\nRemember: **\"CT for Chest Tearing pain\"** (CT = CT angiography for classic dissection chest pain).",
    "bullet_explanations": {
      "CT angiography of the aorta": "Correct – Provides rapid, definitive diagnosis in stable patients.",
      "Transoesophageal echocardiography (TOE)": "Incorrect – Used if patient is unstable or CT is not feasible.",
      "Chest x-ray": "Incorrect – May indicate mediastinal widening but is not diagnostic.",
      "Transthoracic echocardiography (TTE)": "Incorrect – Poor sensitivity for detecting dissection, especially in the distal aorta.",
      "Serum D-dimer test": "Incorrect – May be used to rule out, but cannot confirm, aortic dissection."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Aortic Disease",
    "subsubsection": "Aortic dissection recognition (Type A vs B)",
    "topic": "Aortic dissection recognition (Type A vs B)",
    "keywords": [
      "aortic dissection",
      "CT angiography",
      "chest pain",
      "diagnostic imaging",
      "hypertension"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "e5f398c3-f237-47b9-be4f-8e2dac832299",
    "question_number": 404,
    "question": "A term male infant, delivered via elective Caesarean section due to breech presentation, develops rapid breathing within the first hour of life. He is pink, alert, and feeding normally. His temperature, heart rate, and oxygen saturations are within normal limits. What is the most likely underlying cause of his tachypnoea?",
    "options": [
      "Transient tachypnoea of the newborn",
      "Congenital diaphragmatic hernia",
      "Neonatal sepsis",
      "Meconium aspiration syndrome",
      "Respiratory distress syndrome"
    ],
    "correct_answer": "Transient tachypnoea of the newborn",
    "explanation": "**Explanation**\n**Transient tachypnoea of the newborn (TTN)** most commonly affects term infants delivered by Caesarean section without labour. This condition results from a delay in the resorption of fetal lung fluid, leading to temporary, mild respiratory distress shortly after birth. The typical presentation includes tachypnoea within the first hours of life, but the infant otherwise remains well—pink, with normal oxygen saturations, and no significant work of breathing. Symptoms usually resolve spontaneously within 24–48 hours. In contrast, conditions such as respiratory distress syndrome are more typical in preterm infants and present with worsening respiratory distress, while congenital anomalies (e.g., diaphragmatic hernia) or infectious causes (e.g., sepsis) would be expected to cause more severe or persistent symptoms, often with additional clinical findings.\n\n**Key Points**\n<ul><li>TTN is the most common cause of early tachypnoea in term infants, especially after Caesarean section.</li><li>Caused by delayed clearance of fetal lung fluid.</li><li>Clinical course is self-limiting, resolving within 1–2 days.</li><li>Infants are otherwise well: normal colour, feeding, and vital signs.</li><li>Distinguish from RDS, which is primarily seen in preterm infants and associated with surfactant deficiency.</li></ul><table><thead><tr><th>Condition</th><th>Key Features</th></tr></thead><tbody><tr><td>TTN</td><td>Term, C-section, mild, resolves quickly</td></tr><tr><td>RDS</td><td>Preterm, worsening distress, needs support</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising TTN is essential to avoid unnecessary interventions in otherwise healthy term infants with mild, self-limiting respiratory distress. Differentiating between TTN and more serious causes ensures appropriate monitoring and management. Familiarity with perinatal risk factors, such as Caesarean delivery, supports confident diagnosis.\n\n**Memory Anchor**\nThink: 'TTN = Term, Tachypnoea, Normally well.'",
    "bullet_explanations": {
      "Transient tachypnoea of the newborn": "Correct – classic presentation in a term baby post-C-section with isolated tachypnoea and otherwise normal observations.",
      "Congenital diaphragmatic hernia": "Incorrect – would cause significant respiratory compromise and often scaphoid abdomen or cyanosis.",
      "Neonatal sepsis": "Incorrect – usually presents with temperature instability, poor feeding, and may cause more profound illness.",
      "Meconium aspiration syndrome": "Incorrect – more common in post-term infants and presents with respiratory distress and often meconium-stained amniotic fluid.",
      "Respiratory distress syndrome": "Incorrect – typically affects preterm infants due to surfactant deficiency, with progressive and severe respiratory distress."
    },
    "category": "Paediatrics",
    "subsection": "Neonatology",
    "subsubsection": "Respiratory distress syndrome",
    "topic": "Respiratory distress syndrome",
    "keywords": [
      "TTN",
      "neonatal tachypnoea",
      "caesarean section",
      "respiratory distress",
      "newborn"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "5b6f3458-80ad-443d-90d7-3590aeddc09c",
    "question_number": 405,
    "question": "A 61-year-old man complains of brief episodes of vertigo triggered by tilting his head upwards to reach high shelves at work. He denies hearing loss, tinnitus, or headaches. Examination of his ears and neurological system is normal. What is the most effective initial treatment for his likely diagnosis?",
    "options": [
      "Perform the Epley manoeuvre",
      "Prescribe betahistine",
      "Order urgent CT of the head",
      "Advise visual assessment by an optometrist",
      "Start a short course of prochlorperazine"
    ],
    "correct_answer": "Perform the Epley manoeuvre",
    "explanation": "**Explanation**\n**Benign paroxysmal positional vertigo (BPPV)** is the most common cause of vertigo associated with specific head movements, such as looking up or rolling in bed. It arises from displaced otoconia within the semicircular canals, which disrupt normal vestibular signalling. The **Epley manoeuvre** is a series of controlled head and body movements that repositions these crystals, providing rapid and often complete symptom resolution. Unlike pharmacological options, the Epley manoeuvre directly targets the underlying cause rather than just alleviating symptoms.\n\n**Key Points**\n- BPPV presents with brief vertigo provoked by changes in head position.\n- Diagnosis is clinical and confirmed by history plus Dix-Hallpike manoeuvre.\n- Imaging is unnecessary unless atypical or neurological symptoms are present.\n- The Epley manoeuvre is the recommended first-line therapy (NICE CKS).\n- Drug treatments offer only transient symptom relief and do not address the root cause.\n- Referral is considered if symptoms persist after repeated manoeuvres or if diagnosis is uncertain.\n\n**Clinical Relevance**\nRecognising and treating BPPV promptly with the Epley manoeuvre is safe, evidence-based, and improves patients’ quality of life. Unnecessary imaging or pharmacological treatment should be avoided unless atypical features are present. This approach aligns with NICE guidance for primary care management.\n\n**Memory Anchor**\nEpley for Ear: Epley manoeuvre is first-line for Ear (vestibular) BPPV.",
    "bullet_explanations": {
      "Perform the Epley manoeuvre": "Correct – This is the recommended initial management for BPPV, directly addressing the underlying mechanism.",
      "Prescribe betahistine": "Incorrect – Betahistine is not effective for BPPV and is not recommended by guidelines for this indication.",
      "Order urgent CT of the head": "Incorrect – Imaging is reserved for atypical, persistent, or neurologically complicated vertigo, not classic BPPV.",
      "Advise visual assessment by an optometrist": "Incorrect – Vertigo in BPPV is vestibular in origin, not related to visual or ocular disorders.",
      "Start a short course of prochlorperazine": "Incorrect – This may reduce symptoms briefly but does not resolve the underlying cause; not first-line."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Vertigo (BPPV, vestibular neuritis, Meniere’s)",
    "keywords": [
      "BPPV",
      "Epley manoeuvre",
      "positional vertigo",
      "ENT",
      "dizziness"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Benign paroxysmal positional vertigo",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/benign-paroxysmal-positional-vertigo/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Vertigo",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/vertigo/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "00df1c47-560b-4eb2-93c0-5ec63b0f1e4d",
    "question_number": 406,
    "question": "Which of the following is an early clinical sign suggestive of acute salicylate (aspirin) poisoning?",
    "options": [
      "Tinnitus",
      "Pinpoint pupils",
      "Severe bradycardia",
      "Generalised pruritus",
      "Visual hallucinations"
    ],
    "correct_answer": "Tinnitus",
    "explanation": "**Explanation**\n**Tinnitus (ringing in the ears)** is one of the earliest and most characteristic symptoms of acute salicylate toxicity. Salicylates, such as aspirin, can also cause muffled hearing and deafness in overdose, alongside symptoms like hyperventilation, sweating, and vasodilatation. This auditory disturbance occurs before more severe complications like acid-base disturbances or altered mental status. In contrast, opioid toxicity is typically associated with pinpoint pupils and respiratory depression, and other options listed are not typical features of salicylate overdose.\n\n**Key Points**\n- Tinnitus is a hallmark early symptom of salicylate (aspirin) overdose.\n- Other early features include hyperventilation, sweating, and hearing loss.\n- Acid-base disturbance (initial respiratory alkalosis, later metabolic acidosis) develops as toxicity progresses.\n- Pinpoint pupils are a classic sign of opioid toxicity, not salicylate poisoning.\n- Urgent hospital assessment and monitoring of salicylate levels, blood gases, and electrolytes are required.\n\n**Clinical Relevance**\nRecognising early signs of salicylate poisoning, such as tinnitus, is essential for prompt diagnosis and management, as delayed treatment increases the risk of serious metabolic complications. UK guidelines recommend hospital-based care for monitoring and interventions, including consideration of activated charcoal and urinary alkalinisation in specific cases.\n\n**Memory Anchor**\nSalicylate toxicity: 'S' for Sound (tinnitus) and Sweating.",
    "bullet_explanations": {
      "Tinnitus": "Correct – Tinnitus is a classic early sign of salicylate toxicity.",
      "Pinpoint pupils": "Incorrect – Pinpoint pupils suggest opioid toxicity, not salicylate overdose.",
      "Severe bradycardia": "Incorrect – Aspirin overdose does not typically cause bradycardia.",
      "Generalised pruritus": "Incorrect – Pruritus is not a recognised feature of salicylate poisoning.",
      "Visual hallucinations": "Incorrect – Visual disturbances are not a common early sign of aspirin toxicity."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "General Principles",
    "subsubsection": "Prescribing Safety",
    "topic": "High-risk drugs (warfarin, insulin, opioids)",
    "keywords": [
      "salicylate toxicity",
      "aspirin overdose",
      "tinnitus"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Poisoning, emergency treatment",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/poisoning-emergency-treatment/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "9dd72f76-d0d8-4102-a0f7-75aef2a9b0f1",
    "question_number": 407,
    "question": "A 27-year-old woman presents with a two-week history of painful knees and ankles, dysuria, and a scaly, yellowish rash on her palms and soles. She reports having had a gastrointestinal infection three weeks earlier. What is the most likely diagnosis for her skin findings?",
    "options": [
      "Keratoderma blennorrhagica",
      "Dyshidrotic eczema",
      "Verruca vulgaris",
      "Plantar pustular psoriasis",
      "HIV-associated dermatosis"
    ],
    "correct_answer": "Keratoderma blennorrhagica",
    "explanation": "**Explanation**\n**Keratoderma blennorrhagica** is a distinctive skin manifestation classically associated with reactive arthritis. It presents as well-demarcated, hyperkeratotic, and sometimes pustular lesions on the palms and soles. The patient's preceding gastrointestinal infection, combined with joint pain, dysuria, and the characteristic rash, strongly indicates reactive arthritis. This syndrome often follows infections with certain gastrointestinal or genitourinary pathogens and is notable for its triad of arthritis, urethritis, and mucocutaneous lesions. The rash is pathognomonic when present and helps distinguish reactive arthritis from other dermatological conditions affecting the palms or soles. In contrast, dyshidrotic eczema (pompholyx) involves vesicular eruptions without systemic features, and plantar pustular psoriasis typically presents with symmetrical pustules but lacks the systemic syndrome seen here.\n\n**Key Points**\n- Keratoderma blennorrhagica is a hyperkeratotic rash seen in reactive arthritis.\n- Reactive arthritis typically follows a GI or GU infection and presents with arthritis, urethritis, and characteristic skin lesions.\n- The rash mainly affects the palms and soles and may be pustular or scaly.\n- Differentiation from other palmoplantar eruptions is based on systemic features and recent infection.\n- Other options (eczema, psoriasis, viral warts, HIV-related skin changes) do not fit the full clinical picture.\n\n**Clinical Relevance**\nRecognising keratoderma blennorrhagica is important as it supports the diagnosis of reactive arthritis, prompting appropriate investigation, management, and consideration of underlying infection. Timely recognition prevents complications and guides multidisciplinary care.\n\n**Memory Anchor**\nRemember: Reactive arthritis = 'can't see, can't pee, can't climb a tree' (conjunctivitis, urethritis, arthritis); skin: keratoderma blennorrhagica.",
    "bullet_explanations": {
      "Keratoderma blennorrhagica": "Correct – classic skin sign of reactive arthritis; associated with arthritis, urethritis, and preceding infection.",
      "Dyshidrotic eczema": "Incorrect – presents as small vesicles, primarily on the sides of fingers and soles, without systemic symptoms.",
      "Verruca vulgaris": "Incorrect – manifests as isolated, firm, rough papules caused by HPV, lacking joint or urinary involvement.",
      "Plantar pustular psoriasis": "Incorrect – features pustular lesions on the soles, often bilateral, but not linked to preceding infection or systemic symptoms.",
      "HIV-associated dermatosis": "Incorrect – skin manifestations are varied and not typically restricted to palms/soles, nor linked to this syndrome."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Eczema/atopic dermatitis",
    "keywords": [
      "keratoderma blennorrhagica",
      "reactive arthritis",
      "palmoplantar rash"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "21bead7a-9c68-4dc3-a47b-38e31fdb2a11",
    "question_number": 408,
    "question": "A 48-year-old woman collapses suddenly while walking through the hospital corridor. She is found unresponsive, with no palpable pulse, and the cardiac monitor displays a broad complex, regular tachycardia at 190 bpm. Cardiopulmonary resuscitation is in progress. What is the single most important initial action to take?",
    "options": [
      "Deliver an immediate unsynchronised DC shock",
      "Administer 1 mg intravenous adrenaline",
      "Give 300 mg intravenous amiodarone",
      "Continue CPR alone for 2 minutes before any intervention",
      "Deliver a synchronised DC shock"
    ],
    "correct_answer": "Deliver an immediate unsynchronised DC shock",
    "explanation": "**Explanation**\n**Pulseless ventricular tachycardia (pVT) is a shockable rhythm, requiring urgent defibrillation.** The patient described is unresponsive, pulseless, and presenting with a broad complex, regular tachycardia, which is classic for pVT. In accordance with current advanced life support guidance, the priority is to deliver an immediate unsynchronised DC shock, as this maximises the chance of restoring a perfusing rhythm. Synchronisation is not required in cardiac arrest because there is no organised cardiac activity to synchronise with. Drugs such as adrenaline and amiodarone are important but are given later in the resuscitation sequence if initial shocks are unsuccessful. Continuing CPR alone without prompt defibrillation would delay essential treatment. Timely defibrillation is the single most effective intervention for survival in shockable cardiac arrests.\n\n**Key Points:**\n- pVT and VF are both shockable rhythms; immediate defibrillation is critical\n- The first shock should be unsynchronised in cardiac arrest situations\n- Adrenaline is administered after the third shock in shockable rhythms (VF/pVT)\n- Amiodarone is reserved for shock-refractory VF/pVT (after the third shock)\n- Synchronised cardioversion is used for unstable but conscious patients with a pulse\n- CPR should be paused only briefly to deliver shocks, then resumed immediately\n\n<table><thead><tr><th>Rhythm</th><th>First Action</th></tr></thead><tbody><tr><td>VF/pVT</td><td>Immediate unsynchronised shock</td></tr><tr><td>PEA/Asystole</td><td>CPR + adrenaline</td></tr></tbody></table>\n\n**Clinical Relevance:**\nEarly defibrillation is a cornerstone of cardiac arrest management in shockable rhythms, directly impacting survival rates. Resuscitation guidelines (NICE CKS, Resuscitation Council UK) emphasise not delaying defibrillation for drug administration or prolonged CPR when a shockable rhythm is identified.\n\n**Memory Anchor:**\n\"Shock first for shockable rhythms\"—VF and pulseless VT always get immediate defibrillation.\n\n**Key Points**\n- Immediate defibrillation is lifesaving for VF/pVT\n- Do not delay shock for drug administration\n- Synchronised shocks are for unstable tachycardia with a pulse\n- Adrenaline and amiodarone come after initial shocks if needed\n- CPR is paused only to deliver a shock, then restarted promptly\n\n**Clinical Relevance**\nRecognising pulseless VT as a shockable rhythm and acting without delay is essential for improving cardiac arrest outcomes. Adhering to established resuscitation protocols minimises preventable morbidity and mortality.\n\n**Memory Anchor**\n\"Shock first for shockable rhythms\"—VF and pulseless VT always get immediate defibrillation.",
    "bullet_explanations": {
      "Deliver an immediate unsynchronised DC shock": "Correct; this is the definitive first-line intervention for pulseless VT or VF.",
      "Administer 1 mg intravenous adrenaline": "Incorrect; adrenaline is given after the third shock for shockable rhythms, not as the initial step.",
      "Give 300 mg intravenous amiodarone": "Incorrect; amiodarone is indicated only after persistent VF/pVT following the third shock.",
      "Continue CPR alone for 2 minutes before any intervention": "Incorrect; delaying defibrillation reduces survival chances in shockable cardiac arrest.",
      "Deliver a synchronised DC shock": "Incorrect; synchronised shocks are used for unstable tachycardias with a pulse, not for cardiac arrest."
    },
    "category": "Cardiovascular",
    "subsection": "Arrhythmias & Conduction",
    "subsubsection": "Ventricular Arrhythmias",
    "topic": "ACLS tachycardia algorithm basics",
    "keywords": [
      "pulseless VT",
      "defibrillation",
      "cardiac arrest",
      "shockable rhythm",
      "ALS algorithm"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Cardiac arrest - out of hospital care",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/cardiac-arrest-out-of-hospital-care/"
      },
      {
        "source": "BNF",
        "topic_title": "Arrhythmias",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/arrhythmias/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "df236447-c45a-4344-afc3-eb848068c682",
    "question_number": 409,
    "question": "A 45-year-old woman with chronic schizophrenia has been stable on clozapine for 18 months. She currently smokes heavily but plans to stop due to a recent health scare. What is the expected pharmacokinetic effect on her clozapine therapy after she quits smoking?",
    "options": [
      "Increase in clozapine plasma concentration",
      "No significant change in clozapine levels",
      "Reduced incidence of clozapine-induced agranulocytosis",
      "Decrease in clozapine plasma concentration",
      "Lower risk of clozapine-related constipation"
    ],
    "correct_answer": "Increase in clozapine plasma concentration",
    "explanation": "**Explanation**\nTobacco smoke contains polycyclic aromatic hydrocarbons that induce the enzyme **CYP1A2**, which is crucial for the metabolism of clozapine. When a patient stops smoking, the induction of CYP1A2 decreases, leading to **slower metabolism of clozapine**. As a result, plasma concentrations of clozapine **rise**, increasing the risk of adverse effects such as sedation, seizures, or hypotension. **This pharmacokinetic interaction is not related to nicotine, but to compounds in tobacco smoke**. Dose adjustment and close monitoring are advised when a patient on clozapine stops smoking, to avoid toxicity. This contrasts with the situation where starting smoking would lower clozapine levels.\n\n**Key Points**\n- Clozapine is metabolised mainly by CYP1A2.\n- Smoking induces CYP1A2, increasing clozapine metabolism and lowering its levels.\n- Smoking cessation removes this induction, causing clozapine plasma levels to rise.\n- Monitor for clozapine toxicity (e.g. sedation, seizures) when patients stop smoking.\n- Agranylocytosis risk is unrelated to smoking status.\n- Constipation risk is dose-dependent and not significantly altered by smoking behaviour.\n\n**Clinical Relevance**\nUnderstanding this interaction is vital in psychiatric and primary care settings, as abrupt smoking cessation in patients on clozapine can lead to rapid toxicity if doses are not adjusted. UK guidelines recommend increased vigilance and proactive dose review following smoking cessation in these patients.\n\n**Memory Anchor**\nRemember: 'Smoke out the enzyme, levels shoot up!'—stopping smoking removes enzyme induction, increasing drug levels.",
    "bullet_explanations": {
      "Increase in clozapine plasma concentration": "Correct – Smoking cessation reduces CYP1A2 induction, so clozapine metabolism slows and levels rise.",
      "No significant change in clozapine levels": "Incorrect – There is a well-documented rise in clozapine levels after stopping smoking.",
      "Reduced incidence of clozapine-induced agranulocytosis": "Incorrect – Agranulocytosis risk is not influenced by smoking status.",
      "Decrease in clozapine plasma concentration": "Incorrect – This would occur if the patient started smoking, not when they stop.",
      "Lower risk of clozapine-related constipation": "Incorrect – Constipation risk is dose-dependent and not directly related to smoking."
    },
    "category": "Psychiatry & Neurology",
    "subsection": "Psychosis & Anxiety",
    "subsubsection": "Schizophrenia",
    "topic": "Clozapine monitoring",
    "keywords": [
      "clozapine",
      "smoking cessation",
      "CYP1A2",
      "drug interactions",
      "schizophrenia"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "09ac31c3-9cc1-431f-ac2f-85ba81d82498",
    "question_number": 410,
    "question": "Which of the following medications is classified as an antimuscarinic agent commonly used to treat overactive bladder symptoms such as urgency and urge incontinence?",
    "options": [
      "Tolterodine",
      "Finasteride",
      "Desmopressin",
      "Duloxetine",
      "Tamsulosin"
    ],
    "correct_answer": "Tolterodine",
    "explanation": "**Explanation**\n**Tolterodine** is a muscarinic (anticholinergic) antagonist that reduces bladder overactivity by blocking acetylcholine-mediated contractions of the detrusor muscle. This leads to decreased urinary urgency and frequency. Other antimuscarinics used for similar indications include oxybutynin, solifenacin, and darifenacin. These medications are first-line pharmacological choices when conservative management, such as bladder training, is unsuccessful. It is important to distinguish these agents from other drug classes used in urological conditions, which have different mechanisms of action and indications.\n\n**Key Points**\n<ul><li>Antimuscarinics (e.g., tolterodine, oxybutynin) are first-line for urgency/overactive bladder.</li><li>They work by antagonising muscarinic receptors in bladder smooth muscle.</li><li>Key side-effects include dry mouth, constipation, and possible cognitive effects, especially in older adults.</li><li>Alternative options for those intolerant to antimuscarinics include beta-3 agonists such as mirabegron.</li><li>Other drugs for LUTS (lower urinary tract symptoms) include alpha blockers and 5-alpha reductase inhibitors, but these are not antimuscarinics.</li></ul><table><thead><tr><th>Drug</th><th>Class</th><th>Indication</th></tr></thead><tbody><tr><td>Tolterodine</td><td>Antimuscarinic</td><td>Urge incontinence</td></tr><tr><td>Finasteride</td><td>5-alpha reductase inhibitor</td><td>BPH</td></tr><tr><td>Desmopressin</td><td>ADH analogue</td><td>Nocturnal enuresis</td></tr><tr><td>Duloxetine</td><td>SNRI</td><td>Stress incontinence (2nd line)</td></tr><tr><td>Tamsulosin</td><td>Alpha blocker</td><td>BPH</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the appropriate pharmacological treatment for different types of urinary incontinence is crucial in general practice and specialist settings. Antimuscarinic drugs like tolterodine are recommended in guidelines when bladder retraining fails, and knowing their indications and side effects supports safe prescribing.\n\n**Memory Anchor**\nTolterodine and Oxybutynin—remember the 'O' for 'Overactive bladder': Both are first-line antimuscarinics for urgency symptoms.",
    "bullet_explanations": {
      "Tolterodine": "Correct – it is a muscarinic antagonist specifically licensed for urge incontinence and overactive bladder.",
      "Finasteride": "Incorrect – this is a 5-alpha reductase inhibitor used for benign prostatic hyperplasia, not for urge incontinence.",
      "Desmopressin": "Incorrect – a synthetic antidiuretic hormone analogue used for nocturnal enuresis and diabetes insipidus.",
      "Duloxetine": "Incorrect – a serotonin-noradrenaline reuptake inhibitor sometimes used for stress incontinence, not urgency.",
      "Tamsulosin": "Incorrect – an alpha-1 adrenergic blocker used to treat voiding symptoms in BPH, not an antimuscarinic."
    },
    "category": "Renal & Urology",
    "subsection": "Urology",
    "subsubsection": "Infections",
    "topic": "Cystitis",
    "keywords": [
      "antimuscarinic",
      "urge incontinence",
      "tolterodine",
      "urinary incontinence",
      "pharmacology"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Urinary incontinence and pelvic organ prolapse in women",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/urinary-incontinence-and-pelvic-organ-prolapse-in-women/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Incontinence - urinary, in women",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/incontinence-urinary-in-women/"
      },
      {
        "source": "BNF",
        "topic_title": "Urinary frequency, enuresis and incontinence",
        "citation": "© NICE BNFC, 2025",
        "url": "https://bnfc.nice.org.uk/treatment-summaries/urinary-frequency-enuresis-and-incontinence/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "099a3eef-5491-4c32-863d-90ac99aa1bae",
    "question_number": 411,
    "question": "A 48-year-old woman presents with persistent, painless white plaques on the buccal mucosa that have not resolved over 18 months. She is a non-insulin-dependent diabetic with a 25-pack-year smoking history. Biopsies have excluded oral lichen planus, candidiasis, and squamous cell carcinoma. What is the most accurate statement regarding this patient's likely diagnosis?",
    "options": [
      "It is a diagnosis of exclusion after other causes of white oral lesions have been ruled out.",
      "First-line management is topical corticosteroids.",
      "Routine multivitamin supplementation is recommended for all patients.",
      "Malignant transformation is exceptionally rare, occurring in fewer than 1 in 10,000 cases.",
      "It most commonly affects individuals with type 1 diabetes."
    ],
    "correct_answer": "It is a diagnosis of exclusion after other causes of white oral lesions have been ruled out.",
    "explanation": "**Explanation**\n**Leukoplakia** is defined as a persistent white patch in the oral cavity that cannot be scraped off and does not have another identifiable cause. **Diagnosis relies on exclusion**—biopsies are performed to rule out other potential causes, such as lichen planus, oral candidiasis, and malignancy. Leukoplakia is particularly important due to its potential for malignant transformation. There is no specific laboratory or histological marker for leukoplakia itself; hence, it remains a diagnosis of exclusion. Management focuses on risk factor modification (e.g., smoking cessation) and regular monitoring for dysplastic changes.<br><br>**Key contrasts:** Topical corticosteroids are not first-line treatment for leukoplakia (unlike for aphthous ulcers or lichen planus), and there is no universal indication for multivitamin supplementation in these patients.\n\n**Key Points**\n- Leukoplakia: persistent white oral patch with no other identifiable cause.\n- Diagnosis is made only after excluding other causes via biopsy.\n- Main risk factors: smoking, alcohol use, chronic irritation.\n- Carries a risk of malignant transformation (estimated 1–20%).\n- Management emphasises risk factor reduction and surveillance, not topical steroids.\n- No routine role for multivitamins unless a deficiency is found.\n\n**Clinical Relevance**\nRecognising leukoplakia as a diagnosis of exclusion is vital in primary care and dental practice, as persistent unexplained oral lesions should prompt referral for biopsy to rule out malignancy. Early identification can impact patient outcomes due to the associated risk of transformation to oral cancer.",
    "bullet_explanations": {
      "It is a diagnosis of exclusion after other causes of white oral lesions have been ruled out.": "Correct—leukoplakia is diagnosed only after excluding alternative causes like lichen planus or carcinoma.",
      "First-line management is topical corticosteroids.": "Incorrect—topical corticosteroids are indicated for conditions like aphthous ulcers or lichen planus, not leukoplakia.",
      "Routine multivitamin supplementation is recommended for all patients.": "Incorrect—there is no evidence or guideline supporting routine multivitamin use in leukoplakia without a proven deficiency.",
      "Malignant transformation is exceptionally rare, occurring in fewer than 1 in 10,000 cases.": "Incorrect—malignant transformation risk is significantly higher (1–20%), so surveillance is needed.",
      "It most commonly affects individuals with type 1 diabetes.": "Incorrect—while diabetes can be a risk factor, leukoplakia most commonly affects smokers and those with chronic oral irritation."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Throat",
    "topic": "Pharyngitis causes",
    "keywords": [
      "leukoplakia",
      "oral white patch",
      "diagnosis of exclusion",
      "oral cancer risk"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Oral ulceration and inflammation",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/oral-ulceration-and-inflammation/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "492be436-5a68-42ae-b418-3a7f4f244a3a",
    "question_number": 412,
    "question": "What is the minimum HbA1c value (in mmol/mol) required to make a diagnosis of type 2 diabetes mellitus in adults according to UK guidelines?",
    "options": [
      "Cannot use HbA1c for diagnosis",
      "42 mmol/mol",
      "45 mmol/mol",
      "48 mmol/mol",
      "53 mmol/mol"
    ],
    "correct_answer": "48 mmol/mol",
    "explanation": "**Explanation**\n**An HbA1c value of 48 mmol/mol (6.5%) or higher is the minimum threshold for diagnosing type 2 diabetes mellitus in adults as per UK NICE guidelines.** The HbA1c test reflects average plasma glucose over the previous 2–3 months and is now the standard diagnostic tool for type 2 diabetes (except in certain clinical contexts where it is unreliable, such as in haemoglobinopathies or pregnancy). Values between 42–47 mmol/mol indicate a high diabetes risk (pre-diabetes), but do not meet diagnostic criteria. Values above 48 mmol/mol meet the diagnostic threshold, while higher numbers (e.g. 53 mmol/mol) confirm the diagnosis but are not the minimum required.\n\n**Key Points**\n- Type 2 diabetes can be diagnosed with HbA1c ≥48 mmol/mol (6.5%) in adults.\n- HbA1c measures chronic glycaemia, providing a 2–3 month average.\n- 42–47 mmol/mol = increased risk but NOT diagnostic.\n- HbA1c is not suitable for diagnosis in pregnancy or certain haemoglobinopathies.\n- Diagnosis should be confirmed with repeat testing if asymptomatic.\n- <table><thead><tr><th>HbA1c (mmol/mol)</th><th>Interpretation</th></tr></thead><tbody><tr><td>&lt;42</td><td>Normal</td></tr><tr><td>42–47</td><td>High risk (pre-diabetes)</td></tr><tr><td>≥48</td><td>Diabetes mellitus</td></tr></tbody></table>\n\n**Clinical Relevance**\nAccurate diagnosis of type 2 diabetes using the correct HbA1c threshold is essential for early intervention and complication prevention. UK guidelines standardise this at ≥48 mmol/mol (6.5%), guiding both primary care and specialist management.\n\n**Memory Anchor**\nThink '48 to diagnose'—the minimum mmol/mol for diabetes.",
    "bullet_explanations": {
      "Cannot use HbA1c for diagnosis": "Incorrect: HbA1c is a widely accepted and routinely used diagnostic test for type 2 diabetes in most adults.",
      "42 mmol/mol": "Incorrect: This value indicates increased risk (pre-diabetes), not diagnostic of diabetes.",
      "45 mmol/mol": "Incorrect: Also within the pre-diabetes range; does not meet diagnostic criteria.",
      "48 mmol/mol": "Correct: This is the minimum value for diagnosis according to NICE and WHO recommendations.",
      "53 mmol/mol": "Incorrect: This level confirms diabetes, but is above the minimum required for diagnosis."
    },
    "category": "Endocrinology & Metabolic",
    "subsection": "Diabetes – Chronic",
    "subsubsection": "Type 2 Diabetes",
    "topic": "Metformin first-line and intolerance",
    "keywords": [
      "HbA1c threshold",
      "type 2 diabetes diagnosis",
      "diabetes criteria"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Diabetes - type 2",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/diabetes-type-2/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "87a2c4f3-8017-4a30-9822-8159bf3fdf71",
    "question_number": 413,
    "question": "A 32-year-old woman develops gradually worsening bilateral hearing loss and intermittent tinnitus. Her symptoms have noticeably progressed during pregnancy. On examination, Rinne's test is negative bilaterally and Weber's test is midline. What is the most likely underlying diagnosis?",
    "options": [
      "Otosclerosis",
      "Presbycusis",
      "Meniere’s disease",
      "Cholesteatoma",
      "Acoustic neuroma"
    ],
    "correct_answer": "Otosclerosis",
    "explanation": "**Explanation**\n**Otosclerosis** is characterised by abnormal bone growth around the stapes in the middle ear, leading to progressive conductive hearing loss, often accompanied by tinnitus. It typically presents in adults aged 20–40 and can worsen during pregnancy due to hormonal influences. Rinne's test showing bone conduction greater than air conduction (negative) bilaterally and a midline Weber’s test are classic findings for bilateral conductive hearing loss. In contrast, presbycusis causes sensorineural loss (air conduction remains better than bone), while Meniere’s disease and acoustic neuroma usually present with sensorineural findings and often unilateral symptoms.\n\n**Key Points**\n- Otosclerosis presents with progressive bilateral conductive hearing loss, often worsening during pregnancy.\n- Tuning fork tests: Rinne negative (bone > air) bilaterally, Weber’s midline (symmetric loss).\n- Tinnitus is a common associated symptom.\n- Typically affects adults aged 20–40 years.\n- Sensorineural conditions (e.g., presbycusis, acoustic neuroma) present differently on tuning fork tests.\n\n**Clinical Relevance**\nRecognising the audiological features and demographic patterns of otosclerosis is essential for primary care clinicians. Early identification allows for appropriate referral to audiology or ENT, facilitating timely management such as hearing aids or surgical intervention. Understanding the impact of pregnancy on otosclerosis progression helps guide counselling for affected women.\n\n**Memory Anchor**\nOtosclerosis: 'Oto' = ear, 'sclerosis' = stiffening — think of the stapes becoming stuck, causing conductive loss in young adults, especially women.",
    "bullet_explanations": {
      "Otosclerosis": "Correct: Bilateral, progressive conductive hearing loss in a young adult, exacerbated by pregnancy, fits otosclerosis.",
      "Presbycusis": "Incorrect: Age-related sensorineural hearing loss, typically affects those over 65; tuning fork tests would not show conductive pattern.",
      "Meniere’s disease": "Incorrect: Causes sensorineural loss, vertigo, and fluctuating symptoms, usually unilateral initially.",
      "Cholesteatoma": "Incorrect: Presents with progressive unilateral hearing loss, often with discharge or recurrent infection, not typically bilateral or affected by pregnancy.",
      "Acoustic neuroma": "Incorrect: Causes unilateral sensorineural hearing loss with or without tinnitus; not bilateral and not associated with pregnancy."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Hearing loss causes",
    "keywords": [
      "otosclerosis",
      "conductive hearing loss",
      "tuning fork tests",
      "pregnancy hearing loss",
      "ENT"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hearing loss in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hearing-loss-in-adults/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Tinnitus",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/tinnitus/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "89c0306b-e897-4b3b-b289-627edc80656f",
    "question_number": 414,
    "question": "A 58-year-old woman is reviewed two weeks after discharge following a primary percutaneous coronary intervention for an anterior STEMI. Echocardiography before discharge revealed a left ventricular ejection fraction of 35%, but she is not breathless or oedematous on examination. She is already prescribed aspirin, clopidogrel, ramipril, bisoprolol and atorvastatin. According to current NICE guidance, which additional medication should be initiated to further reduce long-term morbidity and mortality in this scenario?",
    "options": [
      "Mineralocorticoid receptor antagonist (e.g. spironolactone)",
      "Long-acting nitrate",
      "Angiotensin II receptor blocker (ARB)",
      "Loop diuretic",
      "Ivabradine"
    ],
    "correct_answer": "Mineralocorticoid receptor antagonist (e.g. spironolactone)",
    "explanation": "**Explanation**\n**Mineralocorticoid receptor antagonists (MRAs), such as spironolactone or eplerenone, are recommended in post-MI patients with reduced left ventricular ejection fraction (LVEF),** provided there are no contraindications such as significant hyperkalaemia or renal impairment. MRAs confer additional morbidity and mortality benefits beyond standard therapy (ACE inhibitors/ARBs, beta-blockers, antiplatelets, and statins), particularly in those with symptomatic heart failure or substantial LV dysfunction. Unlike loop diuretics, which are reserved for symptomatic fluid overload, MRAs are indicated as disease-modifying agents in stable patients with reduced LVEF after MI. **Other options are either not recommended for mortality reduction or are reserved for specific indications.**\n\n**Key Points**\n- Post-MI patients with reduced LVEF benefit from MRAs for secondary prevention.\n- MRAs reduce mortality and heart failure hospitalisations when added to ACEi and beta-blocker.\n- Initiation requires checking renal function and potassium levels.\n- Loop diuretics are for symptom control, not long-term mortality reduction.\n- ARBs are alternatives only if ACE inhibitors are not tolerated.\n- Long-acting nitrates and ivabradine have no mortality benefit in this setting.\n\n**Clinical Relevance**\nNICE and BNF guidelines emphasise that in patients with significant LV systolic dysfunction after MI, MRAs are essential as part of secondary prevention to improve survival and reduce hospital admissions. This highlights the importance of optimising guideline-directed medical therapy in post-MI care.\n\n**Memory Anchor**\nMRAs are 'Mortality-Reducing Add-ons' for post-MI patients with low EF.",
    "bullet_explanations": {
      "Mineralocorticoid receptor antagonist (e.g. spironolactone)": "Correct – recommended by NICE for patients with reduced LVEF post-MI, unless contraindicated.",
      "Long-acting nitrate": "Incorrect – used for angina symptom relief, not for improving post-MI survival in LV dysfunction.",
      "Angiotensin II receptor blocker (ARB)": "Incorrect – ARBs are only used if ACE inhibitors are not tolerated, not as additional therapy if already on ACEi.",
      "Loop diuretic": "Incorrect – indicated only if there are signs of fluid overload, not routinely for asymptomatic LV dysfunction.",
      "Ivabradine": "Incorrect – reserved for symptomatic heart failure with high heart rate despite maximised beta-blockade, not first-line post-MI."
    },
    "category": "Cardiovascular",
    "subsection": "Secondary Prevention Post-MI",
    "subsubsection": "ACEi/ARB/ARNI and beta-blocker optimisation",
    "topic": "High-intensity statin and lipid targets",
    "keywords": [
      "post-MI",
      "secondary prevention",
      "mineralocorticoid receptor antagonist",
      "left ventricular dysfunction"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "MI - secondary prevention",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/mi-secondary-prevention/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Heart failure - chronic",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/heart-failure-chronic/"
      },
      {
        "source": "BNF",
        "topic_title": "Chronic heart failure",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/chronic-heart-failure/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e4cf141c-9cfd-4bae-9d6b-258144fe6f77",
    "question_number": 415,
    "question": "A 34-year-old man who works as a park ranger in rural Scotland attends his GP with a painless, enlarging, ring-shaped rash on his leg. He recalls removing a tick from the area two weeks ago. He is confirmed to have early Lyme disease but reports a history of severe allergy to tetracyclines. What is the most appropriate antibiotic for initial management?",
    "options": [
      "Amoxicillin",
      "Azithromycin",
      "Flucloxacillin",
      "Ceftriaxone",
      "Metronidazole"
    ],
    "correct_answer": "Amoxicillin",
    "explanation": "**Explanation**\n**Amoxicillin is the recommended oral alternative for early Lyme disease when doxycycline (a tetracycline) is contraindicated, such as due to allergy or pregnancy.** In early, localised Lyme disease presenting as erythema migrans, doxycycline is first-line, but amoxicillin is equally effective and well-tolerated for those unable to take tetracyclines. Other antibiotics are reserved for later, disseminated, or complicated disease, or when both doxycycline and amoxicillin are unsuitable.\n\n**Key Points**\n- Doxycycline is first-line for early Lyme disease unless contraindicated.\n- Amoxicillin is the preferred alternative if tetracyclines are unsuitable (e.g., allergy, pregnancy, age <12).\n- Azithromycin is only used if both doxycycline and amoxicillin are unavailable or unsuitable.\n- Ceftriaxone is reserved for severe or disseminated Lyme disease (e.g., neurological involvement).\n- Flucloxacillin and metronidazole are not effective against Borrelia burgdorferi.\n\n**Clinical Relevance**\nAppropriate antibiotic selection in Lyme disease is essential for effective management and avoidance of complications, particularly in special groups such as pregnant women, children, or those with allergies. National guidelines (BNF, NICE CKS) support amoxicillin as the safe alternative to doxycycline in these cases.\n\n**Memory Anchor**\nRemember: 'A' for Amoxicillin when 'A'llergic to Doxycycline.",
    "bullet_explanations": {
      "Amoxicillin": "Correct – recommended oral alternative to doxycycline for early Lyme disease if tetracyclines are contraindicated.",
      "Azithromycin": "Only used if both doxycycline and amoxicillin are not suitable; not first alternative.",
      "Flucloxacillin": "Not active against Borrelia and not recommended in Lyme disease.",
      "Ceftriaxone": "Indicated for severe, disseminated, or neurological Lyme disease – not first-line for early, uncomplicated cases.",
      "Metronidazole": "Ineffective against Borrelia; not used for Lyme disease."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Respiratory Infections",
    "topic": "Community vs hospital-acquired pneumonia",
    "keywords": [
      "Lyme disease",
      "amoxicillin",
      "tetracycline allergy",
      "tick bite",
      "antibiotic choice"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Lyme disease",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/lyme-disease/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Lyme disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/lyme-disease/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "900d49fc-69ed-43ea-8299-0d2963229734",
    "question_number": 416,
    "question": "A 5-year-old boy presents with multiple small, dome-shaped, centrally dimpled papules on his torso. He is otherwise healthy, and the skin lesions are not causing him any discomfort. What is the most appropriate initial management approach?",
    "options": [
      "Provide reassurance and advise no treatment is necessary",
      "Prescribe topical hydrocortisone cream",
      "Refer urgently to dermatology",
      "Apply topical salicylic acid",
      "Investigate for possible immunodeficiency"
    ],
    "correct_answer": "Provide reassurance and advise no treatment is necessary",
    "explanation": "**Explanation**\n**Molluscum contagiosum** is a common viral skin infection in children, characterised by small, pearly or flesh-coloured papules with central umbilication. It is self-limiting and typically resolves spontaneously within 18 months in otherwise healthy individuals. **No active treatment is required in most cases**, particularly when lesions are mild, not bothersome, and not located on sensitive areas such as the face or genitalia. Reassurance and advice about the benign course, transmission, and avoiding scratching are recommended. Treatments are reserved for troublesome symptoms, secondary infection, or immunocompromised patients.<br><br>Other interventions, such as topical steroids or keratolytics, are not indicated and may cause local irritation or adverse effects.\n\n**Key Points**\n- Molluscum contagiosum is a benign, self-limiting viral skin infection.\n- Most cases in children resolve without intervention within 18 months.\n- Characteristic lesions: small (up to 5 mm), dome-shaped, with central umbilication.\n- Treatment is generally not required unless lesions are problematic or complicated.\n- Parental reassurance is first-line; educate about transmission and natural history.\n\n**Clinical Relevance**\nRecognising molluscum contagiosum and providing appropriate reassurance prevents unnecessary treatments and referrals, reducing anxiety for families. NICE CKS guidelines support a conservative approach for immunocompetent children.",
    "bullet_explanations": {
      "Provide reassurance and advise no treatment is necessary": "Correct. Molluscum contagiosum in healthy children is self-limiting and usually requires no intervention.",
      "Prescribe topical hydrocortisone cream": "Incorrect. Topical steroids are not effective for viral infections and may worsen skin thinning.",
      "Refer urgently to dermatology": "Incorrect. Referral is only needed for atypical, severe, or complicated cases, not for typical, uncomplicated presentations.",
      "Apply topical salicylic acid": "Incorrect. Salicylic acid is used for warts, not molluscum; it can cause local irritation.",
      "Investigate for possible immunodeficiency": "Incorrect. There is no indication of immunodeficiency in this healthy child with a typical presentation."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Infections",
    "topic": "Viral exanthems",
    "keywords": [
      "molluscum contagiosum",
      "paediatric dermatology",
      "self-limiting rash"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Molluscum contagiosum",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/molluscum-contagiosum/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "b9037da1-c684-4b51-a3c6-38a86b5b0084",
    "question_number": 417,
    "question": "A 58-year-old woman with a past history of cervical decompression surgery for degenerative cervical myelopathy now presents with several weeks of progressive hand clumsiness, unsteady gait, and new-onset urinary urgency. What is the most likely diagnosis?",
    "options": [
      "Recurrent cervical myelopathy due to adjacent segment disease",
      "Transverse myelitis",
      "Progression of multiple sclerosis",
      "Cauda equina syndrome",
      "Spinal cord compression secondary to metastatic disease"
    ],
    "correct_answer": "Recurrent cervical myelopathy due to adjacent segment disease",
    "explanation": "**Explanation**\n**Recurrent cervical myelopathy due to adjacent segment disease** is the most likely cause in this scenario. Patients who have undergone cervical decompression for myelopathy remain at risk of developing pathology at spinal segments adjacent to the original surgical site—a phenomenon known as adjacent segment disease. The mechanism involves altered spinal biomechanics following surgery, potentially leading to degenerative changes or instability at untreated levels. Symptoms such as progressive gait disturbance, upper limb dysfunction, and bladder involvement are classic for cervical cord pathology. The subacute onset and her surgical history make recurrence of cervical myelopathy more probable than other causes.\n\n**Key Points**\n- Prior cervical spine surgery increases risk of adjacent segment degeneration.\n- Progressive gait instability, hand dysfunction, and urinary symptoms suggest cervical cord involvement.\n- Adjacent segment disease can present months or years after initial surgery.\n- Transverse myelitis typically presents more acutely, often with a clear sensory level.\n- Cauda equina syndrome causes lower limb and perineal sensory/motor loss, not upper limb or spastic gait.\n- Spinal metastases are less likely without a known malignancy and often have more rapid progression.\n\n**Clinical Relevance**\nRecognising adjacent segment disease in patients with a history of cervical decompression is vital, as timely diagnosis and referral for specialist assessment can prevent further neurological deterioration. Gait disturbance and new urinary symptoms in this context warrant urgent evaluation to avoid permanent disability.\n\n**Memory Anchor**\nRemember: Prior cervical surgery + new cord symptoms = suspect adjacent segment disease.",
    "bullet_explanations": {
      "Recurrent cervical myelopathy due to adjacent segment disease": "Correct – Progressive symptoms after cervical surgery are most often due to pathology at adjacent spinal levels.",
      "Transverse myelitis": "Incorrect – Usually presents acutely with a sensory level and may follow infection or autoimmune flare.",
      "Progression of multiple sclerosis": "Incorrect – Requires prior diagnosis or evidence of demyelinating episodes; presentation is less likely to be so focal.",
      "Cauda equina syndrome": "Incorrect – Presents with saddle anaesthesia, bowel/bladder dysfunction, and lower (not upper) limb signs.",
      "Spinal cord compression secondary to metastatic disease": "Incorrect – Uncommon without history of cancer; symptoms often progress faster and may be more severe."
    },
    "category": "Musculoskeletal",
    "subsection": "Soft Tissue",
    "subsubsection": "Back Pain",
    "topic": "Red flag symptoms",
    "keywords": [
      "adjacent segment disease",
      "cervical myelopathy",
      "spinal surgery complications"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "e756845b-2705-4dd4-a7de-65e4084c97d4",
    "question_number": 418,
    "question": "Which of the following best characterises the physical findings in congenital talipes equinovarus (clubfoot) on newborn examination?",
    "options": [
      "Inverted and plantar flexed foot that cannot be passively corrected",
      "Everted and dorsiflexed foot that is rigid",
      "Inverted and dorsiflexed foot with pes planus",
      "Inverted and plantar flexed foot with flexible correction",
      "Everted and plantar flexed foot with pes cavus"
    ],
    "correct_answer": "Inverted and plantar flexed foot that cannot be passively corrected",
    "explanation": "**Explanation**\nIn congenital talipes equinovarus (clubfoot), the classic clinical features are a foot that is both **inverted (turned inward) and plantar flexed (pointed downward)**. The hallmark of true clubfoot is that the deformity is **rigid and cannot be fully corrected by passive manipulation**. This distinguishes it from positional foot deformities, which are flexible and correctable with gentle movement. Clubfoot is not associated with pes planus (flat foot); rather, there is a high medial longitudinal arch due to the abnormal position of the foot. Early recognition is essential for treatment, typically involving serial casting (Ponseti method) to gradually correct the alignment.<br><br><b>Contrast:</b> Flexible (passively correctable) deformities are not true clubfoot and often resolve spontaneously. Dorsiflexion or eversion are not features of clubfoot.\n\n**Key Points**\n- Clubfoot = inverted + plantar flexed (equinovarus) position\n- Not passively correctable (rigid deformity)\n- Distinguish from positional deformities (which are flexible)\n- No association with pes planus (flat foot)\n- Early treatment with serial manipulation and casting is standard\n\n**Clinical Relevance**\nRecognising the non-correctable, rigid nature of clubfoot on neonatal examination is critical for prompt referral and initiation of appropriate therapy, preventing lifelong disability. Flexibility of the deformity is a key diagnostic discriminator.",
    "bullet_explanations": {
      "Inverted and plantar flexed foot that cannot be passively corrected": "Correct—this is the classic, rigid presentation of clubfoot (talipes equinovarus).",
      "Everted and dorsiflexed foot that is rigid": "Incorrect—eversion and dorsiflexion do not describe clubfoot and suggest another pathology.",
      "Inverted and dorsiflexed foot with pes planus": "Incorrect—involves dorsiflexion and flat foot, both inconsistent with clubfoot.",
      "Inverted and plantar flexed foot with flexible correction": "Incorrect—while the position matches, flexibility excludes true clubfoot.",
      "Everted and plantar flexed foot with pes cavus": "Incorrect—eversion and high arch (pes cavus) are not features of clubfoot."
    },
    "category": "Trauma & Orthopaedics",
    "subsection": "Fractures",
    "subsubsection": "Paediatric fractures",
    "topic": "Paediatric fractures",
    "keywords": [
      "clubfoot",
      "talipes equinovarus",
      "newborn examination",
      "rigid foot deformity"
    ],
    "difficulty": "Easy",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "ddaf4b60-4421-4b2a-9f1f-54e905ed433d",
    "question_number": 419,
    "question": "A 42-year-old woman presents with intensely itchy, violaceous papules on her wrists and ankles. She also reports the appearance of similar lesions developing along the site of a recent scratch on her lower leg. Examination reveals fine, white reticulated lines over the surface of several papules. Which diagnosis most likely explains these findings?",
    "options": [
      "Lichen planus",
      "Lichen sclerosus",
      "Scabies",
      "Morphea",
      "Pityriasis rosea"
    ],
    "correct_answer": "Lichen planus",
    "explanation": "**Explanation**\n**Lichen planus** is a chronic inflammatory condition affecting skin and mucous membranes. It is characterised by **pruritic, violaceous, polygonal papules**—often on the flexor surfaces of the wrists and ankles. A hallmark sign is the presence of **Wickham's striae**, which are fine, white, lacy lines seen on the papule surface. The appearance of new lesions at sites of trauma (Koebner phenomenon) is also typical. Lichen planus can affect both skin and mucosa, and may cause scarring or pigmentary changes if chronic. Other conditions listed do not produce the classical combination of Wickham's striae and Koebnerisation.\n\n**Key Points**\n<ul><li>Lichen planus presents with purple, pruritic, polygonal, flat-topped papules.</li><li>Wickham's striae (white lacy pattern) are characteristic.</li><li>Lesions commonly affect flexor wrists, ankles, lower back, and genitalia.</li><li>Koebner phenomenon: new lesions appear at sites of trauma.</li><li>Mucosal involvement is common (oral, genital).</li></ul>\n\n**Clinical Relevance**\nRecognising lichen planus is important for timely diagnosis and management, as it can be associated with significant morbidity, especially in mucosal disease. Chronic cases may increase the risk of squamous cell carcinoma, particularly in the genital region. Awareness of its distinguishing features, such as Wickham's striae and Koebner phenomenon, helps differentiate it from other pruritic skin eruptions. NICE CKS recommends thorough history and examination when evaluating pruritic rashes, especially when mucocutaneous involvement or scarring is present.\n\n**Memory Anchor**\nThink '5 Ps' for lichen planus: **Purple, Polygonal, Pruritic, Papules, and Plaques**.",
    "bullet_explanations": {
      "Lichen planus": "Correct—classic features include pruritic, violaceous papules with Wickham's striae and Koebner phenomenon.",
      "Lichen sclerosus": "Incorrect—typically causes white, atrophic plaques in the genital area, mostly in postmenopausal women, without Wickham's striae.",
      "Scabies": "Incorrect—intensely itchy, often with burrows in web spaces, but lacks violaceous papules or reticulated white lines.",
      "Morphea": "Incorrect—presents as sclerotic, ivory-coloured plaques without pruritic papules or Wickham's striae.",
      "Pityriasis rosea": "Incorrect—classically starts with a 'herald patch' followed by a scaly, oval rash on the trunk; does not have Wickham's striae or Koebnerisation."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Inflammatory Skin Disease",
    "topic": "Lichen planus",
    "keywords": [
      "lichen planus",
      "Wickham's striae",
      "Koebner phenomenon",
      "pruritic papules",
      "inflammatory skin disease"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Pruritus vulvae",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/pruritus-vulvae/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "018f7dcc-e86c-4865-adb8-e72d0183b35e",
    "question_number": 420,
    "question": "A 45-year-old male with a history of resistant hypertension presents complaining of breast tenderness and visible enlargement over several months. Which medication is most commonly implicated in causing gynaecomastia in this context?",
    "options": [
      "Spironolactone",
      "Finasteride",
      "Tamsulosin",
      "Phenytoin",
      "Mirtazapine"
    ],
    "correct_answer": "Spironolactone",
    "explanation": "**Explanation**\nSpironolactone is a potassium-sparing diuretic that also acts as an aldosterone antagonist, frequently prescribed for resistant hypertension and heart failure. Its anti-androgenic properties—specifically, antagonising androgen receptors and reducing testosterone synthesis—can lead to a relative excess of oestrogen, resulting in gynaecomastia in men. This side effect is well recognised and can affect up to 10% of patients on long-term therapy. Other medications listed may have hormonal effects, but spironolactone is the prototypical drug associated with gynaecomastia due to its direct impact on androgen pathways. In contrast, drugs like tamsulosin (alpha-blocker), phenytoin (anticonvulsant), and mirtazapine (antidepressant) do not typically cause this adverse effect. Finasteride, while capable of causing sexual dysfunction due to its inhibition of 5-alpha-reductase, is more commonly associated with reduced libido and erectile dysfunction than clinically significant gynaecomastia.\n\n**Key Points**\n- Spironolactone inhibits androgen receptors and testosterone synthesis, increasing oestrogen effect.\n- Gynaecomastia is a recognised adverse effect in up to 10% of men taking spironolactone.\n- Finasteride may rarely cause breast changes, but not as commonly as spironolactone.\n- Tamsulosin, phenytoin, and mirtazapine are not typical causes of gynaecomastia.\n- Management may involve dose reduction, switching agents, or adding anti-oestrogen therapy.\n\n**Clinical Relevance**\nRecognising drug-induced gynaecomastia is important to avoid unnecessary investigations and to support medication review for patient comfort and adherence. Spironolactone should be considered as a likely culprit when men present with breast enlargement, and this is reflected in prescribing guidelines and safety summaries.\n\n**Memory Anchor**\n‘S’ for Spironolactone and ‘S’ for Side-effect: Sore, Swollen male breast.",
    "bullet_explanations": {
      "Spironolactone": "Correct – well-known cause of gynaecomastia due to anti-androgen effects.",
      "Finasteride": "Rarely causes breast changes, but not as commonly as spironolactone.",
      "Tamsulosin": "Alpha-blocker; does not impact androgen pathways or cause gynaecomastia.",
      "Phenytoin": "Associated with gingival hyperplasia and hirsutism, not gynaecomastia.",
      "Mirtazapine": "May cause weight gain, but not associated with male breast enlargement."
    },
    "category": "Renal & Urology",
    "subsection": "Chronic Kidney Disease",
    "subsubsection": "Management",
    "topic": "Diuretics",
    "keywords": [
      "spironolactone",
      "gynaecomastia",
      "drug side effects",
      "anti-androgen",
      "hypertension"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Androgens, anti-androgens and anabolic steroids",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/androgens-anti-androgens-and-anabolic-steroids/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "92d3dcc3-cd94-4059-b025-5e815fe4b120",
    "question_number": 421,
    "question": "Which antimalarial agent used for prophylaxis is most commonly associated with photosensitivity as a side effect?",
    "options": [
      "Doxycycline",
      "Mefloquine",
      "Atovaquone with proguanil",
      "Proguanil",
      "Quinine"
    ],
    "correct_answer": "Doxycycline",
    "explanation": "**Explanation**\n**Doxycycline** is well recognised for causing photosensitivity, which can result in exaggerated sunburn reactions in those exposed to sunlight. This adverse effect is distinct among antimalarial prophylactics and is an important consideration when advising travellers. Patients prescribed doxycycline should be counselled to use high-factor sunscreen and to cover up when outdoors. Mefloquine, while used for malaria prevention, is more associated with neuropsychiatric side effects and is not known for photosensitivity. Atovaquone with proguanil and proguanil alone rarely cause significant photosensitivity, and quinine is not recommended for prophylaxis and does not have this side effect profile.\n\n**Key Points**\n<ul><li><b>Doxycycline</b> is the antimalarial most often linked with photosensitivity reactions.</li><li>Travellers taking doxycycline should be warned about the risk of sunburn and advised on sun protection strategies.</li><li>Mefloquine's main concerns are neuropsychiatric side effects, not photosensitivity.</li><li>Atovaquone with proguanil and proguanil alone are generally well tolerated and are not associated with increased sun sensitivity.</li><li>Quinine is reserved for malaria treatment, not prophylaxis, and does not cause photosensitivity.</li></ul>\n\n**Clinical Relevance**\nRecognising the adverse effect profile of antimalarial agents is crucial for personalised travel medicine advice and patient safety. Doxycycline's photosensitivity risk requires clear pre-travel counselling, especially for those likely to have significant sun exposure.\n\n**Memory Anchor**\nThink 'Doxycycline = Daylight sensitivity' to recall the association with photosensitivity.",
    "bullet_explanations": {
      "Doxycycline": "Correct – it is the only common antimalarial prophylactic associated with photosensitivity.",
      "Mefloquine": "Incorrect – it is linked with neuropsychiatric effects, not photosensitivity.",
      "Atovaquone with proguanil": "Incorrect – rarely causes photosensitivity; more likely to cause GI upset.",
      "Proguanil": "Incorrect – not known for photosensitivity as a side effect.",
      "Quinine": "Incorrect – used for treatment, not prophylaxis, and does not cause photosensitivity."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "GI Infections",
    "topic": "Traveller’s diarrhoea basics",
    "keywords": [
      "malaria prophylaxis",
      "doxycycline",
      "photosensitivity",
      "travel medicine"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Malaria, prophylaxis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/malaria-prophylaxis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "87b5ca4a-bae7-433a-888e-ec1d516d5b13",
    "question_number": 422,
    "question": "During a routine eye examination, a 27-year-old man is found to have pupils that constrict when a light is shone into his right eye, but both pupils appear to dilate when the light is moved rapidly to his left eye. What does this clinical finding most likely indicate?",
    "options": [
      "Relative afferent pupillary defect",
      "Bilateral Horner's syndrome",
      "Oculomotor nerve palsy",
      "Pharmacological mydriasis",
      "Argyll Robertson pupil"
    ],
    "correct_answer": "Relative afferent pupillary defect",
    "explanation": "**Explanation**\n**A relative afferent pupillary defect (RAPD), or Marcus-Gunn pupil, is detected by the swinging light test.** When a light is shone into the normal eye, both pupils constrict. Upon moving the light to the affected eye (with a lesion in the optic nerve or retina), both pupils appear to dilate because the impaired afferent pathway results in a reduced direct and consensual response. **This is not true dilation but rather a relative failure to constrict.** The most common causes include optic neuritis (often associated with multiple sclerosis in young adults) and severe retinal disease. This pattern helps localise the defect to the afferent visual pathway, anterior to the optic chiasm.\n\n**Key Points**\n- RAPD is best elicited with the swinging light test.\n- Lesion is anterior to the optic chiasm (optic nerve or retina).\n- Both pupils appear to 'dilate' when light is shone in the affected eye.\n- Common causes: optic neuritis, severe retinal disease, retinal detachment.\n- Distinguished from efferent defects (e.g. oculomotor nerve palsy) which cause abnormal direct responses on the affected side.\n\n**Clinical Relevance**\nRecognition of RAPD is crucial in identifying optic nerve or severe retinal pathology, which may represent urgent or sight-threatening disease. Early detection guides prompt referral and management, such as in optic neuritis or retinal detachment, as highlighted in NICE CKS guidance.\n\n**Memory Anchor**\nRemember: 'Marcus-Gunn = swinging light, optic nerve problem.'",
    "bullet_explanations": {
      "Relative afferent pupillary defect": "Correct—this is the clinical sign detected by the swinging light test in optic nerve or severe retinal disease.",
      "Bilateral Horner's syndrome": "Incorrect—Horner's syndrome causes miosis and ptosis, not an RAPD pattern.",
      "Oculomotor nerve palsy": "Incorrect—this causes a fixed, dilated pupil and ptosis, not a relative afferent defect.",
      "Pharmacological mydriasis": "Incorrect—drug effects cause persistent dilation, not a light-dependent change or RAPD.",
      "Argyll Robertson pupil": "Incorrect—these pupils accommodate but do not react to light, unrelated to the swinging light test."
    },
    "category": "Neurology",
    "subsection": "Headache",
    "subsubsection": "Red flag headache",
    "topic": "Relative afferent pupillary defect",
    "keywords": [
      "relative afferent pupillary defect",
      "RAPD",
      "swinging light test",
      "optic neuritis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Red eye",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/red-eye/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Retinal detachment",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/retinal-detachment/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e55a9413-bd54-45b4-b750-4527d8569997",
    "question_number": 423,
    "question": "A 6-week-old boy presents to urgent care with fever (38.2°C), persistent irritability, and refusal to feed. Examination reveals a red, bulging left tympanic membrane. What is the most appropriate next step in management?",
    "options": [
      "Refer urgently for paediatric assessment",
      "Start a 5-day course of amoxicillin and discharge",
      "Treat pain and fever with paracetamol, observe for 4 hours",
      "Initiate ibuprofen for symptom relief, review in 48 hours",
      "Advise alternating paracetamol and ibuprofen, discharge with safety netting"
    ],
    "correct_answer": "Refer urgently for paediatric assessment",
    "explanation": "**Explanation**\nInfants under 3 months presenting with fever (≥38°C) require urgent specialist assessment due to the higher risk of serious underlying infection and complications. **Otitis media in this age group is managed differently than in older children, as the risk of sepsis, meningitis, and rapid deterioration is significant.** NICE and BNF guidelines recommend immediate hospital referral for children <3 months with fever, regardless of the presumed source, and especially if systemically unwell or with additional concerning features (e.g., poor feeding, irritability). **Antibiotics may be indicated, but initiation and monitoring should occur in a hospital setting.** Symptomatic management and outpatient observation are not appropriate for this high-risk group.\n\n**Key Points**\n- Infants <3 months with fever ≥38°C are high-risk for serious bacterial infection.\n- Otitis media in very young infants may mask more severe illness.\n- Immediate referral for paediatric assessment is required.\n- Antibiotics are considered in hospital if indicated after further evaluation.\n- Symptomatic outpatient management is reserved for older, well-appearing children.\n\n**Clinical Relevance**\nRecognising red-flag features in young infants with fever is crucial to prevent missed diagnoses of life-threatening infections. Adhering to risk stratification guidelines protects patient safety and ensures timely escalation of care, as recommended by NICE CKS and BNF.",
    "bullet_explanations": {
      "Refer urgently for paediatric assessment": "Correct – infants under 3 months with fever require immediate specialist review due to high risk of serious illness.",
      "Start a 5-day course of amoxicillin and discharge": "Incorrect – antibiotics alone are insufficient; urgent hospital assessment is required for this age group.",
      "Treat pain and fever with paracetamol, observe for 4 hours": "Incorrect – observation without escalation is unsafe for a febrile infant under 3 months.",
      "Initiate ibuprofen for symptom relief, review in 48 hours": "Incorrect – delayed review and outpatient management are inappropriate for high-risk infants.",
      "Advise alternating paracetamol and ibuprofen, discharge with safety netting": "Incorrect – safety netting and outpatient care are not suitable; escalation is mandatory."
    },
    "category": "Paediatrics",
    "subsection": "Neonatology",
    "subsubsection": "Resuscitation & Emergencies",
    "topic": "Sepsis in neonates",
    "keywords": [
      "neonatal sepsis",
      "febrile infant",
      "otitis media",
      "urgent referral"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Ear",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/ear/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Otitis media - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/otitis-media-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "1455748f-da37-4530-b86a-912653ff44ef",
    "question_number": 424,
    "question": "A 38-year-old man is referred to genetics after learning that his mother carries a BRCA2 mutation. In addition to an increased risk of male breast cancer, which other malignancy is he particularly at risk of if he is found to carry the BRCA2 mutation?",
    "options": [
      "Prostate cancer",
      "Colorectal cancer",
      "Testicular cancer",
      "Malignant melanoma",
      "Lung cancer"
    ],
    "correct_answer": "Prostate cancer",
    "explanation": "**Explanation**\n**BRCA2 mutations are associated with a significantly increased risk of several cancers. In men, apart from the elevated risk of male breast cancer, the most notable associated malignancy is prostate cancer.** While BRCA2 mutations are classically linked with female breast and ovarian cancer, men with this mutation should be counselled about their higher risk of prostate cancer, which can develop at a younger age and may be more aggressive than sporadic cases. This contrasts with BRCA1, which has a weaker association with prostate cancer and has been linked to some cases of young-onset colorectal cancer, though this is not seen with BRCA2. There is no strong evidence that BRCA2 mutation carriers are at higher risk for colorectal, testicular, malignant melanoma, or lung cancer compared to the general population.\n\n**Key Points**\n- BRCA2 mutations increase the risk of breast cancer in both men and women.\n- Men with BRCA2 mutations are at increased risk of developing prostate cancer.\n- Prostate cancer in BRCA2 carriers may present at a younger age and can be more aggressive.\n- BRCA2 mutations are not associated with a significantly increased risk of colorectal, testicular, or lung cancer.\n- BRCA1, not BRCA2, is sometimes linked with young-onset colorectal cancer.\n- <table><thead><tr><th>BRCA2-Associated Cancers</th><th>Gender</th></tr></thead><tbody><tr><td>Breast</td><td>Male & Female</td></tr><tr><td>Ovarian</td><td>Female</td></tr><tr><td>Prostate</td><td>Male</td></tr></tbody></table>\n\n**Clinical Relevance**\nUnderstanding the cancer risks associated with BRCA2 mutations guides both genetic counselling and cancer surveillance. Men found to carry BRCA2 should be informed about their increased risk of prostate cancer and may require earlier or more intensive screening, as highlighted by NICE guidelines.\n\n**Memory Anchor**\nBRCA2: Think '2' for 'Two' key male cancers—breast and prostate.",
    "bullet_explanations": {
      "Prostate cancer": "Correct. BRCA2 mutations increase the risk of prostate cancer in men.",
      "Colorectal cancer": "Incorrect. BRCA2 is not strongly linked to colorectal cancer; BRCA1 may be associated with early-onset cases.",
      "Testicular cancer": "Incorrect. There is no established association between BRCA2 mutations and testicular cancer.",
      "Malignant melanoma": "Incorrect. BRCA2 does not significantly raise melanoma risk.",
      "Lung cancer": "Incorrect. Lung cancer is not related to BRCA2 mutations."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Genetics",
    "subsubsection": "Cancer Genetics",
    "topic": "BRCA1/2 inheritance",
    "keywords": [
      "BRCA2",
      "prostate cancer",
      "male breast cancer",
      "hereditary cancer",
      "genetic risk"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Breast cancer - managing FH",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/breast-cancer-managing-fh/"
      },
      {
        "source": "BNF",
        "topic_title": "Prostate cancer",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/prostate-cancer/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "7f9dc60b-0b2d-4097-8490-32ece6fdf958",
    "question_number": 425,
    "question": "In a first-trimester combined screening for chromosomal abnormalities, which of the following results is most likely to be observed in a fetus with Down's syndrome (trisomy 21)?",
    "options": [
      "Increased nuchal translucency",
      "Elevated alpha fetoprotein (AFP)",
      "Raised oestriol levels",
      "Reduced human chorionic gonadotrophin (hCG)",
      "Decreased nuchal translucency"
    ],
    "correct_answer": "Increased nuchal translucency",
    "explanation": "**Explanation**\n**Down's syndrome (trisomy 21) is associated with a distinctive pattern in first-trimester screening tests.** The combined test, performed between 11 and 13+6 weeks, includes measurement of nuchal translucency by ultrasound and blood levels of PAPP-A and beta-hCG. In trisomy 21, nuchal translucency is typically increased (thickened). Additionally, beta-hCG is usually elevated, while PAPP-A is reduced. Later, in the triple test (second trimester), low AFP and oestriol, and high hCG are also seen. **A thicker nuchal translucency is a key marker for trisomy 21.** This contrasts with decreased or normal nuchal translucency in unaffected pregnancies.\n\n**Key Points**\n<ul><li><b>Down's syndrome (trisomy 21) screening relies on blood markers and ultrasound findings.</b></li><li><b>Combined test (11–13+6 weeks):</b> thickened nuchal translucency, raised beta-hCG, low PAPP-A.</li><li><b>Triple test (second trimester):</b> low AFP, low oestriol, high hCG.</li><li>Thickened (increased) nuchal translucency is highly suggestive of trisomy 21.</li><li>Screening tests are not diagnostic but identify pregnancies at higher risk for aneuploidy.</li></ul>\n\n**Clinical Relevance**\nUnderstanding the typical screening profile for trisomy 21 is essential for interpreting antenatal screening results, counselling parents, and initiating appropriate diagnostic follow-up. The combined test is standard in the UK, as per NICE guidelines, and recognising the significance of increased nuchal translucency is crucial in clinical practice.\n\n**Memory Anchor**\n‘Nuchal = Neck = Number Up in Down’s’ – Down’s syndrome means a thicker nuchal translucency.",
    "bullet_explanations": {
      "Increased nuchal translucency": "Correct – this is a classic marker for trisomy 21 in first-trimester screening.",
      "Elevated alpha fetoprotein (AFP)": "Incorrect – AFP is typically low in Down's syndrome, not elevated.",
      "Raised oestriol levels": "Incorrect – oestriol is usually decreased in pregnancies affected by trisomy 21.",
      "Reduced human chorionic gonadotrophin (hCG)": "Incorrect – hCG is typically increased, not reduced, in Down's syndrome.",
      "Decreased nuchal translucency": "Incorrect – Down's syndrome is associated with a thickened (increased) nuchal translucency."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "Screening for aneuploidy",
    "keywords": [
      "Down's syndrome",
      "nuchal translucency",
      "combined test",
      "antenatal screening",
      "trisomy 21"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Antenatal care - uncomplicated pregnancy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/antenatal-care-uncomplicated-pregnancy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8ae86768-6c4f-419a-8c3f-57602c60c148",
    "question_number": 426,
    "question": "A 7-year-old girl continues to wet the bed most nights despite positive reinforcement strategies and advice on toileting routines. She is otherwise healthy and has no daytime urinary symptoms. What is the most appropriate next step in her management?",
    "options": [
      "Introduce an enuresis alarm",
      "Start oral desmopressin",
      "Trial imipramine under specialist guidance",
      "Begin intranasal desmopressin",
      "Advise strict fluid restriction in the evening"
    ],
    "correct_answer": "Introduce an enuresis alarm",
    "explanation": "**Explanation**\n**Enuresis alarms are recommended as first-line treatment for nocturnal enuresis in children aged 5 years and above who have not responded to behavioural modifications and positive reinforcement.** Alarms are most effective in motivated and supported families, leading to the highest chance of long-term dryness and a lower relapse rate compared to drug therapies. Pharmacological agents like desmopressin are reserved for situations where alarms are unsuitable or for short-term use (e.g., sleepovers). Intranasal desmopressin is no longer recommended due to safety concerns. Tricyclic antidepressants such as imipramine are only considered by specialists when all other interventions have failed. Fluid restriction is not routinely advised as evidence does not support its effectiveness and it may risk dehydration.\n\n**Key Points**\n- Enuresis alarms are first-line after advice and reward strategies fail.\n- Most effective in motivated, well-supported children aged 5+.\n- Alarms offer lower relapse rates than desmopressin.\n- Pharmacological treatments are reserved for when alarms are not suitable or desired.\n- Intranasal desmopressin is not recommended due to side effects.\n- Imipramine is a last-resort option, under specialist care only.\n- Routine strict fluid restriction is not advised.\n\n**Clinical Relevance**\nPrompt, evidence-based management of primary nocturnal enuresis improves quality of life for children and families. National guidelines (NICE, BNF) support starting with non-drug therapies, reserving medications for selected cases, reinforcing the importance of stepwise care.\n\n**Memory Anchor**\nA for Alarm: After Advice, use Alarm first.",
    "bullet_explanations": {
      "Introduce an enuresis alarm": "Correct. First-line after non-drug measures fail in motivated children over age 5.",
      "Start oral desmopressin": "Incorrect. Desmopressin is a second-line option if alarms are impractical or unsuccessful.",
      "Trial imipramine under specialist guidance": "Incorrect. Imipramine is only considered after failure of all first- and second-line options and requires specialist involvement.",
      "Begin intranasal desmopressin": "Incorrect. Intranasal formulation is not recommended due to risk of hyponatraemia.",
      "Advise strict fluid restriction in the evening": "Incorrect. Fluid restriction is not routinely recommended and may be harmful."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Common Infections",
    "topic": "Enuresis (not on list, but mapped to appropriate age group and context)",
    "keywords": [
      "nocturnal enuresis",
      "bedwetting",
      "enuresis alarm",
      "paediatric continence",
      "child"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Nocturnal enuresis in children",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/nocturnal-enuresis-in-children/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Bedwetting (enuresis)",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/bedwetting-enuresis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "911719b9-7448-4476-989d-326877479b00",
    "question_number": 427,
    "question": "A 7-month-old girl is brought to the paediatric assessment unit with sudden episodes of severe, colicky abdominal pain during which she draws her legs up and cries intensely. Between the episodes, she appears pale and lethargic. Her mother reports she has vomited twice and recently passed a small amount of blood-stained, mucoid stool. On examination, a tender mass is felt in the right side of her abdomen. Which imaging modality is the most appropriate first-line investigation to confirm the suspected diagnosis?",
    "options": [
      "Abdominal ultrasound",
      "Contrast enema",
      "CT abdomen and pelvis",
      "Plain abdominal X-ray",
      "Magnetic resonance imaging (MRI)"
    ],
    "correct_answer": "Abdominal ultrasound",
    "explanation": "**Explanation**\n**Abdominal ultrasound** is the preferred first-line investigation for suspected intussusception in children. It is non-invasive, quick to perform, does not involve radiation, and is highly sensitive and specific. On ultrasound, a characteristic 'target' or 'doughnut' sign is often seen, reflecting the telescoped bowel segments. Alternative imaging such as CT exposes infants to unnecessary ionising radiation and takes longer to arrange. While a contrast enema may be both diagnostic and therapeutic, ultrasound is the standard initial diagnostic test. Plain X-rays have limited sensitivity and are more useful for excluding perforation or obstruction. MRI is not practical for acute presentation and is not used routinely for this diagnosis.<br><br>**Key differences**: Ultrasound is highly accurate for intussusception and avoids radiation, which is especially important in infants and young children.\n\n**Key Points**\n- Intussusception presents with intermittent severe abdominal pain, vomiting, and 'redcurrant jelly' stool.\n- A palpable right-sided abdominal mass is suggestive.\n- Abdominal ultrasound is the diagnostic modality of choice, showing a 'target sign'.\n- Ultrasound is safe, rapid, and does not use ionising radiation.\n- CT and MRI are not routinely indicated due to time, access, and radiation considerations.\n- Contrast enema can be therapeutic but is not first-line for diagnosis.\n\n**Clinical Relevance**\nPrompt diagnosis of intussusception is vital to prevent serious complications such as bowel ischaemia and perforation. Ultrasound is recommended in national and international paediatric guidelines as the initial investigation due to its accuracy and safety profile.\n\n**Memory Anchor**\nRemember: **'U' for Ultrasound and 'U' for Under two years old**—intussusception is most common in infants, and ultrasound is the best first test.",
    "bullet_explanations": {
      "Abdominal ultrasound": "Correct – most sensitive and specific initial test for intussusception.",
      "Contrast enema": "Therapeutic and sometimes diagnostic, but not the recommended initial imaging investigation.",
      "CT abdomen and pelvis": "Not first-line; exposes children to unnecessary radiation and is less accessible in emergency paediatric settings.",
      "Plain abdominal X-ray": "May show signs of obstruction or perforation, but low sensitivity for intussusception specifically.",
      "Magnetic resonance imaging (MRI)": "Rarely used for acute abdominal emergencies in infants due to access and speed; not appropriate here."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Biliary & Pancreas",
    "subsubsection": "Gallstone Disease",
    "topic": "Ultrasound first-line and lab patterns",
    "keywords": [
      "intussusception",
      "ultrasound",
      "paediatric abdominal pain"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "4ef737f5-1ece-4f21-932a-713200bb2bf2",
    "question_number": 428,
    "question": "A 71-year-old man with a history of hypertension and benign prostatic hyperplasia is prescribed a new antihypertensive. Shortly afterwards, he develops new-onset urinary leakage when laughing or lifting heavy objects. Which medication is most likely contributing to his symptoms?",
    "options": [
      "Doxazosin",
      "Amlodipine",
      "Mirabegron",
      "Memantine",
      "Ramipril"
    ],
    "correct_answer": "Doxazosin",
    "explanation": "**Explanation**\n**Doxazosin** is an alpha-1 adrenergic blocker used for hypertension and urinary outflow obstruction in benign prostatic hyperplasia. However, by relaxing smooth muscle at the bladder neck and urethra, it can reduce urethral resistance and worsen or provoke stress incontinence, especially in individuals with predisposing factors. This effect contrasts with medications like mirabegron, which target bladder overactivity rather than outlet tone, and other antihypertensives, which do not impact urinary continence mechanisms.\n\n**Key Points**\n- Doxazosin relaxes smooth muscle in the bladder neck and urethra via alpha-1 blockade.\n- Reduction in urethral resistance can precipitate or aggravate stress incontinence.\n- Stress incontinence is triggered by increased intra-abdominal pressure (e.g., coughing, laughing).\n- Other antihypertensives (amlodipine, ramipril) and cognitive agents (memantine) do not typically affect continence.\n- Mirabegron is used for urge incontinence, not stress incontinence.\n\n**Clinical Relevance**\nRecognising medications that worsen urinary incontinence is crucial, particularly in older adults or those already at risk. Alpha blockers such as doxazosin can exacerbate stress incontinence and should be used cautiously in susceptible patients. Always review new or worsening urinary symptoms in the context of recent medication changes. [BNF guidance: Urinary incontinence and pelvic organ prolapse in women]\n\n**Memory Anchor**\nAlpha blockers = 'Allow leakage' by relaxing the bladder outlet.",
    "bullet_explanations": {
      "Doxazosin": "Correct – alpha blockers can precipitate or worsen stress incontinence by relaxing bladder outlet smooth muscle.",
      "Amlodipine": "Incorrect – a calcium channel blocker, not associated with incontinence side effects.",
      "Mirabegron": "Incorrect – used to manage urge incontinence, not a cause of stress incontinence.",
      "Memantine": "Incorrect – cognitive enhancer used in dementia, unrelated to urinary continence.",
      "Ramipril": "Incorrect – ACE inhibitor, not known to affect continence."
    },
    "category": "Renal & Urology",
    "subsection": "Urology",
    "subsubsection": "Obstruction",
    "topic": "BPH",
    "keywords": [
      "doxazosin",
      "stress incontinence",
      "alpha blocker",
      "medication side effects",
      "BPH"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Urinary incontinence and pelvic organ prolapse in women",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/urinary-incontinence-and-pelvic-organ-prolapse-in-women/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "92b0a920-8170-4af0-baa3-ac3408d2ccac",
    "question_number": 429,
    "question": "Which nerve root is primarily assessed by eliciting the Achilles tendon (ankle jerk) reflex during a neurological examination?",
    "options": [
      "S1-S2",
      "L2-L3",
      "L3-L4",
      "L1-L2",
      "S3-S4"
    ],
    "correct_answer": "S1-S2",
    "explanation": "**Explanation**\nThe Achilles tendon (ankle jerk) reflex tests the integrity of the **S1 and S2 nerve roots**. When the Achilles tendon is tapped, a normal response is plantarflexion of the foot, mediated via the gastrocnemius and soleus muscles, both innervated primarily by S1 and to a lesser extent S2. Loss or reduction of this reflex suggests pathology affecting these sacral roots or their peripheral nerves. In contrast, the patellar (knee jerk) reflex assesses L3-L4, and hip flexion is mainly governed by L2-L3. The S3-S4 segments are predominantly involved in pelvic floor and sphincter control, not in lower limb reflexes.\n\n**Key Points**\n- Achilles reflex = ankle jerk = S1-S2 roots\n- Plantarflexion is the expected response\n- Patellar (knee jerk) reflex = L3-L4 roots\n- S3-S4 roots control pelvic floor and continence\n- Weak or absent ankle jerk may indicate S1/S2 radiculopathy or sciatic nerve injury\n\n**Clinical Relevance**\nAccurate identification of nerve root involvement through reflex testing is crucial for localising neurological lesions. For example, radiculopathy due to disc herniation or neuropathy may present with loss of the ankle jerk, guiding further investigation and referral if necessary.\n\n**Memory Anchor**\n‘S1 steps on the SUN’—S1 mediates plantarflexion (stepping down) and the ankle jerk.",
    "bullet_explanations": {
      "S1-S2": "Correct – the Achilles reflex assesses the S1 and S2 nerve roots.",
      "L2-L3": "Incorrect – these roots mainly control hip flexion, not the ankle jerk.",
      "L3-L4": "Incorrect – these are responsible for knee extension and the patellar reflex.",
      "L1-L2": "Incorrect – these roots are involved in hip flexion but not the ankle reflex.",
      "S3-S4": "Incorrect – these sacral roots are associated with pelvic floor and sphincter function."
    },
    "category": "Musculoskeletal",
    "subsection": "Arthritis",
    "subsubsection": "Osteoarthritis",
    "topic": "Typical presentation and joints affected",
    "keywords": [
      "Achilles reflex",
      "ankle jerk",
      "S1 nerve root",
      "neurological examination",
      "lower limb reflexes"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Achilles tendinopathy",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/achilles-tendinopathy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "8f71714a-ea66-4a4b-8062-44178a99c0dc",
    "question_number": 430,
    "question": "A 26-year-old woman at 10 weeks’ gestation presents with a thin, fishy-smelling vaginal discharge. High vaginal swab confirms bacterial vaginosis. She is otherwise healthy and has no drug allergies. What is the recommended first-line therapy for her symptoms during pregnancy?",
    "options": [
      "Oral metronidazole",
      "Oral doxycycline",
      "Oral cefalexin",
      "Vaginal clindamycin cream",
      "Oral amoxicillin"
    ],
    "correct_answer": "Oral metronidazole",
    "explanation": "**Explanation**\nOral metronidazole is the recommended first-line treatment for symptomatic bacterial vaginosis (BV) during pregnancy. **BV in pregnancy is associated with increased risks of late miscarriage and preterm birth**, thus symptomatic women should be treated. Metronidazole is effective and safe in pregnancy, particularly in the standard 400 mg twice daily dose for 5–7 days. The single high-dose regimen is not advised in pregnancy. **Oral metronidazole is preferred over topical options in pregnancy**. Doxycycline is contraindicated in pregnancy due to teratogenicity, while cefalexin and amoxicillin are not effective against the anaerobic organisms causing BV. Vaginal clindamycin cream is not recommended in the first trimester.\n\n**Key Points**\n- Treat all symptomatic pregnant women with BV to reduce obstetric risks.\n- Oral metronidazole 400 mg twice daily for 5–7 days is first-line.\n- Single high-dose (2 g) metronidazole is not recommended in pregnancy.\n- Doxycycline is contraindicated in pregnancy.\n- Topical clindamycin cream is not advised in the first trimester.\n\n**Clinical Relevance**\nRecognising and treating BV in pregnancy is important to minimise complications such as preterm birth. NICE CKS recommends oral metronidazole for symptomatic pregnant women, highlighting the need for targeted antimicrobial therapy and patient safety.\n\n**Memory Anchor**\nBV = 'Baby Vulnerability'; treat with Metronidazole for symptomatic pregnant women.",
    "bullet_explanations": {
      "Oral metronidazole": "Correct—preferred first-line treatment for symptomatic BV during pregnancy.",
      "Oral doxycycline": "Incorrect—contraindicated in pregnancy due to risk of fetal harm.",
      "Oral cefalexin": "Incorrect—not effective for BV, which is caused by anaerobes.",
      "Vaginal clindamycin cream": "Incorrect—not recommended in the first trimester of pregnancy.",
      "Oral amoxicillin": "Incorrect—not active against the typical organisms in BV."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Early Pregnancy Problems",
    "topic": "Bacterial vaginosis",
    "keywords": [
      "bacterial vaginosis",
      "pregnancy",
      "metronidazole",
      "antenatal infection",
      "BV treatment"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Bacterial vaginosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/bacterial-vaginosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0dd727e9-86bc-41ed-ae36-35b8505a6ff2",
    "question_number": 431,
    "question": "A 26-year-old nulliparous woman reports chronic pelvic pain and deep dyspareunia, which worsen in the days before and after her menstrual period. She has tried regular paracetamol and NSAIDs without sufficient relief. What is the next most appropriate management step for her likely diagnosis?",
    "options": [
      "Initiate a combined oral contraceptive pill",
      "Refer directly for laparoscopic excision",
      "Start clomifene citrate",
      "Commence a GnRH analogue (e.g. leuprorelin)",
      "Offer elagolix therapy"
    ],
    "correct_answer": "Initiate a combined oral contraceptive pill",
    "explanation": "**Explanation**\n**Endometriosis should be suspected based on cyclical pelvic pain and deep dyspareunia.** First-line management involves simple analgesia, but if this fails, the next recommended step is hormonal therapy using either a combined oral contraceptive pill or a progestogen. **These hormonal treatments suppress ovulation and reduce endometrial proliferation, leading to improved pain control.** More invasive options such as surgery or advanced hormonal agents are typically reserved for refractory cases or where fertility is the primary concern. Initiating the combined oral contraceptive pill is supported by both BNF and NICE guidelines, as it is effective, accessible, and generally well-tolerated.\n\n**Key Points**\n- Suspect endometriosis in women with cyclical pelvic pain, dysmenorrhoea, and deep dyspareunia.\n- Initial management is with simple analgesics (paracetamol, NSAIDs).\n- If analgesia is inadequate, hormonal therapy (COCP or progestogen) is the next step.\n- Advanced therapies and surgical intervention are reserved for persistent cases.\n- Fertility treatments are only indicated if conception is a priority and pain is not the main concern.\n\n**Clinical Relevance**\nTimely escalation to hormonal therapy for endometriosis-related pain can prevent unnecessary suffering and reduce the need for invasive interventions. National guidelines endorse the use of the combined oral contraceptive pill as the next step after failed simple analgesia, emphasising a patient-centred and stepwise approach.",
    "bullet_explanations": {
      "Initiate a combined oral contraceptive pill": "Correct – this is the recommended next step after unsuccessful simple analgesia for endometriosis-related pain.",
      "Refer directly for laparoscopic excision": "Incorrect – surgery is considered if medical treatments fail or are not tolerated, not as the next immediate step.",
      "Start clomifene citrate": "Incorrect – clomifene is used for ovulation induction in infertility, not for pain management in endometriosis.",
      "Commence a GnRH analogue (e.g. leuprorelin)": "Incorrect – GnRH analogues are reserved for severe or refractory cases under specialist care.",
      "Offer elagolix therapy": "Incorrect – elagolix is not widely available or recommended in the UK for endometriosis at this stage."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Menstrual Disorders",
    "topic": "Dysmenorrhoea",
    "keywords": [
      "endometriosis",
      "chronic pelvic pain",
      "COCP",
      "hormonal therapy",
      "stepwise management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Endometriosis",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/endometriosis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Endometriosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/endometriosis/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Dysmenorrhoea",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/dysmenorrhoea/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "96d373af-e66d-4ef6-896f-50f293f0762e",
    "question_number": 432,
    "question": "At what age does Perthes' disease most commonly present in children?",
    "options": [
      "4–8 years old",
      "Under 3 years old",
      "9–12 years old",
      "12–16 years old",
      "18–25 years old"
    ],
    "correct_answer": "4–8 years old",
    "explanation": "**Explanation**\n**Perthes' disease** is a paediatric condition characterised by avascular necrosis of the femoral head, leading to hip pain, stiffness, and eventual deformity if untreated. It most commonly presents between the ages of **4 and 8 years**, which is the key age range for diagnosis. Presentation outside this window, particularly in very young children or adolescents, is unusual and should prompt consideration of alternative diagnoses such as developmental dysplasia or slipped upper femoral epiphysis. Early recognition in this age group is crucial for optimal management and prevention of long-term joint dysfunction.\n\n**Key Points**\n- Perthes' disease typically affects children aged 4–8 years.\n- It is due to avascular necrosis of the femoral head epiphysis.\n- Common features: limp, hip pain, reduced range of movement.\n- Radiological findings include flattened/fragmented femoral head.\n- Unusual to present under 3 or over 9 years old; consider other diagnoses in these groups.\n- <table><thead><tr><th>Condition</th><th>Common Age of Presentation</th></tr></thead><tbody><tr><td>Perthes' disease</td><td>4–8 years</td></tr><tr><td>Slipped upper femoral epiphysis</td><td>Over 9 years</td></tr><tr><td>Septic arthritis</td><td>Under 3 years</td></tr></tbody></table>\n\n**Clinical Relevance**\nUnderstanding the typical age of onset for Perthes' disease helps differentiate it from other paediatric hip disorders and ensures timely orthopaedic referral for children presenting with a limp or restricted hip movement. Guidelines highlight the importance of age in narrowing the differential diagnosis of a childhood limp.\n\n**Memory Anchor**\nPerthes' Peaks: **4 to 8** rhymes with 'late primary'—think of it as the age of starting school.",
    "bullet_explanations": {
      "4–8 years old": "Correct—Perthes' disease most commonly presents in this age group.",
      "Under 3 years old": "Incorrect—This age group is more typically affected by septic arthritis or developmental dysplasia.",
      "9–12 years old": "Incorrect—Older children with hip pain are more likely to have slipped upper femoral epiphysis.",
      "12–16 years old": "Incorrect—This age is outside the typical range for Perthes' disease.",
      "18–25 years old": "Incorrect—Perthes' disease does not present in young adults."
    },
    "category": "Musculoskeletal",
    "subsection": "Arthritis",
    "subsubsection": "Osteoarthritis",
    "topic": "Typical presentation and joints affected",
    "keywords": [
      "Perthes disease",
      "paediatric limp",
      "age of onset"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Acute childhood limp",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/acute-childhood-limp/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f2174e67-869b-4839-9d9c-527a319d8982",
    "question_number": 433,
    "question": "Which of the following is a recognised risk factor for developing adhesive capsulitis (frozen shoulder)?",
    "options": [
      "Diabetes mellitus",
      "Male gender",
      "Regular racquet sports participation",
      "Symptoms predominantly in the dominant arm",
      "Age over 70 years"
    ],
    "correct_answer": "Diabetes mellitus",
    "explanation": "**Explanation**\n**Diabetes mellitus is a well-established risk factor for adhesive capsulitis, with up to 20% of diabetic patients experiencing frozen shoulder during their lifetime.** The cause of adhesive capsulitis is not fully understood, but metabolic conditions such as diabetes, and to a lesser extent thyroid disease, are recognised associations. Age and gender trends show increased prevalence in middle-aged females, while symptoms often appear in the non-dominant arm. There is no strong evidence linking adhesive capsulitis to physical activity, handedness, or advanced age alone.\n\n**Key Points**\n- Adhesive capsulitis is commonly known as frozen shoulder.\n- Diabetes mellitus increases the risk—up to 20% of patients may be affected.\n- Most cases occur in women aged 40–60 years.\n- Symptoms often affect the non-dominant shoulder.\n- No direct association with sports activity or arm dominance.\n- Physical trauma or immobilisation can also increase risk.\n\n**Clinical Relevance**\nIdentifying risk factors for adhesive capsulitis is crucial for primary care assessment of shoulder pain, especially in patients with diabetes. Early recognition can prompt appropriate management and diabetes screening, in line with NICE CKS recommendations.\n\n**Memory Anchor**\nRemember: 'Diabetic patients are predisposed to develop a 'stiff shoulder.'",
    "bullet_explanations": {
      "Diabetes mellitus": "Correct: Diabetes is a recognised risk factor for adhesive capsulitis.",
      "Male gender": "Incorrect: Frozen shoulder is more common in females.",
      "Regular racquet sports participation": "Incorrect: Activity or sports participation is not a risk factor.",
      "Symptoms predominantly in the dominant arm": "Incorrect: The non-dominant arm is more commonly affected.",
      "Age over 70 years": "Incorrect: The peak incidence is in middle-aged adults, not the elderly."
    },
    "category": "Musculoskeletal",
    "subsection": "Soft Tissue",
    "subsubsection": "Soft Tissue Injuries",
    "topic": "Tendon rupture management",
    "keywords": [
      "adhesive capsulitis",
      "frozen shoulder",
      "diabetes mellitus",
      "risk factors",
      "shoulder pain"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Shoulder pain",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/shoulder-pain/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "f3e0073b-bf83-4510-968e-4fda6c151491",
    "question_number": 434,
    "question": "What is the most frequent causative organism of vertebral discitis in adults presenting with fever and back pain?",
    "options": [
      "Staphylococcus aureus",
      "Mycobacterium tuberculosis",
      "Escherichia coli",
      "Streptococcus agalactiae",
      "Enterococcus faecalis"
    ],
    "correct_answer": "Staphylococcus aureus",
    "explanation": "**Explanation**\n**Staphylococcus aureus** is the leading cause of vertebral discitis in adults. It enters the bloodstream—often from skin, soft tissue, or invasive procedures—and seeds the intervertebral disc space, resulting in infection. While other organisms such as Gram-negative bacilli or Mycobacterium tuberculosis can cause discitis, they are much less common. S. aureus is particularly important to consider in individuals with risk factors like diabetes, immunosuppression, or recent bacteraemia. Recognising the typical causative organism guides empiric antibiotic therapy and improves outcomes. Other bacteria listed are possible but occur far less frequently in this context.\n\n**Key Points**\n- Staphylococcus aureus accounts for most adult discitis cases.\n- Discitis presents with back pain, fever, and sometimes neurological deficits.\n- Risk factors: diabetes, immunosuppression, previous infection, or invasive procedures.\n- Empiric antibiotics should cover S. aureus pending culture results.\n- Other causes (e.g., tuberculosis, Gram-negatives) are considered with relevant history or risk factors.\n- <table><thead><tr><th>Organism</th><th>Relative Frequency in Discitis</th></tr></thead><tbody><tr><td>Staphylococcus aureus</td><td>Most common</td></tr><tr><td>Gram-negative bacilli</td><td>Uncommon</td></tr><tr><td>Streptococci</td><td>Occasional</td></tr><tr><td>Mycobacterium tuberculosis</td><td>Rare (except high-risk groups)</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrompt recognition of S. aureus as the main cause of adult discitis is vital for selecting empiric antibiotics and preventing severe complications such as epidural abscess or sepsis. Early treatment and multidisciplinary care are especially important in patients with comorbidities such as diabetes. National guidelines stress the need for urgent assessment and appropriate microbiological sampling before antibiotic initiation.\n\n**Memory Anchor**\nS. aureus is the default answer for most bone and joint infections in adults.",
    "bullet_explanations": {
      "Staphylococcus aureus": "Correct—most frequent cause of discitis in adults, especially with risk factors.",
      "Mycobacterium tuberculosis": "Can cause discitis ('Pott's disease'), but is rare in the UK without specific risk factors.",
      "Escherichia coli": "Possible in post-urinary tract infection or immunocompromised patients, but less common than S. aureus.",
      "Streptococcus agalactiae": "May cause discitis, usually in neonates or immunosuppressed adults; less common overall.",
      "Enterococcus faecalis": "Occasionally implicated, typically in healthcare-associated or immunocompromised cases."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "Sepsis & Bacteraemia",
    "topic": "Source control principles",
    "keywords": [
      "discitis",
      "Staphylococcus aureus",
      "bone infection",
      "empiric antibiotics",
      "back pain"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Diabetic foot infections, antibacterial therapy",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/diabetic-foot-infections-antibacterial-therapy/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "50565c81-78ec-4899-8aef-d68d5b92e817",
    "question_number": 435,
    "question": "A 45-year-old man is admitted following collapse at home. He is found to have septic shock and reduced urine output for 24 hours. Which arterial blood gas result best reflects the acid-base disturbance likely to be seen in this scenario?",
    "options": [
      "pH 7.05, pCO2 2.1 kPa, HCO3- 8 mmol/L, anion gap 14 mmol/L",
      "pH 7.48, pCO2 6.1 kPa, HCO3- 32 mmol/L",
      "pH 7.52, pCO2 2.0 kPa, HCO3- 24 mmol/L",
      "pH 7.32, pCO2 7.3 kPa, HCO3- 24 mmol/L",
      "pH 7.41, pCO2 5.3 kPa, HCO3- 24 mmol/L"
    ],
    "correct_answer": "pH 7.05, pCO2 2.1 kPa, HCO3- 8 mmol/L, anion gap 14 mmol/L",
    "explanation": "**Explanation**\nThis blood gas demonstrates a **severe metabolic acidosis** (low pH, very low bicarbonate) with a **normal anion gap**. In the context of sepsis and acute kidney injury, lactic acid accumulation from tissue hypoperfusion and impaired renal acid excretion are the main causes. While typically lactic acidosis produces a raised anion gap, a value of 14 mmol/L is still within the upper normal range (normal: 10–18 mmol/L), so this result is consistent with the scenario described. **Key distinguishing features:** low pH (<7.35), low HCO3- (<22 mmol/L), and low/normal pCO2 (compensatory respiratory alkalosis may occur). Metabolic acidosis is the hallmark of acute kidney injury secondary to sepsis, with or without a mild increase in anion gap depending on the balance of retained acids.\n\n**Key Points**\n- Sepsis leads to tissue hypoperfusion and increased lactate production.\n- Acute kidney injury reduces excretion of acids, worsening acidosis.\n- Anion gap helps differentiate causes of metabolic acidosis.\n- Typical findings: low pH, low HCO3-, variable pCO2.\n- Raised or high-normal anion gap suggests lactic or other organic acid accumulation.\n\n**Clinical Relevance**\nRecognising metabolic acidosis on blood gas is critical in patients with sepsis and acute kidney injury. Early identification prompts rapid resuscitation and management to prevent further organ damage and guide fluid/electrolyte therapy.",
    "bullet_explanations": {
      "pH 7.05, pCO2 2.1 kPa, HCO3- 8 mmol/L, anion gap 14 mmol/L": "Correct – classic for severe metabolic acidosis in sepsis/AKI.",
      "pH 7.48, pCO2 6.1 kPa, HCO3- 32 mmol/L": "Incorrect – represents metabolic alkalosis, not expected in sepsis/AKI.",
      "pH 7.52, pCO2 2.0 kPa, HCO3- 24 mmol/L": "Incorrect – indicates respiratory alkalosis, seen in early sepsis but not with established AKI and acidosis.",
      "pH 7.32, pCO2 7.3 kPa, HCO3- 24 mmol/L": "Incorrect – shows mild acidaemia with minimal metabolic compensation, not consistent with severe metabolic acidosis.",
      "pH 7.41, pCO2 5.3 kPa, HCO3- 24 mmol/L": "Incorrect – normal values, not compatible with acute severe illness."
    },
    "category": "Renal & Urology",
    "subsection": "Acute Kidney Injury",
    "subsubsection": "Diagnosis",
    "topic": "Creatinine and urine output criteria",
    "keywords": [
      "metabolic acidosis",
      "sepsis",
      "acute kidney injury",
      "blood gas",
      "anion gap"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "d7d73a4e-5588-4277-8aba-4ade86c749c4",
    "question_number": 436,
    "question": "A 78-year-old man is found to be acutely short of breath and confused on a medical ward. He has a history of hypertension and type 2 diabetes. On examination, his blood pressure is 85/54 mmHg, pulse is 155 and irregular, and he has bilateral basal crackles with a raised JVP. His ECG confirms new-onset atrial fibrillation. Which is the most appropriate immediate management?",
    "options": [
      "Immediate synchronised electrical cardioversion",
      "Oral beta-blocker administration",
      "IV flecainide administration",
      "Oral digoxin initiation",
      "IV amiodarone infusion"
    ],
    "correct_answer": "Immediate synchronised electrical cardioversion",
    "explanation": "**Explanation**\n**Immediate synchronised DC cardioversion** is indicated for new-onset atrial fibrillation in patients presenting with life-threatening haemodynamic instability, such as hypotension, pulmonary oedema, or altered mental status. In this scenario, the patient exhibits hypotension, heart failure signs, and confusion—clear adverse signs requiring urgent rhythm control. Electrical (not pharmacological) cardioversion is recommended in unstable patients because it rapidly restores sinus rhythm, preventing further compromise. Pharmacological cardioversion, beta-blockers, or digoxin are inappropriate in this acute context, as they act too slowly and may worsen haemodynamics. Flecainide is contraindicated due to structural heart disease and instability. Amiodarone IV may be considered if immediate cardioversion fails or is unavailable, but is not first-line for peri-arrest instability.\n\n**Key Points:**\n- Unstable AF (hypotension, pulmonary oedema, confusion) requires urgent electrical cardioversion.\n- Rate control agents are for stable patients; in unstable cases, they delay definitive management.\n- Electrical cardioversion is preferred over pharmacological methods in emergencies.\n- IV flecainide is contraindicated if structural heart disease or instability is present.\n- Digoxin acts slowly and is not suitable for acute rhythm or rate control in instability.\n\n<table><thead><tr><th>Scenario</th><th>First-line Management</th></tr></thead><tbody><tr><td>Haemodynamically unstable AF</td><td>Electrical cardioversion</td></tr><tr><td>Stable, rapid AF</td><td>Rate control (beta-blocker/CCB/digoxin)</td></tr></tbody></table>\n\n**Clinical Relevance:**\nRecognising and urgently treating haemodynamic compromise in new-onset AF is crucial to prevent cardiac arrest and multi-organ failure. UK guidelines (BNF, NICE CKS) stress that immediate electrical cardioversion is lifesaving in these contexts. Delay in definitive therapy can be fatal.\n\n**Memory Anchor:**\nUnstable = \"Shock the heart\" (electrical shock for shock).\n\n**Key Points**\n- Electrical cardioversion is indicated for AF with adverse features (shock, pulmonary oedema, syncope, ischaemia).\n- Pharmacological cardioversion or rate control is reserved for stable patients.\n- Digoxin and oral agents are too slow for acutely unstable presentations.\n- Flecainide is contraindicated in structural heart disease and instability.\n- Prompt intervention prevents progression to cardiac arrest.\n\n**Clinical Relevance**\nImmediate recognition of unstable atrial fibrillation and urgent electrical cardioversion is a core emergency skill and follows national guidelines. Delay can result in deterioration and increased mortality.\n\n**Memory Anchor**\nUnstable = \"Shock the heart\" (electrical shock for shock).",
    "bullet_explanations": {
      "Immediate synchronised electrical cardioversion": "Correct – indicated for AF causing haemodynamic instability (hypotension, pulmonary oedema, confusion).",
      "Oral beta-blocker administration": "Incorrect – too slow in onset and inappropriate in acute instability.",
      "IV flecainide administration": "Incorrect – contraindicated in structural heart disease and with instability; not first-line in emergencies.",
      "Oral digoxin initiation": "Incorrect – slow onset; unsuitable for acute unstable presentations.",
      "IV amiodarone infusion": "Incorrect – may be considered if cardioversion is not possible, but not first-line for peri-arrest instability."
    },
    "category": "Cardiovascular",
    "subsection": "Arrhythmias & Conduction",
    "subsubsection": "Atrial Fibrillation/Flutter",
    "topic": "Cardioversion (electrical vs pharmacological) indications",
    "keywords": [
      "atrial fibrillation",
      "electrical cardioversion",
      "unstable arrhythmia",
      "emergency management"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Arrhythmias",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/arrhythmias/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "Atrial fibrillation",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/atrial-fibrillation/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "220b1496-37e8-4087-bb98-30b8046c64b9",
    "question_number": 437,
    "question": "A 48-year-old woman presents with a painful, blistering rash on the right side of her forehead and extending onto the tip of her nose. She reports mild eye discomfort, but no visual changes. What is the most significant clinical concern in this scenario?",
    "options": [
      "Ocular involvement requiring urgent ophthalmology review",
      "Development of secondary bacterial skin infection",
      "Progression to post-herpetic neuralgia",
      "Risk of facial scarring",
      "Onset of trigeminal neuralgia"
    ],
    "correct_answer": "Ocular involvement requiring urgent ophthalmology review",
    "explanation": "**Explanation**\n**The presence of vesicles on the tip of the nose (Hutchinson's sign) in herpes zoster involving the ophthalmic branch of the trigeminal nerve signals likely involvement of the nasociliary nerve, which also supplies the cornea.** This raises the risk of serious ocular complications, such as keratitis, uveitis, or even vision loss, and mandates urgent ophthalmology assessment. While pain and skin complications are common in shingles, the most pressing issue in this context is the potential for sight-threatening eye disease.\n\n**Key Points**\n- Hutchinson's sign (vesicles on the nose tip) indicates nasociliary nerve involvement.\n- The nasociliary nerve supplies both the cornea and the nasal tip.\n- Ocular complications can include keratitis, uveitis, and potential vision loss.\n- Urgent ophthalmology review is required if ocular involvement is suspected.\n- Other complications (e.g., post-herpetic neuralgia) are common but less acutely sight-threatening.\n\n**Clinical Relevance**\nRecognising Hutchinson's sign is essential in primary care to prevent irreversible ocular damage from herpes zoster ophthalmicus. The NICE CKS highlights the importance of urgent specialist referral when eye involvement is suspected in shingles.\n\n**Memory Anchor**\nHutchinson's sign = 'Nose means Nerve to the cornea' (Nose tip rash signals corneal risk).",
    "bullet_explanations": {
      "Ocular involvement requiring urgent ophthalmology review": "Correct – Vesicles on the nose tip raise the risk of eye involvement, which can threaten vision.",
      "Development of secondary bacterial skin infection": "Possible, but not the most urgent concern compared to ocular involvement.",
      "Progression to post-herpetic neuralgia": "A common sequela, especially in older adults, but not the immediate threat in this context.",
      "Risk of facial scarring": "Scarring may occur, but sight loss from eye involvement is much more significant.",
      "Onset of trigeminal neuralgia": "Rarely a direct complication of shingles; not the primary concern in acute facial zoster."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "Dermatology",
    "subsubsection": "Infections",
    "topic": "Viral exanthems",
    "keywords": [
      "herpes zoster ophthalmicus",
      "Hutchinson's sign",
      "ocular complications",
      "shingles",
      "urgent referral"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Shingles",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/shingles/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "cd41e7ba-623f-4c67-bfe9-bf4ac8357799",
    "question_number": 438,
    "question": "A 45-year-old man with newly diagnosed discoid lupus erythematosus is started on hydroxychloroquine. Which serious adverse effect should he be specifically warned about before commencing therapy?",
    "options": [
      "Risk of pulmonary fibrosis",
      "Permanent visual impairment",
      "Development of hypothyroidism",
      "Orange discolouration of urine",
      "Haemorrhagic cystitis"
    ],
    "correct_answer": "Permanent visual impairment",
    "explanation": "**Explanation**\n**Hydroxychloroquine can cause a severe and potentially irreversible retinopathy**—even at standard doses. This retinopathy may lead to permanent vision loss if not detected early. The drug accumulates in retinal pigment epithelial cells, particularly with long-term use or higher dosages, and can result in a 'bull's-eye' maculopathy. **All patients starting hydroxychloroquine should be counselled about the risk of visual changes and the need for regular ophthalmological assessments.** This adverse effect differentiates hydroxychloroquine from other disease-modifying antirheumatic drugs (DMARDs), which have different main toxicities (e.g., methotrexate—pulmonary fibrosis, cyclophosphamide—haemorrhagic cystitis).\n\n**Key Points**\n- Hydroxychloroquine is used to treat lupus erythematosus and rheumatoid arthritis.\n- The most concerning long-term adverse effect is retinal toxicity, which can be permanent.\n- Patients should have baseline and annual eye examinations when on long-term therapy.\n- Visual symptoms may be subtle; early detection is crucial to prevent irreversible damage.\n- Other DMARDs have different notable toxicities (see table below).\n- <table><thead><tr><th>Drug</th><th>Key Serious Side Effect</th></tr></thead><tbody><tr><td>Hydroxychloroquine</td><td>Retinopathy</td></tr><tr><td>Methotrexate</td><td>Pneumonitis, hepatotoxicity</td></tr><tr><td>Cyclophosphamide</td><td>Haemorrhagic cystitis</td></tr><tr><td>Rifampicin</td><td>Orange urine/tears</td></tr><tr><td>Amiodarone</td><td>Thyroid dysfunction</td></tr></tbody></table>\n\n**Clinical Relevance**\nRegular ophthalmological monitoring for patients on hydroxychloroquine is mandated by best practice and national guidelines. Missing early signs of retinopathy can lead to irreversible vision loss, so clinicians must educate patients and ensure annual eye checks are arranged.\n\n**Memory Anchor**\nHydroxychloroquine: 'HYDROxychloroquine can HYDROw away your sight' (HYDRO = eye/vision association).",
    "bullet_explanations": {
      "Risk of pulmonary fibrosis": "Methotrexate and other drugs (not hydroxychloroquine) may cause pulmonary fibrosis.",
      "Permanent visual impairment": "Correct – hydroxychloroquine is associated with irreversible retinopathy if not monitored.",
      "Development of hypothyroidism": "Amiodarone, not hydroxychloroquine, is known for thyroid toxicity.",
      "Orange discolouration of urine": "Rifampicin, an antibiotic, can cause this; hydroxychloroquine does not.",
      "Haemorrhagic cystitis": "This is a known complication of cyclophosphamide, not hydroxychloroquine."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Immunology",
    "subsubsection": "Autoimmunity",
    "topic": "SLE diagnostic features",
    "keywords": [
      "hydroxychloroquine",
      "retinopathy",
      "SLE",
      "DMARD adverse effects"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Rheumatic disease, suppressing drugs",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/rheumatic-disease-suppressing-drugs/"
      },
      {
        "source": "NICE CKS",
        "topic_title": "DMARDs",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/dmards/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "e36f9326-ae31-41f5-a2ad-64e7e6fdd22d",
    "question_number": 439,
    "question": "A 54-year-old man with recently diagnosed hypertension is found to have an average ambulatory blood pressure of 142/87 mmHg. He has a 7-year history of type 2 diabetes, managed with diet and metformin. What is the most appropriate first-line antihypertensive agent to initiate for this patient?",
    "options": [
      "Amlodipine",
      "Ramipril",
      "Indapamide",
      "Bisoprolol",
      "Lifestyle advice alone"
    ],
    "correct_answer": "Ramipril",
    "explanation": "**Explanation**\n**ACE inhibitors (such as ramipril)** are recommended as the initial antihypertensive therapy for patients of any age with type 2 diabetes who are newly diagnosed with hypertension, unless contraindicated. This guidance is irrespective of age or ethnic background (except those of black African or African-Caribbean descent, where an ARB is often preferred). ACE inhibitors have proven efficacy in reducing both macrovascular and microvascular complications associated with diabetes. In contrast, calcium channel blockers like amlodipine are the first-line agents in non-diabetic patients over 55. Thiazide-like diuretics and beta-blockers are reserved for subsequent steps or specific indications. Lifestyle advice is important but not sufficient as monotherapy when drug treatment is indicated.\n\n**Key Points**\n- ACE inhibitor or ARB is first-line for hypertension in patients with type 2 diabetes.\n- This applies regardless of the patient's age.\n- Amlodipine is first-line in non-diabetic patients over 55, not in diabetics.\n- Indapamide (thiazide-like diuretic) is used as add-on therapy if needed.\n- Bisoprolol is generally used at later stages or for specific indications.\n- Lifestyle advice should be given to all but is insufficient alone if drug therapy is indicated.\n\n**Clinical Relevance**\nIdentifying the appropriate initial antihypertensive agent in patients with diabetes is essential to optimise cardiovascular and renal outcomes. National guidelines (NICE, BNF) emphasise the need for prompt initiation of an ACE inhibitor or ARB in this group, helping reduce the risk of long-term complications.\n\n**Memory Anchor**\nRemember: 'R' for Ramipril, 'R' for Renal (protects diabetic kidneys).",
    "bullet_explanations": {
      "Amlodipine": "Incorrect: In patients with type 2 diabetes, an ACE inhibitor or ARB is preferred over a calcium channel blocker as initial therapy.",
      "Ramipril": "Correct: Recommended as first-line for hypertension in patients with type 2 diabetes, unless contraindicated.",
      "Indapamide": "Incorrect: Thiazide-like diuretics are considered as add-on therapy if blood pressure is not controlled with first-line agents.",
      "Bisoprolol": "Incorrect: Beta-blockers are not first-line and are reserved for resistant cases or specific comorbidities.",
      "Lifestyle advice alone": "Incorrect: Lifestyle modification should accompany drug therapy when hypertension is diagnosed in patients with diabetes."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "Hypertension in type 2 diabetes: initial therapy",
    "keywords": [
      "hypertension",
      "type 2 diabetes",
      "ACE inhibitor",
      "antihypertensive",
      "ramipril"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "86a0e197-c783-4db7-9685-7dc5e327c19c",
    "question_number": 440,
    "question": "A 6-year-old boy presents to your clinic with a 3-day history of left knee pain and limping. He has no history of trauma, fever, or weight loss. His mother mentions he recently recovered from a mild viral illness. On examination, he is afebrile and able to partially bear weight. What is the most likely diagnosis?",
    "options": [
      "Transient synovitis",
      "Slipped capital femoral epiphysis",
      "Juvenile idiopathic arthritis",
      "Septic arthritis",
      "Perthes disease"
    ],
    "correct_answer": "Transient synovitis",
    "explanation": "**Explanation**\n**Transient synovitis** is the commonest cause of acute hip or knee pain and limp in children aged 3–8 years. It often follows a recent viral infection and presents with mild to moderate pain, sometimes affecting the knee due to referred pain from the hip. The absence of fever, systemic symptoms, or trauma, and the ability to partially weight bear, all favour this benign, self-limiting diagnosis. In contrast, septic arthritis typically presents with fever, inability to weight bear, and a more toxic appearance. Perthes disease and slipped capital femoral epiphysis usually have a more chronic onset, and juvenile idiopathic arthritis often involves morning stiffness and multiple joints.\n\n**Key Points**\n- Transient synovitis usually affects children aged 3–8 years.\n- Often follows a mild viral illness or upper respiratory tract infection.\n- Symptoms: limp, hip or referred knee pain, usually afebrile.\n- Usually able to bear some weight; severe restriction suggests alternative diagnoses.\n- Septic arthritis is an important differential; look for fever and inability to bear weight.\n- Management: conservative—rest, analgesia, and monitoring for red flags.\n- <table><thead><tr><th>Feature</th><th>Transient synovitis</th><th>Septic arthritis</th></tr></thead><tbody><tr><td>Fever</td><td>Rare</td><td>Common</td></tr><tr><td>Weight-bearing</td><td>Usually possible</td><td>Often not possible</td></tr><tr><td>Onset</td><td>Acute, post-viral</td><td>Acute, often severe</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising transient synovitis is key to avoiding unnecessary interventions and ensuring timely identification of more serious conditions, such as septic arthritis. NICE CKS highlights the importance of differentiating between benign and serious causes of limp in children, guiding appropriate management and follow-up.",
    "bullet_explanations": {
      "Transient synovitis": "Correct – most common cause in this age group, especially post-viral, with mild symptoms and ability to bear weight.",
      "Slipped capital femoral epiphysis": "Incorrect – typically affects older children/adolescents (usually over 10 years), often with obesity, and presents with chronic symptoms.",
      "Juvenile idiopathic arthritis": "Incorrect – usually presents with prolonged joint swelling, stiffness (especially morning), and often involves multiple joints.",
      "Septic arthritis": "Incorrect – would expect fever, inability to bear weight, and a toxic appearance.",
      "Perthes disease": "Incorrect – more chronic onset, typically affects boys aged 4–8 years, with gradual limping and sometimes muscle wasting."
    },
    "category": "Paediatrics",
    "subsection": "Infant & Early Childhood",
    "subsubsection": "Common Infections",
    "topic": "Meningitis",
    "keywords": [
      "transient synovitis",
      "childhood limp",
      "hip pain",
      "paediatric orthopaedics",
      "post-viral"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Acute childhood limp",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/acute-childhood-limp/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d572b115-cbc2-4f49-959f-ccb23d1cf9db",
    "question_number": 441,
    "question": "A 69-year-old man taking warfarin for atrial fibrillation presents to the emergency department with mild epistaxis that has now stopped. His INR is 8.4. What is the most appropriate next step in his anticoagulation management?",
    "options": [
      "Withhold warfarin and administer intravenous vitamin K",
      "Continue warfarin at the current dose",
      "Withhold warfarin and administer oral vitamin K",
      "Withhold 1–2 doses of warfarin and restart at a lower dose",
      "Stop warfarin and give prothrombin complex concentrate"
    ],
    "correct_answer": "Withhold warfarin and administer intravenous vitamin K",
    "explanation": "**Explanation**\n**For patients on warfarin with an INR above 8.0 and minor bleeding, the recommended management is to withhold warfarin and give intravenous vitamin K (phytomenadione).** This reverses the excessive anticoagulation and reduces bleeding risk. Oral vitamin K is reserved for cases without bleeding. Major bleeds require immediate reversal with both IV vitamin K and prothrombin complex concentrate. Simply withholding warfarin or reducing the dose is insufficient at this high INR with bleeding.\n\n**Key Points**\n- INR >8.0 with minor bleeding: stop warfarin, give IV vitamin K.\n- INR >8.0 with no bleeding: stop warfarin, give oral vitamin K.\n- Major bleeding: stop warfarin, give IV vitamin K and prothrombin complex.\n- INR 5.0–8.0, no bleeding: withhold 1–2 doses, consider dose reduction.\n- Restart warfarin when INR <5.0.\n\n**Clinical Relevance**\nPrompt and appropriate reversal of warfarin over-anticoagulation is essential to prevent progression to serious haemorrhage. National guidelines (BNF) provide clear thresholds for intervention according to INR and bleeding severity.\n\n**Memory Anchor**\nHigh INR + Bleeding = IV vitamin K (think 'I' for Intravenous and Immediate action)",
    "bullet_explanations": {
      "Withhold warfarin and administer intravenous vitamin K": "Correct—guidelines recommend IV vitamin K for INR >8.0 with minor bleeding.",
      "Continue warfarin at the current dose": "Incorrect—continuing warfarin is unsafe at such a high INR with any bleeding.",
      "Withhold warfarin and administer oral vitamin K": "Incorrect—oral vitamin K is for high INR without bleeding.",
      "Withhold 1–2 doses of warfarin and restart at a lower dose": "Incorrect—this is for INR 5.0–8.0 without bleeding.",
      "Stop warfarin and give prothrombin complex concentrate": "Incorrect—prothrombin complex is only indicated for major or life-threatening bleeding."
    },
    "category": "Pharmacology & Therapeutics",
    "subsection": "Cardiovascular Drugs",
    "subsubsection": "Antiplatelets & Anticoagulants",
    "topic": "Reversal strategies",
    "keywords": [
      "warfarin reversal",
      "INR management",
      "vitamin K",
      "minor bleeding",
      "anticoagulation"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Oral anticoagulants",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/oral-anticoagulants/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "147fac16-e3bc-47af-a47d-10133a2fdef6",
    "question_number": 442,
    "question": "A 29-year-old woman with well-controlled epilepsy on carbamazepine is planning to breastfeed her newborn. Which statement best reflects current clinical advice regarding breastfeeding while taking antiepileptic medication?",
    "options": [
      "Breastfeeding is generally considered safe for women taking most antiepileptic drugs, including carbamazepine.",
      "She should discontinue breastfeeding due to the risk of drug transfer in breast milk.",
      "Her carbamazepine dose should be reduced to minimise infant exposure.",
      "Switching to valproate would be safer for breastfeeding.",
      "Breastfeeding is only permitted if she takes barbiturates instead of carbamazepine."
    ],
    "correct_answer": "Breastfeeding is generally considered safe for women taking most antiepileptic drugs, including carbamazepine.",
    "explanation": "**Explanation**\n**Carbamazepine and most antiepileptic drugs are compatible with breastfeeding**, as only small amounts transfer into breast milk and significant adverse effects in infants are uncommon. The exception is barbiturates, which are not recommended due to sedation and respiratory depression risk in the infant. **Women whose epilepsy is well controlled should continue their current regimen**, as unnecessary changes can destabilise seizure control and expose both mother and baby to risk. There is no need to reduce the dose or switch to alternative antiepileptic drugs solely for breastfeeding purposes.\n\n**Key Points**\n- Carbamazepine is considered safe in breastfeeding; infant monitoring is still advised.\n- Most antiepileptic drugs (AEDs) are compatible with breastfeeding, except barbiturates.\n- Abrupt changes in AED regimen can destabilise seizure control.\n- Dose adjustment for breastfeeding is generally unnecessary if epilepsy is well controlled.\n- Breastfeeding provides significant health benefits and should be encouraged unless contraindicated.\n\n**Clinical Relevance**\nCurrent guidelines support breastfeeding for women on most AEDs, reinforcing the importance of shared decision-making and risk-benefit discussions. Understanding drug safety profiles in lactation is vital to avoid unnecessary changes that could compromise maternal or infant health.\n\n**Memory Anchor**\nRemember: **Barbiturates are the main AEDs to avoid in breastfeeding**.",
    "bullet_explanations": {
      "Breastfeeding is generally considered safe for women taking most antiepileptic drugs, including carbamazepine.": "Correct – Carbamazepine and most AEDs are considered compatible with breastfeeding.",
      "She should discontinue breastfeeding due to the risk of drug transfer in breast milk.": "Incorrect – Discontinuation is unnecessary for most AEDs; benefits of breastfeeding outweigh small risks.",
      "Her carbamazepine dose should be reduced to minimise infant exposure.": "Incorrect – Dose reduction risks seizure recurrence and is not routinely recommended.",
      "Switching to valproate would be safer for breastfeeding.": "Incorrect – Carbamazepine is as safe as valproate; switching is unnecessary and could risk seizure control.",
      "Breastfeeding is only permitted if she takes barbiturates instead of carbamazepine.": "Incorrect – Barbiturates are generally avoided in breastfeeding due to risk of sedation and toxicity."
    },
    "category": "Neurology",
    "subsection": "Epilepsy",
    "subsubsection": "AED side effects",
    "topic": "Breastfeeding and antiepileptic drugs",
    "keywords": [
      "carbamazepine",
      "breastfeeding",
      "antiepileptic drugs",
      "epilepsy",
      "lactation safety"
    ],
    "difficulty": "Medium",
    "references": [],
    "is_flashcard": false
  },
  {
    "id": "0f6fb153-eea7-4a3c-9041-e62f737dac6f",
    "question_number": 443,
    "question": "Which cancer risk is increased with prolonged use of the combined oral contraceptive pill (COC)?",
    "options": [
      "Endometrial cancer",
      "Ovarian cancer",
      "Cervical cancer",
      "Colorectal cancer",
      "Hepatocellular carcinoma"
    ],
    "correct_answer": "Cervical cancer",
    "explanation": "**Explanation**\n**Combined oral contraceptive pills (COCs) are associated with a modestly increased risk of cervical cancer, particularly with longer duration of use.** The likely mechanism is hormone-mediated promotion of persistent human papillomavirus (HPV) infection, the primary cause of cervical cancer. This increased risk appears to diminish after discontinuing the pill. In contrast, COCs confer significant protection against both ovarian and endometrial cancers. There is also some evidence suggesting a reduced risk of colorectal cancer with COC use, but this finding remains less definitive. Hepatocellular carcinoma is not notably linked with COC use in the general population.\n\n**Key Points**\n- COCs increase the risk of cervical cancer, especially with prolonged use.\n- HPV infection is the main cause of cervical cancer; oestrogen/progestogen may promote viral persistence.\n- The raised risk declines after stopping COCs.\n- COCs reduce the risk of ovarian and endometrial cancer.\n- There is no established increase in colorectal or liver cancer risk with COC use.\n\n**Clinical Relevance**\nUnderstanding the cancer risks and benefits associated with COCs is essential for safe contraceptive counselling. Patients should be informed about the small but significant increase in cervical cancer risk with long-term use, balanced against reductions in other gynaecological cancers. This knowledge underpins shared decision-making and aligns with national prescribing guidance.\n\n**Memory Anchor**\nCOC: Cervical risk, Ovarian/Endometrial protection.",
    "bullet_explanations": {
      "Endometrial cancer": "COC use actually lowers the risk of endometrial cancer.",
      "Ovarian cancer": "COCs are protective against ovarian cancer, not a risk factor.",
      "Cervical cancer": "Correct – COCs are associated with a small, duration-dependent increased risk.",
      "Colorectal cancer": "Evidence suggests COCs may mildly reduce colorectal cancer risk.",
      "Hepatocellular carcinoma": "There is no significant link between COCs and liver cancer in typical use."
    },
    "category": "Reproductive Health",
    "subsection": "Gynaecology",
    "subsubsection": "Contraception",
    "topic": "Combined pill",
    "keywords": [
      "COC",
      "cervical cancer",
      "contraceptive risks",
      "cancer prevention",
      "hormonal contraception"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Contraceptives, hormonal",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/contraceptives-hormonal/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a2f3a3cf-7c17-4fee-9518-ae8414762505",
    "question_number": 444,
    "question": "A 62-year-old South Asian woman has essential hypertension, confirmed with home readings averaging 155/95 mmHg. She is taking perindopril 8 mg daily and is adherent. She also has a history of recurrent gout, managed with febuxostat, and no other comorbidities. Her lifestyle risk factors have been addressed. According to current UK guidelines, which is the most suitable next antihypertensive agent to add?",
    "options": [
      "Amlodipine",
      "Chlortalidone",
      "Bisoprolol",
      "Doxazosin",
      "Losartan"
    ],
    "correct_answer": "Amlodipine",
    "explanation": "**Explanation**\n**Amlodipine**, a calcium channel blocker, is the recommended second-line therapy for hypertension in patients already on an ACE inhibitor (or ARB), when blood pressure remains above target. **Thiazide-like diuretics (e.g., chlortalidone)** are a standard alternative, but they can precipitate or worsen gout, making them unsuitable for this patient. NICE and BNF guidelines highlight the importance of individualising therapy based on comorbidities. Beta-blockers and alpha-blockers are not standard second-line options, and adding another renin-angiotensin agent (e.g., losartan) is not appropriate. **Key contrast:** Choose a calcium channel blocker over a thiazide-type diuretic in patients with a history of gout.\n\n**Key Points**\n<ul><li>ACE inhibitors or ARBs are first-line for hypertension in patients under 80 without contraindications.</li><li>Calcium channel blockers (e.g., amlodipine) or thiazide-like diuretics are added at step 2 if blood pressure is uncontrolled.</li><li>Thiazide-type diuretics can exacerbate gout; avoid them in those with a history of gout.</li><li>NICE/BNF guidelines recommend tailoring antihypertensive therapy to comorbidities.</li><li>Beta-blockers and alpha-blockers are reserved for later steps or specific indications.</li></ul><table><thead><tr><th>Step</th><th>Agent</th></tr></thead><tbody><tr><td>1</td><td>ACEi/ARB</td></tr><tr><td>2</td><td>+ CCB or thiazide-like diuretic (avoid thiazide if gout)</td></tr></tbody></table>\n\n**Clinical Relevance**\nSelecting antihypertensive agents that consider comorbidities like gout is essential to optimise efficacy and minimise harm. UK guidelines (NICE, BNF) explicitly recommend calcium channel blockers as the preferred add-on when diuretics are contraindicated due to gout risk.",
    "bullet_explanations": {
      "Amlodipine": "Correct – a calcium channel blocker is the preferred add-on in hypertension when diuretics are unsuitable due to gout.",
      "Chlortalidone": "Incorrect – thiazide-like diuretics increase uric acid and can worsen gout; avoid in patients with a history of gout.",
      "Bisoprolol": "Incorrect – beta-blockers are not standard second-line agents for hypertension without other indications.",
      "Doxazosin": "Incorrect – alpha-blockers are reserved for resistant hypertension or specific indications, not routine second-line use.",
      "Losartan": "Incorrect – adding another agent from the same class (ACEi/ARB) is neither recommended nor effective."
    },
    "category": "Hypertension & Vascular",
    "subsection": "Hypertension",
    "subsubsection": "NICE A/C/D ladder and special cases",
    "topic": "NICE A/C/D ladder and special cases",
    "keywords": [
      "hypertension",
      "gout",
      "antihypertensive",
      "calcium channel blocker",
      "thiazide contraindication"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "a744b19a-95eb-45ab-b1e4-7d7945b14371",
    "question_number": 445,
    "question": "A 72-year-old woman presents with sudden onset severe lower abdominal pain, vomiting, and abdominal distension. On examination, she is hypotensive and tachycardic, with a rigid, tender abdomen and absent bowel sounds. CT imaging reveals a perforated descending colon secondary to an obstructing carcinoma. What is the most appropriate initial surgical management in this emergency setting?",
    "options": [
      "End colostomy",
      "Primary colorectal anastomosis",
      "Loop ileostomy",
      "Total colectomy",
      "Hartmann's procedure"
    ],
    "correct_answer": "End colostomy",
    "explanation": "**Explanation**\n**End colostomy** is the safest and most appropriate initial surgical approach for a perforated distal colon due to malignancy, particularly in the emergency setting. Performing a primary anastomosis in the context of peritonitis and haemodynamic instability carries a high risk of anastomotic leak and further intra-abdominal contamination. Creation of an end colostomy allows control of sepsis and diversion of faecal flow, with the option for reversal or definitive surgery once the patient has recovered. Loop ileostomy is not indicated as it diverts the small bowel, not the affected colon. Total colectomy is reserved for diffuse colonic disease, not a single obstructing lesion. Hartmann's procedure technically involves resecting the diseased colon with formation of an end colostomy and closure of the rectal stump, but the essential element in this context is the formation of an end colostomy.\n\n**Key Points**\n- Perforated colon with obstruction is a surgical emergency requiring prompt intervention.\n- Primary anastomosis is contraindicated due to high risk of leak in peritonitis.\n- End colostomy diverts faeces and helps control sepsis.\n- Loop ileostomy is not suitable for distal colonic pathology.\n- Total colectomy is not indicated unless widespread disease is present.\n- <table><thead><tr><th>Procedure</th><th>Indication</th></tr></thead><tbody><tr><td>End colostomy</td><td>Emergency, distal colonic perforation</td></tr><tr><td>Primary anastomosis</td><td>Elective, stable patients</td></tr><tr><td>Total colectomy</td><td>Diffuse colonic disease (e.g. IBD)</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising when to avoid a primary anastomosis in the context of perforated, obstructed colon is vital for patient safety. National guidelines emphasise diversion and sepsis control as priorities in unstable patients with peritonitis.\n\n**Memory Anchor**\nRemember: 'Perforation = Protect' — divert with colostomy, avoid risky join-ups.",
    "bullet_explanations": {
      "End colostomy": "Correct — safest emergency approach for perforated distal colon, avoiding anastomotic leak.",
      "Primary colorectal anastomosis": "Incorrect — high leak risk in the context of peritonitis and instability.",
      "Loop ileostomy": "Incorrect — diverts small bowel, not suitable for distal colonic disease.",
      "Total colectomy": "Incorrect — reserved for diffuse colonic pathology, not a single obstructing lesion.",
      "Hartmann's procedure": "Incorrect — although similar, the key initial management is end colostomy; Hartmann's is a specific eponym but the question focuses on the principle."
    },
    "category": "Gastroenterology & Nutrition",
    "subsection": "Lower GI",
    "subsubsection": "Diverticular Disease",
    "topic": "Uncomplicated vs complicated presentations",
    "keywords": [
      "colonic perforation",
      "end colostomy",
      "emergency surgery"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Abdominal pain - acute",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/abdominal-pain-acute/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "0336d318-e39d-42c6-95c2-06a8d7933c21",
    "question_number": 446,
    "question": "Which occupational lung disease is most strongly associated with bilateral upper lobe fibrosis and 'egg-shell' calcification of hilar lymph nodes seen on chest radiograph in someone exposed to mineral dust?",
    "options": [
      "Silicosis",
      "Pulmonary tuberculosis",
      "Idiopathic pulmonary fibrosis",
      "Asbestosis",
      "Chronic sarcoidosis"
    ],
    "correct_answer": "Silicosis",
    "explanation": "**Explanation**\n**Silicosis** is a pneumoconiosis resulting from chronic inhalation of crystalline silica dust, commonly found in occupations such as mining, stone cutting, and quarrying. The disease typically develops after prolonged exposure and is radiologically characterised by **upper lobe-predominant fibrosis** and the classic finding of **'egg-shell' calcification of hilar lymph nodes**—thin, peripheral calcification that outlines the lymph node. These imaging features help distinguish silicosis from other causes of interstitial lung disease. In contrast, asbestosis usually involves the lower lobes and is associated with pleural plaques, tuberculosis may cause upper lobe fibrosis but rarely produces egg-shell calcification, idiopathic pulmonary fibrosis is classically basal and peripheral, and sarcoidosis more often shows bilateral hilar lymphadenopathy without the classic calcification pattern.\n\n**Key Points**\n- Silicosis is linked to occupational exposure to silica dust (e.g. mining, quarrying).\n- 'Egg-shell' calcification of hilar lymph nodes is a hallmark radiological sign.\n- Fibrosis is more pronounced in the upper lobes.\n- Asbestosis typically affects the lower lung zones and presents with pleural plaques.\n- Idiopathic pulmonary fibrosis is more common in the lung bases and periphery.\n- Tuberculosis can cause upper lobe disease but rarely causes egg-shell calcification.\n- Sarcoidosis often presents with bilateral hilar lymphadenopathy but not egg-shell calcification.\n\n**Clinical Relevance**\nRecognising the radiological patterns and occupational history in pneumoconioses is essential for accurate diagnosis, workplace safety advice, and monitoring for complications such as respiratory failure or increased infection risk. Early identification allows for intervention to reduce further exposure and optimise respiratory health.\n\n**Memory Anchor**\nThink 'S' for Silica, Silicosis, and Stonework (mining). 'Egg-shell' calcification is 'shell'—mined from the earth.",
    "bullet_explanations": {
      "Silicosis": "Correct – classic association with upper lobe fibrosis and egg-shell calcified hilar nodes in silica-exposed individuals.",
      "Pulmonary tuberculosis": "Incorrect – may cause upper lobe disease but rarely demonstrates egg-shell calcification.",
      "Idiopathic pulmonary fibrosis": "Incorrect – typically affects lower lobes and is not linked to specific occupational exposures or calcified nodes.",
      "Asbestosis": "Incorrect – affects lower lung zones, associated with pleural plaques, and seen in construction or shipyard workers.",
      "Chronic sarcoidosis": "Incorrect – presents with bilateral hilar lymphadenopathy, but egg-shell calcification is not typical."
    },
    "category": "Respiratory",
    "subsection": "Interstitial & Vascular",
    "subsubsection": "ILD",
    "topic": "IPF vs non-IPF patterns",
    "keywords": [
      "silicosis",
      "egg-shell calcification",
      "upper lobe fibrosis",
      "occupational lung disease",
      "pneumoconiosis"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Sarcoidosis",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/sarcoidosis/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "55cb90f7-b2f0-45a8-944a-e02a16dc1369",
    "question_number": 447,
    "question": "A 32-year-old man is diagnosed with classical scabies after presenting with intense nocturnal pruritus and a rash involving his finger webs and wrists. Which of the following statements regarding the management and natural history of scabies is INCORRECT?",
    "options": [
      "Persistent itching may last for several weeks after successful treatment",
      "All close household contacts should be treated simultaneously, regardless of symptoms",
      "Malathion 0.5% lotion is an effective treatment option for scabies",
      "Scabies lesions in adults typically affect the interdigital spaces and flexor surfaces of the wrist",
      "If itching persists 4 weeks after treatment, retreatment is always indicated"
    ],
    "correct_answer": "If itching persists 4 weeks after treatment, retreatment is always indicated",
    "explanation": "**Explanation**\nPersistent pruritus following treatment for scabies does not automatically warrant retreatment. **Itching may persist for up to 6 weeks after effective eradication of the mites**, as this is due to a type IV delayed hypersensitivity reaction to mite antigens remaining in the skin. Retreatment should only be considered if there is evidence of ongoing infestation, such as new burrows, new rashes, or visible mites, rather than solely on the basis of persistent itching. It is important to distinguish post-scabetic pruritus from treatment failure to avoid unnecessary medication exposure.\n\n**Key Points**\n<ul><li>Persistent itch after scabies treatment is common and reflects immune response, not necessarily active infestation.</li><li>Retreatment is reserved for cases with ongoing clinical signs (e.g. new burrows or visible mites), not just ongoing pruritus.</li><li>All household and close contacts should be treated at the same time, irrespective of symptoms.</li><li>Malathion and permethrin are both licensed and effective topical options in the UK.</li><li>Typical adult scabies distribution involves the hands, wrists, and web spaces.</li></ul>\n\n**Clinical Relevance**\nUnderstanding the natural history of scabies and the rationale for management decisions is vital to prevent overtreatment and reduce the risk of drug side effects. National guidelines emphasise treating all contacts and recognising that post-treatment itch is not a reliable marker of treatment failure.",
    "bullet_explanations": {
      "Persistent itching may last for several weeks after successful treatment": "Correct—post-scabetic pruritus can persist for up to 6 weeks due to hypersensitivity.",
      "All close household contacts should be treated simultaneously, regardless of symptoms": "Correct—simultaneous treatment prevents reinfestation from asymptomatic carriers.",
      "Malathion 0.5% lotion is an effective treatment option for scabies": "Correct—malathion is recommended in UK guidelines for scabies eradication.",
      "Scabies lesions in adults typically affect the interdigital spaces and flexor surfaces of the wrist": "Correct—these are classic sites for adult scabies involvement.",
      "If itching persists 4 weeks after treatment, retreatment is always indicated": "Incorrect—persistent itch alone is not an indication for retreatment; new lesions or signs of active infestation are required."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Common Infections",
    "subsubsection": "GI Infections",
    "topic": "Food poisoning organisms",
    "keywords": [
      "scabies",
      "management",
      "pruritus",
      "treatment",
      "malathion"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Scabies",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/scabies/"
      },
      {
        "source": "BNF",
        "topic_title": "Skin infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/skin-infections/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "cec63193-abba-4558-b94f-68b62e5dfd7a",
    "question_number": 448,
    "question": "A 29-year-old woman newly confirmed as 6 weeks pregnant attends for review. She has chronic hypertension, well-controlled on ramipril 5 mg daily. She is otherwise healthy. What is the most appropriate immediate management of her antihypertensive therapy?",
    "options": [
      "Stop ramipril and commence labetalol",
      "Continue ramipril until specialist review",
      "Switch ramipril to atenolol",
      "Discontinue ramipril and start amlodipine",
      "Stop ramipril with no alternative antihypertensive"
    ],
    "correct_answer": "Stop ramipril and commence labetalol",
    "explanation": "**Explanation**\n**ACE inhibitors, such as ramipril, are contraindicated in pregnancy** due to their association with fetal renal dysfunction, oligohydramnios, and congenital malformations. They should be discontinued as soon as pregnancy is confirmed. **Labetalol is the first-line antihypertensive agent for use in pregnancy** due to its safety profile for both mother and fetus. In women with pre-existing hypertension, therapy should be switched immediately to an agent with established safety, such as labetalol, while arranging for specialist obstetric review. Continuing or initiating other antihypertensives (like atenolol or amlodipine) is not recommended due to either safety concerns or lack of evidence for use in pregnancy.\n\n**Key Points**\n- ACE inhibitors and ARBs are teratogenic and must be stopped immediately in pregnancy.\n- Labetalol is first-line for managing hypertension during pregnancy.\n- Nifedipine (modified-release) and methyldopa are alternatives if labetalol is unsuitable.\n- Atenolol is avoided due to risk of fetal growth restriction.\n- Immediate referral to specialist antenatal care is advised for women with chronic hypertension.\n- <table><thead><tr><th>Drug</th><th>Pregnancy Safety</th></tr></thead><tbody><tr><td>Labetalol</td><td>Preferred</td></tr><tr><td>Nifedipine MR</td><td>Alternative</td></tr><tr><td>Methyldopa</td><td>Alternative</td></tr><tr><td>ACEi/ARB</td><td>Contraindicated</td></tr><tr><td>Atenolol</td><td>Avoid</td></tr></tbody></table>\n\n**Clinical Relevance**\nHypertensive disorders in pregnancy pose significant risks to both mother and fetus. Prompt discontinuation of teratogenic antihypertensives (ACE inhibitors or ARBs) and initiation of safer alternatives is essential, as emphasised in national guidelines. Early specialist involvement is key for optimal outcomes.\n\n**Memory Anchor**\nRemember: 'L' for Labetalol and Labour—labetalol is safe for pregnancy.",
    "bullet_explanations": {
      "Stop ramipril and commence labetalol": "Correct—this immediately removes teratogenic risk and substitutes with the safest first-line agent in pregnancy.",
      "Continue ramipril until specialist review": "Incorrect—ACE inhibitors should be stopped immediately due to teratogenicity; delaying discontinuation is unsafe.",
      "Switch ramipril to atenolol": "Incorrect—atenolol is not recommended in pregnancy because of risk of fetal growth restriction.",
      "Discontinue ramipril and start amlodipine": "Incorrect—amlodipine is not routinely recommended for hypertension in pregnancy due to limited safety data.",
      "Stop ramipril with no alternative antihypertensive": "Incorrect—stopping therapy with no substitution risks uncontrolled maternal hypertension, which is dangerous."
    },
    "category": "Reproductive Health",
    "subsection": "Obstetrics – Early",
    "subsubsection": "Antenatal Care",
    "topic": "High-risk pregnancy identification",
    "keywords": [
      "hypertension in pregnancy",
      "ACE inhibitors",
      "labetalol",
      "antenatal care"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Hypertension",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/hypertension/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "03c4ae33-aae6-427f-8cf9-31961e411290",
    "question_number": 449,
    "question": "A 34-year-old man who regularly wears soft contact lenses presents with a 2-day history of a painful, red right eye. He describes marked photophobia, excessive tearing, and a persistent gritty or foreign body sensation. On examination, there is conjunctival injection, but no significant discharge. What is the most likely diagnosis?",
    "options": [
      "Keratitis",
      "Bacterial conjunctivitis",
      "Acute anterior uveitis",
      "Blepharitis",
      "Lacrimal duct obstruction"
    ],
    "correct_answer": "Keratitis",
    "explanation": "**Explanation**\n**Keratitis** is the most likely diagnosis given the combination of contact lens use, significant eye pain, photophobia, foreign body sensation, and conjunctival injection. Keratitis refers to inflammation of the cornea, which is commonly caused by bacterial, viral, or, less frequently, fungal or protozoal pathogens. Contact lens wear increases the risk, particularly if hygiene is suboptimal. Photophobia, pain, and gritty sensation are key features that distinguish keratitis from milder conditions like conjunctivitis. Prompt recognition is vital, as untreated keratitis can rapidly threaten vision and requires urgent specialist assessment and intensive treatment. In contrast, conjunctivitis rarely causes severe pain or photophobia, and blepharitis typically affects the eyelids with irritation but not significant photophobia or corneal involvement.\n\n**Key Points**\n- Keratitis is inflammation of the cornea; most commonly infectious.\n- Classic symptoms: red eye, pain, photophobia, gritty sensation.\n- Contact lens use is a major risk factor, especially with poor hygiene.\n- Conjunctivitis usually causes mild discomfort and minimal photophobia.\n- Blepharitis involves eyelid margins, not the cornea; photophobia is uncommon.\n- Keratitis can progress to corneal ulcer or even endophthalmitis if untreated.\n- <table><thead><tr><th>Condition</th><th>Pain</th><th>Photophobia</th><th>Discharge</th></tr></thead><tbody><tr><td>Keratitis</td><td>Moderate–severe</td><td>+ / prominent</td><td>Minimal</td></tr><tr><td>Conjunctivitis</td><td>Mild</td><td>Usually absent</td><td>+ / mucopurulent</td></tr><tr><td>Blepharitis</td><td>Itching/irritation</td><td>Absent</td><td>Crusting</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising keratitis in contact lens users is critical, as delayed referral increases the risk of vision loss. Guidelines emphasise urgent ophthalmology involvement for suspected keratitis, particularly when associated with pain and photophobia. Early treatment and contact lens cessation are key for preventing serious complications.\n\n**Memory Anchor**\nRemember: 'Contact lens + Painful photophobia = Corneal danger (keratitis)'",
    "bullet_explanations": {
      "Keratitis": "Correct – Presents with red eye, pain, photophobia, and gritty sensation, especially in contact lens users.",
      "Bacterial conjunctivitis": "Incorrect – Typically causes mild discomfort, discharge, but rarely significant photophobia or pain.",
      "Acute anterior uveitis": "Incorrect – Usually presents with pain and photophobia, but often has blurred vision and perilimbal (ciliary) injection; less common in contact lens users.",
      "Blepharitis": "Incorrect – Involves eyelid margins with irritation and crusting, but not marked photophobia or corneal pain.",
      "Lacrimal duct obstruction": "Incorrect – Causes watering and possibly mild discomfort, but not photophobia or red eye with pain."
    },
    "category": "Ophthalmology",
    "subsection": "Red Eye",
    "subsubsection": "Keratitis",
    "topic": "Keratitis",
    "keywords": [
      "keratitis",
      "contact lens",
      "red eye",
      "photophobia",
      "ophthalmology"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "BNF",
        "topic_title": "Eye, infections",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/eye-infections/"
      },
      {
        "source": "BNF",
        "topic_title": "Eye",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/eye/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "96bbfc97-f19f-473c-8ea9-97a022214c6e",
    "question_number": 450,
    "question": "A 19-year-old university student complains of severe lower abdominal cramps that reliably begin the day before her periods and resolve within two days of menstruation starting. Her cycles are regular, she does not report heavy bleeding, and pelvic examination is unremarkable. What is considered the most effective initial pharmacological management for her symptoms?",
    "options": [
      "Mefenamic acid",
      "Combined oral contraceptive pill",
      "Paracetamol",
      "Codeine phosphate",
      "Hyoscine butylbromide"
    ],
    "correct_answer": "Mefenamic acid",
    "explanation": "**Explanation**\n**NSAIDs, such as mefenamic acid, are the recommended first-line therapy for primary dysmenorrhoea.** They alleviate menstrual pain by inhibiting cyclo-oxygenase enzymes, thereby reducing the synthesis of prostaglandins in the endometrium. Prostaglandins are key mediators of the uterine contractions and cramping pain experienced during menstruation, so targeting their production directly addresses the underlying mechanism. NSAIDs are consistently more effective than simple analgesics (like paracetamol), and hormonal options are generally reserved for those who require contraception or do not respond to NSAIDs. This patient’s symptoms and examination findings are typical of primary dysmenorrhoea, with no features suggesting secondary causes.\n\n**Key Points**\n- NSAIDs (e.g. mefenamic acid) are first-line for primary dysmenorrhoea.\n- They act by blocking prostaglandin synthesis, reducing uterine contractions.\n- Paracetamol may help but is less effective than NSAIDs.\n- COCPs are considered if NSAIDs are not tolerated or contraception is required.\n- Antispasmodics and opioids are not recommended as first-line treatments.\n- <table><thead><tr><th>Treatment</th><th>Mechanism</th><th>Place in Therapy</th></tr></thead><tbody><tr><td>NSAIDs</td><td>Inhibit prostaglandins</td><td>First-line</td></tr><tr><td>COCP</td><td>Suppress ovulation, thin endometrium</td><td>Second-line or contraception needed</td></tr><tr><td>Paracetamol</td><td>Non-specific analgesia</td><td>Adjunct/alternative</td></tr></tbody></table>\n\n**Clinical Relevance**\nPrimary dysmenorrhoea is a common cause of menstrual pain in young women and can impact quality of life. Timely recognition and use of NSAIDs as first-line treatment is supported by national guidelines and improves functioning and attendance at school or work.\n\n**Memory Anchor**\nNSAIDs 'Nix' the pain by 'Nixing' prostaglandins in primary dysmenorrhoea.",
    "bullet_explanations": {
      "Mefenamic acid": "Correct – NSAIDs like mefenamic acid directly target prostaglandin-mediated pain and are first-line.",
      "Combined oral contraceptive pill": "Useful if NSAIDs are ineffective or contraception is also needed, but not first-line for isolated pain.",
      "Paracetamol": "Provides general pain relief but is less effective than NSAIDs for menstrual cramps.",
      "Codeine phosphate": "Opioids are generally avoided due to side effects and risk of dependence; not first-line.",
      "Hyoscine butylbromide": "Antispasmodics are not effective for primary dysmenorrhoea, as they do not address prostaglandin-mediated pain."
    },
    "category": "Gynaecology",
    "subsection": "Menstrual Disorders",
    "subsubsection": "Dysmenorrhoea",
    "topic": "Dysmenorrhoea",
    "keywords": [
      "primary dysmenorrhoea",
      "NSAIDs",
      "mefenamic acid",
      "menstrual pain",
      "first-line treatment"
    ],
    "difficulty": "Easy",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Dysmenorrhoea",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/dysmenorrhoea/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "5749f7ef-44b7-4ca8-b3ec-4871f072b9e8",
    "question_number": 451,
    "question": "A 34-year-old man reports several years of slowly worsening hearing difficulty in both ears, accompanied by intermittent tinnitus. There is no history of ear infections, ear discharge, or trauma. His father experienced similar problems in his thirties. On examination, the tympanic membranes are normal. Weber's test does not lateralise, and Rinne's test shows bone conduction greater than air conduction bilaterally. What is the most likely underlying diagnosis?",
    "options": [
      "Otosclerosis",
      "Chronic suppurative otitis media",
      "Cholesteatoma",
      "Cerumen impaction",
      "Stickler syndrome"
    ],
    "correct_answer": "Otosclerosis",
    "explanation": "**Explanation**\n**Otosclerosis** is the most likely diagnosis given the insidious onset of bilateral conductive hearing loss, positive family history, and associated tinnitus. Otosclerosis is a disorder characterised by abnormal bone remodelling in the otic capsule, particularly around the stapes footplate, leading to stapes fixation and impaired transmission of sound. It typically presents in young to middle adulthood, often with a family history due to autosomal dominant inheritance. The classic finding is conductive hearing loss with normal tympanic membranes. Tuning fork tests demonstrate bone conduction exceeding air conduction (Rinne negative) and a non-lateralising Weber if the loss is symmetric. Other conditions—such as chronic otitis media or cholesteatoma—are more likely to present with unilateral symptoms, otoscopic abnormalities, or a history of infection, and cerumen impaction would be evident on examination. Stickler syndrome is associated with sensorineural rather than conductive loss.\n\n**Key Points**\n- Otosclerosis typically causes bilateral, progressive conductive hearing loss in young adults.\n- Family history is common due to autosomal dominant inheritance.\n- Rinne's test: bone conduction > air conduction (conductive loss).\n- Weber's test: non-lateralising if symmetric hearing loss.\n- Tympanic membranes appear normal on otoscopy.\n- Tinnitus may be present.\n- <table><thead><tr><th>Feature</th><th>Otosclerosis</th><th>Cholesteatoma</th><th>Otitis Media</th></tr></thead><tbody><tr><td>Hearing loss</td><td>Conductive, bilateral</td><td>Conductive, usually unilateral</td><td>Conductive, often with effusion</td></tr><tr><td>Family history</td><td>Common</td><td>Uncommon</td><td>Uncommon</td></tr><tr><td>Tympanic membrane</td><td>Normal</td><td>Abnormal</td><td>Effusion/Abnormal</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising otosclerosis is essential as it is a common cause of progressive conductive hearing loss in young and middle-aged adults. Early identification allows timely referral for audiological assessment and consideration of management options, including hearing aids or surgical intervention. Family history and classic tuning fork findings are key diagnostic clues (NICE CKS).\n\n**Memory Anchor**\nOtosclerosis = 'Oto' (ear) + 'sclerosis' (stiffening) — think of stapes becoming 'stiff' and fixed.",
    "bullet_explanations": {
      "Otosclerosis": "Correct – presents with bilateral, progressive conductive hearing loss, tinnitus, and family history; tuning fork tests are consistent.",
      "Chronic suppurative otitis media": "Incorrect – usually presents with discharge and tympanic membrane perforation, not a normal otoscopic exam or family history.",
      "Cholesteatoma": "Incorrect – often causes unilateral hearing loss, usually with abnormal tympanic membranes and sometimes discharge.",
      "Cerumen impaction": "Incorrect – causes conductive hearing loss but would be visible on examination, and lacks family history.",
      "Stickler syndrome": "Incorrect – primarily associated with sensorineural hearing loss, not conductive loss."
    },
    "category": "Dermatology, ENT & Eyes",
    "subsection": "ENT",
    "subsubsection": "Ear",
    "topic": "Hearing loss causes",
    "keywords": [
      "otosclerosis",
      "conductive hearing loss",
      "tuning fork tests",
      "ENT diagnosis",
      "family history deafness"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Hearing loss in adults",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/hearing-loss-in-adults/"
      }
    ],
    "is_flashcard": false
  },
  {
    "id": "d4400421-8ff7-4c29-9d4f-665c461796fb",
    "question_number": 452,
    "question": "A 28-year-old man with a history of poorly controlled coeliac disease presents with repeated upper respiratory tract infections and vague abdominal discomfort. On routine blood tests, he is found to have mild anaemia. What is the most characteristic blood film finding associated with his likely underlying haematological complication?",
    "options": [
      "Howell-Jolly bodies and target cells",
      "Schistocytes",
      "Basophilic stippling",
      "Sickle cells",
      "Burr cells (echinocytes)"
    ],
    "correct_answer": "Howell-Jolly bodies and target cells",
    "explanation": "**Explanation**\nIn coeliac disease, especially when poorly managed, individuals are at risk of developing **functional hyposplenism** due to chronic immune activation and splenic atrophy. The spleen normally filters abnormal red blood cells and removes nuclear remnants (such as Howell-Jolly bodies). When splenic function is reduced, these nuclear remnants and abnormally shaped cells like target cells persist in the peripheral blood. **Howell-Jolly bodies appear as small, round, basophilic inclusions in red cells**, and target cells have a characteristic bullseye appearance. These findings are classic for hyposplenism or asplenia, which is a recognised complication of coeliac disease, increasing vulnerability to infections by encapsulated organisms. <br><br>Other blood film abnormalities are not typical of hyposplenism: schistocytes are seen in microangiopathic haemolytic anaemias, basophilic stippling in lead poisoning or disturbed erythropoiesis, sickle cells in sickle cell disease, and burr cells in renal disease or artefact.\n\n**Key Points**\n- Coeliac disease can lead to functional hyposplenism.\n- Howell-Jolly bodies and target cells are the hallmark blood film findings in hyposplenism.\n- Hyposplenism increases susceptibility to encapsulated bacterial infections.\n- Other findings such as schistocytes, sickle cells, or burr cells indicate alternative pathologies.\n- <table><thead><tr><th>Condition</th><th>Key Blood Film Finding</th></tr></thead><tbody><tr><td>Hyposplenism</td><td>Howell-Jolly bodies, target cells</td></tr><tr><td>Microangiopathic haemolysis</td><td>Schistocytes</td></tr><tr><td>Sickle cell disease</td><td>Sickle cells</td></tr><tr><td>Renal failure</td><td>Burr cells</td></tr><tr><td>Lead poisoning</td><td>Basophilic stippling</td></tr></tbody></table>\n\n**Clinical Relevance**\nRecognising the association between coeliac disease and hyposplenism is vital for guiding immunisation advice and anticipating infectious complications. Blood film examination can provide important diagnostic clues in this scenario, supporting recommendations for additional vaccinations and prompt infection management, as outlined by NICE and the BNF.\n\n**Memory Anchor**\nHowell-Jolly bodies = 'H' for Hyposplenism and Hyposplenic states",
    "bullet_explanations": {
      "Howell-Jolly bodies and target cells": "Correct – These findings are classic for hyposplenism, a known complication of coeliac disease.",
      "Schistocytes": "Incorrect – Schistocytes are associated with microangiopathic haemolytic anaemia, not hyposplenism.",
      "Basophilic stippling": "Incorrect – Seen in lead poisoning or thalassaemia, not related to hyposplenism.",
      "Sickle cells": "Incorrect – Indicative of sickle cell disease, unrelated to coeliac disease or splenic dysfunction.",
      "Burr cells (echinocytes)": "Incorrect – Typically seen in renal disease or as an artefact, not a feature of hyposplenism."
    },
    "category": "Infectious, Haematology, Immunology, Allergy & Genetics",
    "subsection": "Haematology",
    "subsubsection": "Anaemias",
    "topic": "Microcytic (iron, thalassaemia, anaemia of chronic disease)",
    "keywords": [
      "coeliac disease",
      "hyposplenism",
      "Howell-Jolly bodies",
      "target cells",
      "blood film"
    ],
    "difficulty": "Medium",
    "references": [
      {
        "source": "NICE CKS",
        "topic_title": "Coeliac disease",
        "citation": "© NICE Clinical Knowledge Summaries, 2025",
        "url": "https://cks.nice.org.uk/topics/coeliac-disease/"
      },
      {
        "source": "BNF",
        "topic_title": "Coeliac disease",
        "citation": "© NICE BNF, 2025",
        "url": "https://bnf.nice.org.uk/treatment-summaries/coeliac-disease/"
      }
    ],
    "is_flashcard": false
  }
]